Clustering O 0 5.648842602568038e-07
of O 0 4.175166168352007e-07
missense O 0 9.204824777953036e-07
mutations O 0 2.1211706169310673e-08
in O 0 7.89659893030148e-09
the O 0 7.855513786125812e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.2053432328684721e-05
in O 0 1.7731133539200528e-07
a O 0 1.1419064094297937e-07
sporadic B-Disease 0 0.00031783009762875736
T I-Disease 1 0.9995754361152649
- I-Disease 0 0.04392442852258682
cell I-Disease 0 0.15896688401699066
leukaemia I-Disease 1 0.9997956156730652
. O 0 1.5342220649472438e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9998449087142944
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.77386438449912e-09
is O 0 2.5989593810393785e-10
a O 0 3.736831122314044e-10
recessive B-Disease 0 2.580661373485782e-07
multi I-Disease 1 0.8169923424720764
- I-Disease 1 0.9969401359558105
system I-Disease 1 0.9950476884841919
disorder I-Disease 1 0.9999927282333374
caused O 0 2.2112033093435457e-08
by O 0 4.550451682128198e-11
mutations O 0 3.3426594825414213e-10
in O 0 3.211662602531362e-10
the O 0 1.4272130144377115e-09
ATM O 0 9.874057838032968e-08
gene O 0 1.4638204426375978e-08
at O 0 4.653205678550876e-07
11q22 O 0 3.5302565493111615e-07
- O 0 1.1076552652866667e-07
q23 O 0 1.185144569149088e-07
( O 0 1.664813953361488e-09
ref O 0 8.364578008013268e-08
. O 0 1.0209990630727361e-09
3 O 0 6.310483513516374e-08
) O 0 5.668753466636645e-09
. O 0 7.64766667771255e-08

The O 0 4.4828678369412955e-07
risk O 0 3.702783260450815e-06
of O 0 1.0492016144780791e-06
cancer B-Disease 0 0.00010650794865796342
, O 0 1.909116242870823e-08
especially O 0 2.23112337494058e-08
lymphoid B-Disease 0 1.9115595932817087e-06
neoplasias I-Disease 0 1.2709178008663002e-05
, O 0 1.1324150506197839e-09
is O 0 4.829612404444461e-11
substantially O 0 1.8569472626239758e-09
elevated O 0 1.540266652000355e-07
in O 0 4.721313118238868e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3685745443581254e-06
and O 0 7.3608892314780405e-09
has O 0 1.8218911101985924e-10
long O 0 2.7255139117832172e-11
been O 0 1.1132447394479605e-11
associated O 0 1.0671439426568341e-10
with O 0 7.623222053609879e-10
chromosomal O 1 1.0
instability O 1 1.0
. O 0 0.00014529813779518008

By O 0 7.180150252139583e-09
analysing O 0 4.865967753175937e-07
tumour B-Disease 1 0.9999333620071411
DNA O 0 7.666214685286832e-08
from O 0 4.106590179020486e-09
patients O 0 1.4706082185345082e-10
with O 0 2.783365551928263e-11
sporadic B-Disease 0 1.4743343967893452e-07
T I-Disease 0 7.175906830525491e-06
- I-Disease 0 6.933697704880615e-07
cell I-Disease 0 1.0826937568708672e-06
prolymphocytic I-Disease 0 1.0328760254196823e-05
leukaemia I-Disease 0 0.2636595070362091
( O 0 1.4840193074405761e-08
T B-Disease 0 1.33626235765405e-06
- I-Disease 0 2.8480937430686026e-07
PLL I-Disease 0 1.3875330751034198e-06
) O 0 4.434999034685916e-10
, O 0 1.3045924063259662e-10
a O 0 2.2834685531325505e-10
rare O 0 8.918367155885676e-10
clonal B-Disease 0 5.539711267488201e-08
malignancy I-Disease 0 6.596291086680139e-07
with O 0 5.846254036434573e-10
similarities O 0 3.1664706412470878e-09
to O 0 7.887774322590246e-10
a O 0 5.783802325964871e-09
mature B-Disease 0 5.8973185446120624e-08
T I-Disease 0 8.384099601244088e-06
- I-Disease 0 6.251648869692872e-07
cell I-Disease 0 3.6893570154461486e-07
leukaemia I-Disease 0 3.2505581657460425e-06
seen O 0 1.2016601935727067e-08
in O 0 3.1558466950798447e-09
A B-Disease 1 0.9999169111251831
- I-Disease 0 0.06997723877429962
T I-Disease 1 0.999995231628418
, O 0 1.2328456033827706e-09
we O 0 1.6248988266021058e-10
demonstrate O 0 4.412285536936622e-10
a O 0 4.1750443380284e-11
high O 0 1.2614434496960314e-10
frequency O 0 1.2903142998510475e-09
of O 0 1.0526016724909937e-09
ATM O 0 1.333840202732972e-07
mutations O 0 3.4405951421234704e-09
in O 0 2.8034135013399464e-08
T B-Disease 0 7.089421706041321e-05
- I-Disease 0 2.153413515770808e-05
PLL I-Disease 0 0.00019212873303331435
. O 0 1.4386703242053045e-06

In O 0 4.3266265237207335e-08
marked O 0 3.456448993688355e-08
contrast O 0 3.76108033606215e-09
to O 0 1.8057146056182916e-10
the O 0 3.7897457394464595e-10
ATM O 0 7.667179602321994e-08
mutation O 0 3.026761064006678e-10
pattern O 0 1.4945065629490273e-08
in O 0 3.2536295435647844e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999951124191284
T I-Disease 1 1.0
, O 0 5.593592256047941e-09
the O 0 3.36007166534813e-10
most O 0 1.6305082284340244e-11
frequent O 0 2.1696517846225838e-11
nucleotide O 0 1.1821177370308078e-10
changes O 0 9.312377258208215e-11
in O 0 1.292910223327226e-10
this O 0 1.7092183224320934e-10
leukaemia B-Disease 0 6.019432476023212e-06
were O 0 2.7031529015175693e-08
missense O 0 2.0082129594811704e-06
mutations O 0 2.2993408776983415e-07
. O 0 3.898306317751121e-07

These O 0 1.1019736234629818e-08
clustered O 0 1.3690285527445667e-07
in O 0 2.256698827807213e-09
the O 0 8.371721094135864e-10
region O 0 2.6091526716953695e-09
corresponding O 0 2.708772095516565e-09
to O 0 3.7707897915240096e-10
the O 0 3.258683323181799e-09
kinase O 0 9.189158767242134e-09
domain O 0 4.117305962836326e-08
, O 0 2.4567776701900357e-09
which O 0 6.477038350105602e-11
is O 0 5.31961107108625e-11
highly O 0 3.800364467565487e-10
conserved O 0 1.2901421042599281e-09
in O 0 2.791149811276483e-10
ATM O 0 7.666726276056579e-08
- O 0 1.4930847669347713e-08
related O 0 2.0761865560103843e-09
proteins O 0 1.9449422627992874e-10
in O 0 4.608951831297503e-10
mouse O 0 2.014190592092291e-09
, O 0 4.633093353412221e-10
yeast O 0 8.892061309495602e-09
and O 0 2.099209917005851e-09
Drosophila O 0 1.3292699918565631e-07
. O 0 1.0887743684406814e-07

The O 0 1.2839447549595207e-07
resulting O 0 9.951330071089615e-08
amino O 0 6.717397837974204e-08
- O 0 3.694757921834935e-08
acid O 0 8.294970932354317e-09
substitutions O 0 1.0603724120983316e-08
are O 0 4.621846308450195e-11
predicted O 0 2.7612758746187183e-09
to O 0 4.471906456249286e-10
interfere O 0 5.7773991812837266e-08
with O 0 1.2733907261974764e-09
ATP O 0 7.978201210789848e-07
binding O 0 1.6588145967944e-08
or O 0 3.793783065475509e-09
substrate O 0 1.8261305356759294e-08
recognition O 0 4.0928377131876914e-08
. O 0 2.651284489729733e-07

Two O 0 8.293170594697585e-08
of O 0 2.491102861768013e-07
seventeen O 0 4.3428110529930564e-07
mutated O 0 6.083531900458183e-08
T B-Disease 0 1.4693838465973386e-06
- I-Disease 0 1.74960703702709e-07
PLL I-Disease 0 1.4378679225046653e-06
samples O 0 1.3997370373886042e-08
had O 0 4.165177536208375e-09
a O 0 1.1402849775521418e-09
previously O 0 6.406874142328434e-09
reported O 0 1.9835923126265698e-08
A B-Disease 1 0.9998737573623657
- I-Disease 1 0.9507219791412354
T I-Disease 1 0.9999960660934448
allele O 0 1.292366277994006e-06
. O 0 6.980719149396464e-07

In O 0 6.785065664871581e-08
contrast O 0 1.6801362079377213e-08
, O 0 7.491676723425655e-10
no O 0 1.6860991769451772e-10
mutations O 0 1.188561193909976e-10
were O 0 1.1159537183225154e-10
detected O 0 1.625116818892991e-09
in O 0 9.243168036521254e-11
the O 0 3.0309552090379555e-10
p53 O 0 1.4912113766030188e-09
gene O 0 4.489642435601127e-09
, O 0 3.522885316797897e-09
suggesting O 0 5.355206944557267e-09
that O 0 1.6585281759073922e-10
this O 0 5.352773779776498e-10
tumour B-Disease 1 0.9999994039535522
suppressor O 0 1.857320239651017e-05
is O 0 4.08013089980841e-09
not O 0 1.3503349827193034e-10
frequently O 0 1.912197483688871e-10
altered O 0 1.90697546642582e-09
in O 0 6.540778474395381e-10
this O 0 1.0089270530144745e-09
leukaemia B-Disease 0 2.7238451366429217e-05
. O 0 2.868423223389982e-07

Occasional O 0 1.0931748875009362e-06
missense O 0 1.0803379382195999e-06
mutations O 0 1.2285810591095014e-08
in O 0 3.7405483155339425e-09
ATM O 0 7.640055059709994e-07
were O 0 2.7401221291967204e-09
also O 0 1.6477508246737216e-10
found O 0 5.988579077076395e-11
in O 0 8.95391746857932e-11
tumour B-Disease 1 0.9913307428359985
DNA O 0 7.990017536485539e-09
from O 0 5.301603600571525e-10
patients O 0 4.4753600131342e-11
with O 0 2.0046833984488366e-11
B B-Disease 0 1.9919275473512243e-06
- I-Disease 0 2.450431395573105e-07
cell I-Disease 0 5.419159151642816e-06
non I-Disease 0 0.01331046037375927
- I-Disease 1 0.8941166996955872
Hodgkins I-Disease 1 0.9999998807907104
lymphomas I-Disease 0 0.00040588629781268537
( O 0 7.181793826305238e-09
B B-Disease 0 8.202758863262716e-07
- I-Disease 0 1.2083806844032097e-08
NHL I-Disease 0 6.49649649631101e-08
) O 0 8.115972477407141e-11
and O 0 5.5166850254639854e-11
a O 0 1.968140095343074e-09
B B-Disease 0 1.8082930637319805e-06
- I-Disease 0 1.2648963831907167e-07
NHL I-Disease 0 3.773589241973241e-06
cell O 0 7.842319064366166e-06
line O 0 1.4537864672092837e-06
. O 0 1.2258895765171474e-07

The O 0 8.677188390038282e-08
evidence O 0 7.76778819044921e-08
of O 0 6.188425327735558e-09
a O 0 1.398033355748396e-10
significant O 0 9.853085708444453e-11
proportion O 0 9.52271483889433e-10
of O 0 1.1038164160481756e-08
loss O 0 6.68455015784275e-08
- O 0 4.350234661387731e-08
of O 0 5.460373131427332e-08
- O 0 1.1594006643633747e-08
function O 0 1.1191863436010863e-08
mutations O 0 1.0458854893258263e-09
and O 0 2.9397709266909544e-10
a O 0 5.80018255647019e-10
complete O 0 4.736818493000783e-09
absence O 0 1.1863862425798288e-07
of O 0 1.3492910788670542e-08
the O 0 1.4467630427006384e-09
normal O 0 2.2585633363547686e-09
copy O 0 3.326607878051391e-09
of O 0 1.742528343839922e-09
ATM O 0 2.417523248254838e-08
in O 0 4.54325577159409e-10
the O 0 1.879953692718317e-10
majority O 0 4.722020344183342e-11
of O 0 2.690744071998097e-09
mutated O 0 5.331503771799362e-08
tumours B-Disease 1 0.9999908208847046
establishes O 0 9.959549061022699e-07
somatic O 0 2.2609529537476192e-07
inactivation O 0 1.4639401797467144e-06
of O 0 3.035713902477255e-08
this O 0 1.2629262913232964e-10
gene O 0 3.188182773339321e-10
in O 0 1.96386407136373e-10
the O 0 2.231845819267164e-09
pathogenesis O 0 6.382814262906322e-06
of O 0 1.0629263158534741e-07
sporadic B-Disease 0 1.2239742318342905e-05
T I-Disease 0 0.00028577991179190576
- I-Disease 0 5.755101483373437e-06
PLL I-Disease 0 8.428914043179248e-06
and O 0 2.386196351622516e-09
suggests O 0 1.7985282152466198e-09
that O 0 2.12263661508727e-11
ATM O 0 5.914620615499189e-08
acts O 0 1.3655189867733952e-08
as O 0 2.056304015951582e-09
a O 0 2.0037461467836692e-08
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.0005053834756836295
. O 0 3.1737390600028448e-06

As O 0 5.937770097830253e-08
constitutional O 0 3.380485793513799e-07
DNA O 0 2.1310736286750398e-08
was O 0 4.635004380304508e-09
not O 0 1.0594893885829126e-11
available O 0 3.797580305775483e-11
, O 0 3.9215377473089674e-11
a O 0 6.661329265966742e-10
putative O 0 1.1665191834708821e-07
hereditary O 1 0.9941867589950562
predisposition O 0 0.004015690181404352
to O 0 7.313321930269012e-06
T B-Disease 1 0.9999816417694092
- I-Disease 1 0.5000747442245483
PLL I-Disease 0 0.00048299910849891603
will O 0 7.749687114255721e-09
require O 0 6.888136727667415e-10
further O 0 4.93304008752915e-10
investigation O 0 2.685883071507078e-09
. O 0 6.492589244011526e-10
. O 0 7.8945214809778e-09

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.00016638601664453745
kinase O 0 2.8869635571027175e-06
is O 0 3.738465537139746e-09
involved O 0 7.234308707637638e-10
in O 0 1.4413500948329272e-10
the O 0 1.0611158479667537e-10
modulation O 0 4.057957525560596e-09
of O 0 1.7529656615167255e-09
the O 0 8.578771026890308e-10
Ca2 O 0 2.277585764431933e-08
+ O 0 3.494302518447512e-07
homeostasis O 0 1.5130461179069243e-05
in O 0 2.656255162492016e-07
skeletal O 1 0.8435577154159546
muscle O 0 0.0003324837889522314
cells O 0 6.662302439508494e-06
. O 0 7.946634354993876e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9386588335037231
DM B-Disease 1 1.0
) O 0 6.656991047293559e-08
, O 0 3.938074588649698e-10
the O 0 2.705770607569491e-10
most O 0 3.8127506707397174e-10
prevalent O 0 0.0001662513823248446
muscular B-Disease 1 0.9998157620429993
disorder I-Disease 1 0.9999924898147583
in O 0 1.100688535871086e-07
adults O 0 1.2941427485202439e-08
, O 0 2.1110417580683105e-10
is O 0 4.9090939646667664e-11
caused O 0 3.545939097904238e-10
by O 0 3.34240468635727e-10
( O 0 1.1372961461475484e-09
CTG O 0 4.143003309309279e-07
) O 0 1.3317303926285717e-09
n O 0 3.8997558959863454e-08
- O 0 4.431838451779413e-09
repeat O 0 2.768278939413449e-09
expansion O 0 1.6737446983938753e-09
in O 0 1.4869899755964866e-10
a O 0 8.566079096050672e-11
gene O 0 3.748200361197718e-11
encoding O 0 6.114974748783197e-09
a O 0 1.6918608736204988e-08
protein O 0 1.1074905614805175e-07
kinase O 0 7.880966563789116e-07
( O 0 1.7293884013724892e-07
DM B-Disease 1 0.9999756813049316
protein O 0 3.7176125715632224e-06
kinase O 0 3.1546693435302586e-07
; O 0 6.4837815116902675e-09
DMPK O 0 2.7732885428122245e-06
) O 0 5.837729744051501e-10
and O 0 1.0520251336743058e-10
involves O 0 8.94299856391001e-10
changes O 0 9.943200707240862e-10
in O 0 3.419176941577007e-09
cytoarchitecture O 0 7.406224540318362e-07
and O 0 2.862787162882796e-08
ion O 0 0.0011398906353861094
homeostasis O 0 0.029019955545663834
. O 0 5.879443051526323e-06

To O 0 3.074780607903449e-08
obtain O 0 5.779273237749294e-08
clues O 0 1.4602447606648639e-07
to O 0 6.291561160942649e-10
the O 0 1.6803212155025449e-09
normal O 0 2.9388319333634172e-08
biological O 0 2.2286309686592176e-08
role O 0 4.1679673046246535e-09
of O 0 2.8516263128608443e-08
DMPK O 0 3.7301701922842767e-06
in O 0 1.2851962161164465e-08
cellular O 0 2.4362987005588366e-07
ion O 0 5.520562808669638e-06
homeostasis O 0 1.570465428812895e-05
, O 0 6.4663305820999994e-09
we O 0 6.154920462186908e-10
have O 0 1.8306333879336556e-11
compared O 0 7.586462708042419e-11
the O 0 1.1426008750259342e-10
resting O 0 8.611399593405622e-09
[ O 0 6.746461722606512e-10
Ca2 O 0 1.8768664400425905e-09
+ O 0 1.19750982463529e-08
] O 0 2.1022403373649468e-08
i O 0 6.146781750260288e-09
, O 0 8.93191354212064e-11
the O 0 3.905667803061341e-11
amplitude O 0 1.003021221634981e-09
and O 0 2.496017281750085e-10
shape O 0 1.2264691484631385e-08
of O 0 9.748208462667662e-09
depolarization O 0 2.8093227300018953e-08
- O 0 2.7170319327751713e-08
induced O 0 9.848417192870329e-09
Ca2 O 0 6.561561516349457e-09
+ O 0 4.9383455547058475e-08
transients O 0 1.7455020895340567e-07
, O 0 2.096847973032112e-10
and O 0 1.8942566265556238e-11
the O 0 5.881134468310734e-11
content O 0 3.892580424658121e-10
of O 0 1.6098026245359165e-09
ATP O 0 1.7414168951290776e-07
- O 0 3.6507096012883267e-08
driven O 0 9.474960371846919e-09
ion O 0 1.888349316914173e-07
pumps O 0 3.6257212343571155e-08
in O 0 2.0035617609437395e-09
cultured O 0 4.140316178791181e-08
skeletal O 0 3.6435142192203784e-06
muscle O 0 7.967253878859992e-08
cells O 0 5.703654881727971e-09
of O 0 3.5717775404009444e-08
wild O 0 4.2837994262967527e-10
- O 0 2.752766348201874e-10
type O 0 7.37763961033977e-10
and O 0 2.929812503715823e-10
DMPK O 0 2.814271056195139e-07
[ O 0 8.774999393779126e-09
- O 0 4.413720589013792e-08
/ O 0 9.345021112494578e-08
- O 0 5.833528504695096e-08
] O 0 2.7181151551758376e-08
knockout O 0 3.407472468097694e-05
mice O 0 4.283391206172382e-07
. O 0 1.3833759737735818e-07

In O 0 2.689153291157709e-07
vitro O 0 6.692670240227017e-07
- O 0 1.4175289209106268e-07
differentiated O 0 3.6780303247496704e-08
DMPK O 0 1.1485644790809602e-05
[ O 0 1.1586626413873091e-07
- O 0 1.2725978137950733e-07
/ O 0 1.6669903857291501e-07
- O 0 1.8645076593770682e-08
] O 0 3.839828455198813e-09
myotubes O 0 1.5426589783373856e-08
exhibit O 0 9.121104982412476e-10
a O 0 1.0513190318306442e-10
higher O 0 8.399166362416111e-10
resting O 0 1.7406422969656887e-08
[ O 0 1.3575355284345392e-09
Ca2 O 0 2.5371973411125737e-09
+ O 0 2.376813057480831e-08
] O 0 4.9387598011207956e-08
i O 0 1.1954466749841686e-08
than O 0 2.5642260537139805e-10
do O 0 7.07001193700485e-11
wild O 0 6.366521893008681e-11
- O 0 2.595466896959664e-10
type O 0 1.042654740324167e-09
myotubes O 0 4.037939049794659e-08
because O 0 2.1018412010853638e-10
of O 0 5.932850877243823e-10
an O 0 6.558649023186147e-12
altered O 0 2.412665622841814e-10
open O 0 1.7243900751751084e-09
probability O 0 2.230475582010172e-09
of O 0 4.743156090114553e-09
voltage O 0 1.7146852826499526e-07
- O 0 7.938096402426709e-09
dependent O 0 3.6227261190902027e-09
l O 0 7.712555927241738e-09
- O 0 1.129442650515955e-09
type O 0 5.8493210275401e-10
Ca2 O 0 1.7472843172328112e-09
+ O 0 1.1506413599704501e-08
and O 0 3.0001736650575594e-09
Na O 0 1.1585703987293527e-06
+ O 0 1.262396978063407e-07
channels O 0 4.95264544042584e-07
. O 0 1.0433998198777772e-07

The O 0 1.9471495704692643e-07
mutant O 0 5.924324568695738e-07
myotubes O 0 3.1462436709261965e-06
exhibit O 0 2.008965971356247e-08
smaller O 0 2.410127875052126e-09
and O 0 8.312261434717527e-10
slower O 0 1.2173099861456649e-08
Ca2 O 0 4.524751240353453e-09
+ O 0 2.5907647138723178e-09
responses O 0 1.5095281968857677e-10
upon O 0 2.1209916045705768e-09
triggering O 0 9.490854768756662e-10
by O 0 4.408918022336117e-11
acetylcholine O 0 2.099183049608655e-08
or O 0 2.87042922764158e-09
high O 0 5.9563500798276436e-08
external O 0 1.9051684319038031e-07
K O 0 1.445676275579899e-06
+ O 0 8.825448389870871e-07
. O 0 1.6482704268128145e-07

In O 0 4.809139397821127e-08
addition O 0 7.996817430466763e-09
, O 0 2.5212668064433785e-10
we O 0 5.733928609696903e-11
observed O 0 5.1903401715458486e-11
that O 0 8.356393376741933e-13
these O 0 8.561611163949989e-13
Ca2 O 0 2.605307358738429e-10
+ O 0 7.1998162987085834e-09
transients O 0 7.078401154103631e-08
partially O 0 6.564640830930557e-09
result O 0 3.0040717136081696e-10
from O 0 3.618475311051306e-11
an O 0 5.45480327573955e-12
influx O 0 1.19669107956355e-10
of O 0 8.693216146937743e-10
extracellular O 0 4.847419798892361e-09
Ca2 O 0 5.1279975821216794e-09
+ O 0 5.666084046396236e-09
through O 0 4.206860693134473e-10
the O 0 1.4505401324527156e-09
l O 0 1.7261646334532088e-08
- O 0 2.323808701021335e-09
type O 0 1.2300529483866285e-09
Ca2 O 0 8.736003920262192e-09
+ O 0 9.970632675049274e-08
channel O 0 9.226691304320411e-07
. O 0 1.3067597137705889e-07

Neither O 0 3.091203780059004e-06
the O 0 1.0157862107007531e-08
content O 0 7.691622450067825e-09
nor O 0 2.2030353097335365e-09
the O 0 4.9745454283600665e-11
activity O 0 1.337521066124836e-10
of O 0 8.261619166560763e-10
Na O 0 1.007343470860178e-07
+ O 0 1.0684321871679003e-08
/ O 0 4.3806092975273714e-08
K O 0 3.0690504360109117e-08
+ O 0 2.1285710971596927e-08
ATPase O 0 1.4955394078697282e-07
and O 0 5.87692383646754e-09
sarcoplasmic O 0 1.89747481726954e-07
reticulum O 0 1.340719393283507e-07
Ca2 O 0 6.998270407621021e-08
+ O 0 3.772527747969434e-07
- O 0 1.1899646779056638e-07
ATPase O 0 7.152760161943661e-08
are O 0 9.829640573721932e-11
affected O 0 1.0249008586260544e-10
by O 0 1.2211318067834043e-10
DMPK O 0 8.8415899881511e-06
absence O 0 1.5652028650947614e-06
. O 0 1.9909955994990014e-07

In O 0 2.5423366878385423e-07
conclusion O 0 1.4539291726123338e-07
, O 0 2.7952746783910243e-09
our O 0 3.276768856252943e-10
data O 0 5.430724203669968e-10
suggest O 0 5.817111237149675e-10
that O 0 2.3840466059632526e-11
DMPK O 0 2.500952689388214e-07
is O 0 1.4558333705227966e-10
involved O 0 3.6657496482739305e-10
in O 0 6.315448164428972e-11
modulating O 0 1.7134242469296623e-08
the O 0 6.442530398054203e-10
initial O 0 2.2459453741241475e-10
events O 0 1.17716322800554e-10
of O 0 1.5856370660927155e-09
excitation O 0 3.8283059211607906e-07
- O 0 6.425429432965757e-07
contraction O 0 6.201590707632931e-08
coupling O 0 1.435669787497318e-07
in O 0 1.6138400837917288e-08
skeletal O 0 0.00012816341768484563
muscle O 0 3.25506857734581e-06
. O 0 9.112227417062968e-08
. O 0 2.5624913746469247e-07

Constitutional O 0 0.00017359097546432167
RB1 O 0 0.0004887559334747493
- O 0 2.384984099990106e-06
gene O 0 9.991360627736867e-09
mutations O 0 2.648089925116892e-08
in O 0 1.7754364645128362e-09
patients O 0 2.4425177436171452e-09
with O 0 6.118027751078614e-10
isolated O 0 1.248640046469518e-06
unilateral B-Disease 0 8.120882739603985e-06
retinoblastoma I-Disease 1 0.9990277290344238
. O 0 1.163134311354952e-05

In O 0 4.413451293316939e-08
most O 0 3.1438551761908684e-09
patients O 0 1.0107993331232024e-09
with O 0 1.190162829400876e-10
isolated O 0 6.364928140101256e-08
unilateral B-Disease 0 7.399884793812816e-07
retinoblastoma I-Disease 1 0.6542280316352844
, O 0 1.0959913865349336e-08
tumor B-Disease 0 7.196482698645923e-08
development O 0 8.226149539325434e-09
is O 0 1.0991345333888347e-10
initiated O 0 2.9394511824598624e-10
by O 0 1.5147508247714825e-11
somatic O 0 5.218218301905608e-09
inactivation O 0 1.3280092048262304e-07
of O 0 7.967007498166367e-09
both O 0 7.867354545609828e-10
alleles O 0 8.387016081634613e-10
of O 0 1.0886639145724075e-08
the O 0 2.5318133367591145e-08
RB1 O 0 1.4282723896030802e-05
gene O 0 6.883900027787604e-07
. O 0 8.006906568880368e-07

However O 0 1.7908753591200366e-07
, O 0 1.9342960566604006e-09
some O 0 3.823621974596847e-11
of O 0 1.970291152453285e-10
these O 0 9.330862471568224e-12
patients O 0 9.180285698295876e-11
can O 0 1.461046422734924e-10
transmit O 0 2.357934789642968e-07
retinoblastoma B-Disease 0 0.00022372821695171297
predisposition O 0 2.022082526309532e-06
to O 0 8.853931809937876e-09
their O 0 9.299730763245861e-09
offspring O 0 8.995113631726781e-08
. O 0 8.017178032559968e-08

To O 0 3.7030190469522495e-08
determine O 0 4.96827574636427e-08
the O 0 2.099618479078913e-09
frequency O 0 1.7817676223330636e-08
and O 0 1.2298763396589862e-10
nature O 0 5.600357955160007e-10
of O 0 5.066145281062973e-10
constitutional O 0 1.0662522953452935e-07
RB1 O 0 1.4025719110577484e-06
- O 0 5.89707092046865e-08
gene O 0 1.149316086745955e-09
mutations O 0 8.452022415283977e-10
in O 0 3.5461825143023873e-10
patients O 0 8.844711629762969e-10
with O 0 2.447240465830447e-10
isolated O 0 3.710676210744168e-08
unilateral B-Disease 0 1.938352909292007e-07
retinoblastoma I-Disease 0 0.0003756211663130671
, O 0 3.1475870798658434e-09
we O 0 2.0212091722537906e-10
analyzed O 0 6.857854839559252e-10
DNA O 0 1.1426145585247127e-09
from O 0 2.752618966095355e-10
peripheral O 0 5.159611404792486e-08
blood O 0 1.1032144087153029e-08
and O 0 1.6611186870463257e-09
from O 0 7.953267378013607e-09
tumor B-Disease 0 1.5813392337804544e-06
tissue O 0 1.6582932858000277e-06
. O 0 6.25206610038731e-07

The O 0 2.283388234047834e-08
analysis O 0 1.2338412958001754e-08
of O 0 1.0691583440802788e-07
tumors B-Disease 1 0.9999994039535522
from O 0 8.358948377917841e-08
54 O 0 8.175910437557832e-08
( O 0 2.9743499330159295e-10
71 O 0 3.893339872718116e-09
% O 0 1.5307780043549712e-10
) O 0 3.984052671102134e-11
of O 0 2.5865778408018514e-09
76 O 0 2.1099172897720564e-07
informative O 0 1.8584469074767185e-08
patients O 0 8.163020481788408e-09
showed O 0 7.699973991748266e-09
loss O 0 1.6713210371221976e-08
of O 0 5.8528758728471075e-08
constitutional O 0 8.201435775845312e-06
heterozygosity O 0 0.0014592715306207538
( O 0 8.892173468666442e-07
LOH O 1 0.981340229511261
) O 0 1.6107556177757942e-08
at O 0 1.2174119774499559e-06
intragenic O 0 9.511795724392869e-06
loci O 0 2.0755044261022704e-06
. O 0 1.5078800288392813e-06

Three O 0 4.936895336982161e-08
of O 0 9.584604043766376e-08
13 O 0 2.605236204544781e-07
uninformative O 0 5.1758568588411435e-05
patients O 0 7.297759907487489e-07
had O 0 9.446129212165033e-08
constitutional O 0 2.569071057223482e-06
deletions O 0 1.7850113636086462e-06
. O 0 6.88956163230614e-07

For O 0 1.788774284250394e-07
39 O 0 3.099538048445538e-07
randomly O 0 7.4429706842238375e-09
selected O 0 3.787530644672188e-08
tumors B-Disease 1 0.9999996423721313
, O 0 2.6818712584031346e-08
SSCP O 0 2.2410997189581394e-05
, O 0 1.7809114183364727e-08
hetero O 0 1.934531383085414e-06
- O 0 1.552633577261986e-08
duplex O 0 7.120119960291049e-08
analysis O 0 3.444349250258938e-10
, O 0 1.845733982319686e-11
sequencing O 0 1.6491090437664724e-10
, O 0 4.943238526844418e-11
and O 0 7.236264365495515e-11
Southern O 0 1.8198674789360325e-09
blot O 0 1.1137475830480525e-08
analysis O 0 5.846733652781211e-10
were O 0 1.4632942080261557e-10
used O 0 6.334629348847542e-11
to O 0 1.0505232794777442e-10
identify O 0 1.084477485591151e-08
mutations O 0 3.444859260071098e-07
. O 0 6.797286005166825e-07

Mutations O 0 5.962669291648126e-08
were O 0 6.024547083427478e-09
detected O 0 2.0828588631616185e-08
in O 0 6.064191371280003e-10
21 O 0 8.294021469623658e-09
( O 0 5.6712568669015084e-11
91 O 0 4.657513930084178e-09
% O 0 3.9983283350863985e-10
) O 0 2.1897124391490053e-10
of O 0 5.787435597426338e-08
23 O 0 0.018595675006508827
tumors B-Disease 1 1.0
with O 0 0.012570463120937347
LOH O 1 1.0
. O 0 8.559239358874038e-05

In O 0 2.347127576740604e-07
6 O 0 3.879443681853445e-07
( O 0 9.697465053193355e-10
38 O 0 8.541532814376751e-09
% O 0 1.1244359610085297e-10
) O 0 8.379721222473435e-11
of O 0 3.016936744870691e-08
16 O 0 8.507240636390634e-06
tumors B-Disease 1 1.0
without O 0 0.001785410800948739
LOH O 1 0.9999868869781494
, O 0 6.626762250050433e-09
one O 0 1.7391704743019432e-10
mutation O 0 3.900159015191029e-11
was O 0 1.8268229151630067e-09
detected O 0 1.6020927917637096e-09
, O 0 3.032618947629295e-11
and O 0 3.939319703771815e-11
in O 0 2.2853116621313063e-10
9 O 0 1.0980879316946357e-08
( O 0 7.777161553645939e-11
56 O 0 2.4802861986472635e-09
% O 0 2.1232085534172995e-10
) O 0 1.418692802124255e-10
of O 0 9.808899470442611e-09
the O 0 1.4798381187119958e-07
tumors B-Disease 1 1.0
without O 0 0.0029135020449757576
LOH O 1 0.9999996423721313
, O 0 5.1788342503300555e-09
both O 0 1.0820822016199827e-09
mutations O 0 1.7327280721346483e-09
were O 0 4.445672274755452e-09
found O 0 1.0961418439592308e-08
. O 0 4.457570312865755e-08

Thus O 0 3.817281140072737e-07
, O 0 2.259618936406582e-09
a O 0 5.119375479090138e-10
total O 0 2.6337815262067465e-10
of O 0 3.395449477139323e-09
45 O 0 1.6473179487164202e-09
mutations O 0 2.1436723229850685e-10
were O 0 1.2344850142120833e-10
identified O 0 8.091508574281647e-10
in O 0 4.12591960596842e-09
tumors B-Disease 1 1.0
of O 0 0.0006227971171028912
36 O 0 0.00013894886069465429
patients O 0 8.21274625195656e-06
. O 0 1.5954268519635662e-06

Thirty O 0 8.739891200093552e-06
- O 0 2.1895439772379177e-07
nine O 0 5.734350327912807e-09
of O 0 9.482893359447075e-10
the O 0 1.4279474824796523e-10
mutations O 0 2.718522074118823e-10
- O 0 8.264235407118292e-10
including O 0 1.0560882723886778e-10
34 O 0 1.1877691719064387e-08
small O 0 1.109447311797851e-09
mutations O 0 3.5174134715987293e-09
, O 0 4.373652551237228e-09
2 O 0 9.288583413535889e-08
large O 0 1.6463443941461264e-09
structural O 0 1.6035846783779562e-06
alterations O 0 1.5779030491103185e-06
, O 0 4.778133000371554e-09
and O 0 2.729220627273321e-09
hypermethylation O 0 0.0027120443992316723
in O 0 7.07569370206329e-07
3 O 0 0.0008951433701440692
tumors O 1 1.0
- O 0 1.0195730055784225e-06
were O 0 3.2074034539419927e-09
not O 0 8.263348338921617e-11
detected O 0 1.495346846347445e-09
in O 0 3.3261348536539614e-11
the O 0 1.1982442815750005e-10
corresponding O 0 3.6863652130847413e-09
peripheral O 0 1.0619024806146626e-06
blood O 0 8.220789027291175e-08
DNA O 0 2.6254565455019474e-07
. O 0 1.3447555602397188e-07

In O 0 3.7408213415801583e-07
6 O 0 1.095613015422714e-06
( O 0 2.3947315241912293e-09
17 O 0 6.154453835449658e-09
% O 0 6.090478121834053e-11
) O 0 2.2687981701685622e-11
of O 0 5.278357195770411e-10
the O 0 1.3153318434433459e-09
36 O 0 2.0662479727207028e-08
patients O 0 1.0631645563918823e-09
, O 0 1.4070590526049642e-10
a O 0 1.512037994810811e-10
mutation O 0 6.315062361927914e-11
was O 0 5.486197718340691e-09
detected O 0 4.10663725247673e-09
in O 0 1.6072186637128283e-10
constitutional O 0 8.964350151074996e-09
DNA O 0 1.7392444151553832e-09
, O 0 2.0496267183478523e-10
and O 0 5.2626319968496205e-11
1 O 0 6.4305512026408e-09
of O 0 8.992155908771338e-10
these O 0 4.780744550236804e-11
mutations O 0 7.483493824622656e-10
is O 0 2.7152780024408685e-10
known O 0 3.586327901317077e-10
to O 0 1.5055803825880787e-10
be O 0 5.041891903978524e-10
associated O 0 5.69539304606792e-09
with O 0 1.3519282360263674e-09
reduced O 0 4.4744919591721555e-07
expressivity O 0 6.447417399613187e-05
. O 0 6.987646088418842e-07

The O 0 8.318772160009757e-08
presence O 0 4.36990248431357e-08
of O 0 3.142873339356811e-08
a O 0 1.5019555599238288e-09
constitutional O 0 9.088239494303707e-08
mutation O 0 9.443705817346881e-10
was O 0 7.037299631917904e-09
not O 0 4.892306004755653e-11
associated O 0 3.518955127290724e-10
with O 0 8.526691505639228e-12
an O 0 3.586449193182517e-11
early O 0 6.299573751533671e-09
age O 0 4.83360125258514e-08
at O 0 2.6919090601040807e-07
treatment O 0 5.46652017874294e-07
. O 0 1.2897200463157787e-07

In O 0 1.617399902897887e-07
1 O 0 9.022845119943668e-07
patient O 0 6.741978353375089e-08
, O 0 2.1686572537760185e-09
somatic O 0 2.8014122221975413e-07
mosaicism O 0 6.645611574640498e-05
was O 0 9.944233880787579e-08
demonstrated O 0 1.6491823462416733e-09
by O 0 8.633077759612195e-12
molecular O 0 5.373682609999264e-10
analysis O 0 9.455922850287735e-11
of O 0 2.4229171446954467e-10
DNA O 0 9.00903129874564e-10
and O 0 2.6423252474927494e-10
RNA O 0 1.6508542088899958e-08
from O 0 1.2572698437907093e-08
peripheral O 0 4.379216534289299e-06
blood O 0 2.0888919607386924e-06
. O 0 8.808101483737119e-07

In O 0 6.324544870039972e-07
2 O 0 2.005160467888345e-06
patients O 0 6.065744351246849e-09
without O 0 6.400226459923886e-10
a O 0 2.1178130082954993e-10
detectable O 0 3.252742430959188e-08
mutation O 0 1.004844096819113e-09
in O 0 6.114516670763237e-10
peripheral O 0 9.520794606032723e-07
blood O 0 4.879983634964447e-07
, O 0 1.4157828687189067e-08
mosaicism O 0 2.9575814551208168e-05
was O 0 4.2021216017928964e-07
suggested O 0 8.7047018482167e-09
because O 0 3.184724983729126e-10
1 O 0 7.458517359282268e-09
of O 0 7.182721639686918e-10
the O 0 1.189335074869291e-09
patients O 0 1.4655245905714764e-08
showed O 0 1.0126100278284866e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 1.2218407619002392e-07
the O 0 1.468176957786227e-08
other O 0 5.56821255770501e-10
later O 0 1.4052047525581202e-08
developed O 0 5.49082699308201e-08
bilateral B-Disease 0 0.0004708688356913626
retinoblastoma I-Disease 0 0.0021589994430541992
. O 0 5.591631406787201e-07

In O 0 1.731662564452563e-07
conclusion O 0 2.0677231304944144e-07
, O 0 3.3168257029814185e-09
our O 0 5.047703366400924e-10
results O 0 8.430797032721316e-11
emphasize O 0 8.261004658116633e-10
that O 0 4.700164736581858e-12
the O 0 5.1513533022573554e-11
manifestation O 0 6.179484923762857e-09
and O 0 1.2496546020202004e-09
transmissibility O 0 1.7693087102088612e-06
of O 0 5.3126228749533766e-08
retinoblastoma B-Disease 0 5.70441841318825e-07
depend O 0 3.186980679359408e-09
on O 0 5.706266570371099e-09
the O 0 4.2777736908305997e-10
nature O 0 1.4110320689653122e-09
of O 0 5.161988059221301e-10
the O 0 1.080786293794489e-10
first O 0 5.344691009212532e-11
mutation O 0 8.050306081475167e-12
, O 0 1.721772203977512e-11
its O 0 1.0053492760508931e-11
time O 0 1.439229291300137e-10
in O 0 2.989021183341656e-11
development O 0 9.191919447815167e-11
, O 0 2.2971275923100443e-11
and O 0 6.076759321432812e-12
the O 0 1.9587156549483176e-11
number O 0 1.3248986109604122e-11
and O 0 1.8959916969762958e-11
types O 0 8.730203782114643e-10
of O 0 2.0511071952000748e-08
cells O 0 6.719288458967299e-10
that O 0 3.474806553604992e-11
are O 0 3.911928506822315e-12
affected O 0 7.622927289396841e-11
. O 0 1.7756252024270225e-10
. O 0 5.700848682010928e-09

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9968966245651245
the I-Disease 0 2.1743799152318388e-05
fifth I-Disease 0 5.36763127456652e-06
component I-Disease 0 1.7178440430143382e-06
of I-Disease 0 4.040875580813008e-07
complement I-Disease 0 1.6594798069036187e-07
in O 0 1.4319327590328612e-07
man O 0 3.3217957025044598e-06
. O 0 3.278370002135489e-07

I O 0 0.003862499026581645
. O 0 1.563959631312173e-05

Clinical O 0 6.253342871787027e-05
, O 0 5.854394302673427e-08
immunochemical O 0 1.3170470083423425e-05
, O 0 2.172603785766114e-08
and O 0 5.773816535992182e-09
family O 0 6.504653260464011e-09
studies O 0 1.9621662517010918e-08
. O 0 5.414078785292986e-08

The O 0 7.047578520769093e-08
first O 0 1.0674993333736893e-08
recognized O 0 1.3646624275054364e-08
human O 0 5.452567819475007e-08
kindred O 0 7.225761692097876e-06
with O 0 3.6873867514941594e-08
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999914169311523
the I-Disease 0 3.421904693823308e-05
fifth I-Disease 0 1.4596045048165252e-06
component I-Disease 0 3.3877796568049234e-07
of I-Disease 0 5.436558581095596e-07
complement I-Disease 0 9.177257993542298e-07
( O 0 1.5990688950751064e-07
C5 O 0 5.395990956458263e-05
) O 0 3.9615364322287405e-09
is O 0 2.625431871905448e-09
described O 0 5.113486523100619e-08
. O 0 9.844514181622799e-08

The O 0 4.967707809555577e-07
proband O 0 1.6554693502257578e-05
, O 0 1.1735462379647288e-08
a O 0 9.979342685539905e-09
20 O 0 1.496728785355117e-08
- O 0 3.6288396731976036e-09
year O 0 3.9677652829972487e-10
- O 0 2.831567158523285e-08
old O 0 7.171639992975543e-08
black O 0 7.884976005456679e-10
female O 0 2.685242916911079e-09
with O 0 7.744650787344654e-08
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9998430013656616
age O 1 0.7241440415382385
11 O 0 7.024896717666707e-07
, O 0 2.9400639700583042e-09
lacked O 0 2.1198222555085522e-07
serum O 0 1.4650949253791623e-07
hemolytic O 0 6.015346571075497e-06
complement O 0 1.4843298856703768e-07
activity O 0 2.663311704509397e-07
, O 0 2.9341984397746046e-09
even O 0 1.1375631547849707e-09
during O 0 1.8816416869071872e-08
remission O 0 1.1328405946642306e-07
. O 0 4.334217251766859e-08

C5 O 0 0.0028906443621963263
was O 0 3.3100982363976073e-06
undetectable O 0 9.05608703760663e-06
in O 0 3.5957683497400694e-09
her O 0 5.349038434410147e-10
serum O 0 4.347542881255606e-10
by O 0 1.3260312119178774e-11
both O 0 3.85671578007063e-10
immunodiffusion O 0 4.211264581499563e-07
and O 0 1.3368183893192054e-08
hemolytic O 0 0.0006808809121139348
assays O 0 1.8141485043088323e-06
. O 0 1.2582482895595604e-06

Other O 0 1.3790720565509673e-08
complement O 0 2.1159861418595938e-08
components O 0 1.4489377520021662e-07
were O 0 1.4922612034951044e-09
normal O 0 1.2031692975256192e-08
during O 0 1.99907268516597e-09
remission O 0 1.6626600540803338e-08
of O 0 6.275121311460907e-09
lupus O 0 1.2203466326354828e-07
, O 0 3.632946388165692e-09
but O 0 5.00111196899411e-09
C1 O 0 2.1378666133387014e-05
, O 0 8.200696299809351e-08
C4 O 0 0.0009953256230801344
, O 0 2.7296490401340634e-08
C2 O 0 2.212719437011401e-06
, O 0 1.0803648642365715e-08
and O 0 1.0665203831194958e-08
C3 O 0 0.00023837618937250227
levels O 0 6.989491794229252e-06
fell O 0 0.0005038348026573658
during O 0 6.281099445004656e-07
exacerbations O 0 5.106435128254816e-05
. O 0 5.539140488508565e-07

A O 0 3.845551691483706e-05
younger O 0 2.5486849608569173e-06
half O 0 5.708935759685119e-07
- O 0 2.863120869278646e-07
sister O 0 9.598398520438423e-08
, O 0 8.271492824007964e-09
who O 0 4.427783029115062e-09
had O 0 1.3562732270600009e-08
no O 0 1.5413592180379965e-08
underlying O 1 0.5530229806900024
disease O 1 0.6264150142669678
, O 0 1.4685795912683375e-09
was O 0 4.9792806322557226e-08
also O 0 3.2968108798492324e-10
found O 0 2.0845739023833687e-10
to O 0 1.6112579326321708e-10
lack O 0 1.136533924750438e-07
immunochemically O 0 2.3124275685404427e-05
detectable O 0 0.0038052788004279137
C5 O 0 0.007073939777910709
. O 0 1.8134962829208234e-06

By O 0 4.461415059608953e-08
hemolytic O 0 0.0001236834068549797
assay O 0 9.117232480093662e-07
, O 0 1.4386818847356153e-08
she O 0 2.7259638990528856e-09
exhibited O 0 1.6305074623801374e-08
1 O 0 1.0583280385390026e-07
- O 0 3.5097267314654346e-09
2 O 0 4.145751297812694e-09
% O 0 5.268446789941095e-11
of O 0 4.669805098167501e-10
the O 0 3.7138020436700003e-10
normal O 0 3.352777255827277e-08
serum O 0 1.1698141122451489e-08
C5 O 0 1.0477393175278849e-07
level O 0 8.652097704953121e-09
and O 0 6.241715477806054e-11
normal O 0 1.3599197323799217e-09
concentrations O 0 1.4703621653566756e-09
of O 0 2.9320709749036666e-10
other O 0 6.07759745308023e-11
complement O 0 3.0020625985116567e-09
components O 0 4.6484510107802635e-07
. O 0 1.501428528172255e-07

C5 O 0 0.0001844383223215118
levels O 0 8.29059160878387e-07
of O 0 1.1621541773365607e-07
other O 0 2.679455268772557e-10
family O 0 2.1956637896725084e-10
members O 0 1.7663082801933072e-11
were O 0 1.1223404844384888e-10
either O 0 4.08704514676117e-10
normal O 0 2.6364983085613858e-08
or O 0 7.942363433599553e-10
approximately O 0 2.0374581188864482e-10
half O 0 8.455053324141204e-10
- O 0 1.0421771778901245e-10
normal O 0 6.652137174434358e-10
, O 0 4.8515653300329475e-12
consistent O 0 3.882212953887354e-11
with O 0 1.6804221208976955e-11
autosomal O 0 2.803760956737733e-08
codominant O 0 7.201988694305328e-08
inheritance O 0 8.295730324903161e-09
of O 0 3.409174276214344e-09
the O 0 8.81120454376827e-10
gene O 0 3.545530091741966e-08
determining O 0 0.0036768838763237
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 3.4640826925169677e-05

Normal O 0 5.5092743423301727e-05
hemolytic O 0 0.0007859403849579394
titers O 0 1.3843680790159851e-05
were O 0 1.5600161162865334e-08
restored O 0 4.5726007869006935e-08
to O 0 4.80993300744359e-10
both O 0 4.632901173806658e-09
homozygous O 0 1.0181544212173321e-06
C5 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 1.0
( O 0 8.85979625309119e-06
C5D B-Disease 1 1.0
) O 0 3.0900768610564455e-09
sera O 0 2.7599504903719208e-08
by O 0 9.519253441059305e-12
addition O 0 1.6578860506655246e-10
of O 0 1.9806576379011176e-09
highly O 0 8.176534294079829e-08
purified O 0 1.4150599270124076e-07
human O 0 3.8484350284306856e-07
C5 O 0 0.00037451452226378024
. O 0 4.655082932458754e-07

In O 0 7.201342810958522e-08
specific O 0 8.218844982366136e-08
C5 O 0 3.458385617705062e-05
titrations O 0 3.092884753641556e-06
, O 0 9.942029421949883e-09
however O 0 1.4930896519160797e-09
, O 0 1.409573430199984e-10
it O 0 1.1109835273970248e-11
was O 0 1.0351210999459681e-09
noted O 0 2.428010570376671e-10
that O 0 3.768959536826211e-12
when O 0 9.665213941689732e-12
limited O 0 1.3509578004888834e-11
amounts O 0 2.563580736580917e-10
of O 0 4.319837820787598e-09
C5 O 0 1.9128768258269702e-07
were O 0 1.2949098460168784e-09
assayed O 0 2.262634701821753e-08
in O 0 1.447491015937885e-10
the O 0 9.335691941725344e-11
presence O 0 6.799319440808915e-11
of O 0 9.37520283628146e-10
low O 0 2.2947663325112444e-08
dilutions O 0 3.645387209871842e-07
of O 0 1.4343473075939528e-08
either O 0 4.743873205370619e-08
C5D B-Disease 1 0.9999988079071045
serum O 0 1.4012667293172854e-07
, O 0 1.4300032269431995e-09
curving O 0 7.3004442491253485e-09
rather O 0 9.774567821807523e-10
than O 0 9.473000162074641e-11
linear O 0 5.434291239225786e-09
dose O 0 4.032782641161248e-08
- O 0 5.458035134964234e-10
response O 0 4.9880367197774333e-11
plots O 0 2.0167958969530275e-10
were O 0 3.933066025640919e-11
consistently O 0 6.51367224047128e-11
obtained O 0 3.1556032092927566e-11
, O 0 8.202682456881494e-12
suggesting O 0 2.7863504906133763e-11
some O 0 4.757427958523852e-12
inhibitory O 0 8.608082247008042e-09
effect O 0 2.957256413083087e-07
. O 0 1.7308816779859626e-07

Further O 0 5.009362880059598e-08
studies O 0 4.511198525847249e-08
suggested O 0 5.908010969335464e-09
that O 0 1.146692185649556e-10
low O 0 3.974942686113536e-08
dilutions O 0 2.330664983674069e-06
of O 0 1.5667619379655662e-07
C5D B-Disease 1 0.9999991655349731
serum O 0 3.472029419526734e-08
contain O 0 6.00442306986082e-10
a O 0 1.7476566027685436e-10
factor O 0 5.036336347963299e-10
( O 0 4.3705379593195204e-11
or O 0 7.131444740293702e-11
factors O 0 1.6529233537454502e-09
) O 0 2.6960342291992845e-10
interfering O 0 3.2274229511131125e-08
at O 0 4.724946478518177e-08
some O 0 6.512454464591144e-11
step O 0 4.125951136302319e-09
in O 0 2.9500443754493233e-10
the O 0 1.546585526313038e-09
hemolytic O 0 2.508666511857882e-06
assay O 0 5.957406301604351e-07
of O 0 2.3331076590693556e-05
C5 O 0 0.013998952694237232
, O 0 6.9034373773035895e-09
rather O 0 1.3171822521584886e-09
than O 0 2.4712940027704633e-10
a O 0 1.8243262456252296e-09
true O 0 3.9280411812114835e-08
C5 O 0 2.5702676794026047e-05
inhibitor O 0 1.06092261376034e-06
or O 0 2.000874133045727e-08
inactivator O 0 5.019701802666532e-06
. O 0 2.4024194544836064e-07

Of O 0 8.417454750997422e-07
clinical O 0 3.691965503094252e-06
interest O 0 1.0097596714331303e-07
are O 0 4.858478619418349e-10
( O 0 8.831659709107598e-11
a O 0 6.583517758729229e-11
) O 0 3.7169165315042996e-12
the O 0 1.814351446860485e-11
documentation O 0 9.422984170726068e-09
of O 0 5.701199867758078e-08
membranous O 1 0.9989700317382812
glomerulonephritis B-Disease 1 1.0
, O 0 3.649677091743797e-05
vasculitis B-Disease 1 1.0
, O 0 2.3603421084317233e-07
and O 0 2.941047796412022e-07
arthritis B-Disease 1 1.0
in O 0 6.406791044355487e-07
an O 0 2.5017474758470826e-09
individual O 0 3.677993465345253e-09
lacking O 0 0.014032137580215931
C5 O 0 0.0009726565331220627
( O 0 2.0106276366060882e-10
and O 0 6.15152243380046e-12
its O 0 4.032043796065032e-12
biologic O 0 3.0022000441221053e-09
functions O 0 5.660885094016521e-10
) O 0 1.0552139023678464e-11
, O 0 1.3532400894300523e-11
and O 0 4.784429796789169e-11
( O 0 9.486813418169149e-11
b O 0 4.421993438086247e-09
) O 0 3.9978916011040866e-11
a O 0 4.08228506554309e-10
remarkable O 0 1.1753465978259214e-09
propensity O 0 1.711177155527821e-08
to O 0 2.8372044713620426e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 5.403697045380795e-09
the O 0 1.804551619244421e-09
proband O 0 5.611087772194878e-08
, O 0 8.229814052462814e-11
even O 0 1.726507825594581e-11
during O 0 8.071989604507834e-11
periods O 0 9.78359504522075e-10
of O 0 3.345823340605847e-10
low O 0 5.110812217878902e-09
- O 0 6.080754233472874e-10
dose O 0 1.4662229208539657e-09
or O 0 9.705528741799085e-11
alternate O 0 9.187506866403794e-10
- O 0 7.058149176231154e-09
day O 0 3.0700555431195653e-09
corticosteroid O 0 1.957368795046932e-06
therapy O 0 1.0019452929554973e-05
. O 0 8.471074863791728e-08

Other O 0 3.652478852700369e-08
observations O 0 8.264683515335491e-08
indicate O 0 4.025756172865158e-09
that O 0 9.981807741477056e-11
the O 0 2.7013578041135133e-09
C5D B-Disease 1 0.9999911785125732
state O 0 1.7724454126621936e-09
is O 0 3.041597876340951e-11
compatible O 0 1.1852678838408792e-09
with O 0 8.160942061019583e-11
normal O 0 2.515773900313434e-08
coagulation O 0 2.1308379061224514e-08
function O 0 3.187401986792793e-08
and O 0 6.731217805366896e-10
the O 0 8.810851492846439e-10
capacity O 0 2.8355813253000406e-09
to O 0 5.349589105030361e-10
mount O 0 2.234260421118961e-07
a O 0 3.148861793533797e-08
neutrophilic O 0 0.00037995478487573564
leukocytosis O 0 0.00070545932976529
during O 0 1.8155978978029452e-05
pyogenic B-Disease 0 0.0009345368016511202
infection I-Disease 0 2.73515570370364e-06
. O 0 5.832078819878461e-09
. O 0 5.2945559048112045e-08

Susceptibility O 0 0.00016822842007968575
to O 0 6.7248597588331904e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9296818971633911
twins O 0 5.905010311835213e-06
: O 0 2.1808135852730004e-10
the O 0 9.230483738464912e-11
role O 0 2.2415898026650893e-09
of O 0 1.373706126628349e-08
genes O 0 2.5414690352221214e-09
, O 0 2.1014654461026794e-09
HLA O 0 9.205213302720949e-08
, O 0 2.270882815125219e-09
and O 0 3.691696670582445e-10
the O 0 3.3385960662712932e-09
environment O 0 2.4852747060322145e-07
. O 0 1.4006629101004364e-07

OBJECTIVE O 0 1.9486933524603955e-05
To O 0 1.2035985541558603e-08
determine O 0 1.200459820438482e-08
the O 0 4.0875519635719115e-10
relative O 0 1.5235819716963306e-08
effects O 0 4.6034747924750263e-07
of O 0 8.57743387427945e-09
genetic O 0 3.811138515885659e-09
and O 0 6.088991116870446e-11
environmental O 0 6.832082677377116e-10
factors O 0 6.659728879476745e-10
in O 0 2.353250094788706e-10
susceptibility O 0 5.007290155845112e-07
to O 0 6.309917921498709e-07
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9834372997283936
AS B-Disease 1 1.0
) O 0 2.678875254957802e-08
. O 0 6.800691210173682e-08

METHODS O 0 3.969415774918161e-05
Twins O 0 3.859700825614709e-07
with O 0 2.4104314100270585e-09
AS B-Disease 1 0.9999579191207886
were O 0 1.5343040171700295e-09
identified O 0 2.316320191209087e-10
from O 0 3.333413406414465e-11
the O 0 5.053133605992244e-11
Royal O 0 4.95176699644162e-08
National O 0 1.644825964319807e-08
Hospital O 0 1.3453870906232623e-06
for O 0 1.359349965923684e-08
Rheumatic B-Disease 1 0.9999997615814209
Diseases I-Disease 1 0.9999964237213135
database O 0 3.1709437280369457e-06
. O 0 5.455352038552519e-06

Clinical O 0 7.743860805931035e-06
and O 0 1.270998772895382e-08
radiographic O 0 2.2716565126756905e-06
examinations O 0 6.86245357428561e-07
were O 0 2.549567446052947e-09
performed O 0 1.7044401445787116e-09
to O 0 5.923756624115484e-11
establish O 0 4.319706370381482e-09
diagnoses O 0 3.0273389484136715e-07
, O 0 9.07222907908789e-10
and O 0 5.005444503325407e-09
disease O 0 7.546514825662598e-05
severity O 0 7.717937478446402e-06
was O 0 5.312075757046841e-08
assessed O 0 3.825398220413945e-09
using O 0 4.996037472615455e-10
a O 0 2.2987678427455194e-10
combination O 0 1.4665474390440636e-09
of O 0 6.212954151152417e-09
validated O 0 3.169542139858095e-08
scoring O 0 1.2292389328649733e-07
systems O 0 9.340616088593379e-06
. O 0 9.349217293674883e-07

HLA O 0 8.9814830062096e-06
typing O 0 5.894523269489582e-07
for O 0 4.4070077365176985e-08
HLA O 0 1.7529233673485578e-06
- O 0 5.015864417146076e-07
B27 O 0 1.9665654349410033e-07
, O 0 1.5114794971182732e-09
HLA O 0 3.834582429362854e-08
- O 0 3.617245880604969e-08
B60 O 0 3.1346718998293e-08
, O 0 3.034970053050756e-10
and O 0 3.6639810629957026e-10
HLA O 0 5.250598746897595e-07
- O 0 1.8360829017183278e-06
DR1 O 0 0.0007020843913778663
was O 0 4.3998937826472684e-08
performed O 0 2.4821698030308426e-09
by O 0 7.528500739484301e-11
polymerase O 0 2.6336033798202152e-08
chain O 0 2.8916515848464996e-09
reaction O 0 1.3303715074020062e-10
with O 0 2.93177322696625e-11
sequence O 0 6.051827372566265e-10
- O 0 1.8549922708999134e-10
specific O 0 1.5960642529844193e-11
primers O 0 9.441167847512588e-10
, O 0 3.602918310918746e-11
and O 0 2.152451480941231e-11
zygosity O 0 1.958614070929343e-08
was O 0 6.873756230874051e-09
assessed O 0 8.04528355047296e-09
using O 0 2.9139750612472426e-09
microsatellite O 0 1.7310351552168868e-07
markers O 0 2.1927097293428233e-07
. O 0 2.1989961851431872e-07

Genetic O 0 6.265830734264455e-07
and O 0 2.4091997286035394e-09
environmental O 0 1.0744055423117516e-08
variance O 0 3.1071925032932768e-09
components O 0 5.7762207461564685e-08
were O 0 8.934814554883985e-10
assessed O 0 2.9220343922276015e-09
with O 0 4.2189036986162165e-11
the O 0 2.3827204098658683e-10
program O 0 1.817164474449129e-10
Mx O 0 2.6755653248500266e-09
, O 0 8.695064633579275e-12
using O 0 5.430977716158747e-12
data O 0 3.385861382931843e-11
from O 0 2.255926175032119e-11
this O 0 1.7491289449819702e-12
and O 0 3.843390883329079e-12
previous O 0 1.3895687378528976e-10
studies O 0 7.437772620022542e-10
of O 0 5.925729240630062e-09
twins O 0 1.9444547305624837e-08
with O 0 5.028141902840844e-09
AS B-Disease 1 0.999997615814209
. O 0 1.0791826525746728e-06

RESULTS O 0 5.180951916372578e-07
Six O 0 1.227293324745915e-07
of O 0 1.312959341248643e-07
8 O 0 4.3211591105318803e-07
monozygotic O 0 4.4718510139318823e-07
( O 0 6.5084506672974385e-09
MZ O 0 2.9629434266098542e-06
) O 0 3.004250626048588e-09
twin O 0 7.085965592068533e-08
pairs O 0 8.460526501608001e-09
were O 0 3.2936888771928352e-09
disease O 0 4.4699408618953385e-08
concordant O 0 2.823563782783367e-08
, O 0 5.831152782853621e-10
compared O 0 7.487562792007907e-10
with O 0 1.7094531346018016e-10
4 O 0 2.4782920604593528e-08
of O 0 9.643831511141343e-09
15 O 0 7.572735327698865e-09
B27 O 0 1.4739625520121535e-08
- O 0 1.3899776885040183e-09
positive O 0 3.606108120446372e-11
dizygotic O 0 2.204600058064443e-08
( O 0 6.400861507493971e-10
DZ O 0 1.3898848294502386e-07
) O 0 4.649319540472874e-10
twin O 0 5.894503551928665e-09
pairs O 0 5.375651035421924e-10
( O 0 1.8547693936277199e-10
27 O 0 5.0342641166878366e-09
% O 0 7.765273840609765e-11
) O 0 2.671574593493542e-11
and O 0 1.1924532195006776e-10
4 O 0 7.200681384489371e-09
of O 0 1.4838720474585898e-08
32 O 0 2.1537631766932464e-07
DZ O 0 6.767495051462902e-06
twin O 0 1.0934819272279128e-07
pairs O 0 2.0596759853219737e-09
overall O 0 6.597351998038903e-09
( O 0 5.013851001045566e-10
12 O 0 1.4121575020453747e-09
. O 0 8.164398324073119e-11
5 O 0 1.0782583714785687e-09
% O 0 2.193549925033622e-10
) O 0 3.6446390350164393e-10
. O 0 1.49824828099554e-08

Nonsignificant O 0 2.8785601898562163e-05
increases O 0 5.609193465261342e-08
in O 0 7.113109545819896e-10
similarity O 0 8.582436983317621e-10
with O 0 1.0803781480550612e-10
regard O 0 8.059106271218752e-09
to O 0 7.011437541670773e-10
age O 0 1.3757964723026817e-07
at O 0 1.9424585389060667e-06
disease O 0 7.350555279117543e-06
onset O 0 3.2676979344614665e-07
and O 0 3.120542158008277e-10
all O 0 5.880674419644905e-11
of O 0 1.2647468627946523e-09
the O 0 8.242259652568862e-10
disease O 0 1.4900719769173065e-08
severity O 0 2.3603583532150196e-09
scores O 0 1.47134318617681e-10
assessed O 0 3.5120956143330773e-10
were O 0 6.152334891540434e-11
noted O 0 2.1765625413117107e-10
in O 0 2.6713825596047513e-10
disease O 0 3.4977702512151154e-07
- O 0 3.0085362823228934e-07
concordant O 0 4.09914537158329e-06
MZ O 0 0.0003952381666749716
twins O 0 8.581886845604458e-07
compared O 0 8.770033588234583e-08
with O 0 1.784508896207626e-08
concordant O 0 6.289723387453705e-05
DZ O 0 0.0026951569598168135
twins O 0 1.1853511750814505e-05
. O 0 5.361413286664174e-07

HLA O 0 0.00019901833729818463
- O 0 1.1867593457282055e-05
B27 O 0 1.973744019778678e-06
and O 0 3.0741749146301345e-09
B60 O 0 7.486041653237407e-08
were O 0 4.183384194611506e-10
associated O 0 3.9176220600900535e-10
with O 0 1.1980333392003217e-11
the O 0 1.5433204714199178e-09
disease O 0 8.862702429723868e-07
in O 0 1.960145379342748e-09
probands O 0 4.513664464411704e-07
, O 0 1.9019542885079233e-10
and O 0 2.2290103790512106e-11
the O 0 2.412895716563668e-10
rate O 0 5.323818275115855e-09
of O 0 2.0807773282172093e-09
disease O 0 3.457833486208983e-08
concordance O 0 2.8671574003880096e-09
was O 0 2.220703620992026e-09
significantly O 0 2.381057850886492e-10
increased O 0 3.507369117361492e-10
among O 0 3.6302916228692084e-10
DZ O 0 5.519976866708021e-07
twin O 0 4.3966977614218195e-08
pairs O 0 3.271849458030829e-09
in O 0 6.517154593765895e-10
which O 0 7.493931170055035e-11
the O 0 2.2826991408209096e-09
co O 0 1.348883813534485e-07
- O 0 3.172069895640561e-08
twin O 0 3.623301836341852e-08
was O 0 4.187499769159331e-08
positive O 0 4.177690970941228e-10
for O 0 3.843160512051469e-10
both O 0 6.108586525499504e-09
B27 O 0 7.717856078670593e-07
and O 0 1.4956277993860567e-07
DR1 O 0 0.003795970231294632
. O 0 1.3338762983039487e-06

Additive O 0 1.7966557663839922e-07
genetic O 0 1.4838910544767714e-07
effects O 0 1.2637825648198486e-06
were O 0 3.1917803955394675e-09
estimated O 0 1.437703706086424e-10
to O 0 1.4976688292311913e-11
contribute O 0 7.116634365145202e-11
97 O 0 8.504874138282048e-09
% O 0 1.1183402121028863e-10
of O 0 1.222390244581817e-10
the O 0 4.0831317493772445e-11
population O 0 2.3374256089697676e-12
variance O 0 5.318852580593614e-10
. O 0 1.5439690415064433e-08

CONCLUSION O 0 6.717777068843134e-06
Susceptibility O 0 5.4775709941168316e-06
to O 0 1.7992288547930002e-08
AS B-Disease 1 0.9999971389770508
is O 0 7.377249477968917e-09
largely O 0 5.853208140393917e-09
genetically O 0 3.5956154720295785e-10
determined O 0 1.2945937655217676e-09
, O 0 2.521298968216623e-11
and O 0 5.982707818735777e-12
the O 0 5.3164566499175336e-11
environmental O 0 1.6365011568097998e-09
trigger O 0 5.977011108271313e-10
for O 0 6.556463011397895e-11
the O 0 4.204256054407551e-09
disease O 0 3.4385582239337964e-06
is O 0 1.929244541898356e-09
probably O 0 2.3680840399720182e-08
ubiquitous O 0 4.628103624781943e-07
. O 0 2.050235394790434e-07

HLA O 0 7.599963282700628e-05
- O 0 4.267463282303652e-06
B27 O 0 5.046273940934043e-07
accounts O 0 5.14253029049172e-10
for O 0 7.460530110359187e-11
a O 0 3.0113861404501563e-10
minority O 0 1.8693450953843893e-10
of O 0 1.943967875561725e-09
the O 0 4.859331270701261e-10
overall O 0 6.1363794046087605e-09
genetic O 0 1.344540923042814e-08
susceptibility O 0 4.959035493357078e-08
to O 0 1.9512535587296043e-08
AS B-Disease 1 0.9999980926513672
. O 0 3.5738059978029924e-06

Cell O 0 1.2791268090950325e-05
cycle O 0 5.331137913344719e-07
- O 0 4.3005208283375396e-08
dependent O 0 1.6849369899318845e-08
colocalization O 0 7.206839427453815e-07
of O 0 3.270652726428125e-08
BARD1 O 0 6.470073913078522e-06
and O 0 3.140391280354038e-09
BRCA1 O 0 1.658718828956296e-09
proteins O 0 4.714552637175018e-10
in O 0 3.8069664087814203e-10
discrete O 0 7.049285244420389e-08
nuclear O 0 2.534270834075869e-06
domains O 0 5.351697041078296e-07
. O 0 1.1700421254090543e-07

Germ O 0 0.29777371883392334
- O 0 2.4595744889666094e-06
line O 0 3.442172413770095e-08
mutations O 0 7.000640622756293e-10
of O 0 2.134058041391995e-09
the O 0 2.0669959077679323e-09
BRCA1 O 0 2.3503041735040142e-09
gene O 0 3.553252581056654e-09
predispose O 0 5.151302318040507e-08
women O 0 3.22345761194498e-10
to O 0 2.10072292894381e-10
early O 0 3.7562756460829405e-06
- O 0 0.001425266033038497
onset O 1 0.9999829530715942
breast B-Disease 1 0.9999997615814209
and I-Disease 1 0.9999997615814209
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.0167731545607239e-07
compromising O 0 4.52997983302339e-06
the O 0 1.4748120058527547e-08
genes O 0 2.959908984578874e-09
presumptive O 0 4.629621912499715e-07
function O 0 3.8421600123683675e-08
as O 0 5.643487899220645e-09
a O 0 1.4163825667878882e-08
tumor B-Disease 0 1.5511172932747286e-06
suppressor O 0 3.5852714063366875e-05
. O 0 4.9120885705633555e-06

Although O 0 4.8934705176861826e-08
the O 0 4.393920782774785e-09
biochemical O 0 1.6101834887649602e-07
properties O 0 4.478440871480416e-07
of O 0 1.4525157894240692e-06
BRCA1 O 0 6.330157731326835e-08
polypeptides O 0 5.2962526808641996e-08
are O 0 1.2105710878174136e-10
not O 0 7.527510559324213e-11
understood O 0 3.1688147661412813e-09
, O 0 2.6975140871021708e-11
their O 0 2.3527588297739266e-12
expression O 0 2.1790880211369767e-10
pattern O 0 1.5958377952429714e-09
and O 0 1.132740706788482e-10
subcellular O 0 9.773569331628096e-08
localization O 0 6.574316557816928e-07
suggest O 0 2.7535709268278197e-09
a O 0 1.7071331848139693e-10
role O 0 1.454152354085636e-09
in O 0 1.4362518951926972e-09
cell O 0 9.950198318620096e-07
- O 0 1.2655432612973527e-07
cycle O 0 2.9257837041996027e-08
regulation O 0 6.488651820291125e-07
. O 0 9.838207404300192e-08

When O 0 4.3914471348216466e-07
resting O 0 1.0553287211223505e-05
cells O 0 6.558020793079322e-09
are O 0 2.1075295675299088e-10
induced O 0 3.821329030984089e-09
to O 0 1.1104925312643843e-10
proliferate O 0 5.9687663700458415e-09
, O 0 1.7669728180624844e-10
the O 0 3.248120106214003e-10
steady O 0 1.3694836376032526e-08
- O 0 1.984142850020021e-10
state O 0 1.5537925113218165e-11
levels O 0 2.434233370429695e-10
of O 0 2.9106300702963495e-10
BRCA1 O 0 1.1445988601366253e-10
increase O 0 3.429375186603245e-11
in O 0 1.3118135744338844e-10
late O 0 3.1812188439062083e-08
G1 O 0 2.2247023778732e-08
and O 0 2.567279999698968e-10
reach O 0 1.991100395670742e-09
a O 0 2.9628616227128646e-10
maximum O 0 1.7862651358058201e-09
during O 0 1.1604316618729626e-08
S O 0 1.3635987272664352e-07
phase O 0 5.026624876336427e-07
. O 0 1.034295138424568e-07

Moreover O 0 5.186152520764153e-07
, O 0 4.4440784385813e-09
in O 0 1.7921212291938104e-09
S O 0 2.765852613606512e-08
phase O 0 7.504025489879496e-08
cells O 0 1.565864105046444e-09
, O 0 8.225832237584996e-10
BRCA1 O 0 2.115754904608025e-09
polypeptides O 0 4.880976955945471e-09
are O 0 1.8786490418865043e-10
hyperphosphorylated O 0 6.222408188705231e-08
and O 0 7.530213674833419e-10
accumulate O 0 3.4382992009085456e-09
into O 0 8.192261868877893e-10
discrete O 0 1.2962195228283235e-07
subnuclear O 0 3.0133539894450223e-06
foci O 0 6.93223046255298e-06
termed O 0 6.336885576274653e-07
" O 0 2.0039607306898688e-07
BRCA1 O 0 4.78928086522501e-07
nuclear O 0 4.6878108150849584e-06
dots O 0 1.3755999361819704e-06
. O 0 3.536935935244401e-07

" O 0 5.113177394377999e-06
BRCA1 O 0 1.3028875400777906e-06
associates O 0 3.1516253784502624e-06
in O 0 8.533130646526388e-09
vivo O 0 3.0722367228008807e-07
with O 0 3.7119911588945342e-09
a O 0 5.321729901197614e-08
structurally O 0 7.307197665795684e-05
related O 0 1.3206074982008431e-05
protein O 0 6.587988991668681e-06
termed O 0 1.339916889264714e-05
BARD1 O 0 0.0019412385299801826
. O 0 1.95520283341466e-06

Here O 0 1.9263279682490975e-06
we O 0 2.0064462091795576e-08
show O 0 6.438786837037469e-09
that O 0 3.8216749209674106e-11
the O 0 4.265145736592757e-10
steady O 0 1.1929047971648288e-08
- O 0 5.052500084978817e-10
state O 0 2.024981918258284e-11
levels O 0 2.48315840112312e-10
of O 0 3.224189526473964e-10
BARD1 O 0 5.288399052005843e-08
, O 0 8.226910819253419e-11
unlike O 0 7.509556171347853e-11
those O 0 2.703767418288372e-11
of O 0 1.7744953284548615e-09
BRCA1 O 0 2.6729332081032453e-09
, O 0 4.382276208581004e-10
remain O 0 3.4284368677361954e-09
relatively O 0 1.1002342370503015e-09
constant O 0 1.603569388386461e-09
during O 0 6.277959041511849e-09
cell O 0 4.991870738990656e-08
cycle O 0 1.5676729248070842e-08
progression O 0 2.186689300742728e-07
. O 0 1.609052162621083e-07

However O 0 4.2636045805011236e-07
, O 0 4.003575071465093e-08
immunostaining O 0 7.949045084387762e-07
revealed O 0 2.9770887977065286e-08
that O 0 2.247839553382036e-10
BARD1 O 0 1.6617094615867245e-06
resides O 0 2.7894236609427026e-07
within O 0 3.24702078557948e-08
BRCA1 O 0 3.4594826558986824e-08
nuclear O 0 7.651656233065296e-07
dots O 0 1.490592183017725e-08
during O 0 3.180272400982176e-08
S O 0 3.86652310169211e-08
phase O 0 1.6768451516213645e-08
of O 0 1.866210963541448e-09
the O 0 4.387896712643169e-10
cell O 0 8.079175550790296e-09
cycle O 0 5.092185562105556e-10
, O 0 1.262352462144678e-11
but O 0 6.014434610068786e-12
not O 0 9.788587475301203e-12
during O 0 7.571085980373482e-10
the O 0 1.2759799883355072e-09
G1 O 0 1.5876662473601755e-07
phase O 0 9.400123985869868e-07
. O 0 3.691250469728402e-07

Nevertheless O 0 3.316140646347776e-05
, O 0 1.5056829738568922e-07
BARD1 O 0 1.519877969258232e-05
polypeptides O 0 9.118764410231961e-08
are O 0 1.1053912646330488e-10
found O 0 5.3919754078313176e-11
exclusively O 0 1.8652028532795129e-10
in O 0 3.3121567988292355e-11
the O 0 7.077203406646859e-11
nuclear O 0 5.282297266262503e-09
fractions O 0 5.138333647458637e-10
of O 0 1.484637690563062e-10
both O 0 1.1589528642330649e-10
G1 O 0 1.269348981480789e-08
- O 0 2.869783521930458e-09
and O 0 2.4503885032167716e-10
S O 0 9.621016516803138e-08
- O 0 7.480543295912412e-09
phase O 0 2.460249675095838e-07
cells O 0 1.054853271398315e-08
. O 0 2.531494480706442e-08

Therefore O 0 2.6090604023920605e-06
, O 0 4.1956784713192974e-08
progression O 0 3.411512068396405e-07
to O 0 7.0833006127202225e-09
S O 0 6.394851084223774e-07
phase O 0 5.079372158434126e-07
is O 0 4.921321128392719e-10
accompanied O 0 4.86457096826598e-10
by O 0 2.0711612980228722e-11
the O 0 1.1031313362774853e-10
aggregation O 0 1.2414891337186873e-09
of O 0 5.273418590689971e-09
nuclear O 0 5.878316642338177e-07
BARD1 O 0 1.1601160849750158e-06
polypeptides O 0 4.827041166777235e-08
into O 0 1.1673845001780592e-08
BRCA1 O 0 1.201551782514798e-07
nuclear O 0 1.828420749916404e-06
dots O 0 6.899779236846371e-07
. O 0 1.8132925561076263e-07

This O 0 2.8099767845901624e-08
cell O 0 3.268579860105092e-07
cycle O 0 2.6870068836615246e-08
- O 0 4.092890470985822e-09
dependent O 0 1.4931325065248302e-09
colocalization O 0 9.330381800509713e-08
of O 0 1.590271914153618e-08
BARD1 O 0 8.933116077969316e-06
and O 0 1.5591555824201464e-09
BRCA1 O 0 1.6298475902232212e-09
indicates O 0 4.771965045335946e-10
a O 0 1.6186874063350842e-10
role O 0 9.077508189569983e-10
for O 0 7.493834996985527e-10
BARD1 O 0 5.186159341974417e-06
in O 0 3.264856474061162e-08
BRCA1 O 0 2.69730804802748e-07
- O 0 6.657310223090462e-06
mediated O 0 0.0002616885758470744
tumor B-Disease 0 0.005094341468065977
suppression O 0 0.016088074073195457
. O 0 2.368911964367726e-06

Ethnic O 0 9.313490068052488e-08
differences O 0 3.977358744577941e-07
in O 0 4.599978620234424e-09
the O 0 3.648626512031683e-09
HFE O 0 1.2365103430056479e-06
codon O 0 3.7564650057220206e-08
282 O 0 2.1888820356252836e-07
( O 0 3.774139401002685e-08
Cys O 0 0.0004524350515566766
/ O 0 1.8748780348687433e-05
Tyr O 0 1.5540637832600623e-05
) O 0 4.443927892339161e-08
polymorphism O 0 1.6541470131414826e-06
. O 0 5.866018568667641e-07

Recent O 0 3.057516551052686e-08
studies O 0 1.2511553570959677e-08
have O 0 1.174998570663277e-10
shown O 0 1.769138946450255e-09
that O 0 1.066813304362313e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 7.359738083323464e-05
HH B-Disease 1 0.9616627097129822
) O 0 1.0900060409824164e-08
is O 0 7.755183162316825e-10
likely O 0 5.307958517164479e-10
to O 0 7.290960890582454e-11
be O 0 2.664431175691817e-10
caused O 0 7.06206371159368e-10
by O 0 5.176676795559665e-11
homozygosity O 0 3.505339662979168e-08
for O 0 5.025924121326852e-10
a O 0 1.335867083618325e-09
Cys282Tyr O 0 5.951716630647752e-08
mutation O 0 7.619297415217829e-10
in O 0 6.870279345427832e-10
the O 0 3.4624716427344993e-09
HFE O 0 2.5549004476488335e-06
gene O 0 6.775147198823106e-08
located O 0 1.6706795236132166e-07
4 O 0 3.294920816188096e-06
. O 0 8.114697038763552e-07

5 O 0 1.2901218724437058e-05
Mb O 0 5.527808752958663e-05
telomeric O 0 1.1505135262268595e-05
to O 0 2.1925026771896228e-07
HLA O 0 0.0001445683155907318
- O 0 3.422153167775832e-05
A O 0 2.4212070002249675e-06
. O 0 3.0372001447176444e-07

Population O 0 3.0652680393927767e-10
studies O 0 2.1255395221686513e-09
of O 0 1.0612843936996796e-09
this O 0 2.44436554330818e-11
polymorphism O 0 1.1815367573220215e-09
are O 0 1.0907343604704689e-11
facilitated O 0 5.57063450923323e-10
by O 0 2.0023064803420532e-11
the O 0 2.7141749958659034e-10
fact O 0 8.40526814815945e-11
that O 0 4.273381561809009e-12
the O 0 1.1949485845264007e-10
Cys282Tyr O 0 6.015559250727165e-08
mutation O 0 6.441449040828218e-10
creates O 0 5.2163073860356235e-09
a O 0 4.402779474332874e-09
Rsal O 0 3.7746369230262644e-07
restriction O 0 2.0561522262596554e-08
site O 0 6.643317362886592e-08
. O 0 1.2734767551592086e-07

We O 0 6.884176428911815e-08
have O 0 3.8956257664146676e-10
studied O 0 1.6301809679930557e-08
the O 0 3.4892866374036657e-10
codon O 0 2.0074710782580496e-09
282 O 0 4.732720881861496e-08
( O 0 1.0688195217767316e-08
Cys O 0 9.159883484244347e-05
/ O 0 1.4322062042992911e-06
Tyr O 0 1.2977363894606242e-06
) O 0 9.051056015785264e-10
polymorphism O 0 8.565238296398547e-09
in O 0 2.7570012939293065e-10
different O 0 1.2866470389116813e-10
ethnic O 0 1.0567314800979943e-09
groups O 0 3.673035209317277e-10
. O 0 1.623720180532473e-08

In O 0 9.789483357280915e-08
agreement O 0 3.4699638717938797e-08
with O 0 6.216791526014731e-10
previous O 0 5.3506736819031175e-09
observations O 0 9.039208492822581e-09
the O 0 1.278376959845673e-09
Tyr O 0 6.73284148433595e-08
allele O 0 5.612872389093582e-09
appeared O 0 2.0094795161185175e-08
to O 0 1.776045283063965e-10
be O 0 2.0347473705939478e-10
rare O 0 9.03694563625379e-10
or O 0 6.910428895778864e-10
absent O 0 3.004401349926411e-08
in O 0 3.2055196275138087e-09
Asiatic O 0 2.7304924543614106e-08
( O 0 4.420504587376861e-11
Indian O 0 3.65192286133631e-11
, O 0 1.8331561962847687e-11
Chinese O 0 2.2356323736705264e-10
) O 0 4.2894306162555296e-11
populations O 0 5.715660930660782e-11
. O 0 7.88622855907306e-09

The O 0 5.221865251314739e-08
highest O 0 1.2517760161756541e-08
allele O 0 4.507065831660384e-10
frequency O 0 1.125531490231424e-08
( O 0 1.4728004926745086e-10
7 O 0 8.812716667527809e-10
. O 0 3.7811875158721975e-11
5 O 0 7.002590174387535e-10
% O 0 4.8629170135150446e-11
) O 0 2.2257857015817173e-11
was O 0 1.4686944993513862e-09
found O 0 1.8649147504046226e-10
in O 0 4.5721343377991275e-10
Swedes O 0 5.155809503776254e-07
. O 0 2.3141460303577333e-07

Saamis O 0 7.370926323346794e-05
( O 0 7.688032610531081e-08
2 O 0 2.621720796014415e-07
% O 0 1.0884162460200741e-09
) O 0 1.4224074695867728e-10
and O 0 3.2703625918450996e-10
Mordvinians O 0 1.114071039864939e-07
( O 0 2.0255933042001573e-10
1 O 0 3.1073881245902157e-09
. O 0 3.300238207715189e-11
8 O 0 6.100758787042082e-10
% O 0 2.2856418147032542e-11
) O 0 1.0153041601901336e-11
had O 0 6.920370526630748e-11
significantly O 0 7.463063500523504e-11
lower O 0 3.117129221408277e-09
frequencies O 0 1.8764449549735218e-08
of O 0 5.326357577217777e-09
the O 0 5.7523812380111394e-09
Tyr O 0 1.1195641036465531e-06
allele O 0 2.359333990398227e-07
. O 0 3.5354923966224305e-07

Comparisons O 0 7.932712264846487e-08
with O 0 8.862713340995754e-10
allele O 0 5.921209744741418e-09
frequencies O 0 1.7633924542792556e-08
based O 0 4.155724653287507e-10
on O 0 1.1050714787685934e-09
prevalence O 0 4.069599324196815e-09
estimates O 0 2.2419135992102213e-10
of O 0 2.261654197255325e-09
HH B-Disease 0 2.2162053937790915e-05
showed O 0 2.0914822584927606e-07
some O 0 4.0255085376195154e-10
disagreements O 0 4.054818347754008e-08
with O 0 1.178780961730297e-10
the O 0 5.626481502929437e-10
RFLP O 0 1.77174328541696e-08
data O 0 2.4818858079811434e-09
, O 0 6.948016051389061e-10
particularly O 0 3.116202185182715e-09
in O 0 3.4484264332945713e-09
Finns O 0 9.183430620396393e-07
. O 0 2.632991424889042e-07

The O 0 6.712031108691008e-07
newly O 0 1.1502484085212927e-06
described O 0 4.4290354139775445e-07
HFE O 0 9.511722964816727e-06
marker O 0 6.413766300283896e-07
provides O 0 8.474594359597631e-09
a O 0 2.0642143550020364e-09
new O 0 4.198804637312037e-10
approach O 0 1.6917632850166342e-09
to O 0 7.553484920874709e-11
the O 0 3.6393735247663983e-10
screening O 0 2.4175219603961295e-09
of O 0 7.822947623026266e-09
HH B-Disease 0 1.7834508980740793e-06
as O 0 1.0723597565487353e-09
well O 0 2.2294792401122976e-10
as O 0 9.257477423529892e-11
studies O 0 2.514917440965547e-10
of O 0 6.426232324052705e-10
the O 0 8.934950557204502e-10
relationship O 0 1.75880074948509e-08
between O 0 5.398837288339564e-08
the O 0 6.430012078340042e-09
HFE O 0 1.209035190186114e-06
Tyr O 0 1.5108122397577972e-07
allele O 0 7.244958410979052e-09
and O 0 4.348322257818893e-10
different O 0 1.3825142808343571e-08
disorders O 1 0.9999874830245972
including O 0 2.036249725279049e-06
cancer B-Disease 1 0.999992847442627

Autosomal B-Disease 1 0.9999842643737793
dominant I-Disease 1 0.9999991655349731
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9959879517555237
associated O 0 4.777875801664777e-07
with O 0 5.741639164114076e-09
a O 0 2.6637277272811843e-08
missense O 0 4.088476046604228e-08
mutation O 0 7.962370207614811e-10
encoding O 0 4.011998910868897e-08
Gly23 O 0 1.768166657711845e-05
- O 0 5.328399765858194e-06
- O 0 2.082590754071134e-06
> O 0 7.262393069140671e-07
Val O 0 1.8588140164865763e-06
in O 0 2.721424863239008e-08
neurophysin O 0 3.635303437476978e-05
II O 1 0.9999666213989258
. O 0 7.238976650114637e-06

Autosomal B-Disease 1 0.9999895095825195
dominant I-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999998807907104
( O 0 1.4976417332945857e-06
ADNDI B-Disease 0 0.03302673250436783
) O 0 4.433377220891543e-09
is O 0 7.510074784278231e-10
an O 0 1.250582748468787e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.026367705315351486
by O 0 6.6966454603800685e-09
progressive O 1 0.9999991655349731
degeneration O 1 1.0
of O 0 0.0009503052569925785
the O 0 6.052768526387808e-07
magnocellular O 0 3.299428499303758e-05
neurons O 0 2.870259265819186e-07
of O 0 4.704218952156225e-07
the O 0 4.620240190433833e-08
hypothalamus O 0 2.0457140692542453e-07
leading O 0 2.9715065963387133e-08
to O 0 2.8551827568890076e-10
decreased O 0 2.0829542535238943e-08
ability O 0 5.230352817520156e-10
to O 0 1.2289828876799191e-10
produce O 0 2.5358895539007165e-10
the O 0 2.5949089543786386e-09
hormone O 0 1.571367036490301e-08
arginine O 0 8.008298379991174e-08
vasopressin O 0 1.0437296396048623e-06
( O 0 3.5358119987449754e-08
AVP O 0 6.264627700147685e-06
) O 0 5.7844342649104874e-08
. O 0 2.1039414832557668e-07

Affected O 0 1.924053094626288e-08
individuals O 0 8.236755028034892e-11
are O 0 1.856137986366857e-11
not O 0 5.237667591306838e-11
symptomatic O 0 9.948061929776486e-09
at O 0 1.196932064573275e-08
birth O 0 2.1616282097625117e-09
, O 0 6.153297316124906e-11
but O 0 2.9485688196606574e-11
usually O 0 6.201703039998563e-10
develop O 0 2.589904681826738e-07
diabetes B-Disease 1 0.9999648332595825
insipidus I-Disease 0 0.0004184430872555822
at O 0 0.0006927244830876589
1 O 0 4.616026853909716e-05
- O 0 1.1924837508558994e-06
6 O 0 1.8106812831319985e-06
yr O 0 9.087942089536227e-06
of O 0 1.1700900870437181e-07
age O 0 1.466799403715413e-06
. O 0 3.34252632683274e-07

The O 0 1.0403037720152497e-07
genetic O 0 4.142606968571272e-08
locus O 0 2.1145053707982697e-08
of O 0 6.662618545760779e-08
the O 0 7.655518174942699e-08
disease O 0 6.47868091618875e-06
is O 0 6.313053968476368e-10
the O 0 6.805060959180764e-09
AVP O 0 8.169359716703184e-06
- O 0 4.734337380796205e-06
neurophysin O 0 3.5511282476363704e-05
II O 1 0.9999971389770508
( O 0 1.1809335731527426e-08
NPII O 0 1.533708655188093e-06
) O 0 1.9693217889749093e-10
gene O 0 4.5784870339460326e-10
, O 0 1.3923066866095013e-10
and O 0 1.5638844386156592e-10
mutations O 0 2.9734099626921306e-09
that O 0 5.767682442758826e-10
cause O 0 7.647039268476874e-08
ADNDI B-Disease 0 2.220646092609968e-05
have O 0 3.9753553227050986e-10
been O 0 2.601721893480402e-10
found O 0 3.053869310210011e-11
in O 0 1.5113337664685034e-11
both O 0 1.0232224789685773e-11
the O 0 9.694427899331615e-11
signal O 0 2.713700153478271e-09
peptide O 0 6.80442147071858e-10
of O 0 4.892422911240146e-09
the O 0 4.651858453996738e-09
prepro O 0 5.402151600719662e-06
- O 0 2.518213705116068e-06
AVP O 0 2.161332668038085e-05
- O 0 2.8000097245239886e-06
NPII O 0 5.967107063042931e-05
precursor O 0 5.849371405020065e-07
and O 0 3.491112732234569e-09
within O 0 3.758471933679175e-08
NPII O 0 1.3635701179737225e-05
itself O 0 1.1972156244155485e-07
. O 0 9.967818925815664e-08

An O 0 4.265329067720813e-08
affected O 0 6.552846798513201e-08
girl O 0 1.754927865249556e-07
who O 0 1.531877069638199e-09
presented O 0 5.243100620333507e-09
at O 0 4.948340048827049e-08
9 O 0 1.308421548884553e-08
months O 0 8.919898708548146e-10
of O 0 1.0574755515690981e-09
age O 0 3.0889455437943525e-09
and O 0 2.697103929083511e-10
her O 0 3.9824288311507416e-10
similarly O 0 1.03503416948314e-09
affected O 0 1.1147799350297305e-09
younger O 0 1.4287389049627564e-08
brother O 0 7.2305766707359e-08
and O 0 1.4981275109349212e-09
father O 0 6.872906510579924e-08
were O 0 2.4883985982881995e-09
all O 0 1.334979904399347e-10
found O 0 9.673462725290349e-11
to O 0 1.3309063920385888e-11
have O 0 1.5386485488488866e-11
a O 0 5.065920252733669e-11
novel O 0 1.3753614913625256e-10
missense O 0 4.68809102649459e-10
mutation O 0 1.318440773223628e-10
( O 0 2.4480995008957507e-10
G1758 O 0 2.8907487958917955e-08
- O 0 5.639971689674894e-08
- O 0 3.833471140524125e-08
> O 0 9.773901687992748e-09
T O 0 5.1917510290877544e-09
) O 0 1.1842791504401706e-11
encoding O 0 2.5561541772134433e-10
the O 0 2.650927255487545e-10
amino O 0 2.2884099060149765e-09
acid O 0 2.3138044813464376e-09
substitution O 0 5.367539301914803e-09
Gly23 O 0 9.1496343657127e-07
- O 0 3.569707587303128e-07
- O 0 1.6511367562088708e-07
> O 0 1.2337029886566597e-07
Val O 0 8.577418952881999e-07
within O 0 6.341347358329585e-08
NPII O 0 0.00010568865400273353
. O 0 1.5153301546888542e-06

The O 0 3.4521605130066746e-07
mutation O 0 2.4831892986298953e-08
was O 0 2.255271347451071e-08
confirmed O 0 4.268237707716338e-10
by O 0 4.7414780435239834e-11
restriction O 0 2.356426831440217e-09
endonuclease O 0 7.946583480133995e-08
analysis O 0 2.6213703208100014e-08
. O 0 1.16328415344924e-07

A O 0 4.091427763341926e-05
T1 O 0 0.00020146602764725685
- O 0 8.056098010911228e-08
weighted O 0 7.960931469597199e-09
magnetic O 0 1.6148224091239172e-08
resonance O 0 2.6992989177188065e-08
imaging O 0 9.39065273541928e-07
of O 0 4.956983445936203e-08
the O 0 6.678331487819378e-08
fathers O 0 7.909505228553826e-08
pituitary O 0 4.980040557711618e-07
gland O 0 5.45687385056226e-07
demonstrates O 0 1.3332285675460298e-07
an O 0 6.209707859028413e-09
attenuated O 0 1.8883705479311175e-06
posterior O 0 1.1714735592249781e-05
pituitary O 0 0.0016446341760456562
bright O 0 6.239322101464495e-05
spot O 0 2.9147300665499642e-05
. O 0 6.510483672172995e-07

This O 0 1.4874425247057843e-08
mutation O 0 8.329310574595183e-09
may O 0 3.178524554670048e-09
be O 0 1.41343409199024e-10
valuable O 0 1.2830745355074669e-09
for O 0 4.148768828482474e-11
developing O 0 4.493289906815079e-10
models O 0 2.625542006029491e-09
of O 0 9.078502927195586e-08
dominantly B-Disease 1 0.93427574634552
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 8.122131589516357e-08
as O 0 6.184645573448222e-10
the O 0 2.6624094595639747e-10
early O 0 2.7712003802804475e-09
age O 0 4.246996088141941e-09
of O 0 3.9483354363767376e-09
onset O 0 2.1136656869202852e-05
of O 0 1.3682953294846811e-06
symptoms O 0 0.0015578052261844277
suggests O 0 8.016685093537035e-09
that O 0 1.1809813543761649e-11
this O 0 2.1689278845160587e-11
mutation O 0 1.210404831919476e-10
may O 0 5.286356907774348e-10
be O 0 1.311358382993788e-10
particularly O 0 5.372811640036446e-10
deleterious O 0 1.167580521155287e-08
to O 0 9.324289118595175e-10
the O 0 5.334898300901614e-09
magnocellular O 0 1.8129343288819655e-06
neuron O 0 1.682052754858887e-07
. O 0 1.0926392235433013e-08
. O 0 9.227890984675469e-08

Frequent O 0 6.469713298429269e-07
inactivation O 0 4.2605803173501045e-05
of O 0 1.9407962099649012e-05
PTEN O 0 0.024796105921268463
/ O 0 0.0003361509880051017
MMAC1 O 0 0.02144625596702099
in O 0 3.7081193227095355e-07
primary O 1 0.9996645450592041
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.03855309262871742

Sporadic B-Disease 1 0.9999550580978394
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 7.169982836785493e-06
the O 0 5.0350731584103414e-08
most O 0 1.3898902029296778e-09
common O 0 8.659724493043086e-09
male B-Disease 0 3.469891041163464e-08
cancer I-Disease 0 6.7501935063774e-07
in O 0 2.3376387492390904e-09
the O 0 1.3158269140944867e-08
Western O 0 2.498167894771086e-08
world O 0 4.684926890874408e-10
, O 0 2.2537799751476406e-11
yet O 0 2.0980871553999414e-11
many O 0 1.1834339931626747e-12
of O 0 3.679000160072832e-11
the O 0 5.3855003789848865e-11
major O 0 2.5740168330123936e-10
genetic O 0 4.986707713428018e-10
events O 0 4.762399363755776e-10
involved O 0 1.4564256467508585e-09
in O 0 2.0464666072861348e-10
the O 0 7.450352002003058e-10
progression O 0 2.297092294156755e-07
of O 0 1.7569901089586892e-08
this O 0 1.3831255030183343e-09
often O 0 6.786009976167406e-08
fatal O 0 0.0008264221833087504
cancer B-Disease 0 3.596983879106119e-05
remain O 0 1.3350496601560735e-06
to O 0 4.359019811772669e-09
be O 0 1.3817260224868733e-08
elucidated O 0 4.473300214158371e-05
. O 0 4.51588164196437e-07

Numerous O 0 1.5363700356374466e-07
cytogenetic O 0 1.9347093257238157e-05
and O 0 1.60050852571203e-08
allelotype O 0 3.80181859327422e-06
studies O 0 1.4229462053094721e-08
have O 0 8.07018826765038e-11
reported O 0 1.2644835178932112e-10
frequent O 0 1.0549748574728568e-10
loss O 0 2.3596382625612478e-09
of O 0 5.417683723862865e-08
heterozygosity O 0 0.00037851196248084307
on O 0 1.2793621863238513e-05
chromosomal O 0 0.0007482186774723232
arm O 0 9.18705336516723e-05
10q O 0 1.52029242599383e-05
in O 0 8.815801777473098e-08
sporadic B-Disease 1 0.9991962313652039
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0004473117587622255

Deletion O 0 2.3122893253457732e-06
mapping O 0 4.5602246245834976e-07
studies O 0 3.575090090635058e-08
have O 0 1.6223780652246944e-10
unambiguously O 0 6.1165144060737475e-09
identified O 0 7.668112367298363e-09
a O 0 3.853930508057601e-09
region O 0 2.003879906453676e-08
of O 0 6.05208683168712e-08
chromosome O 0 2.8547725605676533e-07
10q23 O 0 2.1502846436760592e-07
to O 0 4.703630818170268e-10
be O 0 1.5926562846324543e-10
the O 0 1.5343441794879453e-10
minimal O 0 2.619381156421241e-08
area O 0 7.993736339528823e-09
of O 0 3.985016050478407e-08
loss O 0 7.243703521453426e-07
. O 0 6.826369940426957e-07

A O 0 8.709869234735379e-07
new O 0 1.981856456723108e-08
tumor B-Disease 0 1.1226503460193271e-07
suppressor O 0 3.627599767241918e-07
gene O 0 4.836552136566752e-08
, O 0 2.9162064762999762e-08
PTEN O 0 2.3040101950755343e-05
/ O 0 1.0779014701256528e-05
MMAC1 O 0 0.006926268804818392
, O 0 3.8174992056383417e-08
was O 0 1.7165488941373042e-07
isolated O 0 7.680334590531857e-09
recently O 0 2.4839506007623413e-09
at O 0 6.4506000541086905e-09
this O 0 1.5747491852180495e-11
region O 0 1.1420110412885265e-09
of O 0 1.6370194089176948e-09
chromosome O 0 9.19257736597956e-09
10q23 O 0 6.042766642622155e-08
and O 0 5.077637199590868e-10
found O 0 2.436500168290223e-10
to O 0 1.3815604910094592e-11
be O 0 1.1155191353973137e-11
inactivated O 0 2.868419390900101e-10
by O 0 3.85735193786374e-12
mutation O 0 1.3698062129030575e-10
in O 0 2.7870694641052296e-10
three O 0 6.044288625162153e-08
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9998124241828918
lines O 0 1.7654843759373762e-05
. O 0 4.311608847729076e-07

We O 0 1.0449871012951917e-07
screened O 0 7.88179363553354e-07
80 O 0 5.222881327426876e-07
prostate B-Disease 0 0.0015818043611943722
tumors I-Disease 1 0.9999985694885254
by O 0 1.7254462303384344e-09
microsatellite O 0 8.566320985892162e-08
analysis O 0 4.216164750658891e-09
and O 0 3.5856032032377527e-10
found O 0 1.4502580247821584e-09
chromosome O 0 1.53428150184709e-08
10q23 O 0 4.530876651642757e-08
to O 0 5.657884161180959e-10
be O 0 6.152467424413999e-10
deleted O 0 8.697333520046868e-09
in O 0 1.1205741889952492e-09
23 O 0 4.451342405786818e-08
cases O 0 6.547209885354732e-09
. O 0 2.9924429156835686e-08

We O 0 9.604240602811842e-08
then O 0 3.5116820562564044e-09
proceeded O 0 2.4661250819235647e-09
with O 0 6.320421182953728e-12
sequence O 0 7.226664405779459e-11
analysis O 0 1.0865613270238939e-10
of O 0 5.318944173993145e-10
the O 0 9.923004640199906e-10
entire O 0 5.468127284302682e-08
PTEN O 0 2.4579894670750946e-06
/ O 0 4.864306788476824e-07
MMAC1 O 0 4.509591235546395e-06
coding O 0 1.240043616235198e-06
region O 0 6.867285406997325e-08
and O 0 2.2029164603587503e-10
tested O 0 5.386633361581517e-10
for O 0 4.5827310696244794e-11
homozygous O 0 1.002527227900174e-10
deletion O 0 1.4711419860091723e-09
with O 0 5.958909060632678e-11
new O 0 1.6964032401034501e-09
intragenic O 0 1.817960679773023e-07
markers O 0 6.806255559155261e-09
in O 0 4.846160139848621e-10
these O 0 8.220385483426185e-11
23 O 0 5.977356387631971e-09
cases O 0 2.2150423162337063e-10
with O 0 1.9657415972762493e-10
10q23 O 0 2.875511597721925e-07
loss O 0 5.840686867486511e-07
of O 0 3.4460726965335198e-06
heterozygosity O 0 0.005954816471785307
. O 0 7.624299541930668e-06

The O 0 1.0444386688845952e-08
identification O 0 1.084820855368207e-08
of O 0 4.0026111314261925e-09
the O 0 8.830922659797125e-10
second O 0 2.0828418989538022e-09
mutational O 0 9.204595308176522e-09
event O 0 2.3492285894377574e-09
in O 0 1.4422693039861656e-09
10 O 0 5.246641787692852e-09
( O 0 2.0780635545669668e-10
43 O 0 9.253779076345836e-09
% O 0 8.252299288358245e-09
) O 0 7.908479915386124e-08
tumors B-Disease 1 1.0
establishes O 0 0.00013676822709385306
PTEN O 0 0.010127671994268894
/ O 0 0.00010462914360687137
MMAC1 O 0 0.00011021971295122057
as O 0 5.9286571207906036e-09
a O 0 6.40733521795056e-10
main O 0 1.3125350806220126e-09
inactivation O 0 8.037767784685457e-09
target O 0 7.928090961506484e-10
of O 0 6.114881490049129e-09
10q O 0 1.63876109127159e-07
loss O 0 1.0692765783915092e-07
in O 0 1.195729559810843e-08
sporadic B-Disease 1 0.9971798658370972
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 5.306511070557463e-07
. O 0 5.03195337842044e-07

Risk O 0 1.368142648061621e-06
reversals O 0 3.8274552593975386e-07
in O 0 7.459722839442406e-10
predictive O 0 2.990987724160732e-08
testing O 0 3.737126874625574e-08
for O 0 1.921720951258976e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.092139741056599e-05

The O 0 6.287941278770859e-09
first O 0 3.432956974247503e-10
predictive O 0 1.1839618174747102e-09
testing O 0 1.6732372154493191e-09
for O 0 3.732283104795897e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.2013989802994729e-08
HD B-Disease 0 2.7647718070511473e-06
) O 0 3.750890986697897e-10
was O 0 1.7442474131712515e-09
based O 0 3.7126388768848884e-11
on O 0 2.1344069567330592e-10
analysis O 0 3.7271502550950686e-10
of O 0 9.282836721524745e-10
linked O 0 8.35005309340886e-09
polymorphic O 0 4.290605204460007e-09
DNA O 0 1.0030484887124658e-08
markers O 0 7.531022028217649e-09
to O 0 9.806457729188978e-11
estimate O 0 2.1891946588858957e-10
the O 0 1.4320604424522543e-10
likelihood O 0 2.4184074742805706e-09
of O 0 5.026262517304758e-09
inheriting O 0 2.776047658414882e-08
the O 0 3.0404754269852674e-09
mutation O 0 5.142942183233856e-10
for O 0 1.5907078987353884e-09
HD B-Disease 0 2.664717612788081e-05
. O 0 1.1543605751285213e-06

Limits O 0 1.9432020792464755e-07
to O 0 2.6678703690663497e-09
accuracy O 0 3.450415420047648e-08
included O 0 5.933529778623381e-10
recombination O 0 1.8985701899509877e-09
between O 0 1.4823012817188896e-09
the O 0 1.6452698925473186e-10
DNA O 0 3.6341848974608126e-10
markers O 0 5.675653280690085e-10
and O 0 3.519913180372036e-11
the O 0 5.96864571655864e-11
mutation O 0 5.930743396387328e-11
, O 0 9.07135963568173e-11
pedigree O 0 7.293245452011377e-10
structure O 0 2.2705493041286218e-09
, O 0 1.0113792442423275e-10
and O 0 1.300182531083216e-11
whether O 0 2.009461173846372e-11
DNA O 0 3.725577832347504e-11
samples O 0 2.376310606622134e-11
were O 0 1.1168518367077329e-11
available O 0 2.5546662008046894e-11
from O 0 2.584761571444716e-10
family O 0 2.5574123374561e-10
members O 0 1.1953480427706609e-09
. O 0 6.089138793186066e-08

With O 0 4.921004936875306e-09
direct O 0 5.373060218971659e-09
tests O 0 3.227684508555484e-10
for O 0 5.1113332316665705e-11
the O 0 2.580554658848655e-10
HD B-Disease 0 6.738442834830494e-07
mutation O 0 8.220530922642411e-10
, O 0 3.748609755938048e-10
we O 0 2.346424166077554e-10
have O 0 8.31586882688029e-12
assessed O 0 1.9689949670720353e-10
the O 0 3.6033995232109817e-11
accuracy O 0 1.0852114762371912e-09
of O 0 9.434268644081811e-11
results O 0 2.389709957695274e-11
obtained O 0 1.4708606554947323e-10
by O 0 3.134738649213098e-11
linkage O 0 2.3775736934794622e-09
approaches O 0 4.046734503049265e-09
when O 0 4.1385914140157354e-10
requested O 0 1.61600466341838e-09
to O 0 3.5799449515927506e-10
do O 0 3.39680145122756e-10
so O 0 2.938205581615172e-11
by O 0 6.022963811719295e-12
the O 0 9.233882408699046e-11
test O 0 2.8101879157027554e-10
individuals O 0 1.5780091122685747e-10
. O 0 4.719451851542544e-08

For O 0 1.1231686158907905e-07
six O 0 7.151175207553706e-09
such O 0 1.6010563708146464e-10
individuals O 0 1.1852597896211403e-11
, O 0 1.48374604269641e-10
there O 0 1.0454940385651312e-10
was O 0 2.7626667620239687e-09
significant O 0 1.590246934135564e-09
disparity O 0 2.388109798800997e-08
between O 0 8.337925905266275e-09
the O 0 1.978411212633091e-09
tests O 0 2.7934521362737996e-09
. O 0 6.825052967229794e-09

Three O 0 4.2942792788380757e-07
went O 0 4.839297389480635e-07
from O 0 5.258142365960339e-09
a O 0 2.9420776925803693e-09
decreased O 0 2.8872220170228502e-08
risk O 0 1.325835330412417e-09
to O 0 4.293711566849545e-11
an O 0 1.7614637179419468e-11
increased O 0 2.0146891099859232e-10
risk O 0 1.9689885277784924e-09
, O 0 1.022676665574096e-10
while O 0 2.6021934607101116e-10
in O 0 9.265779810085917e-11
another O 0 7.730015239015842e-11
three O 0 9.150421739767545e-12
the O 0 2.2081328432399516e-10
risk O 0 5.88130832923639e-09
was O 0 5.14035853882433e-08
decreased O 0 4.032340825688152e-07
. O 0 1.9416829388774204e-07

Knowledge O 0 2.0847424821113236e-05
of O 0 3.1127052579904557e-07
the O 0 3.6712231032964837e-09
potential O 0 3.807128390320713e-09
reasons O 0 5.6750903976166e-10
for O 0 1.8727878622892824e-11
these O 0 3.8460896793768296e-12
changes O 0 3.129206962992903e-11
in O 0 1.2157025386372311e-11
results O 0 2.7078240691369437e-11
and O 0 1.2952297220869546e-11
impact O 0 9.758063246323445e-10
of O 0 8.146451846435809e-10
these O 0 5.040908315767645e-11
risk O 0 1.2721962372452822e-09
reversals O 0 1.1368889829554973e-08
on O 0 9.945557266632932e-09
both O 0 6.851814671193779e-10
patients O 0 1.1103384878197176e-09
and O 0 2.0259642574682601e-10
the O 0 1.7362216109262363e-09
counseling O 0 4.820525312254631e-09
team O 0 5.00647301393542e-10
can O 0 2.0738809974885086e-11
assist O 0 1.428087093024999e-09
in O 0 1.6111165179744091e-10
the O 0 1.7750902137070312e-10
development O 0 2.3905866175510937e-10
of O 0 1.0319944898640188e-09
strategies O 0 5.809914771504054e-10
for O 0 3.2573627822829465e-11
the O 0 9.224305347332873e-11
prevention O 0 1.2515467773255295e-08
and O 0 5.572693001498763e-11
, O 0 2.805955467977128e-11
where O 0 2.4887283206487254e-11
necessary O 0 1.4418292115792042e-09
, O 0 6.796985196899641e-11
management O 0 7.471413487891709e-10
of O 0 6.03573857560491e-09
a O 0 1.6469315911038507e-09
risk O 0 5.736352282070811e-09
reversal O 0 6.1656395544673614e-09
in O 0 1.2174666830233605e-10
any O 0 2.577405129600141e-11
predictive O 0 1.5048260415539971e-09
testing O 0 7.747155694737273e-10
program O 0 8.506492732429649e-10
. O 0 4.1437253628373583e-10
. O 0 1.0413912399087621e-08

A O 0 3.3857736525533255e-07
novel O 0 1.3464271475527312e-08
common O 0 4.248551732644046e-09
missense O 0 3.839369000502302e-08
mutation O 0 1.0528025118361484e-09
G301C O 0 3.0290280506051204e-08
in O 0 9.742330275841482e-10
the O 0 1.9857377964171974e-09
N O 0 5.619365879283578e-07
- O 0 8.049216404515391e-08
acetylgalactosamine O 0 8.796315569270519e-07
- O 0 3.9409007968060905e-07
6 O 0 8.984446253634815e-07
- O 0 1.7911024485783855e-07
sulfate O 0 2.8027406528963184e-07
sulfatase O 0 1.1454822015366517e-06
gene O 0 9.524938349159129e-08
in O 0 5.211696318951908e-08
mucopolysaccharidosis B-Disease 0 0.00011763202928705141
IVA I-Disease 1 0.9983935952186584
. O 0 9.71285771811381e-06

Mucopolysaccharidosis B-Disease 0 0.1018277034163475
IVA I-Disease 1 0.9999978542327881
( O 0 8.334910671692342e-05
MPS B-Disease 1 0.9999961853027344
IVA I-Disease 1 1.0
) O 0 1.9825030506126495e-08
is O 0 5.048762519166416e-10
an O 0 9.309291670867026e-10
autosomal B-Disease 1 0.9999957084655762
recessive I-Disease 1 0.9999995231628418
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.0005185125628486276
by O 0 2.3976931551317193e-09
a O 0 2.2897890517015185e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.5527615460086963e-06
N O 0 0.0010174966882914305
- O 0 3.05241178466531e-06
acetylgalactosamine O 0 3.339583781780675e-05
- O 0 4.110329427930992e-06
6 O 0 9.140475413005333e-06
- O 0 5.494472361533553e-07
sulfate O 0 2.4202881832025014e-06
sulfatase O 0 2.5466986699029803e-05
( O 0 7.196235429773878e-08
GALNS O 0 3.474809636827558e-05
) O 0 3.0545674434279135e-08
. O 0 5.5731163683958584e-08

In O 0 4.4996749437586914e-08
previous O 0 2.9516739274981774e-08
studies O 0 4.7526742541492695e-09
, O 0 1.9804677342527555e-10
we O 0 8.554813107908288e-11
have O 0 4.528388081181944e-12
found O 0 6.818732210811529e-12
two O 0 4.513066136080379e-12
common O 0 3.832726844232859e-11
mutations O 0 2.2262452992194426e-10
in O 0 1.5129678621050857e-09
Caucasians O 0 2.1017189766325828e-08
and O 0 1.6725129059480537e-09
Japanese O 0 2.332318302933345e-07
, O 0 1.051008835517564e-09
respectively O 0 7.174827487688162e-08
. O 0 6.878113367747574e-08

To O 0 5.740941588783244e-08
characterize O 0 4.881808308709878e-07
the O 0 2.803948184748606e-08
mutational O 0 1.2827848649976659e-06
spectrum O 0 1.3668355336449167e-07
in O 0 1.960129281108891e-10
various O 0 9.90307072457064e-11
ethnic O 0 9.735675460254001e-11
groups O 0 7.128884722124029e-12
, O 0 1.5557556978795795e-11
mutations O 0 5.690663565371956e-11
in O 0 1.1755209305963632e-10
the O 0 1.1243164177443532e-09
GALNS O 0 4.991099444850988e-07
gene O 0 5.012466886000766e-09
in O 0 3.4054441488962084e-09
Colombian O 0 1.1281426850473508e-06
MPS B-Disease 1 0.9999542236328125
IVA I-Disease 1 1.0
patients O 0 3.5568393741414184e-06
were O 0 1.0890688351139488e-08
investigated O 0 3.456798225442981e-08
, O 0 8.72004829455264e-11
and O 0 5.80455128407209e-11
genetic O 0 1.101695734639918e-09
backgrounds O 0 1.0160607910592034e-09
were O 0 1.320124148884716e-10
extensively O 0 4.8981135120085284e-11
analyzed O 0 2.3872044965789208e-11
to O 0 2.24696715227235e-12
identify O 0 3.7959579923807496e-11
racial O 0 6.695847348803241e-11
origin O 0 1.4655169439103943e-11
, O 0 2.083729022661629e-12
based O 0 2.1870805947538097e-12
on O 0 6.132184343643488e-11
mitochondrial O 0 4.309022860748968e-10
DNA O 0 6.967870169738433e-10
( O 0 5.842583361559406e-11
mtDNA O 0 3.5149502752851447e-10
) O 0 1.4752219446023673e-09
lineages O 0 6.750406100763939e-08
. O 0 2.3046888486533135e-07

Three O 0 4.4376772478926796e-08
novel O 0 7.06449512222207e-08
missense O 0 4.12115241488209e-07
mutations O 0 1.6589348561524275e-08
never O 0 1.082460521217854e-08
identified O 0 1.1432597091243224e-09
previously O 0 6.160138177335739e-09
in O 0 1.9003226769953585e-10
other O 0 1.119519928149959e-11
populations O 0 3.644760708521044e-12
and O 0 1.324158317717039e-11
found O 0 1.2065093368818225e-10
in O 0 1.5006462739108883e-10
16 O 0 2.524795261749091e-09
out O 0 6.647288275374308e-11
of O 0 2.669285237288932e-09
19 O 0 5.152785931272774e-08
Colombian O 0 4.7491244004049804e-07
MPS B-Disease 1 0.8298909068107605
IVA I-Disease 1 0.9999998807907104
unrelated O 0 4.602350713867054e-07
alleles O 0 1.2545336991465206e-09
account O 0 2.510450458625968e-10
for O 0 1.1816065903502704e-09
84 O 0 3.321591748317587e-07
. O 0 2.071473232945209e-07

2 O 0 7.369681952695828e-06
% O 0 1.050632558730058e-08
of O 0 5.599099850428502e-09
the O 0 7.17338466404982e-10
alleles O 0 2.971446977362291e-10
in O 0 1.7278230235451275e-10
this O 0 7.307946608969829e-11
study O 0 1.1279486233917169e-09
. O 0 1.2222889367308198e-08

The O 0 7.414649161319176e-08
G301C O 0 6.229010409697366e-07
and O 0 1.8080795749497725e-09
S162F O 0 3.51526203701269e-08
mutations O 0 6.551853504177529e-10
account O 0 1.5432226330158727e-10
for O 0 1.290656470587237e-09
68 O 0 7.775747121741006e-07
. O 0 8.25208132937405e-07

4 O 0 6.22558172835852e-06
% O 0 4.207370807307598e-08
and O 0 3.086950073338812e-08
10 O 0 1.607489252819505e-07
. O 0 1.012328283422903e-07

5 O 0 9.352543770546617e-07
% O 0 8.167926779378831e-09
of O 0 1.9349132074353292e-08
mutations O 0 1.1330740790072014e-09
, O 0 7.003151392126483e-10
respectively O 0 3.345367360907403e-08
, O 0 6.600042179449872e-10
whereas O 0 2.2643473762684607e-09
the O 0 4.499260519708059e-09
remaining O 0 1.000045841692554e-07
F69V O 0 4.628435362974415e-06
is O 0 4.168791978287345e-10
limited O 0 2.4479407390032293e-10
to O 0 1.5536273656469035e-10
a O 0 5.84859605190502e-10
single O 0 1.3921745978251465e-09
allele O 0 6.361226212447946e-08
. O 0 3.1557254942526924e-07

The O 0 6.289083387400751e-08
skewed O 0 3.600148090754374e-08
prevalence O 0 4.4884970407110814e-08
of O 0 2.714083402466372e-09
G301C O 0 2.129695886310401e-08
in O 0 1.6228608734625283e-10
only O 0 6.794004248078522e-11
Colombian O 0 1.2142993277564074e-09
patients O 0 1.5298586009127035e-10
and O 0 2.4434378131932277e-11
haplotype O 0 9.54333390090767e-10
analysis O 0 1.5189204061183403e-10
by O 0 9.946377055314315e-12
restriction O 0 1.7619415648706394e-10
fragment O 0 1.003262251053627e-09
length O 0 9.68098046172372e-10
polymorphisms O 0 4.318207125209028e-09
in O 0 4.503809269973402e-10
the O 0 3.569732509589585e-09
GALNS O 0 1.4294497532318928e-06
gene O 0 4.653252005937247e-09
suggest O 0 1.2271144100850506e-09
that O 0 5.096867025655705e-11
G301C O 0 2.344476079940705e-08
originated O 0 2.0966250957599186e-09
from O 0 3.881030496977189e-10
a O 0 8.602251133638106e-10
common O 0 2.032328083600987e-09
ancestor O 0 1.1036674152364867e-07
. O 0 1.4041926021945983e-07

Investigation O 0 6.037088269295054e-07
of O 0 2.696119061340596e-08
the O 0 8.478421853475027e-10
genetic O 0 3.428540229499788e-10
background O 0 1.1491356477488779e-10
by O 0 7.018509037837184e-12
means O 0 5.553024706728138e-10
of O 0 2.116344433034101e-09
mtDNA O 0 7.134128843233611e-10
lineages O 0 4.072051307257851e-10
indicate O 0 3.723661379240184e-10
that O 0 3.001968118532261e-11
all O 0 1.3155218581140105e-10
our O 0 3.731567554954296e-10
patients O 0 1.8811517621397655e-10
are O 0 3.7748879543053615e-12
probably O 0 9.034683418063238e-11
of O 0 2.1373199043939195e-10
native O 0 1.2607030974720601e-09
American O 0 8.145092067479709e-08
descent O 0 7.369956438196823e-05

Low O 0 6.150807507765421e-07
frequency O 0 4.0118158040058916e-07
of O 0 7.644268862350145e-08
BRCA1 O 0 6.56659722153563e-08
germline O 0 1.7045913125457446e-07
mutations O 0 2.974828161583787e-09
in O 0 1.004041405572309e-09
45 O 0 1.957586981404802e-08
German O 1 0.8146196007728577
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.039443418449082e-06
. O 0 7.993478448042879e-07

In O 0 9.288969593512775e-09
this O 0 8.346350693910765e-11
study O 0 1.5307108358619814e-10
we O 0 1.508039700059971e-11
investigated O 0 1.1341897421246472e-09
45 O 0 2.9231603804191764e-09
German O 0 6.349367322400212e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0257134697155834e-08
for O 0 5.85168979938544e-09
germline O 0 6.686960318802448e-07
mutations O 0 1.2887261924277027e-08
in O 0 4.040595413812298e-09
the O 0 1.9193212352774935e-08
BRCA1 O 0 9.833198078013083e-08
gene O 0 3.8643929656245746e-07
. O 0 8.788710488261131e-07

We O 0 5.8162406446626846e-08
identified O 0 3.80970170965611e-08
four O 0 5.533847602379183e-09
germline O 0 2.0166716296898812e-07
mutations O 0 5.551163528849656e-09
in O 0 5.14304288046219e-09
three O 0 5.4522319992145185e-09
breast B-Disease 0 0.0002765660174190998
cancer I-Disease 0 2.856181345123332e-05
families O 0 6.268966595834868e-11
and O 0 4.603803172020804e-10
in O 0 9.646075938007925e-09
one O 0 2.6473530851944815e-06
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0008026122814044356
. O 0 4.526251040637419e-10
among O 0 1.4144877977240178e-11
these O 0 3.1003383454270006e-12
were O 0 9.312838694652825e-11
one O 0 6.201203439637482e-11
frameshift O 0 7.786758793315585e-09
mutation O 0 2.5150420635000614e-10
, O 0 3.300680284645807e-10
one O 0 2.144085464728107e-10
nonsense O 0 3.7248653939059295e-08
mutation O 0 1.1068369554223523e-09
, O 0 4.461810365619101e-10
one O 0 6.787424788878837e-11
novel O 0 1.781616243423656e-10
splice O 0 4.585411161883712e-09
site O 0 7.455981942960932e-10
mutation O 0 3.164929429644303e-10
, O 0 5.441714856502244e-10
and O 0 4.5996167985506986e-10
one O 0 8.413151952879616e-09
missense O 0 1.3190868912715814e-06
mutation O 0 5.693765388059546e-07
. O 0 1.2521672942966688e-06

The O 0 4.7584546791767934e-07
missense O 0 2.2709157292410964e-06
mutation O 0 1.0272248829323871e-08
was O 0 9.200772410622449e-08
also O 0 7.984162775365178e-10
found O 0 5.818332482476762e-10
in O 0 2.742746918471539e-09
2 O 0 1.399087750542094e-06
. O 0 1.2456732179089158e-07

8 O 0 7.270762125699548e-06
% O 0 2.9458526284997788e-08
of O 0 3.175387064402457e-08
the O 0 1.7993275758243499e-09
general O 0 4.6675454612454814e-09
population O 0 1.0656017734866907e-11
, O 0 1.4465829922816198e-10
suggesting O 0 5.176106210313947e-10
that O 0 1.0237007422309041e-11
it O 0 1.581962165431161e-11
is O 0 5.878218051202921e-11
not O 0 2.5318494523141055e-10
disease O 0 1.5640269168670784e-07
associated O 0 1.6934839663917955e-07
. O 0 4.118759591165144e-07

The O 0 8.316201416391777e-08
average O 0 8.142261975763176e-09
age O 0 1.5304468803378768e-08
of O 0 1.4152591099048095e-08
disease O 0 2.4960399969131686e-06
onset O 0 1.273213570129883e-06
in O 0 1.0651902693226134e-09
those O 0 7.740003082901126e-11
families O 0 1.5780446394053627e-11
harbouring O 0 2.9546985302886242e-08
causative O 0 5.3290232671088233e-08
mutations O 0 3.4094103540383e-08
was O 0 2.553925924075884e-06
between O 0 5.185477675695438e-06
32 O 0 9.7901092885877e-06
. O 0 8.534092899026291e-07

3 O 0 2.457636219332926e-05
and O 0 2.568818615600321e-07
37 O 0 1.2120357496314682e-05
. O 0 1.1147782288389863e-06

4 O 0 1.013681321637705e-05
years O 0 1.0457986121537033e-07
, O 0 1.394736659499074e-09
whereas O 0 3.1806226541419846e-09
the O 0 2.68584754437029e-09
family O 0 1.5455475788073159e-09
harbouring O 0 2.412295998510672e-07
the O 0 1.2112235658889858e-08
missense O 0 1.544449901302869e-07
mutation O 0 2.1944339678725555e-09
had O 0 3.1003903888660034e-09
an O 0 1.0429844488069051e-10
average O 0 3.570629625304633e-10
age O 0 5.507165390383761e-09
of O 0 1.9638436654645375e-08
onset O 0 1.0077630577143282e-05
of O 0 2.9921600344096078e-06
51 O 0 3.0084269383223727e-05
. O 0 2.0635168311855523e-06

2 O 0 0.00018860171257983893
years O 0 3.7024619814474136e-06
. O 0 2.1874620870221406e-06

These O 0 7.625698295044003e-09
findings O 0 9.560755742654692e-09
show O 0 7.508532462452422e-09
that O 0 1.853428938103363e-10
BRCA1 O 0 3.527632408406589e-09
is O 0 3.854487562460207e-10
implicated O 0 7.157944015290241e-09
in O 0 3.9013511865526596e-10
a O 0 2.0702618785950477e-10
small O 0 3.184382965648602e-11
fraction O 0 4.761381844353707e-10
of O 0 2.832192080859386e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.7500701715865716e-09
suggesting O 0 7.151294556528853e-10
the O 0 1.2369504032161416e-10
involvement O 0 2.7112792011507736e-09
of O 0 9.982308313283283e-10
another O 0 3.0242794379908844e-10
susceptibility O 0 1.0278932371932115e-08
gene O 0 2.3276601979205225e-08
( O 0 6.51309761678931e-08
s O 0 5.860723376827082e-06
) O 0 1.2212028650537832e-06

Paternal O 0 0.00014284397184383124
transmission O 1 0.9996127486228943
of O 1 0.9999790191650391
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9910131096839905

We O 0 4.120008156860422e-08
report O 0 1.4868914988142024e-09
a O 0 8.455210837032823e-11
rare O 0 8.20993412142812e-11
case O 0 2.223601580642054e-10
of O 0 3.0476461354567164e-09
paternally O 1 0.9999775886535645
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8955577611923218
DM B-Disease 1 1.0
) O 0 1.4863301203149604e-06
. O 0 6.579799105566053e-07

The O 0 9.641037195251556e-07
proband O 0 3.477855716482736e-05
is O 0 2.1807036176824113e-08
a O 0 6.095504989644951e-09
23 O 0 2.7434179372676226e-08
year O 0 1.4005534509919926e-09
old O 0 2.736426267802017e-06
, O 0 7.079480610627797e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 1 0.987273097038269
who O 0 0.0002188966318499297
suffers O 1 0.9999934434890747
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 0 0.47449561953544617

He O 0 4.4891524453305465e-07
presented O 0 8.865257683510208e-08
with O 0 9.340848983185879e-09
respiratory O 1 0.9999560117721558
and O 0 1.1076489414563184e-07
feeding O 0 2.2691699541610433e-07
difficulties O 0 3.910999566869577e-06
at O 0 8.136968062899541e-06
birth O 0 6.54027303426119e-07
. O 0 3.471486991202255e-07

His O 0 1.0131615226782742e-06
two O 0 5.027425231673988e-07
sibs O 0 0.17812886834144592
suffer O 0 2.818844905050355e-06
from O 0 2.5044636231541517e-07
childhood O 0 0.29626375436782837
onset O 1 0.9999990463256836
DM B-Disease 1 1.0
. O 0 0.0002835003542713821

Their O 0 1.7064316182313632e-08
late O 0 3.7822360354766715e-06
father O 0 9.915161314211218e-08
had O 0 1.2388161607645998e-09
the O 0 2.4690091637857847e-10
adult O 0 4.378976070640306e-10
type O 0 3.631006828541672e-09
of O 0 2.32479692385823e-07
DM B-Disease 1 1.0
, O 0 1.0110079884384504e-08
with O 0 1.2680342331705674e-09
onset O 0 4.818969682673924e-05
around O 0 4.3845215458304665e-08
30 O 0 9.02315733242176e-08
years O 0 4.379890938821518e-08
. O 0 6.69238318096177e-08

Only O 0 6.736695468134712e-08
six O 0 2.012232158676852e-09
other O 0 2.0653976792739392e-11
cases O 0 3.4275183385945596e-11
of O 0 2.7879148989384817e-10
paternal O 0 2.1332884614366776e-07
transmission O 1 0.9008612036705017
of O 1 0.9979776740074158
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 5.7622291933512315e-06
been O 0 2.2355449047495313e-08
reported O 0 2.194714410208576e-09
recently O 0 2.2321406945025046e-08
. O 0 1.6142372771810187e-08

We O 0 4.516097007467579e-08
review O 0 4.577232370905904e-09
the O 0 2.751905092690521e-10
sex O 0 6.407261943230935e-10
related O 0 1.2944252614222052e-10
effects O 0 1.5615611914654437e-08
on O 0 2.0034022440995614e-08
transmission O 0 5.095417509437539e-05
of O 0 2.3705850253463723e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.4524436891078949

Decreased O 0 3.2953796562651405e-06
fertility O 0 3.6335100617179705e-07
of O 0 1.307047181597909e-08
males O 0 3.5316632951420956e-10
with O 0 2.3468896270806283e-10
adult O 0 1.0277093309696284e-07
onset O 0 0.00020807345572393388
DM B-Disease 1 1.0
and O 0 7.5245321085049e-09
contraction O 0 2.7937183677551047e-09
of O 0 6.887309056402557e-10
the O 0 9.588997651466258e-11
repeat O 0 2.0702776992731486e-10
upon O 0 4.874936565535393e-10
male O 0 7.200361418213674e-10
transmission O 0 3.889272903734309e-09
contribute O 0 1.0247151044362468e-10
to O 0 7.368101268001581e-11
the O 0 2.1206061906475782e-10
almost O 0 2.6891830429143226e-10
absent O 0 9.277686396913509e-10
occurrence O 0 1.2165289609011865e-10
of O 0 6.525513462918298e-10
paternal O 0 7.725044781636825e-08
transmission O 0 3.3270054700551555e-05
of O 0 0.00017044658306986094
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.20169073343276978

Also O 0 1.0715100984270975e-07
the O 0 2.758797990054518e-08
fathers O 0 4.0080752938820297e-08
of O 0 4.477524573331948e-09
the O 0 5.066569941369892e-10
reported O 0 8.032404075208888e-09
congenitally O 0 1.3660969671036582e-06
affected O 0 2.071993243646375e-09
children O 0 3.039343499100511e-10
showed O 0 2.583776970155327e-09
, O 0 1.7693371767713018e-10
on O 0 3.3109976982359512e-09
average O 0 1.5357972671381503e-09
, O 0 1.1317392578646945e-09
shorter O 0 3.711164708875003e-08
CTG O 0 6.594813157789758e-07
repeat O 0 2.4616054972170787e-08
lengths O 0 1.1295578161707454e-07
and O 0 1.5781716211638042e-10
hence O 0 9.95644788837069e-10
less O 0 1.7795829254652062e-09
severe O 0 4.0626915165375976e-08
clinical O 0 3.127416334791633e-07
symptoms O 0 1.8299805049082352e-07
than O 0 6.540887276251794e-11
the O 0 3.912835333519382e-10
mothers O 0 2.9151747682476525e-10
of O 0 5.345315301497067e-10
children O 0 6.544884079140445e-10
with O 0 1.296979945664134e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9940551519393921

We O 0 1.099509248092545e-07
conclude O 0 2.12521683806699e-07
that O 0 1.1487018281020056e-10
paternal O 0 5.71016691708337e-08
transmission O 0 6.424562161555514e-05
of O 0 0.000140923002618365
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 7.917578841443174e-07
rare O 0 5.223007804033841e-09
and O 0 8.778087284833092e-11
preferentially O 0 4.075159099059533e-10
occurs O 0 2.0668924904931885e-10
with O 0 2.031822106396408e-11
onset O 0 1.8013341787082027e-06
of O 0 3.5449256756692193e-06
DM B-Disease 1 1.0
past O 0 2.7050569428865856e-07
30 O 0 2.895074580067103e-08
years O 0 5.210626929930129e-10
in O 0 7.583279143519306e-11
the O 0 5.459097063287288e-10
father O 0 8.976976495489453e-09
. O 0 1.5619953108725326e-09
. O 0 4.012159493527179e-08

The O 0 5.136409413353249e-07
RB1 O 0 9.70455221249722e-06
gene O 0 2.168012791514684e-08
mutation O 0 5.461901153580584e-09
in O 0 2.1349375600721032e-09
a O 0 3.739392351320703e-09
child O 0 6.539312380482443e-08
with O 0 4.189089608530594e-08
ectopic B-Disease 1 0.999977707862854
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 0.9999998807907104
. O 0 0.00028573928284458816

The O 0 1.6726083913454204e-06
RB1 O 0 2.5032912162714638e-05
gene O 0 6.569039356918438e-08
mutation O 0 3.777140378247168e-09
was O 0 2.602057413980674e-08
investigated O 0 4.5351391975145816e-08
in O 0 5.407705394588902e-10
a O 0 1.0985083953585217e-09
child O 0 5.133184100003518e-09
with O 0 3.878960264103171e-09
ectopic B-Disease 0 0.3987175226211548
intracranial I-Disease 1 0.9999828338623047
retinoblastoma I-Disease 0 0.03022995963692665
using O 0 5.856994000907889e-09
DNA O 0 1.7537616914253817e-09
obtained O 0 1.944364669270726e-09
from O 0 3.8634673238391315e-10
both O 0 1.2309417374289922e-10
the O 0 1.1165823821102094e-09
pineal B-Disease 0 4.6313675738929305e-06
and I-Disease 0 4.781499640671427e-08
retinal I-Disease 1 0.9999456405639648
tumours I-Disease 1 1.0
of O 0 0.11237753182649612
the O 0 3.723910822373e-06
patient O 0 1.294945104746148e-05
. O 0 6.442904805226135e-07

A O 0 3.1865317851043073e-06
nonsense O 0 6.236999752218253e-07
mutation O 0 5.4852979936015345e-09
in O 0 6.09139005902648e-09
exon O 0 2.3954962102834543e-07
17 O 0 9.629425079538123e-08
( O 0 5.044180628743788e-10
codon O 0 4.566750533285813e-09
556 O 0 2.053710268512532e-08
) O 0 2.2406152488940734e-09
of O 0 2.029319290386411e-08
the O 0 3.5323875380299796e-08
RB1 O 0 4.542932401818689e-06
gene O 0 4.57307223200587e-08
was O 0 9.095520567825588e-07
found O 0 1.1478197281533653e-09
to O 0 3.843568865957714e-11
be O 0 5.700385996565416e-11
present O 0 2.497745898999426e-10
homozygously O 0 1.74819092535472e-07
in O 0 9.264087830196388e-10
both O 0 9.632649122792714e-10
the O 0 2.4378494778432014e-09
retinal B-Disease 0 9.27259407035308e-06
and I-Disease 0 1.2997982423712529e-07
the I-Disease 0 1.9654235074995086e-06
pineal I-Disease 1 0.998418927192688
tumours I-Disease 1 1.0
. O 0 0.00012874438834842294

The O 0 7.290775982937703e-08
same O 0 4.628431859998727e-09
mutation O 0 2.2953154654725694e-10
was O 0 2.476452376498628e-09
present O 0 2.4187382652307576e-10
heterozygously O 0 3.2137247529817614e-08
in O 0 1.3880535609800404e-10
the O 0 5.109227971256125e-11
DNA O 0 1.2827508499846374e-10
from O 0 5.0161819142857667e-11
the O 0 4.8116371997863894e-11
constitutional O 0 3.965701989017134e-09
cells O 0 1.1065261901199719e-10
of O 0 1.0569048969344408e-09
the O 0 5.372668421266269e-10
patient O 0 4.539091769117931e-09
, O 0 6.712755351578892e-10
proving O 0 3.132735315602986e-08
it O 0 4.995272598340428e-11
to O 0 5.5620952288393255e-11
be O 0 3.808564019713856e-10
of O 0 1.0754490631370572e-08
germline O 0 3.0320168775688217e-07
origin O 0 5.158007354566507e-08
. O 0 1.2696000339929014e-07

The O 0 1.5156865984522483e-08
initial O 0 3.5534561959593702e-09
mutation O 0 5.280371140337081e-10
was O 0 2.0209721895980692e-08
shown O 0 9.520062516088501e-10
to O 0 1.1202359873063727e-10
have O 0 4.7633594985052596e-11
occurred O 0 8.967512954427548e-09
in O 0 9.265761768961767e-11
the O 0 3.510133017581296e-10
paternally O 0 1.0626506252719992e-07
derived O 0 1.7162665955083867e-08
RB1 O 0 3.4554977901279926e-06
allele O 0 4.076477466696815e-07
. O 0 7.663786050216004e-07

The O 0 6.817574416118077e-08
mutation O 0 4.672961573248813e-09
is O 0 4.315578172597867e-10
in O 0 9.29789439885198e-11
an O 0 1.938667282264106e-11
area O 0 1.0775552672370736e-09
of O 0 2.692500000733844e-09
the O 0 9.905984921232402e-10
gene O 0 3.866047204592604e-10
that O 0 5.161867461245251e-11
encodes O 0 1.2575755714561154e-10
the O 0 1.1841109204269173e-09
protein O 0 3.874937704040349e-09
- O 0 1.3019483269260945e-09
binding O 0 1.1206895411675077e-09
region O 0 4.304427037027381e-08
known O 0 2.1843991060421786e-09
as O 0 6.414402897725324e-10
the O 0 2.515465613583956e-09
pocket O 0 2.880674583138898e-05
region O 0 9.209516349528712e-08
and O 0 3.4136624083025424e-10
has O 0 4.7085384202727454e-11
been O 0 3.54446298700406e-11
detected O 0 3.516989199869869e-10
in O 0 2.3567075374542057e-11
other O 0 5.067241765077668e-12
cases O 0 2.2036393543256594e-10
of O 0 7.86668330476914e-09
retinoblastoma B-Disease 0 7.137753527786117e-06
. O 0 3.5884525573237624e-08
. O 0 3.7174348221924447e-07

Low O 0 2.2423878363042604e-06
levels O 0 1.2500896673373063e-07
of O 0 1.9013107532828144e-08
beta O 0 7.342270436083709e-08
hexosaminidase O 0 4.287878994091443e-07
A O 0 1.2658408543586575e-08
in O 0 4.6176720780444214e-10
healthy O 0 7.569742610513686e-10
individuals O 0 7.905508712935383e-12
with O 0 2.442763491483646e-10
apparent O 0 0.00012613482249435037
deficiency O 1 0.9944843649864197
of O 0 9.455334293306805e-06
this O 0 6.727986612276027e-09
enzyme O 0 7.59539204864268e-08
. O 0 1.1188111415094681e-07

Appreciable O 0 1.5519812222919427e-05
beta O 0 8.688831258041319e-06
hexosaminidase O 0 5.393095125327818e-05
A O 0 1.960978579518269e-06
( O 0 7.25977322701965e-09
hex O 0 8.646986771054799e-08
A O 0 6.970984234300204e-09
) O 0 7.787225031474776e-11
activity O 0 2.407765098411119e-10
has O 0 1.0145298663666313e-11
been O 0 2.2653563053198766e-11
detected O 0 5.170718853086953e-10
in O 0 6.303040728239395e-11
cultured O 0 7.0291701348423885e-09
skin O 0 1.0407201322948367e-08
fibroblasts O 0 1.3926533704022859e-08
and O 0 1.6356525023297763e-09
melanoma B-Disease 0 6.358768132486148e-06
tissue O 0 1.9141594975735643e-07
from O 0 3.235750511976221e-08
healthy O 0 1.7746103475602126e-09
individuals O 0 7.604770979607878e-12
previously O 0 7.04688585262403e-10
reported O 0 2.3598079046394105e-10
as O 0 9.423586216916746e-11
having O 0 1.9533528128334865e-09
deficiency B-Disease 0 2.078856141451979e-06
of I-Disease 0 3.978561551321036e-07
hex I-Disease 0 1.0640581393772663e-07
A I-Disease 0 3.093579614699138e-09
activity O 0 9.208560025619761e-10
indistinguishable O 0 1.1897457463660999e-09
from O 0 3.723006278266716e-11
that O 0 7.460237939557746e-13
of O 0 6.712854577761718e-11
patients O 0 2.8535276919150476e-10
with O 0 2.4285370159304875e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 9.412276995135471e-06
TSD B-Disease 0 0.004899274092167616
) O 0 1.2687951311818324e-07
. O 0 3.158971537686739e-07

Identification O 0 3.7607205172207614e-07
and O 0 4.618539861667159e-08
quantitation O 0 0.0004804529307875782
of O 0 9.202584806189407e-06
hex O 0 1.8544351405580528e-05
A O 0 1.4756525388293085e-06
, O 0 8.395983464026813e-09
amounting O 0 3.032444340078655e-08
to O 0 5.799012825491445e-09
3 O 0 7.153741989895934e-07
. O 0 2.239967358264039e-07

5 O 0 8.024619091884233e-06
% O 0 2.786666470910859e-07
- O 0 2.0979437067580875e-06
6 O 0 2.9897385047661373e-06
. O 0 2.2996719906132057e-07

9 O 0 2.142123094017734e-06
% O 0 7.703381932344655e-09
of O 0 7.508618615759133e-09
total O 0 6.238957128701372e-10
beta O 0 3.478246668464635e-08
hexosaminidase O 0 8.200211709663563e-08
activity O 0 1.328305798686813e-09
, O 0 9.690286073560372e-11
has O 0 8.84910634352254e-12
been O 0 6.5874463002491e-12
obtained O 0 5.1892018460009126e-11
by O 0 1.9027373426849792e-11
cellulose O 0 1.7848254429964072e-08
acetate O 0 1.3761344952456511e-08
gel O 0 1.2677996608090325e-07
electrophoresis O 0 1.7113852379679884e-07
, O 0 1.7165316279488252e-08
DEAE O 0 1.797683216864243e-05
- O 0 4.825393489227281e-07
cellulose O 0 1.0630332099026418e-06
ion O 0 1.0992699571943376e-05
- O 0 1.4519795854539552e-07
exchange O 0 2.4235902174041257e-07
chromatography O 0 2.0252457488822984e-06
, O 0 1.10237885486697e-09
radial O 0 4.5214409993832305e-08
immunodiffusion O 0 3.161662789352704e-07
, O 0 1.6548067360844243e-09
and O 0 2.0940873479702304e-09
radioimmunoassay O 0 6.541485163324978e-06
. O 0 1.9054317590416758e-07

Previous O 0 1.831811914598802e-06
family O 0 1.0085297219575295e-07
studies O 0 1.3969045475903386e-08
suggested O 0 5.56154944320042e-09
that O 0 9.567290536194317e-12
these O 0 4.281875635309129e-12
individuals O 0 1.997758512436998e-12
may O 0 8.279566615643219e-11
be O 0 1.654202295975349e-11
compound O 0 2.189244757699882e-10
heterozygotes O 0 7.09932501674615e-10
for O 0 3.0425145042256574e-11
the O 0 1.8874557472514653e-10
common O 0 8.844306398358981e-10
mutant O 0 1.1814697664647156e-08
TSD B-Disease 0 2.626771333780198e-07
gene O 0 3.6137546288728117e-09
and O 0 7.195666285042535e-10
a O 0 2.706014523568001e-09
rare O 0 5.882306641780133e-09
( O 0 4.4655137920734944e-10
allelic O 0 2.549588273836889e-08
) O 0 3.869280007506859e-09
mutant O 0 1.8182259964305558e-07
gene O 0 6.012037943037285e-07
. O 0 1.4162521893013036e-06

Thus O 0 6.444084874601685e-07
, O 0 3.809663251530537e-09
the O 0 1.7226937654157837e-09
postulated O 0 6.562139986954207e-08
rate O 0 9.909542519892511e-09
mutant O 0 4.053401170267534e-09
gene O 0 2.0026371672088317e-09
appears O 0 1.4127987668643982e-09
to O 0 1.922861522785091e-11
code O 0 3.483738991727492e-11
for O 0 2.3246885319516686e-11
the O 0 2.3609504976040974e-11
expression O 0 1.741407712474441e-10
of O 0 9.723043481457694e-10
low O 0 2.3155259931684213e-09
amounts O 0 7.535975177219711e-10
of O 0 1.1873071414925107e-08
hex O 0 3.0941509976400994e-07
A O 0 2.3589333864038053e-07
. O 0 1.0033741659754014e-07

Heterozygotes O 0 4.866538347414462e-06
for O 0 2.560343403956722e-08
the O 0 7.075387831179114e-09
rare O 0 1.1217423434572993e-08
mutant O 0 1.1219435158693614e-08
may O 0 2.285312827865482e-09
be O 0 2.8408633778731485e-10
indistinguishable O 0 1.5222253679780806e-08
from O 0 5.804310365675747e-10
heterozygotes O 0 2.917734942542438e-09
for O 0 1.6436764449512253e-10
the O 0 1.3243895979897502e-09
common O 0 2.4735223647098792e-08
TSD B-Disease 0 1.644575604586862e-05
mutant O 0 8.127817068270815e-07
. O 0 3.140399087442347e-07

However O 0 2.4241637675004313e-07
, O 0 3.853842578394051e-09
direct O 0 3.995913377963234e-09
visualization O 0 3.2298990504386893e-07
and O 0 1.7622257431071375e-08
quantitation O 0 0.006050546653568745
of O 0 5.076738671050407e-05
hex O 0 8.451274879917037e-06
A O 0 3.768722578456618e-08
by O 0 6.821414960667127e-11
the O 0 1.9988695421080394e-10
methods O 0 6.134097674248551e-09
described O 0 1.1585467030172936e-09
may O 0 9.453614974175295e-11
prevent O 0 1.8670645585139312e-10
false O 0 2.333890858352561e-10
- O 0 5.262815183648684e-10
positive O 0 5.868293351252163e-11
prenatal O 0 1.564250062813244e-08
diagnosis O 0 4.5242874335826855e-08
of O 0 3.476966625726163e-08
TSD B-Disease 0 1.7962676793104038e-05
in O 0 2.8815279051741527e-08
fetuses O 0 4.4605638294115124e-08
having O 0 2.045792424354431e-09
the O 0 1.8278301094909466e-09
incomplete O 0 1.8279845193092115e-08
hex B-Disease 0 1.3918494232711964e-06
A I-Disease 0 1.8638410210769507e-06
deficiency I-Disease 0 0.005895353853702545
of O 0 2.3983134269656148e-06
the O 0 6.11572374964453e-08
type O 0 1.0714728659877437e-06
described O 0 1.530671589478061e-08
in O 0 1.0286301810324971e-09
the O 0 4.4210231031627245e-09
four O 0 1.21509700079514e-08
healthy O 0 7.111786004543319e-08
individuals O 0 3.5654068142321194e-08

The O 0 2.676700319170777e-07
tumor B-Disease 0 1.3618888488053926e-06
suppressor O 0 2.3391485228785314e-06
gene O 0 1.38186365461479e-07
Smad4 O 0 1.0774739166663494e-05
/ O 0 1.7731331354298163e-06
Dpc4 O 0 1.969190179806901e-06
is O 0 1.9487855773547835e-10
required O 0 2.544271182625124e-10
for O 0 8.980496207788846e-11
gastrulation O 0 1.6887431897316674e-08
and O 0 1.6229073640516845e-10
later O 0 1.4023391337047997e-09
for O 0 6.540263469689833e-11
anterior O 0 1.6471554786789966e-08
development O 0 2.737511373140933e-08
of O 0 8.381778826560549e-08
the O 0 1.5115551477151712e-08
mouse O 0 4.23587493969535e-08
embryo O 0 1.4833656081236768e-08
. O 0 8.615182167659441e-08

Mutations O 0 4.4303664026301703e-07
in O 0 1.616575850960089e-08
the O 0 2.905878915271387e-08
SMAD4 O 0 0.00011775897291954607
/ O 0 4.388848537928425e-06
DPC4 O 0 9.63945876719663e-06
tumor B-Disease 0 2.662968938693666e-07
suppressor O 0 2.6779309791891137e-07
gene O 0 2.9841270787756e-08
, O 0 5.236544087239281e-09
a O 0 5.2226192259752224e-09
key O 0 1.8684740155094914e-07
signal O 0 3.0560681807401124e-07
transducer O 0 5.60017099360266e-08
in O 0 2.016939282256658e-09
most O 0 3.288690431091368e-10
TGFbeta O 0 1.0097210889625785e-07
- O 0 5.686947357474992e-09
related O 0 1.0936567207409098e-08
pathways O 0 2.9522690958572184e-09
, O 0 8.894240899337547e-11
are O 0 2.4899899850328033e-12
involved O 0 3.7831356103357194e-11
in O 0 3.934874301392277e-11
50 O 0 6.556329368301306e-10
% O 0 1.2721161901652067e-09
of O 0 1.5536992350462242e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 0.9999997615814209
. O 0 7.545737753389403e-05

Homozygous O 0 1.1998803302049055e-06
Smad4 O 0 4.731340231955983e-05
mutant O 0 2.4608743842691183e-06
mice O 0 3.454677198533318e-06
die O 0 9.375270337841357e-07
before O 0 9.761590291645916e-08
day O 0 5.590565876900655e-08
7 O 0 3.9171109733615594e-07
. O 0 5.218201337697792e-08

5 O 0 1.0145353371626697e-05
of O 0 1.4007766822032863e-06
embryogenesis O 0 9.07451831153594e-05
. O 0 3.578287305572303e-06

Mutant O 0 1.8907167032011785e-06
embryos O 0 1.0003740413822015e-07
have O 0 5.341697639771326e-10
reduced O 0 1.71276004490295e-09
size O 0 9.565949143919283e-10
, O 0 2.562827727814465e-10
fail O 0 7.221501174825562e-10
to O 0 1.0144376311194137e-10
gastrulate O 0 3.792301939142817e-08
or O 0 3.562099504250682e-10
express O 0 1.2382393721477314e-10
a O 0 9.444170445682687e-11
mesodermal O 0 9.02614871733931e-09
marker O 0 2.5937723080460273e-08
, O 0 1.2266370141844618e-09
and O 0 9.75471370345815e-10
show O 0 2.8666667262200463e-08
abnormal O 0 1.3625748351842049e-06
visceral O 0 4.136561983614229e-06
endoderm O 0 3.634502718341537e-05
development O 0 1.9927369976358023e-06
. O 0 7.584822583339701e-07

Growth B-Disease 1 0.9999980926513672
retardation I-Disease 1 1.0
of O 0 2.365048203500919e-05
the O 0 4.005652840533003e-07
Smad4 O 0 7.20059615559876e-05
- O 0 4.374965101305861e-07
deficient O 0 5.763114074852638e-08
embryos O 0 2.908976115545414e-10
results O 0 5.701169050742472e-11
from O 0 5.3051920495539306e-11
reduced O 0 8.686055763540423e-10
cell O 0 5.855329554549371e-09
proliferation O 0 2.5975250395049443e-08
rather O 0 2.2588204917628474e-10
than O 0 3.2056999416107956e-11
increased O 0 4.668095354709578e-10
apoptosis O 0 3.748281756088545e-07
. O 0 7.041491301151837e-08

Aggregation O 0 2.3895137246654485e-07
of O 0 2.037008073330071e-07
mutant O 0 1.479603781717742e-07
Smad4 O 0 5.142769623489585e-06
ES O 0 4.705107130575925e-07
cells O 0 7.6755124478467e-10
with O 0 2.085440847787723e-10
wild O 0 1.6831022131569284e-09
- O 0 4.131211372992993e-09
type O 0 3.16608570471999e-08
tetraploid O 0 1.2056017340000835e-06
morulae O 0 1.2634423001145478e-05
rescues O 0 1.8881687537941616e-06
the O 0 1.206982886969854e-07
gastrulation B-Disease 0 0.000174721673829481
defect I-Disease 0 6.437255797209218e-05
. O 0 2.079099886032054e-06

These O 0 4.732880753977042e-09
results O 0 1.783616476735972e-09
indicate O 0 3.841102991231082e-09
that O 0 1.4279147309004259e-10
Smad4 O 0 1.0352720636319646e-07
is O 0 2.2409901712094893e-10
initially O 0 1.7006333841163013e-10
required O 0 6.487262810273009e-11
for O 0 1.1300793634205775e-11
the O 0 6.336526442440871e-11
differentiation O 0 2.2564750068454487e-09
of O 0 5.3639368502444995e-09
the O 0 2.7385336220930867e-09
visceral O 0 6.427831777955362e-08
endoderm O 0 3.838234761133208e-07
and O 0 1.9944632057011802e-10
that O 0 1.6056060994640298e-11
the O 0 4.225630401144542e-10
gastrulation B-Disease 0 1.3042061652868142e-07
defect I-Disease 0 5.862003504830682e-08
in O 0 9.554043112203203e-10
the O 0 2.4800972386884723e-09
epiblast O 0 1.2601456091942964e-06
is O 0 6.945684583037348e-10
secondary O 0 1.1912086428367274e-08
and O 0 5.821562676366909e-10
non O 0 6.220503792064846e-07
- O 0 7.925540899123007e-07
cell O 0 1.9544552287698025e-06
autonomous O 0 8.664732717988954e-07
. O 0 2.85376529518544e-07

Rescued O 0 8.871158206602558e-05
embryos O 0 1.2151268720117514e-06
show O 0 7.83813788984844e-07
severe O 0 1.0351006494602188e-05
anterior O 0 6.813682557549328e-05
truncations O 1 0.9945849776268005
, O 0 1.6103231814668106e-07
indicating O 0 1.1195432847443954e-07
a O 0 3.661181358083354e-09
second O 0 3.0537499196015006e-09
important O 0 1.0260632343772613e-09
role O 0 8.23468937483085e-09
for O 0 4.067628456283501e-09
Smad4 O 0 1.9640610844362527e-06
in O 0 7.89653942234736e-09
anterior O 0 1.6983779005386168e-06
patterning O 0 0.00011644580081338063
during O 0 8.27596231829375e-05
embryogenesis O 0 0.0001008589388220571
. O 0 1.9892925138265127e-06

Prevalence O 0 6.6657212300924584e-06
of O 0 1.7921328776537848e-07
p16 O 0 4.901204988527752e-07
and O 0 3.1608909267788476e-08
CDK4 O 0 0.00011149648344144225
germline O 0 5.616008365905145e-06
mutations O 0 6.341407754462125e-08
in O 0 2.0921241628002463e-08
48 O 0 4.5238407437864225e-06
melanoma B-Disease 1 0.9998884201049805
- O 0 0.031813204288482666
prone O 0 0.00020499205857049674
families O 0 6.19592210870934e-10
in O 0 8.566349407601592e-09
France O 0 8.458559932478238e-07
. O 0 1.4288866623246577e-07

The O 0 3.067470402129402e-07
French O 0 0.00015768580487929285
Familial B-Disease 1 0.70791095495224
Melanoma I-Disease 1 0.9999821186065674
Study O 0 2.2217240314148512e-07
Group O 0 5.889809173709182e-08
. O 0 1.229864068363895e-07

Germline O 0 4.1760056774364784e-05
mutations O 0 2.4382862306993047e-07
in O 0 1.4219939004078697e-08
the O 0 1.0595677224500832e-08
p16 O 0 9.147944979304157e-08
and O 0 3.0043938448187646e-09
CDK4 O 0 9.75456350715831e-06
genes O 0 4.049460322619325e-09
have O 0 5.3832820146038074e-11
been O 0 4.9228399134904066e-11
reported O 0 2.9706292981046545e-11
in O 0 1.1552929619906838e-11
a O 0 3.25311583226906e-11
subset O 0 3.3010598698979265e-09
of O 0 7.398276125059056e-08
melanoma B-Disease 0 1.2779306416632608e-05
pedigrees O 0 4.826949506764322e-08
, O 0 3.408236470825443e-10
but O 0 1.645978318920438e-11
their O 0 2.024978101866637e-11
prevalence O 0 3.2790088422274266e-09
is O 0 2.2540335917198284e-11
not O 0 1.6173227687654723e-11
well O 0 4.121284702396366e-10
known O 0 8.304437137951481e-09
. O 0 8.394994210902951e-08

We O 0 4.4514614216950577e-08
searched O 0 8.19697447695944e-08
for O 0 2.6999658064852383e-10
such O 0 1.6979821715334964e-10
germline O 0 1.0670925121303299e-07
mutations O 0 5.107148037808429e-09
in O 0 1.0060950295098792e-08
48 O 0 7.370873618128826e-07
French O 0 0.01282262708991766
melanoma B-Disease 1 0.9999973773956299
- O 0 0.04721711575984955
prone O 0 0.00012758765660692006
families O 0 1.2634901458419279e-10
selected O 0 3.629571643237739e-10
according O 0 1.0710100861732741e-10
to O 0 3.634294254428738e-11
two O 0 2.787722136465831e-11
major O 0 1.8242869714857335e-10
criteria O 0 1.5538533792991416e-09
families O 0 1.9421018612741925e-11
with O 0 2.12346269040653e-11
at O 0 3.177829199785265e-08
least O 0 6.958304071824628e-11
three O 0 1.8758624861781037e-11
affected O 0 3.6734539021754387e-11
members O 0 5.788663298700314e-11
( O 0 7.90934331917903e-11
n O 0 1.0292548147106118e-08
= O 0 8.612631496873746e-09
20 O 0 5.208374176390862e-09
) O 0 4.583534940483247e-11
or O 0 3.640774140500902e-11
families O 0 2.441545229880937e-12
with O 0 1.223268968758573e-11
two O 0 6.847369199425302e-11
affected O 0 1.6735747510043808e-10
members O 0 8.601410556030586e-11
, O 0 4.821439775204439e-11
one O 0 2.54300851210143e-11
of O 0 3.289317707100281e-10
them O 0 1.2927789047600946e-11
affected O 0 2.296514194088939e-11
before O 0 1.0926339694128373e-10
the O 0 5.032204514199279e-11
age O 0 6.270237107308674e-10
of O 0 7.976901916784129e-10
50 O 0 5.468204777869801e-10
( O 0 3.8441774069530865e-11
n O 0 6.163041188500529e-09
= O 0 7.756725928231845e-09
28 O 0 2.4406608289950782e-08
) O 0 3.5220504290833787e-10
, O 0 2.383138686390396e-10
and O 0 1.1251440057424844e-10
one O 0 7.913614208376885e-11
additional O 0 1.308842062508475e-10
minor O 0 5.367439470660429e-08
criterion O 0 0.00014023625408299267
. O 0 1.3812895076625864e-06

Sixteen O 0 1.8312040310775046e-06
different O 0 3.683478411176111e-08
p16 O 0 6.210202059264702e-07
germline O 0 7.861584663260146e-07
mutations O 0 2.3727590559019518e-08
were O 0 3.1353277751833275e-09
found O 0 5.47895839808632e-10
in O 0 2.668703591446331e-10
21 O 0 8.561317876853991e-09
families O 0 2.5207558262962948e-11
, O 0 8.174588783660397e-11
while O 0 6.076673053634352e-10
one O 0 4.4513720487415753e-10
germline O 0 6.089639015272041e-08
mutation O 0 2.5577502338336444e-09
, O 0 2.2595414428394633e-09
Arg24His O 0 4.661177968046104e-07
, O 0 1.1504784902527376e-09
was O 0 1.3953386890364072e-08
detected O 0 1.0657009497094805e-08
in O 0 5.009893055962777e-10
the O 0 3.3784528508107314e-09
CDK4 O 0 8.980413440440316e-06
gene O 0 2.6302558353563654e-07
. O 0 3.2029612384576467e-07

The O 0 1.1703251701078443e-08
frequency O 0 5.675984127151423e-08
of O 0 4.830990274484748e-09
p16 O 0 6.036429134326227e-09
gene O 0 6.907345251327968e-10
mutation O 0 1.1626547641307994e-10
in O 0 7.943541657784436e-11
our O 0 7.434790977312034e-11
sample O 0 3.047247870702208e-11
( O 0 1.1586029878551951e-11
44 O 0 1.8388651712442083e-10
% O 0 5.5260050008110184e-11
) O 0 3.5099239487079714e-11
is O 0 2.504862810226438e-11
among O 0 4.380767450185008e-12
the O 0 3.306437762473635e-11
highest O 0 2.9031852477601205e-09
rates O 0 8.490509961767145e-10
yet O 0 4.8074814962273393e-11
reported O 0 6.536497731968183e-11
and O 0 8.062829917609982e-12
the O 0 1.1057075394171889e-10
CDK4 O 0 1.343962026112422e-07
mutation O 0 1.4427968542118919e-10
is O 0 4.776415374330156e-11
the O 0 5.299953184656481e-11
second O 0 3.3388364295561246e-10
mutation O 0 3.689372071735697e-11
detected O 0 1.3423392397626799e-09
in O 0 6.952122211245637e-11
this O 0 2.2522759698939687e-11
gene O 0 1.9722283806089536e-09
worldwide O 0 4.0892538244463594e-09
. O 0 1.0937176142533644e-07

In O 0 3.783957254199777e-07
summary O 0 1.3085109458188526e-06
, O 0 1.6377752487528596e-09
our O 0 5.651262235950583e-10
results O 0 3.503478063215937e-10
show O 0 1.6910501887679175e-09
frequent O 0 4.021778465812531e-10
involvement O 0 2.8249251826650834e-09
of O 0 1.9639625481460143e-09
the O 0 9.941720779949037e-10
p16 O 0 9.954135293810396e-09
gene O 0 7.066055296434115e-09
in O 0 7.926265865876303e-09
familial B-Disease 0 8.168308340827934e-06
melanoma I-Disease 0 0.027742542326450348
and O 0 4.714393320170984e-09
confirm O 0 8.9719787155218e-09
the O 0 1.4245368218368526e-09
role O 0 5.375714984268143e-09
of O 0 1.18710783425513e-08
the O 0 2.1799455574011972e-09
CDK4 O 0 6.271155143622309e-06
gene O 0 9.933689426588899e-09
as O 0 9.465532357921802e-09
a O 0 7.538872637269378e-08
melanoma B-Disease 0 0.19895298779010773
- O 0 2.6970023100147955e-05
predisposing O 0 1.3257218597573228e-05
gene O 0 1.5550097032246413e-06
. O 0 2.610389060464513e-07
. O 0 8.591877076469245e-07

Progression O 0 0.00010218343959422782
of O 0 9.058056093635969e-06
somatic O 0 2.0822824808419682e-05
CTG O 0 2.8089802071917802e-05
repeat O 0 5.310616657538958e-08
length O 0 1.143696026773e-09
heterogeneity O 0 3.1818969681296494e-09
in O 0 1.2365093671196092e-10
the O 0 1.1948642075765292e-10
blood O 0 1.0554001006468638e-09
cells O 0 1.042392838712658e-08
of O 0 3.360691698617302e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.052979324012994766
. O 0 2.778596126518096e-06

The O 0 1.7150624032069572e-08
genetic O 0 1.5846282508391596e-08
basis O 0 3.856812327285297e-07
of O 1 0.8550533056259155
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0011164990719407797
DM B-Disease 1 1.0
) O 0 1.3546625154958747e-08
is O 0 1.833845991727756e-10
the O 0 8.755913355473766e-11
expansion O 0 1.8878274499201098e-09
of O 0 5.364090505111108e-09
an O 0 1.4739113263217973e-09
unstable O 0 2.3919605155242607e-05
CTG O 0 1.2669330317294225e-05
repeat O 0 3.608666077070666e-08
in O 0 1.8983745686540487e-09
the O 0 2.7242070821387188e-09
34 O 0 4.059461389260832e-08
UTR O 0 2.0732177290483378e-06
of O 0 4.241712048269619e-08
the O 0 5.421332716082361e-08
DM B-Disease 1 0.9999977350234985
protein O 0 5.319385536495247e-07
kinase O 0 8.474791712842489e-08
gene O 0 3.226512035325868e-08
on O 0 3.951019778014597e-07
chromosome O 0 1.349628837488126e-05
19 O 0 1.2830482774006668e-05
. O 0 2.05793935492693e-06

One O 0 1.5988371160347015e-07
of O 0 7.626239550972969e-08
the O 0 4.479164594783924e-09
principal O 0 3.4682111049733066e-07
features O 0 1.7010471253797732e-08
of O 0 5.742868580682625e-08
the O 0 1.265158289243118e-07
DM B-Disease 1 1.0
mutation O 0 1.5202147096715635e-08
is O 0 7.544273539217272e-10
an O 0 1.324434312222067e-10
extraordinarily O 0 3.0677625773023465e-08
high O 0 5.093327359873001e-08
level O 0 2.827595722010301e-07
of O 0 7.587167516476256e-08
somatic O 0 4.170435090600222e-07
mosaicism O 0 9.352961569675244e-06
, O 0 1.0859279031549818e-09
due O 0 3.5064011694174724e-09
to O 0 1.256429543738946e-10
an O 0 4.780890613953481e-11
extremely O 0 2.8763922355068416e-09
high O 0 2.105879248759379e-09
degree O 0 3.554420402451797e-08
of O 0 3.555225669416018e-09
somatic O 0 9.777838982927278e-08
instability O 0 1.7147655739790935e-07
both O 0 4.212529491898209e-10
within O 0 6.572982158559171e-10
and O 0 5.652337278783115e-11
between O 0 1.3788267194669857e-09
different O 0 4.0146971858057157e-10
tissues O 0 2.5459728547616578e-08
. O 0 5.9510810501706146e-08

This O 0 1.0730808952530424e-07
instability O 0 9.80317963694688e-06
appears O 0 4.662298280777577e-08
to O 0 3.9660175144007326e-10
be O 0 2.432154200260328e-10
biased O 0 1.1220541162870745e-09
towards O 0 3.8497410814741784e-10
further O 0 5.5305707929997894e-11
expansion O 0 4.4946441013493654e-10
and O 0 3.088671332585058e-11
continuous O 0 1.935772431238547e-09
throughout O 0 5.432775895819475e-10
the O 0 4.934480046792089e-10
life O 0 3.9549358232804366e-10
of O 0 7.579726291062627e-10
an O 0 2.6608647576975564e-11
individual O 0 2.4645003052214953e-11
, O 0 1.5772026740190626e-10
features O 0 9.866574224304259e-10
that O 0 4.624138918996046e-11
could O 0 8.105313642481349e-11
be O 0 4.78315234642146e-11
associated O 0 3.335749176880398e-10
with O 0 1.358751566121752e-11
the O 0 4.708172740564009e-10
progressive O 0 2.1515061234822497e-06
nature O 0 2.7996248874728735e-08
of O 0 3.3798919218952506e-08
the O 0 8.800748219073284e-08
disease O 0 5.8248366258339956e-05
. O 0 1.123271431424655e-07

Although O 0 1.4997635133795484e-08
increasing O 0 2.010295041543486e-09
measured O 0 7.801594925638256e-09
allele O 0 1.9842423260030273e-09
size O 0 3.525076452959297e-09
between O 0 1.5445611012410154e-08
patients O 0 8.243835836196922e-09
clearly O 0 1.903548652038012e-09
correlates O 0 8.36216151878233e-10
with O 0 8.98714002522949e-12
an O 0 6.162549637256376e-12
increased O 0 1.9374261917004532e-10
severity O 0 4.158368938078638e-08
of O 0 5.808455494360487e-09
symptoms O 0 2.5708791540068887e-08
and O 0 3.6788877499915884e-11
an O 0 6.760805023459104e-12
earlier O 0 2.498393991690051e-10
age O 0 1.7297924204129345e-09
of O 0 3.14393910905153e-09
onset O 0 6.180123790500147e-08
, O 0 3.8328951124100286e-11
this O 0 2.152548972400581e-12
correlation O 0 4.8808977692882394e-11
is O 0 1.3452777086753187e-11
not O 0 3.4406227866767836e-12
precise O 0 8.766279369076813e-10
and O 0 4.69045878526142e-11
measured O 0 5.55812118552268e-10
allele O 0 3.7955832921099386e-10
length O 0 1.135705085530958e-09
cannot O 0 6.692224552296011e-10
be O 0 4.057635824561423e-11
used O 0 2.615108823933454e-11
as O 0 6.9050724339769776e-12
an O 0 5.631361262720125e-12
accurate O 0 3.995608288676067e-09
predictor O 0 4.174381729171728e-07
of O 0 2.396953568961635e-08
age O 0 1.1309456340313773e-06
of O 0 1.3499085298462887e-06
onset O 0 0.0015463076997548342
. O 0 1.4485331121250056e-06

In O 0 7.649038025192567e-08
order O 0 3.489827538061263e-09
to O 0 2.428797996056886e-10
further O 0 4.5853912333804203e-10
characterize O 0 2.0338491779625656e-08
the O 0 5.827564653060335e-09
dynamics O 0 8.084525688900612e-06
of O 0 3.287255094619468e-05
DM B-Disease 1 1.0
CTG O 0 0.012164921499788761
repeat O 0 3.0694127417518757e-06
somatic O 0 3.0557496302208165e-06
instability O 0 2.719448502830346e-06
, O 0 2.7772750765819865e-09
we O 0 1.0228371483123055e-09
have O 0 3.964449948878901e-11
studied O 0 3.6202947306662736e-09
repeat O 0 5.288797177982474e-10
length O 0 6.20951276508741e-11
changes O 0 1.8592703765474283e-11
over O 0 3.4976008200793274e-11
time O 0 1.4054685193443106e-10
in O 0 5.308363193456955e-10
111 O 0 2.646935718075838e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.122534467247533e-08
with O 0 1.1016237227989834e-10
varying O 0 2.0649546517148565e-09
clinical O 0 4.087134897190481e-08
severity O 0 1.9953829166752257e-07
and O 0 3.7140308606353756e-09
CTG O 0 5.739785819969256e-07
repeat O 0 5.229776611770376e-09
size O 0 3.5606867454518465e-10
over O 0 2.1292592689015066e-10
time O 0 4.251451968251274e-10
intervals O 0 1.2875707167125938e-09
of O 0 1.4779143464593858e-09
1 O 0 5.572148964461121e-08
- O 0 1.7498864579579276e-08
7 O 0 4.488651583756109e-08
years O 0 3.012480576103371e-08
. O 0 5.9186493928109485e-08

We O 0 8.031457809920539e-08
have O 0 5.117832824197421e-10
found O 0 2.702108814478521e-10
a O 0 7.140073948752601e-11
direct O 0 2.2377782959992487e-10
progression O 0 2.1829007934570654e-08
of O 0 1.149110495646255e-08
the O 0 1.4062737641040712e-09
size O 0 8.782043425803465e-10
heterogeneity O 0 4.9915445110571e-09
over O 0 7.749845210014428e-10
time O 0 1.1708045644098775e-09
related O 0 1.1770381336262403e-09
to O 0 1.1266342719862266e-10
initial O 0 1.999881149572502e-09
CTG O 0 2.761351822755387e-07
repeat O 0 5.580463202647934e-09
size O 0 1.554333550757292e-09
and O 0 2.6619828563667625e-10
the O 0 1.8414834934699087e-10
time O 0 3.6453412510795147e-10
interval O 0 9.65291735433027e-10
and O 0 7.624468417732899e-11
always O 0 2.919114117094779e-10
biased O 0 4.903425443458787e-10
towards O 0 4.716171342344921e-10
further O 0 6.134691088455213e-10
expansion O 0 3.9690181807827685e-08
. O 0 1.0867742616937903e-07

Attempts O 0 2.67865118530608e-07
to O 0 9.270525680449282e-09
mathematically O 0 2.3153558004196384e-07
model O 0 1.2459875797787845e-08
the O 0 1.4196741560112969e-08
dynamics O 0 1.107873504224699e-05
have O 0 4.167418410361279e-09
proved O 0 2.395500757756963e-07
only O 0 1.5715993784137794e-10
partially O 0 5.350030640727255e-09
successful O 0 1.599738563839992e-09
suggesting O 0 9.036721926314328e-10
that O 0 3.3810133512335305e-12
individual O 0 3.4993186191593917e-13
specific O 0 5.6022109694298106e-12
genetic O 0 2.2904959873226716e-10
and O 0 1.7182923139902329e-10
/ O 0 2.7379604361499332e-08
or O 0 4.5519296665297304e-10
environmental O 0 2.4320765401597555e-09
factors O 0 1.494640500254718e-08
also O 0 5.5534693510495e-10
play O 0 1.021751572238827e-08
a O 0 1.6343550957031994e-09
role O 0 6.241697825259962e-09
in O 0 1.5504259209819793e-08
somatic O 0 1.5117590237423428e-06
mosaicism O 0 8.479470125166699e-05
. O 0 1.0362954583342798e-07
. O 0 4.0707007542550855e-07

Aspartylglucosaminuria B-Disease 1 0.9999967813491821
among O 0 3.8971755600414326e-08
Palestinian O 0 1.7917773220688105e-07
Arabs O 0 5.211651341596735e-07
. O 0 4.721478035207838e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.43310242891311646
AGU B-Disease 1 1.0
) O 0 6.846333633347967e-08
is O 0 1.92197613380074e-09
a O 0 2.424883183138604e-09
rare O 0 5.441185066956677e-07
disorder B-Disease 1 0.9999997615814209
of I-Disease 1 0.9959228038787842
glycoprotein I-Disease 1 0.9999066591262817
metabolism I-Disease 1 0.9999860525131226
caused O 0 1.144624889093393e-06
by O 0 5.85112847062419e-10
the O 0 3.103516021951691e-08
deficiency B-Disease 1 0.6272447109222412
of I-Disease 0 3.412980277062161e-06
the I-Disease 0 2.7763240950662293e-07
lysosomal I-Disease 0 0.00027243446675129235
enzyme I-Disease 0 1.1616688766480365e-07
aspartylglucosaminidase I-Disease 0 1.0721848411776591e-05
( O 0 1.4365403977478763e-08
AGA O 0 4.308104962547077e-06
) O 0 5.717959794537819e-08
. O 0 3.0162152597768e-07

AGU B-Disease 1 1.0
is O 0 1.9136534774588654e-06
inherited O 0 0.00011544401058927178
as O 0 5.584618989473711e-08
an O 0 1.7563534626674482e-08
autosomal O 0 0.395751029253006
recessive O 0 0.006027768831700087
trait O 0 4.2404685700603295e-06
and O 0 1.926410497787856e-08
occurs O 0 5.174312533995362e-09
with O 0 1.6046516893020168e-10
a O 0 9.083656604680357e-10
high O 0 1.404947536087775e-08
frequency O 0 3.6107316248035204e-08
in O 0 5.058575225369566e-10
Finland O 0 1.7097482540862075e-08
because O 0 4.1684661278296176e-10
of O 0 1.2079336642045746e-08
a O 0 1.1951367007156932e-08
founder O 0 6.092967623771983e-07
effect O 0 7.768512659822591e-07
. O 0 4.6675435783072317e-07

While O 0 5.87686997732817e-07
very O 0 5.4210946842658814e-08
few O 0 5.87103077265283e-09
patients O 0 1.8697026149538942e-09
with O 0 6.4936207522237055e-09
AGU B-Disease 1 1.0
have O 0 1.8116144140378765e-09
been O 0 2.982701308162916e-10
reported O 0 3.2945840500175905e-11
from O 0 5.1894984837153046e-11
non O 0 2.622174033461988e-09
- O 0 1.3225771589020496e-09
Finnish O 0 1.0929893505817745e-06
origin O 0 1.0231088864998128e-08
, O 0 3.5604827419710716e-10
we O 0 2.712560454032342e-10
diagnosed O 0 9.477205509256237e-08
the O 0 1.8747161600884965e-09
disorder O 0 1.3948591686130385e-06
in O 0 1.2432189722133558e-09
8 O 0 1.0917684534206273e-08
patients O 0 1.7806921215335336e-10
originating O 0 4.936485664686074e-10
from O 0 2.938621568304711e-10
3 O 0 1.02729353912423e-08
unrelated O 0 1.006083572008265e-08
families O 0 2.0697830602212086e-11
, O 0 2.185638649232491e-11
all O 0 3.524923191874918e-12
Palestinian O 0 7.900692877704785e-10
Arabs O 0 1.3526918474227045e-09
from O 0 5.099825006738001e-10
the O 0 2.4292798328495735e-10
region O 0 1.2773996305170954e-09
of O 0 6.5473599875076616e-09
Jerusalem O 0 6.053334118405473e-07
. O 0 4.054277553677821e-07

The O 0 8.300830245389079e-08
clinical O 0 1.2324263479968067e-05
diagnosis O 1 0.9853885769844055
of O 1 0.9400219321250916
AGU B-Disease 1 1.0
is O 0 6.099019742578093e-07
often O 0 3.120996572292256e-09
difficult O 0 6.285794551530444e-09
, O 0 1.1299786800700318e-10
in O 0 5.219566792669106e-11
particular O 0 1.0575718772942722e-10
early O 0 8.577167309731237e-10
in O 0 4.5899041511976435e-11
the O 0 1.9966404918303482e-10
course O 0 2.112932051545613e-09
of O 0 7.666265400274597e-10
the O 0 1.3164663803522103e-09
disease O 0 6.987720269080455e-08
, O 0 5.7819211224385825e-11
and O 0 3.9792835693219786e-11
most O 0 8.422391256646122e-11
of O 0 3.3573701596623096e-09
the O 0 3.217182076298286e-09
patients O 0 1.3924940311937917e-08
are O 0 7.763333725874233e-11
diagnosed O 0 2.612216398745204e-08
after O 0 1.0783900439292893e-09
the O 0 5.903412203522862e-10
age O 0 1.3948385557682741e-08
of O 0 1.630165513688553e-08
5 O 0 3.762287548170207e-08
years O 0 1.8238610621779117e-08
. O 0 4.313714185855133e-08

However O 0 3.385931961474853e-07
, O 0 9.316329929731637e-09
since O 0 2.5314546014953976e-09
these O 0 1.5785930895795275e-10
patients O 0 4.1289091590179794e-10
excrete O 0 6.931738738558124e-09
early O 0 3.174131846250816e-09
large O 0 9.071186163334133e-11
amounts O 0 9.474901974115824e-10
of O 0 2.1751858092500242e-09
aspartylglucosamine O 0 5.326787544390754e-08
in O 0 4.043199108849649e-10
urine O 0 3.945126447746361e-10
, O 0 5.2231319963569334e-11
biochemical O 0 5.595915397726969e-10
screening O 0 8.186638589258166e-10
is O 0 1.0163510311134161e-10
easy O 0 4.550957111160159e-10
by O 0 2.2134798161044245e-10
urine O 0 7.582029226682607e-09
chromatography O 0 8.639203770144377e-07
. O 0 4.2661994825721195e-08
. O 0 2.666381817562069e-07

Detection O 0 3.0378566862054868e-06
of O 0 6.335592672712664e-08
heterozygous O 0 2.65066057991703e-09
carriers O 0 5.363054444984527e-10
of O 0 5.887335063903265e-09
the O 0 2.15515015611345e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 1.3262996390039916e-06
ATM O 0 2.094091360049788e-05
) O 0 2.163769163843199e-09
gene O 0 1.462558296694283e-09
by O 0 1.1970660018789658e-09
G2 O 0 6.976345957809826e-06
phase O 0 3.910476516466588e-05
chromosomal O 0 9.947167563950643e-05
radiosensitivity O 0 8.50742871989496e-05
of O 0 1.98576685761509e-06
peripheral O 0 0.0007433577557094395
blood O 0 2.715234813877032e-06
lymphocytes O 0 1.8687605916056782e-06
. O 0 8.523445558239473e-07

In O 0 5.6627926824148744e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9978402853012085
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.2113045616833915e-08
patients O 0 7.609425978216677e-09
, O 0 2.015034944458094e-10
mutations O 0 1.7240077421210032e-10
in O 0 2.814565247533096e-10
a O 0 2.6084301385509434e-10
single O 0 9.588285027062327e-11
gene O 0 7.485934649942294e-10
, O 0 5.237380529266034e-10
ATM O 0 5.6598974396138146e-08
, O 0 7.06631766989041e-11
result O 0 6.35771227330828e-11
in O 0 4.4184308989336785e-11
an O 0 6.526911455750906e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 2.914800347753044e-07
embraces O 0 7.888262842925542e-08
a O 0 6.481502556887619e-10
variety O 0 4.624476357406593e-10
of O 0 1.4761001310148458e-09
clinical O 0 3.691726702115261e-09
features O 0 1.1068137517611376e-09
and O 0 2.652788544388329e-10
manifests O 0 1.3333679937943543e-08
extreme O 0 2.104804508462621e-07
radiosensitivity O 0 8.000433808774687e-07
and O 0 1.830390949919547e-09
a O 0 2.048322400582947e-09
strong O 0 8.034008458501773e-10
pre O 0 3.8436337490566075e-06
- O 0 3.4797005810105475e-07
disposition O 0 1.3267690519569442e-06
to O 0 1.5489243665456343e-08
malignancy B-Disease 0 0.00034042863990180194
. O 0 4.400280317895522e-07

Heterozygotes O 0 2.448072564220638e-06
for O 0 2.4929605046963843e-08
the O 0 1.0644332526510425e-08
ATM O 0 5.918412284700025e-07
gene O 0 4.050093593832571e-09
have O 0 9.080152602036762e-11
no O 0 7.39837843766189e-11
clinical O 0 8.501723769427372e-10
expression O 0 4.34693125939134e-09
of O 0 3.553197984729195e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.6291085813691097e-08
may O 0 7.036708993268803e-09
be O 0 1.1451540826712403e-09
cancer B-Disease 0 2.1624093449190696e-07
prone O 0 2.0707773273898056e-08
with O 0 8.596293121776455e-11
a O 0 2.605532234412067e-09
moderate O 0 2.2497721019476558e-08
increase O 0 4.27081980891586e-10
in O 0 1.283965600507031e-09
in O 0 4.7130446212406696e-09
vitro O 0 1.5472950565253996e-07
radiosensitivity O 0 1.9160825104336254e-06
. O 0 2.2958525391914009e-07

We O 0 7.690217529443544e-08
performed O 0 3.829646004760434e-07
a O 0 4.459866076444996e-08
blind O 0 1.353342042875738e-07
chromosomal O 0 1.936848690320403e-07
analysis O 0 2.1634525282365757e-08
on O 0 9.579559900885215e-08
G2 O 0 9.204526350004016e-07
- O 0 7.370639210080299e-09
phase O 0 6.337596669681034e-09
lymphocytes O 0 9.145367102503243e-11
from O 0 2.490595785165084e-10
7 O 0 5.2180491039166554e-09
unrelated O 0 3.971857864826234e-08
A B-Disease 1 0.99998939037323
- I-Disease 1 0.9999585151672363
T I-Disease 1 1.0
patients O 0 1.627899592904214e-07
, O 0 1.5984209511543668e-09
13 O 0 7.2104251458426916e-09
obligate O 0 1.4305440387829549e-08
A B-Disease 1 0.9999985694885254
- I-Disease 1 0.9998084902763367
T I-Disease 1 0.9999988079071045
heterozygotes O 0 1.7589635490367073e-06
( O 0 5.528801860776866e-10
parents O 0 4.2731561344933056e-11
of O 0 7.964765652568317e-11
the O 0 4.77493045103472e-11
patients O 0 5.155166918346943e-11
) O 0 7.542913342539759e-12
, O 0 1.7382709854851797e-11
and O 0 4.9779621397183504e-11
14 O 0 2.6831592503384627e-09
normal O 0 6.7352026178468805e-09
controls O 0 9.8987937846573e-09
following O 0 5.449505291466039e-10
X O 0 9.199158057526802e-08
- O 0 7.710217353462667e-09
irradiation O 0 5.762549992738286e-09
with O 0 5.394323876473095e-10
1 O 0 9.652190158249141e-08
Gy O 0 6.24815612582097e-08
in O 0 3.429966033419163e-10
order O 0 1.647732089660181e-10
to O 0 5.5586590885781106e-11
evaluate O 0 1.288017692502308e-09
this O 0 8.677342178131653e-11
cytogenetic O 0 1.8509074095618416e-07
method O 0 3.70802304416884e-08
as O 0 5.770840472152372e-10
a O 0 4.84505102704702e-10
tool O 0 6.064958313345414e-09
for O 0 9.308416537567865e-11
detection O 0 1.1117572285002097e-07
of O 0 9.215314378252515e-08
ATM O 0 1.2967099792149384e-05
carriers O 0 3.815978004695353e-07
. O 0 1.9547930207863828e-07

Both O 0 2.50772154686274e-06
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999993085861206
T I-Disease 1 0.9999998807907104
homozygotes O 0 8.656516911287326e-06
and O 0 1.7171660759984775e-09
heterozygotes O 0 1.553297046541502e-08
showed O 0 7.679085145539943e-10
significantly O 0 1.2619245925993283e-10
increased O 0 1.1599479710078242e-10
levels O 0 7.809689561710798e-10
of O 0 9.289071178919528e-10
radiation O 0 2.6839345082407817e-05
- O 0 2.2563969537259254e-07
induced O 0 4.977371759196103e-07
chromatid O 0 1.3174148989492096e-05
damage O 0 1.5830125903448788e-06
relative O 0 1.5668321395878593e-07
to O 0 2.542539512262465e-10
that O 0 1.1157259838245892e-10
of O 0 3.748661825397903e-09
normal O 0 1.501263966474653e-07
controls O 0 7.713080663052096e-07
. O 0 8.475308987954122e-08

These O 0 5.615677256542995e-09
results O 0 5.25659826777769e-09
show O 0 2.7232096577733955e-09
that O 0 5.2489186608273286e-11
the O 0 1.5034804512481514e-09
G2 O 0 2.892652446462307e-07
- O 0 2.8778536886875372e-08
phase O 0 1.8424205450173758e-07
chromosomal O 0 1.4959931604607846e-07
radiosensitivity O 0 2.0518081100817653e-07
assay O 0 1.082324274648272e-08
can O 0 6.801135349343568e-11
be O 0 1.3939001862472988e-11
used O 0 1.766213911236214e-11
for O 0 2.6134222824020226e-12
the O 0 4.006800100042618e-11
detection O 0 4.008824561196889e-08
of O 0 1.9777563409206778e-07
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
heterozygotes O 0 0.0001310263032792136
. O 0 1.5625017795173335e-06

In O 0 1.4611127596708684e-07
combination O 0 2.036737924981935e-07
with O 0 2.977848190255372e-09
molecular O 0 2.9142131552362116e-06
genetic O 0 1.3997681946875673e-07
analyses O 0 2.0026877933787546e-08
, O 0 4.784012630487666e-10
this O 0 2.586022715411751e-11
test O 0 2.0453311266876995e-10
may O 0 5.504009747969718e-11
be O 0 1.632365943804448e-11
of O 0 2.705449059225984e-11
value O 0 5.768350727630711e-11
in O 0 1.2885201586265715e-11
studies O 0 1.310990760394759e-10
of O 0 1.8925529199353974e-10
familial B-Disease 0 4.702727096628223e-09
and I-Disease 0 1.4955865434984617e-09
sporadic I-Disease 0 9.490099728282075e-07
cancers I-Disease 0 7.873944014136214e-06
aimed O 0 1.1835836488671703e-07
at O 0 4.328962432964545e-08
determination O 0 7.36654870436837e-09
of O 0 1.5882039017256488e-09
the O 0 9.708490261717273e-11
potential O 0 2.6739974123835e-10
involvement O 0 3.070998566556682e-09
of O 0 6.141765762635032e-09
ATM O 0 1.5349596651503816e-06
mutations O 0 7.284879366409314e-09
in O 0 3.837975715015318e-09
tumor B-Disease 0 4.53178563475376e-06
risk O 0 4.4467901716416236e-07
or O 0 8.107347682084765e-09
development O 0 4.7684757475963124e-08
. O 0 1.9362607517336983e-08
. O 0 1.6822178849906777e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
: O 0 2.0672846545721768e-08
identification O 0 2.009739041852754e-09
and O 0 1.750138367562215e-10
detection O 0 1.9733325018478354e-07
of O 0 1.8010869951012864e-07
founder O 0 5.850113211636199e-06
- O 0 1.315024462655856e-07
effect O 0 1.1259602672453184e-07
mutations O 0 2.0283084101180293e-09
in O 0 3.8652361866731155e-10
the O 0 6.468313107355073e-10
ATM O 0 5.0949111596310104e-08
gene O 0 7.081932262842372e-10
in O 0 1.9619696145500853e-10
ethnic O 0 7.056448758646638e-10
populations O 0 4.4732459403284963e-10
. O 0 1.1897372864666522e-08

To O 0 1.3212767768777667e-08
facilitate O 0 2.9387031474925607e-08
the O 0 2.912519558861959e-09
evaluation O 0 3.076247168110058e-08
of O 0 2.494587114654223e-08
ATM O 0 9.93533944892988e-07
heterozygotes O 0 1.347421942909932e-07
for O 0 1.2232211910045976e-09
susceptibility O 0 3.504443668589374e-08
to O 0 2.8020419318153245e-10
other O 0 2.5602200359742255e-09
diseases O 0 0.01641087979078293
, O 0 2.9584965033357946e-10
such O 0 3.4964151018890277e-10
as O 0 9.831885705580135e-08
breast B-Disease 0 0.06537684053182602
cancer I-Disease 1 0.5402030348777771
, O 0 5.3882004635852354e-08
we O 0 9.804709932836886e-09
have O 0 1.5232462513559142e-10
attempted O 0 3.1462665806003542e-09
to O 0 2.692091514988615e-11
define O 0 2.142001909177793e-09
the O 0 2.48851134143635e-10
most O 0 2.210938550295527e-11
common O 0 9.618943662415003e-12
mutations O 0 3.532596090649598e-12
and O 0 1.4667101084012146e-12
their O 0 1.5287457714660557e-12
frequencies O 0 1.3030114764944756e-09
in O 0 1.2210329636275219e-08
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999933242797852
telangiectasia I-Disease 1 1.0
( O 0 0.0001883951626950875
A B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
) O 0 1.1203161953687868e-08
homozygotes O 0 2.861417840449576e-07
from O 0 2.329213488749815e-09
10 O 0 1.3795791176107741e-09
ethnic O 0 6.31837859810247e-10
populations O 0 8.770092430054888e-10
. O 0 2.4404235077213343e-08

Both O 0 2.3630892798109926e-08
genomic O 0 5.898285593275432e-08
mutations O 0 3.079767996183591e-09
and O 0 1.6917880985012346e-10
their O 0 5.736247934984284e-11
effects O 0 1.2695443274424179e-07
on O 0 2.674382670875275e-08
cDNA O 0 5.530209890025617e-08
were O 0 4.561631516963871e-09
characterized O 0 3.772333201368383e-08
. O 0 6.807763952565438e-08

Protein O 0 1.3714030728806392e-06
- O 0 1.1365241903149581e-07
truncation O 0 1.850021504878896e-07
testing O 0 4.208275061756694e-09
of O 0 3.98934885126323e-09
the O 0 4.190571500917173e-10
entire O 0 5.175121664535709e-09
ATM O 0 2.3091939027608532e-08
cDNA O 0 5.65404656427404e-09
detected O 0 5.306128425530687e-09
92 O 0 1.0274933792686625e-08
( O 0 2.0666481026498928e-10
66 O 0 5.144102477316892e-09
% O 0 1.3954279398653568e-10
) O 0 5.5156958861379835e-11
truncating O 0 9.352400631712499e-09
mutations O 0 1.0005906103671691e-09
in O 0 1.0313648823867538e-09
140 O 0 3.414914351296261e-09
mutant O 0 5.816282122594885e-09
alleles O 0 6.605133329173896e-09
screened O 0 4.303803393668204e-07
. O 0 1.502267963360282e-07

The O 0 1.656216568335367e-07
haplotyping O 0 2.3925196728669107e-05
of O 0 1.1614184813879547e-07
patients O 0 2.277775745795907e-09
with O 0 4.118752561232952e-11
identical O 0 1.5915828655010955e-08
mutations O 0 4.5989523300704604e-09
indicates O 0 5.105122102833093e-09
that O 0 9.597726086107983e-11
almost O 0 6.325191481693082e-10
all O 0 2.3474255525512966e-11
of O 0 6.000355767810106e-11
these O 0 1.1574119484006329e-12
represent O 0 1.0035981594380683e-11
common O 0 2.6312443543452524e-11
ancestry O 0 3.39444236607811e-11
and O 0 3.215393576394554e-11
that O 0 7.190774885257323e-12
very O 0 8.710539234346726e-11
few O 0 1.358829992970101e-10
spontaneously O 0 4.48258319352135e-09
recurring O 0 4.9572008720133454e-08
ATM O 0 2.6763073037727736e-06
mutations O 0 5.577625117325624e-08
exist O 0 1.2707315022453258e-07
. O 0 1.8041315286154713e-07

Assays O 0 8.60378349898383e-07
requiring O 0 3.772304424387585e-08
minimal O 0 1.832635092569035e-07
amounts O 0 1.3615322203008873e-08
of O 0 3.423849648243049e-09
genomic O 0 3.729683673014961e-09
DNA O 0 2.5295141536929577e-09
were O 0 2.475917804112271e-10
designed O 0 6.44364839264e-10
to O 0 1.6761134147280643e-11
allow O 0 3.6127725810963796e-11
rapid O 0 1.2121982306823043e-09
screening O 0 1.1427496726668096e-09
for O 0 1.1073707228970164e-10
common O 0 1.3188639069738883e-09
ethnic O 0 7.104570709515201e-09
mutations O 0 1.265830462671147e-07
. O 0 1.556757496246064e-07

These O 0 2.8201230239943698e-09
rapid O 0 2.962192269251318e-08
assays O 0 5.48077982998052e-09
detected O 0 3.4457834363621487e-09
mutations O 0 2.847362345903548e-10
in O 0 9.088036573290381e-11
76 O 0 9.28599330762836e-09
% O 0 4.801820607802654e-10
of O 0 1.3635903961528584e-08
Costa O 0 4.6891196348042286e-07
Rican O 0 1.7650668269197922e-06
patients O 0 4.315672796906256e-08
( O 0 3.58191198923663e-10
3 O 0 3.2871743105289397e-09
) O 0 1.2981977472181772e-11
, O 0 1.5301643632725792e-11
50 O 0 9.898727670876184e-11
% O 0 1.8094026277282182e-11
of O 0 6.895866100364856e-10
Norwegian O 0 3.1372380249194975e-07
patients O 0 8.416731311911008e-09
( O 0 1.7542592378738675e-10
1 O 0 4.5135979398480686e-09
) O 0 1.4059988416581515e-11
, O 0 2.4005417445516208e-11
25 O 0 1.188683595998441e-10
% O 0 3.1341887418712133e-11
of O 0 6.250320261358411e-10
Polish O 0 6.409712227650743e-07
patients O 0 1.581928543714639e-08
( O 0 1.5497028660327317e-10
4 O 0 1.029808016639322e-09
) O 0 1.12136411267727e-11
, O 0 1.0863887046907994e-11
and O 0 5.126503388463988e-12
14 O 0 3.9951267294391357e-10
% O 0 6.596804352776431e-11
of O 0 3.4233924584015085e-09
Italian O 0 1.196419725602027e-05
patients O 0 8.738975054711773e-08
( O 0 3.6614591913952665e-10
1 O 0 2.990291747551055e-08
) O 0 4.0752734520310696e-11
, O 0 3.0128035483079074e-11
as O 0 2.1619806639394668e-11
well O 0 1.685754313918153e-11
as O 0 1.6947649880694193e-11
in O 0 3.794017877645217e-11
patients O 0 2.0061380334723822e-10
of O 0 1.0685464069126738e-08
Amish O 0 6.406816055459785e-08
/ O 0 1.0009523521148367e-07
Mennonite O 0 6.703574939592727e-08
and O 0 2.088984984993658e-09
Irish O 0 4.980866563641939e-08
English O 0 8.345264035369837e-08
backgrounds O 0 8.672423490452275e-08
. O 0 5.7773881678713224e-08

Additional O 0 2.5329240926907914e-08
mutations O 0 3.8881307062865744e-09
were O 0 1.0952342366365997e-09
observed O 0 1.5906714834201807e-09
in O 0 9.010624885119611e-11
Japanese O 0 6.452420819869076e-09
, O 0 2.5683280502342143e-10
Utah O 0 2.8641908400572902e-08
Mormon O 0 1.5797565477981834e-09
, O 0 3.579328153313632e-11
and O 0 8.180094795973147e-11
African O 0 1.1598518590005824e-08
American O 0 6.04274390525461e-08
patients O 0 1.644295082314784e-07
. O 0 2.3513329949764739e-07

These O 0 6.5146732453058576e-09
assays O 0 1.0285169160795249e-08
should O 0 2.0508077180902973e-10
facilitate O 0 4.176479717621362e-10
screening O 0 3.101455092746619e-09
for O 0 3.1663136557114058e-09
A B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999134540557861
T I-Disease 1 0.9999995231628418
heterozygotes O 0 2.85485157291987e-07
in O 0 5.44536971069931e-10
the O 0 1.0578764947366537e-10
populations O 0 2.022723828709605e-11
studied O 0 8.249215532885046e-09
. O 0 4.2958270274340293e-10
. O 0 9.620609198179864e-09

The O 0 1.931871111082728e-06
von B-Disease 1 0.9931782484054565
Hippel I-Disease 1 0.99849534034729
- I-Disease 1 0.9957322478294373
Lindau I-Disease 1 0.9236159324645996
tumor I-Disease 0 1.761980638548266e-05
suppressor O 0 3.4296469948458252e-06
gene O 0 2.845573554566272e-08
is O 0 4.996590363681719e-10
required O 0 9.058482852708494e-10
for O 0 1.0682849049814536e-09
cell O 0 1.0436684760861681e-07
cycle O 0 7.304748361747215e-09
exit O 0 7.34652649825307e-09
upon O 0 4.877682258097593e-09
serum O 0 7.833477155827495e-08
withdrawal O 0 1.1147001544031809e-07
. O 0 3.196979605490924e-07

The O 0 1.2529122273008397e-07
inactivation O 0 4.480936695472337e-06
of O 0 9.587109417452666e-08
the O 0 3.116471347652805e-08
von B-Disease 1 0.8853281140327454
Hippel I-Disease 1 0.9994014501571655
- I-Disease 1 0.9999703168869019
Lindau I-Disease 1 0.9999496936798096
( I-Disease 0 4.112934561817383e-07
VHL I-Disease 0 5.496601079357788e-05
) I-Disease 0 1.804401073002282e-08
tumor I-Disease 0 2.8314807423157617e-06
suppressor O 0 2.1729370928369462e-05
gene O 0 5.14516045768687e-07
predisposes O 0 1.4674583326268476e-06
affected O 0 1.246222858242163e-08
individuals O 0 5.1381156274121764e-11
to O 0 1.1522829912458121e-10
the O 0 1.1823624745943562e-08
human O 0 0.01019720733165741
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 3.949389704160922e-09
is O 0 2.0702738134925625e-10
associated O 0 1.6287412529791823e-09
with O 0 2.194780329700663e-10
sporadic B-Disease 1 0.6761580109596252
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 0.0003038157010450959
RCC B-Disease 1 0.9997126460075378
) O 0 3.8302623295294325e-08
and O 0 5.3981992209628515e-08
brain B-Disease 1 0.9972932934761047
hemangioblastomas I-Disease 0 0.003284656209871173
. O 0 1.3568005670094863e-06

VHL O 0 0.0007008591201156378
- O 0 6.243169082154054e-06
negative O 0 9.918263543795547e-08
786 O 0 1.4226689927454572e-05
- O 0 9.878862329060212e-05
0 O 0 4.376137496819865e-07
RCC B-Disease 0 1.139704545494169e-05
cells O 0 7.0824626163812354e-09
are O 0 3.675635351640949e-10
tumorigenic O 0 2.982750402225065e-07
in O 0 1.0752112089562615e-08
nude O 0 3.0851956580590922e-06
mice O 0 4.233032058209574e-08
which O 0 1.5259156438407473e-10
is O 0 1.5233732678088252e-11
suppressed O 0 5.0150147923311295e-11
by O 0 4.198439772923335e-12
the O 0 7.215605196675412e-11
reintroduction O 0 4.296444089391116e-09
of O 0 2.1767306179754087e-08
VHL B-Disease 0 1.5842368156882003e-05
. O 0 8.404132358919014e-07

Remarkably O 0 2.4134236809914e-05
, O 0 2.683016031568286e-09
this O 0 2.3801211002094647e-11
occurs O 0 1.0081802059858092e-10
without O 0 9.234163433902154e-11
affecting O 0 1.8474853591410323e-10
the O 0 3.8444560035433284e-11
growth O 0 1.0343784856425842e-10
rate O 0 2.0827140012613654e-10
and O 0 2.0945564727092858e-11
cell O 0 2.2336514859944145e-09
cycle O 0 4.089142635610443e-10
profile O 0 1.737801014201068e-10
of O 0 2.64848115660854e-10
these O 0 2.061112218398886e-11
cells O 0 1.6108614442345015e-10
in O 0 5.378091860741563e-10
culture O 0 5.0458986322610144e-08
. O 0 3.1658203170081833e-08

The O 0 3.741521084066335e-07
786 O 0 9.679835784481838e-06
- O 0 6.865143404866103e-06
0 O 0 9.394454281164144e-08
cell O 0 7.981034144677324e-08
line O 0 3.785848079473908e-08
, O 0 2.179495334209136e-10
like O 0 1.0079263812468042e-10
many O 0 8.040520332874834e-11
cancer B-Disease 0 3.839618045731186e-08
cells O 0 8.830771114354263e-10
, O 0 7.49597939275759e-10
fails O 0 3.6979987960705785e-09
to O 0 4.804715514339364e-10
exit O 0 3.2661581883530744e-08
the O 0 5.149226822709352e-09
cell O 0 5.320837104250131e-08
cycle O 0 3.799989656272373e-09
upon O 0 4.4015786571094395e-09
serum O 0 2.0109096610099186e-08
withdrawal O 0 3.3483868122630156e-08
. O 0 1.9956530650233617e-07

Here O 0 2.6759091724670725e-06
, O 0 1.0482485990337409e-08
it O 0 9.14376213634327e-11
is O 0 5.501666396762195e-12
shown O 0 6.07134871891124e-12
that O 0 5.632550632503341e-13
reintroduction O 0 4.7028752420130715e-11
of O 0 8.207898943846104e-11
the O 0 9.859985744542499e-11
wild O 0 3.768309275731241e-10
- O 0 4.206654136140742e-09
type O 0 1.6814505343631936e-08
VHL B-Disease 0 6.339049605230684e-07
gene O 0 6.540457508918962e-09
restores O 0 4.323335289768693e-08
the O 0 1.686579320647752e-09
ability O 0 4.29347046804196e-09
of O 0 4.0038196402747417e-07
VHL O 0 0.001994864549487829
- O 0 0.00016783588216640055
negative O 0 6.139654828984931e-07
RCC B-Disease 1 0.9986067414283752
cancer I-Disease 0 2.662762017280329e-05
cells O 0 5.010182047016087e-09
to O 0 6.29081731151615e-10
exit O 0 1.6453750362188657e-08
the O 0 1.897976442677418e-09
cell O 0 1.298878338218401e-08
cycle O 0 5.738132746735403e-10
and O 0 6.948953912289113e-11
enter O 0 3.1212346041087358e-09
G0 O 0 2.3264988158189226e-06
/ O 0 1.9163641695740807e-07
quiescence O 0 1.0309197477909038e-06
in O 0 8.100159654134131e-09
low O 0 1.8490159447992482e-07
serum O 0 7.797952861210433e-08
. O 0 3.166961448641814e-08

Both O 0 1.8531482055550441e-06
VHL O 0 0.0005088251200504601
- O 0 1.8850417973226286e-06
positive O 0 9.067804285223247e-09
and O 0 1.922050429925548e-08
VHL O 0 0.00017629220383241773
- O 0 2.9842346975783585e-06
negative O 0 3.465664377699795e-08
RCC B-Disease 0 6.240273069124669e-05
cells O 0 4.646210527425865e-09
exit O 0 2.5528777314320905e-08
the O 0 6.554903286826175e-10
cell O 0 1.1113201026091701e-08
cycle O 0 6.998451262951733e-10
by O 0 2.40601028683729e-11
contact O 0 3.411615523418732e-08
inhibition O 0 6.728855055371241e-07
. O 0 4.88973853407515e-07

The O 0 7.633937002538005e-07
cyclin O 0 1.9567492927308194e-05
- O 0 1.3089528465570766e-06
dependent O 0 7.908208488061064e-08
kinase O 0 2.011940267721002e-07
inhibitor O 0 1.8473978968813753e-07
, O 0 3.21398663238881e-09
p27 O 0 1.848016495387128e-07
, O 0 9.293679159583235e-10
accumulates O 0 3.90431598162877e-09
upon O 0 6.011550701678914e-10
serum O 0 2.8261861739764527e-09
withdrawal O 0 8.205804924443783e-10
, O 0 2.1324213228535172e-10
only O 0 1.885267289503112e-11
in O 0 2.95795887783612e-11
the O 0 1.1939871313870754e-10
presence O 0 1.4181686935899052e-09
of O 0 3.896365541322666e-08
VHL B-Disease 0 4.8130127652257215e-06
, O 0 3.447479413054566e-09
as O 0 4.636258044143915e-10
a O 0 2.0271780087899316e-10
result O 0 3.926060032632961e-10
of O 0 9.659161248620762e-10
the O 0 2.6729879420983593e-10
stabilization O 0 1.3387148101173807e-07
of O 0 2.428321579373005e-07
the O 0 9.464632455546962e-08
protein O 0 5.613565008388832e-07
. O 0 2.716913343192573e-07

We O 0 8.950105012672793e-08
propose O 0 3.3188900516734066e-08
that O 0 1.0870733480050632e-10
the O 0 6.625520132530482e-10
loss O 0 1.0119610927006306e-08
of O 0 5.563865101976262e-08
wild O 0 1.5303417200129843e-08
- O 0 4.2611816297721816e-08
type O 0 1.342391584557845e-07
VHL B-Disease 0 2.1836144696862902e-06
gene O 0 4.565078093321517e-09
results O 0 2.5171165152215735e-09
in O 0 3.7762168392241335e-10
a O 0 1.0789655280341037e-10
specific O 0 1.1350505257912147e-10
cellular O 0 1.4449800289639825e-07
defect O 0 2.155696847694344e-07
in O 0 4.234749884091116e-09
serum O 0 3.8604582641710294e-08
- O 0 3.4227412015752634e-08
dependent O 0 1.9345625545952316e-08
growth O 0 4.673273767963337e-09
control O 0 2.397517391727888e-06
, O 0 1.22721266482273e-09
which O 0 5.382738005321741e-11
may O 0 5.46251321953406e-10
initiate O 0 3.110121493676843e-09
tumor B-Disease 0 4.3055931087110366e-07
formation O 0 2.240156163679785e-06
. O 0 2.475741666785325e-06

This O 0 2.793320419414158e-08
is O 0 4.729893809951591e-09
corrected O 0 1.7848833522293717e-08
by O 0 9.801576911216969e-11
the O 0 6.438329314129021e-10
reintroduction O 0 9.782238130640053e-09
of O 0 8.092531977865747e-09
wild O 0 5.268934621938115e-09
- O 0 8.121388361814752e-08
type O 0 1.619878730707569e-06
VHL B-Disease 0 0.0724782645702362
, O 0 6.028320171935775e-07
implicating O 0 0.0030517566483467817
VHL B-Disease 0 0.0010204380378127098
as O 0 4.736044090236646e-08
the O 0 4.0356891162218744e-09
first O 0 2.4612005766755374e-09
tumor B-Disease 0 2.7755447717936477e-08
suppressor O 0 2.0742864137446304e-07
involved O 0 9.924258748128523e-09
in O 0 5.683453152549589e-10
the O 0 8.869037726455531e-10
regulation O 0 4.8314259259996106e-08
of O 0 1.6823038961888415e-08
cell O 0 7.882668029424167e-08
cycle O 0 5.0060173784061135e-09
exit O 0 2.868535853295384e-09
, O 0 2.120311010100906e-10
which O 0 1.5632216007754884e-11
is O 0 3.563225756120225e-11
consistent O 0 2.4644500329351615e-10
with O 0 2.2391519194364662e-11
its O 0 7.144378838530585e-11
gatekeeper O 0 1.1475269623417717e-08
function O 0 2.0954706414499924e-08
in O 0 1.7508338112648403e-09
the O 0 1.296437890374591e-08
kidney O 0 9.193066216539592e-05
. O 0 2.9526647793431948e-08
. O 0 3.240731984988088e-07

Piebaldism B-Disease 1 1.0
with O 0 0.010617449879646301
deafness B-Disease 1 1.0
: O 0 1.1763411578158411e-07
molecular O 0 1.1556423373804137e-07
evidence O 0 4.783029083910151e-09
for O 0 5.157989660387052e-11
an O 0 5.996408924957564e-11
expanded O 0 3.5246824836576707e-07
syndrome O 1 0.9998949766159058
. O 0 2.470731942594284e-06

In O 0 7.073825969428071e-08
a O 0 1.2697823237317607e-08
South O 0 3.874451692809089e-08
African O 0 1.5838546474356008e-08
girl O 0 1.1392160104151117e-08
of O 0 1.4544027315821495e-08
Xhosa O 0 2.101738573401235e-06
stock O 0 4.6267105702213485e-09
with O 0 3.6798983998886925e-11
severe O 0 2.539102013088268e-07
piebaldism B-Disease 0 1.0042871508630924e-05
and O 0 1.239104534533908e-07
profound O 1 0.9999477863311768
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.1187828931724653e-05
identified O 0 9.51143093175233e-08
a O 0 2.7945070701917984e-09
novel O 0 9.40446831521058e-10
missense O 0 2.5004656123428504e-08
substitution O 0 1.6068401720303882e-08
at O 0 1.1587964365844527e-07
a O 0 4.442722634223628e-09
highly O 0 8.056939115874684e-09
conserved O 0 8.550286700881315e-09
residue O 0 4.578710388614127e-08
in O 0 5.20050946750672e-10
the O 0 1.8611445717908737e-10
intracellular O 0 4.29035962312696e-09
kinase O 0 6.118486606254692e-09
domain O 0 6.118218376371942e-09
of O 0 1.529673454570002e-08
the O 0 8.822004460284916e-09
KIT O 0 4.205884033581242e-05
proto O 0 0.0001276532420888543
- O 0 3.4872891774284653e-06
oncogene O 0 3.7477134355867747e-06
, O 0 6.490687809446172e-08
R796G O 0 4.138831172895152e-06
. O 0 8.224708381021628e-07

Though O 0 2.0265544264930213e-07
auditory B-Disease 0 5.018046067561954e-05
anomalies I-Disease 0 2.4803079213597812e-05
have O 0 6.411491892954757e-10
been O 0 2.792236164506079e-10
observed O 0 5.935975044835118e-10
in O 0 1.8650783695228768e-10
mice O 0 4.08483191716158e-10
with O 0 1.3545654875546376e-10
dominant O 0 1.1487200026749633e-05
white O 0 1.3433277956664824e-07
spotting O 0 2.1942083549220115e-05
( O 0 1.7631469617640505e-08
W O 0 6.648027920164168e-06
) O 0 2.5986271467992594e-10
due O 0 6.710914934870971e-09
to O 0 9.05368113812699e-10
KIT O 0 0.0014984059380367398
mutations O 0 1.0324908544134814e-05
, O 0 1.7008764189085923e-05
deafness B-Disease 1 1.0
is O 0 8.13995200132922e-08
not O 0 5.374779510347594e-10
typical O 0 1.4292023564621559e-08
in O 0 4.4842998758731767e-10
human O 0 7.472358731774875e-09
piebaldism B-Disease 0 2.105305384247913e-06
. O 0 1.3728291037296003e-07

Thus O 0 2.816966855334613e-07
, O 0 1.2543279748200575e-09
the O 0 1.870546911808546e-10
occurrence O 0 2.4001652221272707e-08
of O 0 1.3935083416072302e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 1.1952936347370269e-06
this O 0 2.0217114649057066e-09
patient O 0 3.180476992881154e-09
extends O 0 4.44078857020358e-10
considerably O 0 1.6763038734879387e-09
the O 0 1.038343785952911e-10
phenotypic O 0 2.876909555027396e-08
range O 0 1.9127393002804638e-08
of O 0 3.895984423962773e-09
piebaldism B-Disease 0 2.3905526447265402e-08
due O 0 4.305418688232976e-09
to O 0 1.7629635251648068e-10
KIT O 0 1.8437017956784985e-07
gene O 0 2.1000912120427984e-09
mutation O 0 3.5284045130090647e-10
in O 0 8.279065766281235e-10
humans O 0 4.034411915654346e-09
and O 0 3.081564448059737e-10
tightens O 0 2.368552687315173e-09
the O 0 2.691862011072743e-10
clinical O 0 1.5087611160424785e-08
similarity O 0 1.4439022422152448e-08
between O 0 6.368875204998403e-08
piebaldism B-Disease 0 8.286243655675207e-07
and O 0 8.664540612768334e-11
the O 0 2.637937784877309e-11
various O 0 3.188564343115097e-11
forms O 0 6.054691192858286e-10
of O 0 3.0271166906459257e-07
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999297857284546
. O 0 1.1013437273277304e-07
. O 0 5.05053037613834e-07

Cycloheximide O 0 7.752225428703241e-06
facilitates O 0 3.836879969298934e-08
the O 0 1.3838510337649268e-09
identification O 0 3.681025484425504e-09
of O 0 1.5504673100963373e-08
aberrant O 0 1.7894782544658483e-08
transcripts O 0 8.320707678421968e-08
resulting O 0 4.268940312357472e-09
from O 0 1.8095354104019634e-09
a O 0 8.538808549118926e-10
novel O 0 8.926757111282768e-10
splice O 0 1.9598322964498038e-08
- O 0 3.3302582913563583e-09
site O 0 7.508041965920143e-10
mutation O 0 3.278043947396725e-10
in O 0 1.2053669173894832e-09
COL17A1 O 0 1.4930391444067936e-05
in O 0 1.1220354423358003e-08
a O 0 2.5333866116028503e-09
patient O 0 7.827543946348214e-09
with O 0 5.696001004196205e-09
generalized O 0 0.11191312968730927
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999994039535522
bullosa I-Disease 1 0.9999232292175293
. O 0 4.2883515561698005e-05

Patients O 0 1.8758710496058484e-07
with O 0 4.219559812668194e-09
generalized O 0 0.002637831261381507
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999998807907104
bullosa I-Disease 1 0.9998855590820312
often O 0 1.9349981172922526e-08
show O 0 3.3834701707036174e-09
decreased O 0 8.288012054435967e-09
expression O 0 3.121841674058601e-09
of O 0 9.859732585937309e-09
type O 0 5.129497253619775e-07
XVII O 0 0.0005885327700525522
collagen O 0 1.703302473288204e-06
, O 0 1.79728072424723e-08
a O 0 1.0547244855274585e-08
transmembrane O 0 2.586149783212477e-08
hemidesmosomal O 0 2.3145631189436244e-07
protein O 0 5.045049267238255e-09
encoded O 0 1.2788379244454973e-09
by O 0 2.327810166846689e-09
COL17A1 O 0 3.1915267754811794e-05
. O 0 5.518566013051895e-07

This O 0 1.5405596798245824e-08
report O 0 1.256137971417104e-09
documents O 0 4.913257800609472e-09
a O 0 1.1544175615441077e-09
novel O 0 8.796426920198996e-10
splice O 0 1.2756521172718749e-08
- O 0 2.6967450494908007e-09
site O 0 1.069810240394986e-09
mutation O 0 4.68588279289861e-10
in O 0 1.3329832793118612e-09
COL17A1 O 0 2.8108532205806114e-05
in O 0 6.7490906197065215e-09
a O 0 1.9620456370716965e-09
patient O 0 3.236804158035511e-09
with O 0 7.59970308905622e-10
generalized O 0 0.004576190374791622
atrophic B-Disease 1 0.9999998807907104
benign I-Disease 1 1.0
epidermolysis I-Disease 1 0.9999991655349731
bullosa I-Disease 1 0.9993118047714233
, O 0 3.197747844296828e-08
and O 0 1.067309463032018e-09
applies O 0 2.218675465570641e-09
a O 0 2.7034696703509553e-10
new O 0 6.291318160878134e-11
methodology O 0 2.3643504931669668e-09
to O 0 9.292150382478326e-11
define O 0 8.880332913463462e-09
and O 0 8.204177337489682e-10
characterize O 0 5.4415757233527984e-08
the O 0 3.2186060483496703e-09
resulting O 0 5.988242790522236e-09
mRNA O 0 3.052837271866338e-08
splice O 0 3.641908676854655e-07
variants O 0 3.3806631449806446e-07
. O 0 5.281252697386662e-07

Mutational O 0 1.4403683053387795e-05
analysis O 0 2.1077974565741897e-07
of O 0 3.4283706895621435e-07
COL17A1 O 0 8.038595115067437e-05
identified O 0 2.5636427380959503e-07
a O 0 4.802283370963778e-08
maternally O 0 8.215551474677341e-07
inherited O 0 7.044371886877343e-05
G O 0 3.12888587359339e-05
- O 0 8.630927368358243e-07
to O 0 5.0881517665857245e-08
- O 0 7.1209055931831244e-06
T O 0 1.6831820630613947e-06
transversion O 0 7.066879561534734e-07
at O 0 7.998162487865557e-08
the O 0 7.70314367848357e-10
- O 0 2.1636701319494023e-09
1 O 0 3.755252997450498e-09
position O 0 5.268220970577886e-09
of O 0 3.488598210310556e-08
exon O 0 4.4074789684600546e-07
32 O 0 1.2985497050976846e-06
. O 0 4.0088823993755796e-07

This O 0 6.806852859142509e-09
acceptor O 0 6.080687064979884e-09
splice O 0 3.47737170613982e-07
- O 0 6.192501444957088e-08
site O 0 1.237506186413384e-08
mutation O 0 1.186993947577264e-09
led O 0 2.4839506007623413e-09
to O 0 9.045408172481118e-11
the O 0 1.6410459657834053e-09
formation O 0 1.8716413308084157e-07
of O 0 6.329662483040011e-07
aberrant O 0 1.3937115284079482e-07
transcripts O 0 3.159227617288707e-07
present O 0 6.5905734203397515e-09
at O 0 2.2139363409223733e-07
extremely O 0 8.977870891158091e-08
low O 0 2.14101504525388e-07
levels O 0 2.0861557459284086e-07
. O 0 7.269017743283257e-08

Based O 0 1.4110064228134434e-07
on O 0 4.7597886521089094e-08
our O 0 1.6049495066283725e-09
recent O 0 1.8732032591728398e-10
finding O 0 3.1585850601700827e-10
that O 0 7.016384001579112e-11
cycloheximide O 0 5.2106326364764755e-08
stabilized O 0 1.5003980706751463e-06
mutant O 0 8.357832115279962e-08
COL17A1 O 0 1.77197182438249e-06
transcripts O 0 9.283341029231451e-08
in O 0 3.3256483678023585e-10
keratinocytes O 0 1.9768156001020998e-09
homozygous O 0 1.351464162802074e-09
for O 0 2.254254144462564e-10
a O 0 2.730032866438137e-09
frameshift O 0 4.746145165768212e-08
mutation O 0 7.144982383522347e-10
, O 0 1.778581032452209e-10
the O 0 3.6650646406677367e-10
effects O 0 5.666221341016353e-07
of O 0 7.762383091858283e-08
the O 0 7.2454970911906e-09
splice O 0 3.918171387340408e-08
- O 0 2.0600610106669137e-09
site O 0 1.7624121606552023e-10
mutation O 0 6.822391263039407e-11
on O 0 1.857921372305782e-09
splicing O 0 1.4151431138031967e-08
of O 0 2.9256383982101397e-08
COL17A1 O 0 1.9885812889697263e-06
transcripts O 0 8.966507891727815e-08
were O 0 4.6553272348148766e-10
determined O 0 4.4212319916248077e-10
using O 0 1.3293544043335714e-10
reverse O 0 1.3690129030408116e-09
transcriptase O 0 2.0828032631925453e-08
polymerase O 0 7.535363977240195e-08
chain O 0 1.6256075596743358e-08
reaction O 0 2.4063981918232002e-09
of O 0 7.486052666649812e-09
total O 0 8.299239628861699e-10
RNA O 0 1.0043120113323312e-08
from O 0 1.8232201304257956e-09
keratinocytes O 0 1.1918654507780957e-08
incubated O 0 2.1566462393707297e-08
for O 0 2.163946577482534e-09
2 O 0 2.3556512473987823e-07
. O 0 5.2197936639686304e-08

5 O 0 1.8102323338098358e-06
h O 0 2.937807153102767e-07
in O 0 1.1010592437799005e-09
the O 0 4.4048101277560647e-10
presence O 0 3.386463887089519e-10
or O 0 3.61053548170176e-10
absence O 0 1.7267277385712987e-08
of O 0 3.913757140594498e-08
10 O 0 3.522618285956014e-08
microg O 0 6.890967370054568e-07
cycloheximide O 0 5.025412406212126e-07
per O 0 8.199695145094665e-08
ml O 0 6.263632599257107e-07
. O 0 1.2660031245559367e-07

Using O 0 4.971233025230504e-08
this O 0 6.497506976899103e-10
approach O 0 1.3040664548213954e-08
, O 0 3.757407163185178e-10
an O 0 2.9166205561814706e-10
abnormally O 0 5.1833239922416396e-08
spliced O 0 1.1566731927814544e-07
transcript O 0 3.9658027617406333e-07
was O 0 5.145066950262844e-08
identified O 0 5.102744338181253e-10
that O 0 2.824770148693312e-12
contains O 0 7.65042369732516e-12
an O 0 6.392046180553335e-12
extra O 0 2.616547256639734e-10
264 O 0 4.6413187182459126e-10
bases O 0 3.075123211626618e-10
upstream O 0 3.1930591504192307e-09
from O 0 4.249734786299086e-09
exon O 0 9.592321958962202e-08
32 O 0 2.1197227084712722e-08
, O 0 3.5620859040186303e-10
resulting O 0 1.6773112898604836e-09
in O 0 1.9862795852532145e-09
a O 0 7.177480387809965e-09
premature O 0 2.6408969233671087e-08
termination O 0 6.264002649913891e-08
codon O 0 9.32803274622529e-08
27 O 0 1.7826705516199581e-06
bp O 0 5.788837142972625e-07
downstream O 0 2.541563333124941e-07
from O 0 4.4023870771070506e-08
the O 0 2.3813779392867218e-08
cryptic O 0 7.870849572100269e-07
splice O 0 2.0817030872422038e-06
site O 0 5.75190085783106e-07
. O 0 4.971622047378332e-07

Three O 0 2.7059488871827853e-08
other O 0 8.87387663350836e-10
splice O 0 1.6726540152944835e-08
variants O 0 4.079430127035266e-09
, O 0 3.2912633729509366e-10
including O 0 7.05179040161319e-11
one O 0 4.6491841626528085e-11
derived O 0 1.7435880517169267e-10
from O 0 4.2162431879155804e-10
the O 0 5.728760799073029e-10
skipping O 0 1.4301948958461708e-08
of O 0 1.2162145957006487e-08
exon O 0 9.748044504931386e-08
32 O 0 4.595648661620544e-08
, O 0 1.4961057948070788e-09
were O 0 2.4954425192902363e-09
also O 0 1.6046004525094304e-09
identified O 0 1.8024300274532834e-08
. O 0 1.0236090020043775e-07

These O 0 7.193639017799569e-09
results O 0 4.774798778584e-09
indicate O 0 2.1912136549673278e-09
the O 0 1.4494221101113425e-10
usefulness O 0 3.0950375595750756e-09
of O 0 5.156575721976253e-10
cycloheximide O 0 8.340152568564463e-09
treatment O 0 4.3474765454298847e-10
in O 0 1.4302799396237464e-11
evaluating O 0 2.447702596164447e-10
the O 0 8.649184840558988e-11
abnormal O 0 1.4690557659235992e-09
processing O 0 5.568968841629385e-09
of O 0 2.6088144977620686e-09
mRNA O 0 7.722046335700838e-10
due O 0 4.698755606824534e-09
to O 0 3.376602331073286e-10
splice O 0 1.709767794011441e-08
- O 0 3.4505320822830754e-09
site O 0 5.761074950427769e-10
mutations O 0 2.1711724085271555e-10
, O 0 5.650981904636865e-10
because O 0 1.5351178106470798e-09
( O 0 9.249856991466743e-10
i O 0 3.3738050575493617e-08
) O 0 6.89507728690586e-10
aberrant O 0 1.4610590071129081e-08
splicing O 0 6.004256647429429e-08
often O 0 1.4566841066709912e-09
generates O 0 6.326361656761037e-10
a O 0 4.742656267708867e-10
premature O 0 1.108789393633458e-09
termination O 0 1.8801771251020227e-09
codon O 0 2.1201178590501968e-09
, O 0 1.98573024690063e-09
( O 0 3.0571692399838923e-10
ii O 0 9.346676961285993e-07
) O 0 3.812547222370455e-10
transcripts O 0 8.434859033457087e-09
with O 0 2.337142701591688e-10
premature O 0 7.641014931891732e-09
termination O 0 1.0531078231679203e-09
codons O 0 1.1268777022621634e-09
can O 0 8.910031740194668e-11
occur O 0 4.183112745081985e-10
at O 0 7.444120875277349e-09
low O 0 6.75063560606759e-09
or O 0 2.772822249585971e-10
undetectable O 0 2.7733062069046355e-08
levels O 0 1.5318362134308927e-09
due O 0 3.2555460549588133e-09
to O 0 6.444693667617685e-10
nonsense O 0 2.947510502337991e-08
- O 0 1.260025195293224e-09
mediated O 0 4.29361746157042e-09
mRNA O 0 8.124231842820961e-10
decay O 0 1.7839065336033855e-08
, O 0 5.729839866464026e-11
and O 0 2.1271311101411783e-11
( O 0 3.2714653902532476e-11
iii O 0 9.132811129575202e-08
) O 0 6.699577698165982e-11
the O 0 2.771923246491781e-10
levels O 0 4.649526097466605e-09
of O 0 1.6694405857720085e-09
these O 0 4.6532118436193315e-11
transcripts O 0 3.362791822780764e-09
can O 0 1.5323955646073806e-11
be O 0 7.242570692483907e-12
increased O 0 1.3553350282358156e-11
by O 0 8.158638348243485e-11
cycloheximide O 0 4.293931112897553e-07
. O 0 6.311121580893087e-08

A O 0 1.0674381201170036e-06
deletion O 0 2.883829779420921e-07
mutation O 0 7.968830928462012e-09
in O 0 2.770751184044684e-09
COL17A1 O 0 8.625705959275365e-06
in O 0 3.105527612845549e-09
five O 0 3.700607875689599e-10
Austrian O 0 7.846217187079674e-08
families O 0 1.47017554380513e-11
with O 0 1.1103062219630644e-10
generalized O 0 1.050872651831014e-05
atrophic B-Disease 1 0.9999985694885254
benign I-Disease 1 0.9999998807907104
epidermolysis I-Disease 1 0.9999974966049194
bullosa I-Disease 1 0.9895684123039246
represents O 0 5.163254286344454e-07
propagation O 0 7.012125706751249e-07
of O 0 8.521700323171899e-08
an O 0 2.46455456043293e-09
ancestral O 0 2.5583622687008756e-07
allele O 0 4.875982995145023e-07
. O 0 4.2175383896392304e-07

Patients O 0 4.1048582488656393e-07
with O 0 1.7068744639914257e-08
generalized O 0 0.07148133218288422
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999899864196777
, O 0 1.3066238579995115e-07
a O 0 1.0767031710656738e-08
usually O 0 1.199973898025064e-09
nonlethal O 0 2.670608978405653e-07
form O 0 1.891623746530513e-08
of O 0 2.7007697553926846e-06
junctional B-Disease 1 0.9999749660491943
epidermolysis I-Disease 1 0.9999499320983887
bullosa I-Disease 1 0.8207796812057495
, O 0 1.379535063961157e-08
have O 0 1.9355093916484378e-10
generalized O 0 2.4761186878663466e-08
blistering B-Disease 0 1.1938122668198048e-07
, O 0 1.1378483577573206e-07
nail B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.999994158744812
, O 0 1.9092894945060834e-06
patchy B-Disease 1 0.9998892545700073
alopecia I-Disease 1 1.0
, O 0 1.007611331260705e-06
and O 0 1.99574196813046e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.8907049298286438

Skin B-Disease 1 0.6983283162117004
fragility I-Disease 0 0.268103688955307
in O 0 5.480291420667527e-08
most O 0 4.3155698459251823e-10
cases O 0 1.4372157630671012e-10
is O 0 6.460514415107532e-12
due O 0 3.261691194911265e-10
to O 0 3.956744654143307e-11
mutations O 0 2.2258166143540592e-10
in O 0 1.8750549724000365e-10
the O 0 3.1188701621331916e-10
gene O 0 8.10810085738467e-10
encoding O 0 3.4011875982287165e-08
type O 0 1.8106511561200023e-05
XVII O 1 0.5269068479537964
collagen O 0 0.00010229575855191797
( O 0 3.085220328102878e-07
COL17A1 O 0 0.0001229878980666399
) O 0 1.3292014955368359e-07
. O 0 2.4579233581789595e-07

Recently O 0 4.914675173495198e-06
, O 0 1.8003445845238275e-08
we O 0 9.676365264610354e-10
reported O 0 5.379446332831606e-10
five O 0 5.1024889174966503e-11
Austrian O 0 1.1748922723597843e-08
families O 0 5.5670598339552235e-12
with O 0 3.658999839228905e-11
generalized O 0 8.620919288659934e-06
atrophic B-Disease 1 0.9999997615814209
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999957084655762
who O 0 5.403189220487548e-07
share O 0 1.3392199349482325e-08
the O 0 9.184287108610079e-09
same O 0 3.9269924201335016e-08
COL17A1 O 0 3.490125891403295e-05
mutation O 0 1.0855229959361168e-07
. O 0 1.4468788833710278e-07

Affected O 0 2.1808040173709742e-07
individuals O 0 7.351877440164856e-10
in O 0 1.4964710581821805e-09
three O 0 3.3409386368532523e-10
families O 0 6.292238865363009e-12
are O 0 1.8782492922087e-12
homozygous O 0 2.407249573288528e-11
for O 0 7.875788216038515e-11
4003delTC O 0 5.3325384108404705e-09
, O 0 1.4762345512675523e-10
whereas O 0 3.780526169894216e-10
those O 0 2.6212013462534323e-11
in O 0 1.0002008943299501e-10
two O 0 1.3120288189227836e-10
others O 0 2.2795478005210867e-10
are O 0 9.072535778198443e-11
compound O 0 4.0456558991763814e-08
heterozygotes O 0 1.4157363921185606e-06
. O 0 5.140799999026058e-07

To O 0 6.202170510505312e-08
determine O 0 6.379367079034637e-08
if O 0 6.602585700399288e-10
the O 0 1.1041775133113774e-10
occurrence O 0 1.065135424305197e-09
of O 0 8.225518044469027e-10
4003delTC O 0 5.201008068667079e-09
in O 0 9.811004092474818e-11
these O 0 7.458649149694185e-12
unrelated O 0 4.5614029220431007e-10
families O 0 5.004641991622483e-13
signifies O 0 1.952866514332019e-11
propagation O 0 1.188502851690032e-09
of O 0 5.068522823670207e-10
an O 0 5.900031851968635e-11
ancestral O 0 4.249889329344114e-09
allele O 0 4.807064968304076e-09
or O 0 3.2127975835294365e-09
a O 0 3.6010185944235218e-09
mutational O 0 4.7404046199517325e-07
hot O 0 1.2536572739918483e-06
spot O 0 1.4684520976970816e-07
, O 0 9.235330278301035e-10
haplotypes O 0 1.6336203501055024e-08
were O 0 1.1294017943086487e-09
determined O 0 1.8408101709610492e-09
for O 0 3.321559416402664e-10
polymorphisms O 0 1.8077011887385197e-08
both O 0 4.874445735936206e-09
within O 0 3.968238360130272e-08
and O 0 2.7861476681323438e-08
flanking O 0 2.3839311324991286e-05
COL17A1 O 0 0.15354125201702118
. O 0 4.235638698446564e-06

Five O 0 4.7431453253921063e-07
intragenic O 0 4.253518454788718e-06
polymorphisms O 0 1.2071900812316017e-07
were O 0 3.572007356567042e-09
chosen O 0 3.527336200903619e-09
based O 0 4.1875514167344363e-10
on O 0 9.102323339504892e-09
their O 0 2.1802490923761297e-09
informativeness O 0 4.331657237344189e-06
. O 0 2.653707724675769e-07

One O 0 1.2388564130105806e-07
of O 0 4.4839620017000925e-08
these O 0 2.9577967852745246e-10
, O 0 2.2706693469931594e-10
not O 0 3.0968116959684266e-11
previously O 0 6.46794284797636e-10
reported O 0 5.067981589945703e-10
, O 0 1.4341815235408006e-10
was O 0 2.2388647380466864e-08
2988 O 0 1.0739429257000666e-07
A O 0 5.1279414492455544e-08
or O 0 2.8357380887911177e-09
C O 0 7.2663834771447e-07
that O 0 1.6790900614349624e-10
introduces O 0 1.526888837588558e-09
a O 0 1.9607500345575346e-10
new O 0 7.077162467172826e-11
restriction O 0 4.4691861322831983e-10
site O 0 4.1142242390712624e-10
for O 0 4.3247658232381525e-10
Eco0109 O 0 2.731245842824137e-07
I O 0 2.939504383903113e-06
. O 0 4.4231936158212193e-07

All O 0 7.104272281566182e-09
the O 0 5.8637339428457835e-09
4003delTC O 0 3.3386424291848016e-08
alleles O 0 1.009061834089664e-09
showed O 0 1.2014488293132786e-09
the O 0 1.1159473345401238e-10
same O 0 7.150458697369189e-11
haplotype O 0 2.2926431864078722e-09
for O 0 1.1964446100520831e-10
these O 0 7.596453327485264e-11
five O 0 9.955649638015984e-10
polymorphic O 0 2.5224332844686614e-08
markers O 0 4.6571167899855936e-07
. O 0 1.2230898391862866e-06

Fourteen O 0 6.028669304214418e-06
microsatellite O 0 2.8437073069653707e-06
polymorphisms O 0 9.993213012648994e-08
were O 0 2.7896609466893096e-09
selected O 0 8.735650536273454e-10
based O 0 2.890128414367865e-10
on O 0 2.543738775173665e-09
their O 0 2.475941396351544e-10
high O 0 6.184757239680039e-08
heterozygosity O 0 2.912191519044427e-07
and O 0 9.61301038771012e-10
their O 0 1.2659386039448606e-10
location O 0 7.00499835915025e-09
within O 0 2.9161937309396535e-09
10q23 O 0 1.1091732687873446e-07
- O 0 6.700059174136186e-08
q25 O 0 7.586978654217091e-07
near O 0 1.57985448367981e-06
COL17A1 O 0 0.00012260429502930492
. O 0 9.973120995709905e-07

Three O 0 1.4794021296893334e-07
families O 0 2.360840190007707e-09
shared O 0 3.82703504442361e-08
microsatellite O 0 1.3288064337757532e-06
polymorphisms O 0 1.8818576563717215e-07
covering O 0 3.0167871045705397e-06
at O 0 5.782442713098135e-06
most O 0 4.522335839141078e-09
19 O 0 2.0917291010391637e-08
cM O 0 1.299074003924261e-08
, O 0 4.811226417267278e-10
whereas O 0 9.669760547836859e-10
the O 0 4.920607810099398e-10
others O 0 6.343337521919068e-10
shared O 0 7.990561545767605e-10
smaller O 0 6.665828999885548e-10
regions O 0 1.029843321731505e-09
consistent O 0 4.155615407341884e-09
with O 0 2.6188837209950577e-10
cross O 0 7.842084315257125e-09
- O 0 3.95967081345816e-09
over O 0 3.4897659761945476e-10
events O 0 9.227895531038754e-11
during O 0 7.11847081280581e-10
passage O 0 3.026749129109163e-10
of O 0 9.95583407381595e-11
this O 0 2.760650432212519e-12
mutation O 0 9.77455789918924e-12
through O 0 2.604039206488551e-11
several O 0 3.4922428837624864e-10
generations O 0 9.096855713153218e-09
. O 0 3.047554741897329e-08

These O 0 7.041193406109869e-09
results O 0 4.030450639902483e-09
indicate O 0 2.1449781950622082e-09
that O 0 4.16061594898931e-11
4003delTC O 0 4.445104284656054e-09
occurs O 0 1.449137337905526e-10
on O 0 7.273380231431759e-10
a O 0 8.805924045507396e-11
single O 0 5.0755823155501645e-11
ancestral O 0 3.105794288416064e-09
allele O 0 3.865002096148373e-09
. O 0 3.658794156535805e-09
. O 0 5.1722231830808596e-08

The O 0 9.512708061265585e-07
haptoglobin O 0 4.6877939894329756e-05
- O 0 8.909634630072105e-07
gene O 0 2.6190512869561644e-08
deletion O 0 9.516712395907234e-08
responsible O 0 1.1443516712006385e-07
for O 0 3.195534503674935e-08
anhaptoglobinemia B-Disease 0 0.00013324049359653145
. O 0 2.2930657905817498e-06

We O 0 1.358295520503816e-07
have O 0 5.21371890105371e-10
found O 0 8.030894699251334e-11
an O 0 5.9880047968696726e-12
allelic O 0 1.5968485422845902e-09
deletion O 0 1.4974313344850998e-08
of O 0 2.1154978213644426e-08
the O 0 1.2073830824022025e-08
haptoglobin O 0 6.241222308744909e-06
( O 0 3.150866900725191e-09
Hp O 0 1.9857727906469336e-08
) O 0 1.0318640386586253e-10
gene O 0 2.2946938793566574e-10
from O 0 6.068078817200728e-10
an O 0 1.2386408565490115e-10
individual O 0 5.823158621964808e-11
with O 0 1.020045825583793e-08
anhaptoglobinemia B-Disease 0 0.0005159684806130826
. O 0 3.1562510685034795e-06

The O 0 1.2357264722595573e-06
Hp O 0 5.420235993369715e-07
gene O 0 1.2025474838139871e-08
cluster O 0 7.797637202600072e-09
consists O 0 1.8928933975814743e-09
of O 0 8.147031493876966e-09
coding O 0 6.92685091507883e-07
regions O 0 2.2706890590029616e-08
of O 0 2.995812309336543e-08
the O 0 4.479634441167946e-09
alpha O 0 8.485822888815164e-08
chain O 0 2.6807347452972863e-09
and O 0 5.852152790142284e-11
beta O 0 1.4461098984952514e-08
chain O 0 9.854881355408907e-09
of O 0 3.5749312399246946e-09
the O 0 2.4284192434720353e-09
haptoglobin O 0 3.0886144486430567e-07
gene O 0 9.354363506020036e-09
( O 0 1.384732994935689e-09
Hp O 0 7.211828023656608e-09
) O 0 7.168128590695488e-11
and O 0 1.6651179046700548e-10
of O 0 4.50760984094245e-09
the O 0 3.072568643958107e-09
alpha O 0 1.0814888895538388e-07
chain O 0 9.08289887746605e-09
and O 0 2.0542918754973272e-10
beta O 0 3.553735794525892e-08
chain O 0 7.617934727477405e-09
of O 0 4.393024166660098e-09
the O 0 6.9808834268769715e-09
haptoglobin O 0 7.552370675512066e-07
- O 0 1.8938296264536802e-08
related O 0 1.2426981221835831e-08
gene O 0 2.2783841480134015e-09
( O 0 1.0026500740778488e-09
Hpr O 0 5.974452221835236e-08
) O 0 5.781968792639702e-10
, O 0 6.634194860133391e-10
in O 0 1.7744953284548615e-09
tandem O 0 6.817105600021023e-07
from O 0 3.818460569959825e-08
the O 0 4.296077449339464e-08
5 O 0 2.404028123237367e-07
side O 0 3.6273888781579444e-07
. O 0 2.9361154929574695e-07

Southern O 0 2.5565968826413155e-06
blot O 0 3.8007095781722455e-07
and O 0 1.657599280058264e-09
PCR O 0 1.3187865910424534e-08
analyses O 0 1.2538639015957642e-09
have O 0 3.12160054749544e-11
indicated O 0 2.0679649659349764e-10
that O 0 5.870014110204158e-12
the O 0 1.931503221253017e-11
individual O 0 2.4545773399942128e-12
with O 0 3.185446004194681e-11
anhaptoglobinemia B-Disease 0 3.0545731277697996e-08
was O 0 6.854118161925271e-09
homozygous O 0 1.3166463752600777e-10
for O 0 3.6015027765623486e-11
the O 0 1.5124131114152561e-10
gene O 0 3.4142222382627097e-10
deletion O 0 4.0980769888676605e-09
and O 0 1.5845055822971688e-10
that O 0 1.126676703322449e-11
the O 0 7.582064143196732e-11
gene O 0 9.693428698609452e-11
deletion O 0 6.561536203264495e-09
was O 0 2.8939206586642285e-08
included O 0 6.841263111567741e-10
at O 0 2.3455406505945575e-08
least O 0 6.629287119253036e-10
from O 0 3.98407751234231e-10
the O 0 2.718839597903866e-09
promoter O 0 1.2928450814797543e-05
region O 0 6.036408990439668e-07
of O 0 2.714592483243905e-06
Hp O 0 1.4106043408901314e-06
to O 0 3.6218711585433994e-08
Hpr O 0 5.403418981586583e-06
alpha O 0 1.1759782410081243e-06
but O 0 2.5413235960058955e-09
not O 0 4.2026260249627967e-10
to O 0 8.345034108181437e-10
Hpr O 0 2.390847271271923e-07
beta O 0 2.3474635213460715e-07
( O 0 8.448319377407643e-09
Hpdel O 0 9.23202549074631e-07
) O 0 7.461761875049433e-09
. O 0 7.475169638837542e-08

In O 0 5.062412000711447e-08
addition O 0 4.8788364459539935e-09
, O 0 1.049274334086192e-09
we O 0 2.247445146652538e-10
found O 0 1.4194803665823486e-10
seven O 0 2.581035732363013e-11
individuals O 0 1.1323463867951578e-12
with O 0 1.8790566325144198e-11
hypohaptoglobinemia B-Disease 0 2.222807182761244e-07
in O 0 3.4845930585447604e-09
three O 0 4.5219539224206073e-10
families O 0 4.375147813484581e-12
, O 0 1.0896198873733276e-11
and O 0 1.0062738836635887e-11
the O 0 1.4808933246346356e-10
genotypes O 0 6.023409770961052e-09
of O 0 1.6606252373208008e-08
six O 0 2.7301161331649837e-09
of O 0 7.803082624491253e-09
the O 0 4.0033132364669655e-09
seven O 0 6.857331924514654e-10
individuals O 0 6.323677258918137e-12
were O 0 3.5300537493121453e-10
found O 0 6.521342493792659e-11
to O 0 3.2822466966564434e-11
be O 0 1.1581181569297883e-09
Hp2 O 0 3.630458877523779e-06
/ O 0 5.31696832695161e-06
Hpdel O 0 4.6790217311354354e-05
. O 0 7.731743494332477e-07

The O 0 3.244346302722079e-08
phenotypes O 0 4.96600165433847e-08
and O 0 1.1918444009495488e-09
genotypes O 0 2.3663053738687267e-08
in O 0 4.851551937967713e-10
one O 0 3.572548853969515e-11
of O 0 2.2946325395345468e-10
these O 0 1.2764825654820733e-11
three O 0 2.547688622567268e-11
families O 0 6.370114505327429e-12
showed O 0 5.2465493061149e-10
the O 0 5.545298109588259e-10
father O 0 2.3011994532140534e-09
to O 0 1.2148849981574728e-10
be O 0 1.1775748154363441e-09
hypohaptoglobinemic B-Disease 0 1.7808052632517501e-07
( O 0 1.0194890487369435e-09
Hp2 O 0 9.735502715102484e-08
) O 0 3.3684266487199466e-10
and O 0 7.733735318815604e-10
Hp2 O 0 1.40215468036331e-06
/ O 0 4.991366040485445e-07
Hpdel O 0 2.113708660544944e-06
, O 0 1.9587549360267076e-09
the O 0 1.629549162274202e-09
mother O 0 1.5255322560747686e-09
to O 0 2.723675729399133e-10
be O 0 2.188502712385798e-09
Hp2 O 0 5.85697364385851e-07
- O 0 6.395363527644804e-08
1 O 0 5.2456233134989816e-08
and O 0 5.339517716862474e-10
Hp1 O 0 4.705116225522943e-07
/ O 0 8.061800116365703e-08
Hp2 O 0 3.4585468711156864e-07
, O 0 2.457624659335522e-10
one O 0 3.6820328036535344e-11
of O 0 3.3422517531356277e-10
the O 0 4.5037745755038827e-10
two O 0 1.1273264960420804e-10
children O 0 3.069127590960008e-11
to O 0 3.0675358086984517e-11
be O 0 3.5566818934462674e-10
hypohaptoglobinemic B-Disease 0 1.7794725692965585e-07
( O 0 9.91763116076072e-10
Hp2 O 0 1.6190156770790054e-07
) O 0 5.792056834152959e-10
and O 0 1.9527790495743602e-09
Hp2 O 0 2.3858051463321317e-06
/ O 0 5.422630238172133e-07
Hpdel O 0 5.176662853045855e-06
, O 0 3.960267225266989e-09
and O 0 1.7504055149775155e-10
the O 0 4.157310329322428e-10
other O 0 9.945737289296375e-11
child O 0 8.311373256297827e-10
to O 0 1.2255839398900292e-10
be O 0 4.052231883377999e-10
Hp1 O 0 3.116340963060793e-07
and O 0 3.0019482455401203e-09
Hp1 O 0 1.5879705870247562e-06
/ O 0 2.531512279801973e-07
Hpdel O 0 1.4547380260410137e-06
, O 0 5.452416296236606e-10
showing O 0 5.10512965234966e-10
an O 0 4.8617946474260876e-11
anomalous O 0 6.270804675523323e-08
inheritance O 0 3.8110903233246063e-07
of O 0 1.006335082820442e-06
Hp O 0 5.069330768492364e-07
phenotypes O 0 7.987765116013179e-08
in O 0 3.0882503221363322e-09
the O 0 5.099166422439794e-09
child O 0 1.3459931835768657e-08
with O 0 3.943714244059038e-09
Hp1 O 0 6.93783222232014e-05
. O 0 1.3460903574014083e-06

The O 0 1.0783287507365458e-06
Hp2 O 0 5.353470623958856e-05
/ O 0 2.556067784098559e-06
Hpdel O 0 2.5104493488470325e-06
individuals O 0 2.9509897303547916e-10
had O 0 2.13324402587034e-09
an O 0 1.1012329936832543e-10
extremely O 0 6.706973643133551e-09
low O 0 4.5221050015697983e-08
level O 0 4.551691290544113e-07
of O 0 1.7915023420300713e-07
Hp O 0 7.073003160940061e-08
( O 0 1.4535721237773913e-10
mean O 0 6.132819807547207e-10
+ O 0 9.478462459355796e-10
/ O 0 4.9816146763248526e-09
- O 0 4.45672609927783e-09
SD O 0 5.565149407971148e-08
= O 0 1.3423193223616181e-08
0 O 0 3.749634380767475e-09
. O 0 1.611595995543169e-10
049 O 0 2.2028684654173958e-08
+ O 0 9.397102651576006e-09
/ O 0 5.243623135697817e-08
- O 0 1.990945719398951e-08
0 O 0 2.0681594214977395e-09
. O 0 1.7654132322686422e-10
043 O 0 5.969906879954578e-08
mg O 0 8.859915823222764e-08
/ O 0 1.3012191324435207e-08
ml O 0 6.618084302800753e-09
; O 0 2.1109974879252036e-10
n O 0 6.5225429501936105e-09
= O 0 3.099651202376208e-09
6 O 0 3.295247186230199e-09
) O 0 2.1635028837896364e-11
, O 0 1.5170377107298627e-11
compared O 0 4.4343199251395404e-11
with O 0 1.3158048435546466e-11
the O 0 3.856267249968681e-10
level O 0 1.396730624492193e-07
( O 0 1.5602139025183703e-10
1 O 0 1.3400880405356475e-09
. O 0 4.217624513525031e-11
64 O 0 1.337294608383388e-09
+ O 0 2.3057951104021868e-09
/ O 0 1.6528833413076427e-08
- O 0 8.080562885481868e-09
1 O 0 4.603506909006683e-09
. O 0 1.4822468252795318e-10
07 O 0 1.569785368360499e-08
mg O 0 6.418349585146643e-08
/ O 0 6.55100729218816e-09
ml O 0 3.717865126873221e-09
) O 0 3.70487182599355e-11
obtained O 0 1.1348691986157178e-09
from O 0 6.359098247976647e-10
52 O 0 3.155077976657594e-08
healthy O 0 9.145341373084648e-09
volunteers O 0 2.2476349670341733e-09
having O 0 3.26602589417746e-09
phenotype O 0 6.152129916614513e-09
Hp2 O 0 8.141043963405536e-07
, O 0 1.914074010400668e-09
whereas O 0 4.1302423703371005e-09
the O 0 1.6711321215723274e-09
serum O 0 2.867671211603806e-09
Hp O 0 6.333028768068516e-09
level O 0 5.284507054170717e-08
of O 0 5.674433367630627e-09
an O 0 6.296600046917789e-11
individual O 0 9.566286131301727e-12
with O 0 1.6433568394980114e-10
Hp1 O 0 1.8450912193657132e-06
/ O 0 6.920273563082446e-07
Hpdel O 0 4.900082785752602e-06
was O 0 2.189985707445885e-06
0 O 0 2.9488725772353064e-07
. O 0 7.719359018665273e-08

50 O 0 5.180119842407294e-06
mg O 0 7.101157279976178e-06
/ O 0 4.970835334461299e-07
ml O 0 2.165277663834786e-07
, O 0 8.725259403874475e-10
which O 0 7.694211934250461e-11
was O 0 2.6913908879322435e-09
approximately O 0 1.3883183491714135e-10
half O 0 6.078223341310363e-11
the O 0 2.6677809267239283e-11
level O 0 6.891846204837293e-09
of O 0 2.351927541610621e-09
Hp O 0 2.2941610833271397e-09
in O 0 2.0615770202070394e-10
control O 0 4.492977012660049e-08
sera O 0 3.691123495741522e-08
from O 0 1.0546148676571221e-10
the O 0 1.271977245753675e-10
Hp1 O 0 8.143985041897395e-09
phenotype O 0 3.804933867979088e-10
( O 0 1.5944859321770366e-10
1 O 0 3.5612250925964872e-09
. O 0 2.0948333345760517e-10
26 O 0 8.011045160571939e-09
+ O 0 5.309662043373464e-09
/ O 0 4.3256612514142034e-08
- O 0 2.425573697451e-08
0 O 0 3.901189593591425e-09
. O 0 4.0159528480465667e-10
33 O 0 3.560031558436094e-08
mg O 0 8.116866467844375e-08
/ O 0 1.749349287649693e-08
ml O 0 1.310844410795653e-08
; O 0 4.096824546273581e-10
n O 0 1.2954787464991568e-08
= O 0 1.4682610682825725e-08
9 O 0 3.0764816472128587e-08
) O 0 2.824104838872188e-10
, O 0 2.1812046613334246e-10
showing O 0 2.1420305529318284e-09
a O 0 3.8681142733310026e-09
gene O 0 1.9220797398133982e-08
- O 0 1.9313098675866058e-07
dosage O 0 1.6933820461417781e-06
effect O 0 1.974609858734766e-06
. O 0 4.5018640548732947e-07

The O 0 3.610463394920771e-08
other O 0 5.596427765652834e-10
allele O 0 2.1602393207587056e-09
( O 0 4.043029244726881e-10
Hp2 O 0 9.322145189116782e-08
) O 0 2.5444266138485716e-10
of O 0 2.011986577343805e-09
individuals O 0 1.7098565618933748e-11
with O 0 2.7962440696249757e-10
Hp2 O 0 1.816775693441741e-05
/ O 0 1.5639941466361051e-06
Hpdel O 0 4.862891728407703e-06
was O 0 1.1176253167377581e-07
found O 0 7.869887380662632e-11
to O 0 1.7308567773488548e-11
have O 0 3.2456520110413223e-12
, O 0 5.704962544039738e-12
in O 0 1.323267103531256e-11
all O 0 5.456137971981967e-11
exons O 0 2.3857686937134304e-09
, O 0 1.203645516589802e-10
no O 0 8.300216763901247e-11
mutation O 0 1.771253976823317e-11
, O 0 3.6392052565892286e-11
by O 0 1.6077512585144227e-11
DNA O 0 2.5780273471553983e-09
sequencing O 0 1.53865968854916e-08
. O 0 1.3008970256578323e-07

On O 0 5.063310482000816e-07
the O 0 1.0313968346054025e-08
basis O 0 1.8255176925663363e-08
of O 0 2.0591575111694738e-09
the O 0 2.056612796730306e-10
present O 0 3.2576621955549e-10
study O 0 1.5538348385746303e-10
, O 0 1.722041606533331e-11
the O 0 3.057255490435118e-11
mechanism O 0 1.6166280758511675e-08
of O 0 4.809348030931915e-09
anhaptoglobinemia B-Disease 0 5.5487635819417847e-08
and O 0 8.047178895465024e-11
the O 0 5.6125881719992776e-11
mechanism O 0 1.54689310249978e-08
of O 0 3.6709220108122054e-09
anomalous O 0 1.7349040604131005e-07
inheritance O 0 5.291850513344798e-08
of O 0 8.217386948672356e-08
Hp O 0 1.1442512715120756e-07
phenotypes O 0 3.995122810351859e-08
were O 0 8.855384869832506e-09
well O 0 8.798847872526494e-09
explained O 0 2.5694509986351477e-07
. O 0 8.480111546305125e-08

However O 0 2.52858541216483e-07
, O 0 3.5831710931688576e-09
the O 0 7.87619802711248e-10
mechanism O 0 1.092568737703914e-07
of O 0 8.280809993266303e-08
hypohaptoglobinemia B-Disease 0 2.2290418201009743e-05
remains O 0 9.111146937357262e-06
unknown O 0 5.8327073929831386e-05

ATM O 0 1.4666631614090875e-05
mutations O 0 3.025684591762001e-08
and O 0 1.6578205475070718e-09
phenotypes O 0 4.288030197585613e-07
in O 0 9.93971752905054e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 5.260813651375429e-08
in O 0 3.3901881302256243e-09
the O 0 8.772534920709063e-10
British O 0 3.680477700385154e-09
Isles O 0 8.618136426719047e-09
: O 0 2.3266359325258e-11
expression O 0 2.155928630065418e-10
of O 0 1.0643556036527002e-09
mutant O 0 1.484961487108194e-09
ATM O 0 4.13973992863248e-08
and O 0 1.552241113422781e-10
the O 0 2.2764889973103664e-10
risk O 0 4.135578990371869e-09
of O 0 1.4780017920656974e-07
leukemia B-Disease 1 1.0
, O 0 0.002077380195260048
lymphoma B-Disease 1 1.0
, O 0 7.82828556111781e-06
and O 0 3.4457407309673727e-06
breast B-Disease 1 0.9999971389770508
cancer I-Disease 1 0.9999864101409912
. O 0 0.00028782495064660907

We O 0 2.168745005803885e-08
report O 0 7.490748021865556e-10
the O 0 2.2584285830351547e-10
spectrum O 0 9.829350666734626e-09
of O 0 1.9410815177423046e-09
59 O 0 1.3176928881364347e-08
ATM O 0 1.0354083457286833e-07
mutations O 0 1.789422832132459e-09
observed O 0 5.113171663850835e-09
in O 0 7.574949734134862e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9857581853866577
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 6.64482584511461e-08
patients O 0 1.1866414517669455e-08
in O 0 7.910282984191497e-10
the O 0 3.7244234363242867e-09
British O 0 4.4683297062420024e-08
Isles O 0 2.3032849583159987e-07
. O 0 9.414544166475025e-08

Of O 0 2.4607570594525896e-06
51 O 0 1.193612320093962e-06
ATM O 0 3.2132211345015094e-06
mutations O 0 9.62295843009997e-09
identified O 0 2.154918465890887e-09
in O 0 1.1506495756208324e-09
families O 0 2.2781991571019233e-11
native O 0 5.0560257369713923e-11
to O 0 7.64045285372994e-11
the O 0 4.2101197528232603e-10
British O 0 1.0178769827007272e-08
Isles O 0 3.15875716694336e-08
, O 0 9.997512817605525e-10
11 O 0 6.435262989157309e-09
were O 0 2.856393344075059e-09
founder O 0 4.410960130485364e-08
mutations O 0 5.696802474197682e-10
, O 0 1.1633429775059767e-09
and O 0 2.1124000326722125e-09
2 O 0 2.9938590273559385e-07
of O 0 2.8132907559097475e-08
these O 0 1.8239286470045357e-10
11 O 0 4.56403359549995e-09
conferred O 0 1.768293067527793e-08
a O 0 1.5821207677291227e-09
milder O 0 2.362768203312271e-09
clinical O 0 3.1194311578275347e-09
phenotype O 0 4.6109127627147473e-10
with O 0 1.0500244423949923e-10
respect O 0 5.073361286633826e-09
to O 0 3.7887284420889955e-09
both O 0 2.193402082184548e-07
cerebellar B-Disease 1 0.9999997615814209
degeneration I-Disease 1 0.9999998807907104
and O 0 1.0410594768472947e-06
cellular O 0 3.219730933778919e-05
features O 0 5.03151227349008e-07
. O 0 5.057465841673547e-07

We O 0 2.718623193231906e-08
report O 0 1.4849896867730195e-09
, O 0 8.707980864164355e-11
in O 0 5.5101017498726534e-11
two O 0 3.297282447078942e-10
A B-Disease 1 0.9997631907463074
- I-Disease 1 0.9828216433525085
T I-Disease 1 0.9999990463256836
families O 0 8.497715031641206e-11
, O 0 2.4530946718392954e-11
an O 0 1.1350585402136737e-11
ATM O 0 1.8765737408443783e-08
mutation O 0 2.3097290746676435e-10
( O 0 1.9959321695406373e-10
7271T O 0 1.7480685343684854e-08
- O 0 2.956034528267537e-08
- O 0 5.185242102356824e-08
> O 0 1.6063159691270812e-08
G O 0 1.5966597288752382e-07
) O 0 1.4117636226718133e-10
that O 0 4.250176599551736e-11
may O 0 7.83878725818532e-11
be O 0 9.589724847547387e-12
associated O 0 5.055206253601341e-11
with O 0 4.723186360251763e-13
an O 0 8.322052357130627e-13
increased O 0 6.529569246405131e-11
risk O 0 1.1342200512132194e-09
of O 0 3.758263744657597e-08
breast B-Disease 0 4.8246483856928535e-06
cancer I-Disease 0 2.74558090040955e-07
in O 0 2.5831068395376633e-09
both O 0 1.5857278823361298e-09
homozygotes O 0 5.660221447101321e-08
and O 0 4.973987888234888e-10
heterozygotes O 0 1.233344804063563e-08
( O 0 2.3991192366068503e-10
relative O 0 1.6403458147351557e-08
risk O 0 3.841630569212384e-09
12 O 0 5.1267359246764954e-09
. O 0 1.4356431321527197e-10
7 O 0 7.074631991343949e-09
; O 0 2.7585583817213433e-10
P O 0 1.4547488547123066e-07
= O 0 8.299148923640587e-09
. O 0 3.8054273621135337e-10
0025 O 0 8.051596722680188e-08
) O 0 9.175278592454816e-11
, O 0 4.973292958010411e-11
although O 0 5.009938297551031e-11
there O 0 8.168744153325136e-11
is O 0 5.1480038981699394e-11
a O 0 5.153684701220129e-10
less O 0 8.927357519894485e-09
severe O 0 0.00010937645129160956
A B-Disease 1 1.0
- I-Disease 1 0.9999880790710449
T I-Disease 1 0.999995231628418
phenotype O 0 7.830456283386411e-09
in O 0 1.6553425297161084e-10
terms O 0 3.1696292812632976e-10
of O 0 1.1062432914155096e-10
the O 0 7.968473797470566e-11
degree O 0 9.638998932359755e-08
of O 0 1.3138824783709424e-07
cerebellar B-Disease 1 0.9998893737792969
degeneration I-Disease 1 0.999987006187439
. O 0 9.082536053028889e-06

This O 0 8.330486522822866e-09
mutation O 0 2.328564896458829e-09
( O 0 8.356453307101219e-10
7271T O 0 3.308083051933863e-08
- O 0 2.187101877382247e-08
- O 0 1.1068164162963967e-08
> O 0 3.1082951768013345e-09
G O 0 1.0546721718185381e-08
) O 0 1.865372613318872e-11
also O 0 2.191916570123964e-12
allows O 0 1.490427030924335e-12
expression O 0 5.4386412040585697e-11
of O 0 2.2767451812732986e-10
full O 0 6.407481767389811e-10
- O 0 8.557085040550305e-10
length O 0 2.66337452092813e-10
ATM O 0 3.4185529074193255e-08
protein O 0 2.7419204684520082e-09
at O 0 1.0477988254820048e-08
a O 0 5.380451639780404e-10
level O 0 7.9877615632995e-09
comparable O 0 5.227442922972614e-09
with O 0 4.7117636181592815e-11
that O 0 2.9092853126577722e-11
in O 0 1.5102021022617151e-10
unaffected O 0 4.788314189596576e-09
individuals O 0 2.1272499040048132e-10
. O 0 2.988301872619559e-08

In O 0 4.0730494532681405e-08
addition O 0 1.7601018420521086e-09
, O 0 5.23913912253704e-10
we O 0 1.0232639735541227e-10
have O 0 2.626484750176128e-12
studied O 0 4.624487459636839e-09
18 O 0 3.025534311973388e-08
A B-Disease 1 0.9999896287918091
- I-Disease 1 0.9999243021011353
T I-Disease 1 0.9999998807907104
patients O 0 1.0714280129775489e-08
, O 0 5.462781615950263e-11
in O 0 3.985603166944962e-11
15 O 0 4.884932458537605e-10
families O 0 2.2682905900794914e-12
, O 0 4.5284768990239144e-11
who O 0 1.4839385276133044e-10
developed O 0 6.296404535532929e-07
leukemia B-Disease 1 1.0
, O 0 0.009976603090763092
lymphoma B-Disease 1 1.0
, O 0 5.4610363804386e-06
preleukemic O 0 0.011127510108053684
T O 0 0.00031757837859913707
- O 0 4.826562189919059e-07
cell O 0 3.5422760902292794e-07
proliferation O 0 1.5981609976734035e-05
, O 0 1.3666074938356587e-09
or O 0 2.808402257414855e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.1571752622785425e-07
mostly O 0 9.373576359550384e-10
in O 0 7.652328770646477e-10
childhood O 0 3.105624557520059e-07
. O 0 1.1316193848642797e-07

A O 0 8.072984201135114e-07
wide O 0 5.6515695234793384e-08
variety O 0 1.515307879174088e-08
of O 0 9.759482111348916e-09
ATM O 0 2.7185694762010826e-07
mutation O 0 5.163622862625061e-10
types O 0 5.352222554044772e-10
, O 0 4.9443796279469154e-11
including O 0 4.333880129769874e-11
missense O 0 1.3084664018947478e-08
mutations O 0 1.8122815470533737e-09
and O 0 1.3189697112281351e-09
in O 0 9.5152383750019e-09
- O 0 9.79480674345723e-08
frame O 0 7.111431386874756e-06
deletions O 0 5.630696264802282e-08
, O 0 1.0115360771223436e-09
were O 0 1.7925484430136862e-09
seen O 0 4.9189869955057475e-09
in O 0 4.011872223319557e-10
these O 0 3.206875875960691e-10
patients O 0 2.6887702730959973e-08
. O 0 7.205190399872663e-08

We O 0 8.6552049083366e-08
also O 0 1.7639937288649321e-09
show O 0 5.538596248300109e-10
that O 0 8.314251197238942e-12
25 O 0 1.2385274750226216e-10
% O 0 1.6677489250715993e-11
of O 0 3.248665225719094e-10
all O 0 7.202723972810077e-10
A B-Disease 1 1.0
- I-Disease 1 0.9999760389328003
T I-Disease 1 0.9999992847442627
patients O 0 1.5978670830918418e-08
carried O 0 8.412329721707579e-10
in O 0 3.5591452007821545e-10
- O 0 1.4611251097917943e-09
frame O 0 1.250215486692241e-08
deletions O 0 2.556252987062635e-09
or O 0 8.070300538953745e-10
missense O 0 3.2128237847928176e-08
mutations O 0 1.4615377796900475e-09
, O 0 2.3885263211731456e-10
many O 0 2.017271939769305e-11
of O 0 9.839887793461344e-10
which O 0 2.499203101413716e-11
were O 0 6.255421874934441e-11
also O 0 1.2501610857640344e-11
associated O 0 7.51299508716663e-11
with O 0 3.715188920394574e-11
expression O 0 5.1498556530304995e-09
of O 0 5.3710543568286084e-08
mutant O 0 2.9879120688747207e-07
ATM O 0 2.6369911211077124e-05
protein O 0 3.565758106560679e-06
. O 0 4.5133543835618184e-07

The O 0 5.6396388004031905e-08
DMPK O 0 2.1602591004921123e-05
gene O 0 1.4808827586421103e-07
of O 0 8.739722829886887e-07
severely O 1 0.9999959468841553
affected O 1 0.999994158744812
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.7298281788825989
is O 0 1.5573129985568812e-07
hypermethylated O 0 1.1045451174140908e-05
proximal O 0 3.2180664675252046e-06
to O 0 3.91103904817669e-09
the O 0 7.801103762972161e-09
largely O 0 7.75817881049079e-08
expanded O 0 4.593773539340873e-08
CTG O 0 9.443303497391753e-06
repeat O 0 6.886743335599022e-07
. O 0 5.361628154787468e-07

Using O 0 7.268851476283089e-08
methylation O 0 7.997763304956607e-07
- O 0 5.277879466802915e-08
sensitive O 0 3.329560982479052e-08
restriction O 0 1.0717463583276299e-09
enzymes O 0 7.02302827004786e-10
, O 0 1.9327314748629476e-10
we O 0 7.132941459708775e-11
characterized O 0 3.583497110160039e-10
the O 0 5.4296032947487305e-11
methylation O 0 2.5731246022786536e-09
pattern O 0 1.3783330921057768e-08
on O 0 1.738177424215337e-08
the O 0 2.213160099628908e-09
5 O 0 4.789721064213381e-09
side O 0 1.6418505444093512e-09
of O 0 5.330789143442871e-09
the O 0 4.557352717426966e-09
CTG O 0 4.502907415826485e-07
repeat O 0 3.7235923233680523e-09
in O 0 8.799846268336964e-11
the O 0 1.1198642707599404e-10
DMPK O 0 2.8369568028097092e-08
gene O 0 3.32120442259054e-10
of O 0 1.012454786675221e-09
normal O 0 3.3856195624792917e-09
individuals O 0 6.597039754752121e-12
and O 0 2.2834763593881924e-11
of O 0 5.346715070686514e-09
patients O 0 2.1311628017883777e-08
affected O 0 2.1249205062190413e-08
with O 0 8.466892722935881e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.0066604378143893e-08
showing O 0 5.558919546899688e-09
expansions O 0 2.0866435246347237e-09
of O 0 3.827858030547304e-09
the O 0 2.2960608969668783e-09
repetitive O 0 6.323948582576122e-07
sequence O 0 2.8497449733322355e-08
. O 0 1.656990633591704e-07

The O 0 1.8245573585318198e-07
gene O 0 2.5241659429298124e-08
segment O 0 2.4015573529823087e-08
analyzed O 0 1.9165080189509354e-08
corresponds O 0 5.5474163040969415e-09
to O 0 1.4834546091524459e-10
the O 0 5.25753829361264e-10
genomic O 0 6.408976460647864e-09
SacI O 0 1.7844258763943799e-06
- O 0 1.8444522353888715e-08
HindIII O 0 5.384173462630315e-08
fragment O 0 9.332746131462955e-09
carrying O 0 1.0227245716976086e-08
exons O 0 5.469003383495874e-08
11 O 0 1.448601949505246e-07
- O 0 1.5613711923379014e-07
15 O 0 8.261185513447344e-08
. O 0 6.1541392426534e-08

There O 0 8.88570781398812e-08
is O 0 5.397979840893186e-09
constitutive O 0 2.5601244146855606e-07
methylation O 0 3.2359605484089116e-07
in O 0 1.1395412968795426e-07
intron O 0 3.7283525671227835e-06
12 O 0 1.1829651924699647e-07
at O 0 3.5412856647099034e-08
restriction O 0 1.7251270412188546e-09
sites O 0 3.768000356174639e-10
of O 0 2.72393707589913e-09
SacII O 0 1.4870927600441064e-07
and O 0 2.256776099329727e-09
HhaI O 0 3.1925193866300106e-07
, O 0 7.333530449571413e-10
localized O 0 8.633140424763042e-09
1 O 0 8.509730520245284e-08
, O 0 6.735327851004058e-10
159 O 0 6.49360831772583e-09
- O 0 1.0907027281348292e-08
1 O 0 7.245417776857721e-08
, O 0 1.45471834578359e-09
232 O 0 4.019288457612902e-09
bp O 0 2.755406036669683e-08
upstream O 0 1.7043305433617206e-08
of O 0 1.8937754475700785e-08
the O 0 1.2354615108733924e-08
CTG O 0 4.265127699909499e-06
repeat O 0 3.661351044570438e-08
, O 0 8.255412464741596e-10
whereas O 0 6.433750199263955e-10
most O 0 5.320808377229369e-11
, O 0 2.7239809366474965e-11
if O 0 1.0771349957805487e-11
not O 0 7.434984919396648e-12
all O 0 9.037815634771462e-12
, O 0 2.5930214572755794e-11
of O 0 8.504314613633213e-11
the O 0 3.050603519794137e-11
other O 0 3.1332425803193287e-12
sites O 0 3.915535951026783e-11
of O 0 3.5684918908707175e-10
SacII O 0 1.210630387049605e-07
, O 0 1.7069777813460973e-09
HhaI O 0 3.421018845983781e-07
, O 0 1.8142078950234009e-09
and O 0 7.96041121908786e-10
HpaII O 0 1.5165777256243018e-07
in O 0 3.7261124741228e-10
this O 0 3.8699776022665944e-11
region O 0 9.439330428406834e-10
are O 0 9.920515797734453e-12
unmethylated O 0 1.8343552454780365e-08
, O 0 8.937213469284444e-11
in O 0 1.5825303567584825e-10
normal O 0 6.869745661219895e-09
individuals O 0 2.5600122716129547e-11
and O 0 2.9703986492712886e-10
most O 0 1.3148822308739483e-10
of O 0 3.581422047815863e-09
the O 0 7.049578698570258e-09
patients O 0 4.2914340525612715e-08
. O 0 4.9161286597154685e-08

In O 0 1.752518663522551e-08
a O 0 1.8832277959290877e-09
number O 0 2.2328582038877443e-10
of O 0 1.7682053154999267e-08
young O 0 1.3252342334624245e-08
and O 0 1.8069462370817746e-08
severely O 0 0.0002661683829501271
affected O 0 4.502430428487969e-08
patients O 0 9.264834233135844e-09
, O 0 2.5089474942063816e-10
however O 0 2.4826990463466814e-10
, O 0 2.447790060922106e-11
complete O 0 3.6277306159071543e-10
methylation O 0 1.0408630402025665e-08
of O 0 1.4065205666824454e-09
these O 0 1.922788143982057e-11
restriction O 0 1.4913528745275073e-10
sites O 0 1.3426919298620277e-10
was O 0 2.43120479304082e-09
found O 0 1.377246372502583e-10
in O 0 4.7351064041967206e-11
the O 0 2.523046771507609e-10
mutated O 0 1.4897160172111512e-09
allele O 0 2.94298843073193e-08
. O 0 1.5269165487552527e-07

In O 0 1.5327245250773558e-07
most O 0 1.2751600886318215e-09
of O 0 1.797057058716689e-09
these O 0 4.961033667205683e-11
patients O 0 1.4341706988663105e-10
, O 0 2.6014974896515497e-11
the O 0 9.29876314836875e-11
onset O 0 8.471702699353045e-07
of O 0 3.6549806736729806e-08
the O 0 1.2007832594918e-07
disease O 1 0.9997633099555969
was O 0 0.39292481541633606
congenital O 1 1.0
. O 0 0.0003716004139278084

Preliminary O 0 9.705871661935817e-07
in O 0 1.263724414002354e-07
vivo O 0 2.217637302237563e-06
footprinting O 0 9.903601494443137e-06
data O 0 3.099540535345113e-08
gave O 0 8.429197784209919e-09
evidence O 0 5.591074714317301e-09
for O 0 4.191610947223978e-10
protein O 0 6.276318131881453e-09
- O 0 4.267035613736425e-09
DNA O 0 4.455349422727295e-09
contact O 0 3.112485202905191e-08
in O 0 7.054632433778352e-10
normal O 0 1.798474080771939e-08
genes O 0 1.0302088071512117e-09
at O 0 1.3378820717946383e-08
an O 0 1.3306886148534147e-10
Sp1 O 0 2.787417763272515e-08
consensus O 0 8.830034481377425e-09
binding O 0 3.766521761150443e-09
site O 0 7.2799068995266225e-09
upstream O 0 1.2327921794508256e-08
of O 0 7.87319809347764e-09
the O 0 6.783794859188674e-09
CTG O 0 1.7376027017235174e-06
repeat O 0 9.791235378031615e-09
and O 0 1.2119988346270816e-10
for O 0 5.815566431199848e-11
a O 0 3.516034685624447e-11
significant O 0 5.932191543545073e-11
reduction O 0 3.778322099634579e-09
of O 0 1.5890705418186712e-09
this O 0 1.4029209217947258e-11
interaction O 0 8.508179716315567e-10
in O 0 2.4391133557344347e-10
cells O 0 5.4745371430575673e-11
with O 0 8.365794862408293e-11
a O 0 1.40693645622747e-09
hypermethylated O 0 1.8769608800539572e-07
DMPK O 0 1.8718569663178641e-06
gene O 0 1.7794786089098125e-08
. O 0 5.801524149973147e-09
. O 0 5.545134129647522e-08

The O 0 3.0170978789101355e-05
hemochromatosis B-Disease 1 1.0
gene O 0 1.0869800917134853e-06
product O 0 7.965445547597483e-08
complexes O 0 1.5304648570690915e-07
with O 0 4.3168397745319e-09
the O 0 3.454629649013441e-08
transferrin O 0 5.346218472368491e-07
receptor O 0 3.503955881001275e-08
and O 0 5.413105075291469e-09
lowers O 0 2.7543235248117526e-08
its O 0 2.0350189589013468e-10
affinity O 0 1.980884345442746e-09
for O 0 1.3574111834557812e-09
ligand O 0 9.589194149839386e-08
binding O 0 5.449624609354942e-07
. O 0 7.061570954647323e-07

We O 0 4.1476917544969183e-07
recently O 0 5.854160178841994e-08
reported O 0 4.293994493309583e-09
the O 0 2.9069127660541483e-10
positional O 0 7.872525742413927e-08
cloning O 0 2.5612651999296077e-09
of O 0 7.51153639289015e-10
a O 0 6.964574472689833e-10
candidate O 0 1.9647643512143986e-09
gene O 0 4.225803706958686e-08
for O 0 3.2801726774778217e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 0.9999986886978149
HFE O 1 0.9998834133148193
. O 0 3.92800138797611e-05

The O 0 3.27541698652567e-07
gene O 0 1.548729322564668e-08
product O 0 7.95962584732024e-09
, O 0 1.7950906316954729e-09
a O 0 2.119883379947396e-09
member O 0 2.3172403995630475e-09
of O 0 4.913026074859772e-08
the O 0 2.4817875754479246e-08
major O 0 4.7607878173039353e-07
histocompatibility O 0 0.0001589829771546647
complex O 0 0.0006264910916797817
class O 0 4.5489443323276646e-07
I O 0 3.028487526535173e-06
- O 0 5.89550737117861e-08
like O 0 6.087229054152488e-10
family O 0 2.057213149830872e-10
, O 0 6.827610699033926e-11
was O 0 5.868477703785402e-09
found O 0 1.3186017555621987e-10
to O 0 8.5422259543666e-11
have O 0 3.729530573259865e-11
a O 0 2.3573021312728315e-10
mutation O 0 8.68426233702202e-11
, O 0 1.8902919229901727e-09
Cys O 0 2.866335989892832e-06
- O 0 1.8435119386595034e-07
282 O 0 1.4690361638258764e-07
- O 0 4.6059560077083006e-07
- O 0 1.6959469917310344e-07
> O 0 1.5733885305735384e-08
Tyr O 0 6.244820838219312e-08
( O 0 1.586192982516721e-10
C282Y O 0 2.605427873447752e-09
) O 0 1.4073590383356649e-11
, O 0 9.090406379030913e-12
in O 0 1.5274875114767994e-11
85 O 0 5.120430190963532e-10
% O 0 2.79910400413641e-10
of O 0 6.486750248058115e-09
patient O 0 1.7677238872693124e-07
chromosomes O 0 1.0505543741601286e-06
. O 0 4.781298912348575e-07

This O 0 1.1653778386744307e-08
mutation O 0 1.1865056492865733e-08
eliminates O 0 7.256094392005252e-08
the O 0 2.58715981971136e-09
ability O 0 2.3048187802743314e-09
of O 0 5.526782942411046e-08
HFE O 0 2.4289222437801072e-06
to O 0 1.096712853865256e-08
associate O 0 3.3850957947834104e-07
with O 0 1.3139853649590805e-09
beta2 O 0 7.291065230674576e-06
- O 0 1.3461956314131385e-06
microglobulin O 0 4.339265160524519e-06
( O 0 3.088203026635483e-09
beta2m O 0 2.4800849018902227e-07
) O 0 2.614372052178737e-10
and O 0 1.9453318123030527e-10
prevents O 0 5.388403501171979e-09
cell O 0 8.264210009656381e-07
- O 0 5.9235397031898174e-08
surface O 0 6.388706879079109e-07
expression O 0 5.021148581363377e-07
. O 0 1.4596530206745228e-07

A O 0 5.655609129462391e-06
second O 0 1.5721981583283196e-07
mutation O 0 1.256358350687492e-09
that O 0 7.694563736171389e-11
has O 0 3.950643978622992e-11
no O 0 5.8118631435233326e-11
effect O 0 2.0887060969698723e-09
on O 0 3.0925193073017e-08
beta2m O 0 5.913898917242477e-07
association O 0 5.813731274173506e-09
, O 0 7.008643665429304e-10
H63D O 0 4.4586292347048584e-07
, O 0 5.07819952755284e-10
was O 0 8.045621058272445e-09
found O 0 1.2653132708262405e-10
in O 0 6.00695118646577e-11
eight O 0 9.612859119823014e-11
out O 0 1.0375236260407039e-11
of O 0 7.604052942866701e-10
nine O 0 1.999408194564012e-09
patients O 0 8.216235469760136e-10
heterozygous O 0 6.243302541619755e-10
for O 0 3.7195016511226697e-10
the O 0 7.274132851620152e-09
C282Y O 0 7.449506256307359e-07
mutant O 0 9.660161595093086e-07
. O 0 5.198650683269079e-07

In O 0 1.515628689219284e-08
this O 0 1.398310633948796e-10
report O 0 1.2033286866941495e-10
, O 0 2.2901366567018577e-11
we O 0 2.056015774298814e-11
demonstrate O 0 3.979376272944535e-10
in O 0 4.88849349888909e-10
cultured O 0 9.287304258975837e-09
293 O 0 3.6045850748678276e-09
cells O 0 1.4967165284929251e-09
overexpressing O 0 1.654855594779292e-07
wild O 0 1.881120592628349e-09
- O 0 2.6807909225823323e-09
type O 0 3.286346750286384e-09
or O 0 1.5596225422243037e-09
mutant O 0 1.753267575566042e-08
HFE O 0 8.421405937042437e-07
proteins O 0 2.464954240721795e-09
that O 0 8.343294805035484e-11
both O 0 1.599347321246114e-10
the O 0 2.4258164921242553e-10
wild O 0 1.8460059869607193e-10
- O 0 6.676759145562983e-10
type O 0 2.4396589193287355e-09
and O 0 2.2739732319365658e-09
H63D O 0 1.3749317986366805e-05
HFE O 0 2.2311246539175045e-06
proteins O 0 5.04109554100296e-09
form O 0 5.952519810392687e-09
stable O 0 4.813825285054918e-07
complexes O 0 1.2974768814899562e-08
with O 0 3.328789466294779e-10
the O 0 6.8504326655727255e-09
transferrin O 0 9.975826031904944e-08
receptor O 0 1.7285401554545388e-08
( O 0 3.2196743049439647e-09
TfR O 0 2.822078499775671e-07
) O 0 9.497034270111726e-09
. O 0 8.510671989370167e-08

The O 0 1.63211367976146e-07
C282Y O 0 1.8980896356879384e-06
mutation O 0 8.196142431415865e-09
nearly O 0 8.323879363558717e-09
completely O 0 6.60520882433957e-09
prevents O 0 5.446782469498146e-10
the O 0 4.974187173267808e-10
association O 0 4.1628486768807704e-10
of O 0 1.3916435781524683e-09
the O 0 5.16786213822229e-09
mutant O 0 1.0997651855859658e-07
HFE O 0 7.334946076298365e-06
protein O 0 2.0851392434906302e-07
with O 0 2.882554417382721e-09
the O 0 1.100995064007293e-07
TfR O 0 2.159344330721069e-05
. O 0 4.5517955982177227e-07

Studies O 0 2.944246944025508e-07
on O 0 6.855703560404436e-08
cell O 0 1.1460598159374058e-07
- O 0 5.0491117953299636e-09
associated O 0 2.5014137428058802e-09
transferrin O 0 4.828901722930823e-08
at O 0 5.020482944928517e-07
37 O 0 3.8016153780517925e-08
degrees O 0 5.362507522477244e-07
C O 0 3.121685949736275e-07
suggest O 0 8.426203623734807e-10
that O 0 9.586304840214499e-12
the O 0 3.587326546927727e-10
overexpressed O 0 1.445550736889345e-07
wild O 0 4.303554845819235e-09
- O 0 1.4174959872548243e-08
type O 0 3.9742754864846574e-08
HFE O 0 3.216240884285071e-06
protein O 0 4.7478199149963984e-08
decreases O 0 1.0699331198793516e-08
the O 0 1.5544076026330345e-09
affinity O 0 8.25803070370057e-09
of O 0 1.520565717783029e-08
the O 0 8.596072298416857e-09
TfR O 0 5.726608947043133e-07
for O 0 8.899051273658642e-09
transferrin O 0 1.1842367939607357e-06
. O 0 3.096311900208093e-07

The O 0 5.576312105404213e-06
overexpressed O 0 0.0006648036069236696
H63D O 0 0.010555059649050236
protein O 0 1.4924148672434967e-06
does O 0 2.088005102152124e-09
not O 0 5.583694617783408e-11
have O 0 2.0540704553928535e-12
this O 0 1.2230770866580865e-12
effect O 0 2.2860092985244052e-10
, O 0 1.8989738601038475e-11
providing O 0 4.633002315124202e-11
the O 0 1.9784732879779554e-11
first O 0 2.6437860581318695e-11
direct O 0 4.47314095486373e-11
evidence O 0 1.203002697458544e-10
for O 0 1.7666182752784643e-11
a O 0 1.0508198478031971e-10
functional O 0 4.036360579107168e-08
consequence O 0 5.5055718206631354e-08
of O 0 2.7471775965182132e-08
the O 0 1.3623868255763227e-08
H63D O 0 1.631911436561495e-05
mutation O 0 4.454935265130189e-08
. O 0 9.47050153854434e-08

Addition O 0 1.4151274285723048e-07
of O 0 2.5546734150339034e-07
soluble O 0 1.8732213220573612e-06
wild O 0 3.600834830308486e-08
- O 0 1.4041897600236553e-07
type O 0 4.875611239185673e-07
HFE O 0 0.01829751394689083
/ O 0 0.0023190747015178204
beta2m O 0 7.149887824198231e-05
heterodimers O 0 9.176565072266385e-06
to O 0 6.397788965273321e-09
cultured O 0 4.5126530068273496e-08
cells O 0 1.706613073082508e-09
also O 0 5.002900871353688e-11
decreased O 0 1.4086817268221807e-09
the O 0 1.1221991391696662e-10
apparent O 0 1.1508296537954266e-09
affinity O 0 5.76551584252627e-10
of O 0 6.902318272494767e-09
the O 0 2.189471270952481e-09
TfR O 0 2.054411574192727e-08
for O 0 5.7157806265806244e-11
its O 0 1.2874784571792475e-11
ligand O 0 2.5658712932141725e-09
under O 0 1.045674569155608e-08
steady O 0 1.2329995513482572e-07
- O 0 8.23426105078795e-10
state O 0 6.067520097463586e-11
conditions O 0 5.371930678066406e-10
, O 0 1.995714184188646e-11
both O 0 1.1788927473110888e-11
in O 0 4.5882062038593574e-11
293 O 0 1.646035807656432e-10
cells O 0 5.4383088310405725e-11
and O 0 3.856679142710817e-10
in O 0 2.0152051138921934e-09
HeLa O 0 4.0613360852148617e-07
cells O 0 2.2386043241340303e-08
. O 0 4.585553625702232e-08

Furthermore O 0 7.882289878580195e-07
, O 0 2.1448567366633142e-08
at O 0 2.2950119671349967e-07
4 O 0 6.770922311716276e-08
degrees O 0 1.2534397910712869e-06
C O 0 5.532899649551837e-07
, O 0 2.793216213881067e-10
the O 0 3.4739533472105677e-10
added O 0 7.436953719519579e-09
soluble O 0 2.760524431266731e-08
complex O 0 3.0907654036127497e-07
of O 0 2.5823331384344783e-07
HFE O 0 3.4958884498337284e-05
/ O 0 3.3359262943122303e-06
beta2m O 0 1.813982407838921e-06
inhibited O 0 3.946936644183552e-08
binding O 0 3.7752698744952795e-08
of O 0 5.509437883688406e-08
transferrin O 0 5.094474317957065e-07
to O 0 1.275968486424972e-08
HeLa O 0 1.1299365496597602e-06
cell O 0 3.582605927476834e-07
TfR O 0 6.365268063746043e-07
in O 0 2.4828517020125673e-09
a O 0 3.776909895947256e-09
concentration O 0 8.995283451440628e-07
- O 0 6.395485740995355e-08
dependent O 0 2.674290833226678e-08
manner O 0 2.2869193117003306e-07
. O 0 1.3074178184524499e-07

Scatchard O 0 4.445339800440706e-05
plots O 0 3.0519149163410475e-07
of O 0 2.5845965367921053e-08
these O 0 1.5456587398876565e-10
data O 0 1.0577902997965793e-09
indicate O 0 1.044211161982389e-09
that O 0 3.1407654255133366e-11
the O 0 8.87959927808879e-10
added O 0 1.3334900295092211e-08
heterodimer O 0 3.1303340364274845e-08
substantially O 0 7.36086125385782e-09
reduced O 0 2.6146824705364224e-09
the O 0 2.9709595894544805e-10
affinity O 0 1.0562519747736587e-09
of O 0 9.529786737516588e-09
TfR O 0 3.1583661552758713e-07
for O 0 4.712424672703719e-09
transferrin O 0 1.1918732525373343e-06
. O 0 2.020591125528881e-07

These O 0 1.6852006012868515e-08
results O 0 1.1464200255772994e-08
establish O 0 1.1905180841154106e-08
a O 0 1.4733322339921529e-09
molecular O 0 6.02672116656322e-08
link O 0 4.999645852876711e-08
between O 0 1.4774140311146766e-07
HFE O 0 7.746527444396634e-06
and O 0 1.4612317578155398e-08
a O 0 1.8003650126274806e-08
key O 0 6.60338457691978e-07
protein O 0 5.551250836788313e-08
involved O 0 1.3151770339447921e-08
in O 0 4.435297018545725e-09
iron O 0 5.7551129430066794e-05
transport O 0 8.324390421421413e-08
, O 0 4.663200936505518e-10
the O 0 1.0456860932706036e-09
TfR O 0 1.8509690846713056e-07
, O 0 5.66125202272616e-10
and O 0 1.697697121771924e-10
raise O 0 2.2549850875464017e-10
the O 0 2.996489167905736e-10
possibility O 0 2.0869379557808543e-09
that O 0 1.841451123529847e-11
alterations O 0 2.503609319859379e-09
in O 0 1.8914993182850282e-10
this O 0 1.7555738113239627e-11
regulatory O 0 1.0062063182658676e-08
mechanism O 0 8.010221108634141e-07
may O 0 2.3183247321867384e-08
play O 0 8.40409413171983e-08
a O 0 4.009250709202661e-09
role O 0 7.088923226206134e-09
in O 0 1.0070219103042177e-09
the O 0 3.871702070057381e-09
pathogenesis O 0 0.48426035046577454
of O 0 0.007416204549372196
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00010525588731979951
. O 0 5.377443358156597e-06

Genomic O 0 2.926389242929872e-06
organization O 0 8.481794111503405e-08
of O 0 2.057926167253754e-07
the O 0 2.2892038487043465e-07
UBE3A O 0 0.00040582826477475464
/ O 0 2.400331140961498e-05
E6 O 0 7.072630523907719e-06
- O 0 5.841355346092314e-07
AP O 0 1.681638650552486e-06
gene O 0 1.3820362632088745e-09
and O 0 3.4118721736753344e-10
related O 0 2.2384847753187387e-08
pseudogenes O 0 1.465043396819965e-06
. O 0 1.399514673039448e-07

The O 0 8.078313840087503e-07
UBE3A O 0 1.3136375855538063e-05
gene O 0 3.558252714697119e-08
encodes O 0 1.2933408122250967e-08
the O 0 1.9910066484385425e-08
E6 O 0 2.0867933017143514e-06
- O 0 1.9076660464634188e-06
AP O 0 1.018299280985957e-05
ubiquitin O 0 5.849984745509573e-07
- O 0 1.5322861202093918e-07
protein O 0 1.8561548742468403e-08
ligase O 0 1.364222601552001e-08
and O 0 1.10180087276035e-09
has O 0 4.0655553923407695e-10
recently O 0 2.12554351897154e-09
been O 0 8.017823904804544e-11
shown O 0 9.419915368569232e-12
to O 0 1.0302740648462927e-12
be O 0 3.683920356267745e-12
mutated O 0 1.5367342121042071e-10
in O 0 1.147564265835399e-08
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 1.9135119146085344e-05
who O 0 1.0394464844409868e-08
lack O 0 3.450283614370164e-08
15q11 O 0 3.63111297474461e-07
- O 0 7.396019441330282e-08
q13 O 0 9.210815932192418e-08
deletions O 0 2.2986869296914847e-08
or O 0 1.0900373048627898e-08
chromosome O 0 1.8674421653486206e-06
15 O 0 1.6386468359996798e-06
paternal O 0 1.8119982996722683e-05
uniparental B-Disease 0 0.003921333234757185
disomy I-Disease 0 0.00042354263132438064
. O 0 2.090418320221943e-06

Previous O 0 2.1808048131788382e-06
UBE3A O 0 3.824376835837029e-05
cDNA O 0 5.119654815644026e-07
analysis O 0 2.190374814858842e-08
has O 0 2.4401930476258826e-10
shown O 0 1.9110379945175282e-10
a O 0 2.5773180811761165e-10
coding O 0 6.96077009365581e-08
region O 0 3.211016519344412e-08
of O 0 4.257282526509698e-08
approximately O 0 8.860622457973477e-09
2 O 0 6.124840865595615e-07
. O 0 4.4743593718976626e-08

6 O 0 2.4958471840363927e-05
kb O 0 2.939195474027656e-05
and O 0 7.313478533887974e-08
a O 0 4.8673413743927085e-08
3 O 0 1.872269734803922e-07
- O 0 4.22300772129347e-08
untranslated O 0 2.0884675905108452e-05
region O 0 8.295590703255584e-08
( O 0 6.311176026230214e-10
UTR O 0 3.6702803640764614e-07
) O 0 4.857144686454262e-10
of O 0 8.308397525524924e-09
< O 0 1.5597549918311415e-07
50 O 0 5.928253088427482e-08
bp O 0 2.6188764934431674e-08
, O 0 2.4578686308451836e-10
whereas O 0 7.192674789102682e-10
Northern O 0 8.24156798362452e-10
analysis O 0 1.488017070672143e-10
has O 0 2.6099563482651078e-11
indicated O 0 6.331814933480118e-11
mRNA O 0 6.494146193025685e-11
sizes O 0 6.055579926389498e-10
of O 0 3.0667313133392327e-09
5 O 0 3.822198380021291e-08
- O 0 3.910220414127252e-08
8 O 0 1.8383380506747926e-07
kb O 0 8.67290327732917e-06
. O 0 5.268425411486533e-07

We O 0 7.681363456413237e-08
have O 0 9.893706687247317e-11
analyzed O 0 2.1099950953118451e-10
additional O 0 4.937113912140134e-11
cDNA O 0 1.7888904801921512e-09
clones O 0 7.63075713727801e-10
and O 0 3.623427252685829e-11
provide O 0 5.81709784508444e-11
evidence O 0 2.635932583316958e-10
for O 0 4.655253613150556e-11
an O 0 5.962160626316049e-11
additional O 0 2.030266843533468e-09
0 O 0 1.2548075289942062e-07
. O 0 1.2373980950997066e-07

5 O 0 5.225170752964914e-06
kb O 0 2.489081998646725e-05
of O 0 2.0546683572320035e-06
5 O 0 1.385700215905672e-06
- O 0 1.1733474281072631e-07
UTR O 0 2.116500354532036e-06
and O 0 1.9744115231645765e-09
> O 0 1.8036372395613398e-08
2 O 0 4.5896133116229976e-08
kb O 0 4.422008146320877e-07
of O 0 1.3839843404639396e-07
3 O 0 5.101492661196971e-06
- O 0 1.2658415471378248e-06
UTR O 0 5.558695920626633e-05
. O 0 4.950133529746381e-07

We O 0 1.0067500255672712e-07
have O 0 2.6579341505517107e-10
established O 0 4.2926165400025695e-10
the O 0 6.871992558332707e-11
genomic O 0 1.521661463499413e-09
organization O 0 3.586040631109455e-10
of O 0 5.4023368001310246e-09
UBE3A O 0 1.113717758016719e-06
and O 0 5.464493302298479e-10
the O 0 6.506150618257323e-10
sequence O 0 2.4377007079579016e-09
of O 0 4.401337605486333e-08
intron O 0 6.1673513300775085e-06
- O 0 3.907092832378112e-06
exon O 0 4.266470114089316e-06
borders O 0 1.3511342444871843e-07
. O 0 4.1276229012510157e-07

We O 0 6.678833983642107e-07
have O 0 3.5874929693591184e-09
also O 0 6.545607944552501e-10
mapped O 0 4.060419556140005e-09
two O 0 7.742738672433802e-10
highly O 0 6.112875983177446e-09
homologous O 0 8.710215659846199e-09
processed O 0 1.6573377337181228e-08
pseudogenes O 0 6.126722240651361e-08
, O 0 6.034066024618312e-10
UBE3AP1 O 0 2.8364601689645497e-07
and O 0 1.1020866441668886e-09
UBE3AP2 O 0 1.0065155038319062e-06
, O 0 5.77090708553385e-10
to O 0 1.5438436640202724e-10
chromosomes O 0 6.1640639259508134e-09
2 O 0 2.2641673425027875e-08
and O 0 4.1483597112979e-10
21 O 0 7.545601476977026e-09
, O 0 1.8117103650627797e-10
respectively O 0 2.1606638700433223e-09
, O 0 1.8037592253161705e-10
and O 0 1.2097446655534583e-10
determined O 0 1.8899133369387755e-09
their O 0 2.162782036796429e-10
genomic O 0 1.861859999507942e-08
organization O 0 1.894425771808983e-08
. O 0 1.1178683223533881e-07

These O 0 1.0644780168433954e-08
results O 0 1.4209764476191822e-09
will O 0 1.0452587406728497e-10
form O 0 6.619857439993382e-11
the O 0 2.552776566522308e-11
basis O 0 8.369688969667166e-11
for O 0 3.921700204162493e-12
studies O 0 1.4266290405962057e-11
of O 0 7.598597445701571e-11
mutation O 0 2.894578673973136e-11
and O 0 1.493909440597463e-10
imprinting O 0 6.849429041722033e-07
of O 0 1.2481494877647492e-06
UBE3A O 0 0.0025917545426636934
. O 0 3.866076895064907e-06

Mutation O 0 3.651329905096645e-07
spectrum O 0 7.044889116514241e-07
and O 0 7.434968196662339e-09
genotype O 0 3.9973865995079905e-08
- O 0 8.311060284427185e-09
phenotype O 0 3.866570674748715e-10
analyses O 0 4.818297982822628e-10
in O 0 4.679791554274004e-10
Cowden B-Disease 0 8.747546235099435e-05
disease I-Disease 0 6.855166247987654e-07
and O 0 3.1860021287855034e-09
Bannayan B-Disease 1 0.999693751335144
- I-Disease 1 0.9999970197677612
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.4160697503484698e-07
two O 0 1.2938272675455664e-07
hamartoma B-Disease 1 0.9988711476325989
syndromes I-Disease 0 0.017378587275743484
with O 0 9.38693483476527e-06
germline O 1 0.9994003772735596
PTEN O 1 0.9647058248519897
mutation O 0 8.969020200311206e-06
. O 0 2.2761148557037814e-06

The O 0 5.284444341668859e-06
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.0005258644232526422
gene O 0 5.386095836001914e-06
PTEN O 0 0.00012662034714594483
, O 0 3.3844266056348715e-08
which O 0 8.479796309579513e-10
maps O 0 2.4984537105865456e-08
to O 0 1.1184607906500332e-08
10q23 O 0 4.535158041107934e-06
. O 0 6.908602472321945e-07

3 O 0 1.3083088106213836e-06
and O 0 4.462476166366969e-09
encodes O 0 1.5979302325774825e-09
a O 0 1.925325898710639e-09
403 O 0 8.858589417570784e-10
amino O 0 3.050466768073079e-09
acid O 0 4.779618478778502e-09
dual O 0 1.067917168029453e-07
specificity O 0 2.2294052826055122e-07
phosphatase O 0 7.296710828086361e-05
( O 0 3.9620218217351066e-08
protein O 0 3.0881935231263924e-07
tyrosine O 0 3.5338135262463766e-07
phosphatase O 0 1.4739900962013053e-06
; O 0 3.6578591267044658e-09
PTPase O 0 6.514308665828139e-07
) O 0 8.536317208651667e-10
, O 0 8.566508058471811e-10
was O 0 2.264163079246373e-08
shown O 0 1.2213933198168547e-09
recently O 0 2.1037191988426684e-09
to O 0 1.1806169930572707e-10
play O 0 2.183458747140321e-08
a O 0 1.4727731256769516e-09
broad O 0 1.2382517233788803e-09
role O 0 4.11869383043495e-09
in O 0 1.8053194494882518e-09
human O 0 3.2297510443868305e-08
malignancy B-Disease 0 2.4305199985974468e-05
. O 0 3.7639389915966603e-07

Somatic O 0 0.0004108657594770193
PTEN O 0 0.0002024486311711371
deletions O 0 6.098937888054934e-07
and O 0 6.041727562688948e-09
mutations O 0 5.10521935837005e-09
were O 0 8.303688847632884e-10
observed O 0 2.806204379979249e-09
in O 0 5.659891444409482e-10
sporadic B-Disease 0 1.5397833976749098e-06
breast I-Disease 0 0.0007197046652436256
, I-Disease 0 8.931976935855346e-08
brain I-Disease 1 0.9999946355819702
, I-Disease 0 3.837048723198677e-07
prostate I-Disease 1 0.9999895095825195
and I-Disease 0 0.4726238250732422
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999833106994629
lines O 0 1.7558010085849673e-06
and O 0 2.3118413849942954e-09
in O 0 5.183407592035394e-10
several O 0 1.5300044564625637e-10
primary O 0 2.3292375317396363e-07
tumours B-Disease 1 0.9999998807907104
such O 0 5.7392632868413784e-09
as O 0 1.2838630709666177e-06
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9999996423721313
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9999998807907104
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9998911619186401

In O 0 4.153731225642332e-08
addition O 0 3.9074471658295806e-08
, O 0 1.1171922054131755e-08
PTEN O 0 3.300912567283376e-06
was O 0 1.249841687922526e-07
identified O 0 7.677796731719866e-10
as O 0 7.468702739599209e-11
the O 0 5.5777764351727654e-11
susceptibility O 0 1.2266604398902814e-09
gene O 0 2.783207553314071e-10
for O 0 4.626946603636384e-10
two O 0 7.120200962162926e-08
hamartoma B-Disease 1 0.9999938011169434
syndromes I-Disease 1 0.9999971389770508
Cowden B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9996552467346191
( O 0 7.502434229422761e-09
CD B-Disease 0 1.916542942126398e-06
; O 0 1.0334249900267878e-08
MIM O 0 7.413481739604322e-07
158350 O 0 8.696607523006605e-08
) O 0 1.9463451683687794e-10
and O 0 1.9252772986977362e-10
Bannayan B-Disease 0 1.8417808860249352e-06
- I-Disease 0 2.3436389255948598e-06
Zonana I-Disease 0 0.0005601018783636391
( I-Disease 0 2.377855956581243e-08
BZS I-Disease 0 1.0191697583650239e-05
) I-Disease 0 2.207266591724988e-09
or I-Disease 0 4.4463677184580774e-09
Ruvalcaba I-Disease 0 2.3131958641897654e-06
- I-Disease 0 2.7163794129592134e-06
Riley I-Disease 0 7.196058868430555e-05
- I-Disease 1 0.8360146880149841
Smith I-Disease 1 0.9985659718513489
syndrome I-Disease 1 0.9999986886978149
( O 0 3.995683641733194e-07
MIM O 0 0.0005069038015790284
153480 O 0 4.2635430872906e-05
) O 0 6.786800099689572e-08
. O 0 2.6495203542253876e-07

Constitutive O 0 5.892786248296034e-06
DNA O 0 1.1055234949708392e-07
from O 0 1.6822717441300483e-08
37 O 0 1.905623925324562e-08
CD B-Disease 0 7.352696940188252e-08
families O 0 1.0017798396377842e-10
and O 0 3.7218508830427766e-10
seven O 0 2.9141309365599e-09
BZS B-Disease 0 1.891676220111549e-06
families O 0 5.2427950869571305e-11
was O 0 4.9797339585211375e-09
screened O 0 9.272294931861325e-09
for O 0 4.822915844471254e-09
germline O 0 5.943383712292416e-06
PTEN O 0 0.00016963397501967847
mutations O 0 2.6027926196547924e-06
. O 0 1.3075516562821576e-06

PTEN O 0 0.0001229588087880984
mutations O 0 1.4524184166475607e-07
were O 0 6.272752095526357e-09
identified O 0 2.6017927812205244e-09
in O 0 9.557742375321254e-10
30 O 0 3.3630742635182287e-09
of O 0 1.266724769521943e-08
37 O 0 1.7463188228816762e-08
( O 0 2.091639222934205e-10
81 O 0 1.0589535470728606e-08
% O 0 3.0152139118833077e-10
) O 0 4.148847931872979e-11
CD B-Disease 0 1.4571239326244267e-08
families O 0 2.994191006244762e-11
, O 0 7.179019878567061e-11
including O 0 1.4150525196043873e-10
missense O 0 3.4986733510322665e-08
and O 0 3.3019036393966417e-09
nonsense O 0 1.3471253623720258e-06
point O 0 6.815740789534175e-07
mutations O 0 3.719503594012963e-09
, O 0 5.086400189924234e-10
deletions O 0 1.6835677296711538e-09
, O 0 4.730965064148052e-10
insertions O 0 5.808123315631519e-09
, O 0 9.408396284271703e-10
a O 0 4.367125772120062e-09
deletion O 0 2.6544520892457513e-07
/ O 0 1.475351382396184e-06
insertion O 0 3.3976090207943344e-07
and O 0 6.942777019958157e-08
splice O 0 2.6515067474974785e-06
site O 0 2.6976371714226843e-07
mutations O 0 4.5076893684381503e-07
. O 0 1.1844568916785647e-06

These O 0 6.6512018115361116e-09
mutations O 0 7.57283746821713e-09
were O 0 4.1135437278683185e-09
scattered O 0 2.1109702874611003e-09
over O 0 4.767597983068583e-10
the O 0 5.037681383157633e-10
entire O 0 3.297548456515642e-09
length O 0 3.485909338962756e-09
of O 0 1.0930186533641972e-08
PTEN O 0 1.225971431040307e-07
, O 0 2.820444433559999e-10
with O 0 2.5127153829851423e-11
the O 0 3.1872285366496556e-10
exception O 0 3.3547375988263184e-10
of O 0 6.124192264422845e-10
the O 0 2.408371280182564e-10
first O 0 6.947697972492506e-10
, O 0 6.655335171856791e-10
fourth O 0 1.603882182621419e-08
and O 0 2.288968570240968e-09
last O 0 9.448976356907224e-08
exons O 0 1.404133740834368e-06
. O 0 1.9055131588174845e-06

A O 0 9.930338819685858e-06
hot O 0 4.957265900884522e-06
spot O 0 3.7266426033966127e-07
for O 0 8.14266520876572e-09
PTEN O 0 7.626805995641917e-07
mutation O 0 1.0057377153316338e-09
in O 0 1.9258732386617794e-09
CD B-Disease 0 1.7929278328665532e-07
was O 0 9.052325111724713e-08
identified O 0 2.1600705668589626e-09
in O 0 2.028099466144795e-09
exon O 0 2.4193408165729124e-08
5 O 0 3.742789189686846e-09
that O 0 2.1392885726778665e-11
contains O 0 9.075495216448459e-11
the O 0 3.221367894656879e-10
PTPase O 0 1.2079247824203776e-07
core O 0 1.4989262808740023e-07
motif O 0 7.97019872322835e-09
, O 0 1.1270211847103084e-10
with O 0 1.536194088602727e-11
13 O 0 2.1554116269584256e-09
of O 0 5.2394213412298996e-09
30 O 0 7.792760214897498e-09
( O 0 2.002934068601192e-10
43 O 0 2.4308939305939248e-09
% O 0 1.482849260048269e-10
) O 0 6.848779876555966e-11
CD B-Disease 0 3.983739205182246e-08
mutations O 0 1.7586186951135119e-09
identified O 0 3.3953264644281944e-09
in O 0 1.4462856468000496e-09
this O 0 1.7537851171312013e-09
exon O 0 1.8225398434879025e-06
. O 0 3.5930622743762797e-07

Seven O 0 6.969636956455361e-07
of O 0 2.616655194742634e-07
30 O 0 1.570437433429106e-07
( O 0 4.799641240005315e-10
23 O 0 5.529943614135391e-09
% O 0 1.348034461834402e-10
) O 0 2.8216805628145103e-11
were O 0 1.148443284915146e-10
within O 0 1.275385630439274e-10
the O 0 9.830672387245443e-11
core O 0 7.147807679075413e-09
motif O 0 9.007296020158151e-10
, O 0 2.0519334495427977e-11
the O 0 3.352606040007977e-11
majority O 0 2.883734050163067e-11
( O 0 2.934855830583061e-11
five O 0 1.7188069023621466e-10
of O 0 2.0882797713284162e-09
seven O 0 3.7130087893189057e-10
) O 0 2.247143963962639e-11
of O 0 1.2554528527886077e-09
which O 0 7.370125343353351e-11
were O 0 1.1184858594859293e-09
missense O 0 3.109156310188155e-08
mutations O 0 2.1538335559512234e-09
, O 0 1.2629268741903843e-09
possibly O 0 1.4450235674701162e-08
pointing O 0 5.2213273704637686e-08
to O 0 3.179674856745862e-10
the O 0 5.062301133840208e-10
functional O 0 1.0502282066227053e-07
significance O 0 3.4182658481540784e-08
of O 0 7.121285339195538e-09
this O 0 5.817566428589771e-10
region O 0 6.101637239908086e-08
. O 0 6.694222065561917e-08

Germline O 0 0.0002765035314951092
PTEN O 0 3.1674218917032704e-05
mutations O 0 2.6024892463283322e-08
were O 0 1.6661418911212422e-09
identified O 0 5.235662459135426e-10
in O 0 2.531086451540432e-10
four O 0 4.830969513314187e-10
of O 0 7.112136657383417e-09
seven O 0 5.340274000786849e-09
( O 0 4.744103998532978e-10
57 O 0 3.707252460571908e-08
% O 0 1.1289930768043632e-08
) O 0 2.6163501587461724e-08
BZS B-Disease 0 0.0002486934536136687
families O 0 1.6040964112562506e-08
studied O 0 1.4124179870123044e-05
. O 0 7.701628987888398e-07

Interestingly O 0 1.958110033228877e-06
, O 0 2.5716442308976184e-08
none O 0 1.708040286985124e-08
of O 0 1.5263675878784966e-09
these O 0 3.241978560608594e-11
mutations O 0 1.6163366478583185e-10
was O 0 7.74732189512406e-09
observed O 0 1.7736425661496469e-09
in O 0 2.0368480513344167e-10
the O 0 1.5767223082718829e-09
PTPase O 0 8.870566148289072e-07
core O 0 3.858235686493572e-06
motif O 0 1.3159118452676921e-06
. O 0 3.7594691093545407e-07

It O 0 6.181183920261901e-08
is O 0 4.617542348483994e-09
also O 0 6.131965490929758e-10
worthy O 0 9.186775784542078e-09
of O 0 2.5078963350466665e-09
note O 0 1.5339821635151907e-09
that O 0 1.2405268652593282e-11
a O 0 1.5791894181216293e-10
single O 0 2.2643291408552813e-10
nonsense O 0 2.7025548021697432e-08
point O 0 1.8281657077068303e-08
mutation O 0 8.9399244951327e-11
, O 0 1.209294886450607e-10
R233X O 0 1.3790956820969313e-08
, O 0 2.590931358348314e-10
was O 0 4.1690007002159746e-09
observed O 0 5.946796943767652e-10
in O 0 1.1215465361980037e-10
the O 0 3.583620067360016e-10
germline O 0 5.837198280289613e-09
DNA O 0 1.891976575407739e-09
from O 0 5.560401028503748e-10
two O 0 1.0809760031538218e-10
unrelated O 0 4.780694506933969e-09
CD B-Disease 0 9.124853761477425e-08
families O 0 4.0242723042815953e-10
and O 0 4.198734249172276e-09
one O 0 2.4285965238846074e-08
BZS B-Disease 0 0.0006143617792986333
family O 0 4.1874199041558313e-07
. O 0 5.612965310319851e-07

Genotype O 0 1.945892563526286e-06
- O 0 2.391615794294921e-07
phenotype O 0 2.6295061683612175e-09
studies O 0 8.630254844099738e-10
were O 0 9.242268755871308e-11
not O 0 9.387469100674561e-12
performed O 0 4.6103409978570653e-10
on O 0 6.896945237144791e-10
this O 0 8.537627202431786e-12
small O 0 6.087992610037674e-11
group O 0 5.672871616901887e-10
of O 0 3.8250789202720625e-08
BZS B-Disease 0 0.0009800144471228123
families O 0 9.565461311922263e-09
. O 0 1.45409003948771e-07

However O 0 3.363506380082981e-07
, O 0 1.3252191344292896e-08
genotype O 0 1.64882152375867e-08
- O 0 1.6748312958725364e-08
phenotype O 0 1.038894970051274e-09
analysis O 0 5.350346832244668e-09
inthe O 0 3.829539991784259e-07
group O 0 1.2238325908242587e-09
of O 0 8.319879007956388e-09
CD B-Disease 0 9.477365097154689e-07
families O 0 2.1837565089555255e-10
revealed O 0 3.335782539082288e-09
two O 0 6.086192660959e-11
possible O 0 2.2186745496366456e-10
associations O 0 6.002118246861698e-11
worthy O 0 3.896891254129287e-09
of O 0 4.561214073106612e-09
follow O 0 1.4807980397435472e-09
- O 0 5.0702269049907045e-09
up O 0 6.564261911812252e-10
in O 0 3.2804836624933387e-10
independent O 0 1.704108520961256e-09
analyses O 0 7.598909945727428e-09
. O 0 5.7668852804226844e-08

The O 0 5.959804525446089e-07
first O 0 3.161982320420975e-08
was O 0 1.7089372761347477e-07
an O 0 8.535177009605377e-10
association O 0 1.3339980231563686e-09
noted O 0 1.8250989608503687e-09
in O 0 3.4619085376164094e-10
the O 0 4.283643995073305e-10
group O 0 2.777797991626585e-10
of O 0 4.196444969295499e-09
CD B-Disease 0 2.5973622541641816e-06
families O 0 2.37470348940505e-10
with O 0 1.1153717949241582e-08
breast B-Disease 1 0.9999886751174927
disease I-Disease 1 0.9999819993972778
. O 0 8.157596312230453e-06

A O 0 7.047980261631892e-07
correlation O 0 1.705388115169626e-07
was O 0 1.3332208936844836e-07
observed O 0 7.612531938150369e-09
between O 0 1.7964538745474101e-09
the O 0 3.159904837790606e-10
presence O 0 8.924884720151738e-10
/ O 0 1.8464445972199428e-08
absence O 0 2.495734108265424e-08
of O 0 1.5591565372119476e-08
a O 0 1.0218412782592168e-08
PTEN O 0 2.4919296492953436e-07
mutation O 0 4.663806008053939e-10
and O 0 8.81079653680672e-11
the O 0 1.1784032083461682e-10
type O 0 2.316309277716755e-08
of O 0 2.2281321321315772e-07
breast O 0 0.0003001950681209564
involvement O 0 2.828026481438428e-05
( O 0 2.453711545058468e-08
unaffected O 0 7.331466918003571e-07
versus O 0 0.02008606679737568
benign O 0 0.015114770270884037
versus O 0 0.16898123919963837
malignant O 0 0.027123011648654938
) O 0 4.554330956807462e-08
. O 0 1.4239458323572762e-07

Specifically O 0 1.7367332816320413e-07
and O 0 9.462354455536115e-09
more O 0 1.1019683776591904e-10
directly O 0 6.805213059735138e-10
, O 0 9.089128061301466e-11
an O 0 5.646453790641992e-11
association O 0 5.583761231164885e-10
was O 0 3.273536464121207e-08
also O 0 1.4711412643642063e-10
observed O 0 6.491276405284907e-10
between O 0 4.881831605629827e-10
the O 0 7.524151440785332e-11
presence O 0 8.665102663174551e-11
of O 0 2.1272632544366843e-09
a O 0 3.487811151003939e-09
PTEN O 0 1.736710146360565e-05
mutation O 0 9.739997608448903e-08
and O 0 3.044185632461449e-07
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
. O 0 3.090571044594981e-05

Secondly O 0 3.923486656276509e-05
, O 0 1.2863125675721676e-07
there O 0 1.2064646170983906e-08
appeared O 0 9.351668772694666e-09
to O 0 7.261427570348644e-11
be O 0 7.271476476500283e-11
an O 0 1.2488939049593029e-10
interdependent O 0 5.524342441276531e-07
association O 0 7.374551103112026e-08
between O 0 1.5872271319494757e-07
mutations O 0 1.6355752308072624e-08
upstream O 0 4.191343094817057e-08
and O 0 6.389638818049548e-10
within O 0 2.7555833170822552e-09
the O 0 2.6667152930315297e-09
PTPase O 0 8.108299880404957e-07
core O 0 7.95549851773103e-07
motif O 0 7.322146444721511e-08
, O 0 3.9817071861847353e-10
the O 0 3.480619126250417e-10
core O 0 1.4981111462475383e-08
motif O 0 2.0169201864206343e-09
containing O 0 1.1831914614734984e-10
the O 0 4.1208661483160824e-11
majority O 0 5.7045517615206265e-11
of O 0 4.9670605406504365e-09
missense O 0 5.652248802334725e-08
mutations O 0 1.9913968252183167e-09
, O 0 6.531141738541635e-10
and O 0 2.2674925825860726e-10
the O 0 1.5297223487920064e-09
involvement O 0 3.683443239310691e-08
of O 0 1.0879809053676581e-08
all O 0 2.464534687440789e-10
major O 0 1.0140633222022188e-08
organ O 1 0.6342123746871948
systems O 1 0.9999605417251587
( O 0 5.272469024930615e-06
central O 1 0.5218737721443176
nervous O 0 0.0004047614929731935
system O 0 0.0025082724168896675
, O 0 1.3042451882938622e-06
thyroid O 1 1.0
, O 0 2.8377355192787945e-05
breast O 1 0.999994158744812
, O 0 2.687635787879117e-05
skin O 1 0.999998927116394
and O 1 0.9996887445449829
gastrointestinal O 1 1.0
tract O 1 0.9999996423721313
) O 0 1.3236462109489366e-05
. O 0 6.554667379532475e-06

However O 0 4.726843769731204e-07
, O 0 5.671197733647659e-09
these O 0 7.799979412359548e-11
observations O 0 4.538251996422105e-09
would O 0 4.6191164781994587e-10
need O 0 5.334060970696441e-10
to O 0 4.2483853240904423e-11
be O 0 5.509954992266586e-11
confirmed O 0 1.0150995322089074e-10
by O 0 1.3949960978032472e-11
studying O 0 1.8615075036976236e-09
a O 0 3.556965139095425e-11
larger O 0 1.3301019140266046e-11
number O 0 3.455033134591723e-11
of O 0 2.0070267670035946e-09
CD B-Disease 0 6.179782303661341e-07
families O 0 2.2548314326797936e-09
. O 0 7.30161744399993e-08

Molecular O 0 0.09124807268381119
defects O 1 0.9995007514953613
leading O 0 1.9481058188830502e-06
to O 0 3.084871025293978e-09
human O 0 6.781481687312407e-08
complement B-Disease 0 1.0077554179588333e-05
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 2.1973711739065038e-08
an O 0 4.855402746528625e-10
African O 0 1.0976586750643946e-08
- O 0 3.3361342133275684e-08
American O 0 1.8114564070970118e-08
family O 0 6.300534760583787e-09
. O 0 3.7316922885111126e-08

Complement B-Disease 0 6.091461546020582e-05
component I-Disease 1 0.999988317489624
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 4.7463987584706047e-07
C6D B-Disease 0 2.046207373496145e-05
) O 0 2.1505905944962933e-09
was O 0 5.383741807918341e-08
diagnosed O 0 1.8661054923541087e-07
in O 0 1.2922402037318648e-09
a O 0 1.2821375072746832e-09
16 O 0 3.6577472162235836e-09
- O 0 1.1847139935738937e-09
year O 0 3.7647962525255707e-10
- O 0 4.0619068109037926e-09
old O 0 3.300192830124615e-08
African O 0 6.878713598723607e-09
- O 0 5.077736897618479e-09
American O 0 5.690916626832632e-10
male O 0 2.2061805715622995e-09
with O 0 2.6881807002610003e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.4147294677968603e-06

The O 0 1.7266430063500593e-07
patients O 0 5.394956019699748e-07
father O 0 3.78845641080261e-07
and O 0 9.189001559661847e-09
two O 0 1.596234255885065e-08
brothers O 0 3.244745983010944e-07
also O 0 3.248177504744376e-09
had O 0 6.710201461146426e-08
C6D B-Disease 0 0.0005532994400709867
, O 0 1.8206728347180956e-09
but O 0 1.7624154913242762e-10
gave O 0 6.818777764650008e-10
no O 0 2.119858039106859e-10
history O 0 8.049378386054684e-10
of O 0 1.0901993974243851e-08
meningitis B-Disease 1 0.999998927116394
or O 0 2.0242347797960747e-09
other O 0 1.5706350664501656e-09
neisserial B-Disease 0 5.802196483273292e-06
infection I-Disease 0 1.1845262633869424e-05
. O 0 2.173151472106838e-07

By O 0 5.8157496596322744e-09
using O 0 1.1993109616525999e-08
exon O 0 1.1083781004117554e-07
- O 0 2.607207560956226e-09
specific O 0 2.0110647869220344e-10
polymerase O 0 2.3280243510725995e-08
chain O 0 1.2614536082367067e-09
reaction O 0 8.33664526300737e-11
( O 0 3.009903090656074e-11
PCR O 0 2.409175359208149e-10
) O 0 2.550168236303829e-11
/ O 0 4.403004072450756e-10
single O 0 6.13241887825744e-11
- O 0 1.367780888550385e-09
strand O 0 5.339212405530702e-10
conformation O 0 2.102093915601344e-10
polymorphism O 0 2.539713717109038e-10
as O 0 2.8740804874916037e-11
a O 0 1.7694406703738785e-11
screening O 0 6.354705650579717e-11
step O 0 1.9282982155477413e-10
and O 0 9.405193637790354e-12
nucleotide O 0 3.1498917363315115e-10
sequencing O 0 5.091932986367453e-10
of O 0 3.6615235288195436e-09
target O 0 2.532584586489861e-09
exons O 0 1.6316709761099446e-08
, O 0 1.262209337049569e-09
we O 0 2.8382529659864986e-10
determined O 0 5.142020698123417e-10
that O 0 9.974417992941742e-12
the O 0 1.0833000468890575e-10
proband O 0 1.877182320697557e-08
was O 0 9.807234135905674e-09
a O 0 5.036028816185478e-10
compound O 0 2.735130122388796e-09
heterozygote O 0 6.531035268153573e-08
for O 0 4.103364315000135e-09
two O 0 3.6585586116189006e-08
C6 O 0 0.0007449582917615771
gene O 0 8.455019155917398e-07
mutations O 0 2.2358917703968473e-06
. O 0 9.052338896253787e-07

The O 0 2.94148549073725e-07
first O 0 1.921386960646032e-08
, O 0 1.576096808619809e-09
1195delC O 0 2.0483625462475175e-08
located O 0 4.621039995100773e-09
in O 0 1.517152070640293e-09
exon O 0 3.0258004812822037e-07
7 O 0 1.339905111308326e-07
, O 0 2.1656809678916034e-09
is O 0 1.2063276766394182e-10
a O 0 1.3249094876766065e-10
novel O 0 1.7363664672753742e-10
mutation O 0 5.325153859536691e-11
, O 0 7.136125718121278e-11
while O 0 1.839482594023778e-10
the O 0 1.6032750127514817e-10
second O 0 1.3167525958479587e-09
, O 0 2.4236287976542314e-10
1936delG O 0 5.5678115451485155e-09
in O 0 1.6897477861377297e-09
exon O 0 7.468485563322247e-08
12 O 0 3.3922727737945024e-08
, O 0 7.247953903721793e-10
has O 0 1.0542929723689198e-10
been O 0 2.791464004392452e-10
described O 0 7.676361768460538e-10
before O 0 7.408351709869976e-10
to O 0 2.1683829731777848e-10
cause O 0 5.5764628470456046e-09
C6D B-Disease 0 1.5638374861737248e-06
in O 0 1.1202493377382439e-09
an O 0 2.3854487829488846e-10
unrelated O 0 5.663871860406289e-08
African O 0 3.43676020975181e-08
- O 0 4.305527312453705e-08
American O 0 4.751540938485732e-09
individual O 0 1.4669333525674233e-09
. O 0 1.0009580364567228e-07

Both O 0 1.622640439791212e-07
mutations O 0 9.480278606588399e-08
result O 0 2.589392700258486e-08
in O 0 9.269925271837565e-09
premature O 0 5.670595015772051e-08
termination O 0 6.039091715592804e-08
codons O 0 1.4836675177321013e-07
and O 0 3.5673792808665894e-08
C6 O 0 5.902527118450962e-05
null O 0 1.3905790183343925e-05
alleles O 0 1.2343778053036658e-06
. O 0 1.4984447034294135e-06

Allele O 0 4.350488325144397e-07
- O 0 3.368404222214849e-08
specific O 0 1.7990118283961465e-09
PCR O 0 1.059076826237515e-08
indicated O 0 1.8417830593975282e-09
that O 0 1.4426474771733755e-11
the O 0 4.33315466841222e-10
probands O 0 1.6756852971866465e-07
two O 0 2.4265764952957625e-09
brothers O 0 2.594009806955455e-08
also O 0 6.455297962837392e-10
inherited O 0 6.429193177837078e-08
the O 0 4.1620880075754485e-09
1195delC O 0 1.5663427888057413e-08
mutation O 0 2.0542215151131415e-10
from O 0 3.149867588980726e-10
their O 0 3.5320253666260015e-11
heterozygous O 0 3.5381292340375126e-10
mother O 0 4.2361938956680945e-10
and O 0 2.5860031130364725e-11
the O 0 1.4524302593965643e-10
1936delG O 0 2.702460699666176e-09
mutation O 0 9.266168388144536e-11
from O 0 3.826797490003031e-10
their O 0 1.152502884793627e-10
homozygous O 0 4.861771873976295e-09
father O 0 4.0100864850955986e-08
. O 0 4.1115355564613765e-09
. O 0 6.082673564833385e-08

PAX6 O 0 0.00290158879943192
mutations O 0 3.8062337353039766e-06
reviewed O 0 1.5315283235395327e-05
. O 0 3.3009721391863422e-06

Mutations O 0 9.296015264226298e-07
in O 0 1.1324939208634532e-07
PAX6 O 0 1.5167243873293046e-05
are O 0 3.381365187848928e-10
responsible O 0 1.7764663073904785e-09
for O 0 1.8401703771875333e-10
human O 0 3.563468808920334e-08
aniridia B-Disease 1 1.0
and O 0 6.710224376149654e-09
have O 0 5.888430021361302e-11
also O 0 1.3907717859307223e-11
been O 0 8.516045507667158e-12
found O 0 4.343816972784964e-12
in O 0 6.174562163646646e-12
patients O 0 8.903605283605565e-12
with O 0 6.02055488796438e-11
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 2.404065071459627e-07
with O 0 0.00020208375644870102
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.037548407912254333
with O 0 9.939898518496193e-06
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 0.9999996423721313
, O 0 7.661273571102356e-08
and O 0 3.5581493307290657e-09
with O 0 5.5348319705217364e-08
isolated B-Disease 1 0.9999948740005493
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.9448091387748718

No O 0 3.5449289725875133e-07
locus O 0 6.62791492800352e-08
other O 0 1.1434517777075826e-09
than O 0 6.445873834692861e-10
chromosome O 0 8.209084256804999e-08
11p13 O 0 3.206705230240914e-07
has O 0 2.3072554977687787e-09
been O 0 1.578654207357033e-09
implicated O 0 1.6090789145550843e-08
in O 0 1.0709172215683793e-08
aniridia B-Disease 1 0.9999996423721313
, O 0 1.9063580936062863e-08
and O 0 6.363651383622937e-09
PAX6 O 0 1.2320936548348982e-05
is O 0 4.4977848112637275e-09
clearly O 0 9.139900392085565e-09
the O 0 7.903496745953476e-10
major O 0 1.0355915236459623e-08
, O 0 4.765279837393166e-10
if O 0 1.0979695624913077e-10
not O 0 3.689892835723185e-11
only O 0 3.444583854261829e-11
, O 0 1.9257767602809395e-10
gene O 0 3.02986435940511e-09
responsible O 0 1.0168895414608414e-07
. O 0 3.493806275400857e-07

Twenty O 0 3.7376196360128233e-06
- O 0 2.0087385621536669e-07
eight O 0 4.17049594858554e-09
percent O 0 1.4370904466431966e-09
of O 0 7.022787906763028e-10
identified O 0 2.0359556263116474e-09
PAX6 O 0 4.7004252223814547e-07
mutations O 0 8.577920040941933e-10
are O 0 1.310568181756011e-10
C O 0 3.2391765216743806e-06
- O 0 1.5647340489977069e-07
T O 0 7.77565958287596e-08
changes O 0 3.2512394998462923e-09
at O 0 7.502236343270852e-08
CpG O 0 3.757955724381645e-08
dinucleotides O 0 8.888911651183662e-08
, O 0 4.554118193667023e-10
20 O 0 1.418431039290624e-09
% O 0 4.4444215668848486e-11
are O 0 5.990392210053486e-12
splicing O 0 1.097296031815631e-09
errors O 0 1.7426387444174907e-08
, O 0 2.2999344095886443e-10
and O 0 3.985108770754309e-11
more O 0 6.52869381820298e-12
than O 0 1.2541782716535277e-11
30 O 0 4.88641460627548e-10
% O 0 2.521130873511801e-11
are O 0 6.8936371368233385e-12
deletion O 0 1.049282216669667e-09
or O 0 3.453163588407193e-10
insertion O 0 1.4818441584907305e-08
events O 0 1.5111458750993734e-08
. O 0 1.8789847899824963e-07

There O 0 3.08553808281431e-07
is O 0 1.473878263880124e-08
a O 0 9.385764165870114e-09
noticeably O 0 2.644741243784665e-07
elevated O 0 2.922633370872063e-07
level O 0 1.5457700897059112e-07
of O 0 1.0207095613168349e-08
mutation O 0 2.7838339966557157e-10
in O 0 1.5444739931425033e-10
the O 0 1.8293044856676488e-10
paired O 0 4.779607265525954e-10
domain O 0 2.783230090841471e-09
compared O 0 7.843172777910468e-10
with O 0 2.6551460682866512e-11
the O 0 5.261992508387436e-10
rest O 0 4.850943646772521e-09
of O 0 2.043023750175621e-09
the O 0 1.2567226148618715e-09
gene O 0 7.850404770692876e-09
. O 0 4.784838836258132e-08

Increased O 0 2.90809136771486e-08
mutation O 0 2.3588193620582842e-09
in O 0 1.031996488265463e-09
the O 0 1.3176419955129859e-09
homeodomain O 0 1.0142144901692518e-07
is O 0 1.4357745548032597e-10
accounted O 0 2.7431115712239773e-10
for O 0 1.9192449712823745e-11
by O 0 1.5792188737262514e-11
the O 0 7.343048391561524e-10
hypermutable O 0 1.2910244606700871e-07
CpG O 0 9.915671483895494e-08
dinucleotide O 0 3.9882598912299727e-07
in O 0 6.058991974811079e-09
codon O 0 1.1025543500409185e-07
240 O 0 1.5822006105281616e-07
. O 0 2.2934803212137922e-07

Very O 0 3.3640421293057443e-07
nearly O 0 1.3725144576426374e-08
all O 0 1.8843335225504632e-10
mutations O 0 6.463330426420555e-10
appear O 0 1.3482767124983752e-09
to O 0 2.086650296995174e-10
cause O 0 1.661436321853671e-08
loss O 0 2.3980238239573737e-08
of O 0 1.111485872229423e-07
function O 0 1.6600860419657693e-07
of O 0 3.2289129592300014e-08
the O 0 4.2491171692304874e-10
mutant O 0 1.0365588942740089e-10
allele O 0 1.4763978928300503e-10
, O 0 1.2752444933372686e-10
and O 0 2.5394604821760147e-11
more O 0 3.838328960226178e-12
than O 0 9.628194075350649e-12
80 O 0 1.6255653767505152e-10
% O 0 4.3515888809020353e-11
of O 0 1.3439505064383184e-09
exonic O 0 1.4044964302684093e-07
substitutions O 0 8.681092289464232e-09
result O 0 4.697787492347061e-09
in O 0 5.090362353854516e-09
nonsense O 0 2.807740600019315e-07
codons O 0 2.78008087661874e-07
. O 0 2.9107420118634764e-07

In O 0 2.4946282906057604e-07
a O 0 1.0744445333443764e-08
gene O 0 7.820123437696225e-10
with O 0 8.142408969291637e-11
such O 0 7.677883884227299e-10
extraordinarily O 0 1.6734972518861468e-07
high O 0 2.53790997106762e-08
sequence O 0 5.169003003402395e-10
conservation O 0 3.6573127859540477e-10
throughout O 0 1.7174109356865586e-10
evolution O 0 6.396467799874017e-10
, O 0 2.0124374389141053e-11
there O 0 9.73238416940303e-12
are O 0 9.151050577027586e-12
presumed O 0 2.8704638665999482e-08
undiscovered O 0 6.710919024044415e-06
missense O 0 3.2212795986197307e-07
mutations O 0 1.4606048814869155e-08
, O 0 9.022220748278187e-10
these O 0 3.6329217412145454e-11
are O 0 9.692056185395259e-12
hypothesized O 0 5.077550602194947e-10
to O 0 6.444260403082325e-11
exist O 0 1.240495040022438e-09
in O 0 5.8989324536185e-10
as O 0 3.814738747109914e-09
- O 0 1.855705278330788e-08
yet O 0 1.2154440787170984e-09
unidentified O 0 1.884098210780394e-08
phenotypes O 0 8.531438666636859e-09
. O 0 5.6478275389793e-09
. O 0 8.738708601185863e-08

Genetic O 0 9.14044164801453e-07
heterogeneity O 0 4.2427237190167943e-07
and O 0 3.5946781107298875e-09
penetrance O 0 3.326089768052043e-07
analysis O 0 5.125777580161639e-09
of O 0 5.535494285169307e-09
the O 0 3.4296927520216514e-09
BRCA1 O 0 5.6532809544762586e-09
and O 0 1.4266385850447705e-09
BRCA2 O 0 8.542006213474451e-09
genes O 0 1.2621618417085756e-08
in O 0 4.2793939059038166e-08
breast B-Disease 1 0.9868703484535217
cancer I-Disease 1 0.8397003412246704
families O 0 1.0581984177804316e-08
. O 0 6.564761747540615e-07

The O 0 0.00010996418131981045
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.011648776941001415
Consortium O 0 7.338388968491927e-06
. O 0 6.740981461916817e-07

The O 0 1.4559459415863785e-08
contribution O 0 2.2735708427035206e-08
of O 0 9.199597172937501e-08
BRCA1 O 0 1.3528085318625926e-08
and O 0 8.358306935463133e-09
BRCA2 O 0 1.526204584934021e-07
to O 0 3.183119190452999e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.0005686146323569119
assessed O 0 2.279845823238702e-08
by O 0 4.355674501632656e-11
linkage O 0 1.1316529935356812e-09
and O 0 1.4921544902457562e-11
mutation O 0 4.731429657789388e-12
analysis O 0 2.4044320354188464e-11
in O 0 3.202668685808874e-11
237 O 0 1.213599637450713e-10
families O 0 4.234614395248748e-12
, O 0 1.4313333504545334e-11
each O 0 3.90386334370163e-12
with O 0 2.510013724643656e-11
at O 0 3.1752477980262483e-08
least O 0 1.1235355701355587e-10
four O 0 2.778353068444428e-11
cases O 0 1.40081460320296e-10
of O 0 1.3782410768214959e-08
breast B-Disease 0 0.00024889272754080594
cancer I-Disease 0 3.9549054235976655e-06
, O 0 3.990031915979131e-10
collected O 0 1.1011279388295492e-10
by O 0 5.088668722508238e-11
the O 0 7.819086533800146e-08
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.001075084786862135
Consortium O 0 1.8719319996307604e-06
. O 0 5.404812668530212e-07

Families O 0 2.199425708226954e-08
were O 0 3.719120789114072e-09
included O 0 5.622351473277831e-10
without O 0 4.4229525597572206e-10
regard O 0 1.619546941000749e-09
to O 0 1.9614861818118e-11
the O 0 6.04714056606781e-11
occurrence O 0 1.0006140804819097e-08
of O 0 1.019458409245999e-06
ovarian B-Disease 1 0.999983549118042
or I-Disease 0 5.334552497515688e-06
other I-Disease 0 8.744775072955235e-07
cancers I-Disease 1 0.9999860525131226
. O 0 9.771388249646407e-06

Overall O 0 6.1260720940481406e-06
, O 0 3.818558980128728e-07
disease O 0 4.5802367822034284e-05
was O 0 5.016323711970472e-07
linked O 0 2.2250121745059914e-08
to O 0 2.3980398222711585e-10
BRCA1 O 0 5.596192953483126e-10
in O 0 3.3248617747894116e-10
an O 0 6.071224772918882e-11
estimated O 0 1.6045537121200937e-10
52 O 0 1.2424841155933564e-09
% O 0 1.4830245365082817e-10
of O 0 5.046954854037722e-09
families O 0 2.0021690902427558e-11
, O 0 2.8958323586292245e-11
to O 0 2.043879301916185e-11
BRCA2 O 0 1.637087271300075e-10
in O 0 3.138617143960687e-10
32 O 0 1.7401801111205373e-09
% O 0 1.3765898143613953e-10
of O 0 3.441277929283615e-09
families O 0 1.0643869466364642e-11
, O 0 4.733761299613448e-11
and O 0 1.5545544018724655e-11
to O 0 1.2297701051933174e-11
neither O 0 6.076673053634352e-10
gene O 0 1.3483583694018364e-10
in O 0 5.174783379580106e-10
16 O 0 4.178497992057828e-09
% O 0 1.5678926212903121e-10
( O 0 1.8952358779578127e-11
95 O 0 1.2344997246671596e-09
% O 0 2.704738655268102e-10
confidence O 0 1.2636263591048191e-08
interval O 0 4.912791951028339e-08
[ O 0 1.4804231618370522e-08
CI O 0 1.3949110098110395e-06
] O 0 1.9714134324999577e-08
6 O 0 2.1776193293021606e-08
% O 0 3.154593253285043e-10
- O 0 2.0881005813322417e-09
28 O 0 5.116078671818514e-09
% O 0 1.3788969965844444e-10
) O 0 7.228429660388613e-11
, O 0 1.3230407047704063e-10
suggesting O 0 1.5586025803315806e-09
other O 0 5.800270819200648e-10
predisposition O 0 8.284568480121379e-07
genes O 0 7.219633744171006e-07
. O 0 1.2259613413334591e-06

The O 0 7.945158841948796e-08
majority O 0 3.967858486220166e-09
( O 0 4.2568068514547974e-10
81 O 0 6.912383110346809e-09
% O 0 1.1116030318447656e-10
) O 0 2.9332106188384444e-11
of O 0 1.3335350601551e-09
the O 0 2.0775034670350578e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.594466425558494e-08
were O 0 1.1884347950186225e-09
due O 0 3.667667725082424e-09
to O 0 1.9560510156058086e-10
BRCA1 O 0 4.244548601484155e-10
, O 0 5.6531994363506755e-11
with O 0 1.2777662608542961e-11
most O 0 1.5141909948113152e-10
others O 0 2.836099133318726e-10
( O 0 1.0234708913703372e-10
14 O 0 1.5940063713415498e-09
% O 0 2.3584265096410206e-10
) O 0 1.0598031480180126e-10
due O 0 2.7733644714089678e-08
to O 0 3.294048767088498e-08
BRCA2 O 0 1.6911418470044737e-06
. O 0 1.573939925947343e-06

Conversely O 0 1.4456516055361135e-06
, O 0 2.526095777000137e-09
the O 0 3.61762869660609e-10
majority O 0 8.246846955328735e-11
of O 0 1.0145232431924e-09
families O 0 3.0292758319144797e-12
with O 0 1.4713818705103243e-11
male B-Disease 0 8.657577765802671e-09
and I-Disease 0 1.0477828382704502e-08
female I-Disease 0 4.663588697439991e-06
breast I-Disease 1 0.9929596781730652
cancer I-Disease 1 0.9837101697921753
were O 0 2.459665608967043e-07
due O 0 1.1328756954753771e-06
to O 0 9.542318935018557e-09
BRCA2 O 0 1.034778041031359e-08
( O 0 7.968036785932497e-10
76 O 0 1.0266161609706614e-07
% O 0 4.078100079851765e-09
) O 0 5.4826827522447275e-09
. O 0 6.352557591071673e-08

The O 0 4.4697959111772434e-08
largest O 0 5.7793689833829376e-09
proportion O 0 1.2987934061570172e-09
( O 0 8.786294608542633e-11
67 O 0 2.0974451064859068e-09
% O 0 9.759398844622069e-11
) O 0 4.065188463631131e-11
of O 0 1.0935100602793568e-09
families O 0 1.0415923332174337e-11
due O 0 2.733847148661539e-09
to O 0 1.1939552124751174e-10
other O 0 5.017674817309192e-11
genes O 0 1.0408163914066293e-10
was O 0 5.2468616118517275e-09
found O 0 1.0802463090708869e-10
in O 0 1.0711816850195177e-10
families O 0 2.1073104199131887e-12
with O 0 2.805131474326039e-11
four O 0 4.1163433772695157e-10
or O 0 1.3245986252297115e-10
five O 0 6.144067893343319e-11
cases O 0 1.1078354206217611e-10
of O 0 2.6710997858003793e-08
female O 0 5.703826900571585e-06
breast B-Disease 1 0.9994511008262634
cancer I-Disease 1 0.9973143935203552
only O 0 5.834463081555441e-07
. O 0 2.391319867456332e-06

These O 0 6.9018173398660565e-09
estimates O 0 3.570297835153724e-09
were O 0 1.3535951248755396e-09
not O 0 6.342197600428534e-11
substantially O 0 1.612777578152702e-09
affected O 0 1.0806007477714985e-10
either O 0 4.465810013454252e-11
by O 0 6.501455623864061e-12
changing O 0 9.236881259866436e-10
the O 0 3.75481395975541e-10
assumed O 0 8.052039035533198e-09
penetrance O 0 6.5373519930744806e-09
model O 0 1.0413012674348465e-09
for O 0 2.841578639056763e-10
BRCA1 O 0 7.174780214391774e-10
or O 0 1.3710869939398407e-10
by O 0 8.351892788471815e-11
including O 0 6.702111088330298e-10
or O 0 6.325568513432245e-09
excluding O 0 2.1097503122291528e-07
BRCA1 O 0 3.634223588733221e-08
mutation O 0 9.673343903671139e-09
data O 0 9.573423653819191e-08
. O 0 2.1967221641716606e-07

Among O 0 1.1153760581805727e-08
those O 0 5.829562943482358e-10
families O 0 6.983139760885493e-11
with O 0 2.3266372162211724e-10
disease O 0 9.92295326796011e-07
due O 0 1.5486915572182625e-07
to O 0 3.92993548814502e-09
BRCA1 O 0 5.01683761200411e-09
that O 0 2.998392922837212e-10
were O 0 6.423230280994119e-10
tested O 0 1.3701616230488156e-10
by O 0 3.5270350008664852e-12
one O 0 1.0558924394554747e-11
of O 0 3.5781134999357533e-11
the O 0 1.2009664096535033e-11
standard O 0 1.855137155004627e-10
screening O 0 5.70280038469928e-11
methods O 0 2.9033719872728625e-10
, O 0 1.2772034298225154e-11
mutations O 0 2.29269780244179e-11
were O 0 1.1190401383309734e-10
detected O 0 1.3551760824626058e-09
in O 0 7.408149788057372e-11
the O 0 7.642114718819926e-11
coding O 0 4.206092807379491e-09
sequence O 0 3.209874033238691e-10
or O 0 9.107905402094829e-11
splice O 0 9.763871933188284e-10
sites O 0 9.462056832498789e-11
in O 0 2.947101243599981e-11
an O 0 7.272956542569986e-12
estimated O 0 7.534865092972964e-11
63 O 0 4.493788896553497e-09
% O 0 5.248460555051793e-10
( O 0 4.196506753206819e-10
95 O 0 2.403573695630712e-08
% O 0 5.285734516746743e-09
CI O 0 9.566991138854064e-06
51 O 0 9.24307187233353e-07
% O 0 1.1522138798625292e-08
- O 0 6.206513347706277e-08
77 O 0 6.305454292032664e-08
% O 0 9.744694828839329e-09
) O 0 7.056304429653437e-09
. O 0 1.5032553335458942e-07

The O 0 1.1773602892617419e-07
estimated O 0 6.423221510232224e-09
sensitivity O 0 1.8855002892337325e-08
was O 0 8.386220606837469e-09
identical O 0 4.942373732497174e-10
for O 0 4.654117022329096e-11
direct O 0 1.0937890870810207e-10
sequencing O 0 4.466255143498188e-10
and O 0 1.3916216790033076e-10
other O 0 2.442083202325307e-10
techniques O 0 7.673571644772892e-07
. O 0 1.1421057166671744e-07

The O 0 3.693384371672437e-07
penetrance O 0 1.2081168279109988e-05
of O 0 1.4290271792560816e-06
BRCA2 O 0 7.557257220014435e-08
was O 0 5.479235554162187e-08
estimated O 0 1.0600841732211208e-10
by O 0 1.0729253423213958e-11
maximizing O 0 3.7726044510577594e-09
the O 0 2.5663118297103438e-09
LOD O 0 6.039108029654017e-06
score O 0 4.5463028897074764e-08
in O 0 9.177948179228679e-09
BRCA2 O 0 2.1456585841406195e-08
- O 0 2.9369436660431347e-08
mutation O 0 7.287682679546492e-10
families O 0 3.801798112434973e-11
, O 0 1.232758062297279e-10
over O 0 1.002125743498894e-10
all O 0 6.214298520212935e-11
possible O 0 1.1259732035640013e-09
penetrance O 0 1.279795611708323e-07
functions O 0 3.121430154351401e-07
. O 0 5.319223532751494e-07

The O 0 7.801195778256442e-08
estimated O 0 2.3325346099056787e-09
cumulative O 0 1.669785198998852e-08
risk O 0 2.4372090123847556e-08
of O 0 4.496328998015997e-08
breast B-Disease 0 1.5831167274882318e-06
cancer I-Disease 0 1.1774613994930405e-07
reached O 0 2.416136339888908e-07
28 O 0 1.2053219222707412e-07
% O 0 3.968870232462507e-10
( O 0 9.086597446694711e-11
95 O 0 3.7542289277325835e-09
% O 0 6.767223448278514e-10
CI O 0 3.7601645885843027e-07
9 O 0 5.252351087392526e-08
% O 0 2.62070254386515e-10
- O 0 4.378750417810551e-10
44 O 0 1.7719915812453024e-10
% O 0 6.89959547828245e-12
) O 0 1.530893359129315e-12
by O 0 1.3695122509996271e-12
age O 0 3.619491928397167e-10
50 O 0 1.8188565931165357e-10
years O 0 6.742432306916513e-11
and O 0 3.5762576927611534e-11
84 O 0 1.5377670248284403e-09
% O 0 2.0361178021399695e-10
( O 0 9.736900868917431e-11
95 O 0 3.1337972217215793e-09
% O 0 1.5419375776204447e-09
CI O 0 1.7020439599946258e-06
43 O 0 1.3183408498207427e-07
% O 0 1.2982286357043904e-09
- O 0 1.7978248889605197e-09
95 O 0 2.5945625647949555e-09
% O 0 8.943915053016838e-11
) O 0 4.62087399594191e-12
by O 0 1.0421387711123664e-11
age O 0 8.349989144562642e-09
70 O 0 1.657979531444198e-08
years O 0 4.258321695260747e-08
. O 0 7.732828066764341e-08

The O 0 3.1511393672190025e-07
corresponding O 1 0.9736528992652893
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.002268246840685606
were O 0 2.683529771729809e-07
0 O 0 3.2791456305858446e-07
. O 0 4.932810426794276e-08

4 O 0 3.8091459373390535e-06
% O 0 2.3114148817171554e-08
( O 0 1.6802121916015267e-09
95 O 0 2.6487111171036304e-08
% O 0 1.757967993398779e-09
CI O 0 2.0900836261716904e-06
0 O 0 2.3480517086227337e-08
% O 0 3.6207764564366585e-10
- O 0 1.844458252797665e-09
1 O 0 2.4102382312207737e-09
% O 0 6.608903528604326e-12
) O 0 1.2393059668769357e-12
by O 0 2.6591688920274414e-12
age O 0 5.394776847467142e-10
50 O 0 3.995896113995201e-10
years O 0 1.7718970735103312e-10
and O 0 3.5912821327865885e-11
27 O 0 1.850420372484507e-09
% O 0 1.0034301167749504e-10
( O 0 4.481911716758269e-11
95 O 0 2.5702013850548155e-09
% O 0 6.160194021553878e-10
CI O 0 4.281382075532747e-07
0 O 0 8.249577021501864e-09
% O 0 3.1082936224891e-10
- O 0 2.1249759729613515e-09
47 O 0 2.3160384721165883e-09
% O 0 4.698696987048834e-11
) O 0 4.327195719799892e-12
by O 0 1.987353684396176e-11
age O 0 1.4693311456426272e-08
70 O 0 2.1768137514754926e-08
years O 0 3.0819613527910406e-08
. O 0 8.200086654142069e-08

The O 0 6.20914235582859e-08
lifetime O 0 1.3454226177600503e-07
risk O 0 3.5914933960157214e-07
of O 0 7.87980923178111e-07
breast B-Disease 0 0.19171345233917236
cancer I-Disease 0 7.236466626636684e-05
appears O 0 2.5010761461885522e-08
similar O 0 8.56346521471707e-11
to O 0 8.016891317463859e-11
the O 0 2.283639721767372e-09
risk O 0 1.5197073821582308e-08
in O 0 1.2784086012018747e-09
BRCA1 O 0 8.864927680818369e-10
carriers O 0 5.292521421118579e-10
, O 0 1.0836968128424829e-10
but O 0 1.3562245076981227e-11
there O 0 3.642830481709325e-11
was O 0 7.020939385427027e-10
some O 0 6.588942065566261e-12
suggestion O 0 3.150714966704271e-10
of O 0 5.574056216595125e-10
a O 0 3.8622294251666744e-10
lower O 0 1.0175585707372647e-08
risk O 0 4.493377225855966e-09
in O 0 1.245563985285969e-09
BRCA2 O 0 8.602972778604112e-10
carriers O 0 2.828397072107691e-09
< O 0 6.125203100282306e-08
50 O 0 9.896905517337018e-09
years O 0 1.0745382361676548e-09
of O 0 5.317708939855947e-09
age O 0 1.4561909722488053e-07
. O 0 1.118064574257005e-07

Eye B-Disease 0 0.17206473648548126
movement I-Disease 0 4.838245331484359e-06
abnormalities I-Disease 0 0.00014675111742690206
correlate O 0 8.030002618397702e-08
with O 0 1.554054884778111e-09
genotype O 0 1.1076294867962133e-06
in O 0 7.062824636250298e-08
autosomal O 1 0.9999790191650391
dominant O 1 0.9999992847442627
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 0.9999986886978149
I I-Disease 1 0.9999687671661377
. O 0 1.0712199582485482e-05

We O 0 5.3263605082065624e-08
compared O 0 4.610512860381277e-08
horizontal O 0 4.5294424921848986e-07
eye O 0 3.2361138437408954e-05
movements O 0 9.099201747631014e-08
( O 0 1.4730765496295817e-09
visually O 0 9.547325596770406e-09
guided O 0 1.4286072769209568e-07
saccades O 0 1.30944965803792e-06
, O 0 2.6901283423086397e-09
antisaccades O 0 1.8366488063747965e-07
, O 0 1.0780198955728792e-09
and O 0 3.070827203632831e-10
smooth O 0 6.972609156719045e-08
pursuit O 0 1.2977120711354928e-08
) O 0 7.651799333041609e-11
in O 0 6.364215404675022e-11
control O 0 2.9486562080904832e-09
subjects O 0 2.393290010616056e-08
( O 0 6.392244372710465e-11
n O 0 1.628759904725996e-09
= O 0 1.645295788499368e-09
14 O 0 3.036801254907573e-09
) O 0 2.8996902101674493e-11
and O 0 3.465553538584132e-11
patients O 0 7.763763243406885e-11
with O 0 1.204044329516929e-11
three O 0 6.88291923456319e-11
forms O 0 1.2368172264132227e-08
of O 0 1.2710382861769176e-06
autosomal O 1 0.996006190776825
dominant O 1 0.9995922446250916
cerebellar B-Disease 1 0.9999879598617554
ataxias I-Disease 0 0.007019734941422939
type I-Disease 0 0.0020419987849891186
I I-Disease 0 0.00327159371227026
spinocerebellar B-Disease 0 0.0006503037293441594
ataxias I-Disease 0 2.0461291569517925e-05
1 I-Disease 0 1.3517429806597647e-06
and I-Disease 0 4.496995664737824e-09
2 I-Disease 0 1.1551585998859082e-07
( O 0 4.4234588214564496e-10
SCA1 B-Disease 0 2.412461697076651e-07
, O 0 1.2479300925960501e-09
n O 0 9.413283486026103e-09
= O 0 5.455227825024167e-09
11 O 0 4.418545085371761e-09
; O 0 1.2661920123502313e-10
SCA2 B-Disease 0 9.410917556351706e-08
, O 0 5.293702143305268e-10
n O 0 8.984445187820711e-09
= O 0 4.5171373308505736e-09
10 O 0 1.5148042820101182e-09
) O 0 4.3525107129571694e-11
and O 0 1.051965403675581e-09
SCA3 B-Disease 1 0.9999997615814209
/ O 0 9.232887350663077e-06
Machado B-Disease 0 2.156109303541598e-06
- I-Disease 0 2.6416687433084007e-06
Joseph I-Disease 0 0.0005375268519856036
disease I-Disease 0 7.073883898556232e-05
( O 0 1.3341082016893324e-08
MJD B-Disease 1 0.9999998807907104
) O 0 2.555151423777602e-09
( O 0 5.473860809068753e-10
n O 0 1.5872265279881503e-08
= O 0 2.1114464843208225e-08
16 O 0 5.372181277607524e-08
) O 0 3.5763021433155018e-09
. O 0 4.567693778767534e-08

In O 0 9.74134195530496e-07
SCA1 B-Disease 0 2.99165585602168e-05
, O 0 8.581885424518987e-09
saccade O 0 1.0950786588637129e-07
amplitude O 0 1.5704502587254865e-08
was O 0 1.065891908069716e-08
significantly O 0 5.222935417492636e-10
increased O 0 7.583413341727407e-10
, O 0 4.9293982090636845e-11
resulting O 0 2.0517036680711698e-10
in O 0 7.44232786509258e-10
hypermetria B-Disease 0 6.972874189159484e-07
. O 0 7.246163846730269e-08

The O 0 4.2340536765550496e-07
smooth O 0 8.465181053907145e-06
pursuit O 0 9.193560686071578e-07
gain O 0 2.1008779071962635e-07
was O 0 3.8548336078747525e-07
decreased O 0 3.571655611267488e-07
. O 0 1.1642475072903835e-07

In O 0 1.1049044132960262e-06
SCA2 B-Disease 0 4.598811574396677e-05
, O 0 1.732881038662981e-08
saccade O 0 3.7933114072075114e-07
velocity O 0 1.9472331302949897e-07
was O 0 1.4623699939875223e-07
markedly O 0 4.546033949281991e-07
decreased O 0 3.8918798850318126e-07
. O 0 7.922475475652391e-08

The O 0 7.537865798212806e-08
percentage O 0 1.7744497426974704e-07
of O 0 2.2107562003270687e-08
errors O 0 8.91575439254666e-07
in O 0 2.2861206261381994e-08
antisaccades O 0 1.275901126973622e-06
was O 0 5.630266386447147e-08
greatly O 0 5.464996455373239e-09
increased O 0 4.719284962817483e-10
and O 0 1.5612885984062075e-10
was O 0 9.338564366245805e-10
significantly O 0 6.691710380257732e-11
correlated O 0 5.605380604123411e-10
with O 0 5.81598796900451e-11
age O 0 7.745966001948545e-08
at O 0 4.2817314351850655e-06
disease O 0 1.1644138794508763e-05
onset O 0 6.606864644709276e-06
. O 0 5.254626671558071e-07

In O 0 6.223203286026546e-08
addition O 0 9.579191662112407e-09
, O 0 1.3362237982761371e-09
a O 0 9.181551074988192e-10
correlation O 0 6.231313687266038e-09
between O 0 6.078788317154249e-08
smooth O 0 1.9675719613587717e-06
pursuit O 0 1.4342110432608024e-07
gain O 0 3.669486936530575e-09
and O 0 5.760038973567916e-11
the O 0 7.47483117069514e-11
number O 0 1.3721072888994712e-10
of O 0 2.0238266174033015e-08
trinucleotide O 0 1.6373533071600832e-06
repeats O 0 6.91536641284074e-08
was O 0 3.356953186539613e-07
found O 0 2.845937352446981e-08
. O 0 7.032927840100456e-08

In O 0 4.481325504457345e-06
SCA3 B-Disease 1 1.0
, O 0 1.2121615782234585e-06
gaze B-Disease 0 0.000185775279533118
- I-Disease 0 3.499212425595033e-06
evoked I-Disease 0 1.1981259717686044e-07
nystagmus I-Disease 0 6.224444177860278e-07
was O 0 7.346712038724945e-08
often O 0 8.972910608973095e-11
present O 0 2.0662341282395857e-10
as O 0 1.7574307287215873e-10
was O 0 1.545518735213136e-08
saccade O 0 4.484407156724046e-08
hypometria O 0 2.2406747746117617e-07
and O 0 2.3336872434498446e-09
smooth O 0 1.6692730469003436e-06
pursuit O 0 7.021588430689008e-07
gain O 0 1.9947874818626588e-07
was O 0 2.357446788892048e-07
markedly O 0 4.724644213638385e-07
decreased O 0 3.2168344432648155e-07
. O 0 4.754979698873285e-08

Three O 0 9.839746439865849e-08
major O 0 3.302264062199356e-08
criteria O 0 8.658671646344374e-08
, O 0 4.4083257044746915e-09
saccade O 0 1.6301864036449842e-07
amplitude O 0 7.418354641686165e-08
, O 0 3.1706770542427876e-09
saccade O 0 6.116236761499749e-08
velocity O 0 3.447514274057539e-08
, O 0 8.791495864635124e-10
and O 0 1.8529199008465724e-10
presence O 0 1.6379189116122461e-09
of O 0 4.776148898599786e-08
gaze B-Disease 0 2.1630974515574053e-05
- I-Disease 0 4.5217470301395224e-07
evoked I-Disease 0 2.5132223413493193e-08
nystagmus I-Disease 0 2.7889708320572026e-08
, O 0 1.558661255618432e-10
permitted O 0 1.0128561184208351e-10
the O 0 4.294808952920448e-11
correct O 0 1.0229131985894924e-09
assignment O 0 2.0978572212726476e-09
of O 0 2.7382149880850193e-09
90 O 0 2.8457023404371284e-09
% O 0 9.652360161149787e-11
of O 0 6.498486193606823e-10
the O 0 3.9497943804533975e-10
SCA1 B-Disease 0 1.9517844407346274e-07
, O 0 2.757506167849755e-10
90 O 0 1.0193684785164692e-09
% O 0 5.378653425425206e-11
of O 0 3.6038683148831296e-10
the O 0 5.890724574797446e-10
SCA2 B-Disease 0 1.27086352108563e-07
, O 0 7.272988461481944e-11
and O 0 1.7056677251159336e-11
93 O 0 9.239030651642111e-10
% O 0 9.626931890549528e-11
of O 0 1.362937096516248e-09
the O 0 1.254899850700042e-09
patients O 0 1.5700480915370463e-09
with O 0 8.843800136659752e-10
SCA3 B-Disease 1 1.0
to O 0 2.769821039194653e-09
their O 0 2.6780960782346597e-10
genetically O 0 9.048449767234956e-10
confirmed O 0 8.584565835967339e-10
patient O 0 3.618347843570291e-09
group O 0 4.067067793656065e-10
and O 0 4.4238721019773664e-10
, O 0 5.782453960101464e-10
therefore O 0 4.857962032644991e-09
, O 0 8.992773192773029e-10
may O 0 1.8686507896603644e-09
help O 0 2.4213244742554707e-09
orient O 0 5.609314393950626e-05
diagnoses O 0 2.1930663933744654e-06
of O 0 3.3055135872928076e-07
SCA1 B-Disease 0 0.00010758155985968187
, O 0 1.5086518700968554e-08
SCA2 B-Disease 0 4.364939741208218e-06
, O 0 3.575797435928507e-09
and O 0 2.1948189932174955e-09
SCA3 B-Disease 1 1.0
at O 0 1.6848349559950293e-07
early O 0 1.016340434034646e-08
clinical O 0 6.710428657186185e-09
stages O 0 9.034727632695194e-09
of O 0 1.1958024792591004e-08
the O 0 1.1971534874533063e-08
diseases O 0 7.074941822793335e-05
. O 0 7.079194563885949e-09
. O 0 7.297412452089702e-08

Genetic O 0 3.946214803818293e-07
basis O 0 7.176524974283893e-08
and O 0 3.030945272541885e-09
molecular O 0 4.0336678353014577e-07
mechanism O 0 7.494479632441653e-06
for O 0 1.430368911314872e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999394416809082

Ventricular B-Disease 1 0.9999966621398926
fibrillation I-Disease 1 1.0
causes O 0 0.04093180224299431
more O 0 4.081274873612983e-09
than O 0 5.212028586498718e-10
300 O 0 7.487591657806547e-10
, O 0 8.768013398663399e-11
000 O 0 2.244481711599633e-09
sudden O 0 2.676494137432428e-09
deaths O 0 3.6388322910418935e-10
each O 0 1.3898331270578712e-11
year O 0 1.7479366565265053e-10
in O 0 3.554823657658801e-10
the O 0 4.223472682696183e-09
USA O 0 6.256050966158e-08
alone O 0 9.257384192551399e-08
. O 0 1.1343725248025294e-07

In O 0 3.0335263545566704e-07
approximately O 0 1.3054425984648788e-08
5 O 0 2.5749425702770168e-08
- O 0 3.5098872697147954e-09
12 O 0 1.0838959729753128e-09
% O 0 3.812196044949978e-11
of O 0 1.022259360494715e-10
these O 0 1.980314566843444e-12
cases O 0 2.4243072827001555e-11
, O 0 2.3621699214715353e-12
there O 0 3.312578293265811e-12
are O 0 7.302532602053435e-13
no O 0 3.029820838662545e-11
demonstrable O 0 6.128685470230266e-08
cardiac O 0 0.038087937980890274
or O 0 4.5784221924805024e-07
non O 1 0.9719613790512085
- O 1 0.9996639490127563
cardiac O 1 1.0
causes O 0 3.3729479582689237e-06
to O 0 6.22467322131115e-09
account O 0 1.0219849411186033e-09
for O 0 3.546615501281991e-10
the O 0 2.4717241586813543e-09
episode O 0 5.3604387595385106e-09
, O 0 5.48818039625143e-11
which O 0 4.7770776050171104e-12
is O 0 1.4412551013753827e-12
therefore O 0 1.1663945850837187e-11
classified O 0 2.030858398116564e-10
as O 0 2.4710218315959764e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999831914901733
IVF B-Disease 1 1.0
) O 0 2.0837815384311398e-07
. O 0 3.1260324817594665e-07

A O 0 3.2090486001834506e-07
distinct O 0 1.6333212116137474e-08
group O 0 9.028319425397058e-09
of O 0 7.125810498109786e-06
IVF B-Disease 1 1.0
patients O 0 1.5176946988049167e-07
has O 0 4.904996964150143e-10
been O 0 1.908233432379447e-10
found O 0 1.7869586019236827e-11
to O 0 3.678521029448767e-12
present O 0 5.062684299561582e-11
with O 0 7.226885756494994e-11
a O 0 3.3598428483827547e-09
characteristic O 0 3.3474645988462726e-07
electrocardiographic O 0 1.217780118167866e-05
pattern O 0 6.833131919847801e-06
. O 0 7.226673801596917e-07

Because O 0 6.456954082523225e-08
of O 0 6.750058645366153e-08
the O 0 2.740801585687791e-09
small O 0 1.3718770563997396e-10
size O 0 7.946879265752216e-10
of O 0 3.2261289195645304e-09
most O 0 5.626779597811549e-11
pedigrees O 0 3.1446453774286454e-10
and O 0 3.5414626092800106e-11
the O 0 1.993869930272396e-10
high O 0 1.5402982000978227e-08
incidence O 0 3.4335766940785106e-07
of O 0 3.23568869475821e-08
sudden B-Disease 0 3.673900650369433e-08
death I-Disease 0 4.694885369360691e-09
, O 0 2.6517246731749822e-11
however O 0 2.5398188760461515e-11
, O 0 1.2589837158905048e-11
molecular O 0 7.348778807703127e-10
genetic O 0 8.392808670265595e-10
studies O 0 4.751169235817088e-09
of O 0 2.781247587790858e-07
IVF B-Disease 1 0.999990701675415
have O 0 7.985594407955432e-10
not O 0 9.160729813606494e-11
yet O 0 2.863712877942959e-10
been O 0 3.846570284515849e-10
done O 0 4.549744581083814e-09
. O 0 1.1785934006525167e-08

Because O 0 7.2315801844524685e-06
IVF B-Disease 1 1.0
causes O 0 7.531230949098244e-05
cardiac O 1 0.999998927116394
rhythm O 1 1.0
disturbance O 1 0.9999287128448486
, O 0 2.621330175145431e-08
we O 0 3.0801909911559733e-09
investigated O 0 3.183136598750025e-08
whether O 0 1.1218872497664734e-09
malfunction O 0 2.6864237952395342e-05
of O 0 7.781977728882339e-09
ion O 0 2.763548764050938e-06
channels O 0 1.0681661706257728e-06
could O 0 5.167704042463583e-09
cause O 0 6.4487548634417635e-09
the O 0 4.1353562241219777e-10
disorder O 0 6.773156968620242e-08
by O 0 2.9991752137359384e-11
studying O 0 7.121855549740985e-09
mutations O 0 2.8399965712466724e-10
in O 0 2.9748947749652643e-10
the O 0 2.2430526325223354e-09
cardiac O 0 0.00010206717706751078
sodium O 0 2.161334123229608e-06
channel O 0 2.927162313426379e-06
gene O 0 1.0568328434601426e-06
SCN5A O 0 0.00017300847684964538
. O 0 1.564893864269834e-06

We O 0 1.3583797908722772e-07
have O 0 7.89629417408122e-10
now O 0 4.0165581971507436e-10
identified O 0 4.042273737958624e-10
a O 0 3.410967897021777e-10
missense O 0 8.401093154475348e-09
mutation O 0 1.3500369711039184e-09
, O 0 6.22023099694502e-10
a O 0 1.5377347173384237e-09
splice O 0 3.106886126147401e-08
- O 0 1.0171588016305577e-08
donor O 0 9.879832507664332e-10
mutation O 0 1.0591186816455433e-09
, O 0 9.369893749777702e-10
and O 0 8.063468781571714e-10
a O 0 2.7947524294802406e-09
frameshift O 0 4.3232855517771895e-08
mutation O 0 3.4722177910673224e-10
in O 0 2.721281811002285e-10
the O 0 4.897742766907243e-10
coding O 0 2.6400365982226504e-07
region O 0 5.1109317666941934e-08
of O 0 4.6808139586573816e-08
SCN5A O 0 8.027978765312582e-06
in O 0 1.7470883406645044e-08
three O 0 2.919328423445222e-08
IVF B-Disease 1 0.9975920915603638
families O 0 9.163932390698903e-10
. O 0 3.28900746637828e-08

We O 0 5.8356089738254013e-08
show O 0 7.113723388130211e-09
that O 0 2.0908963796473223e-11
sodium O 0 2.4319363189917453e-10
channels O 0 6.357275816881724e-11
with O 0 3.760665823887566e-12
the O 0 1.2244812108708203e-10
missense O 0 6.494029758385977e-09
mutation O 0 2.295499346161023e-10
recover O 0 2.895444417561066e-08
from O 0 2.5480022536328306e-09
inactivation O 0 3.0299440823000623e-07
more O 0 1.1590699927621628e-10
rapidly O 0 7.964846004959725e-10
than O 0 1.877297796382127e-11
normal O 0 7.068410856625462e-10
and O 0 1.8467163562241318e-11
that O 0 3.2993551467297433e-12
the O 0 2.358908068877952e-10
frameshift O 0 4.368802208887246e-08
mutation O 0 1.1738948701989216e-09
causes O 0 1.3509848795223434e-09
the O 0 1.9316634958244094e-09
sodium O 0 1.6048399942292235e-08
channel O 0 1.802842675147076e-08
to O 0 2.7501317889644383e-10
be O 0 6.895945481311117e-10
non O 0 1.5039522338611278e-07
- O 0 9.00467611586464e-08
functional O 0 3.2407770049758255e-06
. O 0 1.1050340162910288e-06

Our O 0 6.842717681365684e-08
results O 0 2.242787067174845e-09
indicate O 0 5.046201789760119e-10
that O 0 2.613747586421855e-11
mutations O 0 2.6089522209282734e-10
in O 0 5.90044013648594e-10
cardiac O 0 4.347756657807622e-06
ion O 0 1.5960104065015912e-05
- O 0 5.361123839975335e-06
channel O 0 3.4521536917964113e-07
genes O 0 5.54709611577664e-10
contribute O 0 1.1109375225304419e-10
to O 0 4.352668225848788e-11
the O 0 1.9100541981398322e-10
risk O 0 2.8857067846388418e-09
of O 0 1.112147085535753e-08
developing O 0 1.6851271311679739e-06
IVF B-Disease 1 0.9996612071990967
. O 0 9.434637959770953e-09
. O 0 3.3741848426416254e-08

Molecular O 0 5.090194008516846e-06
heterogeneity O 0 8.147459311658167e-07
in O 0 6.17434992022936e-08
mucopolysaccharidosis B-Disease 0 3.3596254525036784e-06
IVA I-Disease 0 0.00033084116876125336
in O 0 7.3183867854709206e-09
Australia O 0 1.67558369956744e-10
and O 0 2.6590028789907905e-11
Northern O 0 4.0669281831107185e-10
Ireland O 0 2.538620424985538e-09
: O 0 5.5446182367635544e-11
nine O 0 3.1652855336794516e-10
novel O 0 1.354772266592974e-10
mutations O 0 8.659122030518773e-11
including O 0 2.1117786686009055e-10
T312S O 0 7.731972573310486e-08
, O 0 1.078768518958384e-09
a O 0 1.0727362331763857e-09
common O 0 6.800282559282778e-10
allele O 0 1.6290674365038171e-09
that O 0 2.9002392154531265e-10
confers O 0 7.451880179587533e-08
a O 0 3.00663707264448e-08
mild O 0 2.2503949992369598e-07
phenotype O 0 1.6386329093620589e-07
. O 0 1.8969156201364967e-07

Mucopolysaccharidosis B-Disease 0 0.2658952474594116
IVA I-Disease 1 0.9999979734420776
( O 0 7.188672316260636e-05
MPS B-Disease 1 0.9999865293502808
IVA I-Disease 1 1.0
) O 0 1.9498248349236746e-08
is O 0 5.854098317215062e-10
an O 0 1.050451725603807e-09
autosomal B-Disease 1 0.9999943971633911
recessive I-Disease 1 0.9999997615814209
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.00012404176231939346
by O 0 1.996854681607374e-09
a O 0 2.594982788650668e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.65483174896508e-06
N O 0 0.0017566215246915817
- O 0 3.1073477657628246e-06
acetylgalactosamine O 0 2.060710539808497e-05
- O 0 7.082363026711391e-06
6 O 0 1.239883840753464e-05
- O 0 1.3104140634823125e-06
sulfate O 0 2.8024460334563628e-06
sulfatase O 0 1.9955874449806288e-05
( O 0 3.7824342768999486e-08
GALNS O 0 2.8688858947134577e-05
) O 0 2.311489843975778e-08
. O 0 8.291588926567783e-08

Previous O 0 3.865682174364338e-08
studies O 0 2.5584251162058536e-08
of O 0 9.16218922952794e-09
patients O 0 8.312610599858772e-10
from O 0 6.146180231425546e-10
a O 0 6.886717862641945e-10
British O 0 7.048583050561774e-09
- O 0 9.607846074288773e-09
Irish O 0 1.4229597944392935e-08
population O 0 7.68446938026468e-12
showed O 0 4.370389883323611e-10
that O 0 3.5298346277162773e-12
the O 0 8.349598790147184e-11
I113F O 0 5.705265149202887e-09
mutation O 0 6.84397399863812e-11
is O 0 4.1256005556267183e-11
the O 0 1.5505537825921678e-11
most O 0 5.8271222048988935e-12
common O 0 1.4536241134399663e-11
single O 0 2.0879553294661513e-11
mutation O 0 2.7077942665876265e-10
among O 0 2.864526671420009e-10
MPS B-Disease 1 0.8237411975860596
IVA I-Disease 1 1.0
patients O 0 1.1323289982101414e-05
and O 0 9.225757935382717e-09
produces O 0 4.5704711126859365e-09
a O 0 3.7277563258442115e-09
severe O 0 8.21544972495758e-07
clinical O 0 9.98082896330743e-07
phenotype O 0 5.19892807915312e-07
. O 0 5.636433115796535e-07

We O 0 5.133862401862643e-08
studied O 0 6.908180694153998e-07
mutations O 0 3.0255620231400826e-09
in O 0 6.24040874530607e-10
the O 0 7.918555255947979e-10
GALNS O 0 1.2128353432672156e-07
gene O 0 1.1782645970015437e-09
from O 0 1.5443217815658272e-09
23 O 0 7.636396404109291e-09
additional O 0 3.91480048378412e-09
MPS B-Disease 0 0.00728114927187562
IVA I-Disease 1 1.0
patients O 0 5.722847049582924e-07
( O 0 4.1214343049489344e-10
15 O 0 1.501193724884331e-09
from O 0 1.406973287876312e-10
Australia O 0 2.9118499278446563e-11
, O 0 3.472381757130272e-11
8 O 0 3.71684932831684e-10
from O 0 1.1953815715060045e-10
Northern O 0 7.590489903286368e-10
Ireland O 0 8.103833715189523e-10
) O 0 1.1345824453556919e-11
, O 0 6.3224226201641365e-12
with O 0 1.578742128346966e-12
various O 0 1.6611875763850037e-10
clinical O 0 4.3365904645042974e-08
phenotypes O 0 4.903355588226077e-08
( O 0 6.679322428482237e-09
severe O 0 9.117979402617493e-07
, O 0 2.83847079174393e-09
16 O 0 6.008423980574662e-09
cases O 0 2.580579361310953e-10
; O 0 1.3940438213511097e-11
intermediate O 0 5.748125975202356e-09
, O 0 9.350892976600633e-11
4 O 0 1.741817134970347e-09
cases O 0 1.815183003905929e-10
; O 0 8.723757133344279e-11
mild O 0 1.2293639883864671e-08
, O 0 4.0854708505122517e-10
3 O 0 1.0023446961326954e-08
cases O 0 5.946967363001932e-10
) O 0 6.336783320293193e-10
. O 0 2.6923986595761562e-08

We O 0 7.119304967773132e-08
found O 0 1.3104838325617152e-09
two O 0 3.7219838322499754e-11
common O 0 5.024915206153224e-11
mutations O 0 6.004087504951627e-11
that O 0 5.520787386276149e-12
together O 0 8.377547267013341e-11
accounted O 0 9.65126090157753e-10
for O 0 1.7540081886924241e-10
32 O 0 6.660138662795134e-09
% O 0 8.201861412260314e-10
of O 0 8.518739491591987e-09
the O 0 2.127145348751469e-09
44 O 0 8.009884311377391e-09
unrelated O 0 2.4858748393086216e-09
alleles O 0 4.0847539239941e-10
in O 0 2.578562086075209e-10
these O 0 3.125605607667836e-10
patients O 0 1.7090082238269133e-08
. O 0 5.381976109219977e-08

One O 0 1.3130733123034588e-07
is O 0 3.2583351572412766e-09
the O 0 2.9401254764138685e-09
T312S O 0 8.168164100652575e-08
mutation O 0 1.4593036778975943e-09
, O 0 3.821626071154327e-10
a O 0 4.6421158583775934e-10
novel O 0 2.1211683798316727e-10
mutation O 0 1.330861254533744e-10
found O 0 7.24069623703194e-11
exclusively O 0 7.534639023809575e-10
in O 0 1.0170884134907965e-09
milder O 0 1.3663689912846166e-07
patients O 0 6.260754048525996e-08
. O 0 9.817362922603934e-08

The O 0 4.922189873468596e-07
other O 0 2.7727971030344634e-09
is O 0 2.679797772575654e-10
the O 0 1.9842449905382864e-10
previously O 0 2.1712602826795546e-09
described O 0 2.647138952482919e-09
I113F O 0 1.0186110621646094e-08
that O 0 1.1342973782468846e-10
produces O 0 8.303482901261816e-10
a O 0 3.943985138477046e-09
severe O 0 4.544902765246661e-07
phenotype O 0 2.9132110057616956e-07
. O 0 6.124198534962488e-07

The O 0 7.127457024580508e-08
I113F O 0 2.0704581515929021e-07
and O 0 4.442584633501667e-10
T312S O 0 1.1263840526964941e-08
mutations O 0 1.6354956278163968e-10
accounted O 0 8.925718497643231e-10
for O 0 1.8401212498186936e-10
8 O 0 7.021478953816995e-09
( O 0 5.4318195774616385e-11
18 O 0 1.2568281970715134e-09
% O 0 3.1976515185716536e-11
) O 0 1.554536534220663e-11
and O 0 6.509573435842242e-11
6 O 0 5.36360955649684e-09
( O 0 5.5548014105122334e-11
14 O 0 4.416570997811675e-10
% O 0 3.003033238746511e-11
) O 0 1.2471317381579361e-11
of O 0 6.137991781507424e-10
44 O 0 5.290555549208875e-09
unrelated O 0 7.49316697579161e-09
alleles O 0 1.6662975443892947e-09
, O 0 3.564833539471124e-09
respectively O 0 1.5016634336006973e-07
. O 0 2.0394378452692763e-07

The O 0 2.823203999469115e-07
relatively O 0 2.2541709654433362e-07
high O 0 1.204699060508574e-07
residual O 0 1.2971646583537222e-06
GALNS O 0 1.9207922377972864e-05
activity O 0 3.0761651004240775e-08
seen O 0 2.707676971525075e-09
when O 0 2.0471886685857754e-10
the O 0 1.8645911203929444e-10
T312S O 0 4.038407386275367e-09
mutant O 0 1.7875058100358387e-09
cDNA O 0 9.055895588971907e-09
is O 0 5.820763315789179e-10
overexpressed O 0 6.20754363467313e-08
in O 0 1.2031067253559513e-09
mutant O 0 3.5260314668050796e-09
cells O 0 3.958181005181416e-10
provides O 0 1.6549257797482397e-10
an O 0 2.3728052508942277e-11
explanation O 0 4.032824629796039e-10
for O 0 3.739716869510801e-11
the O 0 2.784237562725167e-10
mild O 0 8.456154887426237e-09
phenotype O 0 1.0353422563724735e-09
in O 0 3.7337746783272507e-10
patients O 0 2.1785145909447579e-10
with O 0 5.613583903274488e-11
this O 0 2.515176400486041e-10
mutation O 0 6.180639999797677e-09
. O 0 7.498231013869372e-08

The O 0 3.5746946736026075e-08
distribution O 0 5.98748872704391e-09
and O 0 1.3356318828705582e-10
relative O 0 3.794094372011614e-09
frequencies O 0 1.3910339546896466e-08
of O 0 1.0080537515833043e-09
the O 0 2.9579885763020286e-10
I113F O 0 3.070535825600018e-09
and O 0 6.731214197142066e-11
T312S O 0 2.095178031069622e-09
mutations O 0 9.77087161180279e-11
in O 0 1.1760546703154517e-10
Australia O 0 7.11687861421062e-11
corresponded O 0 5.407939721036037e-11
to O 0 7.591988669675143e-12
those O 0 9.471585842024677e-12
observed O 0 3.042249230311711e-10
in O 0 5.547918721648948e-11
Northern O 0 6.673155916736562e-10
Ireland O 0 1.0475185163727474e-09
and O 0 2.5181223425874144e-11
are O 0 2.1590374887220376e-12
unique O 0 1.681492965699416e-11
to O 0 7.113807806713446e-12
these O 0 6.7367856085298605e-12
two O 0 1.4027015660111886e-11
populations O 0 2.938304764429911e-12
, O 0 1.544482250426249e-11
suggesting O 0 9.444206527930987e-11
that O 0 5.558126008053943e-12
both O 0 2.954096689489205e-11
mutations O 0 1.689157147488629e-10
were O 0 5.264732538812211e-10
probably O 0 1.318996578625331e-10
introduced O 0 2.8648803815367607e-11
to O 0 9.716988498553736e-12
Australia O 0 2.3331862483710886e-11
by O 0 8.611911531120064e-12
Irish O 0 5.0124859818367895e-09
migrants O 0 5.410656367388356e-10
during O 0 1.8621610919922205e-09
the O 0 9.059640260211665e-10
19th O 0 8.462838252398797e-08
century O 0 1.7004461483338673e-07
. O 0 7.785573075125285e-08

Haplotype O 0 3.4261818200320704e-06
analysis O 0 9.30656511854977e-08
using O 0 2.4191331604583866e-08
6 O 0 2.335436732892049e-07
RFLPs O 0 6.253426363400649e-07
provides O 0 5.702651129091407e-10
additional O 0 5.4865795934277983e-11
data O 0 3.4489641698165485e-10
that O 0 1.3965081695210824e-11
the O 0 8.015866442834252e-11
I113F O 0 5.191771013102198e-09
mutation O 0 1.9598228595540945e-10
originated O 0 2.6753101955989678e-09
from O 0 2.1448420817193892e-10
a O 0 4.773385020584442e-10
common O 0 2.8401985208148517e-09
ancestor O 0 1.8516082889163954e-07
. O 0 2.4037004209276347e-07

The O 0 2.75260703119784e-07
other O 0 7.867464013600056e-09
9 O 0 6.681440112288328e-08
novel O 0 9.89144766094796e-10
mutations O 0 2.698585799265629e-10
identified O 0 3.7222555593352524e-10
in O 0 6.831831628195673e-11
these O 0 3.2744116446048466e-11
23 O 0 4.81294559762091e-09
patients O 0 5.721717544204807e-10
were O 0 1.755052353447084e-10
each O 0 1.42431257760256e-11
limited O 0 8.391044803435221e-11
to O 0 5.041879413969497e-11
a O 0 7.015611425131851e-10
single O 0 3.953588123550844e-09
family O 0 1.883235967170549e-08
. O 0 1.2031583196403517e-07

These O 0 1.3356892480942406e-08
data O 0 8.6978308999619e-09
provide O 0 3.7965897092817613e-10
further O 0 3.182496211007191e-10
evidence O 0 8.643021853771415e-10
for O 0 9.23941409491924e-11
extensive O 0 5.9730935753066206e-09
allelic O 0 3.6210565212968504e-08
heterogeneity O 0 1.5881281001384195e-07
in O 0 1.0022112206797829e-07
MPS B-Disease 1 0.5795145034790039
IVA I-Disease 1 1.0
in O 0 4.126488661881922e-08
British O 0 1.8353915720581426e-07
- O 0 4.465825043098448e-08
Irish O 0 1.3216951089134454e-08
patients O 0 4.841494427587634e-10
and O 0 5.935315433580612e-11
provide O 0 7.76764416676734e-11
evidence O 0 4.570268330450489e-10
for O 0 3.040368651285874e-11
their O 0 3.804612527802398e-11
transmission O 0 6.988903678006864e-09
to O 0 1.9675974391453188e-11
Australia O 0 1.1232992834508959e-11
by O 0 3.2520347092307444e-12
British O 0 2.5161517314131743e-09
- O 0 2.2348147776796168e-09
Irish O 0 4.506767403711365e-09
migrants O 0 5.82176196139983e-10
. O 0 2.9853478022978663e-10
. O 0 1.4856194496815078e-08

Identification O 0 4.759434801826501e-08
of O 0 1.8597009443510615e-07
constitutional O 0 1.7369386114296503e-05
WT1 O 0 9.512819815427065e-05
mutations O 0 7.049419536997448e-08
, O 0 1.1190320892140448e-09
in O 0 5.436051053742119e-10
patients O 0 9.685486856980674e-10
with O 0 1.1796227328275677e-09
isolated O 0 0.00019123555102851242
diffuse B-Disease 1 0.9999908208847046
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 8.227502945601373e-08
and O 0 4.587674684586318e-10
analysis O 0 5.613800535542168e-10
of O 0 2.556472367132301e-09
genotype O 0 3.4163885942462e-08
/ O 0 1.0888906842865254e-07
phenotype O 0 3.8586751571756395e-09
correlations O 0 3.9336773838272165e-09
by O 0 3.514492516454304e-11
use O 0 1.9764828662616196e-10
of O 0 3.364922118720415e-09
a O 0 1.6998656926503486e-09
computerized O 0 2.5852480689536605e-07
mutation O 0 2.6461042246239685e-09
database O 0 1.837478613708754e-08
. O 0 1.4424493599562993e-07

Constitutional O 0 2.856177161447704e-06
mutations O 0 6.612548020257236e-08
of O 0 6.796243212647823e-08
the O 0 1.516747794028106e-08
WT1 O 0 3.5416107380115136e-07
gene O 0 4.825658095342078e-09
, O 0 5.974640227002226e-10
encoding O 0 1.9413047169791753e-08
a O 0 7.348687347530358e-08
zinc O 0 0.00018820630793925375
- O 0 6.766486330889165e-05
finger O 0 0.00020289311942178756
transcription O 0 1.449095088901231e-05
factor O 0 2.2515800424116605e-07
involved O 0 5.355137844276214e-08
in O 0 2.383495534274971e-08
renal O 1 0.999997615814209
and O 0 5.042781481279235e-07
gonadal O 1 0.9999860525131226
development O 0 0.00013302442675922066
, O 0 5.752205822773249e-09
are O 0 2.053534772783472e-11
found O 0 7.879800284493754e-11
in O 0 3.6995753682766974e-11
most O 0 1.9537755094334308e-11
patients O 0 6.281868775159793e-11
with O 0 2.3937349324931745e-10
Denys B-Disease 1 0.9999988079071045
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.633492153516272e-06
DDS B-Disease 1 1.0
) O 0 9.043451321133489e-09
, O 0 2.2691291068355213e-09
or O 0 1.8269039614438043e-08
diffuse B-Disease 1 0.7570676803588867
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.271579655323876e-06
DMS B-Disease 0 0.0006086583598516881
) O 0 3.8028585835903073e-10
associated O 0 2.080943861670903e-09
with O 0 6.934406382441693e-10
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.6992171342499205e-07
/ O 0 0.00807947851717472
or O 0 9.322249638898938e-07
Wilms B-Disease 1 0.9999985694885254
tumor I-Disease 1 0.9547260403633118
( O 0 2.8311624191701412e-06
WT B-Disease 1 0.999997615814209
) O 0 1.364441715168141e-07
. O 0 2.1618588164074026e-07

Most O 0 9.060025618623513e-09
mutations O 0 3.202539033964058e-08
in O 0 3.057714792475963e-08
DDS B-Disease 1 1.0
patients O 0 2.6525692646828247e-06
lie O 0 4.2988663153664675e-06
in O 0 2.2012764944179253e-08
exon O 0 3.2747547606959415e-07
8 O 0 9.997102523584545e-08
or O 0 3.923187108512138e-09
exon O 0 1.5161583633016562e-07
9 O 0 1.12955135023185e-07
, O 0 2.7179583028669185e-09
encoding O 0 1.6004297265226342e-07
zinc O 0 8.249724487541243e-05
finger O 0 0.002408887492492795
2 O 0 0.00015104252088349313
or O 0 3.1043217063597695e-07
zinc O 0 0.0006321471300907433
finger O 0 0.0003052910033147782
3 O 0 4.928437533635588e-07
, O 0 3.3567537638390377e-10
respectively O 0 6.155146614617024e-09
, O 0 9.326170391510402e-11
with O 0 5.615222523069896e-11
a O 0 2.2074182481901516e-09
hot O 0 1.1678849176632866e-07
spot O 0 3.0397348638189214e-08
( O 0 1.5915449513848046e-10
R394W O 0 4.7249799628446e-09
) O 0 1.1760277474071046e-10
in O 0 1.8459154205174855e-09
exon O 0 3.827860552974016e-07
9 O 0 2.072944880637806e-06
. O 0 2.6993151891474554e-07

We O 0 8.69620961907458e-08
analyzed O 0 4.3194940957391736e-08
a O 0 1.051008835517564e-09
series O 0 6.198841440152592e-10
of O 0 1.621815792773873e-09
24 O 0 1.7999084889197547e-08
patients O 0 1.406139760184999e-09
, O 0 3.5908045981081216e-10
10 O 0 1.1954893741616957e-09
with O 0 5.352834842042853e-10
isolated B-Disease 0 1.1839759963550023e-06
DMS I-Disease 1 0.6777437925338745
( O 0 3.05678184986391e-08
IDMS B-Disease 0 1.061749026121106e-05
) O 0 8.00849342397214e-09
, O 0 1.9024306574522143e-09
10 O 0 3.812389071100597e-09
with O 0 1.639178348611381e-09
DDS B-Disease 1 1.0
, O 0 2.25131735476225e-08
and O 0 2.0624670860058814e-09
4 O 0 4.455938196201714e-08
with O 0 1.4383189084199444e-09
urogenital B-Disease 1 0.9790761470794678
abnormalities I-Disease 1 0.9999992847442627
and O 0 0.00010414278949610889
/ O 1 0.9998101592063904
or O 0 0.0006443122401833534
WT B-Disease 1 1.0
. O 0 4.407875621836865e-06

We O 0 4.1925588334379427e-07
report O 0 3.878370335996806e-08
WT1 O 0 2.2607077880820725e-06
heterozygous O 0 4.2020694479560916e-08
mutations O 0 1.2469385524127574e-08
in O 0 3.318331387447415e-09
16 O 0 9.930283084713665e-08
patients O 0 6.326220436392305e-09
, O 0 1.1421482648543702e-09
4 O 0 4.800076425226507e-08
of O 0 6.511942274300964e-08
whom O 0 5.8154647319952346e-08
presented O 0 1.4410949233933934e-07
with O 0 5.326086593981927e-08
IDMS B-Disease 0 0.012845195829868317
. O 0 6.339337687677471e-06

One O 0 8.69569518613389e-08
male O 0 2.3542806815157746e-08
and O 0 1.044782926840071e-09
two O 0 1.9677797169492806e-09
female O 0 2.5148631266347365e-07
IDMS B-Disease 1 0.9658090472221375
patients O 0 8.54199333844008e-06
with O 0 1.1347840427333722e-06
WT1 O 1 0.9999799728393555
mutations O 0 0.0009193680016323924
underwent O 0 0.034801483154296875
normal O 0 0.00024859674158506095
puberty O 0 0.00018158734019380063
. O 0 8.386758167944208e-07

Two O 0 6.105711491954935e-08
mutations O 0 1.0646367343269958e-07
associated O 0 1.8461810213921126e-07
with O 0 1.0627596580548015e-08
IDMS B-Disease 0 0.0023624124005436897
are O 0 7.933733670029142e-10
different O 0 8.804680595719816e-11
from O 0 1.8953129343746156e-10
those O 0 2.274413123115604e-11
described O 0 5.844350337014248e-09
in O 0 8.686225960730098e-09
DDS B-Disease 1 1.0
patients O 0 6.366953584802104e-06
. O 0 8.174481536116218e-07

No O 0 1.0321406307411962e-06
WT1 O 0 1.834828253777232e-05
mutations O 0 5.2626401014777e-08
were O 0 4.717109813867637e-09
detected O 0 1.470951893622896e-08
in O 0 5.284642723424327e-10
the O 0 7.575332028331161e-10
six O 0 1.250486714177157e-09
other O 0 4.961434041383939e-10
IDMS B-Disease 0 0.00019744934979826212
patients O 0 6.075913461245364e-08
, O 0 1.6266238356266172e-09
suggesting O 0 1.0740675016052137e-08
genetic O 0 2.8114079952956672e-08
heterogeneity O 0 2.177354332388859e-07
of O 0 1.0243355319516922e-07
this O 0 2.1974045694150846e-08
disease O 0 6.772283813916147e-05
. O 0 2.876070936963515e-07

We O 0 1.2477799771204445e-07
analyzed O 0 3.334337748128746e-07
genotype O 0 6.462387318606488e-07
/ O 0 2.1334125221983413e-07
phenotype O 0 1.3339530369194108e-08
correlations O 0 9.667925127132548e-08
, O 0 6.541526764713979e-10
on O 0 1.0894588564624996e-09
the O 0 9.047030485875851e-11
basis O 0 5.995393626001544e-10
of O 0 9.205148449042966e-11
the O 0 3.521175712117852e-11
constitution O 0 9.336172807072884e-11
of O 0 1.295566987025154e-09
a O 0 1.226311829860549e-09
WT1 O 0 5.532478297709531e-08
mutation O 0 4.438925615968259e-10
database O 0 2.5143143123074196e-09
of O 0 7.206990204622343e-08
84 O 0 5.85474617764703e-06
germ O 1 0.967573881149292
- O 0 1.9018685634364374e-05
line O 0 4.774878448188247e-07
mutations O 0 1.996359744182996e-09
, O 0 7.646459854182552e-11
to O 0 5.5710327843960794e-12
compare O 0 1.2066314614145313e-10
the O 0 8.868525358529666e-11
distribution O 0 5.035721284407657e-10
and O 0 2.9130167028545983e-11
type O 0 1.2670026805494672e-08
of O 0 2.6051608870147902e-08
mutations O 0 9.580209958670594e-10
, O 0 1.2632490886677061e-10
according O 0 5.8104885486409685e-11
to O 0 2.484924245538256e-11
the O 0 2.920272357265219e-10
different O 0 1.9707806497848424e-09
symptoms O 0 1.8766384073387599e-06
. O 0 1.55935637735638e-07

This O 0 9.722138649692624e-09
demonstrated O 0 1.382451557674358e-07
( O 0 2.126378850775268e-09
1 O 0 1.2881264943587212e-08
) O 0 3.590672204012435e-11
the O 0 8.282535768344701e-11
association O 0 3.531360204256373e-10
between O 0 5.5819404654045e-10
mutations O 0 3.284446603579738e-10
in O 0 4.145227494589676e-10
exons O 0 4.879739279317619e-09
8 O 0 2.6668287134157254e-08
and O 0 7.058831852368996e-10
9 O 0 3.6547088910765524e-08
and O 0 3.4986051833385545e-09
DMS B-Disease 0 1.4884684787830338e-05
; O 0 2.783256514149457e-09
( O 0 6.429444754374458e-10
2 O 0 2.268394894144876e-08
) O 0 1.0352232959753849e-10
among O 0 4.0843235044052406e-11
patients O 0 2.8869770463124667e-10
with O 0 6.005155817057073e-10
DMS B-Disease 0 0.0033275997266173363
, O 0 1.3002656729099726e-09
a O 0 1.5440557166179758e-10
higher O 0 3.666462689011496e-10
frequency O 0 3.935793913001362e-09
of O 0 1.7703134513880059e-09
exon O 0 2.1367309699371617e-08
8 O 0 5.637376787603898e-09
mutations O 0 4.83157736042017e-10
among O 0 1.435725288656542e-10
46 O 0 7.285268832646352e-09
, O 0 1.0685314855152228e-09
XY O 0 6.640012998104794e-06
patients O 0 5.283234738584497e-09
with O 0 1.101056607000217e-10
female O 0 1.611652034050337e-09
phenotype O 0 1.1570737701305234e-09
than O 0 7.366865450997295e-11
among O 0 9.077295165527133e-11
46 O 0 5.365635047382966e-09
, O 0 1.1669387678381327e-09
XY O 0 1.4187114175001625e-05
patients O 0 1.740911237391174e-08
with O 0 2.4212401528167504e-10
sexual O 0 2.53146552608996e-08
ambiguity O 0 1.138924776711292e-08
or O 0 5.713930439910087e-10
male O 0 2.0736605488291815e-10
phenotype O 0 5.652692550150995e-11
; O 0 3.9217844249872513e-11
and O 0 1.563180695995925e-10
( O 0 6.600039265114432e-11
3 O 0 7.406189550529518e-10
) O 0 8.690803285360538e-12
statistically O 0 1.5504775241481639e-10
significant O 0 2.0304546238802956e-11
evidence O 0 1.2066130039567469e-10
that O 0 7.698024509505963e-12
mutations O 0 6.694966109277445e-11
in O 0 3.311122487303919e-10
exons O 0 6.586363454630373e-09
8 O 0 3.300092288327505e-08
and O 0 9.297845271483141e-10
9 O 0 1.8164454829161514e-08
preferentially O 0 3.938392278968195e-09
affect O 0 3.824026872933928e-09
amino O 0 3.270376858210966e-09
acids O 0 2.1108776948608465e-09
with O 0 2.417086149286707e-11
different O 0 2.9108503801777985e-11
functions O 0 2.317713354571538e-09
. O 0 6.724595880136519e-10
. O 0 1.5259288943525462e-08

The O 0 6.819056466156326e-07
185delAG O 0 2.2559570425073616e-06
BRCA1 O 0 9.715468252124992e-08
mutation O 0 3.793486413883329e-09
originated O 0 3.735863618459234e-09
before O 0 1.2489659306780254e-09
the O 0 1.1194969257166676e-10
dispersion O 0 6.255451712178228e-09
of O 0 1.6765500099324981e-09
Jews O 0 1.0801145394756517e-10
in O 0 1.2149121118854023e-11
the O 0 2.2511421546300703e-11
diaspora O 0 2.8897518059012306e-11
and O 0 5.113381246202309e-11
is O 0 2.7127557145067982e-11
not O 0 9.657916827388036e-12
limited O 0 1.6729778673507667e-10
to O 0 4.895183702835482e-10
Ashkenazim O 0 2.108031821990153e-06
. O 0 2.8571258781084907e-07

The O 0 1.1667405175330714e-07
185delAG O 0 5.088326702207269e-07
mutation O 0 1.2096767143532361e-08
in O 0 3.878974919047096e-09
BRCA1 O 0 6.991437206949058e-09
is O 0 2.545892385796833e-10
detected O 0 3.2251690207374395e-09
in O 0 1.0566141711576549e-10
Ashkenazi O 0 2.8692581643952053e-09
Jews O 0 5.666048741304053e-10
both O 0 2.036813079309141e-10
in O 0 1.6354839704746382e-09
familial B-Disease 0 0.0005543240113183856
breast I-Disease 1 0.9999988079071045
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 0.0002124704042216763
in O 0 6.882587655354655e-08
the O 0 4.77165773560273e-09
general O 0 6.639325533797091e-09
population O 0 6.624026327450849e-11
. O 0 2.0773281761421458e-08

All O 0 1.1496821628043108e-07
tested O 0 2.970524235479388e-07
Ashkenazi O 0 1.0706358466450183e-07
mutation O 0 1.9247090587981575e-09
carriers O 0 6.43874675798628e-10
share O 0 2.874295801369442e-10
the O 0 2.1478101241978464e-10
same O 0 6.211576808468067e-10
allelic O 0 2.665638909604695e-08
pattern O 0 5.387152413049989e-08
at O 0 1.5362280691988417e-07
the O 0 1.6841081418306203e-08
BRCA1 O 0 6.075588743215121e-08
locus O 0 2.6875892444877536e-07
. O 0 6.698091397083772e-07

Our O 0 9.787878241240833e-08
previous O 0 1.0936274996709017e-08
study O 0 1.7712862288021824e-09
showed O 0 5.244877865351327e-10
that O 0 1.354765691991e-12
this O 0 4.205982350596882e-12
Ashkenazi O 0 3.318886832026635e-10
mutation O 0 6.269301050521037e-11
also O 0 2.545192008540642e-11
occurs O 0 5.181022624811682e-11
in O 0 5.666088431777183e-11
Iraqi O 0 3.730708186822085e-09
Jews O 0 1.7168508281706352e-10
with O 0 2.2949465244836986e-11
a O 0 1.4320714059046225e-10
similar O 0 5.5463321435578194e-11
allelic O 0 2.4578335811042962e-08
pattern O 0 5.007601089346281e-07
. O 0 3.2112313874677056e-07

We O 0 1.0121970461796082e-07
extended O 0 1.792511739040492e-08
our O 0 2.2577364422460278e-09
analysis O 0 3.6912251033527355e-10
to O 0 4.4580904939861554e-11
other O 0 9.955359453472923e-11
non O 0 8.624417624503167e-09
- O 0 4.7645274392493775e-09
Ashkenazi O 0 2.4993580538534843e-09
subsets O 0 8.184800392996294e-09
354 O 0 1.729020593366215e-09
of O 0 3.1590610682918907e-10
Moroccan O 0 1.7463388957139614e-08
origin O 0 3.1244851150802333e-10
, O 0 5.776343639518622e-11
200 O 0 1.0365153874092314e-10
Yemenites O 0 1.90185112103336e-08
and O 0 4.5153691896615555e-10
150 O 0 1.3835554923957716e-09
Iranian O 0 1.2803322846366427e-08
Jews O 0 1.3291122868963612e-08
. O 0 3.4450231112259644e-08

Heteroduplex O 0 1.2192722351755947e-05
analysis O 0 3.694969308298823e-08
complemented O 0 1.01961017406893e-08
by O 0 1.544485928040018e-10
direct O 0 6.456775669683168e-10
DNA O 0 1.3041403512659144e-09
sequencing O 0 2.8181659228465605e-09
of O 0 6.526413187657454e-09
abnormally O 0 1.6533435953647313e-08
migrating O 0 1.5884704662738613e-09
bands O 0 1.34607542889853e-08
were O 0 6.1289866515323865e-09
employed O 0 1.9713237975338416e-07
. O 0 5.3860532034377684e-08

Four O 0 7.19550783401246e-08
of O 0 2.5202020026426908e-08
Moroccan O 0 1.5853346724270523e-07
origin O 0 4.4762671347342575e-10
( O 0 6.529046053804777e-11
1 O 0 5.366829758379765e-10
. O 0 4.170012425641634e-12
1 O 0 4.459615454699417e-10
% O 0 7.31712086754488e-12
) O 0 5.367469489703236e-12
and O 0 3.757821137595485e-11
none O 0 7.861160056243932e-10
of O 0 1.5457805035978822e-09
the O 0 4.120336072332975e-09
Yemenites O 0 3.23824195902489e-07
or O 0 3.3842315616539054e-09
Iranians O 0 4.757952698497547e-09
was O 0 1.277597672100228e-08
a O 0 6.048827549953728e-10
carrier O 0 8.96694496432815e-10
of O 0 1.6472929686983662e-09
the O 0 2.8222646442088717e-09
185delAG O 0 2.0184957350011246e-07
mutation O 0 2.258680709132932e-08
. O 0 1.0140752237930428e-07

BRCA1 O 0 3.2373636713600717e-06
allelic O 0 1.2123396118113305e-06
patterns O 0 3.185463697263913e-07
were O 0 2.846820557067531e-09
determined O 0 1.7990838818704447e-09
for O 0 8.751973451515127e-11
four O 0 4.788839463865102e-11
of O 0 1.0696320912328972e-10
these O 0 1.2053075551521353e-12
individuals O 0 6.093945877430618e-13
and O 0 1.017188243357392e-11
for O 0 3.544050816706168e-11
12 O 0 7.163594717418675e-10
additional O 0 9.622526386809938e-11
non O 0 3.46128459227657e-08
- O 0 8.047646993247781e-09
Ashkenazi O 0 1.7722053824442696e-09
185delAG O 0 7.468482721151304e-09
mutation O 0 2.3344873256725407e-10
carriers O 0 3.6977995665488095e-10
who O 0 9.492321373372192e-10
had O 0 2.251554178656079e-07
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9741678237915039

Six O 0 2.1575490336545045e-06
non O 0 1.1748711585823912e-05
- O 0 1.0320825367671205e-06
Ashkenazi O 0 7.699610904410292e-08
individuals O 0 5.967621535818424e-11
shared O 0 1.3221483907699394e-09
the O 0 5.094419885942614e-10
common O 0 2.3953106165208737e-10
Ashkenazi O 0 7.040696470284047e-09
haplotype O 0 1.8618209196574753e-08
, O 0 2.759633188631483e-09
four O 0 2.1547046369363443e-09
had O 0 3.3707419078155e-09
a O 0 5.968261995725754e-10
closely O 0 2.928170206306646e-10
related O 0 2.231156370768872e-09
pattern O 0 1.4267890868779887e-08
, O 0 1.3037691759532066e-10
and O 0 2.360581174976062e-11
the O 0 6.164048715895376e-10
rest O 0 4.395538599766269e-09
( O 0 6.179667194627925e-11
n O 0 5.9199227742112726e-09
= O 0 1.5140539488811555e-08
6 O 0 1.696119333871593e-08
) O 0 4.603880124354198e-11
displayed O 0 2.4339421589303356e-09
a O 0 1.0709800823960336e-09
distinct O 0 2.4879429627588934e-09
BRCA1 O 0 5.1474422946284903e-08
allelic O 0 4.99930308706098e-07
pattern O 0 3.3186895507242298e-06
. O 0 7.901180651970208e-07

We O 0 1.283598294321564e-07
conclude O 0 1.40479528454307e-07
that O 0 8.785155242163611e-11
the O 0 2.1038104591752926e-10
185delAG O 0 9.905913422869617e-09
BRCA1 O 0 1.1380578701647437e-09
mutation O 0 1.51341439380559e-10
occurs O 0 1.1997169924171658e-10
in O 0 3.7063276059345895e-11
some O 0 9.909527191875878e-12
non O 0 1.4415880045248741e-08
- O 0 1.2490951384336313e-08
Ashkenazi O 0 1.05279491791066e-08
populations O 0 5.739092881484886e-11
at O 0 2.704275692266833e-09
rates O 0 9.288043667510237e-10
comparable O 0 2.7087980747353413e-09
with O 0 2.4304001519648288e-11
that O 0 5.2918017190428657e-11
of O 0 1.6836006366816036e-08
Ashkenazim O 0 3.037439682884724e-06
. O 0 1.5543469089607242e-07

The O 0 6.395448792773095e-08
majority O 0 3.789003333309893e-09
of O 0 8.379057447882587e-09
Jewish O 0 1.9427706110519694e-09
185delAG O 0 1.7682863173718033e-08
mutation O 0 5.847715089934979e-10
carriers O 0 1.6814007131049635e-10
have O 0 2.6238821879132068e-11
a O 0 7.864575657379191e-11
common O 0 1.158683218815959e-10
allelic O 0 2.4821225075299935e-09
pattern O 0 2.3170384721993287e-08
, O 0 1.4185980168335277e-10
supporting O 0 4.368873041116217e-10
the O 0 3.016020544421849e-09
founder O 0 1.6036260319651774e-07
effect O 0 8.719528210576755e-08
notion O 0 5.622464982479869e-08
, O 0 3.300806294959102e-10
but O 0 6.018511383709679e-11
dating O 0 4.3961398410452546e-10
the O 0 1.1547890421681473e-10
mutations O 0 3.091376807318191e-11
origin O 0 3.565333445143537e-11
to O 0 1.952497885593374e-11
an O 0 2.528817086289159e-11
earlier O 0 1.6769178268205565e-09
date O 0 1.8903579146467564e-08
than O 0 5.092923860416931e-10
currently O 0 2.9650282229454206e-09
estimated O 0 9.299251146899223e-09
. O 0 7.269919422014937e-08

However O 0 1.1179877645872693e-07
, O 0 1.8996280104488505e-09
the O 0 1.7767702586990453e-10
different O 0 8.259565947854597e-11
allelic O 0 4.668364805837655e-09
pattern O 0 3.9185600542168686e-08
at O 0 7.062393336809691e-08
the O 0 1.5964223276654366e-09
BRCA1 O 0 1.3351155736529563e-09
locus O 0 7.253568856668835e-10
even O 0 2.8961100184687893e-10
in O 0 7.175460225994357e-11
some O 0 9.346073394367327e-12
Jewish O 0 8.78639522250424e-11
mutation O 0 1.0298526614826997e-10
carriers O 0 3.310655083410552e-10
, O 0 9.808184264770148e-10
might O 0 5.302767114301332e-10
suggest O 0 6.797170604144753e-10
that O 0 1.9331617903683984e-11
the O 0 2.64255700654914e-10
mutation O 0 3.2074262690251487e-10
arose O 0 3.728880315634342e-09
independently O 0 4.029036215769111e-09
. O 0 2.893969064388102e-09
. O 0 5.3065868144130945e-08

Crystal O 1 0.5603556036949158
structure O 0 2.741756907198578e-05
of O 0 5.3042393119540066e-05
the O 0 5.4010979511076584e-05
hemochromatosis B-Disease 1 1.0
protein O 0 2.4218252292484976e-05
HFE O 0 2.4585808205301873e-05
and O 0 5.028170324550274e-09
characterization O 0 8.097290304931448e-08
of O 0 2.0523671651062614e-08
its O 0 2.5526220026605984e-10
interaction O 0 1.0082927381915852e-08
with O 0 1.8462251727413559e-09
transferrin O 0 1.00015631687711e-06
receptor O 0 2.829181937613612e-07
. O 0 1.8663119760731206e-07

HFE O 0 0.0006068499060347676
is O 0 1.2457540776722453e-07
an O 0 1.6862198748412993e-08
MHC O 0 1.301905376749346e-05
- O 0 0.00013763652532361448
related O 0 6.835315616626758e-06
protein O 0 1.6558973925384635e-07
that O 0 8.828392183968248e-11
is O 0 4.243089213318285e-11
mutated O 0 1.1831237378689963e-10
in O 0 9.817873597439686e-11
the O 0 3.87756982078713e-09
iron B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999325275421143

HFE O 0 4.817269291379489e-05
binds O 0 2.443383948502742e-07
to O 0 2.8263169582487535e-08
transferrin O 0 2.811540298353066e-07
receptor O 0 1.7321935885661333e-08
( O 0 1.776818581156192e-09
TfR O 0 8.169799770030295e-08
) O 0 2.798826448380254e-10
and O 0 1.0915632286945254e-10
reduces O 0 7.385411171512146e-10
its O 0 5.546871295614153e-11
affinity O 0 2.18007012442456e-09
for O 0 4.350083404602856e-09
iron O 0 0.0013398505980148911
- O 0 9.762688790715401e-08
loaded O 0 6.630251458972225e-09
transferrin O 0 9.303477099820157e-08
, O 0 6.333681579206996e-09
implicating O 0 3.600592208385933e-06
HFE O 0 0.00079679413465783
in O 0 6.187960025272332e-06
iron O 1 0.9999939203262329
metabolism O 1 0.9324306845664978
. O 0 2.5242102310585324e-06

The O 0 4.551839992927853e-06
2 O 0 9.188122203340754e-05
. O 0 3.4155332286900375e-06

6 O 0 0.00024170706456061453
A O 0 9.70881046669092e-06
crystal O 0 0.15224547684192657
structure O 0 3.494835254969075e-05
of O 0 1.7825357645051554e-05
HFE O 0 0.00030991475796326995
reveals O 0 5.9582252021073145e-08
the O 0 1.0617116075195554e-09
locations O 0 3.0548101825900176e-09
of O 0 2.610294700389204e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 4.828496003028704e-07
and O 0 3.2086777679296574e-08
a O 0 5.626047894224939e-08
patch O 0 8.12102880445309e-05
of O 0 0.41197943687438965
histidines O 0 0.3513737916946411
that O 0 5.626084598198133e-10
could O 0 3.5633632156084616e-10
be O 0 6.30619167996116e-11
involved O 0 1.0802875954896152e-10
in O 0 2.184714770203655e-10
pH O 0 4.1281816720584175e-07
- O 0 7.721699830653961e-07
dependent O 0 3.315903995826375e-07
interactions O 0 9.794953257369343e-07
. O 0 4.3790890913442126e-07

We O 0 1.9386523320008564e-07
also O 0 2.1788315596182883e-09
demonstrate O 0 2.430384116181017e-09
that O 0 1.1084146100959202e-10
soluble O 0 3.2206344258156605e-08
TfR O 0 6.516291364278004e-07
and O 0 4.8575912181547665e-09
HFE O 0 2.739972615017905e-06
bind O 0 3.134414683358955e-08
tightly O 0 3.337916893997317e-07
at O 0 3.118801927826098e-08
the O 0 4.5166956286202264e-10
basic O 0 1.2190945142265264e-08
pH O 0 5.804670877296303e-08
of O 0 2.0449506976660814e-08
the O 0 2.1989716714188035e-09
cell O 0 1.3481591842889884e-08
surface O 0 5.5549367772300684e-08
, O 0 2.7019800286076645e-10
but O 0 1.8841744137132466e-11
not O 0 3.0211878138119985e-11
at O 0 3.4854970021314102e-09
the O 0 4.921640872623811e-10
acidic O 0 5.391137758437026e-09
pH O 0 2.3900381052044395e-07
of O 0 1.4525321034852823e-07
intracellular O 0 3.373192384970025e-06
vesicles O 0 9.612166650185827e-06
. O 0 2.123098965967074e-06

TfR O 0 8.0357443948742e-05
HFE O 0 4.295760300010443e-05
stoichiometry O 0 1.1511230013638851e-06
( O 0 5.409722803051409e-08
2 O 0 4.068849364102789e-07
1 O 0 3.053245123396664e-08
) O 0 1.0668020633541886e-10
differs O 0 1.5319062685037466e-09
from O 0 1.6521701784455445e-09
TfR O 0 6.192134804905436e-08
transferrin O 0 2.3058840170619987e-08
stoichiometry O 0 4.004491316322856e-08
( O 0 4.596759861641431e-09
2 O 0 7.047295724760261e-08
2 O 0 3.107484758402279e-08
) O 0 2.1775424519088205e-10
, O 0 1.1406194044827345e-10
implying O 0 2.888778105614165e-10
a O 0 6.272829478071174e-11
different O 0 9.479501385245559e-12
mode O 0 8.174472654332021e-09
of O 0 5.686229265222664e-10
binding O 0 2.3615323585524095e-10
for O 0 7.015544811750374e-10
HFE O 0 9.015559498948278e-07
and O 0 2.682586153213151e-09
transferrin O 0 5.765675581415053e-08
to O 0 3.2342120093176163e-09
TfR O 0 1.023262939270353e-06
, O 0 7.175081084831447e-10
consistent O 0 2.6706399314235796e-09
with O 0 6.464535851069542e-11
our O 0 1.1145566691794784e-09
demonstration O 0 2.759843686916952e-09
that O 0 6.772294530721368e-11
HFE O 0 2.939673890978156e-07
, O 0 2.2628796614299063e-09
transferrin O 0 4.899316863316017e-08
, O 0 1.5481025350538857e-09
and O 0 1.1328018523215633e-09
TfR O 0 3.4673479376579053e-07
form O 0 6.488915627045344e-09
a O 0 1.5899564331789406e-08
ternary O 0 7.934737595860497e-07
complex O 0 8.93993565114215e-05
. O 0 1.6258202322205761e-06

Identification O 0 7.129537493710814e-08
of O 0 6.827086451721698e-08
three O 0 6.33634811286754e-10
novel O 0 3.6947683801358266e-10
mutations O 0 2.1335848365833243e-10
and O 0 8.356131064868322e-11
a O 0 2.2561810752996792e-10
high O 0 5.6413567151025745e-09
frequency O 0 3.688315430849798e-08
of O 0 1.7797289197929445e-09
the O 0 2.0410675927173827e-10
Arg778Leu O 0 2.0986906434927732e-08
mutation O 0 8.407801538323767e-11
in O 0 1.1962210388904992e-10
Korean O 0 2.3215842759327643e-07
patients O 0 8.938632611865671e-10
with O 0 7.356422138116159e-10
Wilson B-Disease 0 6.575522547791479e-06
disease I-Disease 0 0.00036935307434760034
. O 0 4.1916109694284387e-07

Four O 0 2.3045217290018627e-07
mutations O 0 3.0266601669382e-08
- O 0 9.962363378690497e-08
- O 0 5.414718984297906e-08
R778L O 0 1.1620888074048707e-07
, O 0 1.2983674135824685e-09
A874V O 0 1.8730835549263247e-08
, O 0 1.223432882779818e-10
L1083F O 0 4.822290566863785e-09
, O 0 1.0968811275935408e-10
and O 0 7.209290109333466e-11
2304delC O 0 8.571841014770598e-09
- O 0 2.7706561489537762e-09
- O 0 8.302833975903923e-10
in O 0 2.6134647224118623e-10
the O 0 8.93708163030027e-10
copper O 0 3.291210646239051e-07
- O 0 3.4659801695369197e-09
transporting O 0 1.9775094894924905e-09
enzyme O 0 5.193917518298008e-10
, O 0 1.1147076595108274e-09
P O 0 8.351090059477428e-07
- O 0 3.228629807949801e-08
type O 0 5.300072913883014e-08
ATPase O 0 5.691518367711978e-07
( O 0 2.966623613431807e-09
ATP7B O 0 7.598839601996588e-07
) O 0 1.136983285299209e-10
, O 0 2.6473738132248847e-11
were O 0 8.881013979777919e-12
identified O 0 2.732624543311246e-11
in O 0 4.666152533805423e-11
Korean O 0 4.780387143910048e-07
Patients O 0 1.3845534718726071e-09
with O 0 7.893131703795575e-10
Wilson B-Disease 0 4.401176192914136e-05
disease I-Disease 0 0.0948806181550026
. O 0 1.0832328598553431e-06

Arg778Leu O 0 0.00023811905703041703
, O 0 3.9842181109861485e-08
the O 0 2.3099284707228662e-09
most O 0 7.939451873717474e-11
frequently O 0 6.10636749498461e-11
reported O 0 1.9848572438418977e-11
mutation O 0 1.1563180968288123e-11
of O 0 1.1889421391853006e-10
this O 0 3.3949455659904038e-12
enzyme O 0 5.185986015621147e-11
, O 0 1.071862321122552e-10
was O 0 3.6183824825286592e-09
found O 0 1.5989018442574832e-10
in O 0 9.414387325268336e-11
six O 0 3.8571204563631056e-10
of O 0 4.1977097353651516e-09
eight O 0 2.7227007315389073e-09
unrelated O 0 3.890743727197332e-08
patients O 0 1.7767711746330406e-09
studied O 0 3.611482313203851e-08
, O 0 8.487752861663367e-11
an O 0 1.4031349866716614e-11
allele O 0 3.6628072797029176e-10
frequency O 0 5.609386022342733e-08
of O 0 3.9599214574082e-08
37 O 0 9.71778263192391e-07
. O 0 3.121689076124312e-07

5 O 0 4.4903481466462836e-06
% O 0 1.6916606782046983e-08
, O 0 2.2676538424803994e-09
which O 0 6.3825222884617e-11
is O 0 1.9672185755381655e-11
considerably O 0 4.56129828352303e-10
higher O 0 6.450006084790516e-10
than O 0 4.316874548798699e-12
those O 0 1.4389972503511816e-12
in O 0 6.185819217963129e-12
other O 0 1.5327112842800084e-11
Asian O 0 6.338076730116882e-10
populations O 0 3.560625405629736e-10
. O 0 1.2211494038183446e-08

The O 0 8.626362557606626e-08
novel O 0 1.544287009380696e-08
single O 0 8.759960534732159e-10
nucleotide O 0 3.6463863040125943e-09
deletion O 0 2.099831775126404e-08
, O 0 8.841034571105411e-10
2304delC O 0 2.6757502880059292e-08
, O 0 1.5794251462253328e-09
was O 0 1.7637219684729644e-08
found O 0 5.376102341081435e-10
in O 0 5.78496861525224e-10
one O 0 1.1970385793702576e-09
patient O 0 6.03318497383043e-08
. O 0 1.9986453025921946e-07

Since O 0 3.2848328146428685e-07
a O 0 1.0756399326794508e-08
mutation O 0 9.804405065594324e-10
at O 0 3.130602621581602e-08
cDNA O 0 1.9600529199692573e-08
nucleotide O 0 1.277291232781863e-07
2302 O 0 7.05378351995023e-06
( O 0 3.5015559340934033e-09
2302insC O 0 3.719909713595371e-08
) O 0 5.559191995629931e-10
had O 0 1.0693206320411264e-09
been O 0 2.2970103596975378e-10
previously O 0 1.8384733735388181e-09
described O 0 1.5505788875103121e-09
, O 0 9.903556273671565e-12
this O 0 3.8446667724456596e-12
region O 0 7.496365195258647e-10
of O 0 1.6719771123163696e-09
the O 0 2.016473876764735e-09
ATP7B O 0 4.543833711068146e-06
gene O 0 1.8084254094219432e-08
may O 0 1.3738527648854415e-08
be O 0 1.4204453169242015e-09
susceptible O 0 7.659955336691837e-09
to O 0 1.1523055842843632e-09
gene O 0 2.2307631297735497e-06
rearrangements O 0 0.04144120216369629
causing O 0 0.14177891612052917
Wilson B-Disease 1 0.6687768697738647
disease I-Disease 1 0.9935553669929504
. O 0 3.2233187994279433e-06

Disruption O 0 2.6829520720639266e-05
of O 0 4.421519292918674e-07
splicing O 0 1.2233365964675613e-07
regulated O 0 4.726289049017396e-08
by O 0 6.915795713879902e-10
a O 0 5.087140486637054e-09
CUG O 0 2.242458322143648e-06
- O 0 5.128440250246058e-08
binding O 0 3.4469685772364755e-08
protein O 0 6.102665793150663e-06
in O 0 1.8963327192977886e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 3.916914283763617e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9929881691932678
DM B-Disease 1 1.0
) O 0 4.3797490434371866e-07
is O 0 2.603177673421442e-09
caused O 0 3.379058588492967e-09
by O 0 2.8758315173682547e-10
a O 0 5.03570474208459e-09
CTG O 0 9.305266530645895e-07
expansion O 0 2.9549577007514927e-08
in O 0 6.67108146501505e-10
the O 0 8.919404659302188e-10
3 O 0 2.292054190888848e-08
untranslated O 0 2.017940687437658e-06
region O 0 8.491890746142872e-09
of O 0 2.0537848754997867e-08
the O 0 1.4156672989429353e-07
DM B-Disease 1 1.0
gene O 0 1.92236393559142e-06
. O 0 1.6158223843376618e-06

One O 0 6.25205416326935e-08
model O 0 1.209015181302675e-07
of O 0 5.43512032891158e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.999951958656311
suggests O 0 8.517231719906704e-08
that O 0 1.4972582895733666e-10
RNAs O 0 5.08587927328108e-09
from O 0 1.2067648269553644e-10
the O 0 5.6787689134418784e-11
expanded O 0 9.369317127694288e-11
allele O 0 8.892171027286011e-11
create O 0 6.161848115082691e-11
a O 0 3.774603685169353e-10
gain O 0 4.7090820132211775e-09
- O 0 6.1043472499022755e-09
of O 0 1.3329229275882426e-08
- O 0 3.05997116534229e-09
function O 0 2.104389551504937e-09
mutation O 0 1.1237285407750264e-10
by O 0 4.8452054868253214e-11
the O 0 1.477631628166165e-10
inappropriate O 0 2.071850913054618e-09
binding O 0 9.159197289498877e-10
of O 0 5.878381337254268e-09
proteins O 0 1.931717980019343e-10
to O 0 5.095897037676878e-10
the O 0 1.2271454075118982e-08
CUG O 0 2.5541119612171315e-05
repeats O 0 8.404973641518154e-07
. O 0 2.6604610070535273e-07

Data O 0 1.0978496334246302e-07
presented O 0 1.4789154079153377e-07
here O 0 8.96513707715485e-09
indicate O 0 8.300046761000601e-10
that O 0 1.704646493405626e-11
the O 0 9.97822866000142e-11
conserved O 0 4.209463444482253e-09
heterogeneous O 0 8.282595587161268e-08
nuclear O 0 3.774298193093273e-06
ribonucleoprotein O 0 2.146154400861633e-07
, O 0 1.66899161158085e-09
CUG O 0 3.2397247196058743e-07
- O 0 7.925389233776059e-09
binding O 0 2.3135087179326774e-09
protein O 0 2.069695348438927e-08
( O 0 1.319185982673332e-09
CUG O 0 1.7720376490615308e-06
- O 0 2.576149142896611e-07
BP O 0 2.975911570501921e-07
) O 0 7.987148165078395e-10
, O 0 8.061530887282231e-10
may O 0 2.470578852609151e-09
mediate O 0 1.2255775061476015e-07
the O 0 1.5592239321904344e-07
trans O 0 2.705002088987385e-06
- O 0 2.8338780566627975e-07
dominant O 0 3.220220037292165e-07
effect O 0 1.569133445400439e-07
of O 0 3.2749664313769244e-08
the O 0 2.3580872365869254e-08
RNA O 0 3.697331294461037e-07
. O 0 2.0000238976081164e-07

CUG O 0 0.18300631642341614
- O 0 0.0002856029022950679
BP O 0 2.073302493954543e-05
was O 0 3.902457308413432e-07
found O 0 5.532725944057404e-10
to O 0 1.9389483074672142e-11
bind O 0 1.1984772896322937e-10
to O 0 6.28369092869896e-11
the O 0 8.146234797834495e-10
human O 0 3.054409702940575e-08
cardiac O 0 0.18590147793293
troponin O 0 0.00013083851081319153
T O 0 1.3773938007943798e-05
( O 0 2.0059898186985947e-09
cTNT O 0 2.873690441163035e-08
) O 0 2.4187521430185654e-10
pre O 0 4.48889103665806e-08
- O 0 6.966889731785386e-09
messenger O 0 1.311323938324449e-09
RNA O 0 5.078724996110395e-09
and O 0 1.5141909948113152e-10
regulate O 0 8.388711947304728e-10
its O 0 1.1257923065999265e-10
alternative O 0 5.2101825076533714e-09
splicing O 0 1.4366545997290814e-07
. O 0 6.090370163747139e-08

Splicing O 0 3.5923399082093965e-06
of O 0 5.270118776934396e-07
cTNT O 0 5.0808284868253395e-06
was O 0 3.0044413961149985e-06
disrupted O 0 5.59232103114482e-06
in O 0 9.835318337536592e-08
DM B-Disease 1 1.0
striated O 0 0.00021422715508379042
muscle O 0 1.4698080121888779e-05
and O 0 2.8915373206928052e-08
in O 0 9.176215343131844e-09
normal O 0 1.235867301829785e-07
cells O 0 6.442898992098378e-10
expressing O 0 6.681689090903831e-10
transcripts O 0 4.01390254367584e-09
that O 0 1.1310670282316249e-11
contain O 0 7.274975066806633e-10
CUG O 0 9.313487794315733e-07
repeats O 0 1.37295884883315e-07
. O 0 6.115082129554139e-08

Altered O 0 9.617676965945066e-08
expression O 0 2.4524061004171926e-08
of O 0 2.4486716654337215e-08
genes O 0 3.202391019030415e-09
regulated O 0 1.8511485677663586e-08
posttranscriptionally O 0 1.1206392969143053e-07
by O 0 2.275978072674434e-09
CUG O 0 0.0004416440788190812
- O 0 7.259905032697134e-06
BP O 0 2.893600822062581e-06
therefore O 0 2.5792584068540236e-08
may O 0 2.0779691300987224e-09
contribute O 0 1.5454945101467388e-09
to O 0 2.2951249789571193e-08
DM B-Disease 1 1.0
pathogenesis O 1 0.9989644289016724
. O 0 1.1077017347815854e-07
. O 0 2.390193003520835e-07

Identification O 0 1.8388359990240133e-07
of O 0 1.943261338510638e-07
a O 0 1.8266810286604596e-08
novel O 0 7.1276451407698005e-09
nonsense O 0 3.189092367961166e-08
mutation O 0 6.629110038680608e-10
and O 0 2.8880564606481585e-10
a O 0 1.0353067292356855e-09
missense O 0 1.2436109919633509e-08
substitution O 0 6.927839191206431e-09
in O 0 1.2862328979679205e-09
the O 0 3.4924712011275005e-09
vasopressin O 0 7.724337081072008e-08
- O 0 8.394177797299562e-08
neurophysin O 0 5.80167068164883e-07
II O 0 0.1531737893819809
gene O 0 8.05609357001913e-09
in O 0 7.115226186016343e-10
two O 0 1.7327866919103485e-10
Spanish O 0 1.3370198281847934e-08
kindreds O 0 1.8508261234728707e-07
with O 0 1.8997727835312617e-09
familial B-Disease 1 0.9921368360519409
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999901056289673
. O 0 5.173191675567068e-05

Familial B-Disease 1 0.9999972581863403
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 6.332653720164672e-05
FNDI B-Disease 1 1.0
) O 0 1.0517694271072742e-08
is O 0 1.8862608697212124e-10
an O 0 5.019208937362407e-10
autosomal B-Disease 1 0.9999996423721313
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 8.437938049610239e-06
by O 0 2.4980282287145883e-09
deficiency O 1 0.9883543252944946
in O 0 9.832204739268491e-08
the O 0 2.8755496828125615e-07
antidiuretic O 0 2.403281769147725e-06
hormone O 0 1.0900750879727639e-07
arginine O 0 2.9018809755143593e-07
vasopressin O 0 5.316607030181331e-07
( O 0 5.6715228069492696e-09
AVP O 0 1.3601271575680585e-07
) O 0 1.1028536417434509e-10
encoded O 0 4.0545358737098525e-10
by O 0 1.6231953281486966e-10
the O 0 5.450588869138073e-09
AVP O 0 4.484972123464104e-06
- O 0 1.9579026684368728e-06
neurophysin O 0 2.8994214517297223e-05
II O 1 0.9999997615814209
( O 0 2.2579102676445473e-07
AVP O 0 1.0914801350736525e-05
- O 0 1.1797109209510381e-06
NPII O 0 1.919034048114554e-06
) O 0 8.23902113200603e-10
gene O 0 3.6039251583019905e-09
on O 0 7.146406488800494e-08
chromosome O 0 1.6459202925034333e-06
20p13 O 0 6.59687884763116e-06
. O 0 4.59504434502378e-07

In O 0 4.3275921512986315e-08
this O 0 3.889722988148492e-10
study O 0 2.745456639807742e-10
, O 0 4.738856182462392e-11
we O 0 1.8079950730998107e-11
analyzed O 0 1.662392029588844e-10
two O 0 1.7569471918998936e-11
families O 0 1.1604956362196162e-12
with O 0 4.609820164480638e-11
FNDI B-Disease 1 0.5536267757415771
using O 0 2.046924185705734e-09
direct O 0 1.5254595364666557e-09
automated O 0 4.4098751317278584e-08
fluorescent O 0 5.690658166912499e-09
, O 0 3.285004213093856e-10
solid O 0 7.626483444767018e-09
phase O 0 5.4745555644331034e-08
, O 0 1.7981360844743222e-10
single O 0 5.870129382579137e-11
- O 0 4.2475614692172314e-10
stranded O 0 1.0978397357863656e-10
DNA O 0 2.123887871130492e-11
sequencing O 0 7.004136159949326e-11
of O 0 3.522346025963685e-10
PCR O 0 4.450355639562531e-09
- O 0 1.9240090409766708e-08
amplified O 0 1.1471905025928208e-07
AVP O 0 1.2195071576570626e-05
- O 0 1.4078224239710835e-06
NPII O 0 1.4603016097680666e-05
DNA O 0 2.6352017812314443e-07
. O 0 9.332677564088954e-08

In O 0 2.3189930686839944e-07
one O 0 4.6539265774470095e-09
of O 0 9.931946820529447e-09
the O 0 1.5676422382426836e-09
families O 0 5.755075582758451e-11
, O 0 4.824862037677846e-11
affected O 0 1.8668320361792112e-11
individuals O 0 3.4905212401015184e-12
presented O 0 8.503021065031646e-10
a O 0 4.0962930270005415e-10
novel O 0 4.0228451125834397e-10
nonsense O 0 2.032882528979485e-09
mutation O 0 1.3700832135477015e-10
in O 0 5.450877527124476e-10
exon O 0 1.4128075598307532e-08
3 O 0 2.213655037053286e-08
of O 0 3.1705198466625006e-09
the O 0 4.5450412877734436e-10
gene O 0 2.8576888078113427e-10
, O 0 1.345986794243359e-10
consisting O 0 5.508906664175584e-10
in O 0 1.7634419480216934e-09
a O 0 6.802257868088191e-09
G O 0 2.8560197051774594e-07
to O 0 1.0934647853844126e-08
T O 0 5.98750784774893e-06
transition O 0 1.4769795598112978e-05
at O 0 1.8386095916866907e-06
nucleotide O 0 2.711052893289434e-08
2101 O 0 8.262822461801989e-07
, O 0 1.4128902492416273e-09
which O 0 5.965528071527615e-11
produces O 0 5.222106080893241e-11
a O 0 4.794003041763695e-11
stop O 0 1.7486502523755831e-10
signal O 0 3.1455404947422494e-09
in O 0 5.877032749346256e-10
codon O 0 2.914864793979177e-09
82 O 0 9.386018007262464e-08
( O 0 5.139218384186961e-09
Glu O 0 1.6504880022694124e-06
) O 0 1.6260168322901336e-08
of O 0 5.377419256547e-07
NPII O 0 0.002078362973406911
. O 0 3.696400654007448e-06

The O 0 5.862808620804572e-07
premature O 0 1.203644160341355e-06
termination O 0 1.8365226139849256e-07
eliminates O 0 1.2216531786179985e-07
part O 0 1.7426721399260714e-08
of O 0 2.273948318531893e-08
the O 0 7.678972124836037e-09
C O 0 3.4918516575999092e-06
- O 0 1.4403538806107008e-08
terminal O 0 4.291032951186935e-08
domain O 0 8.341409341028339e-09
of O 0 8.640454574049272e-09
NPII O 0 6.713964353366464e-07
, O 0 2.529788045713133e-10
including O 0 3.733181819232101e-11
a O 0 4.094395100739945e-10
cysteine O 0 2.3707131813210935e-09
residue O 0 7.894765019500483e-08
in O 0 1.3364735984566778e-09
position O 0 4.417156773683928e-08
85 O 0 2.411048782846592e-08
, O 0 2.317650377170466e-10
which O 0 1.802145585538817e-11
could O 0 2.0479765452940946e-11
be O 0 2.1503833436131714e-11
involved O 0 6.894679271951532e-11
in O 0 3.508578497180004e-11
the O 0 1.3069385851327553e-10
correct O 0 1.6838672678431976e-08
folding O 0 9.769670441528433e-07
of O 0 1.0317710774643274e-07
the O 0 1.2619649680800649e-07
prohormone O 0 0.00014962625573389232
. O 0 1.0765274964796845e-06

In O 0 1.475579267662397e-07
the O 0 3.6622520127593816e-08
second O 0 4.9736801344124615e-08
family O 0 7.271535040764832e-10
, O 0 1.4935531977844363e-10
a O 0 2.3734039733547263e-10
G279A O 0 6.208914271610411e-09
substitution O 0 4.229784966724992e-09
at O 0 3.9262733508849124e-08
position O 0 9.154646818387846e-08
- O 0 1.9245632643105637e-08
1 O 0 2.237959684237012e-08
of O 0 1.072040678451458e-09
the O 0 3.540073234553631e-10
signal O 0 9.262749678384807e-09
peptide O 0 1.6662276003387433e-09
was O 0 1.072260058521124e-08
observed O 0 1.556172746219886e-09
in O 0 2.181658187438984e-10
all O 0 9.524089156220938e-11
affected O 0 6.462171908694359e-10
individuals O 0 2.4090879291449596e-10
. O 0 4.121351793173744e-08

This O 0 2.943269095112555e-08
missense O 0 1.970512585103279e-06
mutation O 0 1.3983173730025555e-08
, O 0 3.807607562578141e-09
which O 0 1.500006008292587e-09
replaces O 0 1.8203355693913181e-06
Ala O 0 1.965524688785081e-06
with O 0 1.7217320902318534e-08
Thr O 0 3.749015013454482e-05
, O 0 6.6051457636717714e-09
is O 0 2.2375222508141945e-10
frequent O 0 9.824885349729584e-10
among O 0 2.405682320016922e-09
FNDI B-Disease 1 1.0
patients O 0 1.1253241609665565e-05
and O 0 4.189321245462452e-08
is O 0 6.209257552569625e-09
thought O 0 1.4003370685244931e-09
to O 0 4.360446032025678e-11
reduce O 0 1.4589307539836227e-09
the O 0 3.0034871811857045e-10
efficiency O 0 5.569372962810348e-09
of O 0 3.9711594013169815e-09
cleavage O 0 4.541837128613224e-09
by O 0 2.892731332249099e-10
signal O 0 3.462866970949108e-07
peptidases O 0 1.6230720802923315e-06
. O 0 1.795903159518275e-08
. O 0 1.925907753275169e-07

Genetic O 0 7.339932039940322e-07
heterogeneity O 0 1.1241239690207294e-06
of O 0 1.0229956615148694e-06
Saethre B-Disease 1 0.9996820688247681
- I-Disease 1 0.9998088479042053
Chotzen I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999998807907104
, O 0 5.025380556133996e-09
due O 0 8.57694786304819e-08
to O 0 3.6868295083536395e-09
TWIST O 0 3.328283582959557e-06
and O 0 1.5275013254267833e-08
FGFR O 0 0.0002199491864303127
mutations O 0 7.319101769098779e-07
. O 0 4.0714616034165374e-07

Thirty O 0 9.57939846557565e-05
- O 0 5.602987130259862e-06
two O 0 1.957600970214912e-09
unrelated O 0 1.2876405719453032e-07
patients O 0 1.9729951006297597e-10
with O 0 5.7866623819069485e-12
features O 0 1.2209974142862734e-09
of O 0 2.437995760828926e-07
Saethre B-Disease 1 0.9999967813491821
- I-Disease 1 0.9999978542327881
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.635346635886492e-09
a O 0 2.146791411306026e-09
common O 0 6.637580440838065e-08
autosomal B-Disease 0 0.016909046098589897
dominant I-Disease 0 0.037546414881944656
condition I-Disease 1 0.53233802318573
of O 0 0.02198292501270771
craniosynostosis B-Disease 1 0.9999921321868896
and O 0 1.9564579361031065e-06
limb B-Disease 1 0.9992293119430542
anomalies I-Disease 1 0.9987865090370178
, O 0 3.173268225964421e-08
were O 0 1.4419639926543937e-09
screened O 0 1.1788467979556572e-09
for O 0 1.400803917306348e-10
mutations O 0 3.459070252453955e-10
in O 0 1.8941248569603886e-09
TWIST O 0 3.6003928016725695e-07
, O 0 2.7884001774225453e-09
FGFR2 O 0 2.886275296987151e-06
, O 0 3.0346587465146513e-09
and O 0 6.576283517745196e-09
FGFR3 O 0 0.00014602149894926697
. O 0 6.227406856851303e-07

Nine O 0 9.710668109619291e-07
novel O 0 7.289219183803652e-08
and O 0 1.914030267613498e-09
three O 0 1.388350878706035e-09
recurrent O 0 3.3147659905807814e-07
TWIST O 0 1.4102452041697688e-06
mutations O 0 5.849056350371029e-09
were O 0 2.4880284499317895e-09
found O 0 3.223722122580597e-10
in O 0 4.6541906439934166e-10
12 O 0 2.2491413176339847e-08
families O 0 9.964065128542643e-10
. O 0 6.19098941001539e-08

Seven O 0 2.899670619171957e-07
families O 0 8.400816708942216e-10
were O 0 3.1670990274790256e-09
found O 0 3.758181266189098e-10
to O 0 7.615748309763859e-11
have O 0 1.69919286974185e-11
the O 0 2.56575261037284e-10
FGFR3 O 0 3.046087897473626e-07
P250R O 0 1.9041415555420826e-08
mutation O 0 1.6056682372589393e-10
, O 0 1.1057919163670604e-10
and O 0 5.0036259857666465e-11
one O 0 3.3452348530138565e-11
individual O 0 7.540870705646796e-12
was O 0 1.343871858239254e-08
found O 0 1.577750291525959e-10
to O 0 1.929702578284953e-11
have O 0 2.6496216679050555e-11
an O 0 6.757430726089808e-11
FGFR2 O 0 8.522584380443732e-07
VV269 O 0 7.423761871905299e-07
- O 0 3.1393571475746285e-07
270 O 0 7.916327859902594e-08
deletion O 0 8.883231430445448e-07
. O 0 3.4756078548525693e-07

To O 0 1.4354912813985266e-08
date O 0 2.1236708391825232e-07
, O 0 3.0173483156481495e-10
our O 0 5.425793148106095e-11
detection O 0 9.635479081282483e-10
rate O 0 2.383984121223648e-10
for O 0 2.1457167639904462e-11
TWIST O 0 1.9770503456584265e-08
or O 0 3.6421371474304465e-10
FGFR O 0 1.8456282191436912e-07
mutations O 0 3.077394172823489e-10
is O 0 1.0547435841390396e-10
68 O 0 5.884439158165833e-09
% O 0 2.7892499421255934e-10
in O 0 2.9473221085929424e-10
our O 0 1.353432477202432e-09
Saethre B-Disease 0 1.487138888478512e-05
- I-Disease 0 6.560469046235085e-05
Chotzen I-Disease 1 0.9687703847885132
syndrome I-Disease 1 0.999812662601471
patients O 0 1.7529664830817637e-08
, O 0 5.402457925463011e-10
including O 0 4.330469316471408e-10
our O 0 5.138669934012796e-09
five O 0 2.88609758314351e-09
patients O 0 2.257688924700574e-09
elsewhere O 0 2.1513248960047804e-09
reported O 0 7.182063832544827e-10
with O 0 7.513413780024791e-10
TWIST O 0 2.3741977202007547e-06
mutations O 0 8.463952383408468e-08
. O 0 1.4353247479448328e-07

More O 0 1.7668636331791276e-08
than O 0 1.0271048456189646e-09
35 O 0 4.875487569222514e-09
different O 0 3.259464920191135e-10
TWIST O 0 8.55884039197008e-08
mutations O 0 1.1407592648282616e-09
are O 0 3.6930330321593985e-11
now O 0 6.544406683239856e-11
known O 0 5.563209615200293e-11
in O 0 7.706696392162371e-11
the O 0 3.1897096075539366e-10
literature O 0 7.613199848321983e-09
. O 0 9.18309694952768e-09

The O 0 1.1960948143041605e-07
most O 0 7.387059852703715e-10
common O 0 2.1912081871189315e-10
phenotypic O 0 1.7487620240785873e-08
features O 0 5.575632844312395e-09
, O 0 3.6872915831764885e-10
present O 0 2.6989360746298985e-10
in O 0 3.941245663163784e-10
more O 0 1.0168391302578517e-11
than O 0 4.042007614030174e-12
a O 0 2.1159950527871452e-11
third O 0 1.7616055836278122e-10
of O 0 8.810498441924608e-10
our O 0 7.044977379244699e-10
patients O 0 2.33483038458715e-10
with O 0 8.88511833552208e-11
TWIST O 0 2.7311912731420307e-07
mutations O 0 1.906528268591501e-09
, O 0 2.974792634446999e-10
are O 0 7.171027660568541e-11
coronal B-Disease 0 2.490984059022594e-07
synostosis I-Disease 0 2.209044396295212e-06
, O 0 9.967054737103354e-09
brachycephaly B-Disease 0 2.9571622235380346e-06
, O 0 2.3909722202120065e-08
low B-Disease 0 1.1002411156368908e-05
frontal I-Disease 1 0.9999264478683472
hairline I-Disease 1 1.0
, O 0 7.115223979781149e-06
facial B-Disease 1 0.9999164342880249
asymmetry I-Disease 1 0.9999587535858154
, O 0 2.1577588995569386e-06
ptosis B-Disease 0 0.0007411035476252437
, O 0 1.4695811501042044e-07
hypertelorism B-Disease 0 0.00029132419149391353
, O 0 9.961394908941656e-08
broad B-Disease 0 1.0523070841372828e-06
great I-Disease 0 0.00023144332226365805
toes I-Disease 0 0.07684339582920074
, O 0 3.8295102200436304e-08
and O 0 3.42545831699681e-08
clinodactyly B-Disease 0 9.34948620852083e-05
. O 0 1.1542526863195235e-06

Significant O 0 8.861755986799835e-07
intra O 0 6.14225136814639e-05
- O 0 2.7542453153728275e-06
and O 0 4.672596087829106e-09
interfamilial O 0 4.255127237229317e-07
phenotypic O 0 1.0132572469956358e-06
variability O 0 3.1383353871206054e-06
is O 0 3.79038911368923e-10
present O 0 1.8851242788997524e-10
for O 0 1.8443940819068416e-10
either O 0 8.817159447005452e-09
TWIST O 0 6.548423812091642e-07
mutations O 0 1.9316868105079266e-08
or O 0 1.1257332843683798e-08
FGFR O 0 2.8667476726695895e-05
mutations O 0 2.3031223861380568e-07
. O 0 2.6561181698525616e-07

The O 0 2.2287802892151376e-07
overlap O 0 1.4955207916500513e-07
in O 0 4.414754339876481e-09
clinical O 0 1.7094222926061775e-08
features O 0 1.914811642578229e-09
and O 0 2.253884440195364e-10
the O 0 1.068961696937265e-09
presence O 0 1.510286451456011e-09
, O 0 1.310463126902306e-10
in O 0 3.4643309054782634e-11
the O 0 4.1031570502392256e-11
same O 0 3.987283420103793e-11
genes O 0 3.5215649840658614e-11
, O 0 2.5739368969546206e-11
of O 0 2.036024543405901e-10
mutations O 0 7.615225811052895e-11
for O 0 1.696654761129679e-10
more O 0 5.4118813597181514e-11
than O 0 1.8846425808849432e-10
one O 0 2.746153304755694e-10
craniosynostotic B-Disease 0 5.567623517777065e-08
condition I-Disease 0 1.8057907880120183e-07
- O 0 1.2583303288238312e-08
such O 0 2.953275957118251e-10
as O 0 1.7716174083304281e-09
Saethre B-Disease 0 7.471747380805027e-07
- I-Disease 0 1.1178300240999306e-07
Chotzen I-Disease 0 3.913515342901519e-07
, I-Disease 0 2.012362720904548e-09
Crouzon I-Disease 0 3.544786864040361e-07
, I-Disease 0 3.970265449737553e-09
and I-Disease 0 5.5137450161169e-09
Pfeiffer I-Disease 0 0.000204378244234249
syndromes I-Disease 0 2.8045718863722868e-05
- O 0 5.205318416301452e-07
support O 0 1.6838447081113372e-08
the O 0 4.7318817308905636e-08
hypothesis O 0 6.805346508542698e-09
that O 0 3.4773326579307096e-11
TWIST O 0 1.2567472396085577e-08
and O 0 1.5694065491622666e-10
FGFRs O 0 4.8200767821526824e-08
are O 0 5.754435990212858e-12
components O 0 2.1366484137530506e-09
of O 0 6.695850540694437e-10
the O 0 9.58726015243272e-11
same O 0 1.5874641878799167e-10
molecular O 0 3.219987609881514e-09
pathway O 0 5.516035406216702e-10
involved O 0 2.188459830021472e-10
in O 0 2.2200448077103196e-11
the O 0 5.905886890644751e-11
modulation O 0 1.9683136898152043e-08
of O 0 2.4381861862821097e-07
craniofacial O 1 0.999998927116394
and O 0 9.285877240472473e-06
limb O 1 0.9610888957977295
development O 0 7.689256563025992e-06
in O 0 2.3629772272215632e-07
humans O 0 6.895005100204799e-08
. O 0 1.4256131830592267e-09
. O 0 2.3695887918506742e-08

Mutation O 0 4.8887315529100306e-08
analysis O 0 2.0595315675109305e-08
of O 0 4.171794643070825e-08
UBE3A O 1 0.958685040473938
in O 0 0.0005087017198093235
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.6603913307189941
. O 0 3.323500550322933e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.33401617407798767
AS B-Disease 1 1.0
) O 0 3.5114357643806215e-08
is O 0 1.3209081606291306e-09
caused O 0 2.0841057768450355e-09
by O 0 2.1491296242626134e-10
chromosome O 0 1.4543618931384117e-07
15q11 O 0 2.7347778086550534e-07
- O 0 1.3559421141451367e-08
q13 O 0 1.667652860248836e-08
deletions O 0 8.169667720103746e-10
of O 0 1.0032986663688348e-09
maternal O 0 1.0553679041791497e-09
origin O 0 2.1613139056242403e-10
, O 0 1.4200754287763129e-11
by O 0 2.2039871663825927e-11
paternal O 0 7.985023131595881e-08
uniparental B-Disease 0 0.00020191793737467378
disomy I-Disease 0 0.006543491967022419
( O 0 3.459971935626527e-07
UPD B-Disease 1 0.9999935626983643
) O 0 2.6225054128303782e-08
15 O 0 5.0266674378462994e-08
, O 0 2.0040231973883493e-10
by O 0 6.740052960196863e-11
imprinting O 0 2.728761319303885e-05
defects O 1 0.8177158832550049
, O 0 3.146296556622019e-09
and O 0 2.1403671890407594e-10
by O 0 2.514149999299775e-10
mutations O 0 2.894896544702874e-09
in O 0 3.4909661827953187e-09
the O 0 6.254702356045527e-08
UBE3A O 0 0.0002606012858450413
gene O 0 3.854546775983181e-06
. O 0 2.4689843485248275e-06

UBE3A O 0 0.0002693717833608389
encodes O 0 8.665741120239545e-07
a O 0 5.305747663442162e-07
ubiquitin O 0 1.5562825410597725e-06
- O 0 8.337418648807216e-07
protein O 0 3.735188869313788e-08
ligase O 0 1.6307003747328963e-08
and O 0 1.124097703808502e-09
shows O 0 1.1975920699569542e-08
brain O 0 1.8161521438742056e-05
- O 0 7.734259099834162e-08
specific O 0 9.077114171418543e-09
imprinting O 0 1.1441619790275581e-05
. O 0 5.796057394036325e-07

Here O 0 1.4699458006361965e-06
we O 0 2.2750763051249123e-08
describe O 0 6.226456861213592e-08
UBE3A O 0 1.2533271728898399e-05
coding O 0 1.118215368478559e-05
- O 0 7.570355364805437e-07
region O 0 2.995189518628649e-08
mutations O 0 1.0003273764880305e-09
detected O 0 3.121597647037788e-09
by O 0 5.67339925039434e-11
SSCP O 0 3.565019710549677e-07
analysis O 0 4.563354583098089e-09
in O 0 2.02978678309762e-09
13 O 0 3.5032407197377324e-08
AS B-Disease 1 0.9866033792495728
individuals O 0 5.230392230437531e-10
or O 0 1.4943497106401082e-08
families O 0 1.5296754973803672e-09
. O 0 4.337740122650757e-08

Two O 0 1.0478511569544935e-07
identical O 0 2.8825596132264764e-07
de O 0 1.1156418622704223e-05
novo O 0 2.509372279746458e-06
5 O 0 2.018720351770753e-06
- O 0 1.6967203464446357e-07
bp O 0 7.052270944996053e-08
duplications O 0 1.8022552694674232e-07
in O 0 1.1879231820444147e-08
exon O 0 1.464937213313533e-06
16 O 0 3.2362353863391036e-07
were O 0 4.624860494573113e-08
found O 0 3.3579098612790403e-08
. O 0 8.544388663267455e-08

Among O 0 1.7807348484666363e-08
the O 0 3.0590199262547912e-09
other O 0 2.0175577875036765e-10
11 O 0 1.1482467199286361e-09
unique O 0 1.7134289820308624e-10
mutations O 0 2.840040147500389e-10
, O 0 2.574782886899385e-10
8 O 0 7.663155443538017e-09
were O 0 1.0930680804932535e-09
small O 0 1.9603461909323272e-10
deletions O 0 3.110080193380327e-09
or O 0 3.393047620647849e-09
insertions O 0 1.1627683704773517e-07
predicted O 0 7.009077762631932e-08
to O 0 4.712100931669738e-09
cause O 0 2.534000032028416e-07
frameshifts O 0 1.0685773304430768e-05
, O 0 1.5119933749474512e-08
1 O 0 1.3634830509090534e-07
was O 0 2.2134987176514187e-08
a O 0 1.7190790457810579e-10
mutation O 0 1.0254908033857646e-11
to O 0 5.934930324968946e-11
a O 0 7.913965038852666e-10
stop O 0 1.4436509765403116e-09
codon O 0 1.828687867799772e-09
, O 0 1.7856792711157254e-09
1 O 0 2.909883534130131e-08
was O 0 2.265631771081189e-08
a O 0 3.1632170216511213e-09
missense O 0 1.1100701691191261e-08
mutation O 0 2.864657677736915e-10
, O 0 4.96009011641263e-10
and O 0 5.085003529359255e-10
1 O 0 1.2579923236444301e-07
was O 0 5.33434132421462e-08
predicted O 0 5.712168515970006e-09
to O 0 1.5582392320911964e-10
cause O 0 1.5738257364006358e-09
insertion O 0 1.1534297961190987e-08
of O 0 1.0901790403750056e-07
an O 0 3.1471427686113884e-09
isoleucine O 0 2.3445888928108616e-06
in O 0 9.390150879085013e-09
the O 0 1.8258729639342164e-08
hect O 0 6.069914206818794e-07
domain O 0 7.797997625402786e-08
of O 0 3.928850489387514e-08
the O 0 2.389335485020183e-08
UBE3A O 0 7.840404578018934e-06
protein O 0 2.477488614260892e-08
, O 0 2.9396080014620907e-10
which O 0 9.681247990778186e-12
functions O 0 1.329519938586543e-09
in O 0 2.302670276677077e-09
E2 O 0 6.835633712398703e-07
binding O 0 4.0702538228742924e-08
and O 0 1.075088196245133e-08
ubiquitin O 0 7.805436439412006e-07
transfer O 0 2.4625364858366083e-06
. O 0 8.503441222273977e-07

Eight O 0 2.4038311607910146e-07
of O 0 2.1531855409762102e-08
the O 0 1.2097590706972028e-09
cases O 0 5.475855324732493e-10
were O 0 2.1742886657794003e-10
familial O 0 1.0711133313634491e-08
, O 0 8.838404452760074e-10
and O 0 6.874303348780586e-10
five O 0 1.4101656509168947e-09
were O 0 6.606279523424519e-09
sporadic O 0 4.377515097075957e-07
. O 0 1.546209347225158e-07

In O 0 1.9147729801716196e-07
two O 0 2.1313000253542214e-09
familial O 0 3.9491476400144165e-07
cases O 0 8.206654023013016e-09
and O 0 1.6968294824781793e-10
one O 0 2.2917622660711956e-11
sporadic O 0 7.512199751147364e-09
case O 0 2.7695887805379016e-09
, O 0 1.6016184212208628e-10
mosaicism O 0 2.420875944153522e-07
for O 0 2.4192101655273746e-09
UBE3A O 0 6.264203420869308e-06
mutations O 0 5.2758433177757524e-09
was O 0 1.2562630935519792e-08
detected O 0 5.606195951912696e-09
in O 0 1.0437008202135445e-10
the O 0 2.2193813453696976e-10
mother O 0 1.865965160163796e-09
of O 0 8.94351437352725e-09
three O 0 7.187604733616126e-09
AS B-Disease 1 0.9999998807907104
sons O 0 3.8130460211505124e-07
, O 0 1.842228314341554e-10
in O 0 1.0947617812284705e-10
the O 0 1.5435972500199568e-09
maternal O 0 3.28800126681017e-07
grandfather O 0 2.554013690314605e-06
of O 0 9.238102620656718e-07
two O 0 2.657435160813293e-08
AS B-Disease 1 0.9999997615814209
first O 0 7.912523614095335e-08
cousins O 0 4.799563768642656e-08
, O 0 8.065930146017308e-10
and O 0 1.0795996041590428e-10
in O 0 2.3963298012574796e-10
the O 0 3.0640594506081698e-09
mother O 0 1.1461423810033011e-08
of O 0 7.392409173689884e-08
an O 0 9.197838046759443e-09
AS B-Disease 1 1.0
daughter O 0 0.011891953647136688
. O 0 4.822707069251919e-06

The O 0 7.224882381251518e-08
frequencies O 0 3.44857333800519e-08
with O 0 1.709166280727814e-10
which O 0 2.2413395792120205e-11
we O 0 1.776152662447128e-11
detected O 0 1.9488116675958622e-10
mutations O 0 1.0572425747368275e-11
were O 0 1.9022373953792027e-10
5 O 0 4.660498098552068e-10
( O 0 1.545121669499494e-11
14 O 0 4.66506888674445e-10
% O 0 2.4126183689743286e-11
) O 0 1.4022039605821046e-11
of O 0 1.1474585726034547e-09
35 O 0 2.270211574284531e-09
in O 0 1.7782078587380568e-10
sporadic O 0 4.403543751863026e-09
cases O 0 2.031900758758809e-10
and O 0 1.8102733201352805e-10
8 O 0 4.139682818760093e-09
( O 0 8.78401587578459e-11
80 O 0 1.043657604782311e-09
% O 0 1.0533483113528419e-10
) O 0 5.6597594666474293e-11
of O 0 1.5829084709650942e-09
10 O 0 3.062791575914048e-09
in O 0 2.778137164760608e-10
familial O 0 5.7840257028374253e-08
cases O 0 5.868074914872068e-09
. O 0 2.683445909923421e-09
. O 0 3.398295334022805e-08

The O 0 2.764135024335701e-05
hemochromatosis B-Disease 1 0.9999997615814209
845 O 0 1.0765855222416576e-05
G O 0 1.163453907793155e-05
- O 0 4.54085210321864e-07
- O 0 7.771241428145004e-08
> O 0 1.0688664175972917e-08
A O 0 2.5825352967245863e-09
and O 0 1.1455335985344206e-10
187 O 0 2.737529647411918e-10
C O 0 5.3960164336785965e-08
- O 0 7.802696266878684e-09
- O 0 3.3534790500056033e-09
> O 0 2.207982463531266e-09
G O 0 6.233108251763042e-09
mutations O 0 1.4557334504505803e-10
: O 0 1.8463080023178868e-11
prevalence O 0 3.661103087360118e-10
in O 0 1.0587444809750934e-10
non O 0 9.384926613620337e-08
- O 0 1.8704119497670035e-07
Caucasian O 0 2.637781619796442e-07
populations O 0 6.6073759796836384e-09
. O 0 6.83658640809881e-08

Hemochromatosis B-Disease 1 0.9998691082000732
, O 0 3.20347453452996e-07
the O 0 5.5600207815587055e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 6.991919008214609e-07
leads O 0 6.457385097746737e-07
, O 0 1.4984312457499982e-08
if O 0 6.763035997892075e-08
untreated O 1 0.9998118281364441
, O 0 3.8509031519140535e-09
to O 0 6.267000252080379e-09
progressive O 1 0.9999998807907104
iron B-Disease 1 1.0
overload I-Disease 1 0.9999998807907104
and O 0 0.0005553436349146068
premature B-Disease 0 0.001487891306169331
death I-Disease 0 9.831201168708503e-06
. O 0 6.015031885908684e-07

The O 0 3.3315773180220276e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.56580233326531e-06
, O 0 1.2136035820731195e-07
HFE O 0 7.253392686834559e-05
, O 0 5.3415192269312683e-08
recently O 0 2.200042459321594e-08
has O 0 1.5675996611896892e-10
been O 0 4.3913359060177015e-11
identified O 0 1.1977187297507186e-10
, O 0 2.848925262366464e-11
and O 0 2.946185309604665e-11
characterization O 0 5.37133892919428e-09
of O 0 5.911956257875772e-09
this O 0 8.249143729210928e-11
gene O 0 8.276192509093505e-10
has O 0 2.032497503634545e-10
shown O 0 1.2188072773255954e-10
that O 0 3.945017056083966e-12
it O 0 9.039431529689335e-13
contains O 0 1.472425480153472e-12
two O 0 1.969999901055286e-12
mutations O 0 7.74834450073536e-12
that O 0 2.4387946089693413e-12
result O 0 9.799427241885539e-11
in O 0 1.6219016407692521e-10
amino O 0 2.931019871255103e-10
acid O 0 7.93674570509495e-10
substitutions O 0 2.6696773680612296e-09
- O 0 2.3308177610203984e-09
cDNA O 0 2.5947157755723538e-09
nucleotides O 0 1.167918428635062e-09
845 O 0 2.334725657249237e-08
G O 0 1.1273377253928629e-07
- O 0 4.172200718244312e-08
- O 0 1.1844504044233872e-08
> O 0 4.509725037848966e-09
A O 0 3.3142706357125462e-09
( O 0 2.530139119050201e-11
C282Y O 0 9.668377209948176e-10
) O 0 1.510751766742313e-11
and O 0 3.210766721939429e-11
187 O 0 6.309370248480661e-10
C O 0 4.368727601899991e-08
- O 0 1.8365676979215095e-08
- O 0 2.4854163171994514e-08
> O 0 2.8692815234876434e-08
G O 0 4.3113951164741593e-07
( O 0 5.8948863568275556e-09
H63D O 0 5.92886817685212e-06
) O 0 2.6797337682182842e-08
. O 0 1.343886424365337e-07

Although O 0 1.5283285392797552e-05
hemochromatosis B-Disease 1 1.0
is O 0 9.344804929867223e-09
common O 0 1.6599721597287953e-09
in O 0 1.0597733801631648e-09
Caucasians O 0 5.994001739395571e-09
, O 0 2.398798937264246e-10
affecting O 0 1.4610305187900963e-09
> O 0 4.831967270746418e-09
= O 0 1.0044729492619808e-08
1 O 0 4.1778065451580915e-08
/ O 0 2.841482826809738e-09
300 O 0 6.480276038001165e-11
individuals O 0 1.0359293717981943e-12
of O 0 2.9378480204123036e-10
northern O 0 4.2583095383186276e-10
European O 0 8.158923536782936e-10
origin O 0 1.1787343323632626e-09
, O 0 9.087914448757672e-11
it O 0 8.933340178707283e-12
has O 0 3.227428740926186e-12
not O 0 8.19834651555329e-13
been O 0 4.883744884193186e-12
recognized O 0 2.018349549992582e-11
in O 0 4.033414574555749e-11
other O 0 3.340758225611751e-11
populations O 0 1.8422739722634418e-10
. O 0 2.6988255186211063e-08

The O 0 2.3566663287510892e-08
present O 0 2.2725552550895145e-09
study O 0 4.911221984649217e-10
used O 0 5.655572538065812e-11
PCR O 0 4.759402871812313e-10
and O 0 2.1954575310512148e-11
restriction O 0 6.46410702742628e-10
- O 0 6.852520217925928e-10
enzyme O 0 9.79554076740996e-11
digestion O 0 1.1378993303168272e-09
to O 0 9.904468217802886e-11
analyze O 0 1.0083884838252288e-09
the O 0 1.4690802740968678e-10
frequency O 0 4.23029344887027e-09
of O 0 7.67191199457784e-10
the O 0 3.5546202092895385e-10
845 O 0 3.856033714555451e-09
G O 0 3.058175579440103e-08
- O 0 8.747108815043703e-09
- O 0 3.504535772691497e-09
> O 0 9.493008601424435e-10
A O 0 6.05083483318225e-10
and O 0 4.328411240539509e-11
187 O 0 1.4798429148754622e-10
C O 0 2.41996378491649e-08
- O 0 5.159667360032927e-09
- O 0 5.000749592198872e-09
> O 0 2.2635271434978677e-09
G O 0 6.847166833523488e-09
mutations O 0 2.6617288928498795e-10
in O 0 2.855068403917471e-10
HLA O 0 7.420729808416127e-09
- O 0 1.6888616061194739e-09
typed O 0 9.166135628291272e-10
samples O 0 1.4411301318961733e-10
from O 0 1.8111367960926827e-10
non O 0 1.3592928560512973e-08
- O 0 4.424220545473645e-09
Caucasian O 0 1.6437274874547825e-09
populations O 0 1.774293906242619e-11
, O 0 1.740397409522032e-11
comprising O 0 3.0753975754915786e-11
Australian O 0 5.825116500268734e-10
Aboriginal O 0 3.4464406883927268e-09
, O 0 2.518882602497996e-10
Chinese O 0 2.178835556421177e-09
, O 0 2.567701051781057e-10
and O 0 5.00877506137698e-10
Pacific O 0 3.0170841114340874e-07
Islanders O 0 3.1612635211786255e-06
. O 0 2.1498047431123268e-07

Results O 0 1.774970996848424e-07
showed O 0 4.3667448323958524e-08
that O 0 1.5523536622819023e-10
the O 0 2.028741619142238e-09
845 O 0 2.0673557088457528e-08
G O 0 3.229991420994338e-07
- O 0 1.043628614638692e-07
- O 0 1.676429306485261e-08
> O 0 2.2123496368209317e-09
A O 0 4.2938611000131743e-10
mutation O 0 9.084877815312975e-12
was O 0 6.063728963390247e-10
present O 0 1.8677615010176396e-11
in O 0 1.416539715387577e-11
these O 0 1.1733982925934971e-12
populations O 0 1.7007994676260935e-13
( O 0 5.77655815976047e-13
allele O 0 5.026609337099863e-12
frequency O 0 8.649106431057874e-10
0 O 0 4.79649320261899e-10
. O 0 1.3610003748998345e-11
32 O 0 7.703936932834665e-10
% O 0 4.023733429781018e-11
) O 0 5.6915860913164806e-11
, O 0 6.108859945674894e-11
and O 0 5.1869356032518965e-11
, O 0 8.286660246881183e-11
furthermore O 0 1.0894671831351843e-09
, O 0 8.723874400651255e-11
it O 0 2.6805783287509044e-11
was O 0 6.694499621318073e-09
always O 0 5.583995488223081e-10
seen O 0 1.6888092313482872e-10
in O 0 1.3177537186437327e-11
conjunction O 0 4.584724613843072e-11
with O 0 1.0598456140487045e-10
HLA O 0 1.6596476370978053e-07
haplotypes O 0 1.9283613994502957e-07
common O 0 2.3291969242222876e-08
in O 0 1.7121077888759828e-08
Caucasians O 0 5.5099107498790545e-08
, O 0 1.0019350904499902e-09
suggesting O 0 2.0085280105774928e-09
that O 0 2.2586871262220143e-10
845 O 0 2.476855343047646e-08
G O 0 9.39046515213704e-07
- O 0 4.641022712803533e-07
- O 0 2.8256172868168505e-07
> O 0 4.765847805288104e-08
A O 0 2.5841924156111418e-08
may O 0 6.332989133106537e-10
have O 0 5.6248022732574565e-12
been O 0 7.319270189931615e-12
introduced O 0 8.85783720677713e-12
into O 0 1.125357511171099e-12
these O 0 2.0191561909879002e-13
populations O 0 9.781821755589296e-14
by O 0 1.0434615844989725e-11
Caucasian O 0 3.061309783447541e-08
admixture O 0 4.745294290842139e-07
. O 0 6.915827270859154e-07

187 O 0 1.5562350199616048e-06
C O 0 9.207000402966514e-06
- O 0 4.438041685261851e-07
- O 0 6.412512476572374e-08
> O 0 1.6871045005473206e-08
G O 0 4.176030188318691e-08
was O 0 5.812311965058825e-09
present O 0 2.5597793329446006e-10
at O 0 2.034445722998157e-09
an O 0 5.883307729881437e-12
allele O 0 2.336349447240593e-10
frequency O 0 1.8293377479494666e-08
of O 0 5.999563512659734e-08
2 O 0 1.54325130097277e-06
. O 0 2.9501438802981284e-07

68 O 0 4.711016572400695e-06
% O 0 1.808908400846576e-08
in O 0 2.830118583929675e-09
the O 0 1.0198877298250864e-09
two O 0 6.739564462066028e-11
populations O 0 1.889982744959773e-12
analyzed O 0 1.8278291380458e-10
( O 0 9.811728686470733e-12
Australian O 0 1.4314814611449123e-10
Aboriginal O 0 1.1834674351618446e-09
and O 0 2.2293174251064585e-10
Chinese O 0 7.561174797388048e-09
) O 0 1.0349354706562508e-09
. O 0 1.4590289865168415e-08

In O 0 2.2865611626343707e-08
the O 0 1.310591302150499e-09
Australian O 0 2.2070896221748626e-09
Aboriginal O 0 5.764976829247814e-10
samples O 0 7.656587863724695e-11
, O 0 3.6509548856367147e-11
187 O 0 2.2164031721061406e-10
C O 0 4.841951906087161e-08
- O 0 1.2320375830654484e-08
- O 0 1.0832474472977083e-08
> O 0 8.368548520820696e-09
G O 0 1.1657574106038737e-07
was O 0 4.137506337542618e-08
found O 0 1.875469779477612e-10
to O 0 8.94390984884641e-12
be O 0 1.4295026100341612e-11
associated O 0 2.300741819283303e-10
with O 0 1.2386645875661628e-10
HLA O 0 6.875934559502639e-07
haplotypes O 0 5.061465913058782e-07
common O 0 7.67172849691633e-08
in O 0 3.1794172627996886e-08
Caucasians O 0 1.0625917923334782e-07
, O 0 7.951867497801857e-10
suggesting O 0 7.798168777384262e-10
that O 0 1.353216930871648e-11
it O 0 5.666809903270842e-12
was O 0 3.078814980739253e-10
introduced O 0 4.959444313556993e-11
by O 0 6.98490874515012e-12
recent O 0 1.3829638823015244e-10
admixture O 0 5.6124253688949466e-08
. O 0 1.2031721041694254e-07

In O 0 3.25195443906523e-08
the O 0 1.010968975201365e-09
Chinese O 0 1.2458586384767045e-09
samples O 0 6.640369504262722e-11
analyzed O 0 2.0253075605491944e-10
, O 0 6.19466630769061e-11
187 O 0 3.544856908010985e-10
C O 0 2.2185457027035227e-08
- O 0 7.163571513757461e-09
- O 0 5.0258024408833535e-09
> O 0 2.4890538519173333e-09
G O 0 2.7037406979957268e-08
was O 0 4.618308402370985e-09
present O 0 1.313015113302285e-10
in O 0 1.555347101112048e-10
association O 0 1.03547205532184e-10
with O 0 1.7120692016869832e-11
a O 0 1.1969193691729885e-10
wide O 0 2.4748744720248794e-10
variety O 0 4.113227536350905e-10
of O 0 3.099698497877057e-09
HLA O 0 6.130602514531347e-08
haplotypes O 0 2.798877396514854e-08
, O 0 7.004273827604379e-10
showing O 0 1.0185716714516957e-09
this O 0 1.625933589155526e-11
mutation O 0 1.9804175660498302e-11
to O 0 3.394675165968586e-11
be O 0 6.649215900100813e-11
widespread O 0 1.6966805738150015e-10
and O 0 5.573532954605831e-11
likely O 0 2.344017757671679e-10
to O 0 4.682146337309234e-11
predate O 0 8.351104696657785e-09
the O 0 5.843511785563749e-10
more O 0 3.947525292757881e-11
genetically O 0 9.331668771039858e-11
restricted O 0 2.9246424726458997e-10
845 O 0 1.9606472889677207e-08
G O 0 4.3003404925912037e-07
- O 0 2.5868661168715334e-07
- O 0 1.5205401382445416e-07
> O 0 4.070812664735968e-08
A O 0 8.906064330460595e-09
mutation O 0 2.2423980450270165e-09
. O 0 1.584585795910698e-08

Genotype O 0 1.8142514818464406e-05
- O 0 2.278747388118063e-06
phenotype O 0 8.471575796420439e-08
correlations O 0 1.9252775018685497e-06
in O 0 2.3142519012253615e-07
attenuated B-Disease 1 0.6996058225631714
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999985694885254
coli I-Disease 1 0.9999979734420776
. O 0 2.6755602448247373e-05

Germ O 1 0.9917248487472534
- O 0 4.552324389806017e-05
line O 0 3.4285997685401526e-07
mutations O 0 5.372722267082963e-09
of O 0 2.5672224346351413e-09
the O 0 8.401009332636988e-10
tumor B-Disease 0 6.558948939527909e-08
suppressor O 0 4.196190843686054e-07
APC O 0 4.534845032821977e-08
are O 0 3.6947753190297306e-10
implicated O 0 1.1531817278864764e-07
in O 0 3.664410996861989e-08
attenuated B-Disease 1 0.9738031625747681
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 5.171811062609777e-05
AAPC B-Disease 1 1.0
) O 0 1.0866494370986857e-08
, O 0 2.6857999158025336e-10
a O 0 1.211518108057419e-10
variant O 0 1.2326573539667152e-07
of O 0 0.0004582906258292496
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 2.2735443053534254e-05
FAP B-Disease 0 7.643008757440839e-06
) O 0 1.2669995896885666e-07
. O 0 4.628650742688478e-07

AAPC B-Disease 1 0.9999996423721313
is O 0 4.142749432389792e-08
recognized O 0 1.6396694002551726e-09
by O 0 5.2039202808051854e-11
the O 0 1.6115651868542358e-10
occurrence O 0 3.1724192162130294e-09
of O 0 1.6906026800711516e-08
< O 0 3.3342135452585353e-07
100 O 0 5.4641443369973786e-08
colonic B-Disease 0 3.519711526678293e-06
adenomas I-Disease 0 2.8114002361689927e-06
and O 0 1.8659795930631162e-09
a O 0 1.2202943100447783e-09
later O 0 8.886670066488023e-09
onset O 0 0.00016086437972262502
of O 1 0.9203323125839233
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.7396143903170014e-07
age O 0 2.609291414046311e-07
> O 0 4.7462265229114564e-08
40 O 0 1.1843260594446292e-08
years O 0 4.340849901751653e-09
) O 0 1.4429571981722233e-09
. O 0 1.988327191781991e-08

The O 0 2.486972618953587e-07
aim O 0 2.498037190434843e-07
of O 0 1.261588966627869e-08
this O 0 7.72214583943942e-11
study O 0 2.491797879144997e-10
was O 0 1.3409420240861891e-09
to O 0 6.257617340965638e-11
assess O 0 1.2156695206044787e-08
genotype O 0 6.711147904070458e-08
- O 0 1.245743419531209e-07
phenotype O 0 1.7940919860848226e-08
correlations O 0 1.4326050177260186e-06
in O 0 8.517977221345063e-07
AAPC B-Disease 1 0.9999994039535522
families O 0 9.051772309476291e-08
. O 0 4.4900900775246555e-07

By O 0 2.4281519017677056e-08
protein O 0 1.1525572318760169e-07
- O 0 3.712035478997677e-08
truncation O 0 7.170477545059839e-08
test O 0 6.9217502840501766e-09
( O 0 2.0043709747508132e-10
PTT O 0 1.822977502285994e-08
) O 0 4.5966151024368074e-11
assay O 0 1.5387411345102464e-09
, O 0 8.571799520185053e-11
the O 0 8.6258888920554e-11
entire O 0 1.9348718183209712e-09
coding O 0 1.3944186605385767e-07
region O 0 2.7553166859206613e-08
of O 0 7.118379219406279e-09
the O 0 2.5414013116176193e-09
APC B-Disease 0 1.2595981147001112e-08
gene O 0 5.094364041724475e-09
was O 0 1.9130638406750222e-08
screened O 0 2.664463094603775e-09
in O 0 9.63451887714406e-11
affected O 0 3.43868926389046e-11
individuals O 0 2.0508771764182754e-11
from O 0 5.275621717260037e-09
11 O 0 1.2196082934678998e-06
AAPC B-Disease 1 0.9999992847442627
kindreds O 0 3.8810558180557564e-05
, O 0 7.298272652889182e-09
and O 0 2.0735260730653238e-10
their O 0 1.3343461058301642e-10
phenotypic O 0 4.5647496449419123e-07
differences O 0 6.357715278682008e-07
were O 0 4.61681359809063e-08
examined O 0 1.0294156709278468e-06
. O 0 9.120260813233472e-08

Five O 0 4.452119810594013e-07
novel O 0 2.7179086714568257e-07
germ O 0 0.00015034862735774368
- O 0 6.238326477614464e-07
line O 0 6.414653341835219e-08
APC B-Disease 0 1.722224851619103e-08
mutations O 0 1.750473210826442e-09
were O 0 2.6686425291799765e-10
identified O 0 5.295358596058009e-10
in O 0 2.5238371392788395e-09
seven O 0 3.9326440770537374e-08
kindreds O 0 1.0552642379479948e-05
. O 0 8.434298024440068e-07

Mutations O 0 6.709394995141338e-08
were O 0 2.4692706546147747e-08
located O 0 8.047400967825524e-09
in O 0 2.332448956199329e-10
three O 0 2.966094383993756e-11
different O 0 1.0462536219335572e-11
regions O 0 1.667078697309421e-10
of O 0 1.622945444701429e-09
the O 0 8.054353850539542e-10
APC B-Disease 0 3.959141903209229e-09
gene O 0 3.919432778332066e-09
( O 0 1.8127067624718052e-09
1 O 0 5.6310611284970946e-08
) O 0 2.3270897708815852e-10
at O 0 1.2629227441607327e-08
the O 0 1.087673284771995e-09
5 O 0 6.086628534518468e-09
end O 0 1.3624076089513437e-08
spanning O 0 4.450968660307808e-08
exons O 0 1.7077049108138453e-08
4 O 0 2.694330092367636e-08
and O 0 5.976190098344603e-10
5 O 0 9.861461869320465e-09
, O 0 5.182171913808986e-10
( O 0 2.2287649503738294e-10
2 O 0 4.562893174409055e-09
) O 0 5.200209360345376e-11
within O 0 4.987658619448609e-10
exon O 0 1.4778700041517823e-08
9 O 0 1.9091091374434654e-08
, O 0 2.4961552269608944e-10
and O 0 2.6835161870408797e-10
( O 0 2.3962107298380886e-10
3 O 0 1.0183468290847486e-08
) O 0 2.1079234191478946e-10
at O 0 1.485302014714307e-08
the O 0 5.7731996960797005e-09
3 O 0 6.994294210471708e-08
distal O 0 2.3178235153409332e-07
end O 0 6.519174888808266e-08
of O 0 3.567692274941692e-08
the O 0 1.3008766508448844e-08
gene O 0 4.9663050560866395e-08
. O 0 2.270572707629981e-07

Variability O 0 3.798577017732896e-05
in O 0 1.2685067218853874e-08
the O 0 7.56317619643454e-10
number O 0 2.5508906098536954e-09
of O 0 0.00010887801909120753
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0197819322347641
most O 0 1.201027166608526e-09
apparent O 0 1.0745265122125147e-08
in O 0 1.4098476552870665e-10
individuals O 0 4.135572960473066e-12
with O 0 3.8485499509466337e-11
mutations O 0 2.7470294927667283e-09
in O 0 9.539225409582741e-09
region O 0 5.798949018753774e-07
1 O 0 2.330967163288733e-06
, O 0 1.4302923290188119e-09
and O 0 1.963400775295554e-09
upper O 1 0.5677613615989685
- O 0 0.13617148995399475
gastrointestinal O 1 0.9999468326568604
manifestations O 1 0.9626516103744507
were O 0 1.0614513712425833e-07
more O 0 1.2474844768295412e-10
severe O 0 2.5200671771585803e-08
in O 0 5.160865623743405e-10
them O 0 1.1721094095307194e-09
. O 0 2.610054927743022e-08

In O 0 2.227279694011486e-08
individuals O 0 5.2425147556434126e-11
with O 0 2.5375929135762476e-10
mutations O 0 5.381490808531453e-09
in O 0 2.797706954993373e-09
either O 0 1.4118889168912574e-08
region O 0 2.2617615513809142e-07
2 O 0 4.3246012637609965e-07
or O 0 2.547681399178714e-09
region O 0 3.3674403709937906e-08
3 O 0 2.933886378286843e-08
, O 0 1.3394843567660075e-10
the O 0 1.2121374737272816e-10
average O 0 4.239174289377701e-11
number O 0 4.757766403074015e-11
of O 0 4.145798371268938e-09
adenomas B-Disease 0 5.171473844711727e-07
tended O 0 1.3217152705635726e-08
to O 0 2.6426025256931496e-10
be O 0 7.518445310772393e-10
lower O 0 1.440134234087509e-08
than O 0 6.234363025825473e-11
those O 0 1.2529015151752088e-11
in O 0 1.689272333127434e-11
individuals O 0 7.991616808415702e-13
with O 0 1.493048393252927e-11
mutations O 0 3.8553993331191805e-10
in O 0 1.0385106108401487e-09
region O 0 1.5168115652386405e-08
1 O 0 3.9386947037201026e-08
, O 0 1.1157579721254862e-10
although O 0 1.6063297914037378e-10
age O 0 2.1510171421823543e-09
at O 0 1.808597893671049e-08
diagnosis O 0 7.704120719154162e-08
was O 0 1.8675185842198516e-08
similar O 0 3.2438189911943027e-09
. O 0 6.673391084177638e-08

In O 0 4.3584614672909083e-07
all O 0 3.5997197755932575e-07
AAPC B-Disease 1 0.9999995231628418
kindreds O 0 2.518273140594829e-05
, O 0 4.994763269650093e-09
a O 0 1.2443577279697138e-09
predominance O 0 8.017239139235244e-08
of O 0 6.221138733053522e-07
right O 1 0.9879244565963745
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9998390674591064
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9853224754333496
sparing O 0 2.2802059902460314e-06
was O 0 5.51589323549706e-07
observed O 0 2.0697375191502942e-07
. O 0 5.30741708359983e-08

No O 0 1.886568497866392e-05
desmoid B-Disease 1 0.9986777901649475
tumors I-Disease 1 1.0
were O 0 1.7244772720914625e-07
found O 0 2.277289246066516e-09
in O 0 3.2291808116369225e-10
these O 0 5.04416175495237e-10
kindreds O 0 1.1815022844530176e-06
. O 0 1.35711474058553e-07

Our O 0 1.0453639021079653e-07
data O 0 2.1296107988177937e-08
suggest O 0 3.6558365223982037e-09
that O 0 1.0399967692586998e-10
, O 0 5.090495802662076e-10
in O 0 6.017989662154832e-09
AAPC B-Disease 1 0.9999997615814209
families O 0 3.045697860581953e-10
, O 0 6.735426799631128e-11
the O 0 1.751877636013699e-11
location O 0 4.630540118011339e-10
of O 0 1.366657009782557e-09
the O 0 2.1816926043527474e-09
APC B-Disease 0 1.0691461227452237e-07
mutation O 0 1.1339762906459327e-08
may O 0 1.4817000959510551e-08
partially O 0 2.7934001778362472e-08
predict O 0 1.390689075009277e-08
specific O 0 1.1774692332267023e-09
phenotypic O 0 1.5154428183450364e-06
expression O 0 1.4774760757063632e-06
. O 0 1.1711445040418766e-06

This O 0 2.2408983113564318e-08
should O 0 6.775532135350204e-09
help O 0 8.490412817252491e-10
in O 0 2.60374249938522e-10
the O 0 1.771072455358791e-10
design O 0 1.7842978650151053e-08
of O 0 8.781277927027986e-09
tailored O 0 3.1133859934584507e-09
clinical O 0 1.1558792323285161e-07
- O 0 1.131804605591924e-08
management O 0 6.435459720677272e-09
protocols O 0 1.814932772958855e-07
in O 0 2.792545084062681e-10
this O 0 2.4766425889277688e-12
subset O 0 6.527778873000045e-10
of O 0 1.4074303944511257e-09
FAP B-Disease 0 1.8802927215233467e-08
patients O 0 6.85098111574689e-09
. O 0 5.519595447367465e-09
. O 0 8.247315719245307e-08

Wilms B-Disease 1 0.9995684027671814
' I-Disease 0 1.963665636139922e-05
tumor I-Disease 0 1.3037865755904932e-05
1 O 0 6.873653546790592e-06
and O 0 4.5916184632233126e-08
Dax O 1 0.56437087059021
- O 0 9.408357186657668e-07
1 O 0 1.0474735745447106e-07
modulate O 0 1.7042719235860204e-08
the O 0 2.918224550896298e-09
orphan O 0 1.94386124974244e-08
nuclear O 0 1.0348495749212816e-07
receptor O 0 1.0812446493702055e-09
SF O 0 6.078799970055115e-07
- O 0 2.800260467950011e-08
1 O 0 1.2964477491550497e-08
in O 0 5.7119448060305444e-11
sex O 0 1.505339186635979e-10
- O 0 2.8146283914676218e-11
specific O 0 1.3341620343221283e-11
gene O 0 4.714282852980034e-10
expression O 0 7.619867403718672e-09
. O 0 7.97509898120552e-08

Products O 0 8.685583452461287e-08
of O 0 7.964625581280416e-08
steroidogenic O 0 2.862716428353451e-06
factor O 0 1.0164396968548317e-07
1 O 0 2.8625942150029005e-07
( O 0 3.663736536374529e-10
SF O 0 4.414373506733682e-07
- O 0 3.0668264372479825e-08
1 O 0 1.511197744719084e-08
) O 0 3.707204335179348e-11
and O 0 2.0986405668832475e-10
Wilms B-Disease 0 2.8472884878283367e-05
tumor I-Disease 0 3.883977569785202e-06
1 O 0 6.980485522944946e-06
( O 0 2.8194668821868163e-09
WT1 O 0 2.467945705575403e-07
) O 0 6.842568178733188e-10
genes O 0 4.6425585598086627e-10
are O 0 3.3868886861743164e-11
essential O 0 2.5817670223915457e-09
for O 0 8.097962855835306e-10
mammalian O 0 1.4730287034581124e-07
gonadogenesis O 0 3.887157618009951e-07
prior O 0 2.3147105565612947e-08
to O 0 2.630318851615243e-09
sexual O 0 4.073367776413761e-08
differentiation O 0 4.4896620465806336e-07
. O 0 4.092393339760747e-07

In O 0 1.6508109013102512e-07
males O 0 2.2118486597832998e-08
, O 0 1.617337552772824e-08
SF O 0 1.9418403098825365e-05
- O 0 5.680061008206394e-07
1 O 0 1.107896210328363e-07
participates O 0 6.637739247139507e-10
in O 0 5.91948712269641e-11
sexual O 0 1.3292833500599954e-10
development O 0 1.8502633453154615e-11
by O 0 3.716136773301848e-12
regulating O 0 3.731953857055714e-09
expression O 0 2.0693982083486162e-09
of O 0 2.0052743909815263e-09
the O 0 4.273877252103375e-09
polypeptide O 0 2.4789946451164724e-07
hormone O 0 5.3304358260675144e-08
Mullerian O 0 6.114178745519894e-07
inhibiting O 0 1.614889129086805e-07
substance O 0 8.995455573312938e-06
( O 0 4.36748592846925e-08
MIS O 0 1.2478979442676064e-05
) O 0 6.355939063951155e-08
. O 0 3.154299292873475e-07

Here O 0 1.2442121715139365e-06
, O 0 1.0177759079965654e-08
we O 0 7.18952009037821e-10
show O 0 1.263336546486471e-09
that O 0 1.770724677996327e-10
WT1 O 0 1.6359049368475098e-06
- O 0 1.1340387118252693e-06
KTS O 0 6.526697688968852e-05
isoforms O 0 1.2227067713865836e-07
associate O 0 5.553580422201776e-07
and O 0 2.6772088990156817e-09
synergize O 0 3.786877584843751e-07
with O 0 1.6646653833163327e-08
SF O 0 0.0025240015238523483
- O 0 1.0397347068646923e-05
1 O 0 5.222682375460863e-07
to O 0 1.2258604131787365e-09
promote O 0 8.332237655395147e-08
MIS O 0 3.5675537219503894e-05
expression O 0 7.170435765146976e-07
. O 0 4.5799768599863455e-07

In O 0 1.2762244239183929e-07
contrast O 0 3.251666385040153e-07
, O 0 2.105563012833045e-08
WT1 O 0 3.1877552828518674e-05
missense O 0 1.7919720676218276e-06
mutations O 0 4.4535674703638506e-08
, O 0 1.4590419983306901e-09
associated O 0 9.335736628202085e-09
with O 0 1.2549309369447315e-09
male B-Disease 0 4.219725724396994e-06
pseudohermaphroditism I-Disease 1 1.0
in O 0 3.1091174150787992e-06
Denys B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999972581863403
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 2.1768538260857895e-07
fail O 0 7.214596280391561e-07
to O 0 1.0414130890978868e-08
synergize O 0 5.732002591685159e-06
with O 0 2.0180742410502717e-07
SF O 1 0.9998873472213745
- O 0 0.021338526159524918
1 O 0 0.0001292330416617915
. O 0 3.1478776918447693e-07

Additionally O 0 3.587498440538184e-07
, O 0 6.3497203051099405e-09
the O 0 2.9746012319975534e-09
X O 0 6.6159309426438995e-06
- O 0 1.1950635325774783e-06
linked O 0 8.424733266565454e-08
, O 0 3.460799424814809e-10
candidate O 0 4.135151110418178e-10
dosage O 0 2.889624184376771e-08
- O 0 4.9038018090641344e-09
sensitive O 0 3.714046670211246e-08
sex O 0 9.236815756707983e-09
- O 0 1.2818416328386206e-09
reversal O 0 1.4096412925823643e-09
gene O 0 4.5106438029129947e-10
, O 0 1.3900598450078405e-09
Dax O 0 0.0002164507459383458
- O 0 3.302501170310279e-07
1 O 0 1.7001332253130386e-07
, O 0 6.412494424345994e-10
antagonizes O 0 2.1681328732370275e-08
synergy O 0 6.321711509826855e-08
between O 0 1.7864439882941952e-07
SF O 0 3.654382089735009e-05
- O 0 3.9915437355375616e-07
1 O 0 3.207949816896871e-08
and O 0 3.322015440510029e-10
WT1 O 0 1.2580319719290856e-07
, O 0 1.8269612211962993e-10
most O 0 1.3607745139032623e-11
likely O 0 3.9336284229918306e-11
through O 0 1.830294769911145e-11
a O 0 1.4375886592254972e-10
direct O 0 2.781350150193873e-10
interaction O 0 3.4513349955744843e-09
with O 0 1.0651969084563007e-08
SF O 0 0.0006565686780959368
- O 0 2.0121804482187144e-05
1 O 0 7.95650794316316e-06
. O 0 1.709334895849679e-07

We O 0 1.8588197292501718e-07
propose O 0 1.0015595819368173e-07
that O 0 9.311387216826006e-10
WT1 O 0 2.0311626940383576e-06
and O 0 4.348542503862518e-08
Dax O 1 0.8681107759475708
- O 0 3.101157744822558e-06
1 O 0 2.560700806952809e-07
functionally O 0 1.8486081998503323e-08
oppose O 0 9.282854485093139e-10
each O 0 2.001833074305459e-11
other O 0 1.7773456317815572e-11
in O 0 6.980942907075516e-11
testis O 0 1.5506802952813814e-08
development O 0 8.200297663130129e-10
by O 0 7.813861224725827e-10
modulating O 0 2.6702420541369065e-07
SF O 0 0.00012918598076794297
- O 0 1.303489443671424e-05
1 O 0 1.2338843589532189e-05
- O 0 1.768933088897029e-07
mediated O 0 4.154924795329862e-07
transactivation O 0 6.434139322664123e-06
. O 0 2.8481256464374383e-08
. O 0 7.694047354789291e-08

A O 0 1.3702501746593043e-06
mouse O 0 4.855028024053354e-08
model O 0 4.1613919421479295e-08
for O 0 2.5058946562239726e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 0.9999995231628418
- O 1 0.9999581575393677
centre O 1 0.9184262752532959
mutations O 0 1.7701678416415234e-06
. O 0 3.2936881666500994e-07

Imprinting O 0 1.190326383948559e-05
in O 0 5.452546858464302e-08
the O 0 1.2885982947352659e-08
15q11 O 0 2.2714866076967155e-07
- O 0 1.4475310727846136e-08
q13 O 0 1.7737381341476066e-08
region O 0 1.9018975283557893e-09
involves O 0 6.730036528068695e-10
an O 0 6.512007599823733e-11
imprinting O 0 1.5487582061268768e-07
centre O 0 4.311701104597887e-06
( O 0 2.3351565126006335e-09
IC O 0 2.311567612878207e-07
) O 0 5.623992382908227e-10
, O 0 2.8429342213698305e-10
mapping O 0 4.286588861646123e-09
in O 0 1.0307001918619108e-09
part O 0 1.0471750133689284e-09
to O 0 8.228750458805223e-10
the O 0 9.582024063092831e-09
promoter O 0 1.5337131117121316e-05
and O 0 3.977071560967715e-09
first O 0 2.5046086093993836e-08
exon O 0 7.746866117486206e-07
of O 0 4.904683805762033e-07
SNRPN O 0 0.000746331934351474
. O 0 2.473768745403504e-06

Deletion O 0 2.2222313873498933e-06
of O 0 1.273628669196114e-07
this O 0 8.956620445310648e-10
IC O 0 4.843619194616622e-07
abolishes O 0 6.053472390021852e-08
local O 0 8.077754021229566e-10
paternally O 0 7.894190190427253e-09
derived O 0 1.2165823903842465e-10
gene O 0 7.159779713550307e-11
expression O 0 7.528572903980901e-11
and O 0 1.5005881953689126e-11
results O 0 1.6481908893251074e-10
in O 0 1.3619918526330821e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.999987006187439
PWS B-Disease 1 1.0
) O 0 6.977051270951051e-06
. O 0 2.775381290121004e-06

We O 0 9.802207756592907e-08
have O 0 2.0388420118866435e-10
created O 0 1.8865163597947543e-10
two O 0 6.016284692655915e-11
deletion O 0 5.6499280809418906e-09
mutations O 0 4.103505535368868e-09
in O 0 8.356760616834435e-09
mice O 0 3.310683638346745e-08
to O 0 5.167585914733763e-09
understand O 0 6.107632543717045e-06
PWS B-Disease 1 1.0
and O 0 8.04442379376269e-09
the O 0 2.4682709209855602e-09
mechanism O 0 1.2917659830691264e-07
of O 0 9.398035238916691e-09
this O 0 1.1146609191214907e-09
IC O 0 6.957125606277259e-06
. O 0 4.0597637962491717e-07

Mice O 0 9.523296284896787e-06
harbouring O 0 7.24017854736303e-06
an O 0 1.0169066477772049e-08
intragenic O 0 3.239800435039797e-06
deletion O 0 5.549916295422008e-07
in O 0 7.862333895047868e-09
Snrpn O 0 3.0516666811308824e-06
are O 0 6.776032512867403e-10
phenotypically O 0 1.287596774091071e-06
normal O 0 8.76423058571163e-08
, O 0 1.7256954198963115e-10
suggesting O 0 4.754448501564923e-10
that O 0 8.907580402450765e-12
mutations O 0 6.91079748982304e-10
of O 0 7.652463551721667e-09
SNRPN O 0 1.8270906139150611e-06
are O 0 7.063945955954054e-11
not O 0 5.806234312788483e-11
sufficient O 0 8.183957511675999e-09
to O 0 5.761517485325385e-09
induce O 0 5.917344424233306e-06
PWS B-Disease 1 0.9999997615814209
. O 0 3.2357558666262776e-05

Mice O 0 1.1233523764531128e-06
with O 0 5.1331157102652014e-09
a O 0 3.273360027478134e-09
larger O 0 8.079633628810257e-10
deletion O 0 3.357448719043532e-08
involving O 0 1.6291272331159234e-08
both O 0 2.7898205967602507e-09
Snrpn O 0 4.779288360623468e-07
and O 0 1.6332146746123044e-09
the O 0 6.00774852088648e-09
putative O 0 3.1766901997798414e-07
PWS O 1 0.9999945163726807
- O 0 1.372739006910706e-06
IC O 0 1.1791643146352726e-06
lack O 0 1.8421212999442105e-08
expression O 0 1.2401590865351864e-09
of O 0 1.8066456108911666e-09
the O 0 5.857895835070792e-10
imprinted O 0 9.719357763060543e-09
genes O 0 1.970728025213475e-09
Zfp127 O 0 4.755963800562313e-07
( O 0 1.0615172074679435e-09
mouse O 0 9.823053481738953e-09
homologue O 0 2.5029666517184523e-07
of O 0 1.0739756817201851e-07
ZNF127 O 0 7.582706166431308e-05
) O 0 1.4893843491847747e-08
, O 0 3.284199223685391e-08
Ndn O 0 4.468131464818725e-06
and O 0 1.1789575538045938e-08
Ipw O 0 4.6019563342269976e-06
, O 0 3.7591010304538486e-09
and O 0 3.7710201628016193e-10
manifest O 0 2.6702338118411717e-08
several O 0 3.4614858201997833e-10
phenotypes O 0 2.4844066359719363e-08
common O 0 2.1864259736048552e-08
to O 0 3.934865446808544e-07
PWS B-Disease 1 1.0
infants O 1 0.9989650249481201
. O 0 6.043544090061914e-06

These O 0 6.149772246999419e-09
data O 0 1.4762472133611482e-08
demonstrate O 0 1.5062195046766647e-08
that O 0 9.110893289809852e-11
both O 0 3.7119041174094036e-10
the O 0 5.910284484045292e-10
position O 0 1.1938972477310017e-08
of O 0 3.965029193864211e-09
the O 0 9.291906133412908e-10
IC O 0 3.746526289205576e-08
and O 0 1.3891553185541028e-10
its O 0 6.794182404179505e-12
role O 0 3.0191557587322393e-10
in O 0 2.4181559532543417e-11
the O 0 9.94611164262249e-12
coordinate O 0 1.0839676378715524e-10
expression O 0 8.88617401884062e-10
of O 0 5.9523044271259096e-09
genes O 0 9.538819734089543e-10
is O 0 4.417430587988491e-10
conserved O 0 1.355337087005637e-08
between O 0 1.1397115251554624e-08
mouse O 0 5.5903068840734704e-09
and O 0 2.2410159838948118e-10
human O 0 1.4633173561762192e-09
, O 0 1.23072815827463e-10
and O 0 4.211482898530683e-11
indicate O 0 1.8417224689759593e-10
that O 0 7.074243968396843e-12
the O 0 1.6245023382044366e-10
mouse O 0 8.25783774693889e-10
is O 0 2.1279183276545766e-11
a O 0 1.4967437012014528e-11
suitable O 0 2.1783774784012166e-10
model O 0 2.2095231200225385e-10
system O 0 2.4235793372184844e-09
in O 0 2.0384764709557857e-10
which O 0 6.22601753139107e-12
to O 0 6.832192797623371e-12
investigate O 0 4.3008446803938227e-10
the O 0 6.195883389681356e-11
molecular O 0 5.913027401049931e-09
mechanisms O 0 1.0855023191425062e-07
of O 0 3.5614373672387956e-08
imprinting O 0 2.686707887278317e-07
in O 0 9.534564249236155e-10
this O 0 5.8187399343268e-11
region O 0 1.1497567342644288e-09
of O 0 5.196622576697507e-10
the O 0 1.2093893941855782e-10
genome O 0 6.254586432108411e-11
. O 0 4.0398689948872857e-10
. O 0 1.3484729777246685e-08

Mutations O 0 6.416122033670035e-08
of O 0 5.748194809029883e-08
the O 0 4.878296877564026e-09
ATM O 0 2.1941008299108944e-07
gene O 0 2.2300672419817147e-09
detected O 0 1.8302522164503898e-08
in O 0 8.028203102306009e-10
Japanese O 0 0.006210234947502613
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.0016630619065836072
: O 0 9.628791097782141e-10
possible O 0 4.789282748163259e-09
preponderance O 0 3.672930915854522e-06
of O 0 3.3006333666207865e-08
the O 0 4.900165162524672e-09
two O 0 5.582049489305518e-09
founder O 0 3.3777044450289395e-07
mutations O 0 1.3880575799873895e-08
4612del165 O 0 4.688114074724581e-07
and O 0 2.7873221952745553e-08
7883del5 O 0 5.0904413910757285e-06
. O 0 6.39026666249265e-07

The O 0 5.050617346569197e-07
ATM O 0 4.1742216126294807e-05
( O 0 9.768236850504763e-07
A O 1 0.9999982118606567
- O 1 0.9990670084953308
T O 1 0.9999954700469971
, O 0 2.4245594421046235e-09
mutated O 0 2.2931756493704825e-10
) O 0 2.8597757842363514e-11
gene O 0 1.86623494435878e-10
on O 0 4.517938467785143e-09
human O 0 4.148622778643585e-09
chromosome O 0 5.797190851808409e-07
11q22 O 0 4.7461358008149546e-06
. O 0 3.445017000558437e-07

3 O 0 2.4708859200472943e-05
has O 0 1.766856883023138e-08
recently O 0 2.1735944599754475e-08
been O 0 4.402743725151481e-10
identified O 0 1.7633940141426052e-10
as O 0 2.6945163114633353e-11
the O 0 2.071860738528386e-11
gene O 0 2.798632853240335e-11
responsible O 0 1.9800522332857895e-10
for O 0 1.0073684941769301e-11
the O 0 2.6577315348497166e-10
human O 0 2.183951892220648e-06
recessive B-Disease 1 0.9999995231628418
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999847412109375
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.814091312255186e-07
. O 0 4.4853095459984615e-07

In O 0 6.434136423649761e-08
order O 0 3.3241087660229596e-09
to O 0 1.2173854979646848e-10
define O 0 2.340136751044497e-09
the O 0 1.8391739520229322e-10
types O 0 3.2770330893328037e-09
of O 0 5.964147931081243e-08
disease O 0 0.00016062267241068184
- O 0 1.4057735597816645e-07
causing O 0 2.6557479770872305e-08
ATM O 0 1.110169705498265e-06
mutations O 0 1.8488575115327421e-09
in O 0 1.1200699256974644e-09
Japanese O 0 3.0608712222601753e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 1.0
patients O 0 3.0188081723281357e-07
as O 0 5.1923252364360906e-09
well O 0 7.428798132202985e-10
as O 0 1.5832367361579003e-10
to O 0 7.38340777406421e-11
look O 0 1.8285195579892388e-10
for O 0 4.971661970998298e-11
possible O 0 5.386099344306672e-10
mutational O 0 3.0572483211699364e-08
hotspots O 0 2.771788487621052e-08
, O 0 1.1100950159104173e-09
reverse O 0 1.8881921803881596e-08
- O 0 1.0459976884646949e-08
transcribed O 0 5.194623398097065e-09
RNA O 0 1.873082799974668e-09
derived O 0 2.1005146233488148e-10
from O 0 1.5398678165912116e-10
ten O 0 1.1573584313140373e-09
patients O 0 7.582209166079323e-11
belonging O 0 2.519305319914622e-10
to O 0 3.238449786113762e-11
eight O 0 7.280319125335666e-10
unrelated O 0 2.888114458698965e-08
Japanese O 0 3.593943802115973e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999896287918091
T I-Disease 1 1.0
families O 0 3.015903915493112e-10
was O 0 3.2801221738765207e-09
analyzed O 0 2.2621275685974496e-10
for O 0 1.2591206723089332e-11
mutations O 0 1.6848189510199063e-11
by O 0 8.813816863850743e-12
the O 0 5.5223908779211683e-11
restriction O 0 1.945383715229454e-10
endonuclease O 0 2.7790076906342165e-09
fingerprinting O 0 9.805420475572646e-09
method O 0 4.75143444589321e-08
. O 0 8.578435739536872e-08

As O 0 2.3803023907476017e-07
has O 0 1.3793265418726719e-09
been O 0 1.7717888267654303e-10
reported O 0 5.555585505523375e-11
by O 0 1.034241876168851e-11
others O 0 1.3933640352625787e-10
, O 0 9.467147898956085e-11
mutations O 0 2.320166975211535e-10
that O 0 1.9147887442283462e-10
lead O 0 1.3581630042835968e-08
to O 0 8.1724609302114e-09
exon O 0 3.7336615150707075e-06
skipping O 0 1.2170648915343918e-06
or O 0 3.785306645909259e-08
premature O 0 1.0706398967386122e-07
protein O 0 3.38854775350228e-08
truncation O 0 1.6254361412393337e-07
were O 0 6.099761140632154e-09
also O 0 3.729596353974074e-10
predominant O 0 3.707818052589573e-08
in O 0 9.738539974435412e-10
our O 0 6.6918444119323794e-09
mutants O 0 1.4276797344336956e-07
. O 0 6.015122977487408e-08

Six O 0 2.6145942300104252e-08
different O 0 1.2931419823836166e-10
mutations O 0 6.826429421735725e-10
were O 0 2.2619982276150807e-10
identified O 0 3.5814201604367213e-10
on O 0 5.32069233116772e-09
12 O 0 7.22049975365735e-09
of O 0 1.9575150389528062e-09
the O 0 1.444080521828539e-09
16 O 0 3.324414876715309e-08
alleles O 0 1.1582380388119873e-08
examined O 0 9.623968253436033e-07
. O 0 5.336804633770953e-07

Four O 0 1.2638653856811288e-07
were O 0 1.099508928348314e-08
deletions O 0 4.7445972484183585e-08
involving O 0 8.371585380473334e-08
a O 0 9.743840401199577e-09
loss O 0 1.1454545045808118e-07
of O 0 5.75059004859213e-07
a O 0 1.9705675313730353e-08
single O 0 6.6817178456801685e-09
exon O 0 2.6235719019496173e-07
exon O 0 2.7847269734593283e-07
7 O 0 4.3636310920192045e-07
, O 0 1.407302274714084e-08
exon O 0 6.827932566011441e-07
16 O 0 4.2248652221132943e-07
, O 0 2.8370974902713897e-08
exon O 0 9.004441494653292e-07
33 O 0 9.887982059808564e-07
or O 0 1.3105562857163022e-07
exon O 0 9.63928505370859e-06
35 O 0 5.352010248316219e-06
. O 0 1.1345645134497317e-06

The O 0 6.594278261218278e-07
others O 0 6.063306301484772e-08
were O 0 3.6031349015530623e-09
minute O 0 9.82436532126485e-09
deletions O 0 1.960631434982929e-09
, O 0 2.9968205694785865e-10
4649delA O 0 1.1837028246475256e-08
in O 0 2.11074890898999e-09
exon O 0 6.546662945083881e-08
33 O 0 7.505972376975478e-08
and O 0 1.674351435276833e-09
7883del5 O 0 1.3218570416029252e-07
in O 0 1.2444628438856853e-08
exon O 0 1.39280280109233e-06
55 O 0 1.7949190578292473e-06
. O 0 5.75954175019433e-07

The O 0 7.008743097003389e-08
mutations O 0 1.3323002256981908e-08
4612del165 O 0 7.0061503265606e-08
and O 0 4.558993460523908e-10
7883del5 O 0 1.088875656307664e-08
were O 0 3.841262308235116e-10
found O 0 8.571815479641032e-11
in O 0 1.043696379321446e-11
more O 0 5.133633860891773e-13
than O 0 8.850536406188048e-13
two O 0 3.3953148452503523e-12
unrelated O 0 1.8724244377210653e-10
families O 0 6.329996748120903e-13
; O 0 3.0869380402559488e-12
44 O 0 2.257954934137274e-10
% O 0 1.4251502755691092e-10
( O 0 1.1886472361943845e-10
7 O 0 6.863472012952343e-09
of O 0 1.3366756590471596e-08
16 O 0 1.2940143179207553e-08
) O 0 1.1979631175940142e-10
of O 0 9.268011358365413e-10
the O 0 2.602908166782214e-10
mutant O 0 5.691285220876807e-10
alleles O 0 2.533085963207782e-10
had O 0 2.0479358209257725e-09
one O 0 1.8036973303825476e-10
of O 0 1.2913384805912642e-09
the O 0 1.1940970434665132e-09
two O 0 2.735813575682755e-09
mutations O 0 2.882951832816616e-08
. O 0 1.5139188747070875e-07

The O 0 1.1788635134735159e-07
4612del165 O 0 2.917960273407516e-07
mutations O 0 1.9539452278394265e-09
in O 0 2.5088231492276236e-10
three O 0 3.2443291109185424e-11
different O 0 1.609493961718389e-11
families O 0 4.312611899537355e-12
were O 0 4.974070808017039e-11
all O 0 1.2828773633677404e-11
ascribed O 0 8.750491997666643e-10
to O 0 6.13588208020488e-11
the O 0 5.34197241996992e-10
same O 0 5.509392941860369e-09
T O 0 2.3065160803525941e-07
- O 0 3.817761395907837e-08
- O 0 1.2247252989538993e-08
> O 0 9.954681523538511e-10
A O 0 5.338601227755646e-10
substitution O 0 1.714651753914609e-10
at O 0 1.5893311111625508e-09
the O 0 1.1349098050228434e-10
splice O 0 1.9099386516785444e-09
donor O 0 4.490770533216448e-10
site O 0 5.145152748298187e-09
in O 0 1.1257976773038081e-08
intron O 0 1.5308551155612804e-05
33 O 0 1.9188810256309807e-05
. O 0 6.083090283937054e-06

Microsatellite O 0 3.981809277320281e-05
genotyping O 0 7.643154276593123e-06
around O 0 6.185028667005099e-08
the O 0 1.279975858636817e-08
ATM O 0 3.835870643342787e-07
locus O 0 2.0036507564213935e-08
also O 0 1.967464413610287e-09
indicated O 0 1.9541428475378098e-09
that O 0 1.930100176905647e-11
a O 0 1.177868497181933e-10
common O 0 2.2983558112255054e-10
haplotype O 0 9.906782949542503e-09
was O 0 3.782491830861545e-08
shared O 0 3.8542966040999715e-10
by O 0 1.3479566421392697e-11
the O 0 6.66048743935832e-11
mutant O 0 3.2067595800988613e-10
alleles O 0 3.708535978308447e-10
in O 0 7.150258163335366e-10
both O 0 3.679284432678287e-09
mutations O 0 8.330823675350985e-08
. O 0 2.3591472597672691e-07

This O 0 2.8767722426437103e-08
suggests O 0 3.0856668331580295e-08
that O 0 4.148658153124707e-11
these O 0 3.040519225283589e-11
two O 0 3.893768918405982e-10
founder O 0 5.8796064905664025e-08
mutations O 0 2.145657429508674e-09
may O 0 3.313335383836602e-09
be O 0 5.678934544839365e-10
predominant O 0 3.533115489062766e-08
among O 0 4.235278794340047e-11
Japanese O 0 6.730219492823153e-09
ATM O 0 1.4951601201573794e-07
mutant O 0 3.700287010133252e-08
alleles O 0 2.7882899544806605e-08
. O 0 1.288746318550693e-07

W474C O 0 2.2449841708294116e-05
amino O 0 7.278340490302071e-07
acid O 0 7.833297388515348e-08
substitution O 0 1.2372513680247721e-08
affects O 0 4.199230740908888e-09
early O 0 2.1878974187927724e-09
processing O 0 9.492543640021722e-09
of O 0 2.8345539249130525e-09
the O 0 7.145227187699277e-10
alpha O 0 6.405603159009843e-09
- O 0 1.0577417830504032e-09
subunit O 0 1.3344867433318086e-09
of O 0 4.294026911821902e-09
beta O 0 5.94187135050106e-08
- O 0 2.4648661778314818e-08
hexosaminidase O 0 7.637360965873086e-08
A O 0 6.032665478272747e-09
and O 0 6.953594644532046e-11
is O 0 1.843443626914354e-11
associated O 0 8.237387438825294e-10
with O 0 1.5518807350289876e-09
subacute O 0 0.0006013605743646622
G B-Disease 0 0.1709534227848053
( I-Disease 0 1.443704604753293e-07
M2 I-Disease 0 1.2982021871721372e-05
) I-Disease 0 7.605960661294375e-08
gangliosidosis I-Disease 0 1.1170428479090333e-05
. O 0 4.947405614075251e-07

Mutations O 0 1.5536961939233151e-07
in O 0 2.279380595382463e-08
the O 0 2.0293928315595622e-08
HEXA O 0 2.022994976869086e-06
gene O 0 5.175003092716679e-09
, O 0 4.337570580492667e-10
encoding O 0 1.9019772423689574e-09
the O 0 5.4033262308905705e-09
alpha O 0 7.515900790622254e-08
- O 0 6.65162014357179e-09
subunit O 0 7.0208088231993315e-09
of O 0 6.8722614265936954e-09
beta O 0 2.072012676990198e-07
- O 0 7.383826527984638e-08
hexosaminidase O 0 1.3337397319901356e-07
A O 0 5.653585688492058e-08
( O 0 3.6470032549473785e-10
Hex O 0 1.8537914314720183e-08
A O 0 1.1076041417368288e-08
) O 0 1.3468727522170099e-10
, O 0 6.125089324626742e-11
that O 0 9.90189440858158e-12
abolish O 0 1.175239550121887e-08
Hex O 0 3.36283854096564e-08
A O 0 1.6195593754986248e-09
enzyme O 0 2.541464372285418e-09
activity O 0 5.710733574915139e-08
cause O 1 0.84278404712677
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.403987870522542e-07
TSD B-Disease 0 8.16920874058269e-05
) O 0 2.4778983309658997e-09
, O 0 5.594570917644148e-10
the O 0 3.046373375781286e-09
fatal O 0 3.6611002087738598e-06
infantile B-Disease 0 1.3013676607442903e-06
form I-Disease 0 1.1069541727692922e-07
of I-Disease 0 0.014562309719622135
G I-Disease 1 0.6524918079376221
( I-Disease 0 2.2560758594636354e-08
M2 I-Disease 0 1.4268973700382048e-06
) I-Disease 0 1.8758035125188144e-09
gangliosidosis I-Disease 0 6.533240792805373e-08
, I-Disease 0 1.1205314454088011e-09
Type I-Disease 0 1.1608715055899665e-07
1 I-Disease 0 2.1002820176363457e-06
. O 0 1.689646182967408e-07

Less O 0 3.696827434396255e-06
severe O 0 2.4738494175835513e-05
, O 0 7.093010623293594e-08
subacute O 0 0.0005250340327620506
( O 0 3.401823178705854e-08
juvenile O 0 0.00016164964472409338
- O 0 3.0761626135245024e-07
onset O 0 6.491973908850923e-05
) O 0 2.538523391493186e-09
and O 0 2.420956413118347e-08
chronic O 1 0.9999998807907104
( O 0 3.523659941606638e-08
adult O 0 3.0058114930398006e-07
- O 0 2.7607384822658787e-07
onset O 0 1.952268121385714e-06
) O 0 2.1754419099462297e-10
variants O 0 9.585766624908842e-10
are O 0 1.0472658330817897e-11
characterized O 0 1.1530437021844975e-10
by O 0 4.086495464933337e-12
a O 0 7.641152988124844e-11
broad O 0 3.162027029102177e-10
spectrum O 0 6.800740415258133e-09
of O 0 4.2523845555919593e-10
clinical O 0 1.3230666562336069e-09
manifestations O 0 2.9065592155319564e-09
and O 0 3.8978684863133495e-11
are O 0 2.2057943579317785e-12
associated O 0 7.379029332010845e-11
with O 0 1.0393894078752908e-11
residual O 0 5.658094437421823e-07
levels O 0 8.00791440269677e-07
of O 0 1.707233394654395e-07
Hex O 0 2.2511783015488618e-07
A O 0 2.2728988469111755e-08
enzyme O 0 1.0398311545145589e-08
activity O 0 3.8416324343870656e-08
. O 0 8.782085814118545e-08

We O 0 1.925085086895706e-07
identified O 0 7.627883746863517e-08
a O 0 3.195412290324384e-08
1422 O 0 3.488995616862667e-06
G O 0 3.1361391847894993e-06
- O 0 5.147157935425639e-07
- O 0 2.0867426542281464e-07
> O 0 1.8825678793632505e-08
C O 0 3.54596352281078e-07
( O 0 9.602816458675889e-11
amino O 0 5.988627926889478e-10
acid O 0 5.84742476661404e-10
W474C O 0 6.608875668945302e-09
) O 0 2.2860168619187604e-11
substitution O 0 3.0118801896961145e-10
in O 0 5.534073893587177e-11
the O 0 3.6695393251795494e-11
first O 0 6.204989994040844e-11
position O 0 3.2486051626534618e-09
of O 0 2.5059321728804207e-08
exon O 0 1.1913125064211272e-07
13 O 0 5.795411084363877e-08
of O 0 7.108016575330112e-08
HEXA O 0 5.832390525029041e-05
of O 0 6.116738973105385e-07
a O 0 2.6626560511999742e-08
non O 0 6.784819106542272e-07
- O 0 1.4380019308646297e-07
Jewish O 0 1.0524235705133833e-08
proband O 0 3.674441131806816e-06
who O 0 6.839322441720697e-09
manifested O 0 3.634979250932702e-08
a O 0 5.5140394472630305e-09
subacute O 0 1.0526543974265223e-06
variant O 0 7.914741928516378e-08
of O 0 1.063182844518451e-05
G B-Disease 0 0.06448287516832352
( I-Disease 0 3.9939799023613887e-08
M2 I-Disease 0 1.3446056982502341e-05
) I-Disease 0 5.693809868034805e-08
gangliosidosis I-Disease 0 6.515659151773434e-06
. O 0 3.035175950572011e-07

On O 0 2.0108768694626633e-06
the O 0 7.845513749771271e-08
second O 0 1.8869758378059487e-07
maternally O 0 3.447209167006804e-07
inherited O 0 1.5962517352363648e-07
allele O 0 7.964774617619241e-09
, O 0 2.6838439803889003e-10
we O 0 3.2498472662956246e-11
identified O 0 8.340335366785467e-11
the O 0 1.0931592436813631e-10
common O 0 1.8579223493020436e-08
infantile O 0 0.20505718886852264
disease O 1 0.9856094717979431
- O 0 3.495235068839975e-05
causing O 0 0.00012016030814265832
4 O 0 0.00031745489104650915
- O 0 1.192111881209712e-06
bp O 0 4.906779338398337e-08
insertion O 0 1.60579833874408e-08
, O 0 2.4533639564339182e-09
+ O 0 6.134334284979559e-08
TATC O 0 1.3944767488283105e-05
1278 O 0 1.839390279201325e-05
, O 0 8.240424342886854e-09
in O 0 1.8541733481924894e-08
exon O 0 3.352596877448377e-06
11 O 0 1.8123328118235804e-06
. O 0 1.0056011205961113e-06

Pulse O 0 0.0008965719025582075
- O 0 1.4309938478618278e-06
chase O 0 1.939883453871971e-08
analysis O 0 7.452171657540418e-10
using O 0 1.27169164088059e-09
proband O 0 5.777410549967499e-08
fibroblasts O 0 3.818269256328222e-09
revealed O 0 5.3083049067481625e-09
that O 0 6.346272032192735e-12
the O 0 1.1496837509783475e-10
W474C O 0 1.7339513158631803e-09
- O 0 2.2302105995297694e-10
containing O 0 1.0274295303425163e-10
alpha O 0 9.732677774820786e-09
- O 0 1.5281708121150928e-09
subunit O 0 5.66180569094854e-09
precursor O 0 1.785561032363603e-08
was O 0 1.0280853501853926e-08
normally O 0 2.7493241017140235e-10
synthesized O 0 7.919733202577106e-10
, O 0 2.26170367156886e-11
but O 0 4.562999717655503e-12
not O 0 1.1143488475723329e-12
phosphorylated O 0 5.442844092096166e-11
or O 0 3.6782844131666437e-11
secreted O 0 1.5341423964532197e-10
, O 0 7.619700009842134e-11
and O 0 5.269261069140718e-11
the O 0 7.298477378014923e-10
mature O 0 2.234470564133062e-08
lysosomal O 0 4.718079708254663e-06
alpha O 0 2.3946952296682866e-06
- O 0 8.065568124493439e-08
subunit O 0 8.194614053991245e-08
was O 0 1.7040436262050207e-07
not O 0 1.941192762089372e-09
detected O 0 1.6305347116940538e-07
. O 0 5.7132609754262376e-08

When O 0 8.994015843200032e-08
the O 0 1.3663422393506153e-08
W474C O 0 9.181103166611138e-08
- O 0 2.674912069622337e-09
containing O 0 2.8614249858449625e-10
alpha O 0 4.665658970282038e-09
- O 0 2.915081509513584e-09
subunit O 0 6.815166653240112e-09
was O 0 1.689523543291216e-07
transiently O 0 2.760161805781536e-07
co O 0 8.367067749759372e-08
- O 0 1.4557729466346814e-09
expressed O 0 1.5769320571568102e-10
with O 0 2.5910783935101378e-11
the O 0 2.5944130177535385e-10
beta O 0 5.242239975444818e-09
- O 0 8.519027705489179e-10
subunit O 0 3.0474353596154913e-10
to O 0 1.5300803679618724e-10
produce O 0 3.855472885394562e-10
Hex O 0 5.6939622794516254e-08
A O 0 3.7684927178816e-08
( O 0 6.036253163976824e-10
alphabeta O 0 2.0777246589887e-08
) O 0 3.5204655857157263e-10
in O 0 3.1821336676784995e-09
COS O 0 8.411136150243692e-06
- O 0 6.473632083725533e-07
7 O 0 9.20846261465158e-08
cells O 0 6.271791974654661e-10
, O 0 2.9530616840744983e-10
the O 0 4.379452078762114e-10
mature O 0 2.0545163348373308e-09
alpha O 0 2.7793431556233372e-08
- O 0 1.6453083340195462e-09
subunit O 0 1.0408862660682416e-09
was O 0 6.063824109503457e-09
present O 0 3.0908767212345367e-10
, O 0 8.378825411270441e-11
but O 0 7.470764458450407e-12
its O 0 5.562379116336169e-12
level O 0 3.7222147586390975e-09
was O 0 2.983112423748935e-09
much O 0 1.4638384948639782e-10
lower O 0 5.407529979351011e-10
than O 0 3.0361826334340813e-12
that O 0 7.661956464254105e-13
from O 0 2.5935111697128477e-11
normal O 0 9.36439148446766e-10
alpha O 0 4.031811329241464e-09
- O 0 1.0994957166943209e-09
subunit O 0 1.046180697628074e-09
transfections O 0 2.763738216060574e-08
, O 0 5.483827975050204e-11
although O 0 2.2239906097287765e-11
higher O 0 7.317933065076332e-11
than O 0 3.249529768531434e-12
in O 0 1.84654028179132e-11
those O 0 6.118967312007673e-12
cells O 0 1.0219059973226585e-11
transfected O 0 7.693922166041034e-10
with O 0 1.5261011204747987e-11
an O 0 3.8887049830238496e-11
alpha O 0 1.6977862671296862e-08
- O 0 4.0782088817081785e-09
subunit O 0 1.2324254505813315e-08
associated O 0 3.558483641086241e-08
with O 0 1.3007402266396184e-08
infantile O 0 0.018137140199542046
TSD B-Disease 0 0.0029773388523608446
. O 0 2.388534994679503e-06

Furthermore O 0 1.1158738288941095e-06
, O 0 9.094339503690207e-09
the O 0 8.669371887037869e-10
precursor O 0 1.716381170524528e-08
level O 0 8.40159373183269e-08
of O 0 1.453642806126254e-08
the O 0 2.6987416745782866e-09
W474C O 0 3.5976224666001144e-08
alpha O 0 4.014118815121037e-08
- O 0 2.762245099319216e-09
subunit O 0 4.840518208482081e-09
was O 0 4.970360834022358e-08
found O 0 4.0559280933827324e-10
to O 0 1.1405867916813861e-10
accumulate O 0 1.4201230191801528e-09
in O 0 4.384483331953959e-10
comparison O 0 8.63741800305462e-10
to O 0 1.895855139544267e-10
the O 0 1.640344970965657e-09
normal O 0 1.1076426176259702e-07
alpha O 0 9.126888471655548e-07
- O 0 7.543129498799317e-08
subunit O 0 9.559555280702625e-08
precursor O 0 4.358141438842722e-07
levels O 0 2.8968844389964943e-07
. O 0 9.779424203770759e-08

We O 0 2.9765615749965946e-07
conclude O 0 3.9170288346213056e-07
that O 0 3.1416358403646427e-10
the O 0 3.1126496935485193e-09
1422 O 0 2.9147552140784683e-06
G O 0 2.3396037249767687e-06
- O 0 3.4193359965684067e-07
- O 0 6.338131441907535e-08
> O 0 8.179822152953875e-09
C O 0 1.3077108462766773e-07
mutation O 0 2.3007945548769726e-10
is O 0 4.03600035336904e-11
the O 0 5.937942498812632e-11
cause O 0 1.7440544564095717e-09
of O 0 2.5844684614639846e-08
Hex B-Disease 0 4.422111032909015e-06
A I-Disease 0 2.623641375976149e-05
enzyme I-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 5.889112841828137e-08
the O 0 4.1353363400276066e-08
proband O 0 8.123376574076246e-06
. O 0 1.289038920049279e-07

The O 0 8.030400522329728e-08
resulting O 0 1.868302490493079e-08
W474C O 0 1.1449115788764175e-07
substitution O 0 2.085570116605595e-08
clearly O 0 1.7564206089559775e-08
interferes O 0 5.0629407333246945e-09
with O 0 3.3093547346929597e-10
alpha O 0 2.362264694966143e-08
- O 0 1.4935910286340004e-09
subunit O 0 1.6154498849729748e-09
processing O 0 8.361527470412966e-09
, O 0 2.885604602487213e-11
but O 0 5.999928852362668e-12
because O 0 4.310596584539139e-12
the O 0 2.993208805812664e-11
base O 0 2.6996052615579913e-10
substitution O 0 6.312957379073225e-10
falls O 0 1.6633896038342755e-08
at O 0 1.474994792971529e-08
the O 0 6.519517148362297e-10
first O 0 1.8228504816697466e-10
position O 0 6.222085513485354e-09
of O 0 3.238745094336082e-08
exon O 0 1.9099982750958588e-07
13 O 0 6.141697639350241e-08
, O 0 1.978716746009468e-09
aberrant O 0 8.931087869257226e-09
splicing O 0 5.2370459968642535e-08
may O 0 1.8747813967934235e-08
also O 0 3.635405310120632e-10
contribute O 0 1.981458774835687e-09
to O 0 3.131126691258146e-09
Hex B-Disease 0 2.892773409257643e-05
A I-Disease 0 4.386594446259551e-05
deficiency I-Disease 0 0.42150068283081055
in O 0 2.851512093116071e-08
this O 0 2.853267844216134e-09
proband O 0 7.015376581875898e-07
. O 0 1.09375681844881e-08
. O 0 6.758432391507085e-08

Two O 0 4.3789889048184705e-08
frequent O 0 1.0232966474177374e-07
missense O 0 4.5167275857238565e-06
mutations O 0 9.79102196652093e-07
in O 0 2.936901410066639e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0005325317033566535

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.103741098518185e-07
an O 0 1.5097540199349169e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9999715089797974
by O 0 6.107293781809631e-09
early O 0 0.40921106934547424
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999358654022217
goiter B-Disease 1 1.0
. O 1 0.9545722603797913

A O 0 1.4755160009372048e-06
century O 0 1.8163663639825245e-07
after O 0 1.6782488732047796e-09
its O 0 1.1377983624716315e-11
recognition O 0 3.3366781559962533e-10
as O 0 3.349854393874807e-09
a O 0 1.3535958132138148e-08
syndrome O 0 2.2569868463051534e-07
by O 0 5.958583071397072e-10
Vaughan O 0 5.875261877008597e-07
Pendred O 0 1.2741368209390203e-06
, O 0 1.2592443754400051e-09
the O 0 4.10281630891518e-09
disease O 0 9.818483022172586e-07
gene O 0 1.7734711477146448e-08
( O 0 1.101143709547614e-08
PDS O 0 3.1172612580121495e-06
) O 0 2.5782140866681402e-09
was O 0 3.411003746123242e-08
mapped O 0 4.053092084177479e-09
to O 0 2.3394095549633676e-09
chromosome O 0 1.1127154948553653e-06
7q22 O 0 6.971877610340016e-06
- O 0 1.7248898984689731e-06
q31 O 0 5.0242133511346765e-06
. O 0 3.585117838156293e-07

1 O 0 9.321616744273342e-06
and O 0 7.619374464695738e-09
, O 0 8.689337027689703e-10
recently O 0 3.5689837751817777e-09
, O 0 1.502112462192784e-10
found O 0 5.086397969478185e-11
to O 0 3.535671755372505e-11
encode O 0 3.1077378448429727e-09
a O 0 3.2683644235476095e-08
putative O 0 3.329039145683055e-06
sulfate O 0 0.00015629590780008584
transporter O 0 0.002909274771809578
. O 0 6.022061370458687e-06

We O 0 2.1841710662329206e-08
performed O 0 1.911681479782601e-08
mutation O 0 1.1631871160711071e-10
analysis O 0 2.4531476849887213e-10
of O 0 9.896504726825128e-10
the O 0 1.174342623144753e-09
PDS B-Disease 0 4.6064522507549555e-07
gene O 0 4.258839503279432e-09
in O 0 1.0695531127424829e-09
patients O 0 1.804882132638852e-09
from O 0 1.6053872675669822e-09
14 O 0 9.134777378960734e-09
Pendred B-Disease 0 6.432713206550034e-08
families O 0 1.4925644054031295e-11
originating O 0 4.901087868880438e-10
from O 0 2.3643989544019917e-10
seven O 0 1.3174100699231417e-10
countries O 0 1.6006831277115552e-11
and O 0 3.986713043024892e-11
identified O 0 4.844764589506667e-10
all O 0 3.8812675295929466e-10
mutations O 0 1.7496995852184227e-08
. O 0 1.682907964095648e-07

The O 0 1.6006067937723856e-07
mutations O 0 1.6518999501613507e-08
include O 0 1.5506085304650696e-09
three O 0 4.547807408439297e-10
single O 0 4.567331512994599e-10
base O 0 7.58788765153895e-09
deletions O 0 1.0059261867922942e-08
, O 0 9.101710496395299e-10
one O 0 2.6296453903285055e-10
splice O 0 1.62717714857763e-08
site O 0 3.890771704817553e-09
mutation O 0 1.449674380538113e-09
and O 0 2.0917680920717885e-09
10 O 0 1.130946145622147e-07
missense O 0 1.3160612297724583e-06
mutations O 0 4.517036131801433e-07
. O 0 9.75439434114378e-07

One O 0 2.4625617811580014e-07
missense O 0 5.499190365299e-07
mutation O 0 5.908247668884314e-09
( O 0 1.9057029287949945e-09
L236P O 0 2.469133875138141e-08
) O 0 3.1120306331899883e-10
was O 0 1.7998948109720914e-08
found O 0 1.847309250013751e-10
in O 0 5.0067571616407847e-11
a O 0 9.678816081937214e-11
homozygous O 0 7.659362727396868e-11
state O 0 6.633154442381439e-11
in O 0 9.554912416831485e-11
two O 0 1.9392526473538396e-10
consanguineous O 0 1.1037010949621617e-07
families O 0 2.0459776234327265e-11
and O 0 6.658733980868803e-11
in O 0 1.0567008379425147e-10
a O 0 8.263568995747761e-11
heterozygous O 0 4.885703994150781e-11
state O 0 4.0514102489508375e-11
in O 0 4.919272975079103e-11
five O 0 2.8199588497646033e-11
additional O 0 7.734970303152622e-11
non O 0 2.931566029928945e-07
- O 0 2.0009638319606893e-06
consanguineous O 0 1.0430190741317347e-05
families O 0 8.193797640387857e-09
. O 0 2.451740215292375e-07

Another O 0 1.6913661511352984e-06
missense O 0 4.4696612349071074e-06
mutation O 0 1.4252060864805571e-08
( O 0 3.439269979921278e-09
T416P O 0 1.802740143830306e-07
) O 0 1.733759469324525e-09
was O 0 2.1644927628017285e-08
found O 0 5.681718984185125e-10
in O 0 1.7104445637627919e-10
a O 0 2.231904244753835e-10
homozygous O 0 1.5490114746441463e-10
state O 0 2.4096577511123485e-10
in O 0 4.4933581855310933e-10
one O 0 2.726097680927353e-10
family O 0 9.917246884816322e-11
and O 0 2.8871405266528427e-11
in O 0 1.0116976006946388e-10
a O 0 2.528741105400911e-10
heterozygous O 0 1.2837005070043261e-10
state O 0 3.610245991048089e-10
in O 0 6.121063100827939e-10
four O 0 1.253208758988933e-09
families O 0 2.9538560486486176e-10
. O 0 3.8142893288295454e-08

Pendred B-Disease 0 0.00031952420249581337
patients O 0 2.838500279267464e-07
in O 0 1.4345551413441626e-08
three O 0 3.190368413896749e-09
non O 0 6.990512133597804e-07
- O 0 1.7665977338765515e-06
consanguineous O 0 2.3264181436388753e-05
families O 0 3.5569056033857294e-10
were O 0 9.79917147425624e-10
shown O 0 3.780483148752012e-10
to O 0 2.0344590595522405e-11
be O 0 8.959794017826539e-11
compound O 0 1.6055464735487135e-09
heterozygotes O 0 1.1298116220359589e-08
for O 0 1.2356399237134497e-09
L236P O 0 2.1300866137607954e-07
and O 0 7.06038338904591e-09
T416P O 0 1.750826641000458e-06
. O 0 1.6072101516328985e-07

In O 0 1.0749409540267152e-07
total O 0 8.273859819496465e-09
, O 0 2.0129002908930715e-09
one O 0 2.830052303615105e-10
or O 0 5.533662417178675e-11
both O 0 5.944288117287755e-11
of O 0 5.045547313287102e-10
these O 0 5.983814572313451e-12
mutations O 0 2.546711973250293e-11
were O 0 6.905866156703411e-11
found O 0 1.9634736544982268e-11
in O 0 1.605563251794173e-11
nine O 0 2.1838980623911652e-10
of O 0 5.883459830435811e-10
the O 0 9.263239619805574e-10
14 O 0 1.2891735678977057e-08
families O 0 6.870708169071094e-11
analyzed O 0 2.652396702274018e-08
. O 0 4.861347591145204e-08

The O 0 1.945671534997473e-08
identification O 0 2.143106492269453e-08
of O 0 1.9420085095589457e-08
two O 0 1.093733326129609e-09
frequent O 0 1.6415194536989475e-08
PDS B-Disease 0 1.7542328123454354e-06
mutations O 0 2.9186253414081875e-09
will O 0 1.0322341592594597e-10
facilitate O 0 2.6723518953275516e-09
the O 0 4.407129661210263e-10
molecular O 0 4.231034438362258e-07
diagnosis O 0 5.343025623005815e-05
of O 0 6.912025128258392e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.584725194144994e-05

Insertional O 0 2.409789703960996e-05
mutation O 0 3.183112440297009e-08
by O 0 1.9408743501259096e-09
transposable O 0 2.1073699826956727e-05
element O 0 1.0728225561251747e-06
, O 0 1.1136797262167875e-08
L1 O 0 3.237021019231179e-06
, O 0 2.644666041717869e-09
in O 0 6.113455852663208e-10
the O 0 4.509527418150583e-09
DMD B-Disease 1 0.9999971389770508
gene O 0 4.211374360352238e-09
results O 0 2.789458664054223e-09
in O 0 3.876637677535655e-09
X B-Disease 1 0.9998761415481567
- I-Disease 1 0.9998217225074768
linked I-Disease 1 0.9969084858894348
dilated I-Disease 1 0.9998706579208374
cardiomyopathy I-Disease 1 1.0
. O 1 0.6126305460929871

X B-Disease 1 0.9999929666519165
- I-Disease 1 0.9999990463256836
linked I-Disease 1 0.9999436140060425
dilated I-Disease 1 0.9999773502349854
cardiomyopathy I-Disease 1 1.0
( O 0 6.747001316398382e-05
XLDCM B-Disease 1 0.9842740893363953
) O 0 5.289738425062751e-09
is O 0 2.2395417464959877e-10
a O 0 2.979653468404564e-10
clinical O 0 7.673993884793617e-09
phenotype O 0 4.885671422982796e-09
of O 0 1.225168517748898e-07
dystrophinopathy B-Disease 0 4.372101102489978e-06
which O 0 3.087529953926804e-10
is O 0 3.1743833256436815e-11
characterized O 0 1.1143585360029462e-10
by O 0 1.2317372816150751e-11
preferential O 0 4.3822641515589567e-08
myocardial B-Disease 0 0.2077445536851883
involvement I-Disease 0 1.5797731123257108e-07
without O 0 3.173702189940286e-09
any O 0 5.903592059652851e-10
overt O 0 7.0083130410125705e-09
clinical O 0 3.7036762989828276e-08
signs O 0 2.779182182166551e-07
of O 0 0.00027463267906568944
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9988705515861511

To O 0 3.2674403183108325e-09
date O 0 5.289196280955366e-08
, O 0 1.1578524250488442e-10
several O 0 6.772007000305225e-12
mutations O 0 1.5851644996622838e-10
in O 0 6.146168574083788e-10
the O 0 5.548304216063116e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 0.9999995231628418
gene O 0 4.309998621465638e-05
, O 0 7.254056527017383e-06
DMD O 1 1.0
, O 0 1.0355797108729803e-08
have O 0 4.474403833554241e-11
been O 0 2.7507808531002098e-11
identified O 0 8.134506956913867e-11
in O 0 1.287358830648344e-10
patients O 0 3.1056623939207384e-10
with O 0 4.931902108928909e-10
XLDCM B-Disease 0 0.016724498942494392
, O 0 2.1109582970524343e-09
but O 0 8.397160050632735e-11
a O 0 6.776572358813127e-11
pathogenic O 0 2.6479760051323353e-10
correlation O 0 9.104818565752737e-10
of O 0 4.2270814626377273e-10
these O 0 2.375223108475044e-11
cardiospecific O 0 3.609994791986537e-08
mutations O 0 2.2851909253773783e-09
in O 0 6.777496341925371e-09
DMD O 1 0.9999603033065796
with O 0 2.2038675329127955e-09
the O 0 1.4263047631857262e-08
XLDCM B-Disease 0 1.8296877897228114e-05
phenotype O 0 2.3539438842590243e-08
has O 0 1.9854764499172006e-09
remained O 0 5.28899448681841e-08
to O 0 2.806781196351693e-10
be O 0 1.0471469247264054e-09
elucidated O 0 5.929139661020599e-06
. O 0 2.762647852705413e-07

We O 0 1.8556740144504147e-07
report O 0 4.5792232228336616e-09
here O 0 4.782425011562452e-10
the O 0 5.43704387068189e-11
identification O 0 2.233071089152716e-10
of O 0 1.6885716158654418e-09
a O 0 5.37343669559931e-10
unique O 0 1.8136196988649544e-09
de O 0 1.0323965398129076e-06
novo O 0 3.99271243622934e-07
L1 O 0 8.02034946900676e-07
insertion O 0 8.110738036748444e-08
in O 0 1.0162551689063548e-08
the O 0 8.34412983152788e-09
muscle O 0 6.662504148380322e-08
exon O 0 4.102412560769153e-07
1 O 0 6.249068178476591e-07
in O 0 2.5324894181721902e-08
DMD O 1 0.9999949932098389
in O 0 1.0765203839468995e-08
three O 0 2.33396746374126e-09
XLDCM B-Disease 0 5.064207016403088e-06
patients O 0 4.17005052710806e-09
from O 0 5.99319871508186e-10
two O 0 3.4486483113660427e-10
unrelated O 0 1.33749171737918e-08
Japanese O 0 7.77170114929504e-08
families O 0 5.946785841537405e-10
. O 0 2.687396261080721e-08

The O 0 1.519896386525943e-07
insertion O 0 2.081412020515927e-07
was O 0 1.585204699949827e-06
a O 0 2.082271066683461e-08
5 O 0 2.073808857971926e-08
- O 0 1.067602561910519e-09
truncated O 0 4.5896611511331287e-10
form O 0 2.7563334947799945e-10
of O 0 4.056935676288731e-09
human O 0 1.7624535164628696e-09
L1 O 0 8.291225128687074e-08
inversely O 0 3.536601056453037e-08
integrated O 0 5.484463372340542e-08
in O 0 3.344349519540657e-10
the O 0 7.397309986778566e-10
5 O 0 5.161616467574959e-09
- O 0 1.485284339963755e-09
untranslated O 0 1.0040324696092284e-06
region O 0 5.373377742756702e-09
in O 0 2.676942001400562e-10
the O 0 1.315685671521294e-09
muscle O 0 1.4328707109712013e-08
exon O 0 1.9114105498374556e-07
1 O 0 2.229543412113344e-07
, O 0 3.5802111275629045e-10
which O 0 1.1281561622389358e-11
affected O 0 1.6701967933685502e-11
the O 0 7.39344141464926e-11
transcription O 0 2.419320965785232e-09
or O 0 1.9953155794283362e-10
the O 0 6.305424515851143e-10
stability O 0 3.136717623419827e-07
of O 0 2.983307467729901e-08
the O 0 2.858028258501122e-09
muscle O 0 4.4772772156420615e-09
form O 0 4.042584489383216e-09
of O 0 1.7697007592687442e-07
dystrophin O 0 4.003590845513827e-07
transcripts O 0 1.0525283045126343e-07
but O 0 7.22377088702153e-11
not O 0 3.832286484678482e-12
that O 0 2.226485272191492e-12
of O 0 1.357938761437083e-10
the O 0 6.469411117926427e-10
brain O 0 9.691770173958503e-06
or O 0 1.2450231068328321e-08
Purkinje O 0 3.881266820826568e-06
cell O 0 1.4598105053664767e-06
form O 0 4.0308908211272865e-08
, O 0 2.8740672064486716e-09
probably O 0 1.026121965175264e-09
due O 0 8.168919984896661e-10
to O 0 2.6986668108519574e-11
its O 0 7.726650916306532e-12
unique O 0 9.52579751190008e-11
site O 0 3.3931688014909867e-10
of O 0 2.0619674856448e-09
integration O 0 4.7331320729426807e-07
. O 0 7.981709018167749e-07

We O 0 1.9548451746231876e-07
speculate O 0 3.328805320279571e-08
that O 0 2.7441831793040272e-11
this O 0 9.109673952678587e-12
insertion O 0 7.842349547537708e-10
of O 0 1.0087038981865248e-09
an O 0 1.4361689615327577e-10
L1 O 0 1.0780680526067954e-07
sequence O 0 1.2437176621915569e-08
in O 0 3.5035750300949076e-08
DMD O 1 0.9999995231628418
is O 0 8.56591964026876e-10
responsible O 0 7.540936208805249e-10
for O 0 5.4312603026129835e-11
some O 0 4.793040530443049e-12
of O 0 1.2849596386921291e-10
the O 0 2.1452626133844355e-11
population O 0 1.3674397985469211e-12
of O 0 9.751546792280408e-11
Japanese O 0 1.534735183383873e-08
patients O 0 6.296735355348915e-10
with O 0 3.4707278717682755e-10
XLDCM B-Disease 0 4.796864686795743e-06
. O 0 1.217537537456792e-08
. O 0 7.549751046553865e-08

Severe O 0 0.00022528957924805582
early O 0 0.00847504660487175
- O 1 0.9997974038124084
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 5.1895767683163285e-05
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9766497611999512
red O 0 0.0004414516733959317
hair O 0 0.00463582668453455
pigmentation O 0 0.007631212938576937
caused O 0 8.319659059452533e-07
by O 0 9.330022088249734e-09
POMC O 0 0.0006339674000628293
mutations O 0 1.5180798129676987e-07
in O 0 6.120298223777354e-08
humans O 0 6.821046554250643e-07
. O 0 1.8934564138817223e-07

Sequential O 0 2.478260057614534e-06
cleavage O 0 1.4465368849414517e-06
of O 0 2.9873706353100715e-07
the O 0 1.1709883729338344e-08
precursor O 0 6.061051749384205e-08
protein O 0 1.2836822271822257e-08
pre O 0 3.5505723872120143e-07
- O 0 1.6289415327719325e-07
pro O 0 4.163748599239625e-06
- O 0 6.285665676841745e-07
opiomelanocortin O 0 1.167152845482633e-06
( O 0 1.2975949204019344e-09
POMC O 0 9.695624214600684e-08
) O 0 1.784255382331068e-10
generates O 0 2.8361640813656663e-10
the O 0 1.0183734966418e-09
melanocortin O 0 1.9890485702944716e-07
peptides O 0 1.507339475459446e-09
adrenocorticotrophin O 0 3.796362477714865e-07
( O 0 6.341123737207965e-10
ACTH O 0 2.0879623363612154e-08
) O 0 4.6088904914753925e-10
, O 0 1.090735501918516e-09
melanocyte O 0 3.895466988979024e-07
- O 0 6.438580726353393e-07
stimulating O 0 2.2801140175943146e-07
hormones O 0 4.4821319988841424e-08
( O 0 9.431969649753569e-10
MSH O 0 2.897649835631455e-07
) O 0 3.8901240562161377e-10
alpha O 0 1.917447711718978e-08
, O 0 2.601488746645231e-10
beta O 0 8.333946865946018e-10
and O 0 8.087353703389866e-11
gamma O 0 1.8912258425984874e-09
as O 0 1.7452217448976626e-10
well O 0 5.4392945009196225e-11
as O 0 2.996716416681089e-11
the O 0 8.285759578452456e-11
opioid O 0 6.071001479313054e-08
- O 0 3.364051082144215e-08
receptor O 0 2.906764606791512e-09
ligand O 0 2.0391634336647257e-07
beta O 0 9.907465027936269e-06
- O 0 5.936676188866841e-06
endorphin O 0 1.4130996532912832e-05
. O 0 3.8151046055645566e-07

While O 0 2.719368126236077e-07
a O 0 2.3900602386106584e-08
few O 0 1.93811833248958e-09
cases O 0 1.1536779309651024e-09
of O 0 4.8744858816007763e-08
isolated O 0 4.93399556944496e-06
ACTH B-Disease 0 0.0009522262844257057
deficiency I-Disease 1 0.9963808655738831
have O 0 6.13783113223576e-09
been O 0 3.2692979434756353e-09
reported O 0 1.4806483816798277e-09
( O 0 1.572324909160372e-10
OMIM O 0 1.1878897510086972e-07
201400 O 0 1.0363032743043732e-07
) O 0 3.3419331191275603e-10
, O 0 2.5736240916174324e-10
an O 0 1.371121771676087e-09
inherited O 1 0.9936360120773315
POMC O 1 0.9999887943267822
defect O 1 0.9899842739105225
has O 0 2.403614907109386e-08
not O 0 4.95879393103138e-10
been O 0 1.7563391851993515e-09
described O 0 2.3674731064460275e-09
so O 0 2.0249134313754524e-10
far O 0 3.467818476821094e-09
. O 0 1.2465390497595763e-08

Recent O 0 2.4574349666295348e-08
studies O 0 1.7488622106043294e-08
in O 0 8.621420244381284e-10
animal O 0 9.021910440942804e-10
models O 0 1.1315796077937534e-09
elucidated O 0 8.495181305079313e-07
a O 0 4.831109734482197e-09
central O 0 1.2356594858431436e-08
role O 0 6.254210926925907e-09
of O 0 5.530758429017624e-08
alpha O 0 1.2760606296069454e-06
- O 0 1.5697995081609406e-07
MSH O 0 7.916098638816038e-07
in O 0 2.7690594261997603e-10
the O 0 1.0294697039281431e-10
regulation O 0 2.7258078016956233e-09
of O 0 3.46529083206093e-10
food O 0 5.3835078756003796e-11
intake O 0 1.1027415959541376e-11
by O 0 3.891832331664319e-13
activation O 0 1.500508883811591e-10
of O 0 2.3504207469216e-09
the O 0 2.8532569640304928e-09
brain O 0 1.1113963864772813e-06
melanocortin O 0 2.43505905928032e-06
- O 0 1.3403422371993656e-07
4 O 0 8.450482624766664e-08
- O 0 7.096728982247669e-09
receptor O 0 7.070757312988007e-10
( O 0 4.915879925349032e-10
MC4 O 0 6.085737709327077e-07
- O 0 1.866304870645763e-07
R O 0 7.523472618231608e-07
; O 0 9.886581553431029e-10
refs O 0 1.5480655690680578e-07
3 O 0 3.515047808377858e-08
- O 0 1.9298738163087137e-09
5 O 0 3.6616826237789724e-10
) O 0 3.3955802579421768e-12
and O 0 4.8148386319613046e-12
the O 0 3.713942001160042e-11
linkage O 0 5.225927690588605e-09
of O 0 1.4803920755923627e-08
human O 0 5.460757392938831e-07
obesity B-Disease 1 0.9999998807907104
to O 0 4.495752214950244e-09
chromosome O 0 6.952847115826444e-07
2 O 0 7.491754558941466e-07
in O 0 7.1852466199118226e-09
close O 0 7.945007496346079e-08
proximity O 0 4.8626738191615004e-08
to O 0 2.7797129042994584e-09
the O 0 1.682406391978475e-08
POMC O 0 1.5507002899539657e-06
locus O 0 4.3640138613909585e-08
, O 0 4.028775091313719e-09
led O 0 5.630969579506484e-10
to O 0 5.961978827295766e-11
the O 0 2.8913027527721624e-10
proposal O 0 7.472211738246415e-10
of O 0 1.4508445556060678e-09
an O 0 3.1567964908774115e-10
association O 0 8.681356966633302e-09
of O 0 1.7508021699086385e-07
POMC O 0 0.00015998253365978599
with O 0 1.2828836304379365e-07
human O 0 0.026694001629948616
obesity B-Disease 1 1.0
. O 0 6.161789769976167e-06

The O 0 5.0239453486256025e-08
dual O 0 3.820438791990455e-07
role O 0 1.634362831737235e-07
of O 0 2.9990798111612094e-07
alpha O 0 3.3849903502414236e-06
- O 0 1.5845063217057032e-06
MSH O 0 4.259587058186298e-06
in O 0 1.1627329099539452e-09
regulating O 0 1.0793623061999824e-07
food O 0 1.0892428070619076e-09
intake O 0 9.940565037780402e-10
and O 0 2.6154342580575474e-10
influencing O 0 2.532874248117878e-07
hair O 0 3.634154666087852e-07
pigmentation O 0 5.608267201751005e-07
predicts O 0 8.132530204818522e-09
that O 0 1.6629111282417952e-11
the O 0 1.6735907104603598e-10
phenotype O 0 2.5993660002221475e-10
associated O 0 7.150203207295647e-10
with O 0 1.1379205216988098e-10
a O 0 1.1995694215727326e-08
defect O 0 7.32239698209014e-07
in O 0 3.902873757510861e-08
POMC O 0 4.9243685680266935e-06
function O 0 3.478174335214135e-07
would O 0 4.447097357029861e-09
include O 0 8.945291796180754e-08
obesity B-Disease 1 1.0
, O 0 2.151936406846744e-09
alteration O 0 2.233357918157708e-06
in O 0 1.516778809218522e-07
pigmentation O 0 0.3722298741340637
and O 0 5.332833097781986e-06
ACTH B-Disease 1 0.9181132316589355
deficiency I-Disease 1 0.9999732971191406
. O 0 9.469313226873055e-06

The O 0 1.5284958010397531e-07
observation O 0 1.573138069943525e-05
of O 0 3.6164799155358196e-08
these O 0 5.315506368397394e-10
symptoms O 0 5.248546131042531e-07
in O 0 1.4640375578522935e-09
two O 0 7.33264893248986e-10
probands O 0 1.2100278468096803e-07
prompted O 0 1.6911438915911958e-09
us O 0 2.38799813256918e-10
to O 0 2.8154444053907213e-11
search O 0 6.37157882010797e-10
for O 0 2.0572170356114583e-10
mutations O 0 1.0360928781594225e-09
within O 0 2.632005058345044e-09
their O 0 3.09145620214224e-09
POMC O 0 1.4812184417678509e-05
genes O 0 1.8939999790745787e-07
. O 0 2.631791176099796e-07

Patient O 0 1.5513420294155367e-05
1 O 0 1.1005286978615914e-05
was O 0 6.643779784099024e-07
found O 0 8.049746424987347e-10
to O 0 5.039985442878425e-11
be O 0 1.090928458680196e-10
a O 0 2.5879631770919787e-10
compound O 0 2.4638542317489964e-09
heterozygote O 0 2.2443373381975107e-08
for O 0 3.378225477135288e-10
two O 0 2.434521473304585e-10
mutations O 0 2.420150468918081e-10
in O 0 2.959728240270465e-09
exon O 0 1.3233832873993379e-07
3 O 0 1.491699066491492e-07
( O 0 4.1329903388565015e-10
G7013T O 0 2.776275387361693e-08
, O 0 1.088511725200192e-09
C7133delta O 0 4.34986944242155e-08
) O 0 9.035976827886927e-11
which O 0 1.0600715617814505e-11
interfere O 0 1.7471167568228196e-10
with O 0 2.637066346539152e-12
appropriate O 0 2.266342530310439e-10
synthesis O 0 9.2868788215128e-09
of O 0 1.922299652790116e-08
ACTH O 0 2.1516814285860164e-07
and O 0 1.4598612096961006e-08
alpha O 0 1.419170257577207e-05
- O 0 1.2054651051585097e-05
MSH O 0 0.0002991399960592389
. O 0 9.94125343822816e-07

Patient O 0 1.5367395462817512e-05
2 O 0 3.70554585060745e-06
was O 0 1.267859062181742e-07
homozygous O 0 9.2443186439084e-10
for O 0 2.1671839323111897e-10
a O 0 2.3687546368833523e-10
mutation O 0 9.898085823190073e-11
in O 0 1.5109953288572342e-09
exon O 0 1.6248037582045072e-07
2 O 0 3.8562384929718974e-07
( O 0 1.2137529870059893e-09
C3804A O 0 3.2013971917876916e-08
) O 0 9.686854651747012e-10
which O 0 1.5454975077489053e-09
abolishes O 0 5.956969175713311e-07
POMC O 0 3.595704401959665e-05
translation O 0 4.374566287879134e-06
. O 0 1.993885007323115e-06

These O 0 1.0703904429476552e-08
findings O 0 6.1008553764452245e-09
represent O 0 9.092496755513935e-10
the O 0 1.889602502247456e-10
first O 0 1.3377275676074163e-10
examples O 0 1.5181015333709524e-09
of O 0 3.1986671089612173e-09
a O 0 3.7208820913292584e-08
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 1.0
within O 0 7.663515475542226e-07
the O 0 5.460268681645175e-08
POMC O 0 2.0068459889444057e-06
gene O 0 7.002781021725468e-09
and O 0 2.595323400633731e-10
define O 0 1.3325848868817047e-08
a O 0 3.0540878714901964e-09
new O 0 5.564427851822984e-08
monogenic B-Disease 1 0.9999995231628418
endocrine I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999254941940308
resulting O 0 7.674290003478745e-08
in O 0 3.5364036143903377e-09
early O 0 2.761288442343357e-06
- O 0 0.00020496858633123338
onset O 1 0.9999947547912598
obesity B-Disease 1 1.0
, O 0 0.00012317394430283457
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 1 0.9963204860687256
red O 0 0.00269672111608088
hair O 0 0.0005593688110820949
pigmentation O 0 8.43989328132011e-05
. O 0 5.717054563092461e-08
. O 0 2.238120373476704e-07

A O 0 3.9502813820035954e-07
European O 0 1.0955528040312856e-07
multicenter O 0 4.044733486807672e-06
study O 0 3.141591164990132e-08
of O 0 8.433107154814934e-07
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 4.9946706326409185e-08
classification O 0 4.20481143237339e-07
of O 0 2.65068536009494e-07
105 O 0 3.024095747150568e-07
mutations O 0 3.3806832888672034e-09
and O 0 6.444890732204556e-10
a O 0 9.160472935754171e-10
general O 0 1.4170844497840562e-09
system O 0 1.373176239383156e-09
for O 0 4.0993100580699604e-10
genotype O 0 7.725659223467574e-09
- O 0 3.9431347076401835e-09
based O 0 9.99026972259287e-10
prediction O 0 1.1176678782476301e-07
of O 0 7.172022975510117e-08
metabolic O 0 0.00039135661791078746
phenotype O 0 4.677565073052392e-07
. O 0 6.432645704990136e-07

Phenylketonuria B-Disease 0 0.003709628013893962
( O 0 9.446306421523332e-07
PKU B-Disease 0 5.1582606829470024e-05
) O 0 3.019544791982298e-08
and O 0 1.903458901608701e-08
mild B-Disease 0 0.008043632842600346
hyperphenylalaninemia I-Disease 1 1.0
( O 0 2.2917954993317835e-05
MHP B-Disease 1 1.0
) O 0 9.165458614290856e-09
are O 0 2.7419347348178746e-10
allelic B-Disease 0 4.8451661314175e-06
disorders I-Disease 1 0.9999425411224365
caused O 0 6.954227416144931e-08
by O 0 1.2942129312687456e-10
mutations O 0 1.527325710348748e-09
in O 0 4.100467465573132e-10
the O 0 5.691784266126376e-10
gene O 0 9.48291112301547e-10
encoding O 0 2.104748375586496e-07
phenylalanine O 0 2.992797271872405e-05
hydroxylase O 0 0.0003774735960178077
( O 0 1.5270693438651506e-06
PAH O 0 0.008561920374631882
) O 0 1.118468048844079e-06
. O 0 3.748943299797247e-06

Previous O 0 6.818913220740797e-07
studies O 0 1.0664353311540253e-07
have O 0 1.763716950264893e-10
suggested O 0 1.3430562217919828e-09
that O 0 2.0374246994386835e-12
the O 0 2.6671755082308124e-11
highly O 0 7.733824136657574e-10
variable O 0 2.075787541855334e-08
metabolic O 0 0.00011903220001840964
phenotypes O 0 4.122408427065238e-06
of O 0 0.00038332375697791576
PAH B-Disease 1 1.0
deficiency I-Disease 1 0.9999871253967285
correlate O 0 6.0967850004089996e-05
with O 0 7.451988494722173e-06
PAH O 1 0.9999932050704956
genotypes O 0 0.0006901565939188004
. O 0 7.0210649028012995e-06

We O 0 5.7365738825865265e-08
identified O 0 1.0342827927445342e-08
both O 0 5.72176139801428e-10
causative O 0 5.24431307269424e-08
mutations O 0 8.433089782045045e-09
in O 0 2.4782245144905346e-09
686 O 0 2.1298083652254718e-07
patients O 0 2.5786334845179226e-08
from O 0 6.1816067820075205e-09
seven O 0 7.427144232963201e-09
European O 0 3.833054407209602e-08
centers O 0 1.284080610730598e-07
. O 0 1.1563720647700393e-07

On O 0 4.0803749357110064e-07
the O 0 1.644395397626397e-09
basis O 0 2.772347684754095e-09
of O 0 3.7990599555115523e-10
the O 0 3.254406466535187e-11
phenotypic O 0 1.5765426297775775e-08
characteristics O 0 5.418590465211537e-09
of O 0 3.087927780143218e-08
297 O 0 2.861908221518661e-08
functionally O 0 3.1972084002518386e-07
hemizygous O 0 1.0170268751608091e-06
patients O 0 7.120578793262666e-09
, O 0 8.212318602929258e-10
105 O 0 8.988627619999079e-09
of O 0 1.999854504219911e-09
the O 0 7.730003859229839e-10
mutations O 0 1.2298786988829136e-10
were O 0 4.081864846128269e-10
assigned O 0 1.0005906103671691e-09
to O 0 9.981845905393527e-11
one O 0 1.372515573416777e-10
of O 0 1.0280769568993264e-09
four O 0 1.6490525611700946e-10
arbitrary O 0 2.794837472563927e-09
phenotype O 0 2.937754484122479e-09
categories O 0 3.661497771645372e-08
. O 0 1.342718007890653e-07

We O 0 1.2006950100840186e-07
proposed O 0 3.399630799094666e-08
and O 0 5.729427487999317e-10
tested O 0 1.4161332106965574e-09
a O 0 7.835647408693802e-11
simple O 0 5.280871920310126e-11
model O 0 1.343214428572992e-10
for O 0 3.862956829414621e-11
correlation O 0 1.8569047410821327e-09
between O 0 6.993304157987268e-09
genotype O 0 2.1854086540429307e-08
and O 0 6.488825587958047e-10
phenotypic O 0 3.448169252351363e-07
outcome O 0 1.1677695965772728e-06
. O 0 3.370290926341113e-07

The O 0 2.128882243823682e-07
observed O 0 4.746823734080863e-08
phenotype O 0 6.659223839022843e-09
matched O 0 9.626427655007319e-09
the O 0 1.3540650822818634e-09
predicted O 0 4.770529304920501e-09
phenotype O 0 2.470643689633789e-10
in O 0 2.6501892347319256e-10
79 O 0 6.77992728626009e-09
% O 0 2.5690727323279816e-10
of O 0 1.0172319653278805e-09
the O 0 2.0004675693741092e-10
cases O 0 1.3321793668197301e-10
, O 0 1.4370451009715346e-11
and O 0 5.310261345231604e-12
in O 0 3.5969581479999846e-11
only O 0 2.9749501473386175e-11
5 O 0 5.99166716241939e-10
of O 0 9.088214070196443e-10
184 O 0 1.4481351673367726e-09
patients O 0 2.7874258456961343e-10
was O 0 4.933014441377281e-09
the O 0 2.4724916558582777e-10
observed O 0 4.639566508757298e-10
phenotype O 0 8.624195108053456e-11
more O 0 8.973112183841003e-12
than O 0 6.7009535940909526e-12
one O 0 1.2995950669780765e-11
category O 0 2.9150912239650495e-10
away O 0 7.093735043817162e-10
from O 0 3.75061925961262e-10
that O 0 4.866767405742323e-11
expected O 0 1.0487865687025533e-08
. O 0 4.4173589230922516e-08

Among O 0 2.1544590111943762e-08
the O 0 4.159421695959509e-09
seven O 0 1.3877075044632647e-09
contributing O 0 2.6988278278849975e-10
centers O 0 7.258939005438947e-10
, O 0 1.787913046780165e-11
the O 0 2.365232315559851e-11
proportion O 0 2.964902490187882e-10
of O 0 4.515078533273709e-09
patients O 0 7.052614603431095e-10
for O 0 7.304298832444545e-10
whom O 0 2.2425732382203023e-09
the O 0 5.158513616265736e-10
observed O 0 1.075383004867092e-09
phenotype O 0 1.2415928007936117e-10
did O 0 1.951631217744776e-10
not O 0 3.727752828641684e-11
match O 0 1.8750916375154247e-09
the O 0 1.2666100113190026e-10
predicted O 0 3.358066325009901e-10
phenotype O 0 7.620106629024903e-11
was O 0 5.3569024771604745e-09
4 O 0 2.155419842608808e-09
% O 0 2.7009236513997337e-10
- O 0 5.007048997640595e-09
23 O 0 1.148142203533098e-08
% O 0 9.688184698930513e-10
( O 0 1.0045873022335172e-09
P O 0 7.463913220817631e-07
< O 0 2.905147411524922e-08
. O 0 8.582862753847564e-10
0001 O 0 5.268274776426551e-07
) O 0 1.1644078756756215e-10
, O 0 7.593034534458809e-11
suggesting O 0 1.7152666786923731e-10
that O 0 3.6089273930395294e-12
differences O 0 2.0726008409521768e-10
in O 0 1.4224501784787513e-11
methods O 0 1.2030211549163283e-10
used O 0 1.1690226911498236e-11
for O 0 1.5563730859646796e-11
mutation O 0 8.0506178112838e-11
detection O 0 2.1119822335435856e-08
or O 0 8.344460677989218e-10
phenotype O 0 2.7595490337262163e-09
classification O 0 9.924637112135315e-09
may O 0 1.6684281733958528e-09
account O 0 3.6306912337691344e-11
for O 0 4.570195957787071e-11
a O 0 6.085125459076579e-11
considerable O 0 3.723107377950896e-10
proportion O 0 5.246478806952837e-10
of O 0 3.2560492080335734e-09
genotype O 0 9.366006992195253e-08
- O 0 6.04663000558503e-07
phenotype O 0 3.037411033801618e-08
inconsistencies O 0 3.128496075532894e-07
. O 0 3.072547372084955e-07

Our O 0 2.8174315502838e-07
data O 0 2.9175584614904437e-08
indicate O 0 6.765639604111584e-09
that O 0 1.7292935139412435e-10
the O 0 8.251623384580853e-09
PAH O 0 0.00011341409845044836
- O 0 1.198873860630556e-06
mutation O 0 2.7747282249634964e-09
genotype O 0 2.5552209237389434e-08
is O 0 1.7629030180099647e-10
the O 0 1.3551547384249574e-10
main O 0 3.8195433482712815e-09
determinant O 0 8.533639572760876e-08
of O 0 1.7134864194190413e-08
metabolic O 0 1.4157514669932425e-05
phenotype O 0 5.1994013539058415e-09
in O 0 1.7842016752922518e-09
most O 0 1.253364079190078e-09
patients O 0 1.3556317846052934e-08
with O 0 5.114349619361747e-07
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.991496741771698

In O 0 3.420189642611149e-08
the O 0 2.947818433796101e-09
present O 0 1.6931448465484777e-09
study O 0 1.8305366944471047e-10
, O 0 2.1162694860410447e-11
the O 0 2.4448224694717524e-11
classification O 0 1.833248886029537e-09
of O 0 4.329904257360795e-08
105 O 0 3.009580268553691e-06
PAH O 0 0.0014067835872992873
mutations O 0 3.553593330707372e-08
may O 0 8.408579610375e-09
allow O 0 7.643343180596673e-10
the O 0 1.5705992062464702e-09
prediction O 0 2.884024219440562e-08
of O 0 6.159198484567696e-09
the O 0 1.7815492414641199e-09
biochemical O 0 2.282674138598395e-08
phenotype O 0 3.760879607739298e-09
in O 0 2.4062880576991574e-09
> O 0 1.0568389718912385e-08
10 O 0 1.8490410313987127e-09
, O 0 1.607568106409829e-10
000 O 0 1.7833986509785404e-09
genotypes O 0 1.3597128756259735e-08
, O 0 8.807641838082247e-10
which O 0 8.989287786365097e-11
may O 0 2.547781985384745e-10
be O 0 2.477522527410958e-11
useful O 0 1.875462563027952e-10
for O 0 1.6728366955542917e-11
the O 0 1.2602985322018867e-10
management O 0 5.78587666666408e-09
of O 0 1.2855019804192125e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 3.2757540679995145e-07
newborns O 0 2.866298416392965e-07
. O 0 1.731272902816272e-07

Somatic O 0 8.233321568695828e-05
instability O 0 0.00010118589125340804
of O 0 1.2264525821592542e-06
the O 0 5.1587058180757595e-08
CTG O 0 1.402966972818831e-05
repeat O 0 9.829935976313209e-08
in O 0 5.185832652188083e-09
mice O 0 3.7219309856340033e-09
transgenic O 0 4.1887679991248206e-09
for O 0 7.677913860248964e-10
the O 0 7.221436135296244e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0006336448714137077
is O 0 5.285109239139274e-09
age O 0 1.871583776846819e-08
dependent O 0 3.520648661492487e-09
but O 0 5.078942821867827e-11
not O 0 4.180747761872716e-12
correlated O 0 1.1979676972639908e-10
to O 0 3.273493975886055e-11
the O 0 1.5608390968591124e-10
relative O 0 3.728163733285328e-08
intertissue O 0 3.448041070441832e-07
transcription O 0 2.1130787786205474e-07
levels O 0 1.6462202268030524e-07
and O 0 2.7496467325249796e-08
proliferative O 0 0.00018077107961289585
capacities O 0 7.838315650587901e-05
. O 0 1.2915357956444495e-06

A O 0 3.741193359019235e-05
( O 0 8.489465841421406e-08
CTG O 0 7.694274245295674e-06
) O 0 5.73549829852027e-09
nexpansion O 0 1.5425185040385259e-07
in O 0 4.831588906739626e-09
the O 0 3.740262766172009e-09
3 O 0 1.1059600524276902e-07
- O 0 2.845410840279783e-08
untranslated O 0 8.694227290106937e-06
region O 0 1.1657073173410026e-07
( O 0 8.511523708065738e-10
UTR O 0 8.103615414256637e-07
) O 0 5.766571664622688e-10
of O 0 1.5563783151151256e-08
the O 0 7.543460611714181e-08
DM O 1 0.9999996423721313
protein O 0 1.2049397355440306e-06
kinase O 0 1.9515499616318266e-07
gene O 0 4.544248355387026e-08
( O 0 7.2912742510311546e-09
DMPK O 0 1.458860083403124e-06
) O 0 6.31401708695023e-10
is O 0 2.156438499989477e-10
responsible O 0 5.104362710284249e-09
for O 0 3.625977029741989e-08
causing O 1 0.9999991655349731
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9160199165344238
DM B-Disease 1 1.0
) O 0 5.406848799793806e-07
. O 0 4.0751325514065684e-07

Major O 0 2.7137355573358946e-05
instability O 0 0.008913329802453518
, O 0 2.2244055486453362e-08
with O 0 7.114968059163118e-10
very O 0 1.2133571924977105e-09
large O 0 2.438634294499309e-10
expansions O 0 3.3281184474986958e-09
between O 0 2.601580995076347e-08
generations O 0 1.4444578866346092e-09
and O 0 1.4171890050374003e-10
high O 0 6.404235364243505e-09
levels O 0 3.4714184860007435e-09
of O 0 5.432871486021895e-09
somatic O 0 1.9949509066918836e-07
mosaicism O 0 5.503290594788268e-06
, O 0 1.55736046281163e-09
is O 0 1.2032644325365993e-10
observed O 0 3.410273619053328e-09
in O 0 1.3604074533546395e-09
patients O 0 1.2562773932245364e-08
. O 0 4.1379639270644475e-08

There O 0 1.5188501834018098e-07
is O 0 5.8817684056577946e-09
a O 0 1.3401595388984333e-09
good O 0 1.7558334786116347e-09
correlation O 0 1.642373570476252e-09
between O 0 9.38524458149459e-09
repeat O 0 3.911412083112964e-09
size O 0 1.815609773636595e-09
( O 0 1.4348601473646028e-10
at O 0 2.7548947567623827e-09
least O 0 1.9579090085319883e-11
in O 0 6.256113682656661e-11
leucocytes O 0 9.316649673962729e-09
) O 0 9.042545184856365e-11
, O 0 6.324500645416009e-11
clinical O 0 3.855018526621734e-09
severity O 0 4.842607737032267e-08
and O 0 1.7365162641169718e-09
age O 0 1.0842400399724283e-07
of O 0 2.7083558507001726e-07
onset O 0 4.403644925332628e-05
. O 0 3.940994588447211e-07

The O 0 2.076252712868154e-06
trinucleotide O 0 0.003683930728584528
repeat O 0 5.854137725691544e-06
instability O 0 1.133504520112183e-05
mechanisms O 0 2.397123898845166e-05
involved O 0 1.0197700106573393e-07
in O 0 2.2333203730795503e-08
DM B-Disease 1 1.0
and O 0 6.179885492230142e-09
other O 0 1.687567086072761e-09
human O 0 6.184986705193296e-05
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 4.064929282066032e-09
unknown O 0 9.187442628899589e-07
. O 0 8.633308823391417e-08

We O 0 2.062230777255536e-07
studied O 0 4.034170160593931e-06
somatic O 0 2.2435235678130994e-06
instability O 0 4.772752504322852e-07
by O 0 2.6737285718780868e-09
measuring O 0 8.131104550557211e-06
the O 0 9.623732921681949e-08
CTG O 0 9.509773917670827e-06
repeat O 0 2.683457545060719e-08
length O 0 2.2846242675456097e-09
at O 0 4.0585454996744375e-09
several O 0 6.053510470671597e-11
ages O 0 6.246398953635435e-10
in O 0 1.4496149072784625e-11
various O 0 4.470411540946628e-11
tissues O 0 6.008512576372027e-10
of O 0 5.993132656811895e-09
transgenic O 0 6.255237217089871e-09
mice O 0 2.30131336209638e-09
carrying O 0 2.0878856421546743e-09
a O 0 5.34770494553527e-09
( O 0 3.8697506310469976e-10
CTG O 0 2.9387345534814813e-07
) O 0 8.77891204176251e-10
55expansion O 0 1.4205414800017024e-07
surrounded O 0 1.3098097717545443e-08
by O 0 2.8505248161891927e-10
45 O 0 1.3238043550245493e-08
kb O 0 1.0118521913682343e-06
of O 0 1.1900645802143117e-07
the O 0 2.414647681803217e-08
human O 0 3.1080955409379385e-07
DM B-Disease 1 1.0
region O 0 6.798628646720317e-07
, O 0 3.8379741051919325e-10
using O 0 3.3844879676614426e-10
small O 0 6.244386119291789e-10
- O 0 5.557943882905647e-09
pool O 0 4.4960547285199937e-08
PCR O 0 8.761439573845564e-08
. O 0 5.803940084092574e-08

These O 0 3.525219582911632e-08
mice O 0 6.127212515139036e-08
have O 0 2.9988161953653503e-10
been O 0 1.0117400667253307e-10
shown O 0 4.950654469704219e-11
to O 0 6.252221830538307e-12
reproduce O 0 2.1456890431093e-10
the O 0 1.3376409702114955e-10
intergenerational O 0 4.633926131702992e-09
and O 0 6.220515769150836e-10
somatic O 0 1.4240899304240884e-07
instability O 0 2.2935415699976147e-07
of O 0 2.8244633298868393e-08
the O 0 1.1899369489754008e-08
55 O 0 1.5098083849807153e-07
CTG O 0 2.5561432721588062e-06
repeat O 0 2.586416414374071e-08
suggesting O 0 2.4434076983936848e-09
that O 0 3.325044059532267e-11
surrounding O 0 3.0292096608874886e-10
sequences O 0 3.743386711718699e-10
and O 0 6.094114796129091e-11
the O 0 1.1319545994981084e-10
chromatin O 0 1.0612748013727469e-08
environment O 0 3.824245364825174e-09
are O 0 8.142264640298436e-12
involved O 0 1.3932896503199288e-10
in O 0 1.5715273526950568e-10
instability O 0 1.271324236995497e-07
mechanisms O 0 8.87449368747184e-06
. O 0 6.446740030696674e-07

As O 0 4.676940790204753e-08
observed O 0 2.070785143359899e-08
in O 0 8.867684364588513e-10
some O 0 4.1457944716105644e-11
of O 0 4.084224347611354e-10
the O 0 1.736051857825771e-10
tissues O 0 6.031606769596465e-09
of O 0 1.0538949481997406e-06
DM B-Disease 1 1.0
patients O 0 3.673386288483016e-07
, O 0 1.2804781679420785e-09
there O 0 3.0529798134004693e-10
is O 0 6.776158106847063e-11
a O 0 1.4965161054814047e-10
tendency O 0 3.2329153243360054e-10
for O 0 1.9446232124575857e-10
repeat O 0 1.8241940180629967e-09
length O 0 1.7239165650551058e-09
and O 0 7.379469257884352e-10
somatic O 0 2.3173742036419753e-08
mosaicism O 0 4.255732051205996e-07
to O 0 2.390089792747574e-10
increase O 0 9.377076198857637e-11
with O 0 4.218726756821667e-11
the O 0 6.613891656570559e-10
age O 0 1.608508348738269e-08
of O 0 4.533770248116298e-09
the O 0 2.538712351451977e-09
mouse O 0 3.1449182813503285e-08
. O 0 2.709021451607896e-08

Furthermore O 0 6.013276561134262e-07
, O 0 5.424381388507982e-09
we O 0 3.200013865001239e-10
observed O 0 5.697845528729317e-10
no O 0 3.31010427401246e-11
correlation O 0 1.3229094208977443e-10
between O 0 2.529715603660776e-10
the O 0 8.276772323068116e-11
somatic O 0 2.181222313879516e-09
mutation O 0 2.3263618809110653e-10
rate O 0 1.2958017991948623e-09
and O 0 1.5475584702606682e-10
tissue O 0 1.0826814111908334e-08
proliferation O 0 1.8080068002745975e-06
capacity O 0 4.2776761688401166e-07
. O 0 1.2646249558656564e-07

The O 0 1.2279302552542504e-07
somatic O 0 5.162997922525392e-07
mutation O 0 8.64111449061511e-09
rates O 0 6.658843254570002e-09
in O 0 1.0305069991778382e-10
different O 0 3.757849934005186e-11
tissues O 0 8.750075108920896e-10
were O 0 5.22241805356316e-10
also O 0 2.3365084172999318e-11
not O 0 2.785031536986504e-12
correlated O 0 1.0902357489017689e-10
to O 0 1.1144945383234628e-10
the O 0 1.006397853942076e-09
relative O 0 8.749380526751338e-07
inter O 0 0.0573914535343647
- O 0 6.46257234393488e-08
tissue O 0 9.346301510504418e-09
difference O 0 5.569577510300405e-08
in O 0 2.1329013555337895e-10
transcriptional O 0 2.1974873032348796e-09
levels O 0 3.435336237700426e-09
of O 0 1.067737009918801e-09
the O 0 3.317494612353755e-10
three O 0 2.679670096927822e-10
genes O 0 1.0565234104253918e-10
( O 0 1.7626979043061652e-10
DMAHP O 0 1.4664703940070467e-07
, O 0 2.387257058700243e-09
DMPK O 0 9.051786946656648e-07
and O 0 6.5846172958572424e-09
59 O 0 3.3896597528837447e-08
) O 0 3.6418870696941497e-10
surrounding O 0 6.841305744131887e-09
the O 0 4.02053812464942e-09
repeat O 0 3.144594273862822e-08
. O 0 3.3082074857304633e-09
. O 0 3.09814005561293e-08

A O 0 4.292948574402544e-07
novel O 0 4.1618363866291475e-08
missense O 0 2.1508095926492388e-07
mutation O 0 4.540884113168886e-09
in O 0 1.4973333684054069e-09
patients O 0 5.081631559988864e-09
from O 0 6.31992458366426e-09
a O 0 2.7990054718429747e-08
retinoblastoma B-Disease 0 7.410866965074092e-05
pedigree O 0 7.166458004803644e-08
showing O 0 5.576441530763532e-09
only O 0 3.901277079165766e-10
mild O 0 1.2748738065226917e-08
expression O 0 2.0119712562660652e-09
of O 0 2.033845269977519e-08
the O 0 6.563463994524454e-09
tumor B-Disease 0 2.670397520887491e-07
phenotype O 0 5.4144091876651146e-08
. O 0 1.407224914373728e-07

We O 0 6.290582632573205e-08
have O 0 1.0445690840077404e-10
used O 0 3.2841628722080074e-11
single O 0 1.9191096628512483e-11
strand O 0 2.2290921886103376e-10
conformation O 0 9.448530846611902e-11
polymorphism O 0 3.1087560303788564e-10
analysis O 0 1.05771717773262e-10
to O 0 2.0776701539770848e-11
study O 0 1.4647240365039949e-10
the O 0 3.702203266175985e-10
27 O 0 1.483122247236679e-08
exons O 0 3.137710535838778e-08
of O 0 1.9231064740665715e-08
the O 0 6.3871814504068425e-09
RB1 O 0 2.9617325481012813e-07
gene O 0 1.7852979095067667e-09
in O 0 9.728645666839952e-10
individuals O 0 3.3596216086895225e-11
from O 0 3.844826679255675e-09
a O 0 8.65586091691739e-09
family O 0 1.5112777695946988e-09
showing O 0 4.345588777709963e-09
mild O 0 3.9119587569302894e-08
expression O 0 6.089833526345956e-09
of O 0 5.999494590014365e-08
the O 0 2.410781974049314e-08
retinoblastoma B-Disease 0 1.0601585017866455e-05
phenotype O 0 1.1992040072072996e-07
. O 0 2.328335995116504e-07

In O 0 8.331474532496941e-08
this O 0 1.420526585249604e-09
family O 0 7.579494809561993e-10
affected O 0 2.2903737240120847e-10
individuals O 0 1.3528013778629777e-11
developed O 0 5.775030942345438e-08
unilateral B-Disease 0 3.5880261748388875e-06
tumors I-Disease 1 1.0
and O 0 1.329166110508595e-07
, O 0 1.4856470498259e-09
as O 0 3.400638937112177e-10
a O 0 2.0325674476850963e-10
result O 0 6.681166730970745e-10
of O 0 1.1576505087873556e-08
linkage O 0 6.442192557187809e-08
analysis O 0 7.315107630745388e-09
, O 0 5.717790130255196e-10
unaffected O 0 6.387961271059339e-09
mutation O 0 2.0586223004048776e-10
carriers O 0 3.706202289510685e-10
were O 0 2.5731233810333265e-10
also O 0 3.689991368016621e-11
identified O 0 4.510617712671916e-10
within O 0 1.315482389685485e-09
the O 0 5.969813976491878e-09
pedigree O 0 3.853675991649652e-07
. O 0 1.6375722111661162e-07

A O 0 7.316359074138745e-07
single O 0 1.199432109189047e-08
band O 0 1.540914524866821e-07
shift O 0 3.9933173212602924e-08
using O 0 5.196526320361272e-09
SSCP O 0 7.237971431095502e-07
was O 0 1.7814006270100435e-08
identified O 0 6.904552485309523e-10
in O 0 8.378797655694825e-10
exon O 0 2.6813495423994027e-08
21 O 0 9.763299502196787e-09
which O 0 7.120300182794637e-11
resulted O 0 1.1139212885424854e-09
in O 0 3.565457373788661e-10
a O 0 2.3271264915081247e-09
missense O 0 1.1007847078303712e-08
mutation O 0 3.944375936981714e-09
converting O 0 2.2315771275316365e-07
a O 0 9.980259818576087e-08
cys O 0 5.82365901209414e-05
- O 0 7.4989552558690775e-06
- O 0 2.5122719762293855e-06
> O 0 1.4863937281006656e-07
arg O 0 2.8611387037358327e-08
at O 0 1.1413347777988747e-07
nucleotide O 0 1.0742970069088642e-08
position O 0 7.391139433821081e-08
28 O 0 8.236420967477898e-08
in O 0 2.8898983206460116e-09
the O 0 2.0699953751091016e-08
exon O 0 2.5683166313683614e-06
. O 0 5.893180059501901e-07

The O 0 8.393553230234829e-08
mutation O 0 7.713629734951155e-09
destroyed O 0 9.11921702595464e-08
an O 0 1.3390174524730014e-09
NdeI O 0 3.136478312626423e-07
restriction O 0 1.0769784175579389e-08
enzyme O 0 1.4706040829537415e-08
site O 0 4.317854873647775e-08
. O 0 1.72146854993116e-07

Analysis O 0 4.064772838319186e-07
of O 0 2.123033056022905e-07
all O 0 9.872564987745136e-09
family O 0 2.7900015631132646e-09
members O 0 7.29818150357886e-11
demonstrated O 0 8.337507906297503e-10
that O 0 1.1622151158130478e-11
the O 0 2.1242373138274928e-10
missense O 0 1.9470711265512364e-08
mutation O 0 2.9224467290589473e-09
co O 0 5.883543963136617e-07
- O 0 6.240634888854402e-07
segregated O 0 9.706059955760793e-08
with O 0 5.061663310712561e-10
patients O 0 5.3755233153651716e-08
with O 0 7.886878705676281e-08
tumors B-Disease 1 1.0
or O 1 0.9809067845344543
who O 0 1.8904606804426294e-06
, O 0 3.3981901736979125e-09
as O 0 6.993540746513816e-10
a O 0 3.523542291272719e-10
result O 0 1.2943073279814143e-09
of O 0 2.863234982442009e-08
linkage O 0 5.1305242720900424e-08
analysis O 0 7.92752086198334e-09
had O 0 3.6643252876444876e-09
been O 0 5.721455531570996e-10
predicted O 0 9.743519324700856e-10
to O 0 3.0301098435936424e-11
carry O 0 3.5942440690384103e-10
the O 0 7.687027681058112e-10
predisposing O 0 4.5141078430788184e-07
mutation O 0 2.0850538362537918e-07
. O 0 7.710749514444615e-07

These O 0 2.2681266642621267e-08
observations O 0 1.594327159182285e-07
point O 0 1.0909466396924472e-07
to O 0 1.7082601999618419e-10
another O 0 4.167305112101616e-10
region O 0 4.682025878111062e-09
of O 0 6.030537402779146e-09
the O 0 1.997381460228098e-08
RB1 O 0 1.0253397704218514e-06
gene O 0 1.307488517454658e-08
where O 0 4.1834664621376305e-09
mutations O 0 7.802364310194321e-10
only O 0 5.783200654474463e-11
modify O 0 5.704870464917633e-10
the O 0 2.949560595766343e-10
function O 0 3.85751963705161e-09
of O 0 5.208900422104534e-09
the O 0 3.0478017332136176e-10
gene O 0 2.4359519956718145e-10
and O 0 2.408095667316701e-10
raise O 0 2.2431197177485984e-10
important O 0 3.984890473152092e-10
questions O 0 2.1961453489094396e-10
for O 0 5.975822614523452e-11
genetic O 0 2.39083397524098e-09
counseling O 0 2.5925392943548786e-09
in O 0 2.237791063564032e-10
families O 0 4.961390673297039e-12
with O 0 9.373083906250024e-12
these O 0 2.8868652260372052e-11
distinctive O 0 1.139526251137113e-09
phenotypes O 0 1.3804247522841706e-08
. O 0 3.5529137409895384e-09
. O 0 5.478357678612156e-08

Maternal B-Disease 0 6.128940003691241e-05
disomy I-Disease 0 0.00020670669618993998
and O 0 9.936742571881041e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.05260917544364929
with O 0 1.6653038059644132e-08
gamete O 0 2.840465413100901e-06
complementation O 0 5.712101028620964e-06
in O 0 3.496950506942653e-09
a O 0 4.94735363787413e-10
case O 0 8.859468159094774e-10
of O 0 1.4397241177022124e-09
familial O 0 2.3806878246546148e-08
translocation O 0 1.6087069809600507e-07
( O 0 2.9859243966257054e-09
3 O 0 2.4713436630463548e-08
; O 0 1.996107307222772e-10
15 O 0 2.657464248656538e-09
) O 0 7.452025801990558e-11
( O 0 9.177729409781676e-11
p25 O 0 1.9615450597143536e-08
; O 0 3.54764384535855e-10
q11 O 0 2.05325978441806e-08
. O 0 7.0969558008116e-10
2 O 0 6.048774991995742e-08
) O 0 1.1914261799361725e-09
. O 0 2.2387579790006384e-08

Maternal B-Disease 0 0.005203495267778635
uniparental I-Disease 1 0.9570525884628296
disomy I-Disease 0 0.43858060240745544
( I-Disease 0 3.307286988274427e-06
UPD I-Disease 1 0.9999879598617554
) I-Disease 0 1.6529527968600632e-08
for I-Disease 0 4.337639136764437e-09
chromosome I-Disease 0 2.8457753842303646e-07
15 I-Disease 0 3.977437756930158e-08
is O 0 1.9370641202165473e-10
responsible O 0 6.382842032692793e-10
for O 0 6.447493233752155e-11
an O 0 1.7643823901902778e-11
estimated O 0 6.521019141336737e-11
30 O 0 1.4194539987855137e-09
% O 0 5.0345089208647664e-11
of O 0 2.288788464310798e-10
cases O 0 2.19843365734107e-10
of O 0 2.8334238777460996e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9993738532066345
PWS B-Disease 1 1.0
) O 0 1.3763044535153313e-06
. O 0 3.7209960623840743e-07

We O 0 8.05270232717703e-08
report O 0 2.9455926586763326e-09
on O 0 3.1254463461749538e-09
an O 0 2.5297144587432818e-11
unusual O 0 4.6026621403072454e-10
case O 0 6.887769243846265e-10
of O 0 6.006943276126719e-10
maternal B-Disease 0 1.835467955402237e-08
disomy I-Disease 0 8.816035119707522e-07
15 I-Disease 0 5.483302700781678e-08
in O 0 1.6226149313069982e-08
PWS B-Disease 1 0.9999986886978149
that O 0 1.4573844353549248e-09
is O 0 1.1381549869238228e-10
most O 0 5.7041684743686094e-12
consistent O 0 8.218550839877992e-11
with O 0 8.899751595403682e-12
adjacent O 0 3.1266089717263412e-09
- O 0 9.917597409980772e-09
1 O 0 1.3672215004589816e-07
segregation O 0 7.286855918664514e-08
of O 0 3.1011653245371917e-09
a O 0 1.3091373540774498e-09
paternal O 0 6.851399447782569e-09
t O 0 1.820691153398002e-08
( O 0 2.606763693790981e-10
3 O 0 2.744337868065827e-09
; O 0 7.553802028326118e-11
15 O 0 1.6092684962387693e-09
) O 0 5.297335833875927e-11
( O 0 5.3338548855474954e-11
p25 O 0 4.890127858203641e-09
; O 0 5.17642005648522e-11
q11 O 0 3.021548122816853e-09
. O 0 5.5915383434523847e-11
2 O 0 1.584243514152206e-09
) O 0 4.627047876792911e-12
with O 0 2.1318223228372624e-11
simultaneous O 0 3.756162492152271e-09
maternal O 0 2.3664999559969147e-07
meiotic O 0 5.497677648236277e-06
nondisjunction O 0 4.253952283761464e-06
for O 0 6.749505132574996e-08
chromosome O 0 7.688810910622124e-06
15 O 0 2.2647602690994972e-06
. O 0 6.671443202321825e-07

The O 0 3.547692131178337e-07
patient O 0 9.219057233167405e-07
( O 0 4.090392913269625e-09
J O 0 2.56345913385303e-07
. O 0 4.385370122594878e-10
B O 0 1.9870647349762294e-08
. O 0 3.893514330388648e-11
) O 0 7.095310450289105e-12
, O 0 1.816103344098874e-11
a O 0 2.377658625540846e-10
17 O 0 2.5418471771843087e-09
- O 0 1.804871807564723e-09
year O 0 1.7248868999786282e-09
- O 0 4.349214322019179e-08
old O 0 2.0176297255147801e-07
white O 0 1.0203644595918604e-09
male O 0 8.526699901700852e-10
with O 0 1.175817443410665e-09
PWS B-Disease 1 1.0
, O 0 2.3568954787833718e-08
was O 0 1.893010335152212e-07
found O 0 3.6581224160947556e-10
to O 0 8.210889607118688e-11
have O 0 8.531332584826856e-11
47 O 0 2.2177912839538294e-09
chromosomes O 0 7.164469018050568e-10
with O 0 1.2888476397243664e-10
a O 0 3.593094488607562e-09
supernumerary O 0 2.716358835641586e-07
, O 0 1.876361732655596e-09
paternal O 0 7.525741096969796e-08
der O 0 0.0004577876243274659
( O 0 2.0360295671650874e-09
15 O 0 3.77292819209174e-09
) O 0 4.9653600675547693e-11
consisting O 0 8.877601986867489e-10
of O 0 2.9279370039603236e-09
the O 0 2.174347812911037e-09
short O 0 5.325464069727559e-09
arm O 0 7.126696033310509e-08
and O 0 1.2527928694439083e-09
the O 0 2.276560806535599e-08
proximal O 0 1.1360933058313094e-05
long O 0 5.158775024938222e-07
arm O 0 3.542039848980494e-06
of O 0 1.386519784318807e-06
chromosome O 0 2.1043520064267796e-06
15 O 0 2.613842013943213e-07
, O 0 8.879468715861094e-09
and O 0 2.1703547403717494e-08
distal O 0 0.00011897796503035352
chromosome O 0 0.002000117441639304
arm O 0 0.20586884021759033
3p O 1 0.5835682153701782
. O 0 1.7887394278659485e-05

The O 0 3.7696827348554507e-06
t O 0 2.2121287202025997e-06
( O 0 9.023360725279872e-09
3 O 0 2.5334990993997053e-08
; O 0 2.942272536721191e-10
15 O 0 6.120432494149952e-10
) O 0 2.559055398143606e-11
was O 0 1.6392440738144387e-09
present O 0 1.415362965717648e-10
in O 0 1.9360520131517234e-10
the O 0 1.2121884052085363e-10
balanced O 0 2.6093505134383577e-10
state O 0 6.822416936946851e-11
in O 0 2.7799909943504453e-11
the O 0 8.526728628721614e-11
patients O 0 5.103970579511952e-10
father O 0 8.531796602539998e-09
and O 0 3.637279810675409e-09
a O 0 3.2000173177948454e-08
sister O 0 2.06412869374617e-06
. O 0 7.696144166402519e-07

Fluorescent O 0 5.598157031272422e-07
in O 0 2.1616584078287815e-08
situ O 0 3.69354637541619e-07
hybridization O 0 3.382953694952562e-09
analysis O 0 1.673061689189126e-09
demonstrated O 0 3.4375386981366773e-09
that O 0 7.600656215522861e-11
the O 0 3.43282113846044e-09
PWS B-Disease 1 0.9999847412109375
critical O 0 4.856037776335143e-07
region O 0 6.722691381355617e-08
resided O 0 8.182993838090624e-08
on O 0 9.331571071413691e-09
the O 0 6.779354300157081e-10
derivative O 0 4.612568993422883e-09
chromosome O 0 3.58359635299621e-08
3 O 0 1.606772670470491e-08
and O 0 1.549779887755065e-10
that O 0 1.3648087000828202e-11
there O 0 4.517451690499996e-11
was O 0 1.0251203219624472e-09
no O 0 5.1104755843800476e-11
deletion O 0 1.0600240685221252e-09
of O 0 4.653127660958489e-09
the O 0 1.3849396296450323e-08
PWS B-Disease 1 0.9999998807907104
region O 0 1.5235985983963474e-07
on O 0 2.758613781850272e-08
the O 0 1.2738279320245738e-09
normal O 0 2.0369471442904796e-08
pair O 0 3.7936893626522306e-09
of O 0 2.526148845660714e-09
15s O 0 1.071536672725415e-07
present O 0 5.2030322272855756e-09
in O 0 3.2836418029091874e-08
J O 0 5.1443341362755746e-05
. O 0 5.364358912629541e-07

B O 0 0.004377901088446379
. O 0 1.6288764527416788e-05

Methylation O 0 3.054677335967426e-06
analysis O 0 1.7372353511291294e-07
at O 0 8.862846243573586e-07
exon O 0 3.8082961850705033e-07
alpha O 0 1.1809204636392678e-07
of O 0 1.7710608091192626e-08
the O 0 2.301620671829596e-09
small O 0 3.5350009586210263e-09
nuclear O 0 7.394368140012375e-07
ribonucleoprotein O 0 1.3951449773230706e-07
- O 0 6.343994218838134e-09
associated O 0 8.51630233000833e-09
polypeptide O 0 8.390112071765543e-08
N O 0 6.031287398400309e-07
( O 0 6.369185734378391e-10
SNRPN O 0 1.1997153137599526e-07
) O 0 1.814241534781047e-10
gene O 0 1.0294819441369896e-09
showed O 0 2.9826003888899777e-09
a O 0 1.6606933883611674e-10
pattern O 0 7.090275033760918e-09
characteristic O 0 3.794602676521208e-08
of O 0 1.3567079015786021e-08
only O 0 1.2472917143568907e-10
the O 0 3.6863773145157097e-10
maternal O 0 3.214711696841732e-08
chromosome O 0 6.006936814628716e-08
15 O 0 1.2000070626072556e-07
in O 0 6.036545840970575e-08
J O 0 9.965929348254576e-05
. O 0 1.577552438902785e-06

B O 0 0.004513878840953112
. O 0 1.9819488443317823e-05

Maternal B-Disease 0 1.7739361283020116e-05
disomy I-Disease 0 1.3563809261540882e-05
was O 0 1.1140115674379558e-07
confirmed O 0 1.815003924932057e-09
by O 0 9.304031850509986e-11
polymerase O 0 4.473514891856212e-08
chain O 0 3.765961764656822e-09
reaction O 0 3.8280967284975986e-10
analysis O 0 3.0821067920072664e-09
of O 0 1.0325621246920491e-08
microsatellite O 0 1.5389026941647899e-07
repeats O 0 2.163691981138527e-08
at O 0 3.8876059704762156e-08
the O 0 1.2025676010551933e-09
gamma O 0 9.918093013538964e-08
- O 0 2.3308322383286395e-08
aminobutyric O 0 5.056380913970315e-08
acid O 0 3.958817273996829e-09
receptor O 0 4.925624796925376e-09
beta3 O 0 2.4585750679761986e-07
subunit O 0 2.391136888491019e-07
( O 0 1.1972677071980797e-08
GABRB3 O 0 2.0043116819579154e-06
) O 0 1.5051798030185637e-08
locus O 0 2.631153677157272e-07
. O 0 4.1812708673205634e-07

A O 0 1.7698572264635004e-05
niece O 0 1.6291374777210876e-05
( O 0 1.3369229279192041e-08
B O 0 1.5318828161525744e-07
. O 0 1.8261914203065999e-10
B O 0 5.935276270463419e-09
. O 0 3.1479503032061373e-11
) O 0 5.3069202678168725e-12
with O 0 1.9662094868921898e-11
45 O 0 8.740184131994511e-10
chromosomes O 0 1.207117739099317e-09
and O 0 1.3457711334208255e-10
the O 0 1.9290778696667843e-10
derivative O 0 6.5909877555725416e-09
3 O 0 3.199118747687635e-09
but O 0 1.770308379056562e-11
without O 0 6.372535832355197e-11
the O 0 2.939226917408888e-10
der O 0 2.9950920179544482e-06
( O 0 1.533981414114649e-10
15 O 0 1.4521734925665442e-09
) O 0 4.4338886728834126e-11
demonstrated O 0 1.0582099640998877e-09
a O 0 5.037892880643824e-10
phenotype O 0 2.5174945461614584e-10
consistent O 0 2.0822819024601813e-09
with O 0 1.955994220759205e-11
that O 0 4.5595627967687236e-12
reported O 0 7.580185090727554e-11
for O 0 3.947307064544603e-11
haploinsufficiency O 0 7.758163889093339e-08
of O 0 9.31658163949578e-08
distal O 0 4.646597517421469e-05
3 O 0 0.00015565386274829507
p O 0 9.578073513694108e-05
. O 0 1.0278480431225034e-06

Uniparental B-Disease 1 0.9999997615814209
disomy I-Disease 1 0.9999899864196777
associated O 0 1.5439183016496827e-06
with O 0 3.549621929721525e-09
unbalanced O 0 3.711956742336042e-05
segregation O 0 3.0195100407581776e-05
of O 0 1.7190060930261097e-07
non O 0 3.4843703815568006e-06
- O 0 8.340297767972515e-07
Robertsonian O 0 2.8128724807174876e-06
translocations O 0 2.0773686060238106e-07
has O 0 9.232336561915133e-10
been O 0 3.950984817091552e-10
reported O 0 2.0392931787682755e-10
previously O 0 9.91797199922928e-10
but O 0 6.386784850986871e-11
has O 0 1.7065461890841682e-11
not O 0 1.2497509971343135e-11
, O 0 1.4293745874416341e-11
to O 0 1.3672891811811194e-11
our O 0 2.351092376340347e-10
knowledge O 0 3.3595866089086712e-09
, O 0 6.517052175691873e-11
been O 0 2.5267968273290364e-11
observed O 0 2.8987956479653576e-10
in O 0 8.320506089676272e-11
a O 0 6.721287970634648e-10
case O 0 1.2158017703711721e-08
of O 0 1.3255659325750457e-07
PWS B-Disease 1 0.999998927116394
. O 0 1.0916519386228174e-05

Furthermore O 0 1.9676697775139473e-05
, O 0 3.6157423721761006e-08
our O 0 5.8585243323250324e-09
findings O 0 5.494467658628821e-10
are O 0 1.0624560259353544e-11
best O 0 6.311726835628306e-11
interpreted O 0 3.0747598911418095e-10
as O 0 2.3416849015411856e-10
true O 0 3.268543657952705e-09
gamete O 0 1.5211900006306678e-07
complementation O 0 1.6910466911213007e-06
resulting O 0 4.8839780220077955e-08
in O 0 3.732283104795897e-08
maternal B-Disease 0 0.00010118338104803115
UPD I-Disease 1 0.9999998807907104
15 I-Disease 0 8.978792175184935e-05
and O 0 1.0324032700737007e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.8482866883277893
- I-Disease 1 0.9997403025627136
Jampel I-Disease 1 0.9999915361404419
syndrome I-Disease 1 0.9999996423721313
type I-Disease 0 0.0028084139339625835
2 I-Disease 0 0.0001811567199183628
and O 0 3.2677036188033526e-08
Stuve B-Disease 1 0.9986804127693176
- I-Disease 1 0.9999661445617676
Wiedemann I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999992847442627
: O 0 2.64476707201311e-09
a O 0 9.669465228512308e-10
case O 0 1.7807610941389385e-09
for O 0 1.9076512591809092e-10
" O 0 1.7893408976732417e-09
lumping O 0 2.179801228407996e-08
" O 0 2.3494404643997768e-08
. O 0 2.883611749382453e-08

Recent O 0 1.6709831740513437e-08
studies O 0 5.995876684039558e-09
demonstrated O 0 3.287487837511094e-09
the O 0 4.3689063478069556e-10
existence O 0 1.827537343679353e-09
of O 0 2.230160722760388e-09
a O 0 3.994554964581454e-10
genetically O 0 1.6355923559974173e-10
distinct O 0 1.0283040391412257e-10
, O 0 7.677045804621585e-11
usually O 0 2.1820482920542617e-11
lethal O 0 1.5732037894622408e-10
form O 0 2.4354443808882742e-11
of O 0 3.710318996485995e-10
the O 0 4.857320101692153e-10
Schwartz B-Disease 0 2.2718775198882213e-06
- I-Disease 0 2.6740910470834933e-05
Jampel I-Disease 0 0.08239433914422989
syndrome I-Disease 1 0.9964882135391235
( O 0 2.5303794615183506e-08
SJS B-Disease 0 0.0004486642428673804
) O 0 8.052069233599468e-09
of O 0 6.78869582770858e-07
myotonia B-Disease 1 0.9998805522918701
and O 0 4.701717625721358e-05
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 9.584342478774488e-06
which O 0 5.41884848104246e-09
we O 0 1.061428633875039e-08
called O 0 8.065890710895474e-08
SJS B-Disease 1 0.9095765352249146
type I-Disease 0 0.000355261261574924
2 I-Disease 0 0.00010732561349868774
. O 0 4.4477911842477624e-07

This O 0 1.6912130718083063e-07
disorder O 1 0.99864262342453
is O 0 2.994709547010643e-08
reminiscent O 0 7.171465404098853e-05
of O 0 2.1105492464812414e-07
another O 0 5.230554656066033e-09
rare O 0 5.758561627544623e-09
condition O 0 2.2190158688317752e-07
, O 0 8.967903086798401e-10
the O 0 2.9888476138495434e-09
Stuve B-Disease 0 0.28879037499427795
- I-Disease 1 0.999948263168335
Wiedemann I-Disease 1 0.9999995231628418
syndrome I-Disease 1 1.0
( O 0 1.6144210235324863e-07
SWS B-Disease 0 7.192034900072031e-06
) O 0 9.63378821161598e-10
, O 0 2.0355897523138822e-10
which O 0 3.6972615941044396e-11
comprises O 0 1.4702106199138143e-09
campomelia B-Disease 0 5.27039503595006e-07
at O 0 2.969858599044528e-07
birth O 0 4.473463377507869e-08
with O 0 1.1480764783300401e-08
skeletal B-Disease 1 0.9999997615814209
dysplasia I-Disease 1 1.0
, O 0 2.510765079932753e-05
contractures B-Disease 1 0.999968409538269
, O 0 7.157510140132217e-08
and O 0 1.0519198845315714e-08
early B-Disease 0 2.2710585199092748e-06
death I-Disease 0 1.7356567241222365e-06
. O 0 1.9162490616508876e-07

To O 0 1.2432148643881646e-08
test O 0 5.8549609605051955e-09
for O 0 2.2604237925882842e-10
possible O 0 2.0349542051434355e-09
nosologic O 0 2.0549883572584804e-07
identity O 0 9.0775991168357e-09
between O 0 2.4062616788000923e-08
these O 0 3.2225864199375565e-09
disorders O 0 0.06505203247070312
, O 0 4.5343218069149316e-10
we O 0 4.232541400694956e-11
reviewed O 0 1.778913405470206e-10
the O 0 1.085531230876624e-11
literature O 0 4.3474248506703006e-11
and O 0 3.6250846074947773e-12
obtained O 0 7.63162658068417e-11
a O 0 2.860326558939974e-11
follow O 0 3.702950099326863e-11
- O 0 2.7017790782402074e-10
up O 0 2.2416400680125292e-10
of O 0 1.3185973424256758e-09
the O 0 2.5767085687355973e-10
only O 0 5.198702232589447e-11
two O 0 7.803283713636588e-11
surviving O 0 1.0034426622951287e-08
patients O 0 1.3593880465734287e-09
, O 0 4.3971462582170773e-10
one O 0 2.9694977032868053e-10
with O 0 1.6825534299158562e-09
SJS B-Disease 0 0.0037330538034439087
type I-Disease 0 1.4247040780901443e-05
2 I-Disease 0 3.4371516903775046e-06
at O 0 2.3664794923661248e-07
age O 0 4.168064293708085e-08
10 O 0 2.247523278597896e-09
years O 0 4.5698150819006855e-10
and O 0 8.448891586354534e-11
another O 0 3.0230914993545355e-10
with O 0 6.978084776676496e-10
SWS B-Disease 0 3.453623094173963e-06
at O 0 2.192434749304084e-06
age O 0 8.944231808527547e-07
7 O 0 1.0258268048346508e-06
years O 0 1.2582731301336025e-07
. O 0 1.3114714647599612e-07

Patients O 0 7.873574077166268e-07
reported O 0 3.708992224460417e-08
as O 0 2.2323565218584918e-09
having O 0 9.621674124105084e-09
either O 0 3.0390052074835694e-07
neonatal O 1 0.9999842643737793
SJS B-Disease 1 0.9999865293502808
or O 0 8.278755103674484e-07
SWS B-Disease 0 4.545671345113078e-06
presented O 0 2.694330092367636e-08
a O 0 1.0818387297106824e-09
combination O 0 4.7133141833910486e-09
of O 0 5.179170425861912e-09
a O 0 9.930047895068128e-10
severe O 0 5.8792920754058287e-08
, O 0 1.2259399051472997e-09
prenatal O 0 1.3969045539852232e-05
- O 0 0.0003425602917559445
onset O 1 0.9999988079071045
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 7.236811825350742e-07
with O 0 1.8652423250387073e-06
congenital B-Disease 1 1.0
joint I-Disease 1 0.9999998807907104
contractures I-Disease 1 1.0
, O 1 0.6199453473091125
respiratory O 1 1.0
and O 0 8.168600470526144e-05
feeding O 0 0.00010028055112343282
difficulties O 0 0.07549617439508438
, O 0 1.812963468239559e-08
tendency O 0 1.0079504342286327e-08
to O 0 6.1776699311622e-09
hyperthermia B-Disease 1 0.9999213218688965
, O 0 2.7761679621818303e-09
and O 0 3.9414260744052854e-10
frequent O 0 3.0449209820204715e-09
death O 0 3.6057762997643295e-08
in O 0 8.989553101912406e-09
infancy O 0 1.1953051171076368e-06
) O 0 9.354568508701533e-11
with O 0 3.6158055716217774e-11
a O 0 1.1695011625789675e-09
distinct O 0 9.833964753624969e-09
campomelic B-Disease 0 0.23350843787193298
- I-Disease 1 0.8842936158180237
metaphyseal I-Disease 1 0.9878169894218445
skeletal I-Disease 1 0.9999996423721313
dysplasia I-Disease 1 1.0
. O 0 0.0028187555726617575

The O 0 4.6138115550320435e-08
similarity O 0 1.7165685051168111e-07
of O 0 7.29355846829094e-08
the O 0 3.79555631369044e-09
clinical O 0 4.973556499976439e-08
and O 0 2.2920955411454003e-10
radiographic O 0 2.546461530528177e-07
findings O 0 2.8948743402423815e-09
is O 0 1.475429362018943e-10
so O 0 2.1606903766180352e-11
extensive O 0 4.657831897958431e-10
that O 0 1.8553309930058326e-11
these O 0 1.7352408399062824e-10
disorders O 0 0.0004713028611149639
appear O 0 1.832215090757927e-08
to O 0 4.19093926229408e-10
be O 0 4.4912504271188425e-10
a O 0 4.3720740916519674e-10
single O 0 2.998135906207011e-10
entity O 0 1.0484308887726002e-07
. O 0 6.47082401883381e-07

The O 0 1.679235168694504e-07
follow O 0 2.7916744471667698e-08
- O 0 2.077875116412997e-08
up O 0 1.5074171910711698e-09
observation O 0 1.3440774182527093e-07
of O 0 1.8500816434396938e-09
an O 0 3.4033106194319984e-11
identical O 0 1.7729381851516735e-10
and O 0 4.502965014752114e-11
unique O 0 9.046361437725636e-10
pattern O 0 1.9881420598721888e-07
of O 0 2.741865046118619e-06
progressive O 1 0.9999992847442627
bone B-Disease 1 1.0
dysplasia I-Disease 1 0.9999998807907104
in O 0 1.3249368748802226e-06
the O 0 4.898461725133529e-07
two O 0 2.078592586940431e-08
patients O 0 3.894879441190824e-08
( O 0 4.344823667512543e-10
one O 0 1.54098719895579e-10
with O 0 5.501514799277629e-10
SJS B-Disease 0 0.05187399685382843
type I-Disease 0 5.363782838685438e-05
2 I-Disease 0 9.75182956608478e-06
, O 0 3.550933991292027e-10
one O 0 5.1038125115088206e-11
with O 0 1.9823270802632464e-10
SWS B-Disease 0 1.1398503829695983e-06
) O 0 4.407981091247848e-09
surviving O 0 1.3831916021445068e-06
beyond O 0 3.5014020340895513e-06
infancy O 0 2.675049245226546e-06
adds O 0 3.0113185278679566e-09
to O 0 1.98916730309584e-10
the O 0 3.852518026814522e-10
evidence O 0 1.3448250291148156e-09
in O 0 2.359776540838965e-10
favor O 0 4.437937572987494e-09
of O 0 3.1488840424032105e-09
identity O 0 2.9473699925119945e-08
. O 0 1.949613448459786e-07

The O 0 1.7565922405538004e-07
hypothesis O 0 1.2117300229874672e-07
that O 0 1.5268364350617958e-09
SWS B-Disease 0 3.1628194392396836e-06
and O 0 3.384349156476674e-08
SJS B-Disease 1 0.5982558727264404
type I-Disease 0 0.00015434263332281262
2 I-Disease 0 2.904643451984157e-06
are O 0 9.851093552004642e-11
the O 0 1.576571095895929e-10
same O 0 3.506748891268785e-09
disorder O 0 2.5511119474685984e-06
should O 0 4.031009692706533e-10
be O 0 7.562248743875344e-11
testable O 0 4.054551416832197e-10
by O 0 5.637777571176894e-12
molecular O 0 5.919956524991221e-09
methods O 0 2.0055049176903594e-08
. O 0 4.287528998503376e-09
. O 0 8.788286010030788e-08

A O 0 6.411779054360522e-07
mouse O 0 1.7677468377996775e-08
model O 0 4.606221182257286e-09
of O 0 4.042570722617711e-08
severe O 1 0.9980415105819702
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 7.97927441453794e-06
defects O 1 0.9604278206825256
in O 0 3.0963383323978633e-07
hemostasis O 1 0.9996250867843628
and O 0 5.8278088545193896e-05
thrombosis B-Disease 1 0.9999910593032837
. O 0 4.8084850277518854e-05

von B-Disease 1 0.9885634183883667
Willebrand I-Disease 1 0.9993501305580139
factor I-Disease 0 0.0001554500631755218
( I-Disease 0 1.4190238744049566e-06
vWf I-Disease 0 0.0021955943666398525
) I-Disease 0 3.755265788640827e-05
deficiency I-Disease 1 1.0
causes O 1 0.999853253364563
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.02926248125731945
humans O 0 2.0906116333208047e-05
. O 0 2.4618785232632945e-07

We O 0 7.67004593171805e-08
generated O 0 4.089862226663854e-09
a O 0 1.1753039652617758e-09
mouse O 0 4.64785682163793e-10
model O 0 3.7285083354099413e-10
for O 0 3.193963496461727e-11
this O 0 3.6537765868427385e-11
disease O 0 8.218665192849528e-10
by O 0 3.6223960029474478e-12
using O 0 2.1274161599027508e-10
gene O 0 3.5976341905552545e-09
targeting O 0 5.719715545637882e-08
. O 0 1.5763674809932127e-07

vWf B-Disease 0 0.0055063278414309025
- I-Disease 1 0.998913049697876
deficient I-Disease 1 0.587070643901825
mice O 0 6.452007710322505e-06
appeared O 0 4.0916637544796686e-07
normal O 0 1.5316901169626362e-07
at O 0 3.696921879736692e-08
birth O 0 7.063599150036737e-10
; O 0 1.552524601933225e-11
they O 0 6.653805544737379e-12
were O 0 1.7353665726638212e-10
viable O 0 5.12912246009023e-09
and O 0 8.204489865271114e-10
fertile O 0 5.98545852881216e-08
. O 0 6.675554686808027e-08

Neither O 0 3.5661691072164103e-05
vWf O 0 0.00012917119602207094
nor O 0 2.431101893307641e-05
vWf O 0 5.8857654948951676e-05
propolypeptide O 0 9.674659668235108e-05
( O 0 1.5630233463070908e-07
von B-Disease 0 7.143863331293687e-05
Willebrand I-Disease 0 3.217839912394993e-05
antigen O 0 9.902461073352242e-08
II O 1 0.84745854139328
) O 0 1.1944888411719035e-09
were O 0 3.10525355429192e-10
detectable O 0 8.876657631162743e-09
in O 0 1.2730985710085463e-10
plasma O 0 4.998272729039854e-08
, O 0 2.1696697216633254e-10
platelets O 0 3.1407865197508045e-09
, O 0 4.875150283467633e-10
or O 0 1.5590834179235458e-10
endothelial O 0 1.1271635846910044e-09
cells O 0 6.956794584844772e-10
of O 0 2.6420696741524807e-09
the O 0 2.0861856686593683e-09
homozygous O 0 1.3698389977889747e-08
mutant O 0 1.22302978411426e-07
mice O 0 2.0387125232446124e-07
. O 0 8.411134189145741e-08

The O 0 2.1660565607817261e-07
mutant O 0 1.2439666079444578e-06
mice O 0 1.4663514491530805e-07
exhibited O 0 1.6988298057185602e-06
defects O 0 7.65496733947657e-05
in O 0 2.5492088440159932e-08
hemostasis O 0 5.424382470664568e-05
with O 0 8.70126548591088e-09
a O 0 5.972777472607049e-08
highly O 0 3.4853695979109034e-05
prolonged O 0 0.17065197229385376
bleeding O 1 0.8493795990943909
time O 0 1.0063755695455257e-07
and O 0 3.2291824769714594e-09
spontaneous O 0 1.9195590894582892e-08
bleeding O 0 8.353520115633728e-07
events O 0 1.8532108070345998e-09
in O 0 4.061184166737064e-10
approximately O 0 4.4254333531057455e-10
10 O 0 9.544061096988798e-10
% O 0 3.562418970926018e-10
of O 0 9.665524380864099e-09
neonates O 0 2.786167101476167e-07
. O 0 2.5153977389891224e-07

As O 0 4.7661298907542005e-08
in O 0 3.985561658481629e-09
the O 0 1.824684736639881e-09
human O 0 4.459160507508386e-08
disease O 0 2.1398740557287965e-07
, O 0 9.576258536148075e-11
the O 0 1.5051324075976424e-10
factor O 0 7.395828394152204e-10
VIII O 0 1.5773598533996847e-06
level O 0 4.2992007820430445e-07
in O 0 1.1978311675875375e-09
these O 0 9.755434654534767e-11
mice O 0 1.0201075539839621e-09
was O 0 3.463138442683089e-09
reduced O 0 5.065101671419825e-10
strongly O 0 1.6642258404697685e-10
as O 0 4.6278800236443374e-11
a O 0 7.225975373614801e-11
result O 0 1.9732961098473112e-10
of O 0 1.1704651692312495e-09
the O 0 6.107161998336608e-10
lack O 0 3.3432860924165198e-09
of O 0 1.53909340827596e-09
protection O 0 2.325813097669993e-09
provided O 0 8.384136718220248e-10
by O 0 1.322047471497001e-09
vWf O 0 1.962314399861498e-06
. O 0 6.896358968333516e-07

Defective O 1 0.9197311997413635
thrombosis B-Disease 1 0.9713478088378906
in O 0 3.97419626096962e-07
mutant O 0 6.167759352138091e-07
mice O 0 1.1677379774255314e-07
was O 0 4.453091762002259e-08
also O 0 1.7206470970254628e-10
evident O 0 2.1010126971532372e-09
in O 0 5.835834593348466e-11
an O 0 1.158547823648659e-11
in O 0 4.3720048414908064e-11
vivo O 0 1.285532214012619e-08
model O 0 2.7559526216691665e-08
of O 0 1.7851169786808896e-06
vascular B-Disease 1 0.9999982118606567
injury I-Disease 1 0.9999994039535522
. O 0 0.000531771860551089

In O 0 2.1616457956952218e-08
this O 0 3.4081715227785025e-10
model O 0 1.9194044131864985e-09
, O 0 3.3226682516485084e-10
the O 0 7.225648412934049e-10
exteriorized O 0 1.751009222061839e-07
mesentery O 0 1.6681798342688126e-06
was O 0 1.51792207248036e-07
superfused O 0 1.1466106997204406e-07
with O 0 5.514583789612004e-10
ferric O 0 1.5541170796495862e-05
chloride O 0 9.096978033085179e-07
and O 0 7.183917460906741e-09
the O 0 1.4152266913924905e-08
accumulation O 0 8.672125659359153e-06
of O 0 2.1066907720523886e-05
fluorescently O 0 1.5015551980468445e-05
labeled O 0 1.00806040848056e-07
platelets O 0 1.911507183649519e-07
was O 0 3.000272741360277e-08
observed O 0 8.486964464538005e-10
by O 0 7.44208306091565e-11
intravital O 0 1.4015834892688872e-07
microscopy O 0 9.404400884704955e-07
. O 0 2.0581910575856455e-07

We O 0 4.207101653719292e-07
conclude O 0 6.440644142458041e-07
that O 0 4.0725950389841614e-10
these O 0 7.241331839713538e-11
mice O 0 3.062820885801898e-09
very O 0 3.516586744023442e-10
closely O 0 9.23241216810311e-09
mimic O 0 1.4496165476884926e-06
severe O 0 3.783242209465243e-05
human O 0 0.0005076333764009178
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.6651598571115755e-06
will O 0 4.5058734521319366e-09
be O 0 5.191055363340524e-10
very O 0 6.025942939080764e-11
useful O 0 1.5180082191257327e-10
for O 0 9.269415963963912e-12
investigating O 0 2.675676069596733e-10
the O 0 4.4476946431393216e-11
role O 0 1.762930801341156e-09
of O 0 5.365942357116182e-09
vWf O 0 6.040070843482681e-08
in O 0 1.773331481658147e-09
normal O 0 1.2109732949738827e-07
physiology O 0 2.972737718209828e-07
and O 0 2.0254696531107896e-10
in O 0 3.7543054776101314e-10
disease O 0 6.900159110756476e-09
models O 0 1.936584892447968e-09
. O 0 1.004890171074635e-09
. O 0 2.353912442742967e-08

Oral O 0 0.005108675919473171
contraceptives O 0 0.00028085047961212695
and O 0 6.677459696291521e-10
the O 0 1.467423182965888e-09
risk O 0 3.3274221777901403e-07
of O 0 0.0007434661383740604
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9928421974182129

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999998807907104
Clinical O 1 0.8819106221199036
Study O 0 3.856451712636044e-06
Group O 0 2.2377318487087905e-07
. O 0 3.875195204727788e-07

BACKGROUND O 0 4.274546427041059e-06
Women O 0 6.056912305041351e-09
with O 0 2.483883099202444e-10
mutations O 0 1.913935454567195e-09
in O 0 1.477406974537132e-09
either O 0 5.1600710371246805e-09
the O 0 4.7104209421888754e-09
BRCA1 O 0 4.422600508036112e-09
or O 0 2.3521609104903973e-09
the O 0 3.859816022355744e-09
BRCA2 O 0 2.6625124327495087e-09
gene O 0 1.6799751589857692e-09
have O 0 1.0065162592276522e-10
a O 0 2.9482780106171447e-10
high O 0 7.175180893881361e-09
lifetime O 0 4.467143099873283e-09
risk O 0 5.605209025816293e-07
of O 0 0.13434909284114838
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0005285051302053034

Oral O 1 0.735200822353363
contraceptives O 1 0.9983874559402466
protect O 0 2.5090346753131598e-05
against O 1 0.9999998807907104
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 0.001082648173905909
general O 0 2.8877207114419434e-06
, O 0 3.6450025220347015e-09
but O 0 1.2366485613313216e-10
it O 0 7.084262430151478e-12
is O 0 7.149009682849705e-12
not O 0 1.7648019547469862e-12
known O 0 2.689540604117191e-11
whether O 0 7.683037539507609e-11
they O 0 1.3891546767064167e-11
also O 0 2.0409340883986715e-11
protect O 0 1.2288328687937167e-10
against O 0 5.508089984118669e-09
hereditary B-Disease 1 0.9992831349372864
forms I-Disease 0 0.12337394803762436
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.007563125807791948

METHODS O 0 4.975254341843538e-06
We O 0 1.3964863043725018e-08
enrolled O 0 5.8321820262108304e-08
207 O 0 2.235587537313677e-08
women O 0 5.638299271915059e-10
with O 0 2.5984996376848812e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.893120717497368e-07
161 O 0 7.070426732980195e-08
of O 0 7.435652094045508e-08
their O 0 2.521037156810735e-09
sisters O 0 1.3928446840338893e-08
as O 0 4.000227649125776e-10
controls O 0 3.758350075599992e-08
in O 0 2.973489454660694e-09
a O 0 2.4366872963810238e-09
case O 0 2.001985066613088e-08
- O 0 1.133137317310684e-08
control O 0 1.6282798753763927e-07
study O 0 1.735884680442723e-08
. O 0 4.598735259264686e-08

All O 0 2.7700869154045904e-08
the O 0 6.078159309197417e-09
patients O 0 8.119863670330574e-10
carried O 0 1.6961369808665694e-10
a O 0 2.212600762330208e-11
pathogenic O 0 8.798235057172477e-11
mutation O 0 4.001278475218584e-11
in O 0 1.2062700838200158e-10
either O 0 1.6925572055015436e-09
BRCA1 O 0 1.9316783728129394e-09
( O 0 4.55151305533974e-10
179 O 0 3.373102241965853e-09
women O 0 3.1725930216275344e-10
) O 0 1.8440353410920096e-10
or O 0 1.5689224364123788e-09
BRCA2 O 0 5.977720984873258e-09
( O 0 4.107718165613505e-09
28 O 0 2.74511734232874e-07
women O 0 9.171595927170983e-09
) O 0 8.191672229429514e-09
. O 0 1.6606132646757032e-07

The O 0 2.105402643337584e-07
control O 0 4.9806753850134555e-06
women O 0 1.870754884336634e-09
were O 0 7.479855068659447e-10
enrolled O 0 1.1244793984843682e-09
regardless O 0 1.2536390814332776e-09
of O 0 1.3046976832242763e-09
whether O 0 3.650866275961562e-10
or O 0 7.684004127428423e-11
not O 0 1.9558932598529033e-11
they O 0 1.6620201742645335e-11
had O 0 2.1033531860670251e-10
either O 0 7.043070016088393e-10
mutation O 0 1.24103705090306e-09
. O 0 1.9166797926573054e-08

Lifetime O 0 5.198898520575312e-07
histories O 0 2.4783824414953415e-07
of O 0 8.165904574752858e-08
oral O 0 4.746606919070473e-06
- O 0 1.831617524317153e-08
contraceptive O 0 2.835684131952121e-09
use O 0 1.0736854461068646e-10
were O 0 1.472039434791128e-10
obtained O 0 1.2222037271136799e-10
by O 0 2.8773660537551038e-11
interview O 0 2.3373845081664513e-09
or O 0 2.5274669510078063e-11
by O 0 4.6873980391604064e-12
written O 0 1.3764342096656002e-11
questionnaire O 0 2.080973761364735e-11
and O 0 7.540396258776116e-12
were O 0 5.4465723597907356e-11
compared O 0 7.222396569694922e-10
between O 0 7.161358173135568e-09
patients O 0 3.4285938532718774e-09
and O 0 5.856610751919789e-10
control O 0 3.911044132109964e-06
women O 0 4.4906167673275377e-10
, O 0 5.117537643650749e-11
after O 0 2.3038113083906353e-10
adjustment O 0 3.5535645537265736e-09
for O 0 4.214086371523429e-11
year O 0 2.5791362101568183e-11
of O 0 6.371676519734137e-10
birth O 0 2.63943533695965e-09
and O 0 2.736184168128375e-09
parity O 0 1.5125378922675736e-06
. O 0 1.2592359155405575e-07

RESULTS O 0 6.013884217281884e-07
The O 0 1.8746918684087177e-08
adjusted O 0 1.4072919896079839e-07
odds O 0 5.781648155789298e-07
ratio O 0 1.072589768114085e-07
for O 0 3.3193973081324657e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 5.7128636399284005e-06
with O 0 1.858017184552807e-09
any O 0 1.565992557850393e-09
past O 0 4.881058335293176e-10
use O 0 7.653244704641793e-11
of O 0 2.0174741877099223e-09
oral O 0 1.2757417380271363e-06
contraceptives O 0 4.423494374350412e-06
was O 0 1.224697030011157e-06
0 O 0 3.0275728590822837e-07
. O 0 8.891930036725171e-08

5 O 0 8.77539378052461e-07
( O 0 5.503931088668423e-09
95 O 0 6.286276743594499e-08
percent O 0 8.2454398864229e-09
confidence O 0 1.1402921273884203e-08
interval O 0 1.0795677241048907e-08
, O 0 3.4274547089374607e-10
0 O 0 3.2451352716122983e-10
. O 0 3.483911770185699e-11
3 O 0 8.369230308780118e-10
to O 0 7.309549493461631e-11
0 O 0 4.659709063048467e-09
. O 0 3.3048824787940134e-10
8 O 0 4.790006968846683e-08
) O 0 3.0408120466063338e-09
. O 0 7.193696660579008e-08

The O 0 1.6631047117243725e-07
risk O 0 4.1670787709335855e-08
decreased O 0 1.0355915236459623e-08
with O 0 5.592626362016517e-11
increasing O 0 2.730421722052512e-10
duration O 0 3.1792517507511775e-09
of O 0 1.1597577065369791e-10
use O 0 2.4660003206111725e-11
( O 0 1.97289615200269e-11
P O 0 4.216888616070946e-09
for O 0 6.488599241238902e-11
trend O 0 2.54019938417116e-09
, O 0 1.5947961007345413e-10
< O 0 1.4583826368763653e-09
0 O 0 3.7383066087137706e-10
. O 0 1.8252607758562078e-11
001 O 0 2.287999567585075e-09
) O 0 7.551867117761013e-12
; O 0 1.9529176453064734e-12
use O 0 1.2057911093210638e-11
for O 0 5.659996776818943e-11
six O 0 2.9190250216970526e-10
or O 0 5.777203368473316e-11
more O 0 4.295478469446001e-12
years O 0 1.2701881213494914e-10
was O 0 1.5664676222826301e-09
associated O 0 2.7072777353254196e-10
with O 0 1.2144371445976798e-11
a O 0 5.600998553845216e-10
60 O 0 1.541699545803965e-09
percent O 0 2.8886968372887623e-09
reduction O 0 4.782630824706757e-08
in O 0 1.1091961127362993e-08
risk O 0 2.855935292700451e-07
. O 0 1.0713977616205739e-07

Oral O 0 0.00022070818522479385
- O 0 1.057032363860344e-06
contraceptive O 0 1.1050597947814822e-07
use O 0 4.1474121914575335e-09
protected O 0 2.7663334094540915e-06
against O 1 0.999987006187439
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 5.559834193036295e-08
for O 0 7.209018382248189e-10
carriers O 0 2.810354171600693e-10
of O 0 2.335143189924338e-09
the O 0 1.3904497553340889e-09
BRCA1 O 0 1.1511940289921085e-09
mutation O 0 2.6309296408122407e-10
( O 0 1.382868958232919e-10
odds O 0 1.6356844767528855e-08
ratio O 0 2.2535846522231395e-09
, O 0 3.114215829658207e-10
0 O 0 6.604777280649898e-10
. O 0 3.2236775748817337e-11
5 O 0 2.36071273640448e-10
; O 0 2.4596774270135846e-11
95 O 0 2.227915851804596e-09
percent O 0 2.5905670941739345e-09
confidence O 0 6.763897886230552e-09
interval O 0 1.0740879297088668e-08
, O 0 3.287323191436542e-10
0 O 0 3.2536012772865774e-10
. O 0 1.332633656203619e-11
3 O 0 4.6359924232852734e-10
to O 0 1.0352311369254963e-10
0 O 0 1.0719548582116545e-09
. O 0 4.7142269254951685e-11
9 O 0 2.007084498600875e-09
) O 0 1.474134703194352e-11
and O 0 7.889798189775199e-12
for O 0 2.8221217029944512e-11
carriers O 0 1.0743778089405964e-10
of O 0 1.0866655353325427e-09
the O 0 1.8991423988978795e-09
BRCA2 O 0 1.768157176229579e-09
mutation O 0 2.708780977300762e-10
( O 0 2.5226715161252855e-10
odds O 0 2.2800634269515285e-08
ratio O 0 3.848260377026236e-09
, O 0 6.801502139275328e-10
0 O 0 8.62681537316945e-10
. O 0 3.440979098878749e-11
4 O 0 6.452023915137772e-10
; O 0 1.3191141755297675e-11
95 O 0 1.7428707366207163e-09
percent O 0 1.3686003441648609e-09
confidence O 0 5.876856778996853e-09
interval O 0 6.065778990205217e-09
, O 0 8.46250791664005e-10
0 O 0 1.2794332260313013e-09
. O 0 5.865987556807895e-11
2 O 0 3.2606108923971533e-09
to O 0 2.649163111101416e-10
1 O 0 2.838613077926766e-08
. O 0 3.9700895348993015e-10
1 O 0 6.112108508204983e-08
) O 0 2.4114799046515145e-09
. O 0 4.215571536292373e-08

CONCLUSIONS O 0 1.5413892242577276e-06
Oral O 0 4.931346848024987e-05
- O 0 3.622262170210888e-07
contraceptive O 0 2.815647270892896e-08
use O 0 3.836136963641934e-10
may O 0 9.190867511499334e-11
reduce O 0 1.300423796424255e-10
the O 0 1.0827216900821668e-10
risk O 0 4.352375881921944e-08
of O 0 0.001427640556357801
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 5.018524689148762e-07
women O 0 7.955004016624301e-11
with O 0 1.4190736259689363e-11
pathogenic O 0 1.989896913912048e-09
mutations O 0 5.50027634549366e-10
in O 0 5.619435472503653e-10
the O 0 4.055412006209735e-09
BRCA1 O 0 5.6636771716966905e-08
or O 0 1.9479482205042586e-07
BRCA2 O 0 5.071475698059658e-06
gene O 0 4.031311618746258e-05

A O 0 9.854261406871956e-07
Japanese O 0 3.64010361408873e-06
family O 0 1.6815018710758523e-08
with O 0 4.61305260657241e-09
adrenoleukodystrophy B-Disease 1 1.0
with O 0 9.464033112749348e-09
a O 0 3.103421164496467e-08
codon O 0 2.4036882706468532e-08
291 O 0 1.4144441173868927e-08
deletion O 0 1.1404676314441531e-07
: O 0 5.216742593461277e-10
a O 0 4.903706329884017e-10
clinical O 0 2.436609669587142e-08
, O 0 9.219983665431641e-10
biochemical O 0 5.734330557061185e-07
, O 0 1.2196037957323824e-08
pathological O 0 0.0005333119770511985
, O 0 7.0998158463453365e-09
and O 0 3.340468568424626e-09
genetic O 0 4.834753752902543e-08
report O 0 1.6538828973011732e-08
. O 0 1.3319476011020015e-07

We O 0 7.319869865796136e-08
report O 0 2.7913322764305804e-09
a O 0 6.777764460785818e-10
Japanese O 0 1.5634983085988097e-08
family O 0 1.2783208935829293e-09
with O 0 1.4051269481285544e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 0 1.2993737982469611e-05
ALD B-Disease 1 1.0
) O 0 7.942897894963608e-09
with O 0 8.735034362494787e-10
a O 0 4.363811534346951e-09
three O 0 6.949606445871837e-10
base O 0 5.8493574428553075e-09
pair O 0 5.655278556560006e-08
deletion O 0 3.884248300778381e-08
( O 0 1.0626617363840296e-09
delGAG O 0 5.385867751783735e-08
291 O 0 2.5012560911363835e-09
) O 0 3.071530252363175e-10
in O 0 1.1560171708779876e-09
the O 0 8.003610929563365e-08
ALD B-Disease 1 1.0
gene O 0 1.3608303561341017e-05
. O 0 2.906960162363248e-06

A O 0 5.114008558848582e-07
variety O 0 1.0589151777651296e-08
of O 0 7.498486276347194e-09
phenotypes O 0 1.2999390897050489e-08
were O 0 9.894202124272056e-10
observed O 0 1.8189407757773779e-09
within O 0 4.720851487505229e-10
this O 0 1.8468018780914974e-10
family O 0 4.7621107057693735e-09
. O 0 2.3571564256030797e-08

While O 0 1.757570657900942e-07
the O 0 6.318842338259856e-08
proband O 0 7.02058287060936e-06
( O 0 1.0641287850887693e-08
patient O 0 9.1910372645998e-08
1 O 0 2.541507342357363e-07
) O 0 1.2293345508229692e-10
was O 0 7.3630515018408005e-09
classified O 0 7.150571801339822e-10
as O 0 2.0998977556807574e-10
having O 0 1.9911108872783245e-10
a O 0 8.031598996982581e-11
rare O 0 7.595685885819492e-11
intermediate O 0 1.7369271576583856e-09
type O 0 1.7965156029475793e-09
of O 0 1.0147404694293982e-08
adult O 0 1.7620668302242848e-07
cerebral O 0 4.532580351224169e-05
and O 0 7.254209233309439e-09
cerebello O 0 4.736319533549249e-05
- O 0 8.304898528876947e-07
brain O 0 8.056978003878612e-06
stem O 0 4.977397605188116e-09
forms O 0 3.6461986763214327e-09
, O 0 2.617046301889303e-10
his O 0 1.1623226825463462e-09
younger O 0 2.087771200365296e-08
brother O 0 1.8300694648587523e-07
( O 0 5.797384239336623e-10
patient O 0 1.6040290873320373e-08
2 O 0 8.996624245583007e-08
) O 0 3.3266947530030677e-10
and O 0 3.8588221507041e-09
nephew O 0 2.053107527899556e-05
( O 0 4.355629190655463e-09
patient O 0 1.231604613849413e-07
3 O 0 1.1758470463973936e-06
) O 0 2.4035540224787155e-09
had O 0 9.449336602074254e-08
a O 0 1.7119697304224246e-07
childhood O 1 0.5153113603591919
ALD B-Disease 1 1.0
type O 1 0.6612843871116638
. O 0 1.7759608454070985e-05

Another O 0 4.050319148518611e-06
nephew O 0 0.0014447307912632823
( O 0 3.946643190033683e-08
patient O 0 4.52827180197346e-07
4 O 0 6.27970962341351e-07
) O 0 1.650475645043059e-09
of O 0 1.1336295813180186e-07
patient O 0 9.711260418043821e-07
1 O 0 2.7466464871395146e-06
was O 0 9.101753306595128e-08
classified O 0 2.006471877535887e-09
as O 0 2.981034863402954e-10
having O 0 3.41803418901776e-10
an O 0 2.4208154925098313e-10
adolescent O 0 2.146578026440693e-07
form O 0 6.57386536317972e-08
. O 0 6.303963004938851e-07

The O 0 9.377256446896354e-07
tau O 0 1.670293841016246e-06
level O 0 7.611561159137636e-07
in O 0 4.8220698545264895e-09
the O 0 7.836432835972573e-09
cerebrospinal O 0 1.5901217921054922e-05
fluid O 0 5.5175969464471564e-05
( O 0 4.143705822912125e-08
CSF O 0 5.33452803210821e-05
) O 0 1.8721542094368715e-09
in O 0 2.2062900395525276e-09
patient O 0 2.003448074106018e-08
1 O 0 1.887159299940322e-07
was O 0 3.439744133970635e-08
as O 0 1.2346970668097867e-10
high O 0 7.997331685771769e-10
as O 0 1.1796665207175483e-11
that O 0 1.3115921109613238e-12
of O 0 2.9324456751744776e-10
patients O 0 2.8673419194547023e-10
with O 0 5.517711176850071e-09
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 0 0.3674985468387604
( O 0 6.500052052160754e-09
AD B-Disease 0 1.4309553364455496e-07
) O 0 4.263309261176573e-09
. O 0 4.511310436328131e-08

His O 0 1.3086581702737021e-06
brain O 0 9.793339813768398e-06
magnetic O 0 4.353241365606664e-06
resonance O 0 2.451892896715435e-06
image O 0 1.3282220834298641e-07
( O 0 4.511736262369226e-10
MRI O 0 8.572880005885963e-07
) O 0 4.669644670940443e-10
showed O 0 9.741703443921779e-09
abnormalities B-Disease 0 4.702156729763374e-06
in I-Disease 0 3.293952666183486e-09
the I-Disease 0 1.0900330416063753e-08
bilateral I-Disease 1 0.9869533181190491
cerebellar I-Disease 1 0.9999960660934448
hemispheres I-Disease 0 0.0006994311697781086
and O 0 2.3240669833057837e-08
brain O 0 6.938057049410418e-05
stem O 0 3.751582156041877e-08
, O 0 1.345588918066909e-10
but O 0 1.532752397226389e-11
not O 0 7.1537016761713534e-12
in O 0 2.7414261832836573e-11
the O 0 1.0130092320537187e-09
cerebral O 0 2.0175108147668652e-05
white O 0 3.063878484255156e-09
matter O 0 2.6628590887867176e-08
, O 0 2.5313652216030214e-11
where O 0 4.844556179828263e-12
marked O 0 1.983316982867578e-11
reductions O 0 7.694010428771492e-10
of O 0 4.637000783347389e-10
the O 0 1.3636755058499261e-09
cerebral O 0 1.9467593119770754e-06
blood O 0 3.8943501756705245e-09
flow O 0 1.1073759687008078e-08
and O 0 7.875476937257986e-10
oxygen O 0 8.82385542411157e-09
metabolism O 0 5.310900164090526e-08
were O 0 2.3958909856069965e-10
clearly O 0 2.2570807722832598e-10
demonstrated O 0 8.475248280959136e-11
by O 0 3.86647137917695e-12
positron O 0 1.5393223362636377e-09
emission O 0 3.2318441256506958e-09
tomography O 0 3.4486231470509665e-07
( O 0 4.157438837637528e-09
PET O 0 6.061051749384205e-08
) O 0 4.774971973375841e-09
. O 0 3.765920553178148e-08

In O 0 5.894427772545896e-07
patients O 0 4.298200337871094e-07
2 O 0 1.7026593468472129e-06
and O 0 6.716434519660197e-09
3 O 0 6.871700719557339e-08
, O 0 9.310316406718755e-11
the O 0 6.12155048873575e-11
autopsy O 0 3.7485334836162565e-09
findings O 0 8.095368264626757e-10
showed O 0 5.4752424816228995e-09
massive O 0 8.665247719363833e-08
demyelination B-Disease 1 1.0
of I-Disease 0 5.742887151427567e-05
the I-Disease 0 2.4054552341112867e-06
cerebral I-Disease 1 0.9957306981086731
white I-Disease 0 2.186847147811477e-08
matter I-Disease 0 2.503099594264313e-08
with O 0 4.536862552306786e-11
sparing O 0 1.2422093353947616e-09
of O 0 4.408401199640366e-09
the O 0 1.8622115405264594e-08
U O 0 0.0009354713256470859
- O 0 5.960343514743727e-06
fibers O 0 1.9093754133336915e-07
, O 0 6.601074131751261e-10
compatible O 0 7.500087662037913e-09
with O 0 4.386354821028782e-11
the O 0 1.3770730389328634e-10
findings O 0 5.088855448143192e-10
of O 0 2.025537426675328e-08
childhood O 0 0.00011420228111092001
ALD B-Disease 1 1.0
. O 0 1.1916075891349465e-05

Oleic O 0 0.00023369980044662952
and O 0 4.529960904164909e-07
erucic O 0 0.002861675340682268
acids O 0 5.700225642613077e-07
( O 0 8.733305634223143e-09
Lorenzos O 0 7.04517162830598e-07
Oil O 0 5.275765602164029e-08
) O 0 3.549943325409366e-11
were O 0 3.901290054897366e-11
administered O 0 4.0303850534773034e-11
to O 0 1.9553860267085277e-11
patients O 0 4.1721329169241983e-10
1 O 0 2.857811587375636e-08
and O 0 9.535363609813885e-10
4 O 0 2.489809958206024e-08
, O 0 1.4242562684785298e-10
but O 0 2.34599336484953e-11
sufficient O 0 5.573737582587057e-10
effectiveness O 0 1.4079780674691733e-09
was O 0 9.625344965513705e-09
not O 0 1.5601096803319336e-10
obtained O 0 9.655426680410528e-09
. O 0 4.001406850306921e-08

The O 0 1.5648205931029224e-07
findings O 0 1.3130690312834759e-08
in O 0 2.1538417716016056e-09
this O 0 1.880717664937137e-10
family O 0 1.5972650979634295e-10
suggest O 0 1.2661582893258583e-10
that O 0 3.792063017760139e-12
delGAG291 O 0 1.4945029658264275e-09
is O 0 2.76546337912853e-11
part O 0 5.5265111931213085e-11
of O 0 6.749241721060173e-10
the O 0 3.5810510112810334e-10
cause O 0 8.70772431937894e-09
of O 0 1.3791510156124787e-08
Japanese O 0 1.6025043805711903e-05
ALD B-Disease 1 0.9999997615814209
with O 0 1.4680082704998654e-09
phenotypic O 0 3.6086432828597026e-06
variations O 0 5.279095148580382e-06
. O 0 7.269710522450623e-07

Moreover O 0 7.764779752506001e-07
, O 0 2.4159823031055794e-09
although O 0 6.1740856871495e-10
the O 0 2.5543217541112995e-10
scale O 0 7.95340326931182e-09
of O 0 9.021635660744209e-10
the O 0 1.194274124038941e-10
study O 0 3.851222812878419e-11
is O 0 2.8869517453705695e-12
limited O 0 1.360380124520999e-11
, O 0 2.9772320025989174e-11
there O 0 4.4201590304604466e-11
is O 0 5.7696711991406247e-11
a O 0 1.7627282966614644e-10
possibility O 0 1.3321420633261027e-09
that O 0 1.4853061836017645e-10
PET O 0 5.031288274892631e-09
can O 0 8.196603118459933e-11
detect O 0 3.064464237922948e-08
an O 0 4.281955678919758e-09
insidious B-Disease 0 1.4322745300887618e-06
lesion I-Disease 0 1.6302192307193764e-05
which O 0 3.0189097888211336e-09
is O 0 1.8397001977366045e-10
undetectable O 0 6.767704618937387e-09
by O 0 4.9742987506817826e-11
computed O 0 4.1933262195925636e-08
tomogram O 0 8.046059747357504e-07
( O 0 1.957261241969377e-09
CT O 0 1.1480084367576637e-06
) O 0 2.9113295108018633e-10
or O 0 1.498035306912726e-10
MRI O 0 2.8655603045990574e-07
analysis O 0 2.7248097111964853e-09
, O 0 2.684642508299362e-10
and O 0 2.7640027419617574e-11
that O 0 4.324208959655129e-12
the O 0 3.4644696833563415e-11
higher O 0 1.0525093019353449e-09
level O 0 1.0921224813387198e-08
of O 0 1.1312903946958386e-09
tau O 0 3.3280802558266487e-09
reflects O 0 9.422903429756602e-11
the O 0 7.815434063807025e-12
process O 0 1.7065862611964633e-10
of O 0 2.233966789333408e-09
neuronal B-Disease 0 4.472798991628224e-06
degeneration I-Disease 1 0.9799254536628723
in O 0 3.157901119266171e-06
ALD B-Disease 1 1.0
. O 0 1.8223283404950052e-05

Lorenzos O 0 0.00031215479248203337
Oil O 0 1.5194369780147099e-06
should O 0 4.03309563523635e-09
be O 0 4.774329542822642e-11
given O 0 1.1667238355994591e-11
in O 0 9.729024877391801e-12
the O 0 3.0343203644145333e-11
early O 0 1.2626883982846948e-09
stage O 0 5.879524866969632e-09
. O 0 1.1108829411909937e-09
. O 0 1.8954990466113486e-08

Nonsense O 0 2.1231344362604432e-05
mutation O 0 7.118571687669828e-08
in O 0 3.0804507389348146e-08
exon O 0 1.3582713336290908e-06
4 O 0 2.562696579389012e-07
of O 0 3.380717217282836e-08
human O 0 1.0920766513322633e-08
complement O 0 8.034859177996623e-08
C9 O 0 3.279977318015881e-05
gene O 0 1.546905004090604e-08
is O 0 2.9402810741707697e-10
the O 0 1.6567133775957643e-10
major O 0 1.680468653120215e-09
cause O 0 3.4651339575475504e-09
of O 0 1.0343716105865042e-08
Japanese O 0 2.616196297822171e-06
complement B-Disease 0 8.135276402754243e-06
C9 I-Disease 1 0.9973887801170349
deficiency I-Disease 1 0.9989394545555115
. O 0 6.9280531533877365e-06

Deficiency B-Disease 1 0.9999536275863647
of I-Disease 0 7.718187407590449e-05
the I-Disease 0 4.557815884709271e-07
ninth I-Disease 0 3.7718336898251437e-07
component I-Disease 0 1.2809165639282583e-07
of I-Disease 0 3.263275161202728e-08
human I-Disease 0 2.7334614571827842e-09
complement I-Disease 0 2.3219225653292597e-08
( O 0 3.054705377536493e-09
C9 O 0 1.234519004356116e-06
) O 0 1.693234441546565e-10
is O 0 3.07887222661396e-11
the O 0 5.592028923251391e-11
most O 0 5.301702479809656e-11
common O 0 1.1991553527934684e-08
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 3.9181571764856926e-07
Japan O 0 9.47304883425204e-08
but O 0 1.123424200888401e-10
is O 0 1.3019767555744188e-11
rare O 0 4.194471853180559e-11
in O 0 3.042874285874575e-11
other O 0 4.9258923329187354e-11
countries O 0 8.095553671871869e-10
. O 0 3.789380897956107e-08

We O 0 1.0436545494485472e-07
studied O 0 2.6877404479819234e-07
the O 0 9.538455580937466e-10
molecular O 0 9.740588780005055e-09
basis O 0 8.551624297581384e-09
of O 0 3.9290156905735785e-08
C9 B-Disease 0 0.0047185299918055534
deficiency I-Disease 0 0.000449715880677104
in O 0 1.5628126348588012e-08
four O 0 4.632370931290097e-09
Japanese O 0 3.934738117550296e-07
C9 B-Disease 0 0.1761656552553177
- I-Disease 0 0.0008022644324228168
deficient I-Disease 0 0.0002806965494528413
patients O 0 1.8411293467579526e-06
who O 0 5.201665942422551e-08
had O 0 1.0174517228733748e-06
suffered O 1 0.9600266218185425
from O 0 8.6468797235284e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 6.249824764381628e-07

Direct O 0 7.847370397939812e-08
sequencing O 0 2.6318959456261837e-08
of O 0 2.3679849192603797e-08
amplified O 0 8.466680867513787e-08
C9 O 0 1.7396355360688176e-06
cDNA O 0 4.4607173066424366e-08
and O 0 4.458722280276106e-10
DNA O 0 8.255696126724388e-10
revealed O 0 2.974362756091864e-09
a O 0 3.977828066936695e-10
nonsense O 0 1.2250891412435294e-09
substitution O 0 3.940245907330109e-10
( O 0 1.5218988569376535e-10
CGA O 0 7.85124711910612e-08
- O 0 1.4560848526912196e-08
- O 0 4.740071890552144e-09
> O 0 2.2232293783730483e-09
TGA O 0 1.758498768822392e-08
) O 0 8.127203077190615e-11
at O 0 2.7584754480614038e-09
codon O 0 1.7800242391174947e-09
95 O 0 2.0368617015265045e-08
in O 0 3.006119353443637e-09
exon O 0 1.1574655189861005e-07
4 O 0 5.166307914805657e-08
in O 0 2.205335025706745e-09
the O 0 7.11645142814632e-09
four O 0 6.023905996244139e-08
C9 B-Disease 0 0.0004066038818564266
- I-Disease 0 4.160931712249294e-05
deficient I-Disease 0 4.681769951275783e-06
individuals O 0 3.95665056274197e-09
. O 0 2.0771388165030658e-07

An O 0 1.6980875372496484e-08
allele O 0 2.02547170147227e-08
- O 0 7.895424758430636e-09
specific O 0 6.789875328649941e-10
polymerase O 0 7.509279953410442e-08
chain O 0 7.999913620437837e-09
reaction O 0 3.8589087481000206e-10
system O 0 1.98247196436796e-09
designed O 0 2.4871458226272125e-09
to O 0 1.3196886639033067e-10
detect O 0 3.346018218053359e-08
exclusively O 0 1.2021370565662437e-08
only O 0 4.0096995168603655e-10
one O 0 1.520935322130157e-10
of O 0 8.557101693895675e-10
the O 0 2.551259203897871e-10
normal O 0 3.8774587984846676e-09
and O 0 4.2011977230416164e-11
mutant O 0 1.2367924739908887e-10
alleles O 0 6.392366497243174e-11
indicated O 0 9.88944814928061e-10
that O 0 9.784444088278832e-12
all O 0 2.006871925586129e-11
the O 0 7.258353640349213e-11
four O 0 3.590871003322782e-11
patients O 0 1.3423966799264164e-11
were O 0 1.2555569431360603e-11
homozygous O 0 1.2747283263669917e-11
for O 0 1.12048963857303e-11
the O 0 1.6180146111821614e-10
mutation O 0 9.244437160216279e-11
in O 0 1.129337068306313e-09
exon O 0 9.472669404431144e-08
4 O 0 1.716751185654175e-08
and O 0 1.4625353705888244e-10
that O 0 9.245684946812549e-12
the O 0 1.2768679169550268e-10
parents O 0 5.590194973592588e-11
of O 0 1.312880582027276e-09
patient O 0 1.1602014460265764e-08
2 O 0 4.6468196046589583e-07
were O 0 1.916248493216699e-08
heterozygous O 0 6.489326409564455e-08
. O 0 7.642795907258915e-08

The O 0 3.319884100960735e-08
common O 0 9.135439071883411e-09
mutation O 0 1.3850551816574352e-09
at O 0 1.861575960049322e-08
codon O 0 3.104562162903335e-09
95 O 0 1.4693311456426272e-08
in O 0 8.432413878267653e-09
exon O 0 5.99782424615114e-07
4 O 0 1.5095247363206e-07
might O 0 1.7949811637052449e-09
be O 0 3.925346853117517e-11
responsible O 0 1.591174414450336e-10
for O 0 4.9671308732790465e-11
most O 0 2.851264502279349e-10
Japanese O 0 1.7905250615513069e-06
C9 B-Disease 1 0.5075559616088867
deficiency I-Disease 0 0.004125696606934071
. O 0 5.8593769836079446e-08
. O 0 3.0860266519994184e-07

BRCA1 O 0 1.2842606622598396e-07
required O 0 5.777385236882537e-09
for O 0 1.6936486657570526e-09
transcription O 0 9.455058034291142e-07
- O 0 2.30252794608532e-06
coupled O 0 2.3260950001713354e-06
repair O 0 0.0009542696643620729
of O 0 6.89506987328059e-06
oxidative O 0 5.255891301203519e-05
DNA O 0 6.1865084717283025e-06
damage O 0 0.0008723047794774175
. O 0 1.5670951825086377e-06

The O 0 2.1535363430302823e-06
breast B-Disease 1 0.9999921321868896
and I-Disease 1 0.999182403087616
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 0.9999442100524902
gene O 0 2.3488860279030632e-06
BRCA1 O 0 3.2790671866678167e-07
encodes O 0 5.31549133597764e-08
a O 0 2.6673583874980977e-07
zinc O 0 0.0009537734440527856
finger O 0 0.00022709490440320224
protein O 0 6.846327096354798e-07
of O 0 1.752248692810099e-07
unknown O 0 6.948022246433538e-07
function O 0 5.165184688848967e-07
. O 0 4.0017889091359393e-07

Association O 0 5.922657919654739e-07
of O 0 1.8382714017661783e-07
the O 0 7.731647855280244e-08
BRCA1 O 0 2.5350409771363047e-08
protein O 0 5.27564214536369e-09
with O 0 2.60786281458536e-10
the O 0 4.910812645420037e-09
DNA O 0 4.045586621259645e-08
repair O 0 3.834170001937309e-06
protein O 0 2.335327451419289e-07
Rad51 O 0 4.097212240594672e-07
and O 0 3.053457209301058e-10
changes O 0 2.9127736334011445e-10
in O 0 6.479670272563354e-11
the O 0 3.921462807254805e-11
phosphorylation O 0 3.3607511218392006e-10
and O 0 3.5299460576787567e-10
cellular O 0 3.746490762068788e-08
localization O 0 3.1518625291937497e-06
of O 0 1.1795709298212387e-07
the O 0 1.4466119857559079e-08
protein O 0 1.0010492879075628e-08
after O 0 9.733216010943124e-09
exposure O 0 2.614324934313572e-08
to O 0 3.3877950444960447e-10
DNA O 0 7.446324445936625e-08
- O 0 4.485433535705852e-08
damaging O 0 1.597434362565764e-08
agents O 0 8.677279450530762e-10
are O 0 7.468072167615691e-12
consistent O 0 2.1876001010667778e-10
with O 0 1.39479911995255e-11
a O 0 1.7077193825709713e-10
role O 0 2.1984263298691076e-09
for O 0 1.5237177075633213e-09
BRCA1 O 0 1.2629853607393215e-08
in O 0 2.0529348887521337e-08
DNA O 0 4.6037555989641987e-07
repair O 0 0.00011869761510752141
. O 0 9.849019306784612e-07

Here O 0 1.8455873487255303e-06
, O 0 4.428695188352094e-09
it O 0 5.6717328750233165e-11
is O 0 1.701067238457643e-11
shown O 0 7.749619695962551e-11
that O 0 8.819804261928077e-12
mouse O 0 5.328915642088816e-10
embryonic O 0 3.4150577921110425e-09
stem O 0 2.8510429572747853e-09
cells O 0 1.2571637064695551e-09
deficient B-Disease 0 5.511497747079375e-08
in I-Disease 0 2.8623599046539994e-09
BRCA1 I-Disease 0 2.2608346306185467e-09
are O 0 4.9637974286476094e-11
defective O 0 1.501440927142994e-08
in O 0 1.6398249425009226e-10
the O 0 6.31066726652918e-11
ability O 0 2.142212275624278e-11
to O 0 8.470379779523807e-12
carry O 0 3.797659756110683e-11
out O 0 3.2278613809610945e-11
transcription O 0 1.5492583216314415e-08
- O 0 3.991284103221915e-08
coupled O 0 6.030711574567249e-08
repair O 0 1.4821099284745287e-05
of O 0 1.2419443464750657e-06
oxidative O 0 2.380028490733821e-06
DNA O 0 3.713009846251225e-07
damage O 0 4.58120703115128e-05
, O 0 1.141273386906505e-08
and O 0 3.1087457053047274e-09
are O 0 5.913554645964325e-10
hypersensitive O 0 3.625645774718578e-07
to O 0 8.38977243233785e-09
ionizing O 0 0.000750588602386415
radiation O 0 0.023107893764972687
and O 0 5.027125382639497e-09
hydrogen O 0 3.793835645637955e-08
peroxide O 0 1.41492108696184e-07
. O 0 4.03239006629974e-08

These O 0 8.679105434339363e-09
results O 0 1.5383076146235908e-08
suggest O 0 1.3544998012093856e-08
that O 0 2.2564609902797628e-10
BRCA1 O 0 2.5258743985290266e-09
participates O 0 2.9087776631797624e-09
, O 0 3.0905586423379816e-10
directly O 0 2.5091104194352454e-10
or O 0 5.824269538878823e-11
indirectly O 0 5.230881283679878e-10
, O 0 6.520210066307541e-11
in O 0 1.6386367263088175e-10
transcription O 0 1.9827608355171833e-07
- O 0 6.769398055439524e-07
coupled O 0 4.737191261483531e-07
repair O 0 0.00017807201948016882
of O 0 2.5107462988671614e-06
oxidative O 0 7.96605945652118e-06
DNA O 0 5.25491714142845e-07
damage O 0 9.368483915750403e-06
. O 0 1.961170958963976e-08
. O 0 1.3458524961151852e-07

Truncation O 0 2.6778010578709655e-05
mutations O 0 2.29211821078934e-07
in O 0 9.845336990110809e-09
the O 0 3.04760527924941e-09
transactivation O 0 3.625255658334936e-06
region O 0 1.474933526424138e-07
of O 0 6.922466155856455e-08
PAX6 O 0 7.5842608566745184e-06
result O 0 2.1185343257457134e-08
in O 0 5.848844075728721e-09
dominant O 0 5.035005415265914e-06
- O 0 1.4301299700036907e-07
negative O 0 7.61267671123278e-09
mutants O 0 1.189158069792029e-07
. O 0 1.2411446448368224e-07

PAX6 O 0 9.401957504451275e-05
is O 0 2.2115914433129547e-08
a O 0 2.4895807637648204e-09
transcription O 0 1.2970809315504539e-08
factor O 0 2.8212099323354778e-09
with O 0 5.07484679279635e-11
two O 0 1.9634595338491323e-10
DNA O 0 9.380981547124634e-10
- O 0 5.337888464573837e-10
binding O 0 3.135422199651572e-10
domains O 0 1.4427185668353104e-08
( O 0 2.894132988817688e-10
paired O 0 1.7141947861176732e-09
box O 0 2.2967716617472433e-08
and O 0 1.5168223344019793e-09
homeobox O 0 2.4226702421970003e-08
) O 0 1.2682682681841584e-10
and O 0 2.9604493856361103e-10
a O 0 6.959399723172055e-09
proline O 0 3.1471751071876497e-07
- O 0 1.0546399380473304e-06
serine O 0 3.8709438854311884e-07
- O 0 2.6179782253166195e-07
threonine O 0 2.486946470980911e-07
( O 0 3.801367221001328e-09
PST O 0 1.971757592400536e-05
) O 0 1.4982312279698817e-08
- O 0 5.5950248878389175e-08
rich O 0 5.577505124421123e-09
transactivation O 0 2.0873346784355817e-06
domain O 0 1.22810990887956e-06
. O 0 3.04370956882849e-07

PAX6 O 0 0.0038180360570549965
regulates O 0 9.993029379984364e-06
eye O 0 2.7174130082130432e-05
development O 0 7.591814465968127e-08
in O 0 4.267776354538455e-09
animals O 0 1.8704006399250517e-10
ranging O 0 9.988712079689321e-09
from O 0 6.451568723697676e-10
jellyfish O 0 2.625936412758989e-10
to O 0 4.355834859470775e-10
Drosophila O 0 1.4860700225938217e-08
to O 0 8.464981604561217e-09
humans O 0 2.678232249309076e-07
. O 0 1.591821927604542e-07

Heterozygous O 0 7.770780143800948e-07
mutations O 0 1.575890991034612e-07
in O 0 6.676609487499263e-09
the O 0 4.140125131613104e-09
human O 0 8.922642180664297e-09
PAX6 O 0 1.363120759378944e-06
gene O 0 3.7890899307058135e-09
result O 0 2.229216589100247e-09
in O 0 7.373190946680097e-11
various O 0 9.73563868411631e-11
phenotypes O 0 2.681624255984616e-09
, O 0 1.4768879175175442e-10
including O 0 7.884043418115994e-10
aniridia B-Disease 1 1.0
, O 0 5.989833198327688e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 9.035744028551562e-07
autosomal B-Disease 1 0.9364017248153687
dominant I-Disease 1 0.9995142221450806
keratitis I-Disease 1 0.9999915361404419
, O 0 3.7701650512644846e-07
and O 0 9.007060839394398e-07
familial B-Disease 1 0.9999814033508301
foveal I-Disease 1 0.9999998807907104
dysplasia I-Disease 1 1.0
. O 0 0.16908226907253265

It O 0 3.909101664589798e-08
is O 0 4.986957513608559e-09
believed O 0 1.733220567068372e-09
that O 0 7.558727081746763e-12
the O 0 2.6484595766484986e-11
mutated O 0 1.1565370189314805e-10
allele O 0 1.10097941874443e-09
of O 0 8.256771266701435e-09
PAX6 O 0 1.4590367527489434e-06
produces O 0 1.681773720285662e-09
an O 0 2.1330313904055487e-10
inactive O 0 3.397167702701154e-08
protein O 0 7.378856992090732e-08
and O 0 8.097132742079793e-09
aniridia B-Disease 1 1.0
is O 0 1.703050145351881e-08
caused O 0 2.367637108591225e-08
due O 0 4.3881442479687394e-08
to O 0 5.752446963214197e-09
genetic O 0 3.634924041762133e-07
haploinsufficiency O 0 1.023373260977678e-05
. O 0 4.039904411001771e-07

However O 0 1.6618838571957895e-07
, O 0 3.2753333378821026e-09
several O 0 3.5178610024999557e-10
truncation O 0 5.0312429777932266e-08
mutations O 0 2.457138492673039e-09
have O 0 1.5278085740977332e-10
been O 0 2.4768390116669536e-10
found O 0 2.912060870219335e-11
to O 0 7.648264833959306e-12
occur O 0 1.3361008133205843e-10
in O 0 8.93569593318766e-11
the O 0 8.394345774043188e-10
C O 0 2.8685758479696233e-06
- O 0 4.7646846468296644e-08
terminal O 0 2.0800329991743638e-07
half O 0 2.069615590016838e-09
of O 0 1.0978109532544522e-09
PAX6 O 0 1.5662718055864389e-07
in O 0 3.1168542746762284e-10
patients O 0 1.2607938304487476e-10
with O 0 1.4233247913608693e-10
Aniridia B-Disease 1 0.999996542930603
resulting O 0 7.675077462465651e-09
in O 0 1.029077600911421e-09
mutant O 0 1.0452791965320785e-09
proteins O 0 1.2919981751124965e-10
that O 0 3.577090013084927e-11
retain O 0 1.5921771678861774e-09
the O 0 4.726707913960126e-10
DNA O 0 2.3193231779572443e-09
- O 0 4.305982792551788e-10
binding O 0 5.455807472465324e-10
domains O 0 7.881100216877712e-09
but O 0 8.150555230734824e-10
have O 0 9.405538847762074e-11
lost O 0 4.6429500244471456e-09
most O 0 3.387767150142551e-11
of O 0 3.2797076165991257e-10
the O 0 3.2001912231294227e-10
transactivation O 0 3.9356987713290437e-07
domain O 0 6.193505441842717e-07
. O 0 6.710508273499727e-07

It O 0 4.66509142427185e-08
is O 0 3.6967369165807895e-09
not O 0 2.1853231724211497e-10
clear O 0 9.294636171830462e-10
whether O 0 9.357654928709991e-11
such O 0 5.0420813357821004e-11
mutants O 0 1.0492447799492766e-08
really O 0 8.606768631125306e-09
behave O 0 1.6360018895156259e-09
as O 0 9.319773841554024e-10
loss O 0 7.41367012224714e-09
- O 0 4.240838435976002e-08
of O 0 2.539586319016962e-07
- O 0 1.2038630359256786e-07
function O 0 1.427466003178779e-07
mutants O 0 7.008662805674248e-08
as O 0 3.2007665407007835e-09
predicted O 0 4.613943715980895e-08
by O 0 2.5416144744383473e-09
haploinsufficiency O 0 7.690862730669323e-06
. O 0 5.519702881429112e-07

Contrary O 0 5.180571633900399e-07
to O 0 1.5529348917908692e-09
this O 0 2.79191114671562e-10
theory O 0 6.075542557937297e-08
, O 0 1.294000739893164e-10
our O 0 7.959966713544375e-11
data O 0 4.02385819109341e-10
showed O 0 2.0950889634274716e-10
that O 0 2.061425682930995e-12
these O 0 1.851300146168966e-12
mutants O 0 1.6476973951906615e-10
are O 0 4.627736562012874e-12
dominant O 0 5.502482913755102e-09
- O 0 1.310591302150499e-09
negative O 0 2.8439645083366827e-10
in O 0 1.7675425012519952e-10
transient O 0 4.194556257886006e-09
transfection O 0 2.390808084840046e-08
assays O 0 3.825157524062206e-09
when O 0 1.4517026469818006e-09
they O 0 8.659254563392338e-11
are O 0 2.607816740329838e-11
coexpressed O 0 1.5662115160353096e-08
with O 0 2.8427388221174965e-10
wild O 0 5.920735457465298e-09
- O 0 7.190487139041579e-08
type O 0 1.0315088729839772e-06
PAX6 O 0 0.0004244595183990896
. O 0 2.297156470376649e-06

We O 0 2.8992945999561925e-07
found O 0 4.6040078416353936e-09
that O 0 1.4216907165409687e-11
the O 0 1.0875274986110739e-10
dominant O 0 4.034697909105489e-08
- O 0 4.364211214635816e-09
negative O 0 1.4737418230215127e-10
effects O 0 4.672803299854422e-08
result O 0 1.1722793846757895e-09
from O 0 2.244814750751445e-10
the O 0 5.212582795954823e-11
enhanced O 0 2.0172422066089268e-10
DNA O 0 1.2395744153348431e-10
binding O 0 2.809480426080313e-10
ability O 0 1.8892422348759652e-10
of O 0 3.06160008456402e-09
these O 0 7.312606631337815e-10
mutants O 0 1.3607667881387897e-07
. O 0 8.676857987666153e-08

Kinetic O 0 4.352195446699625e-06
studies O 0 5.4571245300394366e-08
of O 0 9.551824220466187e-09
binding O 0 1.0168058395265689e-08
and O 0 1.716858211153749e-09
dissociation O 0 1.5731483671288515e-08
revealed O 0 1.974693963902041e-09
that O 0 4.008288926465875e-12
various O 0 6.163258098323965e-11
truncation O 0 1.4304403883613759e-08
mutants O 0 3.811690962862713e-09
have O 0 3.122715697134737e-10
3 O 0 1.0810842887565286e-08
- O 0 2.037816582145524e-09
5 O 0 3.229434941687259e-09
- O 0 7.235246846093446e-10
fold O 0 5.606513586720041e-10
higher O 0 7.944105928636702e-10
affinity O 0 9.594468275420098e-11
to O 0 2.3867675197353222e-11
various O 0 7.915078314990609e-11
DNA O 0 1.3928432018861514e-10
- O 0 2.5971048228656812e-11
binding O 0 1.991675747936572e-11
sites O 0 3.1021442359335794e-11
when O 0 3.1233453323675775e-11
compared O 0 7.036701082929753e-11
with O 0 7.303149404669362e-12
the O 0 1.3690200362237448e-10
wild O 0 7.542690916295669e-10
- O 0 9.837566317116853e-09
type O 0 1.2503662105700641e-07
PAX6 O 0 5.654267079080455e-05
. O 0 1.1113772870885441e-06

These O 0 7.578891292325807e-09
results O 0 3.995715314175641e-09
provide O 0 1.6371943800663757e-09
a O 0 9.487360896898167e-10
new O 0 3.1858185534083816e-10
insight O 0 8.813893503933912e-10
into O 0 9.677080664571847e-11
the O 0 4.631138528221612e-11
role O 0 1.5368610828403462e-09
of O 0 4.040579870689953e-09
mutant O 0 3.793068614754702e-08
PAX6 O 0 1.2146183507866226e-05
in O 0 4.1783007276308126e-08
causing O 0 1.195612981064187e-06
aniridia B-Disease 1 0.999998927116394
. O 0 1.3673765408839245e-07
. O 0 4.75977515179693e-07

Reversal O 0 1.2950229574926198e-05
of O 0 2.7294413484924007e-06
severe O 1 0.999806821346283
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.018182823434472084
excellent O 0 8.963736036093906e-05
neuropsychologic O 0 5.753060395363718e-05
outcome O 0 1.278828449358116e-06
in O 0 7.579123106893348e-09
very B-Disease 0 4.267002751134896e-09
- I-Disease 0 4.6958099630955985e-08
long I-Disease 0 1.5099875128044005e-08
- I-Disease 0 1.0238940717499645e-07
chain I-Disease 0 2.2953441813911013e-08
acyl I-Disease 0 9.244430110300073e-09
- I-Disease 0 3.258274716699816e-08
coenzyme I-Disease 0 2.443973023957824e-08
A I-Disease 0 2.561961537139723e-06
dehydrogenase I-Disease 0 0.00010827502410393208
deficiency I-Disease 1 0.8907763361930847
. O 0 3.556041974661639e-06

Very B-Disease 0 1.1573368965400732e-06
- I-Disease 0 2.9346952032938134e-06
long I-Disease 0 8.92753178050043e-08
- I-Disease 0 9.31302892581698e-08
chain I-Disease 0 6.0589453454440445e-09
acyl I-Disease 0 1.6017384085742492e-09
- I-Disease 0 1.421529449707748e-09
coenzyme I-Disease 0 3.8418776493465145e-10
A I-Disease 0 8.170793819317623e-09
dehydrogenase I-Disease 0 1.7253219297685973e-08
( I-Disease 0 9.6590502263183e-10
VLCAD I-Disease 0 9.526875146548264e-06
) I-Disease 0 1.4266204217960876e-08
deficiency I-Disease 0 2.619301449158229e-05
is O 0 1.0966975105830556e-09
a O 0 1.1128387988890154e-08
disorder O 1 0.9998688697814941
of O 0 0.00012068760406691581
fatty O 0 3.909745646524243e-05
acid O 0 5.485111387315555e-07
beta O 0 2.845191602318664e-07
oxidation O 0 3.4911209922938724e-08
that O 0 2.8546925934236356e-10
reportedly O 0 6.2714362591975714e-09
has O 0 8.628353240225373e-12
high O 0 1.616811406979224e-10
rates O 0 1.6124752921786722e-10
of O 0 1.6605793129453872e-10
morbidity O 0 1.8101509624557366e-08
and O 0 8.669223672264081e-10
mortality O 0 3.6536289371724706e-07
. O 0 7.960753123370523e-08

We O 0 5.7303953582277245e-08
describe O 0 3.201061105073677e-08
the O 0 1.89474258505129e-09
outcome O 0 2.615916017134623e-08
of O 0 1.4128775482902256e-08
a O 0 3.010709903605857e-09
5 O 0 9.008211065975047e-09
- O 0 1.881037992035317e-09
year O 0 5.309943040820997e-10
- O 0 2.7281913617116516e-08
old O 0 1.392247526155188e-07
girl O 0 2.0423625457510752e-08
with O 0 1.2592425768787052e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 5.496758240042254e-05
was O 0 6.323668003460625e-06
first O 0 5.336160402436008e-09
seen O 0 9.309792936562644e-09
at O 0 4.5780030433206775e-08
5 O 0 1.6813599401643842e-09
months O 0 3.5844680001950735e-10
of O 0 9.964653546745694e-10
age O 0 7.568909055066797e-09
with O 0 2.0399242295354725e-09
severe O 1 0.5438365340232849
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999998807907104
hepatomegaly B-Disease 1 1.0
, O 1 0.9999988079071045
encephalopathy B-Disease 1 0.9999743700027466
, O 0 1.6453539330996136e-07
and O 0 7.460270126102841e-07
hypotonia B-Disease 1 0.9988287091255188
. O 0 2.1369005480664782e-05

Biochemical O 0 2.2865644496050663e-05
studies O 0 1.5931066172925057e-06
indicated O 0 0.0020395119208842516
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0038838530890643597
by O 0 4.487784366347114e-09
a O 0 2.606453186615454e-08
stable O 0 4.926214387523942e-06
yet O 0 1.205254740455075e-08
inactive O 0 1.209400295465457e-07
enzyme O 0 5.587058993228311e-08
. O 0 8.418597730042165e-08

Molecular O 0 4.886288934358163e-06
genetic O 0 1.0037761200010209e-07
analysis O 0 5.028125116268711e-08
of O 0 1.4713636176111322e-07
her O 0 4.86647806496876e-08
VLCAD O 0 3.9588492654729635e-05
gene O 0 3.708299090021683e-08
revealed O 0 1.0372406933356615e-07
a O 0 1.4074900356320086e-08
T1372C O 0 7.810546520659045e-08
( O 0 9.929782551765243e-10
F458L O 0 7.068660323739095e-08
) O 0 1.903849966566895e-09
missense O 0 2.4338140747204307e-07
mutation O 0 8.152921893156417e-09
and O 0 7.885672559382328e-09
a O 0 2.5173559947688773e-07
1668 O 0 0.00024873969960026443
ACAG O 0 0.000997323775663972
1669 O 0 0.00022944522788748145
splice O 0 8.755634553381242e-06
site O 0 6.669744720966264e-07
mutation O 0 1.7510492966721358e-07
. O 0 3.756777289254387e-07

After O 0 9.083630203576831e-08
initial O 0 1.9072601276093337e-08
treatment O 0 7.629658682617446e-08
with O 0 9.167604453352851e-10
intravenous O 0 1.615791688891477e-06
glucose O 0 6.7416699494060595e-06
and O 0 3.73235220507695e-09
carnitine O 0 3.6413183579497854e-07
, O 0 1.1988666726026054e-09
the O 0 2.0246442300475564e-09
patient O 0 9.832969993794904e-09
has O 0 2.3095352019719684e-10
thrived O 0 4.707519707380925e-09
on O 0 2.0106438736178234e-09
a O 0 8.765844716762672e-10
low O 0 3.938544423931489e-08
- O 0 1.7860445566952876e-08
fat O 0 8.144156460332397e-09
diet O 0 3.3138897181927973e-10
supplemented O 0 5.546088588381792e-11
with O 0 2.1714279679896364e-11
medium O 0 5.7363223504580674e-08
- O 0 1.3541277432693732e-08
chain O 0 7.731334683569457e-09
triglyceride O 0 3.293935435522144e-08
oil O 0 2.3860611264581166e-08
and O 0 2.959207323627311e-10
carnitine O 0 9.315532878417798e-08
and O 0 6.472434810333993e-10
avoidance O 0 1.0743070788521436e-06
of O 0 2.984059221944335e-07
fasting O 0 5.843940584782104e-07
. O 0 6.39936601487534e-08

Her O 0 1.1960511983488686e-05
ventricular O 1 0.9685142636299133
hypertrophy O 1 0.9820966720581055
resolved O 0 0.0002538456756155938
significantly O 0 1.744523672186915e-07
over O 0 1.8414011648815176e-08
1 O 0 1.8465220463781407e-08
year O 0 1.0358829766188293e-10
, O 0 7.086090741958984e-11
and O 0 9.29863894216787e-11
cognitively O 0 1.689447941544131e-07
, O 0 6.167094057651923e-10
she O 0 1.7234520754971783e-10
is O 0 2.7116486139844298e-11
in O 0 4.489569480070621e-11
the O 0 2.396818576944071e-10
superior O 0 9.772600151336519e-08
range O 0 1.0304941788774613e-08
for O 0 1.6246642919881538e-09
age O 0 2.637057150423061e-07
. O 0 2.0119728105782997e-07

Clinical O 0 3.3141257063107332e-06
recognition O 0 3.038534941879334e-06
of O 1 0.9998866319656372
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.2446752154792193e-06
important O 0 1.1530617882726801e-07
because O 0 8.482481939076081e-10
it O 0 6.362807503101919e-11
is O 0 2.889448923182325e-11
one O 0 1.7772032109841795e-11
of O 0 2.293512463280578e-10
the O 0 1.8468231111068434e-10
few O 0 3.8642483657369553e-10
directly O 0 4.050487500961708e-09
treatable O 0 0.00019917968893423676
causes O 0 1.0097288338783983e-07
of O 0 3.98606152884895e-06
cardiomyopathy B-Disease 1 1.0
in O 0 1.8939592337119393e-05
children O 0 3.9414903341139507e-08
. O 0 8.448464150490054e-09
. O 0 9.836519154760026e-08

Cloning O 0 1.0480105174792698e-06
of O 0 1.1269518296330716e-07
a O 0 5.885449017029032e-09
novel O 0 1.380165981501591e-09
member O 0 1.4459327069005212e-09
of O 0 2.496370887783428e-09
the O 0 1.2234194768367956e-09
low O 0 4.132928381750389e-07
- O 0 1.5295858801778195e-08
density O 0 2.9632869491535985e-09
lipoprotein O 0 1.209487322739733e-06
receptor O 0 2.657965580965538e-07
family O 0 2.7101384603156475e-07
. O 0 2.2649626885140606e-07

A O 0 4.257266255081049e-07
gene O 0 7.783224731383598e-09
encoding O 0 7.298819326706507e-08
a O 0 3.572281670471966e-08
novel O 0 2.788172892564944e-08
transmembrane O 0 5.1494943420493655e-08
protein O 0 1.2016785788659945e-08
was O 0 8.81805117813883e-09
identified O 0 8.337313478490316e-11
by O 0 1.3486554538075235e-12
DNA O 0 5.180479309419006e-11
sequence O 0 5.065060523778975e-11
analysis O 0 1.9774706871977799e-10
within O 0 1.1032722652126736e-10
the O 0 3.7573069655572056e-10
insulin B-Disease 0 1.8162023479817435e-05
- I-Disease 0 0.08307241648435593
dependent I-Disease 1 0.999995231628418
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 8.483992814944941e-07
IDDM B-Disease 0 1.9937897377531044e-05
) O 0 1.0101941505524792e-09
locus O 0 9.416067037193443e-09
IDDM4 O 0 9.608653499526554e-07
on O 0 1.409423475706717e-07
chromosome O 0 1.269104018319922e-06
11q13 O 0 4.758377144753467e-06
. O 0 4.667663802138122e-07

Based O 0 6.317782208498102e-08
on O 0 3.520153413205662e-08
its O 0 2.6421137500065583e-10
chromosomal O 0 3.318779704386543e-07
position O 0 3.794393421685527e-07
, O 0 5.550229165152132e-10
this O 0 2.098831525243483e-11
gene O 0 2.858888126233694e-10
is O 0 5.449273671187527e-11
a O 0 2.6208027414931223e-10
candidate O 0 7.571504534453766e-10
for O 0 5.639869682383392e-10
conferring O 0 1.6386954371228057e-07
susceptibility O 0 6.685316748189507e-06
to O 0 2.776244514279824e-07
diabetes B-Disease 1 0.9999978542327881
. O 0 2.2425834686146118e-05

The O 0 8.558938446867614e-08
gene O 0 2.4035278656242554e-08
, O 0 3.488729527489909e-09
termed O 0 4.6466379188814244e-08
low O 0 3.212073806935223e-07
- O 0 1.7982305422492573e-08
density O 0 1.1619193385214999e-09
lipoprotein O 0 4.4495426010371375e-08
receptor O 0 7.887868136435827e-09
related O 0 1.4749673482583603e-07
protein O 0 4.600226688467046e-08
5 O 0 1.8083495589849008e-08
( O 0 1.9524540317839012e-10
LRP5 O 0 4.253645968788078e-08
) O 0 7.16367312691979e-11
, O 0 8.23392742876905e-11
encodes O 0 2.728740289281717e-10
a O 0 1.829853268908721e-09
protein O 0 1.8898242970522006e-08
of O 0 7.670163171269451e-08
1615 O 0 1.2533246263046749e-05
amino O 0 8.617006130862137e-08
acids O 0 9.044262228030675e-09
that O 0 5.921124701657732e-11
contains O 0 4.231628936146592e-11
conserved O 0 1.0684805262783925e-09
modules O 0 4.1395247230013865e-09
which O 0 1.7077901592887912e-11
are O 0 2.937901224381312e-12
characteristic O 0 4.749028947870215e-10
of O 0 4.912037443460804e-10
the O 0 2.685513200706424e-10
low O 0 2.6543704123582756e-08
- O 0 2.4098889550572267e-09
density O 0 4.955116317262309e-10
lipoprotein O 0 1.536806877311392e-07
( O 0 4.727873648135983e-09
LDL O 0 2.7976852834399324e-07
) O 0 1.2468196253223596e-08
receptor O 0 1.5314826384837943e-07
family O 0 2.389759323762064e-08
. O 0 8.803014850400359e-08

These O 0 3.2585281140029565e-09
modules O 0 6.863776036425406e-08
include O 0 3.2877638389550157e-09
a O 0 2.568956380955001e-09
putative O 0 7.003155388929372e-09
signal O 0 3.0794229388675376e-08
peptide O 0 2.0766457442533692e-09
for O 0 3.1412042411638197e-10
protein O 0 6.353545467518984e-10
export O 0 1.724058007468443e-09
, O 0 1.073931221728941e-10
four O 0 2.1442316672226625e-11
epidermal O 0 1.8421932035384003e-10
growth O 0 2.172311497350421e-10
factor O 0 1.3603503878911738e-09
( O 0 1.7059971491040216e-10
EGF O 0 3.540898907417045e-09
) O 0 1.7066904833829e-10
repeats O 0 6.378825800901211e-10
with O 0 1.0047841725313589e-10
associated O 0 1.0683222306795415e-08
spacer O 0 4.20284294477824e-07
domains O 0 3.504431447254319e-07
, O 0 1.70044689440374e-08
three O 0 3.0006084283940027e-09
LDL O 0 1.518004495437708e-07
- O 0 9.487295073995483e-07
receptor O 0 2.1758715718078747e-08
( O 0 3.9669654228191575e-09
LDLR O 0 1.0028956012320123e-06
) O 0 6.523820927917257e-10
repeats O 0 3.943819493201772e-09
, O 0 2.653162967103384e-10
a O 0 3.7925004803263107e-10
single O 0 7.194541074007077e-10
transmembrane O 0 2.0523718546883174e-07
spanning O 0 1.0148778528673574e-06
domain O 0 1.577638215621846e-07
, O 0 3.190502084748914e-09
and O 0 7.547958369436003e-10
a O 0 2.8761180104197592e-09
cytoplasmic O 0 3.8956297743197865e-08
domain O 0 3.0590072697123105e-07
. O 0 2.7099497401650297e-07

The O 0 1.0430590009491425e-06
encoded O 0 2.3325719666900113e-07
protein O 0 2.840625938915764e-07
has O 0 1.7366289517539713e-09
a O 0 5.137471559280016e-10
unique O 0 7.208647567757964e-10
organization O 0 1.3028127465730677e-09
of O 0 4.3329443144557445e-08
EGF O 0 5.026639087191143e-07
and O 0 4.1121573701730085e-08
LDLR O 0 4.520450602285564e-05
repeats O 0 3.207349763556522e-08
; O 0 2.2955169709515388e-10
therefore O 0 1.4319219143743567e-09
, O 0 3.985057839273054e-10
LRP5 O 0 1.3392960909186513e-06
likely O 0 1.3947960120219705e-08
represents O 0 1.402917004789117e-09
a O 0 2.0375047482534825e-10
new O 0 1.0601691052825046e-10
category O 0 6.775712879658613e-09
of O 0 5.5466760073841215e-09
the O 0 1.2620703593313465e-08
LDLR O 0 0.00010753500100690871
family O 0 7.339638585790453e-08
. O 0 1.2732120069358643e-07

Both O 0 1.7687963804746687e-07
human O 0 4.9657838729899595e-08
and O 0 4.2178860404362695e-09
mouse O 0 4.0509451793013795e-08
LRP5 O 0 5.5508285186078865e-06
cDNAs O 0 2.540746493195911e-07
have O 0 7.445788430260336e-11
been O 0 6.642548316948549e-11
isolated O 0 3.083109115231686e-11
and O 0 6.408685648134904e-12
the O 0 2.0175874859695853e-11
encoded O 0 2.6316021584094074e-10
mature O 0 2.833611956187809e-10
proteins O 0 2.094880172109903e-11
are O 0 9.757085764339202e-12
95 O 0 4.345147297524221e-10
% O 0 2.912749902383993e-11
identical O 0 3.5800676312369717e-10
, O 0 1.1793206688981428e-10
indicating O 0 1.132667848402491e-09
a O 0 5.451688545043964e-10
high O 0 6.385792783447641e-09
degree O 0 1.3105623963838298e-07
of O 0 7.232987542238334e-09
evolutionary O 0 1.2334648857859065e-08
conservation O 0 9.010285295651954e-10
. O 0 6.035367206003173e-10
. O 0 1.618442269091247e-08

The O 0 4.343664272710157e-07
APC B-Disease 0 3.1504933417636494e-07
variants O 0 3.766839995478222e-08
I1307K O 0 2.6167302280555305e-07
and O 0 1.1241535480266407e-09
E1317Q O 0 4.3745139066686534e-08
are O 0 2.7860156889825127e-11
associated O 0 3.044609186986236e-08
with O 0 8.622376481071115e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 0.019953856244683266
but O 0 3.951725613404733e-09
not O 0 2.860491843392765e-10
always O 0 2.1602382382912566e-10
with O 0 2.441597792002259e-11
a O 0 7.749919039845565e-10
family O 0 1.169487839902672e-09
history O 0 1.5401042219309602e-08
. O 0 3.860539266042906e-08

Classical O 1 0.9999856948852539
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.5970123058650643e-05
FAP B-Disease 0 2.1246423784759827e-06
) O 0 1.3417767341650233e-08
is O 0 2.2915984665417e-09
a O 0 1.9653041416489714e-09
high O 0 2.841998684743885e-05
- O 1 0.9237605929374695
penetrance O 1 0.9999748468399048
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999754428863525
that O 0 1.9315531396557617e-09
predisposes O 0 3.350411859059932e-08
to O 0 2.3088392309134065e-10
hundreds O 0 1.7991927392380092e-10
or O 0 1.496353319030419e-10
thousands O 0 1.7565594812030128e-10
of O 0 0.00022335565881803632
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999984502792358
carcinoma I-Disease 1 1.0
and O 0 3.0275467111096077e-07
that O 0 4.23078350131334e-10
results O 0 1.1280174572192436e-09
from O 0 1.349321321342245e-09
truncating O 0 6.634365945501486e-08
mutations O 0 1.3037474433374996e-09
in O 0 8.636529269523407e-10
the O 0 3.7442884348593e-09
APC B-Disease 0 2.425749983103742e-07
gene O 0 2.200798405738169e-07
. O 0 7.710079898970434e-07

A O 0 2.6576688583190844e-07
variant O 0 2.1991786525177304e-07
of O 0 4.8230379690039626e-08
FAP B-Disease 0 4.0221669905804447e-07
is O 0 1.2872979482381197e-07
attenuated B-Disease 0 0.013327931985259056
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999628067016602
coli I-Disease 1 0.9998056292533875
, O 0 8.532333062305497e-09
which O 0 1.3369215456915384e-10
results O 0 6.026394938629664e-10
from O 0 2.8890330128206188e-09
germ O 0 0.0001272680819965899
- O 0 8.422966146781619e-08
line O 0 2.2624707440854763e-08
mutations O 0 2.0160230429500103e-10
in O 0 2.5340909926008237e-10
the O 0 7.286987679933077e-10
5 O 0 4.0774623677464206e-09
and O 0 2.0973919823141784e-10
3 O 0 4.064355962896116e-09
regions O 0 1.053774845161115e-09
of O 0 8.049918953645374e-09
the O 0 1.2741785404557504e-08
APC B-Disease 0 2.7068992380918644e-07
gene O 0 5.43522162388399e-07
. O 0 9.366440849589708e-07

Attenuated B-Disease 1 0.9999837875366211
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
patients O 0 2.047524731096928e-06
have O 0 2.50570536541872e-10
" O 0 6.497048454789933e-10
multiple O 0 1.1451502857084961e-08
" O 0 0.0002152176311938092
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 6.483017500613641e-08
typically O 0 7.833365067710929e-10
fewer O 0 9.274796902714044e-11
than O 0 3.814399837653859e-11
100 O 0 1.2413085836993076e-10
) O 0 2.9455656663790464e-12
without O 0 3.960821948201243e-11
the O 0 1.384790337954911e-10
florid O 0 2.471716165075577e-08
phenotype O 0 1.6860227658455074e-09
of O 0 9.683478907618337e-09
classical O 0 3.3178603189298883e-06
FAP B-Disease 0 1.118501131713856e-06
. O 0 2.535876149067917e-07

Another O 0 3.429593959936028e-07
group O 0 1.647036107499389e-08
of O 0 9.493940922311594e-08
patients O 0 1.715605435492762e-08
with O 0 1.8442261051632158e-09
multiple O 0 1.294687876907119e-06
adenomas B-Disease 0 0.052614081650972366
has O 0 1.262347115726925e-08
no O 0 8.205742196842891e-10
mutations O 0 2.475691041059491e-10
in O 0 3.7932817997798907e-10
the O 0 2.170059687500725e-09
APC B-Disease 0 9.841581771752317e-09
gene O 0 6.039988065253965e-09
, O 0 1.2091916357093169e-09
and O 0 3.777715085195865e-10
their O 0 1.5796050578664733e-10
phenotype O 0 2.971062951218073e-09
probably O 0 6.818986486578638e-10
results O 0 2.6681437614861636e-10
from O 0 3.0386712590591003e-10
variation O 0 5.757210708168259e-09
at O 0 4.039810974632019e-08
a O 0 7.651131950225931e-10
locus O 0 4.617689564057059e-10
, O 0 1.9973946108198248e-10
or O 0 1.24725132999437e-10
loci O 0 6.374787919760649e-10
, O 0 3.7515138218147115e-10
elsewhere O 0 9.446083915065628e-10
in O 0 1.2693404660701901e-10
the O 0 1.5182811674563368e-09
genome O 0 1.0315325482679327e-08
. O 0 1.564907137208138e-07

Recently O 0 1.5034919442769024e-06
, O 0 6.935679586206334e-09
however O 0 6.246387296293676e-10
, O 0 1.3527221010001256e-10
a O 0 1.7705659161038056e-10
missense O 0 6.814269593036215e-09
variant O 0 1.9096116687933318e-08
of O 0 1.7322370240435703e-06
APC B-Disease 0 1.1722362387445173e-06
( O 0 2.1712077469260294e-08
I1307K O 0 3.296248962669779e-07
) O 0 5.264461644394203e-10
was O 0 1.728273169021577e-08
described O 0 4.253025431832924e-10
that O 0 2.708370203455268e-12
confers O 0 2.1881342571195006e-10
an O 0 4.5620334766793835e-12
increased O 0 2.4245491725416457e-10
risk O 0 1.4419103422369517e-07
of O 1 0.9713488817214966
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.946445763678639e-06
including O 0 6.568874333368058e-09
multiple O 0 4.081059614691185e-07
adenomas B-Disease 0 0.11972340941429138
, O 0 8.288300534786686e-08
in O 0 1.4182538166096492e-07
Ashkenazim O 0 0.00026354394503869116
. O 0 1.388411874359008e-06

We O 0 1.112849830064988e-07
have O 0 5.811666148325401e-10
studied O 0 9.709240522681739e-09
a O 0 1.5259214725116266e-10
set O 0 2.5658014601859236e-10
of O 0 2.997929959835943e-10
164 O 0 8.015840213815295e-10
patients O 0 2.0748118501057178e-10
with O 0 1.9615506441361674e-10
multiple O 1 0.999763548374176
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.4572157859802246
/ I-Disease 1 0.9999884366989136
or I-Disease 0 0.0005126120522618294
carcinoma I-Disease 1 1.0
and O 0 2.2094248208759382e-07
analyzed O 0 1.4188084662691836e-07
codons O 0 6.598021684567357e-08
1263 O 0 7.365554210991831e-07
- O 0 6.111642392170324e-08
1377 O 0 1.3119796449245769e-06
( O 0 3.871916121056529e-09
exon O 0 7.724926120999953e-08
15G O 0 2.2698907287121983e-07
) O 0 5.061914221116126e-10
of O 0 2.6119608698138563e-09
the O 0 3.32068683661646e-09
APC B-Disease 0 2.7698648707996654e-08
gene O 0 1.519067005517627e-08
for O 0 2.8702119792001213e-08
germ O 0 0.16454923152923584
- O 0 3.6244950933905784e-06
line O 0 4.38159560189888e-07
variants O 0 1.2037276064802427e-07
. O 0 7.627097886597767e-08

Three O 0 1.502120312579791e-07
patients O 0 5.401894043188804e-09
with O 0 2.983366886866179e-10
the O 0 2.1365749169888204e-09
I1307K O 0 1.3903549422877859e-08
allele O 0 4.1228020997152726e-10
were O 0 2.38936509466825e-10
detected O 0 1.5573277112324035e-09
, O 0 2.038988769492711e-11
each O 0 9.172719007966013e-12
of O 0 7.488219488926973e-10
Ashkenazi O 0 6.562878240856662e-08
descent O 0 1.021564457914792e-06
. O 0 4.990609454580408e-07

Four O 0 1.006688307825243e-06
patients O 0 3.746741015220323e-07
had O 0 9.84455255093053e-08
a O 0 6.869224478123215e-08
germ O 0 0.0004693038063123822
- O 0 6.239046115297242e-07
line O 0 1.293393125934017e-07
E1317Q O 0 7.128857504312691e-08
missense O 0 1.8173535565324528e-08
variant O 0 1.9817923302412055e-08
of O 0 5.008751813306844e-08
APC O 0 2.9062945827718067e-08
that O 0 2.8015290087779476e-10
was O 0 1.804841787134137e-08
not O 0 4.510890619369157e-11
present O 0 9.922998533973271e-11
in O 0 1.331871973819787e-10
controls O 0 1.0871096911557743e-08
; O 0 1.0248265430723436e-10
one O 0 6.348357950436423e-11
of O 0 5.259423452308454e-10
these O 0 2.4475099030807357e-11
individuals O 0 1.4144257813597516e-11
had O 0 8.957167785261788e-10
an O 0 6.597647428385756e-11
unusually O 0 5.215618492648844e-10
large O 0 1.0322257805450707e-11
number O 0 7.113404310032934e-11
of O 0 6.9423768955800824e-09
metaplastic B-Disease 0 2.2031138087186264e-06
polyps I-Disease 0 3.183738499501487e-07
of I-Disease 0 1.651866057272855e-07
the I-Disease 0 1.486463219180223e-07
colorectum I-Disease 0 3.074834603467025e-05
. O 0 9.696971119410591e-07

There O 0 1.0083969925744896e-07
is O 0 6.259279761167136e-10
increasing O 0 3.254209401948316e-10
evidence O 0 1.0362510849404316e-09
that O 0 7.258211393024183e-12
there O 0 2.586989476804913e-11
exist O 0 3.7816080822317133e-10
germ O 0 1.8654436928500218e-07
- O 0 1.37854017090433e-09
line O 0 7.297224491331633e-10
variants O 0 2.696713130578843e-10
of O 0 1.2134543370123652e-09
the O 0 1.1175476100078185e-09
APC B-Disease 0 6.842792998895675e-09
gene O 0 1.785202430326649e-09
that O 0 1.688728740179002e-10
predispose O 0 5.977356387631971e-09
to O 0 1.4310447271626003e-10
the O 0 3.2289218521164287e-10
development O 0 6.5796204040680095e-09
of O 0 2.1809640315950674e-07
multiple O 1 0.9999879598617554
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999974966049194
carcinoma I-Disease 1 1.0
, O 0 4.5703558271270595e-07
but O 0 5.894995602773179e-10
without O 0 8.133627660278364e-10
the O 0 1.0091311120064006e-09
florid O 0 7.337482799130157e-08
phenotype O 0 2.331044468562027e-09
of O 0 4.7035255690275335e-09
classical O 0 1.2782310250258888e-06
FAP B-Disease 0 2.496862627765495e-08
, O 0 4.310009293906347e-10
and O 0 3.4729778081166174e-11
possibly O 0 3.4330485676470346e-10
with O 0 6.7949079522733324e-12
importance O 0 1.1293855095573235e-07
for O 0 1.4714910321345087e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.6025074124336243
in O 0 4.050750401773939e-09
the O 0 4.643479212251833e-10
general O 0 1.0745053735661259e-09
population O 0 5.888887034261048e-12
. O 0 2.0405771516962545e-10
. O 0 6.506129857086762e-09

Genomic O 0 1.700630832601746e-06
structure O 0 8.82890788034274e-07
of O 0 2.361188649047108e-07
the O 0 9.566048930764737e-08
human O 1 0.9883190393447876
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9948099851608276
CLD B-Disease 1 0.9999158382415771
) O 0 1.419598874008443e-07
gene O 0 3.279430131897243e-07
. O 0 3.689532945827523e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9927948117256165
CLD B-Disease 1 0.9999945163726807
) O 0 7.271112423268278e-08
is O 0 1.313043340722686e-09
caused O 0 2.5705884088012e-09
by O 0 4.2762054314193776e-11
mutations O 0 1.6661290125341566e-09
in O 0 7.367431109628342e-10
a O 0 1.5488645921379884e-09
gene O 0 1.0775654812889002e-09
which O 0 2.4783181062915105e-10
encodes O 0 2.109593610910565e-09
an O 0 2.403641286008451e-09
intestinal O 0 0.0005048330058343709
anion O 0 2.95182726404164e-05
transporter O 0 0.0017186987679451704
. O 0 3.81030872631527e-06

We O 0 8.363222292473438e-08
report O 0 2.7829647475385855e-09
here O 0 5.78518954963414e-10
the O 0 7.053444633919881e-11
complete O 0 3.5634586947885794e-10
genomic O 0 1.4133646475400496e-09
organization O 0 3.1727867555453315e-10
of O 0 2.5564430572444508e-09
the O 0 3.497617750980453e-09
human O 0 1.817755546085209e-08
CLD B-Disease 0 3.2025536711444147e-06
gene O 0 1.754020040323212e-08
which O 0 1.7791994544325007e-09
spans O 0 2.5131456027338572e-08
approximately O 0 9.943883494401007e-10
39kb O 0 5.2386244675517446e-08
, O 0 5.547963755070384e-10
and O 0 2.452904268590572e-10
comprises O 0 5.018254256583532e-09
21 O 0 3.666236239041609e-07
exons O 0 1.2366010651021497e-06
. O 0 8.942474210016371e-07

All O 0 4.932245474265073e-07
exon O 0 1.98386624106206e-05
/ O 0 5.016399427404394e-06
intron O 0 6.341072548821103e-06
boundaries O 0 2.8180274114220083e-08
conform O 0 9.392769584337657e-08
to O 0 1.6196157304193548e-08
the O 0 1.0511200088103578e-07
GT O 0 1.2113839147787075e-05
/ O 0 6.243737880140543e-05
AG O 0 0.0019775060936808586
rule O 0 4.75884007755667e-06
. O 0 1.7512574004285852e-06

An O 0 9.184375926452049e-09
analysis O 0 1.937982396782445e-08
of O 0 2.688078204471367e-08
the O 0 1.2028664286845014e-08
putative O 0 1.8407132529318915e-07
promoter O 0 2.00677641259972e-05
region O 0 7.787504330281081e-08
sequence O 0 1.4714204965571298e-08
shows O 0 1.1280201661634237e-08
a O 0 1.2215338074383908e-08
putative O 0 1.1642696762237392e-07
TATA O 0 2.311848447789089e-06
box O 0 1.4066414451008313e-06
and O 0 8.281375585283968e-09
predicts O 0 2.3703163876120925e-08
multiple O 0 3.877850929256965e-09
transcription O 0 1.3956321254227078e-07
factor O 0 1.439494301536115e-08
binding O 0 3.222256239610033e-08
sites O 0 9.897022579252734e-08
. O 0 2.0695716784757678e-07

The O 0 2.471645927926147e-07
genomic O 0 4.088539355961984e-07
structure O 0 5.0532668183223e-07
was O 0 9.505519216190805e-08
determined O 0 3.072328613740183e-09
using O 0 1.694216572589724e-10
DNA O 0 4.6321740887478313e-10
from O 0 8.771677134644662e-11
several O 0 1.1376725082834493e-11
sources O 0 2.233944418339462e-10
including O 0 1.4567159978273736e-11
multiple O 0 3.901403644590573e-10
large O 0 4.988764956692648e-09
- O 0 8.583165822528827e-08
insert O 0 7.573866156462827e-08
libaries O 0 4.5395401571113325e-07
and O 0 2.757101214001523e-10
genomic O 0 6.61563603898685e-09
DNA O 0 5.907740519006666e-09
from O 0 3.912307366960022e-09
Finnish O 0 6.612556899199262e-05
CLD B-Disease 1 0.7159097790718079
patients O 0 1.4125332370440447e-07
and O 0 1.4285726379625885e-08
controls O 0 7.786791684338823e-06
. O 0 7.549109000137832e-07

Exon O 0 2.237750777567271e-05
- O 0 4.6869782721614683e-08
specific O 0 1.1073353345381065e-09
primers O 0 2.0960982283213525e-08
developed O 0 1.4451110308399961e-09
in O 0 7.915756938814411e-11
this O 0 3.3861117035294264e-12
study O 0 8.562464973160822e-12
will O 0 7.401250294060413e-13
facilitate O 0 3.064553125153857e-11
mutation O 0 1.461921035617042e-11
screening O 0 7.093221010556761e-10
studies O 0 9.18724429865847e-10
of O 0 9.288008140373449e-10
patients O 0 1.7808417240861019e-10
with O 0 5.485355225598454e-11
the O 0 2.139161381364829e-08
disease O 0 8.055837679421529e-05
. O 0 1.0209843992470269e-07

Genomic O 0 8.385022738366388e-07
sequencing O 0 2.2977582148087095e-07
of O 0 1.4729052963957656e-06
a O 0 2.0686832158389734e-06
BAC O 1 0.9945811629295349
clone O 0 4.317992352298461e-05
H O 1 0.9999998807907104
_ O 0 9.065300332622428e-08
RG364P16 O 0 1.0403157091332105e-07
revealed O 0 1.1724364590293135e-08
the O 0 2.2388199627521033e-10
presence O 0 5.161279181820078e-10
of O 0 2.780460528484241e-09
another O 0 5.598947971918733e-10
, O 0 1.9394819084084247e-10
highly O 0 1.1141337852293987e-09
homologous O 0 1.7060598489493373e-09
gene O 0 5.524841029114214e-09
3 O 0 1.0684509987868296e-07
of O 0 4.1694956820492735e-08
the O 0 6.411448794096941e-08
CLD B-Disease 0 3.354396903887391e-05
gene O 0 1.782219705148691e-08
, O 0 1.0383918169765138e-09
with O 0 3.4111092422906e-11
a O 0 1.1770577568182006e-10
similar O 0 3.452582317264863e-11
genomic O 0 3.0536277950687918e-09
structure O 0 2.1373652714373748e-07
, O 0 1.0184473264729377e-09
recently O 0 5.341616038379016e-10
identified O 0 1.6718262885184743e-10
as O 0 1.7250635642174217e-10
the O 0 9.228467767741222e-09
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 7.4812119237321895e-06
( O 0 2.0121147770169046e-07
PDS B-Disease 0 1.8259208445670083e-05
) O 0 1.2942957816619582e-08
. O 0 1.4297911299365751e-08
. O 0 1.0026662522477636e-07

The O 0 3.7473807878996013e-07
APCI1307K O 0 1.2008730664092582e-05
allele O 0 7.387362899180516e-08
and O 0 1.2064462318051028e-08
cancer B-Disease 0 2.807962346196291e-06
risk O 0 6.238320082729842e-08
in O 0 4.373193362994243e-09
a O 0 1.4563118488908344e-09
community O 0 6.013175374297575e-11
- O 0 2.289491374263264e-10
based O 0 5.540389674818513e-11
study O 0 7.004911234398392e-11
of O 0 7.758260145429574e-10
Ashkenazi O 0 5.180240236768441e-08
Jews O 0 3.126026015820571e-08
. O 0 7.495629006371018e-08

Mutations O 0 1.2267719284864143e-06
in O 0 3.311138385697632e-08
APC O 0 1.4201715714534657e-07
are O 0 3.712371798858527e-10
classically O 0 2.1585111653621425e-07
associated O 0 2.1182924569984607e-07
with O 0 2.649156385814422e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 6.5547174017410725e-06
FAP B-Disease 0 6.440496918003191e-07
) O 0 2.4569324352796684e-09
, O 0 1.8745757723870327e-10
a O 0 7.371113164289511e-10
highly O 0 1.4862337138765724e-06
penetrant O 1 0.999998927116394
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.9558873176574707
by O 0 8.500139259126627e-09
multiple O 0 1.0194447668254725e-06
intestinal O 1 0.9998512268066406
polyps B-Disease 0 2.3632535885553807e-05
and O 0 1.4182748309110593e-08
, O 0 1.017788964219335e-09
without O 0 4.246607510083322e-09
surgical O 0 0.017604496330022812
intervention O 0 2.550352974139969e-06
, O 0 9.865158689947862e-11
the O 0 6.393999912868154e-11
development O 0 3.59289735740731e-08
of O 1 0.9999148845672607
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.834828253777232e-05
CRC B-Disease 0 1.666072967054788e-05
) O 0 1.3660088171718598e-08
. O 0 7.803696178143582e-08

APC B-Disease 0 7.388640369754285e-06
is O 0 1.5041129586279567e-07
a O 0 1.1289719736851112e-07
tumour O 1 0.9999998807907104
- O 0 2.0042592950630933e-05
suppressor O 0 1.104024818232574e-06
gene O 0 1.354143197573876e-08
, O 0 1.7628837278849119e-09
and O 0 2.051473879660648e-09
somatic O 0 1.90634568753012e-06
loss O 0 8.489560627822357e-07
occurs O 0 1.0062543651656597e-06
in O 0 4.6090801220088906e-07
tumours B-Disease 1 1.0
. O 0 2.3753236746415496e-05

The O 0 4.875285412708763e-06
germline O 0 1.8009193809120916e-05
T O 0 9.77473428065423e-06
- O 0 1.1343141181896499e-07
to O 0 2.904996465602494e-09
- O 0 9.169339953984945e-09
A O 0 8.683278096555114e-09
transversion O 0 5.0352273461840014e-08
responsible O 0 1.21404697406291e-09
for O 0 1.7261431173309916e-10
the O 0 8.643334381552847e-10
APC O 0 6.302253385825907e-09
I1307K O 0 1.6152842619021612e-08
allele O 0 8.395002470962254e-10
converts O 0 6.334305857613742e-10
the O 0 3.480771504360547e-10
wild O 0 1.1638461722141002e-10
- O 0 1.085604314776667e-10
type O 0 1.1362288887539762e-10
sequence O 0 2.0842001735577043e-10
to O 0 2.004340304839758e-10
a O 0 9.166297054719053e-09
homopolymer O 0 6.601353561563883e-06
tract O 0 8.652579708723351e-06
( O 0 1.9820568297745922e-08
A8 O 0 5.772519102720253e-07
) O 0 6.340519220771057e-10
that O 0 4.902581118848559e-11
is O 0 3.3318128811465897e-10
genetically O 0 1.538066918271852e-08
unstable O 0 1.839256947278045e-05
and O 0 2.445604962986181e-08
prone O 0 2.1675950847566128e-06
to O 0 5.578473238898596e-09
somatic O 0 1.2752874681609683e-05
mutation O 0 2.710301316710684e-07
. O 0 2.951100555037556e-07

The O 0 7.612244701249438e-08
I1307K O 0 1.6068990760231827e-07
allele O 0 7.623807363188462e-09
was O 0 7.20598691827945e-08
found O 0 1.6729213569988133e-09
in O 0 1.6616954479076185e-09
6 O 0 2.522311319808068e-07
. O 0 6.591053391957757e-08

1 O 0 1.1939895557588898e-05
% O 0 3.249232349844533e-08
of O 0 4.4324494297143247e-08
unselected O 0 5.466658330988139e-05
Ashkenazi O 0 3.3739604532456724e-07
Jews O 0 4.677170650779772e-09
and O 0 1.5055516555673165e-10
higher O 0 1.0422352980654637e-09
proportions O 0 2.7057203144664754e-09
of O 0 7.336919960465593e-09
Ashkenazim O 0 1.0160074026543953e-07
with O 0 2.2574908609129807e-09
family O 0 1.3077272598138734e-09
or O 0 2.568127099866757e-10
personal O 0 8.165137899140973e-09
histories O 0 7.415497549345673e-08
of O 0 1.8323186168345273e-06
CRC B-Disease 0 4.872930730925873e-05
( O 0 3.651419788752719e-08
ref O 0 9.543221040075878e-07
. O 0 6.117401252225818e-09
2 O 0 4.126875126075902e-07
) O 0 7.205256391529247e-09
. O 0 1.2418148287451913e-07

To O 0 2.1087460666535662e-08
evaluate O 0 9.931893174552897e-08
the O 0 5.573102868083879e-09
role O 0 3.639453538539783e-08
of O 0 2.855741243479315e-08
I1307K O 0 1.873609392077924e-07
in O 0 5.757869736555676e-09
cancer B-Disease 0 9.51836369722514e-08
, O 0 1.5171289780013808e-09
we O 0 1.3661852760193938e-09
genotyped O 0 3.046924632599257e-07
5 O 0 2.2337589555831983e-08
, O 0 1.6390502288743392e-09
081 O 0 1.0007209994000732e-06
Ashkenazi O 0 7.844361959996604e-08
volunteers O 0 6.72382993727183e-09
in O 0 1.0436754793730074e-09
a O 0 2.228396134285049e-09
community O 0 8.421255359714053e-10
survey O 0 1.5295478661414563e-08
. O 0 5.948028558577789e-08

Risk O 0 6.379169462888967e-06
of O 0 1.220995500261779e-06
developing O 1 0.763358473777771
colorectal B-Disease 1 1.0
, I-Disease 0 1.705872477941739e-06
breast I-Disease 0 0.0012089883675798774
and I-Disease 0 9.07143693495982e-09
other I-Disease 0 1.0253320859021642e-08
cancers I-Disease 1 0.9542028307914734
were O 0 3.348648647261143e-08
compared O 0 2.809290755578786e-08
between O 0 4.1458481092604416e-08
genotyped O 0 1.4640919232533633e-07
I1307K O 0 8.686789065848188e-09
carriers O 0 1.555507112005472e-10
and O 0 3.08735190190923e-11
non O 0 1.4764379718812393e-09
- O 0 5.953867954211489e-10
carriers O 0 4.417032017922651e-11
and O 0 1.5972978148481864e-11
their O 0 1.9957180005802932e-11
first O 0 6.396614349313268e-10
- O 0 4.2999523941489315e-09
degree O 0 2.2387330034234765e-07
relatives O 0 1.12896723081235e-08
. O 0 5.3423956813958284e-08

Sperm O 0 5.112589107625354e-08
DNA O 0 1.8431370207849795e-08
analysis O 0 4.060543457029553e-09
in O 0 1.7348843472930753e-09
a O 0 4.796864061518136e-08
Friedreich B-Disease 0 0.0007117009372450411
ataxia I-Disease 1 0.6747182607650757
premutation O 0 0.0012429021298885345
carrier O 0 5.8152477322437335e-06
suggests O 0 4.6375978968171694e-07
both O 0 1.8097606968581204e-08
meiotic O 0 6.102060979173984e-06
and O 0 5.604121611213486e-09
mitotic O 0 8.575246113196044e-08
expansion O 0 5.907315170361471e-08
in O 0 6.262853347038799e-09
the O 0 3.3505909158293434e-08
FRDA B-Disease 0 3.241311424062587e-05
gene O 0 7.747353834020032e-07
. O 0 6.090115221013548e-07

Friedreich B-Disease 1 0.9999802112579346
ataxia I-Disease 1 0.9999991655349731
is O 0 1.2755283023579977e-05
usually O 0 1.1767372853910274e-07
caused O 0 1.11340572317431e-08
by O 0 3.389667713182831e-11
an O 0 1.2359906154113531e-10
expansion O 0 2.1539579009299814e-08
of O 0 6.818718247814104e-07
a O 0 3.0190153665898833e-07
GAA O 0 7.497010301449336e-06
trinucleotide O 0 1.3591482456831727e-05
repeat O 0 2.27456908419299e-07
in O 0 2.912098828744547e-08
intron O 0 2.067040441033896e-06
1 O 0 5.069195481155475e-07
of O 0 4.628831717923276e-08
the O 0 6.85043559656151e-08
FRDA B-Disease 0 5.81960630370304e-05
gene O 0 4.933384047944855e-07
. O 0 3.5930659691985056e-07

Occasionally O 0 1.3050774896328221e-06
, O 0 9.620939600551992e-09
a O 0 1.618941536385421e-09
fully O 0 3.2607225808334306e-09
expanded O 0 7.854654704431141e-10
allele O 0 6.436929322894969e-10
has O 0 2.3026986567531438e-11
been O 0 3.404531517814391e-11
found O 0 1.3205138371663594e-11
to O 0 5.069058454237885e-12
arise O 0 1.6050803741674002e-10
from O 0 1.5443445133822564e-10
a O 0 3.093872935622244e-10
premutation O 0 3.530515257921252e-08
of O 0 1.4466781550481755e-08
100 O 0 1.7611336389222743e-08
or O 0 2.4366499928873964e-09
less O 0 3.266177017735572e-08
triplet O 0 1.2506791335908929e-06
repeats O 0 1.3135145309206564e-06
. O 0 3.619634298956953e-07

We O 0 7.139076529938393e-08
have O 0 2.738271276392368e-10
examined O 0 2.295815759723041e-09
the O 0 1.4010149984589049e-10
sperm O 0 2.4534752007809857e-10
DNA O 0 1.4557480776389298e-09
of O 0 5.008682357754424e-09
a O 0 8.562559550284732e-09
premutation O 0 7.012988589849556e-07
carrier O 0 3.8181622130650794e-07
. O 0 2.3123833159388596e-07

This O 0 4.9292552262159006e-08
mans O 0 1.6412977856816724e-06
leucocyte O 0 8.933184858506138e-07
DNA O 0 5.53390293589473e-08
showed O 0 2.218837558132236e-08
one O 0 2.1995408272523775e-10
normal O 0 1.479335653975511e-09
allele O 0 6.537497765357614e-10
and O 0 1.2275538918693485e-10
one O 0 2.7390950618766396e-11
allele O 0 1.6343668085561092e-10
of O 0 1.6043893991124492e-09
approximately O 0 1.053043430232492e-09
100 O 0 8.439428711426444e-09
repeats O 0 4.8486523240853785e-08
. O 0 4.72331542766824e-08

His O 0 1.2051052635797532e-06
sperm O 0 4.191695168742626e-08
showed O 0 1.2170407792666538e-08
an O 0 8.135810775078411e-11
expanded O 0 5.689234083838812e-10
allele O 0 1.773331481658147e-09
in O 0 1.4646799328943416e-09
a O 0 4.145047860504292e-09
tight O 0 4.718605950415622e-08
range O 0 3.030016060279195e-08
centering O 0 2.9142213975319464e-08
on O 0 3.832365536027282e-09
a O 0 4.3229844703951414e-10
size O 0 4.066943726233063e-10
of O 0 3.661041914071461e-09
approximately O 0 4.231713646163371e-09
320 O 0 6.569391075572639e-08
trinucleotide O 0 6.0623278841376305e-06
repeats O 0 1.1813017408712767e-06
. O 0 3.310008480639226e-07

His O 0 4.48748369308305e-06
affected O 0 5.349472189664084e-07
son O 0 1.2513027286331635e-05
has O 0 6.401548180434702e-09
repeat O 0 1.6115668799443483e-08
sizes O 0 8.059028999696238e-09
of O 0 3.819363669776976e-08
1040 O 0 5.801892370982387e-07
and O 0 1.593180520842452e-08
540 O 0 7.005174325058761e-07
. O 0 1.3435365531222487e-07

These O 0 6.7926118063610375e-09
data O 0 1.062595433864999e-08
suggest O 0 1.2223162482172256e-09
that O 0 8.142886538664573e-12
expansion O 0 6.81716516570674e-10
occurs O 0 1.719013403844727e-10
in O 0 5.4872491966895254e-11
two O 0 2.6449762519087372e-11
stages O 0 2.317532166173919e-09
, O 0 3.040832169398655e-11
the O 0 8.849414950828915e-11
first O 0 2.431245205158916e-10
during O 0 2.3315960273606606e-09
meiosis O 0 6.962532772547547e-09
followed O 0 1.0160783325829925e-09
by O 0 1.2717008002205432e-10
a O 0 1.5657117824474653e-09
second O 0 8.743805679500838e-09
mitotic O 0 1.4190871411301487e-07
expansion O 0 4.320079369790619e-07
. O 0 9.518597607893753e-07

We O 0 7.311219718530992e-08
also O 0 3.252635050188246e-09
show O 0 1.6915470135714372e-09
that O 0 9.426996509798169e-12
in O 0 6.396939922215239e-11
all O 0 6.515386841154935e-11
informative O 0 8.161008535623182e-10
carrier O 0 2.8989521894118297e-09
father O 0 4.503038386616254e-09
to O 0 3.0444666232476436e-10
affected O 0 1.761771173391935e-09
child O 0 6.546660547002148e-09
transmissions O 0 3.6099674360912104e-08
, O 0 1.0170840558654248e-10
with O 0 1.6697636329165988e-11
the O 0 1.2870986221269476e-10
notable O 0 2.68994215790741e-10
exception O 0 4.991246860264198e-10
of O 0 4.909342266046224e-09
the O 0 9.510611853613682e-09
premutation O 0 6.011269988448475e-07
carrier O 0 1.59211417383176e-08
, O 0 8.400592443891242e-10
the O 0 3.6950076331976334e-10
expansion O 0 2.1901895852494135e-09
size O 0 2.305130974988856e-09
decreases O 0 1.2739306498588121e-08
. O 0 2.789277919745814e-09
. O 0 3.6486074606045804e-08

The O 0 2.673014307674748e-07
R496H O 0 2.482363925082609e-06
mutation O 0 5.733817687314513e-08
of O 0 1.333126817826269e-07
arylsulfatase O 0 1.8230584828415886e-05
A O 0 3.349601058744156e-07
does O 0 2.465396109485596e-09
not O 0 4.215875204494068e-09
cause O 0 3.848002052109223e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.015345307881944e-05

Deficiency B-Disease 1 0.9981038570404053
of I-Disease 0 0.00047472957521677017
arylsulfatase I-Disease 1 0.9962413311004639
A I-Disease 0 0.0001211795533890836
( O 0 1.555835282829321e-08
ARSA O 0 7.564548923255643e-06
) O 0 4.1925063420933384e-10
enzyme O 0 4.444773438194716e-09
activity O 0 1.3173918489428615e-07
causes O 0 1.4168455891194753e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 9.979667083825916e-06
MLD B-Disease 1 0.9999997615814209
) O 0 3.0342613399625407e-07
. O 0 2.2476881156308082e-07

A O 0 2.902539790738956e-07
number O 0 9.12199737967967e-09
of O 0 1.202224666485563e-07
ARSA O 0 7.406239456031471e-05
gene O 0 1.1762335105913735e-07
mutations O 0 2.114078156978394e-08
responsible O 0 7.236771182306256e-08
for O 0 1.2675904770276247e-07
MLD B-Disease 1 1.0
have O 0 8.145057961428392e-09
been O 0 1.7676784480613605e-09
identified O 0 6.7896586131155345e-09
. O 0 1.8460077910731343e-08

Recently O 0 1.2137231806264026e-06
, O 0 3.531510195387e-09
the O 0 2.738298698901076e-09
R496H O 0 4.4472351135027566e-08
mutation O 0 1.1588915382887421e-09
of O 0 4.9218893849456435e-08
ARSA O 0 4.966122651239857e-05
was O 0 4.6588937152591825e-07
proposed O 0 2.9080953201088278e-09
to O 0 3.547603044662395e-10
be O 0 4.4970965840107624e-10
a O 0 1.0739419353811286e-09
cause O 0 2.069683624483787e-08
of O 0 1.863076818153786e-06
MLD B-Disease 1 1.0
( O 0 6.220011528057512e-08
Draghia O 0 1.3970558256914956e-06
et O 0 7.565735700154619e-07
al O 0 7.03212279518084e-08
. O 0 3.0597305245017026e-10
, O 0 3.3183172876150024e-10
1997 O 0 2.9991666927742244e-09
) O 0 3.018955974098958e-09
. O 0 4.118043861467413e-08

We O 0 3.9163342080428265e-07
have O 0 1.1985236136879962e-09
investigated O 0 1.0774776626476523e-08
the O 0 3.659504366204658e-10
R496H O 0 8.288976616199761e-09
mutation O 0 9.498202224733632e-11
and O 0 2.3671637566780035e-11
found O 0 1.9819292040867964e-11
this O 0 6.625538659377206e-12
mutation O 0 5.2461462257680225e-11
at O 0 3.348059385288593e-09
a O 0 1.8186727124280821e-10
relatively O 0 1.8994095185576043e-10
high O 0 1.0811532918930666e-10
frequency O 0 2.7716060002624943e-10
in O 0 9.361488147174857e-12
an O 0 1.4795084645261025e-12
African O 0 4.321283955666111e-11
American O 0 2.177994243290904e-11
population O 0 7.548522896159982e-13
( O 0 9.463820352384467e-12
f O 0 9.906632847389574e-09
= O 0 5.150287307742474e-09
0 O 0 3.819376370728378e-09
. O 0 1.6560530724518685e-10
09 O 0 1.2572170859925791e-08
, O 0 1.5547545473282298e-09
n O 0 3.948894544691939e-08
= O 0 5.143438031041114e-08
61 O 0 1.0211558532091658e-07
subjects O 0 3.434913082855928e-07
) O 0 2.9008839774746775e-08
. O 0 1.65364866688833e-07

The O 0 1.472632789045747e-06
ARSA O 0 8.233997505158186e-05
enzyme O 0 3.372492685116413e-08
activity O 0 1.688907502739312e-08
in O 0 6.37717156859452e-10
subjects O 0 1.1954444545381193e-08
with O 0 2.567273650611046e-11
and O 0 5.96896490567822e-11
without O 0 1.7672729946127674e-10
the O 0 1.1243931480331426e-10
R496H O 0 3.0716487131599024e-09
mutation O 0 1.5147080811850344e-10
was O 0 2.982998736911213e-09
determined O 0 2.8946203212143473e-09
and O 0 1.780522396188644e-10
found O 0 1.0704423458740564e-10
to O 0 6.642548316948549e-11
be O 0 5.645143241750361e-10
normal O 0 2.1273115180520108e-07
. O 0 1.0208831469071811e-07

It O 0 2.414887134705168e-08
is O 0 1.1209568828718375e-09
therefore O 0 7.412860880684491e-10
concluded O 0 1.522686421395747e-09
that O 0 2.7780919925612935e-12
the O 0 5.419215423629886e-11
R496H O 0 2.830512713103417e-09
mutation O 0 2.2987195480439482e-10
of O 0 3.771323697776552e-09
ARSA O 0 1.7097570434998488e-06
does O 0 2.038422070027579e-10
not O 0 2.610245179723858e-11
negatively O 0 2.1442776720892454e-10
influence O 0 1.788863279728048e-09
the O 0 1.0585526899475894e-10
activity O 0 8.199250167706396e-10
of O 0 2.1201986832863895e-09
ARSA O 0 4.379713118396467e-06
and O 0 7.064313578553083e-10
is O 0 3.3670391474949213e-10
not O 0 1.4753225030528228e-10
a O 0 2.6708029121635946e-09
cause O 0 2.1373510605826596e-07
of O 0 4.011403871118091e-05
MLD B-Disease 1 1.0

Down O 0 1.774612974259071e-05
- O 0 9.842015060712583e-07
regulation O 0 2.2946706224047375e-07
of O 0 2.7103910227310735e-08
transmembrane O 0 1.8502803413866786e-06
carbonic O 0 0.006557659711688757
anhydrases O 0 5.9753812820417807e-05
in O 0 4.132711524107435e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999605417251587
lines O 0 1.2654635384024004e-07
by O 0 1.3828266309801052e-10
wild O 0 3.1256428556503124e-09
- O 0 1.047567099732305e-08
type O 0 1.0801505823110347e-06
von B-Disease 1 0.9996604919433594
Hippel I-Disease 1 0.9999023675918579
- I-Disease 1 0.9999425411224365
Lindau I-Disease 1 0.9987059831619263
transgenes O 0 0.000983135076239705
. O 0 3.0440744467341574e-06

To O 0 1.0681270623535966e-07
discover O 0 1.1415829703764757e-07
genes O 0 1.1020325096922079e-08
involved O 0 8.944742724281696e-09
in O 0 1.2124578674388431e-08
von B-Disease 1 0.9647243022918701
Hippel I-Disease 1 0.9998270869255066
- I-Disease 1 0.9999978542327881
Lindau I-Disease 1 0.9999938011169434
( O 0 2.1736580038123066e-06
VHL B-Disease 0 0.0006554107530973852
) O 0 4.6168227640919213e-07
- O 0 9.023774509842042e-06
mediated O 0 6.015287362970412e-05
carcinogenesis O 1 0.9995343685150146
, O 0 7.679162195017852e-09
we O 0 1.0118197391051353e-09
used O 0 7.472289809129506e-08
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999649524688721
lines O 0 6.2260091908683535e-06
stably O 0 5.379100002755877e-06
transfected O 0 1.1180090808693421e-07
with O 0 4.6557177557637885e-10
wild O 0 2.9435314186088135e-09
- O 0 1.558835371895384e-08
type O 0 3.165023656492849e-07
VHL O 0 0.00022363140305969864
- O 0 5.8924097174895e-06
expressing O 0 1.340618354106482e-07
transgenes O 0 1.4209157598088495e-05
. O 0 4.6588536406488856e-07

Large O 0 2.09269330753159e-07
- O 0 1.239470890368466e-07
scale O 0 8.345470803305943e-08
RNA O 0 1.7131563723182808e-08
differential O 0 1.0449890908148518e-07
display O 0 7.492594988889323e-09
technology O 0 7.520113420866892e-09
applied O 0 3.807302473290974e-09
to O 0 2.608493282485469e-11
these O 0 1.1405013218557247e-11
cell O 0 1.5119293594878513e-09
lines O 0 1.634457152954738e-10
identified O 0 5.31704472117589e-11
several O 0 8.145542400306294e-12
differentially O 0 2.8801143692192e-09
expressed O 0 9.271117901166193e-11
genes O 0 6.405206226522964e-11
, O 0 4.2618665541116485e-11
including O 0 2.695816833653275e-11
an O 0 1.6585503803678847e-10
alpha O 0 2.0015668269479647e-06
carbonic O 0 0.0008310334524139762
anhydrase O 0 0.00033588605583645403
gene O 0 2.9739683782281645e-07
, O 0 5.136849523523779e-08
termed O 0 4.377495770313544e-06
CA12 O 0 0.0005440706154331565
. O 0 2.7344121917849407e-06

The O 0 2.254486872743655e-07
deduced O 0 1.8207039431672456e-07
protein O 0 7.385218214750466e-09
sequence O 0 1.4994139263535544e-09
was O 0 1.984243169772526e-08
classified O 0 1.2026225570949123e-09
as O 0 3.1995198157552807e-10
a O 0 6.679383157681684e-10
one O 0 5.473484998574918e-10
- O 0 2.3285483763402226e-08
pass O 0 4.5828254968682813e-08
transmembrane O 0 1.6865917586983414e-06
CA O 0 2.374168161622947e-06
possessing O 0 3.708717031258857e-07
an O 0 1.5943925069095144e-09
apparently O 0 6.766570948002482e-08
intact O 0 6.241629080250277e-08
catalytic O 0 7.179674099688782e-08
domain O 0 1.033557595064849e-07
in O 0 1.3116748576180726e-08
the O 0 2.276096289222096e-08
extracellular O 0 2.1318584913387895e-05
CA O 0 0.00013287761248648167
module O 0 0.00022982926748227328
. O 0 2.4504597604391165e-06

Reintroduced O 0 2.7517248781805392e-06
wild O 0 5.562675937653694e-07
- O 0 2.710055753141205e-07
type O 0 7.558221568615409e-07
VHL B-Disease 0 2.1870804630452767e-05
strongly O 0 4.3885290068601535e-08
inhibited O 0 9.62435375839732e-09
the O 0 1.7204248026203572e-09
overexpression O 0 2.58957051357811e-08
of O 0 2.875262472556983e-09
the O 0 1.3876306770299607e-09
CA12 O 0 4.5259750436343893e-07
gene O 0 8.431091380600719e-10
in O 0 1.2654001457779174e-10
the O 0 3.913828150459153e-10
parental O 0 2.012423720998413e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999992847442627
lines O 0 0.0005276373703964055
. O 0 2.1908442704443587e-06

Similar O 0 1.4296247741185653e-08
results O 0 6.091785298423247e-09
were O 0 1.87023396769348e-09
obtained O 0 1.541678895655707e-09
with O 0 2.226716866449152e-10
CA9 O 0 8.00295947556151e-06
, O 0 2.8986426592325643e-09
encoding O 0 4.430150468692773e-08
another O 0 7.692931802694147e-08
transmembrane O 0 2.192645979448571e-06
CA O 0 9.65719550549693e-07
with O 0 2.102355622923824e-09
an O 0 3.055789177253132e-09
intact O 0 4.862748141931661e-07
catalytic O 0 1.5392283785331529e-06
domain O 0 2.9132572763046483e-06
. O 0 1.1772327752623823e-06

Although O 0 7.696718284933013e-08
both O 0 9.511572862663797e-09
domains O 0 1.7524558870718465e-07
of O 0 1.822699999820543e-07
the O 0 1.3348545735425432e-07
VHL B-Disease 0 2.4570410460000858e-05
protein O 0 8.1611247537694e-08
contribute O 0 4.426195410189848e-09
to O 0 5.944880698827149e-10
regulation O 0 1.0495433855339797e-07
of O 0 2.7962894222355317e-08
CA12 O 0 4.1201406020263676e-06
expression O 0 8.32200619527157e-09
, O 0 2.8844779342840354e-10
the O 0 1.8782549127127623e-10
elongin O 0 1.1613748185368422e-08
binding O 0 1.4464125452917642e-09
domain O 0 2.2464316629111636e-08
alone O 0 1.5545449372211806e-08
could O 0 9.880868345746308e-10
effectively O 0 3.4035366525131394e-08
regulate O 0 4.6538625042558124e-07
CA9 O 0 0.0003464824112597853
expression O 0 7.274426252479316e-07
. O 0 5.495468258231995e-07

We O 0 3.643023944732704e-07
mapped O 0 7.654648470634129e-07
CA12 O 0 3.502629624563269e-05
and O 0 6.622973813819044e-08
CA9 O 0 0.00011600272409850731
loci O 0 9.843087411809393e-08
to O 0 6.22947160522358e-09
chromosome O 0 2.2813907207819284e-07
bands O 0 3.2638391189721006e-07
15q22 O 0 1.270460302293941e-06
and O 0 4.712687839969476e-08
17q21 O 0 2.6964692096953513e-06
. O 0 2.888754409013927e-07

2 O 0 9.118953130382579e-06
respectively O 0 8.895124778973695e-07
, O 0 1.0443709896890141e-08
regions O 0 5.250966328418372e-09
prone O 0 5.7880981785274344e-08
to O 0 5.750875331500538e-10
amplification O 0 2.025099661295826e-07
in O 0 1.862203724556366e-09
some O 0 7.168405868895888e-10
human O 0 1.4256661984290986e-07
cancers B-Disease 0 0.23688344657421112
. O 0 1.1817603535746457e-06

Additional O 0 9.874716511149018e-08
experiments O 0 1.6728687057820935e-07
are O 0 3.0345992385605314e-10
needed O 0 1.8062321638367962e-09
to O 0 5.791943660793386e-11
define O 0 3.559092798255392e-09
the O 0 1.234963797891453e-09
role O 0 4.183316804073911e-08
of O 0 4.679841083543579e-07
CA O 0 2.453239858368761e-06
IX O 0 6.222061347216368e-05
and O 0 5.9487884840336847e-08
CA O 0 4.560054946978198e-07
XII O 0 1.514847554062726e-06
enzymes O 0 8.42639624742958e-10
in O 0 3.724229813428792e-10
the O 0 2.5449556351198055e-10
regulation O 0 1.0680980544464092e-08
of O 0 8.834511455724225e-10
pH O 0 2.521250053177937e-08
in O 0 6.313463640772454e-10
the O 0 1.137500094117172e-09
extracellular O 0 4.35357137007486e-08
microenvironment O 0 1.8468500684321043e-07
and O 0 2.4764656991749234e-10
its O 0 4.205542858404243e-11
potential O 0 1.7103271576779377e-10
impact O 0 5.623909782315195e-09
on O 0 1.3874110038614162e-07
cancer B-Disease 0 2.3732491172268055e-06
cell O 0 5.140981329532224e-07
growth O 0 5.102506506204918e-08
. O 0 8.773614013080078e-08

A O 0 3.013107345850585e-07
gene O 0 2.182442848663868e-08
encoding O 0 3.301150286461052e-07
a O 0 1.825575566272164e-07
transmembrane O 0 5.414738666331687e-07
protein O 0 4.6820460397611896e-08
is O 0 1.056285753309183e-10
mutated O 0 8.03733468668355e-10
in O 0 1.3176287838589928e-10
patients O 0 7.882935193492813e-09
with O 0 6.206234957062406e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 0.9999996423721313
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.4001664112583967e-06
. O 0 6.957848768252006e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0023449657019227743
WFS B-Disease 1 0.6353707313537598
; O 0 2.9246325539133977e-07
OMIM O 0 3.107345037278719e-05
222300 O 0 7.24752453606925e-07
) O 0 4.617777826787517e-10
is O 0 3.9293093084813435e-11
an O 0 7.909045640630552e-10
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 2.440573041440075e-07
by O 0 2.0059438554653752e-09
young O 0 4.7579280959553216e-08
- O 0 6.256820483940828e-07
onset O 1 0.9959134459495544
non O 1 0.9992534518241882
- O 1 0.9660637974739075
immune O 1 0.7939416170120239
insulin B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
dependent I-Disease 1 1.0
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999734163284302
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.001337043009698391

Linkage O 0 1.25706183098373e-05
to O 0 3.2374046554650704e-08
markers O 0 2.4846514179444057e-07
on O 0 6.418827069865074e-07
chromosome O 0 2.775201210170053e-06
4p O 0 0.00016774836694821715
was O 0 1.7740909186159115e-07
confirmed O 0 8.281532792864255e-09
in O 0 9.662606270666174e-10
five O 0 1.7247979711143557e-09
families O 0 2.29626137548955e-10
. O 0 2.2371828833911422e-08

On O 0 2.3555973882594117e-07
the O 0 5.751514819962722e-09
basis O 0 2.3791896452962646e-08
of O 0 3.6462491692645926e-08
meiotic O 0 3.656783974292921e-06
recombinants O 0 1.4335002560983412e-05
and O 0 3.0754961244383594e-08
disease O 0 6.233999010873958e-05
- O 0 3.039190232811961e-08
associated O 0 7.817924085884442e-08
haplotypes O 0 5.4793758863525e-07
, O 0 4.604042480593762e-09
the O 0 2.0361975217042527e-08
WFS B-Disease 0 1.4550025298376568e-05
gene O 0 1.2328815301998475e-08
was O 0 7.744754526584074e-08
localized O 0 2.0780019482913303e-08
to O 0 4.531470754187694e-09
a O 0 7.362969967061872e-08
BAC O 0 0.0006504078046418726
/ O 0 2.2204012566362508e-06
P1 O 0 1.3345098523132037e-05
contig O 0 3.3904148040164728e-06
of O 0 2.5145457271946725e-08
less O 0 5.739394293158284e-09
than O 0 3.82633036366542e-10
250 O 0 2.2091366513876665e-09
kb O 0 1.0366032938691205e-06
. O 0 2.358200248409048e-07

Mutations O 0 2.8286882525208057e-07
in O 0 2.1956031659442488e-08
a O 0 7.11727921043348e-09
novel O 0 2.1895381063785635e-09
gene O 0 1.697889051577306e-09
( O 0 6.502354210624617e-10
WFS1 O 0 2.0903556219309394e-07
) O 0 2.9241462029538923e-10
encoding O 0 2.2514203834589352e-08
a O 0 1.5886712390056346e-08
putative O 0 6.689703724305218e-08
transmembrane O 0 5.6548689286728404e-08
protein O 0 2.2397916410454854e-08
were O 0 1.1089733575886385e-09
found O 0 5.772962663463943e-11
in O 0 1.9435692638625213e-11
all O 0 7.318180783588701e-12
affected O 0 1.2688750224143508e-11
individuals O 0 3.242793403593347e-12
in O 0 2.3244901836694254e-10
six O 0 6.475241676184851e-09
WFS B-Disease 0 1.5523144156759372e-06
families O 0 7.976608956683506e-11
, O 0 5.897578952973603e-11
and O 0 1.1250682677155233e-11
these O 0 5.928726693610331e-12
mutations O 0 8.106241372596301e-11
were O 0 8.754143937528269e-11
associated O 0 6.204542990495554e-10
with O 0 6.62564308973046e-11
the O 0 9.614959495252151e-09
disease O 0 1.5509765944443643e-05
phenotype O 0 6.112318118312032e-08
. O 0 3.028687558526144e-07

WFS1 O 0 0.00020194989338051528
appears O 0 1.2883801048246823e-07
to O 0 4.969550326805461e-10
function O 0 6.470191937779646e-09
in O 0 1.0908769443318533e-09
survival O 0 1.0024866270441635e-07
of O 0 1.9052675881425785e-08
islet O 0 2.4479950866407307e-07
beta O 0 1.2888179981018766e-06
- O 0 1.7653215422797075e-07
cells O 0 7.596485662730856e-10
and O 0 5.458139495928549e-10
neurons O 0 1.0772393643776468e-08
. O 0 2.5051807295284334e-09
. O 0 1.5672513953290945e-08

Stable O 0 7.718274719081819e-05
interaction O 0 1.3350726248972933e-06
between O 0 7.285800052159175e-08
the O 0 1.5222739735420987e-09
products O 0 1.0392001703607434e-09
of O 0 5.438560712889284e-10
the O 0 3.4175126617519425e-10
BRCA1 O 0 9.778166054630333e-10
and O 0 7.090677489607344e-10
BRCA2 O 0 2.8150821673733617e-09
tumor B-Disease 0 2.524146758275947e-08
suppressor O 0 1.0474875011823315e-07
genes O 0 3.3129938792342273e-09
in O 0 4.572598744090328e-09
mitotic O 0 1.6011611592148256e-07
and O 0 1.8024747916456363e-08
meiotic O 0 4.890692071057856e-05
cells O 0 8.577370067541779e-07
. O 0 8.195596592486254e-07

BRCA1 O 0 4.364394044387154e-06
and O 0 6.558773435472176e-08
BRCA2 O 0 2.3139467231203525e-08
account O 0 3.171334583829122e-10
for O 0 7.855999878403352e-11
most O 0 1.3771196856471324e-11
cases O 0 3.2724014470408846e-11
of O 0 4.643479212251833e-10
familial O 0 3.0091211300486975e-08
, O 0 5.656956569843885e-10
early O 0 5.6858876718024476e-08
onset O 0 0.00014375180762726814
breast B-Disease 0 4.415036073623924e-06
and I-Disease 0 6.466918875958072e-07
/ I-Disease 1 0.9999998807907104
or I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 7.099168328750238e-07
encode O 0 1.2149996564403409e-08
products O 0 9.467915340621857e-09
that O 0 2.3692776907058288e-11
each O 0 1.3707307858212836e-11
interact O 0 5.088496290994726e-10
with O 0 1.7283340036922112e-10
hRAD51 O 0 3.2642935821058927e-07
. O 0 6.131678986776024e-08

Results O 0 8.087782532584242e-08
presented O 0 3.494019438221585e-07
here O 0 3.765934764032863e-08
show O 0 6.203859648223897e-09
that O 0 1.2277036331997948e-10
BRCA1 O 0 1.6449380746408337e-09
and O 0 1.2770220436664204e-09
BRCA2 O 0 1.2068190891056929e-08
coexist O 0 1.2856669506788876e-08
in O 0 1.3312047020264117e-09
a O 0 1.3084507921590216e-09
biochemical O 0 1.2253332215550472e-07
complex O 0 2.7941976554757275e-07
and O 0 1.0252845239477892e-09
colocalize O 0 2.6655351348381373e-07
in O 0 2.143113464470048e-09
subnuclear O 0 6.796268507969216e-07
foci O 0 1.3502651654562214e-06
in O 0 2.1782913250945057e-09
somatic O 0 2.124506970346829e-08
cells O 0 6.012433884095003e-10
and O 0 1.3499641682290786e-10
on O 0 1.3488118399962445e-09
the O 0 1.4150848548499795e-10
axial O 0 1.4709511386712393e-09
elements O 0 6.457358203704189e-09
of O 0 8.886059887913689e-09
developing O 0 1.417153328020504e-07
synaptonemal O 0 5.1188667384849396e-06
complexes O 0 9.760135526448721e-07
. O 0 4.6282005428111006e-07

Like O 0 3.5218838547734777e-06
BRCA1 O 0 2.9366606213443447e-06
and O 0 4.6175622969713004e-07
RAD51 O 0 0.0005915419897064567
, O 0 1.6849892858772364e-07
BRCA2 O 0 8.527033656946514e-08
relocates O 0 2.945490962247277e-07
to O 0 9.92387949594331e-09
PCNA O 0 6.329448297037743e-06
+ O 0 3.4928923753341223e-08
replication O 0 3.892033362262737e-09
sites O 0 1.8736820428522094e-10
following O 0 6.582287492840067e-11
exposure O 0 2.8705185783906018e-08
of O 0 2.047104885605222e-08
S O 0 3.867217230890674e-07
phase O 0 5.130260660735075e-07
cells O 0 1.1407156330633939e-09
to O 0 1.5494140415128754e-09
hydroxyurea O 0 5.470327550938237e-07
or O 0 5.7593414481971195e-09
UV O 0 6.734923317708308e-06
irradiation O 0 9.988408464778331e-07
. O 0 5.3960992119073126e-08

Thus O 0 5.047891704634822e-07
, O 0 2.4201114001698443e-08
BRCA1 O 0 4.494157046508462e-09
and O 0 1.4080854260356546e-09
BRCA2 O 0 1.7936395702022878e-09
participate O 0 1.5976772127501704e-09
, O 0 1.9529382278005158e-10
together O 0 2.149441180598899e-10
, O 0 8.509766502573513e-11
in O 0 1.1542231753702836e-10
a O 0 4.801655739683497e-10
pathway O 0 3.4725906594701428e-09
( O 0 6.158795695654362e-10
s O 0 3.468982434640111e-09
) O 0 4.449179913379453e-11
associated O 0 3.490152056251361e-10
with O 0 3.880428617319964e-11
the O 0 1.6410764414054313e-10
activation O 0 4.231504036056322e-09
of O 0 2.0731286909381197e-08
double O 0 3.4276805394029e-08
- O 0 2.1217759638147982e-07
strand O 0 1.3788721275886928e-08
break O 0 2.747649219259074e-08
repair O 0 1.0004863497670158e-06
and O 0 1.3595858661119564e-08
/ O 0 2.381765398240532e-06
or O 0 3.198363529577364e-08
homologous O 0 4.777425033353211e-07
recombination O 0 1.1122519936179742e-06
. O 0 5.070433530818264e-07

Dysfunction O 1 0.9998453855514526
of O 0 1.3230202966951765e-05
this O 0 2.1874022593237896e-08
pathway O 0 2.561580174642586e-07
may O 0 7.54345652609345e-09
be O 0 2.119478065276681e-10
a O 0 5.313871564993633e-11
general O 0 2.0679809253909553e-10
phenomenon O 0 1.043227726427176e-09
in O 0 3.916948015936228e-11
the O 0 2.8301104515460196e-11
majority O 0 1.5527851573993168e-11
of O 0 1.1179372011449473e-10
cases O 0 1.8397282308679763e-10
of O 0 3.6262104430306863e-09
hereditary B-Disease 1 0.9996668100357056
breast I-Disease 1 0.9989683628082275
and I-Disease 0 0.25413668155670166
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.010276946239173412
. O 0 5.705893727281364e-06

A O 0 1.5364653336291667e-06
novel O 0 7.399603418889455e-08
Arg362Ser O 0 8.789103844719648e-07
mutation O 0 3.5678402454664138e-09
in O 0 1.1653239484488154e-09
the O 0 2.5739395059787284e-09
sterol O 0 6.73718361099418e-08
27 O 0 2.0043830772920046e-07
- O 0 3.352598199057866e-08
hydroxylase O 0 5.636616506876635e-08
gene O 0 9.437445491755625e-09
( O 0 3.147418992099915e-09
CYP27 O 0 2.0516879430942936e-06
) O 0 7.673989776968426e-10
: O 0 5.904489397412505e-11
its O 0 1.40089944852817e-11
effects O 0 5.969904570690687e-09
on O 0 1.2656331982441316e-08
pre O 0 7.869958551509626e-08
- O 0 2.330653448012754e-09
mRNA O 0 5.668339686515367e-10
splicing O 0 4.0980769888676605e-09
and O 0 1.476882227624543e-10
enzyme O 0 1.0555812890444827e-09
activity O 0 2.3759971767844945e-08
. O 0 7.977655513968784e-08

A O 0 2.0009024410683196e-06
novel O 0 5.528575286462001e-08
C O 0 3.904244181285321e-07
to O 0 3.4322564235189645e-10
A O 0 2.1091954849339345e-09
mutation O 0 4.489269719853972e-11
in O 0 7.59067461664209e-11
the O 0 4.2970565994338017e-10
sterol O 0 1.4612764331900507e-08
27 O 0 9.082850027652967e-08
- O 0 2.452345349013285e-08
hydroxylase O 0 5.974144556830652e-08
gene O 0 1.8739054752359152e-08
( O 0 9.313362525631419e-09
CYP27 O 0 3.206905603292398e-06
) O 0 1.4759311550704979e-09
was O 0 9.62112345348487e-09
identified O 0 2.649158115097805e-10
by O 0 2.6908697492444844e-11
sequencing O 0 2.818724809117157e-09
amplified O 0 5.944410119695931e-08
CYP27 O 0 1.0741391633928288e-06
gene O 0 1.0753957724318752e-08
products O 0 1.3251635344602164e-08
from O 0 3.629240907798703e-09
a O 0 1.543715155705172e-09
patient O 0 7.788807820929833e-09
with O 0 6.754473425019114e-09
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 7.330754101531056e-07
CTX B-Disease 0 0.00010507567640161142
) O 0 9.092921970932366e-08
. O 0 2.3495620382618654e-07

The O 0 4.668794417739264e-08
mutation O 0 4.084272919868681e-09
changed O 0 1.4425177496946162e-08
the O 0 3.3868403637171696e-09
adrenodoxin O 0 1.409445076205884e-07
cofactor O 0 9.000396872238525e-09
binding O 0 4.652790597248213e-09
residue O 0 1.0186017362912025e-07
362Arg O 0 6.29759355774695e-08
to O 0 1.7036340116405313e-09
362Ser O 0 2.846003042122902e-07
( O 0 4.970491129796528e-09
CGT O 0 7.44552835385548e-07
362Arg O 0 6.498343196881251e-08
to O 0 5.083163223673637e-09
AGT O 0 9.421039976587053e-06
362Ser O 0 2.277434276720669e-07
) O 0 7.41768313439195e-10
, O 0 1.5755791116234263e-10
and O 0 6.906591271116369e-11
was O 0 6.571556188106342e-09
responsible O 0 3.000803161512522e-09
for O 0 5.040192263550125e-09
deficiency O 0 0.0003485099005047232
in O 0 7.148941705281686e-08
the O 0 5.954634829663519e-08
sterol O 0 1.6398429636410583e-07
27 O 0 3.774118511046254e-07
- O 0 2.0336473838256097e-08
hydroxylase O 0 1.1257938581366034e-07
activity O 0 8.112993832298798e-09
, O 0 2.6767479899270086e-10
as O 0 5.945104131210854e-11
confirmed O 0 1.4056160402287077e-10
by O 0 1.4667473832719047e-11
expression O 0 5.197832164682836e-10
of O 0 3.4348250910198885e-09
mutant O 0 5.476516573565959e-09
cDNA O 0 2.9785145017058312e-08
into O 0 3.6928835100979995e-08
COS O 0 7.380618626484647e-05
- O 0 3.560966206350713e-06
1 O 0 1.2845133596783853e-06
cells O 0 3.167982498553101e-08
. O 0 1.045832505042199e-07

Quantitative O 0 1.4948664102121256e-06
analysis O 0 7.038711657969543e-08
showed O 0 2.1018554008378487e-08
that O 0 2.655379041649475e-11
the O 0 1.2195676413195855e-10
expression O 0 5.009033188230205e-10
of O 0 1.8178586413952758e-09
CYP27 O 0 9.123949240574802e-08
gene O 0 3.2140096140054197e-10
mRNA O 0 2.4940147724805684e-09
in O 0 6.789862561085158e-10
the O 0 1.0963921992512837e-09
patient O 0 6.7622853983095865e-09
represented O 0 1.9559111663625117e-08
52 O 0 9.125930660047743e-07
. O 0 3.267591921485291e-07

5 O 0 1.8689904663915513e-06
% O 0 1.3920531394262525e-08
of O 0 3.354542599254273e-08
the O 0 1.0565365471393307e-08
normal O 0 5.329572445589292e-07
level O 0 2.967004093079595e-06
. O 0 1.4942877157864132e-07

As O 0 3.574367113401422e-08
the O 0 4.221741178866978e-09
mutation O 0 3.592162567400692e-09
occurred O 0 1.1739003724642316e-07
at O 0 2.0926149701949726e-08
the O 0 1.2525013248776418e-09
penultimate O 0 2.4982441004794964e-08
nucleotide O 0 1.958762485543275e-09
of O 0 2.1026211882713142e-08
exon O 0 1.4091385480696772e-07
6 O 0 3.7734562852165254e-07
( O 0 5.391199486837195e-09
- O 0 2.2187951032037745e-08
2 O 0 3.50766704571015e-08
position O 0 3.243399859798046e-08
of O 0 1.196375620793333e-07
exon O 0 4.291941593237425e-07
6 O 0 2.3139571112551494e-06
- O 0 6.45387615350046e-07
intron O 0 1.0741022151705693e-06
6 O 0 1.6819902270981402e-07
splice O 0 5.134224778657881e-08
site O 0 7.1145240809755705e-09
) O 0 2.5271310044594486e-10
of O 0 5.863163732300336e-09
the O 0 3.08274761273708e-09
gene O 0 7.942489332890545e-09
, O 0 3.3131204446590345e-09
we O 0 1.1869487615001617e-09
hypothesized O 0 7.135833701710226e-09
that O 0 3.4265770776364946e-11
the O 0 5.118437895745842e-10
mutation O 0 1.420190742784655e-09
may O 0 3.459283082207776e-09
partially O 0 1.386850900786385e-08
affect O 0 6.6831451484006266e-09
the O 0 1.7362546955723701e-09
normal O 0 1.688134432242805e-08
splicing O 0 5.897562882495322e-09
efficiency O 0 1.3077030125430156e-08
in O 0 1.059736964847957e-09
exon O 0 5.847140371884052e-08
6 O 0 1.6844005301663856e-08
and O 0 4.1585473953276164e-10
cause O 0 4.737683578781571e-10
alternative O 0 5.549138371030438e-10
splicing O 0 2.5175197482241174e-09
elsewhere O 0 1.1012462053372474e-09
, O 0 2.634051483874078e-11
which O 0 3.5354744305771124e-12
resulted O 0 2.9027238945822376e-10
in O 0 9.992589394824947e-11
decreased O 0 7.255066769573659e-09
transcript O 0 2.106961005665653e-08
in O 0 4.4211054262000005e-10
the O 0 1.1145885325802851e-09
patient O 0 3.727260633468177e-08
. O 0 6.408392039247701e-08

Transfection O 0 2.0330273400759324e-05
of O 0 4.832094191442593e-07
constructed O 0 8.949436391958443e-07
minigenes O 0 3.303154699096922e-06
, O 0 5.893567855963511e-10
with O 0 2.936149240406749e-11
or O 0 1.3407315535562958e-10
without O 0 2.105175200828313e-10
the O 0 1.6465538654752976e-10
mutation O 0 3.04893957303598e-11
, O 0 9.89381979121795e-11
into O 0 2.6969355637618264e-09
COS O 0 2.8361666409182362e-05
- O 0 1.555908625050506e-06
1 O 0 2.169835795484687e-07
cells O 0 3.356599997950127e-10
confirmed O 0 2.3313024843929497e-09
that O 0 1.0313952816809469e-11
the O 0 4.3517137809923057e-11
mutant O 0 1.6660559598591362e-09
minigene O 0 8.359682368563881e-08
was O 0 1.4703516626468627e-08
responsible O 0 5.456348706189829e-10
for O 0 8.487299751891442e-11
a O 0 1.882921457641018e-10
mRNA O 0 1.5512763296143817e-10
species O 0 3.640994623854699e-12
alternatively O 0 1.4089586164445222e-09
spliced O 0 2.989681746612405e-08
at O 0 6.86563552676489e-08
an O 0 1.0324492372149052e-09
activated O 0 8.643818887321686e-07
cryptic O 0 4.646487639092811e-07
5 O 0 7.537419577374749e-08
splice O 0 3.834543065295293e-07
site O 0 1.6041124695220788e-07
88 O 0 3.0788598337494477e-07
bp O 0 3.7051711387903197e-07
upstream O 0 4.407781517556941e-08
from O 0 3.525627789713326e-09
the O 0 4.687342514131387e-09
3 O 0 4.3855667541947696e-08
end O 0 3.1572636061127923e-08
of O 0 7.366299570321644e-08
exon O 0 2.5017998268594965e-06
6 O 0 3.7546858493442414e-06
. O 0 3.8934092572162626e-07

Our O 0 1.1243817965578273e-07
data O 0 2.919645858412423e-08
suggest O 0 1.5376878659267845e-09
that O 0 2.3425057033010788e-11
the O 0 2.0475167394895522e-10
C O 0 2.4125023756482733e-08
to O 0 9.7441096857942e-11
A O 0 4.442052947695174e-09
mutation O 0 3.2093724899873166e-10
at O 0 4.555666954786375e-09
the O 0 7.757668951668961e-10
penultimate O 0 1.7040443722748932e-08
nucleotide O 0 2.6439095357488895e-09
of O 0 8.090000669369601e-09
exon O 0 9.461997052540028e-08
6 O 0 8.900990877691584e-08
of O 0 1.3112019914274242e-08
the O 0 4.664840069779075e-09
CYP27 O 0 1.6316653272951953e-06
gene O 0 4.428762689911991e-09
not O 0 2.2520450781993162e-10
only O 0 2.4516275121122533e-10
causes O 0 1.989198805674164e-09
the O 0 8.02780864006536e-09
deficiency B-Disease 0 1.458127030673495e-06
in I-Disease 0 8.497626602377295e-09
the I-Disease 0 1.150979400676988e-08
sterol I-Disease 0 3.684728966391049e-08
27 I-Disease 0 7.146064717744594e-08
- I-Disease 0 5.921051648982711e-09
hydroxylase I-Disease 0 5.308996620101425e-08
activity I-Disease 0 5.666343394494788e-09
, O 0 7.158404424778553e-10
but O 0 1.0320176657696578e-10
also O 0 1.8198351159348647e-10
partially O 0 5.528024260570419e-09
leads O 0 5.33735888819109e-10
to O 0 8.41958031072565e-11
alternative O 0 4.113190676946488e-09
pre O 0 6.248203732184265e-08
- O 0 5.15998266337192e-09
mRNA O 0 2.7381368283840857e-09
splicing O 0 1.628269963305229e-08
of O 0 2.8452409317480942e-09
the O 0 1.1807302913169337e-09
gene O 0 2.36614727811002e-08
. O 0 1.757037892957669e-07

To O 0 2.0337721196028724e-07
our O 0 1.1948499434311088e-07
knowledge O 0 4.557502961688442e-07
, O 0 6.630906379534451e-10
this O 0 2.5346986662344584e-11
is O 0 6.89959547828245e-12
the O 0 2.079323171977343e-11
first O 0 7.983393460198052e-12
report O 0 9.361523709006114e-12
regarding O 0 1.2925305270528042e-10
effects O 0 5.563862259805319e-09
on O 0 9.55998924467849e-09
pre O 0 4.170879819298534e-08
- O 0 1.1978700253933994e-09
mRNA O 0 3.301152684542785e-10
splicing O 0 6.371266181304236e-09
of O 0 3.1213178708355827e-09
a O 0 4.526320152020702e-10
mutation O 0 7.099605625615624e-11
at O 0 1.2622243694693225e-08
the O 0 1.5378814888222792e-09
- O 0 1.891457834801713e-08
2 O 0 2.8306438082381646e-08
position O 0 3.7730455204609825e-08
of O 0 4.765293581954211e-08
a O 0 2.0040214820937763e-08
5 O 0 8.476860813289022e-08
splice O 0 4.00596633198802e-07
site O 0 3.2928431892287335e-07
. O 0 3.9035367649375985e-07

ATM O 0 0.00016220023098867387
germline O 0 8.597323358117137e-06
mutations O 0 4.9189424089490785e-08
in O 0 2.488827099966784e-08
classical O 1 0.9999992847442627
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 0.010531192645430565
in O 0 3.0963438035769286e-08
the O 0 9.502433506725083e-09
Dutch O 0 1.3752649465459399e-05
population O 0 5.861293117526145e-10
. O 0 2.0090656249749372e-08

Germline O 0 0.00011634291877271608
mutations O 0 3.652594386949204e-07
in O 0 8.303644882801109e-09
the O 0 3.007099902418986e-09
ATM O 0 1.8746085572729498e-07
gene O 0 6.822303277864705e-10
are O 0 1.4045426063521993e-12
responsible O 0 2.705722798590493e-11
for O 0 1.567850016481742e-11
the O 0 2.459311190250446e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999572038650513
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.765716660884209e-06
. O 0 7.231927270368033e-07

In O 0 1.1869588689705779e-07
our O 0 7.867253515314587e-09
study O 0 1.0460331489881014e-09
, O 0 3.735111872571473e-11
we O 0 2.776260471515357e-11
have O 0 1.423524167466772e-12
determined O 0 2.5509415760294196e-11
the O 0 1.9733702519286744e-11
ATM O 0 3.1077613815710947e-09
mutation O 0 5.793843876888971e-11
spectrum O 0 3.485443933470833e-09
in O 0 4.3954023754011473e-10
19 O 0 1.5822271492993423e-08
classical O 0 2.9069407901261002e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
T I-Disease 1 1.0
patients O 0 5.549980386376774e-08
, O 0 5.393847868351287e-11
including O 0 1.579321222411334e-11
some O 0 2.9940409960321768e-12
immigrant O 0 7.222365067116598e-11
populations O 0 2.424121233607357e-12
, O 0 1.2782684633005914e-11
as O 0 2.8272077387536676e-11
well O 0 4.321531327233785e-11
as O 0 1.2101554480725696e-10
12 O 0 6.67999433545674e-10
of O 0 1.064926147265055e-09
Dutch O 0 3.609874852372741e-07
ethnic O 0 1.951475869788055e-09
origin O 0 1.4090158373392114e-08
. O 0 2.310387792192614e-08

Both O 0 8.479221946799953e-08
the O 0 1.7582237887836527e-08
protein O 0 6.993864598570099e-09
truncation O 0 5.2717020082582167e-08
test O 0 5.564477767450171e-09
( O 0 1.712520680818841e-10
PTT O 0 1.8215386532460798e-08
) O 0 4.303862127796876e-11
and O 0 1.405475996002492e-11
the O 0 5.7438897388406573e-11
restriction O 0 1.276619504553267e-10
endonuclease O 0 1.627350143529327e-09
fingerprinting O 0 1.0026468544310774e-08
( O 0 3.5083863592078046e-10
REF O 0 2.0340353401593347e-08
) O 0 4.725227500945728e-11
method O 0 5.485755738554587e-10
were O 0 6.489961346112239e-11
used O 0 4.747975970720297e-11
and O 0 7.124263418784027e-12
compared O 0 8.807637258412271e-11
for O 0 7.340086004281599e-12
their O 0 5.0835043639840816e-12
detection O 0 1.777991642804011e-09
efficiency O 0 1.0154020957386933e-09
, O 0 2.0708887729647962e-11
identifying O 0 2.89633095285069e-10
76 O 0 5.560234050960844e-09
% O 0 9.951960783238789e-11
and O 0 9.615499368953451e-11
60 O 0 8.91132778679804e-10
% O 0 1.549374795128955e-10
of O 0 1.2095467960548945e-09
the O 0 1.6688164183875642e-09
mutations O 0 1.4119150293367966e-09
, O 0 1.3049141767140782e-09
respectively O 0 9.168224579525486e-08
. O 0 1.5453588275704533e-07

Most O 0 5.133519564992639e-08
patients O 0 3.411849647250165e-08
were O 0 5.076361997424783e-09
found O 0 9.152141822177384e-10
to O 0 2.348156946663238e-10
be O 0 2.79079981346797e-09
compound O 0 3.8977745475676784e-07
heterozygote O 0 1.9273704310762696e-05
. O 0 4.537986058039678e-07

Seventeen O 0 6.129317284830904e-07
mutations O 0 1.8113388122742435e-08
were O 0 8.712637278307511e-10
distinct O 0 7.384707290114534e-10
, O 0 1.4749371168853997e-10
of O 0 1.9427113251424544e-09
which O 0 6.601322960486655e-11
10 O 0 1.4373534584777303e-09
were O 0 1.85239004690807e-10
not O 0 2.2641898772546298e-11
reported O 0 8.588528777053739e-10
previously O 0 1.7240161298559542e-08
. O 0 3.391509295624928e-08

Mutations O 0 3.577034419777192e-07
are O 0 4.776372075632196e-10
small O 0 8.682412011573604e-10
deletions O 0 9.269429668279372e-09
or O 0 1.1719893500128364e-08
point O 0 1.2179020814073738e-06
mutations O 0 6.950246600467835e-09
frequently O 0 5.784045242762659e-09
affecting O 0 1.3330169856828888e-08
splice O 0 2.4238238438556436e-07
sites O 0 1.8218235808831196e-08
. O 0 1.6516170830982446e-07

Moreover O 0 9.69430311670294e-06
, O 0 5.533977187610617e-08
a O 0 5.3731753268948523e-08
16 O 0 8.267820135188231e-07
. O 0 2.9162407599869766e-07

7 O 0 2.2779369828640483e-05
- O 0 7.855318813199119e-07
kb O 0 1.5012597032182384e-06
genomic O 0 1.4740390952283633e-07
deletion O 0 6.639706953137647e-07
of O 0 1.9688324925937195e-07
the O 0 4.3557559337159546e-08
3 O 0 6.148237474690177e-08
end O 0 1.3141839616537254e-08
of O 0 2.901087148288184e-09
the O 0 3.7745029324298685e-10
gene O 0 1.9614833368652995e-10
, O 0 1.3688293554192654e-10
most O 0 3.930568717724903e-11
likely O 0 1.1156642970577835e-10
a O 0 5.189122395665713e-11
result O 0 1.9884920099411119e-10
of O 0 3.4065092968660338e-09
recombination O 0 2.5996000907468897e-09
between O 0 3.0755490598721735e-08
two O 0 1.8609856988760498e-09
LINE O 0 9.653662402797636e-08
elements O 0 5.2207298040229944e-08
, O 0 8.186076816407706e-10
was O 0 2.3202137100497566e-08
identified O 0 2.229243101226075e-08
. O 0 9.348391216690288e-08

The O 0 8.491392833320788e-08
most O 0 4.376362605640338e-10
frequently O 0 1.8659288003597396e-10
found O 0 3.207314622222235e-11
mutation O 0 1.3615534047439759e-11
, O 0 1.0103819690632232e-11
identified O 0 1.0260568089615063e-10
in O 0 1.0704300640318465e-10
three O 0 7.21922521762508e-11
unrelated O 0 4.664964414757833e-09
Turkish O 0 1.436294354562051e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9998015761375427
T I-Disease 1 0.9999996423721313
individuals O 0 2.8709370991641947e-10
, O 0 1.4914559587353438e-09
was O 0 1.7816283559568546e-08
previously O 0 2.887782457605681e-09
described O 0 4.962067978731e-10
to O 0 1.5015990187383643e-11
be O 0 9.405449336030713e-11
a O 0 3.345523302833442e-10
Turkish O 0 1.7097035254209914e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
founder O 0 0.002158564515411854
mutation O 0 3.5743408943744726e-07
. O 0 7.762884024486993e-07

The O 0 7.067702512131291e-08
presence O 0 2.9568690607106873e-08
of O 0 4.190591695873991e-08
a O 0 1.0032704444995488e-08
founder O 0 8.641909232665057e-08
mutation O 0 3.5786340557564245e-10
among O 0 2.230634947586463e-11
relatively O 0 1.3593458303429173e-10
small O 0 8.239641607898918e-12
ethnic O 0 1.4259054874343757e-11
population O 0 5.522975197840008e-13
groups O 0 1.086197646583964e-12
in O 0 2.894799504271628e-11
Western O 0 1.4161603001383583e-09
Europe O 0 7.026351722672075e-10
could O 0 4.040098117163993e-11
indicate O 0 1.1572034303020118e-10
a O 0 2.0704908620938767e-10
high O 0 8.599692069566345e-10
carrier O 0 1.6600347485518085e-10
frequency O 0 5.796292779081114e-09
in O 0 1.0128638205930685e-10
such O 0 5.7210378795469197e-11
communities O 0 2.9235269760619076e-10
. O 0 2.0533773792408283e-08

In O 0 1.3026685508066294e-07
patients O 0 6.343597647173738e-08
of O 0 4.228182248766643e-08
Dutch O 0 1.4716285477334168e-05
ethnic O 0 5.028007787899469e-09
origin O 0 1.2462388898626386e-09
, O 0 5.865025826112813e-11
however O 0 8.306282744952043e-11
, O 0 4.042611037591293e-11
no O 0 6.374809013998117e-11
significant O 0 1.9376822368855073e-09
founder O 0 2.8570332233357476e-07
effect O 0 2.5065926934075833e-07
could O 0 9.887981100575871e-09
be O 0 1.952235262336899e-09
identified O 0 2.1527585047920184e-08
. O 0 5.569726369003547e-08

The O 0 4.563827005199528e-08
observed O 0 6.607618274756533e-08
genetic O 0 9.926454325182021e-09
heterogeneity O 0 1.803272553502211e-08
including O 0 1.635492574703079e-10
the O 0 1.8497146037077528e-09
relative O 0 1.8172326576859632e-07
high O 0 1.7746155833719968e-07
percentage O 0 6.113551886954838e-09
of O 0 1.029506080385545e-08
splice O 0 8.861166378437701e-08
- O 0 2.769442275507572e-08
site O 0 7.151735204047327e-09
mutations O 0 4.214130822077777e-09
had O 0 9.007093737523064e-09
no O 0 1.9145707241818855e-09
reflection O 0 1.994731491095081e-08
on O 0 3.707421925014387e-08
the O 0 9.764584696370093e-09
phenotype O 0 5.566136707102487e-08
. O 0 1.57836353764651e-07

All O 0 1.0094819202777217e-08
patients O 0 2.5482742582738638e-09
manifested O 0 4.4668957421833966e-09
classical O 0 5.1653394621098414e-05
A B-Disease 1 0.9999984502792358
- I-Disease 0 0.3889915347099304
T I-Disease 1 0.9999566078186035
and O 0 1.974957530848087e-09
increased O 0 3.4184337582843227e-09
cellular O 0 6.169570809788638e-08
radioresistant O 0 7.067783514003168e-08
DNA O 0 1.2463345910873613e-08
synthesis O 0 1.564363998340923e-07
. O 0 7.976149163368973e-08

Determination O 0 4.463727691472741e-06
of O 0 3.1588601245857717e-07
the O 0 6.829558696352933e-09
genomic O 0 3.8713341865559414e-08
structure O 0 1.573551173805754e-07
of O 0 3.872102283253298e-08
the O 0 3.249869484633905e-09
COL4A4 O 0 6.008117452438455e-07
gene O 0 3.414235283383249e-10
and O 0 1.4987091428997346e-11
of O 0 3.1253555299315394e-10
novel O 0 3.161256811878843e-09
mutations O 0 3.3802825782913715e-07
causing O 0 6.873063284729142e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.027241423726081848

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.3405613117356552e-06
a O 0 6.138729418125877e-07
progressive O 1 0.999993085861206
hematuric B-Disease 1 0.9999997615814209
glomerulonephritis I-Disease 1 1.0
characterized O 1 0.7648356556892395
by O 0 1.1819062706308614e-07
glomerular B-Disease 1 0.9999998807907104
basement I-Disease 1 0.9999994039535522
membrane I-Disease 1 0.7422987222671509
abnormalities I-Disease 1 0.9993014335632324
and O 0 2.027124912373779e-09
associated O 0 2.1590169652085933e-08
with O 0 3.217517918763235e-10
mutations O 0 1.7467852941877027e-08
in O 0 3.2764142510188776e-09
either O 0 6.8148549026147975e-09
the O 0 1.0300855279865573e-08
COL4A3 O 0 6.0568845583475195e-06
or O 0 1.3272294374644389e-09
the O 0 2.385086128597891e-09
COL4A4 O 0 7.776696406835981e-07
gene O 0 1.2382375125241651e-09
, O 0 1.4764907352304846e-10
which O 0 8.90350380228222e-12
encode O 0 2.1361989954726823e-10
the O 0 8.390936279134564e-10
alpha3 O 0 1.3742568683028367e-07
and O 0 1.3725163228173187e-09
alpha4 O 0 7.582378316328686e-07
type O 0 1.2508386134868488e-05
IV O 1 1.0
collagen O 0 0.16447483003139496
chains O 0 2.6340103431721218e-05
, O 0 3.321993347071839e-08
respectively O 0 7.053736794659926e-07
. O 0 1.731753371814193e-07

To O 0 1.2541179650327194e-08
date O 0 1.2852235897753417e-07
, O 0 2.226725331899715e-10
mutation O 0 3.2502875391138275e-11
screening O 0 8.80186479257361e-10
in O 0 2.577141278159445e-10
the O 0 8.145271679360633e-10
two O 0 5.028024108177931e-10
genes O 0 8.001450613193128e-10
has O 0 2.646350083512772e-10
been O 0 1.8218146435877713e-10
hampered O 0 7.497598986105913e-09
by O 0 4.437823025726928e-11
the O 0 2.3811030924747456e-10
lack O 0 2.621193928575849e-09
of O 0 1.6313994599670423e-09
genomic O 0 5.799090541103169e-09
structure O 0 7.479604846594157e-08
information O 0 3.0015890217782726e-08
. O 0 2.1775120728761976e-07

We O 0 8.811077378823029e-08
report O 0 3.0799911510115408e-09
here O 0 1.2156828876896952e-09
the O 0 7.53556869681482e-11
complete O 0 2.9161759118601083e-10
characterization O 0 3.483955124394811e-09
of O 0 2.5431663441821684e-09
the O 0 1.119286108242079e-09
48 O 0 1.5684266330140417e-08
exons O 0 2.0159211189252346e-08
of O 0 1.6238718814065578e-08
the O 0 8.259826600465203e-09
COL4A4 O 0 1.6653727925586281e-06
gene O 0 3.1636455677386266e-09
, O 0 3.202438036975508e-10
a O 0 8.747567947775536e-11
comprehensive O 0 5.176856721078593e-10
gene O 0 1.2480508293499781e-10
screen O 0 4.780149964744851e-08
, O 0 8.451990773927776e-10
and O 0 6.512578670792024e-11
the O 0 3.531358191977141e-11
subsequent O 0 1.3049858416103177e-10
detection O 0 1.601384802540906e-08
of O 0 1.3197748449655933e-09
10 O 0 2.9441307725086574e-10
novel O 0 4.6253032653931214e-11
mutations O 0 1.8853617278491441e-10
in O 0 1.1487675394272756e-10
eight O 0 2.1768791214071825e-09
patients O 0 4.798904740255239e-08
diagnosed O 0 0.0006326389266178012
with O 0 2.1643747913913103e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00022313515364658087

Furthermore O 0 2.2840843030280666e-06
, O 0 4.039526046994979e-08
we O 0 2.3716493213754575e-09
identified O 0 1.5838477196439271e-09
a O 0 7.080298014550124e-10
glycine O 0 2.282159350386337e-09
to O 0 1.9446085020025095e-10
alanine O 0 4.037529421907493e-09
substitution O 0 1.3842055501811501e-08
in O 0 6.888504766600079e-10
the O 0 2.9722193595205226e-09
collagenous O 0 2.66699203166354e-07
domain O 0 4.634986616736114e-09
that O 0 2.4113671129311065e-11
is O 0 2.936804618935973e-11
apparently O 0 2.528374731802785e-10
silent O 0 5.566449523541905e-10
in O 0 2.1972503677636368e-11
the O 0 4.534319447691004e-11
heterozygous O 0 4.443921272634377e-11
carriers O 0 1.0277392825663867e-10
, O 0 9.065218714576773e-11
in O 0 6.204708413726223e-10
11 O 0 4.302424017055273e-08
. O 0 1.2996333964565565e-07

5 O 0 7.177496286203677e-07
% O 0 5.352919441037329e-09
of O 0 9.927874522475122e-09
all O 0 1.1250131382034567e-10
control O 0 1.2217947542580987e-08
individuals O 0 2.4921341032491107e-11
, O 0 6.142181208090847e-11
and O 0 3.919324240153621e-11
in O 0 1.8286278047341398e-10
one O 0 4.7776269052057785e-11
control O 0 2.534957577182695e-09
individual O 0 3.134463869014503e-11
homozygous O 0 1.3110106056313242e-10
for O 0 6.218520143264072e-11
this O 0 1.7090619197634993e-10
glycine O 0 4.806462072792783e-08
substitution O 0 1.4228449174424895e-07
. O 0 2.0762139740782004e-07

There O 0 3.551131158019416e-07
has O 0 4.850388535260208e-09
been O 0 2.714304336848272e-10
no O 0 4.833077688060072e-11
previous O 0 8.071065343839834e-11
finding O 0 1.419416140180374e-09
of O 0 1.0548426576661996e-09
a O 0 4.667151665138647e-10
glycine O 0 3.787897551177366e-09
substitution O 0 2.488669270661603e-09
that O 0 6.041098871145678e-11
is O 0 6.380392741922591e-11
not O 0 1.4511364332392418e-11
associated O 0 2.098036050446339e-10
with O 0 1.558057155515158e-11
any O 0 1.9945813056754247e-10
obvious O 0 3.6730722907662994e-09
phenotype O 0 1.0833046681923975e-09
in O 0 1.3907202056628876e-09
homozygous O 0 9.538243084250553e-09
individuals O 0 1.3587037051010498e-09
. O 0 1.3108974883380142e-07

Founder O 0 0.0019812937825918198
BRCA1 O 0 2.868411456802278e-06
and O 0 8.730744838203464e-08
BRCA2 O 0 4.826792832091087e-08
mutations O 0 2.5849895557428226e-09
in O 0 9.570512160550493e-10
French O 0 6.027136123520904e-07
Canadian O 0 1.7439811927033588e-05
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.8610311599331908e-05
. O 0 4.142720626987284e-06

We O 0 6.54719940484938e-08
have O 0 1.8552469283061868e-10
identified O 0 8.980706178718378e-10
four O 0 8.780330629232225e-11
mutations O 0 4.559460795028336e-11
in O 0 3.302473572386333e-11
each O 0 9.270406491068695e-12
of O 0 9.042583903884349e-10
the O 0 8.731973366593593e-09
breast B-Disease 0 0.000907955807633698
cancer I-Disease 0 0.011525264009833336
- O 0 5.197143764235079e-05
susceptibility O 0 1.3476944332069252e-05
genes O 0 7.47388639865676e-08
, O 0 1.139218142043319e-08
BRCA1 O 0 7.04598912548704e-09
and O 0 1.680686589899949e-09
BRCA2 O 0 2.4015103239349855e-09
, O 0 1.1986557579835022e-10
in O 0 2.8428134846159026e-11
French O 0 2.784909547415282e-08
Canadian O 0 3.5456827163216076e-07
breast B-Disease 1 0.975493848323822
cancer I-Disease 1 0.9977757334709167
and O 0 0.4510848820209503
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3611734175356105e-06
from O 0 6.416562428057659e-07
Quebec O 0 1.3482420399668626e-05
. O 0 3.293779116120277e-07

To O 0 8.227016223827377e-08
identify O 0 2.3742068151477724e-06
founder O 0 0.00027550410595722497
effects O 1 0.9417415261268616
, O 0 7.697746440271658e-08
we O 0 2.966193513032067e-09
examined O 0 5.330718089169295e-09
independently O 0 6.515837869258689e-10
ascertained O 0 6.1294427311509025e-09
French O 0 9.552279855995494e-09
Canadian O 0 1.0940051531349582e-08
cancer B-Disease 0 2.780398133950257e-08
families O 0 2.4567600558078606e-12
for O 0 9.837889183850201e-12
the O 0 3.3642387486931824e-11
distribution O 0 5.02387353940037e-10
of O 0 1.319185982673332e-09
these O 0 7.65096735966253e-11
eight O 0 2.7713960015773864e-09
mutations O 0 7.056492723478414e-09
. O 0 8.507636550803e-08

Mutations O 0 2.216847860836424e-07
were O 0 1.6602136554411118e-08
found O 0 1.1484919681947758e-09
in O 0 4.702169209558349e-10
41 O 0 1.8416679736787955e-08
of O 0 1.9497431225090622e-08
97 O 0 8.693802442394372e-07
families O 0 4.663470054566687e-09
. O 0 1.742824196071524e-07

Six O 0 1.3179611357827525e-07
of O 0 5.880256992440991e-08
eight O 0 4.789574958863341e-09
mutations O 0 1.9365246906044575e-10
were O 0 4.692931598881955e-10
observed O 0 2.3009798510997825e-09
at O 0 2.5370532341639773e-08
least O 0 8.600544720849257e-10
twice O 0 2.686099875859327e-08
. O 0 3.000833359578792e-08

The O 0 1.0425935670355102e-06
BRCA1 O 0 4.233019978983066e-07
C4446T O 0 6.807269983255537e-07
mutation O 0 8.252346361814489e-09
was O 0 2.6385006179907577e-08
the O 0 4.446704671146051e-10
most O 0 2.61849795318847e-11
common O 0 5.102119421396267e-11
mutation O 0 4.588626353885239e-11
found O 0 1.8381569877323756e-10
, O 0 1.9395363787255704e-11
followed O 0 3.2865567906048554e-11
by O 0 2.6041882192351373e-11
the O 0 1.4587332453075419e-09
BRCA2 O 0 3.00898328475796e-08
8765delAG O 0 6.356351036629349e-07
mutation O 0 1.4128498548870994e-07
. O 0 4.600139220656274e-07

Together O 0 1.0348495749212816e-07
, O 0 3.068475029621709e-09
these O 0 6.11464212596502e-11
mutations O 0 2.7390859025366865e-10
were O 0 1.227741103226876e-10
found O 0 9.767033709584538e-11
in O 0 8.02062305460538e-11
28 O 0 4.742532144774714e-09
of O 0 1.731830145956792e-08
41 O 0 7.404939594835014e-08
families O 0 1.56152382690955e-10
identified O 0 1.6843449968106938e-09
to O 0 7.201061968942213e-10
have O 0 4.14899226086618e-10
a O 0 5.330118124646788e-09
mutation O 0 2.3626567369205986e-08
. O 0 3.129337358132034e-07

The O 0 1.6598565366621187e-07
odds O 0 9.453371490053541e-07
of O 0 4.357606719906926e-09
detection O 0 5.132138980457057e-08
of O 0 1.8864776407667705e-09
any O 0 6.788580808603228e-10
of O 0 1.3889395411581518e-08
the O 0 6.053493262214715e-09
four O 0 8.401686457659707e-09
BRCA1 O 0 4.88589524394456e-09
mutations O 0 7.947581259770686e-09
was O 0 1.2131677067372948e-06
18 O 0 2.89655781671172e-06
. O 0 8.983340649137972e-07

7x O 0 0.0035069945733994246
greater O 0 2.550163344494649e-06
if O 0 3.7174700651121384e-08
one O 0 1.0048326615219594e-09
or O 0 3.882435345436974e-11
more O 0 2.064203408896903e-12
cases O 0 2.4382573737824487e-10
of O 0 9.349778906653228e-07
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 1.4255263067752821e-06
also O 0 4.335411751821283e-10
present O 0 3.2843086583689285e-10
in O 0 2.789867226127285e-10
the O 0 3.2454836595974257e-09
family O 0 8.972286913433436e-09
. O 0 3.7414633169419176e-08

The O 0 2.538675687446812e-07
odds O 0 1.6734315977373626e-06
of O 0 9.406714518434e-09
detection O 0 1.0254537130549579e-07
of O 0 5.707224026707536e-09
any O 0 5.418556159320076e-10
of O 0 5.975429484550432e-09
the O 0 2.854269265384346e-09
four O 0 6.636299509921173e-09
BRCA2 O 0 6.735253688106013e-09
mutations O 0 8.37976088519099e-09
was O 0 8.919308811528026e-07
5 O 0 9.022087965604442e-07
. O 0 3.569299167338613e-07

3x O 0 0.00033094212994910777
greater O 0 5.9529878626563e-07
if O 0 5.778994616179034e-09
there O 0 4.4229525597572206e-10
were O 0 2.254202519091919e-10
at O 0 1.4113470392373983e-09
least O 0 7.604553271811643e-12
five O 0 4.675209872018193e-12
cases O 0 1.6621565235297453e-11
of O 0 9.629140818034898e-10
breast B-Disease 0 2.682211970750359e-06
cancer I-Disease 0 2.2026510123396292e-05
in O 0 3.5427245137498176e-08
the O 0 4.3594300791482965e-07
family O 0 8.541977081222285e-08
. O 0 7.646558231044764e-08

Interestingly O 0 7.59967974772735e-07
, O 0 3.988953611866464e-09
the O 0 3.432786555013223e-10
presence O 0 1.3840569801359948e-09
of O 0 5.0477854784958254e-08
a O 0 1.41724783020436e-07
breast B-Disease 0 9.720509115140885e-05
cancer I-Disease 0 7.052437285892665e-05
case O 0 1.832423322412069e-06
< O 0 1.9524641459156555e-07
36 O 0 2.303093005195933e-08
years O 0 2.6733206759388395e-09
of O 0 3.5800831188481652e-09
age O 0 5.8633311539324495e-09
was O 0 3.6666185643241533e-09
strongly O 0 2.268003007621644e-10
predictive O 0 1.243157354835489e-09
of O 0 1.1653106257725199e-09
the O 0 1.3327461356738013e-10
presence O 0 2.300864637705402e-10
of O 0 6.261703933141405e-10
any O 0 1.7345790082057277e-10
of O 0 1.2625174239389025e-09
the O 0 5.669702485278094e-10
eight O 0 2.4328050685085145e-09
mutations O 0 9.073111151280955e-10
screened O 0 8.752370206366322e-08
. O 0 1.2397511284234497e-07

Carriers O 0 9.172421755465621e-08
of O 0 3.352700517211815e-08
the O 0 1.0699774399824946e-09
same O 0 2.572347890250626e-10
mutation O 0 6.443153649504652e-11
, O 0 2.605311105741137e-11
from O 0 3.6237866873900515e-11
different O 0 1.658849967112186e-11
families O 0 1.3566377838822308e-12
, O 0 5.424269540477145e-12
shared O 0 3.34696402537471e-11
similar O 0 3.15944527484735e-11
haplotypes O 0 2.155946310367085e-09
, O 0 2.662104703343715e-10
indicating O 0 1.2532540560883376e-09
that O 0 2.1332826130593396e-11
the O 0 5.686865908738348e-11
mutant O 0 4.964652022820815e-10
alleles O 0 6.168223709579479e-10
were O 0 7.807932078662816e-10
likely O 0 1.048617512267036e-10
to O 0 1.499352204892279e-11
be O 0 2.005949573113952e-11
identical O 0 6.828249077273085e-11
by O 0 2.8601955873175378e-11
descent O 0 6.1049987287731255e-09
for O 0 5.320385243479109e-10
a O 0 5.836661154390299e-10
mutation O 0 3.6634290045967077e-10
in O 0 3.670080073181481e-10
the O 0 3.86320397893769e-09
founder O 0 1.6358504240088223e-07
population O 0 2.5835833472598324e-10
. O 0 6.1064916678788e-08

The O 0 4.612392690006573e-09
identification O 0 3.434039053118454e-09
of O 0 1.2079359734684658e-08
common O 0 2.3108373881086663e-08
BRCA1 O 0 4.396739683443229e-08
and O 0 1.4597777209246487e-08
BRCA2 O 0 2.596672921129084e-08
mutations O 0 1.2598762033633193e-09
will O 0 1.2701638352208278e-10
facilitate O 0 6.963485343902676e-10
carrier O 0 1.514027236915183e-09
detection O 0 3.296556627674363e-08
in O 0 2.93465585166075e-10
French O 0 1.7478726022090996e-07
Canadian O 0 8.122981398628326e-07
breast B-Disease 1 0.9649115204811096
cancer I-Disease 1 0.9958206415176392
and O 0 0.04789411276578903
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.04115097707836e-06
. O 0 1.9816313852061285e-06

Are O 0 1.0583396381491639e-08
Dp71 O 0 1.9778742625931045e-06
and O 0 3.569800677283297e-09
Dp140 O 0 3.1734789445181377e-06
brain O 0 1.3018892786931247e-05
dystrophin O 0 7.258467462634144e-07
isoforms O 0 3.35917178517775e-08
related O 0 1.0845498721323565e-08
to O 0 6.230965188258608e-10
cognitive B-Disease 0 0.04875791817903519
impairment I-Disease 1 0.9999998807907104
in O 1 0.999871015548706
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9609240889549255

Molecular O 0 2.2239403278945247e-06
study O 0 2.0295361835565018e-08
and O 0 3.611086152321974e-10
neuropsychological O 0 1.5936848285491578e-08
analysis O 0 6.514619399489163e-10
were O 0 4.5058519415608345e-11
performed O 0 1.9854602684166167e-10
concurrently O 0 3.1639513231596084e-10
on O 0 2.4499222650575803e-09
49 O 0 3.281200378069116e-08
patients O 0 1.2722163766909489e-08
with O 0 4.036956852360163e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.056011050939559937
DMD B-Disease 1 1.0
) O 0 3.278758597957676e-09
in O 0 3.035212914337393e-10
order O 0 1.13362687292895e-10
to O 0 1.061913612598886e-10
find O 0 7.135639856770126e-10
a O 0 2.1520830950638725e-10
molecular O 0 9.457086669328874e-09
explanation O 0 2.0621444551949253e-09
for O 0 2.1998429466929537e-10
the O 0 2.1632780011771047e-09
cognitive B-Disease 0 6.376130477292463e-05
impairment I-Disease 0 0.00032683779136277735
observed O 0 3.759426192573301e-07
in O 0 1.1214129180814325e-08
most O 0 7.061895246351924e-08
DMD B-Disease 1 1.0
patients O 0 2.720631300690002e-06
. O 0 3.347352617311117e-07

Complete O 0 8.128794206641032e-07
analysis O 0 6.62220358549348e-08
of O 0 4.682438969894065e-08
the O 0 1.2151619266376201e-08
dystrophin O 0 1.8459344630628038e-07
gene O 0 9.256144295477498e-09
was O 0 1.65539859153796e-07
performed O 0 3.404562676223577e-08
to O 0 1.4022319971829234e-09
define O 0 3.3619343753343855e-08
the O 0 1.039327468532747e-08
localization O 0 1.5670069615225657e-06
of O 0 1.4293712879975828e-08
deletions O 0 9.165160186341836e-09
and O 0 2.0569159708827556e-09
duplications O 0 2.838965826867934e-07
in O 0 5.358680610356714e-09
relation O 0 6.291986665019067e-08
to O 0 1.1907446140213551e-09
the O 0 4.7343076126082906e-09
different O 0 9.502818443252181e-08
DMD B-Disease 1 1.0
promoters O 0 2.9760336474282667e-05
. O 0 8.548819891984749e-07

Qualitative O 0 5.782018206446082e-07
analysis O 0 6.56351701877611e-08
of O 0 3.6819400861531904e-08
the O 0 7.286824921237667e-09
Dp71 O 0 4.268967188636452e-07
transcript O 0 2.1745604428247134e-08
and O 0 4.459842564696892e-11
testing O 0 7.878102337155468e-11
for O 0 6.007222930898282e-12
the O 0 1.2464325578609436e-11
specific O 0 2.32751474343873e-11
first O 0 5.901047983591923e-10
exon O 0 4.9300638238491956e-08
of O 0 1.61062647663357e-08
Dp140 O 0 5.159080274097505e-08
were O 0 1.362269075322331e-09
also O 0 1.4923032254365864e-10
carried O 0 2.276749622165397e-10
out O 0 6.371980165731372e-10
. O 0 8.324545497373492e-09

Neuropsychological O 0 8.880217137630098e-06
analysis O 0 8.055313571730949e-08
assessed O 0 1.4173546958318184e-07
verbal O 0 2.6493484028833336e-07
and O 0 2.2647071773462812e-08
visuospatial O 0 2.356393997615669e-05
intelligence O 0 1.9872889822636353e-07
, O 0 2.0591259808355744e-09
verbal O 0 2.4656841901560256e-08
memory O 0 4.8016663640737534e-05
, O 0 1.5880138093393725e-08
and O 0 3.3150482359189937e-09
reading O 0 7.735113172202546e-07
skills O 0 2.0546705854940228e-05
. O 0 3.1798330724086554e-07

Comparison O 0 5.83895996442152e-07
of O 0 1.346188867046294e-07
molecular O 0 5.47073454981728e-07
and O 0 2.2459636372929026e-09
psychometric O 0 3.108359578618547e-07
findings O 0 3.6249518942099712e-09
demonstrated O 0 1.4465947328901052e-09
that O 0 3.2559649421060044e-11
deletions O 0 1.139702221486516e-09
and O 0 2.1092869118000124e-10
duplications O 0 3.8497010024229894e-08
that O 0 7.556279907339203e-11
were O 0 5.108606870862786e-10
localized O 0 1.4519913271726637e-08
in O 0 8.880954860401857e-10
the O 0 2.014229005808943e-09
distal O 0 1.9906862291918515e-07
part O 0 1.6359715360181326e-08
of O 0 1.4653589630597708e-07
the O 0 2.5323105390384626e-08
gene O 0 2.5974209449941554e-08
seemed O 0 1.015236392731822e-07
to O 0 1.134102672883941e-10
be O 0 1.013861147813877e-10
preferentially O 0 6.590557544150499e-10
associated O 0 5.608805420109775e-09
with O 0 3.0050759658450943e-09
cognitive B-Disease 1 0.9680241942405701
impairment I-Disease 1 0.99996018409729
. O 0 5.1565981266321614e-05

Two O 0 4.0508446375042695e-08
altered O 0 1.7004251162688888e-07
Dp71 O 0 2.3873369627835928e-06
transcripts O 0 2.6691373022913467e-07
and O 0 4.790440821800246e-10
two O 0 9.561803432367455e-11
deleted O 0 6.418612863434703e-10
Dp140 O 0 2.1422881246735415e-09
DNA O 0 1.5917087092809368e-10
sequences O 0 1.562244777986166e-10
were O 0 4.764241084975751e-11
found O 0 2.2730602122766896e-11
in O 0 1.6643486935863372e-11
four O 0 7.195717632857423e-11
patients O 0 6.953796982678284e-10
with O 0 5.709336114989583e-09
severe O 1 0.9999997615814209
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.014961907640099525

These O 0 3.7268677033353015e-09
findings O 0 2.3008437377569635e-09
suggest O 0 8.055751621327545e-10
that O 0 3.681202478261758e-12
some O 0 3.0343069636756814e-12
sequences O 0 1.6981505090996052e-10
located O 0 7.385735356635337e-10
in O 0 2.5409541137833003e-10
the O 0 1.2729001186428945e-09
distal O 0 9.039349890826998e-08
part O 0 7.462160667159878e-09
of O 0 1.2348135847162212e-08
the O 0 5.184109808098469e-10
gene O 0 1.8290255421327117e-10
and O 0 1.6288709270284585e-10
, O 0 3.866753098269449e-11
in O 0 2.4203063164751626e-11
particular O 0 8.566291426204131e-11
, O 0 7.748644087479661e-11
some O 0 5.89970503006576e-11
DMD B-Disease 1 0.8071240186691284
isoforms O 0 2.9353419250810475e-08
expressed O 0 5.986803497393112e-09
in O 0 2.8291038400851676e-09
the O 0 7.618530695197023e-09
brain O 0 3.6559609725372866e-05
may O 0 4.244121498686582e-09
be O 0 3.067418888336171e-11
related O 0 1.0509000614167263e-10
to O 0 1.528889514990084e-11
the O 0 3.980568374917226e-10
cognitive B-Disease 0 5.863665137439966e-05
impairment I-Disease 0 0.0012804094003513455
associated O 0 6.114783900557086e-06
with O 0 7.781459316902328e-07
DMD B-Disease 1 1.0
. O 0 2.813769128806598e-07
. O 0 2.7483866915645194e-07

I1307K O 0 2.0701689209090546e-05
APC O 0 1.145274609370972e-06
and O 0 1.649632963562908e-08
hMLH1 O 0 1.449211310955434e-07
mutations O 0 2.1496635582707313e-09
in O 0 7.878391827809139e-10
a O 0 7.781794653105578e-10
non O 0 1.920401899724311e-07
- O 0 6.583439926544088e-08
Jewish O 0 2.008263777497632e-09
family O 0 1.0746872836087107e-10
with O 0 1.1572078018051712e-10
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9989118576049805

We O 0 6.551234577045761e-08
describe O 0 2.9161341785766126e-08
a O 0 1.8218851982609863e-09
French O 0 3.178319829544307e-08
Canadian O 0 5.9472455404829816e-08
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9745525121688843
HNPCC B-Disease 1 0.9996993541717529
) O 0 5.643673617328204e-08
kindred O 0 1.228066594194388e-06
which O 0 6.853696499220518e-10
carries O 0 2.3205044552554455e-09
a O 0 2.561214851315441e-10
novel O 0 3.0680755158662976e-10
truncating O 0 1.854473907769716e-08
mutation O 0 1.4318208840791158e-09
in O 0 3.816427174285764e-09
hMLH1 O 0 1.4702626458529267e-06
. O 0 2.813396235978871e-07

Interestingly O 0 5.490670105245954e-07
, O 0 6.664306440029577e-09
the O 0 1.8452395167400937e-09
I1307K O 0 4.101644890397438e-08
APC O 0 1.1725080462099413e-08
polymorphism O 0 2.8385914063733253e-08
, O 0 4.13371614715885e-10
associated O 0 5.115139423139681e-10
with O 0 1.7238687907705774e-11
an O 0 2.426379756836905e-11
increased O 0 3.685915350715163e-09
risk O 0 3.837103577097878e-06
of O 1 0.9999769926071167
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.2351832765489235e-06
is O 0 3.6134634173734526e-10
also O 0 3.4178694596764814e-11
present O 0 2.0119357568848528e-10
in O 0 3.077088861491717e-10
this O 0 1.7537908625353538e-10
family O 0 4.164486533397849e-09
. O 0 2.6916950446320698e-08

The O 0 1.8670952783850225e-07
I1307K O 0 1.0154451501875883e-06
polymorphism O 0 1.2428040463419165e-07
has O 0 6.570199384547948e-10
previously O 0 2.113778707624192e-09
only O 0 2.4799337930425658e-11
been O 0 1.804178161035619e-11
identified O 0 2.940470436585407e-11
in O 0 8.169114690259605e-12
individuals O 0 1.3129862865349229e-12
of O 0 4.146273102634268e-09
self O 0 1.2036265673032176e-07
- O 0 6.128147589379296e-08
reported O 0 4.716218970912678e-09
Ashkenazi O 0 8.71969074722756e-09
Jewish O 0 1.8416882463512252e-09
origins O 0 6.122037632394495e-08
. O 0 5.582296935813247e-08

In O 0 7.113699496130721e-08
addition O 0 1.2679043592811468e-08
, O 0 8.483969637929079e-10
in O 0 3.857973940313286e-10
this O 0 8.106426641063535e-11
family O 0 5.225964661015325e-10
, O 0 2.565953283184541e-10
there O 0 1.9004023354973754e-10
appears O 0 5.349548581889962e-10
to O 0 3.8888239850543016e-11
be O 0 4.4014086819643694e-10
no O 0 6.940863994664426e-10
relationship O 0 2.261455689378522e-09
between O 0 1.8800121459605634e-09
the O 0 3.8220923648246696e-10
I1307K O 0 1.1889653706020908e-09
polymorphism O 0 4.583030344118555e-10
and O 0 1.4764927128152472e-11
the O 0 3.6274240555744797e-11
presence O 0 1.7165038834754398e-10
or O 0 3.0952895802016656e-10
absence O 0 5.706160521867787e-08
of O 0 1.524687291976079e-07
cancer B-Disease 0 3.112276772299083e-06
. O 0 2.2595683546455803e-08
. O 0 1.5619907856034843e-07

Identification O 0 1.718268691774938e-07
of O 0 8.360702707932433e-08
a O 0 4.707277234672347e-09
novel O 0 9.43679245857254e-10
mutation O 0 4.1427136721061686e-10
of O 0 7.183301509172679e-09
the O 0 1.2336201393736701e-08
CPO O 0 3.930087473236199e-07
gene O 0 4.034242273576183e-09
in O 0 1.17496556928387e-09
a O 0 2.0728034844097465e-09
Japanese O 0 8.298659395222785e-07
hereditary B-Disease 1 0.9999436140060425
coproporphyria I-Disease 1 0.9814051985740662
family O 0 9.65588810686313e-07
. O 0 6.936534759915958e-07

Hereditary B-Disease 1 0.9999990463256836
coproporphyria I-Disease 1 0.9999525547027588
( O 0 1.4544310033670627e-05
HCP B-Disease 1 0.9707924723625183
) O 0 2.1205961431292053e-08
is O 0 1.6277722503232894e-09
an O 0 4.02577926550407e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
characterized O 0 5.503271722773206e-07
by O 0 1.0073119005582498e-09
a O 0 2.8225027648431933e-08
deficiency B-Disease 0 0.02581988461315632
of I-Disease 0 0.013160431757569313
coproporphyrinogen I-Disease 0 0.0010249842889606953
oxidase I-Disease 0 2.477101190834219e-08
( O 0 9.555901625546426e-10
CPO O 0 1.9144547280802726e-08
) O 0 9.975526654715239e-11
caused O 0 2.436904567026943e-10
by O 0 3.297255524170595e-11
a O 0 2.745613736365726e-10
mutation O 0 3.5572381151816046e-10
in O 0 1.4667879133511974e-09
the O 0 8.08973865673579e-09
CPO O 0 2.901963171098032e-06
gene O 0 1.3522544861643837e-07
. O 0 2.0805508427201858e-07

Only O 0 8.211387125811598e-08
11 O 0 9.469761153013678e-08
mutations O 0 6.6389578279313355e-09
of O 0 1.7312357769583286e-08
the O 0 6.354239356909375e-09
gene O 0 2.153127010018352e-09
have O 0 4.57030073508502e-11
been O 0 2.088099693153822e-10
reported O 0 6.284389120203571e-10
in O 0 2.8448667865887955e-09
HCP B-Disease 0 0.141611248254776
patients O 0 7.977752829901874e-06
. O 0 1.6938681710598757e-06

We O 0 6.019989484684629e-08
report O 0 2.0744566064934133e-09
another O 0 1.2009006289392943e-10
mutation O 0 9.092353953077392e-11
in O 0 1.7078496949984867e-10
a O 0 1.2850533970265587e-09
Japanese O 0 6.617082703996857e-07
family O 0 1.5609774806080168e-08
. O 0 4.527870345327756e-08

Polymerase O 0 1.1966501915594563e-05
chain O 0 6.070376912248321e-07
reaction O 0 5.199282337997602e-09
- O 0 4.490241956034424e-09
single O 0 9.205815276747131e-11
strand O 0 1.17351428574608e-09
conformational O 0 3.4843650187355024e-10
polymorphism O 0 6.332856461455094e-10
and O 0 4.052384469654946e-11
direct O 0 1.9306903298321743e-10
sequence O 0 3.2417574180598763e-10
analyses O 0 7.890482711658819e-10
demonstrated O 0 2.0024690794429034e-09
a O 0 1.8730756945473104e-09
C O 0 4.0328515638066165e-08
to O 0 8.051451172441659e-10
T O 0 1.6195539132013437e-08
substitution O 0 2.474511928696188e-09
in O 0 9.542096002235212e-10
exon O 0 2.3370246182707888e-08
1 O 0 3.273536464121207e-08
of O 0 5.700826921639646e-09
the O 0 4.697393141128714e-09
CPO O 0 8.796452277692879e-08
gene O 0 2.4959661004686495e-09
at O 0 4.535935005378633e-08
nucleotide O 0 1.7586396339197563e-08
position O 0 1.3152239830560575e-07
85 O 0 7.017344216819765e-08
, O 0 1.384474201948649e-09
which O 0 2.1909156433519428e-10
lies O 0 5.7933640107421525e-09
in O 0 2.9375846199997113e-10
the O 0 1.1495132623551285e-09
putative O 0 3.0972415743235615e-08
presequence O 0 1.3361905359943194e-07
for O 0 1.0458635069099387e-09
targeting O 0 6.738800628625086e-09
to O 0 6.854379730469873e-09
mitochondria O 0 5.190719321035431e-07
. O 0 6.34048888059624e-07

This O 0 6.52307807769148e-09
mutation O 0 1.6939782909730638e-09
changes O 0 1.1257670351483284e-09
the O 0 1.2702565665989596e-09
codon O 0 2.5149280435954324e-09
for O 0 8.284578578710011e-10
glutamine O 0 3.1077260764789116e-09
to O 0 7.977678517789855e-10
a O 0 2.3151198735860135e-09
termination O 0 9.440073611699518e-09
codon O 0 1.8682881020026798e-08
at O 0 2.885048502321297e-07
amino O 0 9.911871501344649e-08
acid O 0 7.457325779114399e-08
position O 0 1.7269670706809848e-06
29 O 0 7.664307304366957e-06
. O 0 7.717621315350698e-07

MaeI O 0 2.5307535906904377e-05
restriction O 0 3.291323764642584e-07
analysis O 0 7.416841896201731e-08
showed O 0 1.25071633050311e-08
two O 0 1.8626111764064035e-10
other O 0 3.402837039923057e-11
carriers O 0 3.2454572362894396e-10
in O 0 2.6611146619615056e-10
the O 0 1.4086227739795731e-09
family O 0 3.844225382465538e-09
. O 0 4.936179820447251e-08

The O 0 1.919656369864242e-06
C O 0 0.07982427626848221
- O 0 5.63714602321852e-05
T O 0 6.078568617340352e-07
mutation O 0 1.2940901683577977e-09
is O 0 2.3397295212390645e-10
located O 0 7.950518021715425e-10
within O 0 5.708484240862788e-10
a O 0 3.0427832475865557e-10
recently O 0 4.6495057803852546e-10
proposed O 0 1.2973715157738042e-10
putative O 0 3.2657748727515923e-10
alternative O 0 2.1986937270845885e-10
translation O 0 1.5369401307196995e-09
initiation O 0 2.813659749634212e-09
codon O 0 1.0095069669091572e-08
( O 0 4.58805304859311e-09
TIC O 0 5.913447580496722e-07
- O 0 1.4677254966954933e-07
1 O 0 5.860281859781935e-08
) O 0 9.748942625398271e-11
, O 0 6.730020013501203e-11
supporting O 0 1.6994984586293782e-10
that O 0 3.10899334055037e-10
TIC O 0 8.714770842743746e-07
- O 0 2.2232163132684946e-07
1 O 0 1.1223077933664172e-07
is O 0 1.169629948449824e-10
the O 0 2.9429852999030004e-10
real O 0 1.2336934673840005e-07
TIC O 0 7.935206554066099e-07
rather O 0 2.158576428712422e-08
than O 0 1.907674018752914e-09
TIC O 0 8.187113280655467e-07
- O 0 1.5660060626032646e-07
2 O 0 6.642950012292204e-08
. O 0 1.4744679921463444e-09
. O 0 1.4186968932961008e-08

Human B-Disease 0 5.102778644072714e-08
complement I-Disease 0 6.476726639448316e-07
factor I-Disease 0 0.00021803406707476825
H I-Disease 1 1.0
deficiency I-Disease 1 0.9998890161514282
associated O 0 5.204479384701699e-05
with O 0 0.0008917208760976791
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999934434890747

This O 0 1.1806813304815478e-08
study O 0 5.935921087996121e-09
reports O 0 1.1737246730092465e-09
on O 0 3.0652751448201343e-09
six O 0 2.7756796860956e-10
cases O 0 2.406433663448837e-10
of O 0 3.992561392607286e-09
deficiency B-Disease 0 6.760876203770749e-06
in I-Disease 0 6.645482386602453e-09
the I-Disease 0 3.526542835530222e-09
human I-Disease 0 1.0058183175232216e-09
complement I-Disease 0 1.7219645709332099e-09
regulatory I-Disease 0 2.692162404116516e-08
protein I-Disease 0 4.049261193017628e-08
Factor I-Disease 0 4.872691761192982e-07
H I-Disease 1 0.9999772310256958
( O 0 9.637230569126132e-09
FH O 0 1.0732016875181216e-07
) O 0 2.456411185569607e-10
in O 0 3.955552552170616e-11
the O 0 3.963981226595692e-11
context O 0 8.303704390755229e-10
of O 0 5.263458002779942e-10
an O 0 2.535184728813533e-09
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.6191553473472595

Five O 0 8.372703064196685e-08
of O 0 2.366707008150115e-08
the O 0 4.903163430824975e-10
cases O 0 4.087222574278293e-11
were O 0 7.000260180550777e-12
observed O 0 1.7719771830404518e-11
in O 0 1.4816771941317253e-12
children O 0 1.6882663886677585e-12
presenting O 0 2.2803305077534475e-10
with O 0 4.708893719396201e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999972581863403
HUS B-Disease 1 1.0
) O 0 2.0225192201905884e-05
. O 0 7.238286343635991e-06

Two O 0 6.001909724773213e-08
of O 0 5.740043462765243e-08
the O 0 1.0753998580526059e-08
children O 0 9.88318760164475e-10
exhibited O 0 1.2655685566187458e-07
a O 0 1.7189627499192284e-08
homozygous O 0 1.5422685351040855e-07
deficiency O 0 0.000784686126280576
characterized O 0 2.2860145065806137e-07
by O 0 4.082534310612118e-10
the O 0 5.6584052998687184e-09
absence O 0 1.2198253784845292e-07
of O 0 1.0076544931791886e-08
the O 0 1.3845428137315707e-09
150 O 0 1.2252012737690166e-09
- O 0 8.724094779921643e-10
kD O 0 4.619198357147525e-09
form O 0 7.106112365207196e-10
of O 0 7.346862673784926e-09
Factor O 0 5.636713495960066e-08
H O 1 0.999977707862854
and O 0 1.1752524509134332e-09
the O 0 4.095340178089657e-10
presence O 0 2.0334980921354884e-10
, O 0 3.2795436505361764e-11
upon O 0 1.1365279550812346e-10
immunoblotting O 0 3.687405936148025e-09
, O 0 5.267623143234701e-11
of O 0 2.4809854171081724e-10
the O 0 2.3642410251767387e-10
42 O 0 8.963119135785291e-09
- O 0 7.082111785905454e-09
kD O 0 9.550989688023037e-08
Factor O 0 2.0756398555477062e-07
H O 1 0.9999480247497559
- O 0 1.2553083479360794e-06
like O 0 1.0650933468525636e-08
protein O 0 2.302166279832818e-08
1 O 0 2.627718629355513e-07
( O 0 9.976787174181823e-10
FHL O 0 1.9196144762645417e-07
- O 0 1.812987626692575e-08
1 O 0 2.176323832259186e-08
) O 0 3.766431957985539e-11
and O 0 2.860206689547784e-11
other O 0 6.77418121597384e-11
FH O 0 8.277588392502366e-08
- O 0 1.3181503888404222e-08
related O 0 3.1833007341219854e-08
protein O 0 3.6158525063001434e-08
( O 0 1.1288245893581461e-09
FHR O 0 8.351217388735677e-07
) O 0 3.198795450742864e-09
bands O 0 4.574328329454147e-07
. O 0 2.445752613766672e-07

Southern O 0 3.4730805964500178e-06
blot O 0 7.395052534775459e-07
and O 0 1.812651251320574e-09
PCR O 0 1.2738990307070708e-08
analysis O 0 7.893026232608236e-10
of O 0 7.947834057553393e-10
DNA O 0 2.9848994387293715e-09
of O 0 6.8909264960836936e-09
one O 0 3.303073647931143e-10
patient O 0 3.85257115098625e-09
with O 0 3.1006093248464595e-09
homozygous O 0 7.258785785779764e-07
deficiency O 1 0.7732536196708679
ruled O 0 1.7818747437559068e-05
out O 0 5.138608427657232e-10
the O 0 1.4917284074655868e-10
presence O 0 2.476857607902616e-10
of O 0 1.9546646523593836e-09
a O 0 4.705533185322963e-10
large O 0 3.3648306363431857e-10
deletion O 0 7.645927446731093e-09
of O 0 2.2638175778411096e-08
the O 0 1.143548278292883e-08
FH O 0 5.531570081984682e-07
gene O 0 5.760417920441796e-09
as O 0 6.267033003659606e-10
the O 0 1.4736442066620725e-09
underlying O 0 2.140604192391038e-05
defect O 0 2.3277370928553864e-06
for O 0 2.9484384711508937e-08
the O 0 1.4368795291375136e-06
deficiency O 1 0.999961256980896
. O 0 5.089269325253554e-05

The O 0 8.787883132299612e-08
other O 0 1.463942633783688e-09
four O 0 6.307830369145506e-10
children O 0 2.6432109972995832e-11
presented O 0 1.303173124966861e-09
with O 0 5.335984432086605e-10
heterozygous O 0 5.884992049232096e-08
deficiency O 0 0.002066655782982707
and O 0 7.72655806002831e-09
exhibited O 0 9.191771823680028e-07
a O 0 2.6804021224791086e-09
normal O 0 3.352201360939944e-08
immunoblotting O 0 6.942273955701239e-08
pattern O 0 1.4169094342264543e-08
of O 0 4.185892521491041e-09
proteins O 0 8.424886344116089e-10
of O 0 1.786869319175821e-08
the O 0 2.219519146251514e-08
FH O 0 8.179205906344578e-06
family O 0 3.3430648471721724e-08
. O 0 8.731544198781194e-08

Factor B-Disease 1 0.916554868221283
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999990463256836
is O 0 8.465195122653313e-08
the O 0 6.684420572611316e-09
only O 0 6.9871179952940565e-09
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 0.0005560419522225857
with O 0 2.53472285294265e-06
HUS B-Disease 1 1.0
. O 0 2.8873248083982617e-05

These O 0 2.8821601105732952e-08
observations O 0 5.58709096765142e-08
suggest O 0 1.920166958768732e-08
a O 0 8.068669066219059e-10
role O 0 4.8345571990182634e-09
for O 0 3.0382147908625257e-09
FH O 0 1.5957432424329454e-06
and O 0 3.759274846970584e-08
/ O 0 1.0553079619057826e-06
or O 0 5.5487077155191855e-09
FH O 0 1.11850816608694e-07
receptors O 0 1.699013152389739e-09
in O 0 1.9502506554136545e-10
the O 0 8.707321530465606e-10
pathogenesis O 0 2.7135702111991122e-05
of O 0 1.7099479521220928e-07
idiopathic O 0 0.19790402054786682
HUS B-Disease 1 0.9999996423721313
. O 0 3.025252226507291e-07
. O 0 6.384662469827163e-07

Further O 0 7.673411772657346e-08
evidence O 0 2.2130260290964543e-08
for O 0 2.2835994206715782e-10
a O 0 2.2746401984186093e-10
major O 0 4.697023880950724e-10
ancient O 0 1.1614816486371637e-07
mutation O 0 9.242833698408504e-07
underlying O 1 0.9999456405639648
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 6.267504772949906e-07
linkage O 0 5.4375982472265605e-06
disequilibrium O 0 3.950163772969972e-06
studies O 0 2.0305999104408556e-09
in O 0 5.649534659535327e-11
the O 0 1.5456912139111267e-10
Japanese O 0 1.0154916907367806e-08
population O 0 7.759885095603991e-11
. O 0 8.97526497567469e-09

The O 1 0.7396530508995056
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00014165008906275034
DM B-Disease 1 1.0
) O 0 4.2022594293200655e-09
mutation O 0 9.108848120220614e-10
is O 0 1.4518126978391166e-10
an O 0 3.0933539063582316e-10
unstable O 0 0.0013766912743449211
( O 0 2.1021399732035206e-08
CTG O 0 3.605413212426356e-06
) O 0 1.3769397844143327e-09
n O 0 4.490269844836803e-08
repeat O 0 1.1777529174139545e-08
, O 0 4.753034632543063e-10
present O 0 8.928885963932487e-10
at O 0 1.9200935952312648e-08
a O 0 1.4982010076991514e-10
copy O 0 4.906793305003987e-10
number O 0 1.0696381974595326e-10
of O 0 5.4941979854561396e-09
5 O 0 2.500279627781765e-08
- O 0 1.3149538347079215e-08
37 O 0 9.186880589595603e-09
repeats O 0 1.7740925395415275e-09
on O 0 3.3629972140403197e-09
normal O 0 4.11673806155477e-09
chromosomes O 0 4.563474043095539e-10
but O 0 1.2698248008646829e-10
amplified O 0 1.0640145431395354e-09
to O 0 1.5746418058348866e-10
50 O 0 1.5482265469657364e-09
- O 0 2.926461573071748e-10
3000 O 0 4.424589306051274e-10
copies O 0 1.5837239297766814e-09
on O 0 9.775135367817711e-08
DM B-Disease 1 0.9999604225158691
chromosomes O 0 1.6019765780583839e-06
. O 0 2.2304217850432906e-07

Previous O 0 5.961020832501163e-08
findings O 0 6.528953377937796e-09
in O 0 1.5263821318001192e-09
Caucasian O 0 1.8490313280494775e-08
populations O 0 3.734586806469764e-10
of O 0 3.662202985310614e-08
a O 0 6.156030281090352e-07
DM B-Disease 1 1.0
founder O 1 0.9994524121284485
chromosome O 0 1.3049796507402789e-05
raise O 0 5.941667069464529e-08
a O 0 1.1518534570598149e-08
question O 0 4.443129419939851e-09
about O 0 1.839572938422407e-11
the O 0 2.3837282842054108e-11
molecular O 0 1.4214914800803058e-09
events O 0 1.5060973301839198e-10
involved O 0 3.552532712447487e-10
in O 0 1.1461499804799047e-10
the O 0 5.72014602351345e-10
expansion O 0 2.5096490219311818e-08
mutation O 0 2.4988921154545096e-08
. O 0 1.5280701859410328e-07

To O 0 6.694808973861655e-08
investigate O 0 1.8720393768489885e-07
whether O 0 2.306750879199626e-08
a O 0 3.5851414281751204e-08
founder O 0 4.4274855781623046e-07
chromosome O 0 4.509520934448119e-08
for O 0 7.771979504411775e-09
the O 0 6.760327408983358e-08
DM B-Disease 1 1.0
mutation O 0 7.324472139913496e-10
exists O 0 3.214309929333581e-10
in O 0 1.239689600973648e-11
the O 0 7.43073224479529e-12
Japanese O 0 2.0205692674579723e-10
population O 0 1.0944176608799344e-13
, O 0 2.4979339343506046e-12
we O 0 7.680777021346064e-12
genotyped O 0 8.476804258528148e-10
families O 0 1.0291152695643402e-12
using O 0 1.770483933072331e-11
polymorphic O 0 1.0241919534692556e-09
markers O 0 1.2675609895040907e-08
near O 0 4.2031675206999353e-07
the O 0 6.54125855703569e-08
( O 0 7.826006509503713e-09
CTG O 0 1.8435151787343784e-06
) O 0 4.477003656688794e-09
n O 0 2.608154829886189e-07
repeat O 0 9.431690983774388e-08
region O 0 3.387048863601194e-08
and O 0 6.235605809479239e-09
constructed O 0 9.868010693026008e-07
haplotypes O 0 4.0520421862311196e-06
. O 0 9.60460397436691e-07

Six O 0 6.766132543134518e-08
different O 0 1.2706248275762277e-09
haplotypes O 0 2.8673065699535982e-08
were O 0 2.073305527261482e-09
found O 0 1.3582296398695348e-09
and O 0 1.2167569174437176e-09
DM B-Disease 1 0.9999905824661255
alleles O 0 1.2200203514112218e-08
were O 0 2.2899742546655943e-08
always O 0 1.308723529547251e-08
haplotype O 0 1.8540555402069003e-07
A O 0 3.111339879069419e-07
. O 0 2.0021956004256936e-07

To O 0 5.4111158220848665e-08
find O 0 7.1984151972515065e-09
an O 0 1.2045572872487753e-10
origin O 0 5.297965399719828e-10
of O 0 3.5016760602246677e-09
the O 0 1.400700444520453e-09
( O 0 6.041401823253523e-10
CTG O 0 1.3227385409209091e-07
) O 0 5.206940989488373e-10
n O 0 2.48378597689225e-08
repeat O 0 9.188632965617671e-09
mutation O 0 6.04560901340534e-10
and O 0 2.4745674953585706e-10
to O 0 1.172775210278587e-10
investigate O 0 3.706628337596385e-09
the O 0 7.232625054420794e-10
mechanism O 0 1.1300976865413759e-07
of O 0 1.3857006209150313e-08
the O 0 8.944687213130464e-10
expansion O 0 2.246336228139967e-09
mutation O 0 3.875332693636935e-11
in O 0 4.72299317710867e-11
the O 0 8.439549753491704e-11
Japanese O 0 1.3093069961556125e-09
population O 0 8.959545345216258e-13
we O 0 1.641125776941088e-11
have O 0 1.417136265106922e-12
studied O 0 7.410499991422625e-10
90 O 0 6.865510937537067e-10
Japanese O 0 1.7337173474629708e-08
DM B-Disease 1 0.8681559562683105
families O 0 1.0910886777404372e-10
comprising O 0 5.035452610435698e-10
190 O 0 6.692403298202976e-10
affected O 0 1.2335624188786198e-10
and O 0 2.1503022973323738e-10
130 O 0 7.215570807517224e-09
unaffected O 0 5.8291902860219125e-08
members O 0 3.975084705842846e-09
. O 0 6.915577444033261e-08

The O 0 8.969416143145281e-08
results O 0 8.673429086059059e-09
suggest O 0 2.749692473713594e-09
that O 0 2.4124251207791048e-11
a O 0 9.260708866420941e-11
few O 0 2.0014283633185137e-11
common O 0 1.930376171410675e-11
ancestral O 0 9.05117758520646e-10
mutations O 0 3.7926525808806844e-10
in O 0 1.4353583599469033e-10
both O 0 7.629243903295446e-10
Caucasian O 0 2.5552600035894102e-08
and O 0 3.257712155591008e-10
Japanese O 0 1.3409681365317283e-08
populations O 0 5.534852524219369e-12
have O 0 9.381432262978162e-13
originated O 0 6.167111959998195e-12
by O 0 1.8890519302896397e-13
expansion O 0 4.1284423796250636e-11
of O 0 9.047479432311434e-11
an O 0 1.5699747057951186e-11
ancestral O 0 6.949819053581052e-10
n O 0 1.5786429941044844e-08
= O 0 8.15270428944359e-09
5 O 0 3.5103693285520876e-09
repeat O 0 7.912244748276009e-10
to O 0 5.299177763262719e-10
n O 0 6.925583306838234e-08
= O 0 1.4936179582036857e-07
19 O 0 5.305029162627761e-07
- O 0 1.0309252473916786e-07
37 O 0 2.9405700985307703e-08
copies O 0 2.7920791012547852e-08
. O 0 1.661861830370981e-07

These O 0 1.8409717084111321e-09
data O 0 2.327534831536582e-09
support O 0 6.97677970951105e-10
multistep O 0 1.491987973167852e-07
models O 0 1.612489342051049e-08
of O 0 2.1088993662488065e-07
triplet O 0 2.7879632398253307e-06
repeat O 0 1.732002914422992e-07
expansion O 0 7.503953725063184e-08
that O 0 5.4864539994481376e-11
have O 0 5.838726203910571e-12
been O 0 2.495743412281315e-12
proposed O 0 6.860935430896831e-12
for O 0 1.8631717696449002e-11
both O 0 1.3303493862082405e-09
DM B-Disease 1 1.0
and O 0 7.767062726315999e-08
Friedreichs B-Disease 0 0.009548533707857132
ataxia I-Disease 0 0.0021265146788209677
. O 0 7.709912352993342e-08
. O 0 2.8905952831337345e-07

The O 0 2.1119822335435856e-08
molecular O 0 5.48443154002598e-07
basis O 0 5.009965207136702e-07
of O 0 0.0040531945414841175
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 6.65823591816661e-08
the O 0 2.4600366188565204e-09
western O 0 5.951168891016323e-09
Cape O 0 2.343054461562133e-08
, O 0 1.2513688696369485e-10
South O 0 1.577769137561802e-09
Africa O 0 2.7522268908342085e-09
. O 0 1.0687705831458061e-08

Deficiency B-Disease 1 0.9998806715011597
of I-Disease 0 4.8148031055461615e-05
the I-Disease 0 5.8720632978293e-07
sixth I-Disease 0 7.403576205433637e-07
component I-Disease 0 3.8026999504836567e-07
of I-Disease 0 1.968293474874372e-07
human I-Disease 0 1.2142328920106138e-08
complement I-Disease 0 1.990175491073387e-07
( O 0 3.6509327117073553e-08
C6 O 0 3.7914016957074637e-06
) O 0 7.388257783347285e-10
has O 0 1.0044757386973302e-10
been O 0 7.686731112732659e-11
reported O 0 7.069364538203615e-11
in O 0 6.6654277583455546e-12
a O 0 5.049344622976015e-12
number O 0 5.833939234478613e-12
of O 0 2.6902449712373766e-10
families O 0 4.401085398897386e-12
from O 0 2.7779450614828782e-11
the O 0 8.250151256605776e-11
western O 0 1.3771025431097428e-09
Cape O 0 1.8553407699073432e-08
, O 0 2.5469609754580347e-10
South O 0 2.4547401888952436e-09
Africa O 0 1.3471156634636827e-08
. O 0 2.4931697595320657e-08

Meningococcal B-Disease 1 0.9997393488883972
disease I-Disease 0 0.37146079540252686
is O 0 1.3947905941336103e-08
endemic O 0 5.034590522257076e-09
in O 0 7.030936388652265e-10
the O 0 1.304981345207068e-09
Cape O 0 9.850637638919579e-08
and O 0 9.033305353733923e-11
almost O 0 3.189186414953582e-10
all O 0 1.7105936458983173e-11
pedigrees O 0 8.135675466647285e-10
of O 0 1.2998020437748892e-09
total O 0 1.4700592032568238e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.6601236413625884e-07
C6Q0 O 0 2.9195456590969115e-05
) O 0 4.435734834995486e-10
have O 0 1.0969516961445436e-11
been O 0 1.1348681543121852e-11
ascertained O 0 7.379469257884352e-10
because O 0 3.270423515333576e-11
of O 0 1.8255167377745352e-09
recurrent O 0 9.403122385265306e-05
disease O 0 0.06655238568782806
. O 0 7.145083600335056e-07

We O 0 7.262740808755552e-08
have O 0 1.4030553108224098e-10
sequenced O 0 5.472796105188138e-10
the O 0 2.0301846315184946e-10
expressed O 0 4.173485723679704e-10
exons O 0 1.1247117015500407e-08
of O 0 5.884079889995064e-09
the O 0 8.291459074882823e-09
C6 O 0 9.93829644357902e-07
gene O 0 1.904155055854062e-09
from O 0 3.137635429251162e-10
selected O 0 1.6580284367684328e-10
cases O 0 6.489725423719506e-11
and O 0 1.6468262517554955e-11
have O 0 5.536964116370502e-12
found O 0 3.234838091836778e-11
three O 0 4.3128851184848216e-11
molecular O 0 3.6277833714848384e-07
defects O 0 0.0033614824060350657
leading O 0 1.540932089483249e-06
to O 0 7.422725545325193e-09
total O 0 3.1339220640802523e-07
deficiency O 1 0.999940037727356
879delG O 0 3.3701078791636974e-05
, O 0 4.0603342910117135e-09
which O 0 4.5363091755179497e-11
is O 0 1.4268249776128172e-11
the O 0 4.829410135687162e-11
common O 0 4.194090075237966e-10
defect O 0 1.3739759552322539e-08
in O 0 4.2042616610338257e-10
the O 0 1.174132124859284e-09
Cape O 0 7.350243436121673e-08
and O 0 2.400977749950073e-10
hitherto O 0 1.1018433276888118e-08
unreported O 0 3.3067819593668446e-09
, O 0 4.085102395245954e-11
and O 0 5.4309702568478e-11
1195delC O 0 3.746017274153246e-09
and O 0 4.878815129671921e-10
1936delG O 0 2.510089203155985e-08
, O 0 3.6207625786488506e-10
which O 0 8.345327900949329e-12
have O 0 5.879728995350497e-12
been O 0 9.499484532327074e-12
previously O 0 6.749534958716552e-11
reported O 0 2.2477270045229147e-11
in O 0 1.7312134364955156e-11
African O 0 2.0282309165509105e-09
- O 0 2.5187121721614858e-08
Americans O 0 2.090300155188629e-09
. O 0 3.6808376790986586e-08

We O 0 1.5831967914436973e-07
also O 0 1.9094577030642768e-09
show O 0 4.5071946175312405e-10
that O 0 5.973038903761552e-12
the O 0 2.390184231093606e-11
879delG O 0 7.663312762140606e-10
and O 0 1.5030381106395652e-10
1195delC O 0 4.736243042202659e-08
defects O 0 4.76728928333614e-07
are O 0 1.8137907842330492e-11
associated O 0 3.293550765448572e-09
with O 0 1.3408525401104043e-09
characteristic O 1 0.9987508058547974
C6 O 1 0.9999996423721313
/ O 1 0.9925395846366882
C7 O 0 0.0009450047509744763
region O 0 6.487544368383169e-08
DNA O 0 1.2824097339603213e-08
marker O 0 2.1399774396968496e-08
haplotypes O 0 3.5542846887892665e-08
, O 0 7.363637477553198e-10
although O 0 2.1046052400830462e-10
small O 0 1.3058597259085758e-10
variations O 0 7.132255230857254e-09
were O 0 5.090615040614921e-09
observed O 0 6.5301257734518e-08
. O 0 7.101484555960269e-08

The O 0 5.103898388369998e-07
1936delG O 0 4.119845925742993e-06
defect O 0 9.193786354444455e-06
was O 0 8.747585980017902e-07
observed O 0 3.392848668681836e-08
only O 0 4.752653270934104e-10
once O 0 3.3821279110668456e-09
in O 0 2.772383156379732e-10
the O 0 1.0023862850871978e-09
Cape O 0 5.5906831164520554e-08
, O 0 1.1771318642050943e-10
but O 0 2.0665247291162814e-11
its O 0 2.055129677547285e-11
associated O 0 6.028812116198878e-09
haplotype O 0 7.350649866566528e-08
could O 0 8.150682795360353e-09
be O 0 3.5954665911219763e-09
deduced O 0 1.0347785206477056e-07
. O 0 8.96279672701894e-08

The O 0 8.538654583389871e-08
data O 0 2.5649772084079814e-08
from O 0 2.778413943360647e-09
the O 0 8.919387450845306e-10
haplotypes O 0 1.638819568938743e-08
indicate O 0 1.7769203886075502e-09
that O 0 1.2033923336984831e-11
these O 0 1.4337570193589944e-11
three O 0 1.2852244268835022e-10
molecular O 0 7.341038354979901e-08
defects O 0 7.688778396186535e-07
account O 0 3.3498206986060097e-10
for O 0 4.0720821159467846e-10
the O 0 1.4009736482023527e-08
defects O 0 0.00018925686890725046
in O 0 8.444485111169797e-09
all O 0 1.0862095667363292e-09
the O 0 2.867523773986136e-09
38 O 0 1.9759193392587804e-08
unrelated O 0 1.8290238656959446e-08
C6Q0 O 0 6.521202635667578e-07
individuals O 0 4.830865915628202e-11
we O 0 3.943817217244572e-10
have O 0 3.6652025164896074e-11
studied O 0 6.050561385251285e-09
from O 0 2.1171467357028462e-10
the O 0 1.4284766702843399e-09
Cape O 0 2.513168055884307e-07
. O 0 3.626170652637484e-08

We O 0 1.0644702541640072e-07
have O 0 3.0199678868747526e-10
also O 0 2.6219113685721496e-11
observed O 0 8.007920715424888e-11
the O 0 3.738975101752473e-11
879delG O 0 7.639615162702285e-09
defect O 0 9.304963910494735e-09
in O 0 6.221275716811192e-10
two O 0 3.946242443930714e-09
Dutch O 1 0.9999983310699463
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.0004368052468635142
, O 0 3.01530733715083e-09
but O 0 6.58540166842414e-11
the O 0 1.3947040744533012e-10
879delG O 0 1.9895905367661726e-08
defect O 0 6.67396378162266e-08
in O 0 1.7897642257125312e-09
the O 0 1.868580490338445e-08
Cape O 0 1.451741582059185e-06
probably O 0 4.552088483933403e-09
did O 0 1.2365777846135018e-10
not O 0 1.7169940816352813e-11
come O 0 3.6263866909358455e-11
from O 0 4.366405154110353e-11
The O 0 2.1367531355398484e-10
Netherlands O 0 2.9311401306131302e-08
. O 0 9.495689790028905e-10
. O 0 3.9639264315383116e-08

Complement B-Disease 1 0.9999948740005493
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.9130998768778227e-07
seven O 0 6.444033306962638e-09
further O 0 1.5902953398594377e-09
molecular O 0 1.7402394405507948e-06
defects O 0 3.029980871360749e-05
and O 0 3.9186405231816934e-09
their O 0 7.272297763982749e-10
associated O 0 2.2440042357629864e-07
marker O 0 1.3131050309311831e-06
haplotypes O 0 1.3793167454423383e-05
. O 0 2.9601756068586838e-06

Seven O 0 8.113461547054612e-08
further O 0 2.7581912309670997e-09
molecular O 0 6.240890826347822e-08
bases O 0 2.0399486544420142e-08
of O 0 0.012229761108756065
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.6555058834910596e-07
described O 0 5.301963597048598e-07
. O 0 1.2806600580006489e-07

All O 0 7.13128933682583e-09
these O 0 1.92043242419615e-10
new O 0 4.764652561384253e-10
molecular O 0 8.227487313661186e-08
defects O 0 3.994811095253681e-07
involve O 0 1.2236978541579902e-08
single O 0 3.4987386321461145e-09
- O 0 1.335477950448194e-08
nucleotide O 0 6.277395936393759e-09
events O 0 1.7121231099537226e-09
, O 0 2.521045594505722e-10
deletions O 0 1.129901616714335e-09
and O 0 3.5741318238358133e-10
substitutions O 0 6.108376471303245e-09
, O 0 2.791629150067365e-10
some O 0 4.4719641184576275e-11
of O 0 1.0289401553009725e-09
which O 0 5.8130937563571905e-11
alter O 0 3.4687179795156453e-09
splice O 0 3.091333766747084e-08
sites O 0 1.757471834729074e-09
, O 0 6.249342709985228e-10
and O 0 8.134776185997339e-10
others O 0 4.25318980035172e-09
codons O 0 1.2204222343825677e-07
. O 0 2.693182352686563e-07

They O 0 8.219060987357807e-09
are O 0 4.2784734088918697e-11
distributed O 0 3.103671139537134e-11
along O 0 1.4258572100800393e-10
the O 0 1.2009950811631143e-09
C7 O 0 4.2736556338240916e-07
gene O 0 2.215846395259291e-09
, O 0 4.527943298082704e-10
but O 0 5.094777377756543e-11
predominantly O 0 4.794459967927267e-11
towards O 0 4.4720599445824405e-10
the O 0 5.898088684119784e-10
3 O 0 3.0489967883795543e-08
end O 0 1.0938615702116294e-07
. O 0 1.4491934052784927e-07

All O 0 2.0969981306961927e-08
were O 0 5.029772154330203e-09
found O 0 3.170530227247781e-10
in O 0 8.725404426757066e-11
compound O 0 3.791793545815381e-09
heterozygous O 0 1.9383366023362214e-09
individuals O 0 8.601955814313555e-10
. O 0 1.0902559921532884e-07

The O 0 2.01030070456909e-05
C6 O 1 0.9989818930625916
/ O 0 0.003107881173491478
C7 O 0 0.00020880262309219688
marker O 0 1.1709021237038542e-06
haplotypes O 0 7.717267749285384e-07
associated O 0 2.6095031557815673e-07
with O 0 1.5440692280321855e-08
most O 0 9.119693231696147e-07
C7 B-Disease 1 0.9999765157699585
defects I-Disease 1 0.9984795451164246
are O 0 5.710033335049047e-09
tabulated O 0 4.909181257062301e-07
. O 0 1.4163501482755692e-08
. O 0 4.661213637291439e-08

A O 0 3.139931095574866e-06
genome O 0 3.909400092538817e-08
- O 0 2.8811323105060183e-08
wide O 0 2.926652920010042e-09
search O 0 1.1224694507205868e-09
for O 0 3.195226305763299e-10
chromosomal O 0 2.7515884539752733e-06
loci O 0 4.2546446366031887e-07
linked O 0 2.3304114620259497e-06
to O 0 3.926857772285075e-08
mental O 1 0.9998008608818054
health O 0 1.7527245290693827e-06
wellness O 0 4.090421953151235e-06
in O 0 4.628608607504248e-09
relatives O 0 9.917252574709323e-10
at O 0 1.329512855363646e-08
high O 0 2.6573998113121888e-08
risk O 0 8.765831616130981e-09
for O 0 4.9819970371345335e-08
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 3.410580973195465e-08
the O 0 3.042728025093311e-08
Old O 0 9.054878091774299e-07
Order O 0 1.6369140709571184e-08
Amish O 0 2.1072226275009598e-07
. O 0 2.6602650748941414e-08

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.953052818775177
BPAD B-Disease 1 1.0
; O 1 0.9994662404060364
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 3.155247156882979e-07
is O 0 1.7363673832093696e-09
characterized O 0 1.0761010971194196e-09
by O 0 1.3195571371693582e-11
episodes O 0 5.994299279166171e-09
of O 0 3.599379283514281e-08
mania B-Disease 0 1.3523269899451407e-06
and O 0 7.066918161768854e-09
/ O 0 6.06150706516928e-06
or O 0 1.0794239813094464e-07
hypomania B-Disease 0 0.0008053550263866782
interspersed O 0 8.759634795296734e-08
with O 0 8.674466700497874e-10
periods O 0 3.003163783432683e-06
of O 0 2.217381506852689e-06
depression B-Disease 1 0.9969136714935303
. O 0 1.0349684771426837e-06

Compelling O 0 1.6530715356566361e-06
evidence O 0 1.0965479191327177e-07
supports O 0 1.1570759905765726e-09
a O 0 4.0078954044453496e-10
significant O 0 2.3066296095386463e-10
genetic O 0 2.9201678852786017e-09
component O 0 2.313664282382888e-08
in O 0 7.180831484987493e-10
the O 0 1.188294240783705e-09
susceptibility O 0 3.278798033079511e-08
to O 0 4.2292769286689236e-09
develop O 0 8.68233746587066e-06
BPAD B-Disease 1 1.0
. O 0 2.2453010387835093e-05

To O 0 2.5661172742275085e-08
date O 0 7.97820263187532e-08
, O 0 2.272350502208198e-10
however O 0 1.2290977957629678e-10
, O 0 1.2025806739313083e-10
linkage O 0 3.3308109603780167e-09
studies O 0 1.0600078592659656e-09
have O 0 2.0256771954274555e-11
attempted O 0 9.370824116672338e-10
only O 0 1.3158424870540752e-11
to O 0 2.1789705456631836e-11
identify O 0 3.181587215905779e-09
chromosomal O 0 2.969806701003108e-06
loci O 0 9.553978230769644e-08
that O 0 2.3786712599616067e-09
cause O 0 5.1844704529457886e-08
or O 0 1.8382514954673468e-10
increase O 0 9.644152837440245e-11
the O 0 3.128426684373409e-10
risk O 0 5.4083169054308655e-09
of O 0 2.1505014657918764e-08
developing O 0 6.241287792363437e-06
BPAD B-Disease 1 1.0
. O 0 2.6000809612014564e-06

To O 0 9.078018337049798e-08
determine O 0 5.138785468261631e-07
whether O 0 4.6263071595831207e-08
there O 0 1.8623492747948944e-09
could O 0 2.431403134384169e-10
be O 0 5.724858434530411e-11
protective O 0 5.925115398319747e-10
alleles O 0 7.701494303402612e-11
that O 0 1.571814380041392e-11
prevent O 0 9.680242163412345e-10
or O 0 3.1980065817727166e-10
reduce O 0 2.802861276407498e-09
the O 0 6.455101453362033e-10
risk O 0 5.853364015706575e-09
of O 0 9.552188373618264e-09
developing O 0 5.541935479413951e-07
BPAD B-Disease 1 1.0
, O 0 7.490076336935658e-10
similar O 0 1.5149414708814923e-11
to O 0 1.4173694336261367e-11
what O 0 1.111929038427606e-11
is O 0 2.485074646063623e-12
observed O 0 2.986593611309374e-11
in O 0 1.0766091143588064e-11
other O 0 6.83500256393188e-10
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 7.807549273763925e-09
we O 0 7.92547583117198e-10
used O 0 4.027776334680766e-09
mental O 0 0.01578456163406372
health O 0 3.24386746797245e-07
wellness O 0 3.010808995895786e-06
( O 0 1.1183706183359732e-09
absence O 0 1.0357065605148819e-07
of O 0 3.099428269592863e-08
any O 0 2.715001201636369e-08
psychiatric B-Disease 1 0.9995989203453064
disorder I-Disease 0 0.0003182154905516654
) O 0 1.0120605048458131e-10
as O 0 1.2028789075912982e-10
the O 0 6.826347820343415e-11
phenotype O 0 1.3051400238328625e-10
in O 0 1.9528004213675842e-10
our O 0 6.353351178489675e-10
genome O 0 7.175368632594825e-10
- O 0 1.7362281612420816e-09
wide O 0 3.6446827778036095e-09
linkage O 0 2.1844961395345308e-08
scan O 0 3.1117346566134074e-07
of O 0 1.9818982011088337e-08
several O 0 5.186819862501579e-10
large O 0 1.0852404530581339e-09
multigeneration O 0 2.470406457177887e-07
Old O 0 1.009784682537429e-07
Order O 0 5.688975956985587e-09
Amish O 0 2.6977497569191655e-08
pedigrees O 0 1.1736066340972684e-08
exhibiting O 0 6.49482201353635e-09
an O 0 1.2667573934255216e-10
extremely O 0 1.0177837239666587e-08
high O 0 6.636542337901119e-08
incidence O 0 6.514403594337637e-06
of O 0 1.3982360542286187e-05
BPAD B-Disease 1 1.0
. O 0 1.1999091839243192e-05

We O 0 2.0372877429508662e-07
have O 0 8.408511664725893e-10
found O 0 1.2618861511271007e-10
strong O 0 4.281134474704018e-11
evidence O 0 3.3446684311044805e-10
for O 0 4.115477750255003e-11
a O 0 1.5920427476334709e-10
locus O 0 5.850659956507798e-10
on O 0 6.361663196230438e-08
chromosome O 0 5.161058425073861e-07
4p O 0 3.385951276868582e-05
at O 0 1.304996658291202e-06
D4S2949 O 0 2.3032056617466878e-07
( O 0 9.303965931017899e-10
maximum O 0 1.3124606290659813e-08
GENEHUNTER O 0 1.8885326653617085e-06
- O 0 7.25659248246302e-08
PLUS O 0 5.24630401343984e-08
nonparametric O 0 1.1106614294931205e-07
linkage O 0 2.9588154148996182e-08
score O 0 4.4329738102533156e-08
= O 0 1.0302053432553748e-08
4 O 0 6.0405525026396845e-09
. O 0 1.8287428515950666e-10
05 O 0 1.5008740916755414e-08
, O 0 1.5521885998737162e-09
P O 0 7.305308713512204e-08
= O 0 4.442587187014624e-09
5 O 0 2.2550981082503085e-09
. O 0 7.836156029616959e-11
22 O 0 1.0570883057781089e-09
x O 0 1.714319886048088e-08
10 O 0 1.8828766101819383e-08
( O 0 5.069064057394712e-10
- O 0 3.573629392406019e-09
4 O 0 5.162040128681156e-09
) O 0 1.0004317513301331e-10
; O 0 1.5709010481312902e-10
SIBPAL O 0 5.957895155006554e-08
Pempirical O 0 1.0477373280082247e-07
value O 0 1.0618984802590603e-08
< O 0 2.6982952761045453e-08
3 O 0 1.2597759280197351e-08
x O 0 1.5509346695807835e-08
10 O 0 7.974183091619125e-09
( O 0 2.0860295435465304e-10
- O 0 1.3479271032679208e-09
5 O 0 4.314631429913618e-10
) O 0 7.437424807965609e-12
) O 0 5.112032758908258e-12
and O 0 2.0052952354188136e-11
suggestive O 0 1.239643609984853e-09
evidence O 0 6.121051443486181e-10
for O 0 4.414968737820324e-11
a O 0 1.5703167932645812e-10
locus O 0 7.013042924164381e-10
on O 0 6.291855214612951e-08
chromosome O 0 1.3704641332878964e-07
4q O 0 2.8934249485246255e-07
at O 0 1.463440071347577e-07
D4S397 O 0 6.416880182769091e-08
( O 0 5.581546336230758e-10
maximum O 0 1.1297038859936492e-08
GENEHUNTER O 0 5.716901227970084e-07
- O 0 2.595331238808285e-08
PLUS O 0 2.611573890476393e-08
nonparametric O 0 3.296921136097808e-08
linkage O 0 1.3756856098723347e-08
score O 0 2.2306680946826418e-08
= O 0 8.294717801504703e-09
3 O 0 4.04781541618604e-09
. O 0 1.6051414364337546e-10
29 O 0 9.294711666996136e-09
, O 0 8.059563572082595e-10
P O 0 6.647805150805652e-08
= O 0 8.562281550439366e-09
2 O 0 1.000053195809869e-08
. O 0 1.147889214236919e-10
57 O 0 3.6298710703874804e-09
x O 0 3.093988354407884e-08
10 O 0 2.937671794711605e-08
( O 0 6.655664908095105e-10
- O 0 6.48877929165792e-09
3 O 0 3.2123319559929087e-09
) O 0 6.452586381877623e-11
; O 0 7.913568411677119e-11
SIBPAL O 0 7.844780469667967e-08
Pempirical O 0 9.988506377567319e-08
value O 0 1.3068127913129501e-08
< O 0 3.032363338206778e-08
1 O 0 2.0964943558965388e-08
x O 0 4.0452469818319514e-08
10 O 0 2.721419711804174e-08
( O 0 8.721282585000267e-10
- O 0 8.086205482982223e-09
3 O 0 9.387250088366272e-09
) O 0 7.43601014097095e-11
) O 0 3.866723607970357e-11
that O 0 9.89034288495505e-12
are O 0 1.6391736926135714e-11
linked O 0 1.7400838547843023e-09
to O 0 6.302225963317198e-10
mental O 1 0.9366931319236755
health O 0 1.1664289559121244e-05
wellness O 0 3.1039220630191267e-05
. O 0 5.004674221709138e-07

These O 0 6.779901529085919e-09
findings O 0 6.932505680623535e-09
are O 0 7.161486681450668e-11
consistent O 0 1.9076340507240275e-09
with O 0 2.7646775493939124e-11
the O 0 2.5906746192738694e-10
hypothesis O 0 4.3883824352164424e-10
that O 0 2.356468102246434e-12
certain O 0 3.477922810857237e-11
alleles O 0 2.867538706485817e-10
could O 0 8.739099999210964e-10
prevent O 0 1.8380595934175403e-09
or O 0 2.8505900417918895e-10
modify O 0 6.843847155657556e-10
the O 0 1.4493170552576373e-10
clinical O 0 8.944059715076946e-09
manifestations O 0 1.488691907525208e-07
of O 0 7.582045213894162e-07
BPAD B-Disease 1 1.0
and O 0 6.365605820235487e-09
perhaps O 0 8.010475616160306e-10
other O 0 1.754730943881455e-10
related O 0 1.7931464526554919e-06
affective B-Disease 1 0.9851326942443848
disorders I-Disease 1 0.9999997615814209
. O 0 2.7462683647172526e-05

Segregation O 0 0.0945897325873375
distortion O 1 0.999825656414032
in O 0 0.03200790286064148
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0005249860696494579

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9792918562889099
DM B-Disease 1 1.0
) O 0 4.804757125498327e-08
is O 0 1.1451497528014443e-09
an O 0 4.91198137719806e-10
autosomal B-Disease 1 0.9998031258583069
dominant I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999778270721436
which O 0 1.8061218076681484e-09
, O 0 1.4832339523263016e-10
in O 0 8.235748888418826e-11
the O 0 6.380431738506331e-10
typical O 0 1.5355578142361992e-08
pedigree O 0 3.1834750391368516e-09
, O 0 1.255069104200146e-10
shows O 0 1.3812300192483917e-09
a O 0 7.562080406309235e-10
three O 0 1.001767002684062e-09
generation O 0 1.1645117581338127e-07
anticipation O 0 1.709323669274454e-07
cascade O 0 3.6502892726275604e-06
. O 0 7.379911721727694e-07

This O 0 4.692752297863478e-10
results O 0 1.2693603945734822e-09
in O 0 7.0676056118657016e-09
infertility B-Disease 1 0.9999568462371826
and O 1 0.998391330242157
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00152295152656734
CDM B-Disease 0 0.025448011234402657
) O 0 1.5529526553592632e-09
with O 0 9.086511404410302e-11
the O 0 2.3537944926488308e-09
disappearance O 0 1.1612323902454591e-07
of O 0 2.8925117590006266e-07
DM B-Disease 1 1.0
in O 0 4.971820999344345e-08
that O 0 2.1372270619934852e-09
pedigree O 0 1.438595944591725e-07
. O 0 8.510557591989709e-08

The O 0 1.2051421194314571e-08
concept O 0 1.8070531737635065e-08
of O 0 1.3516607388908142e-08
segregation O 0 6.413845881070301e-07
distortion O 0 1.5827394008738338e-06
, O 0 2.9404492729590004e-10
where O 0 6.166750443625801e-11
there O 0 9.869952945218419e-12
is O 0 3.5262682530901035e-12
preferential O 0 2.974440971303949e-10
transmission O 0 9.005169943065994e-09
of O 0 6.867920676612016e-10
the O 0 1.7683621233999247e-10
larger O 0 1.3466006087980986e-10
allele O 0 2.673594678981317e-10
at O 0 1.5125760199907745e-08
the O 0 3.6012111070959918e-09
DM B-Disease 1 0.993800938129425
locus O 0 1.090883738896764e-08
, O 0 9.511604837086907e-10
has O 0 1.1432940705269345e-10
been O 0 1.0736444372438925e-10
put O 0 4.4723158509896166e-10
forward O 0 3.4958034245136105e-09
to O 0 1.7894220827319174e-10
explain O 0 2.187434233746899e-09
partially O 0 1.096991031346306e-08
the O 0 1.2060360488064248e-09
maintenance O 0 7.344119126173609e-07
of O 0 5.237363438936882e-06
DM B-Disease 1 1.0
in O 0 2.6440016398510124e-08
the O 0 3.4876783683301937e-09
population O 0 7.836215704104532e-11
. O 0 1.7212528291565832e-08

In O 0 2.809374564094469e-07
a O 0 1.5275071874043533e-08
survey O 0 6.281228870363975e-09
of O 0 6.741605318438815e-08
DM B-Disease 1 1.0
in O 0 4.1015745466665976e-08
Northern O 0 6.312446032552543e-08
Ireland O 0 1.0086851354174087e-08
, O 0 5.579630646401768e-10
59 O 0 1.945448779849812e-08
pedigrees O 0 2.8526708106824117e-08
were O 0 1.140838179480852e-08
ascertained O 0 1.1127028756163782e-06
. O 0 1.4408875870230986e-07

Sibships O 0 2.1209771148278378e-05
where O 0 2.0237763465047465e-08
the O 0 1.1235318231328506e-09
status O 0 6.129162066770277e-09
of O 0 6.4042473546521705e-09
all O 0 1.4267875769746752e-10
the O 0 5.440635719722309e-10
members O 0 7.485873726453818e-11
had O 0 1.435928043136414e-10
been O 0 2.0113322465875605e-11
identified O 0 4.107322468249741e-11
were O 0 5.283773418796045e-11
examined O 0 6.517801298677739e-10
to O 0 3.033671924779213e-11
determine O 0 1.0375503789461504e-09
the O 0 6.442358313485386e-10
transmission O 0 8.347906543804129e-08
of O 0 8.291522135550622e-09
the O 0 1.1178699743652487e-08
DM B-Disease 1 0.9999991655349731
expansion O 0 1.5472566872176685e-07
from O 0 3.883461552334211e-09
affected O 0 8.480248725462047e-10
parents O 0 6.270688135412428e-11
to O 0 1.035772301261062e-10
their O 0 3.7987266110484086e-10
offspring O 0 1.5684147314232177e-08
. O 0 8.004633400560124e-08

Where O 0 2.1957376361569914e-07
the O 0 3.6499994138239344e-08
transmitting O 0 1.027649068419123e-05
parent O 0 6.108425765205538e-08
was O 0 6.971105790398724e-07
male O 0 1.66808540313923e-08
, O 0 6.864008472717842e-09
58 O 0 4.981237680112827e-07
. O 0 5.192506478124415e-07

3 O 0 2.230880227216403e-06
% O 0 1.4047706109465707e-08
of O 0 2.9037568793910395e-08
the O 0 4.35092939454762e-09
offspring O 0 1.7370430649421564e-09
were O 0 3.2171312835949095e-10
affected O 0 8.484386804230581e-11
, O 0 5.473691291890681e-11
and O 0 3.105862095287293e-11
in O 0 5.883299403208753e-11
the O 0 1.7550054465242937e-10
case O 0 1.7100474369868834e-09
of O 0 7.566235415978895e-10
a O 0 5.064328956194686e-10
female O 0 2.2342563354982303e-09
transmitting O 0 2.1660989659721963e-06
parent O 0 3.0758187108403945e-08
, O 0 2.121328357418406e-08
68 O 0 1.9118858745059697e-06
. O 0 7.979783163136744e-07

7 O 0 1.3084288184472825e-05
% O 0 8.255168637560928e-08
were O 0 3.640321466491514e-08
affected O 0 2.917380292899452e-08
. O 0 1.0190058929993029e-07

Studies O 0 6.178851208460401e-07
on O 0 3.8894381759746466e-07
meiotic O 0 4.754961537400959e-06
drive O 0 1.4623826416482189e-07
in O 0 3.2377567293906395e-08
DM B-Disease 1 0.9999949932098389
have O 0 2.186069381071576e-10
shown O 0 4.235133077568065e-11
increased O 0 2.2958922957228012e-11
transmission O 0 6.177984235300471e-10
of O 0 1.1664263999122682e-10
the O 0 3.098537051937633e-11
larger O 0 4.4819377376104086e-11
allele O 0 2.2267082622207113e-10
at O 0 1.0423212515320301e-08
the O 0 3.1966056468490933e-09
DM B-Disease 0 0.021860692650079727
locus O 0 8.224298575498779e-09
in O 0 4.629641559006359e-09
non O 0 1.4665839671579306e-06
- O 0 6.744563961547101e-06
DM O 1 0.9999991655349731
heterozygotes O 0 3.3823828289314406e-06
for O 0 3.965862660493258e-08
CTGn O 0 2.8241263862582855e-05
. O 0 5.792360866507806e-07

This O 0 4.234725459184574e-09
study O 0 3.5690381761099843e-09
provides O 0 1.94645632944912e-10
further O 0 1.0829281915647471e-10
evidence O 0 6.066597224574366e-10
that O 0 1.5970053404701368e-11
the O 0 1.8041318439188103e-09
DM B-Disease 1 0.9999990463256836
expansion O 0 3.1023267865748494e-07
tends O 0 1.6487428311506847e-08
to O 0 2.1604648625661582e-10
be O 0 2.4935095654932127e-10
transmitted O 0 3.379045931950486e-09
preferentially O 0 8.733438860986098e-09
. O 0 3.182851315841617e-08

Diagnosis O 1 0.9964630007743835
of O 0 0.01029434334486723
hemochromatosis B-Disease 1 1.0
. O 0 0.0003621820651460439

If O 0 1.5375824659713544e-05
untreated O 1 0.9999990463256836
, O 0 1.4533772628055885e-05
hemochromatosis B-Disease 1 1.0
can O 0 4.661311777454102e-06
cause O 0 0.0013362749014049768
serious O 1 0.598299503326416
illness O 1 0.9617699980735779
and O 0 1.0690921481426585e-09
early B-Disease 0 8.186053435110807e-08
death I-Disease 0 1.4975455542298732e-08
, O 0 6.072104624665897e-11
but O 0 1.4838330217314954e-11
the O 0 5.380924039677382e-10
disease O 0 1.1431278323925653e-07
is O 0 9.140711104693722e-11
still O 0 1.738623273128681e-10
substantially O 0 3.911412083112964e-09
under O 0 2.051021681381826e-07
- O 0 3.715529601322487e-05
diagnosed O 0 0.00014104224101174623
. O 0 4.492008827128302e-07

The O 0 1.0946150297286295e-07
cornerstone O 0 8.140297723002732e-06
of O 0 1.2559085327268349e-08
screening O 0 1.5543958342689734e-09
and O 0 1.0858279553271899e-10
case O 0 2.1415431927795936e-10
detection O 0 2.332725790310519e-09
is O 0 4.997481161533868e-12
the O 0 2.1256791465917857e-11
measurement O 0 1.518528058852553e-08
of O 0 7.919013000901032e-09
serum O 0 2.2359373019753548e-08
transferrin O 0 5.8575999162258086e-08
saturation O 0 8.105882187692259e-08
and O 0 2.943245203113065e-09
the O 0 1.1085574236346929e-08
serum O 0 9.810175072288985e-08
ferritin O 0 2.12215559258766e-06
level O 0 2.2450753931479994e-06
. O 0 2.6379930773146043e-07

Once O 0 4.550745131837175e-07
the O 0 1.1580657321985655e-08
diagnosis O 0 1.9222172795707593e-06
is O 0 8.735100420764752e-10
suspected O 0 3.569209994225275e-08
, O 0 9.700759084907418e-10
physicians O 0 2.5028787931091756e-09
must O 0 7.724757500326973e-10
use O 0 1.3637015960910048e-09
serum O 0 1.0547771722713151e-07
ferritin O 0 4.5301089812710416e-06
levels O 0 3.144168942981196e-07
and O 0 2.904676499326797e-08
hepatic O 1 0.9489833116531372
iron O 1 0.9983832836151123
stores O 0 3.7153576215587236e-08
on O 0 4.641482931333485e-08
liver O 0 7.903443588475056e-08
biopsy O 0 3.780111867968117e-08
specimens O 0 5.51762413536494e-10
to O 0 7.426131237719957e-11
assess O 0 1.6122923440775594e-08
patients O 0 2.604642945769342e-09
for O 0 4.268433106968672e-10
the O 0 2.484718208961567e-09
presence O 0 1.836728813486843e-08
of O 0 4.638789050659398e-06
iron B-Disease 1 0.9999953508377075
overload I-Disease 0 0.2740125060081482
. O 0 3.46828778674535e-06

Liver O 0 0.0004138734075240791
biopsy O 0 0.00014687080692965537
is O 0 6.73299567210961e-08
also O 0 7.215484876255118e-10
used O 0 4.513698581565251e-10
to O 0 2.0046768411940974e-10
establish O 0 9.18292109020058e-09
the O 0 1.7514383277017487e-09
presence O 0 1.5149979049056128e-09
or O 0 1.4471577269858926e-09
absence O 0 8.613061908135933e-08
of O 0 8.690453228155093e-07
cirrhosis B-Disease 1 0.9999998807907104
, O 0 8.857750088964167e-09
which O 0 1.5207379799875298e-10
can O 0 1.769971530451997e-10
affect O 0 1.6295187421633273e-08
prognosis O 0 8.533457958037616e-07
and O 0 1.5859827229292023e-08
management O 0 2.0311683783802437e-06
. O 0 3.6979486139898654e-07

A O 0 1.6574505252719973e-06
DNA O 0 9.270813450257265e-08
- O 0 1.1117101017532605e-08
based O 0 5.284622739409883e-10
test O 0 1.3480704053048242e-10
for O 0 6.153039189271681e-11
the O 0 7.297809578865611e-10
HFE O 0 3.301934441424237e-07
gene O 0 3.374633905650626e-09
is O 0 2.513037833384857e-10
commercially O 0 3.7350708637085006e-10
available O 0 1.2594936205090335e-10
, O 0 1.8638326992892473e-11
but O 0 5.265269990839538e-12
its O 0 1.622970746510688e-12
place O 0 1.4260312375391493e-10
in O 0 9.280119207810689e-12
the O 0 5.732113395051641e-11
diagnosis O 0 3.884827037836658e-07
of O 0 4.937404014526692e-07
hemochromatosis B-Disease 1 1.0
is O 0 4.944358877878585e-08
still O 0 7.346806274455275e-09
being O 0 1.329616194922778e-09
evaluated O 0 2.6838669953122007e-08
. O 0 2.2814031552798042e-08

Currently O 0 4.5985206043042126e-07
, O 0 1.0974137154562413e-08
the O 0 1.3607551752059521e-09
most O 0 9.462346184374582e-11
useful O 0 9.190995187147166e-10
role O 0 1.105950664381794e-09
for O 0 1.6517250067682454e-10
this O 0 1.537856300637408e-11
test O 0 7.155425557625605e-11
is O 0 3.2846247423334862e-12
in O 0 2.671991100600124e-12
the O 0 1.5078096757270565e-11
detection O 0 7.503150101229039e-09
of O 0 3.035702533793483e-08
hemochromatosis B-Disease 1 1.0
in O 0 4.266769337846199e-08
the O 0 2.5802719960665854e-08
family O 0 9.271141077071832e-10
members O 0 7.203874996530857e-11
of O 0 9.585661153721503e-09
patients O 0 3.2507436742434948e-09
with O 0 5.112856804601051e-10
a O 0 2.4651482632975785e-08
proven O 0 1.0762230886030011e-05
case O 0 4.770322448166553e-08
of O 0 1.7911652605562267e-08
the O 0 3.129909842414236e-08
disease O 0 6.42942832200788e-05
. O 0 1.8149343361528736e-07

It O 0 8.406783713610366e-09
is O 0 2.466162829506402e-09
crucial O 0 1.126922768435179e-07
to O 0 1.0509592307528237e-08
diagnose O 1 0.9999998807907104
hemochromatosis B-Disease 1 1.0
before O 1 0.9999992847442627
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 0 1.1014558367605787e-05
because O 0 4.120573748878087e-08
phlebotomy O 0 0.09992127865552902
therapy O 0 0.0005067583988420665
can O 0 1.8924961597832635e-09
avert O 0 2.624775561343995e-06
serious O 1 0.9983059167861938
chronic O 1 1.0
disease O 1 0.9999998807907104
and O 0 6.967889731868127e-08
can O 0 4.57691795574533e-09
even O 0 1.6734829078046687e-09
lead O 0 2.592648096211292e-09
to O 0 1.6604399799557967e-10
normal O 0 3.4854031127906637e-07
life O 0 1.7067115720692527e-08
expectancy O 0 1.0280265527740085e-08
. O 0 7.110884658878547e-10
. O 0 1.2156441187016753e-08

Prevalence O 0 2.1028508854215033e-05
of O 0 3.4449317354301456e-07
the O 0 7.121192169279311e-08
I1307K O 0 7.974290952006413e-07
APC B-Disease 0 5.0341899537897916e-08
gene O 0 3.86462639667684e-09
variant O 0 3.783695134984555e-09
in O 0 1.194515597546797e-10
Israeli O 0 9.08303321445203e-10
Jews O 0 1.2029913176725415e-10
of O 0 4.133555997487548e-11
differing O 0 7.094945290997412e-12
ethnic O 0 9.148223845123482e-12
origin O 0 1.7561766277318647e-11
and O 0 1.7005513316958876e-11
risk O 0 2.414425326335845e-09
for O 0 2.2157422563395812e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5120221972465515

BACKGROUND O 0 1.044670534611214e-05
& O 0 1.7922027382155648e-06
AIMS O 0 6.184049539115222e-08
Israeli O 0 2.0363412289725602e-08
Jews O 0 4.3603174404438505e-09
of O 0 1.4713047447045824e-09
European O 0 1.0627935198570526e-09
birth O 0 6.180698619573377e-09
, O 0 5.859415175279992e-10
i O 0 8.688276209589674e-10
. O 0 2.577513376345042e-11
e O 0 1.3641041074485827e-10
. O 0 2.5033725092882264e-11
, O 0 2.331363713192758e-10
Ashkenazim O 0 2.5625222832559302e-08
, O 0 2.1867825605870195e-10
have O 0 9.708559477183965e-12
the O 0 2.2419179013244417e-10
highest O 0 5.027966108173132e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.9376628994941711
of O 0 4.72499124271053e-08
any O 0 1.179399355955013e-10
Israeli O 0 4.602778158613319e-09
ethnic O 0 7.634924692467848e-09
group O 0 1.1147464284988473e-08
. O 0 4.702559408542584e-08

The O 0 6.490663508884609e-07
I1307K O 0 1.7921190647030016e-06
APC B-Disease 0 2.1105914527197456e-07
gene O 0 1.4709070406127012e-08
variant O 0 1.4428648853481718e-07
was O 0 5.319304818840465e-07
found O 0 4.187338031869103e-09
in O 0 3.4642086976788278e-09
6 O 0 8.417407002525579e-07
. O 0 1.9582523691497045e-07

1 O 0 1.2669152056332678e-06
% O 0 3.509713408789139e-09
of O 0 5.311454831513629e-09
American O 0 1.36281230744828e-09
Jews O 0 4.265625630495151e-10
, O 0 2.8416640568407203e-11
28 O 0 4.246281659625595e-10
% O 0 1.8944661811515218e-11
of O 0 1.3130758702573075e-09
their O 0 2.032476409397077e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 3.774297874770127e-05
, O 0 6.609162106485655e-10
but O 0 3.568421946820166e-11
not O 0 8.114095333133786e-12
in O 0 4.219861265974956e-11
non O 0 2.7789136325395702e-08
- O 0 9.1096211463082e-08
Jews O 0 1.471322264023911e-08
. O 0 5.4417416350815984e-08

We O 0 1.4940653159101203e-07
assessed O 0 2.2221288986656873e-07
the O 0 3.209606580512059e-09
I1307K O 0 4.519431939797869e-08
prevalence O 0 2.6342801273671057e-09
in O 0 1.7161591592262937e-11
Israeli O 0 2.7121985213263144e-10
Jews O 0 1.2711914854079964e-10
of O 0 4.0997930744746114e-11
differing O 0 4.5361683159717e-12
ethnic O 0 5.060480680330048e-12
origin O 0 2.1572355013432798e-11
and O 0 9.701192106581491e-12
risk O 0 5.763913346612526e-09
for O 0 4.4540010435412114e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.07142626494169235

METHODS O 0 1.0435902595418156e-06
DNA O 0 8.086236569226912e-09
samples O 0 1.1529827093070821e-09
from O 0 2.2306700930840861e-10
500 O 0 8.548500796123903e-11
unrelated O 0 1.1622695028634666e-09
Jews O 0 2.0345532203425165e-10
of O 0 6.336940416851178e-10
European O 0 1.861418796877956e-09
or O 0 3.337423115645777e-10
non O 0 2.6516364659556757e-09
- O 0 1.2893541789793517e-10
European O 0 6.813079961309754e-11
origin O 0 4.381396634389745e-11
, O 0 2.106956753164524e-12
with O 0 1.4782193481430173e-12
or O 0 1.928286176566818e-11
without O 0 1.0786795068273847e-10
a O 0 1.443708069759353e-10
personal O 0 2.1270643024706715e-09
and O 0 2.960987455224995e-09
/ O 0 5.036014840698044e-07
or O 0 1.97030445292512e-08
family O 0 1.4970649164780525e-09
history O 0 6.3776739445131625e-09
of O 0 3.117915881034605e-08
neoplasia B-Disease 0 3.197219257344841e-06
, O 0 2.3520623226858106e-09
were O 0 8.54630366475817e-10
examined O 0 3.735949327676735e-09
for O 0 1.741507354990901e-10
the O 0 3.4853489538910765e-10
I1307K O 0 5.71624481082722e-09
variant O 0 3.2772939917435906e-10
by O 0 2.0133204131633775e-11
the O 0 1.6450815709667665e-10
allele O 0 2.7344507214088765e-10
- O 0 3.209984500429641e-10
specific O 0 6.839719762785634e-11
oligonucleotide O 0 2.4303529855274064e-08
( O 0 2.7373430189214787e-09
ASO O 0 1.1814223626060993e-06
) O 0 1.164239815665269e-09
method O 0 6.173949884669128e-08
. O 0 6.791837137143375e-08

RESULTS O 0 9.904274378413902e-08
In O 0 5.020647453335414e-09
persons O 0 1.3300448520325858e-09
at O 0 2.0448648996307384e-08
average O 0 7.29314775238521e-10
risk O 0 1.112327385754952e-08
for O 0 4.3183163711546513e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 1.8678362323498732e-07
I1307K O 0 2.0210960371969122e-07
was O 0 8.470024681628274e-08
found O 0 1.2193939191718073e-09
in O 0 1.158498075248815e-09
5 O 0 3.1736920647063016e-08
. O 0 2.780345376152127e-08

0 O 0 5.491455112860422e-07
% O 0 3.388895164491146e-09
of O 0 7.006575319934427e-09
120 O 0 5.367764455144197e-09
European O 0 5.1681774415612836e-09
and O 0 6.300486798949123e-09
1 O 0 1.7254394606425194e-06
. O 0 8.637096726715754e-08

6 O 0 2.4534879230486695e-06
% O 0 1.4352941946071951e-08
of O 0 9.965724245830643e-09
188 O 0 5.1788640043071155e-09
non O 0 2.5103288336936203e-08
- O 0 3.762436584509032e-09
European O 0 2.3022617146040147e-09
Jews O 0 2.1955306461762802e-09
( O 0 1.7432952303941818e-10
P O 0 4.369844219809238e-08
= O 0 4.221829552619738e-09
0 O 0 3.802817172271489e-09
. O 0 1.499624729950355e-10
08 O 0 1.5636056005519094e-08
) O 0 2.8339919300179872e-09
. O 0 5.701308580796649e-08

It O 0 9.742728224182429e-08
occurred O 0 3.002662651852006e-06
in O 0 3.193304465298752e-08
15 O 0 2.6401599484415783e-07
. O 0 1.2213887146117486e-07

4 O 0 1.1487530855447403e-06
% O 0 4.997879443635611e-09
of O 0 6.954091968935927e-09
52 O 0 2.4367304618522212e-08
Ashkenazi O 0 3.043488661091942e-08
Israelis O 0 7.238618593419233e-09
with O 0 2.0483770235557586e-09
familial O 0 2.251572141176439e-06
cancer B-Disease 0 0.0010848556412383914
( O 0 3.06969418772951e-08
P O 0 1.2944488844368607e-05
= O 0 6.06745942377529e-08
0 O 0 4.6579402557256344e-09
. O 0 8.45001985050331e-11
02 O 0 6.196019253223994e-09
) O 0 1.4669439274417329e-10
and O 0 1.1211594153071047e-10
was O 0 4.89587703711436e-09
not O 0 3.8719635137018926e-11
detected O 0 1.7916700345566028e-09
in O 0 3.06081604506403e-10
51 O 0 1.3113996999436495e-08
non O 0 1.3726472047892457e-07
- O 0 1.716256647910086e-08
European O 0 7.45324157946925e-09
Jews O 0 1.978286645609728e-09
at O 0 8.893384695340956e-09
increased O 0 2.9060824857651824e-09
cancer B-Disease 0 3.4716856589511735e-07
risk O 0 6.773002070303846e-08
. O 0 1.0804744476899941e-07

Colorectal B-Disease 1 0.9999569654464722
neoplasia I-Disease 1 0.996198832988739
occurred O 0 0.006094430573284626
personally O 0 6.950937745386909e-07
or O 0 2.4914761365124605e-09
in O 0 2.9171104420910865e-10
the O 0 2.5723578822578475e-10
families O 0 6.392412207206766e-12
of O 0 9.327846273166074e-10
13 O 0 6.697590482218629e-09
of O 0 1.3431953327369683e-08
20 O 0 2.0284138813053687e-08
Ashkenazi O 0 5.986735107654795e-09
I1307K O 0 1.0962673435699344e-08
carriers O 0 4.107034712319546e-10
, O 0 1.5223806937303408e-10
8 O 0 3.807099080432863e-09
of O 0 4.182101775995761e-09
whom O 0 4.3313388431442945e-09
also O 0 1.286613260376157e-09
had O 0 1.8848842486818285e-09
a O 0 1.5096210947973532e-09
personal O 0 4.4867167758866344e-08
or O 0 1.776751723525649e-08
family O 0 2.3941744142774724e-09
history O 0 3.763190203898148e-09
of O 0 5.687894244488234e-08
noncolonic O 0 3.585377271519974e-05
neoplasia B-Disease 0 0.0025567985139787197
. O 0 1.105369119613897e-05

CONCLUSIONS O 0 1.851062279456528e-06
The O 0 1.4113953739069984e-07
I1307K O 0 6.30221961728239e-07
APC O 0 1.339734012617555e-07
variant O 0 6.606761360217206e-08
may O 0 7.955163638939666e-09
represent O 0 9.810110501717872e-10
a O 0 8.572424436970039e-10
susceptibility O 0 2.3012267647004592e-08
gene O 0 8.688180841431858e-09
for O 0 2.6450509338360462e-08
colorectal B-Disease 1 1.0
, I-Disease 0 5.358203338801104e-07
or I-Disease 0 6.5274092797551475e-09
other I-Disease 0 3.896524769508858e-10
, I-Disease 0 1.6429062554834672e-09
cancers I-Disease 0 1.2534573215816636e-05
in O 0 5.636302091716061e-09
Ashkenazi O 0 1.6098655919449811e-07
Jews O 0 6.63571686487785e-09
, O 0 2.948187804996394e-10
and O 0 7.20190990177727e-11
partially O 0 1.0116851356656298e-08
explains O 0 3.565770456681605e-10
the O 0 2.4484249697143134e-11
higher O 0 1.433613561196978e-09
incidence O 0 1.5580868648612523e-06
of O 0 0.0006882426678203046
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.1533510852787003e-08
European O 0 3.215453503457866e-08
Israelis O 0 1.1151296774869479e-07
. O 0 8.339296897474924e-08

Systematic O 0 3.389931180208805e-08
analysis O 0 1.334716515088985e-08
of O 0 1.6047451367739995e-08
coproporphyrinogen O 0 3.8328794289554935e-06
oxidase O 0 4.2585659798533015e-07
gene O 0 3.916314653906738e-06
defects O 0 0.16670501232147217
in O 0 7.878329029153974e-07
hereditary B-Disease 1 0.9999995231628418
coproporphyria I-Disease 1 0.999198853969574
and O 0 1.0762745006331897e-07
mutation O 0 1.017255790713989e-08
update O 0 9.574920056820702e-08
. O 0 3.077338988077827e-07

Hereditary B-Disease 1 0.9999996423721313
coproporphyria I-Disease 1 0.9999669790267944
( O 0 3.117992491752375e-06
HC B-Disease 1 1.0
) O 0 3.722138330886082e-08
is O 0 9.126795430525192e-10
an O 0 1.6234561472927567e-09
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0006580263143405318
autosomal O 1 1.0
dominant O 1 0.9999994039535522
inheritance O 0 0.008772654458880424
caused O 0 1.549909143250261e-07
by O 0 2.701377177505293e-10
deficient B-Disease 0 9.885363994044383e-08
activity I-Disease 0 7.384063138715646e-09
of I-Disease 0 3.547011218074658e-08
coproporphyrinogen I-Disease 0 5.08889797856682e-06
III I-Disease 1 0.9966187477111816
oxidase I-Disease 0 9.30244752339604e-08
( O 0 9.35985955408114e-09
CPO O 0 7.869235219004622e-07
) O 0 6.758842374665619e-09
. O 0 6.859117007707027e-08

Clinical O 0 1.6968197087408043e-05
manifestations O 0 0.0010543243261054158
of O 0 1.7818512105804984e-06
the O 0 2.320517324960747e-07
disease O 0 0.02052767388522625
are O 0 4.499923003664641e-12
characterized O 0 9.294347930177693e-11
by O 0 8.601110275396895e-12
acute O 0 0.006768350023776293
attacks O 0 2.591596448553446e-08
of O 0 8.337573672179133e-05
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.9770000392327347e-07
precipitated O 0 4.5996038977591525e-08
by O 0 1.4758121114066824e-10
drugs O 0 2.1488817836257113e-08
, O 0 2.2070549554609187e-10
fasting O 0 3.7047340750717694e-09
, O 0 4.904145423090256e-10
cyclical O 0 7.964197834553488e-07
hormonal O 0 7.939134775369894e-06
changes O 0 9.354383934123689e-08
, O 0 2.5236797540628686e-08
or O 0 1.718327666822006e-07
infectious B-Disease 1 0.9999557733535767
diseases I-Disease 1 0.9998340606689453
. O 0 3.4419015264575137e-06

Skin O 1 0.9999730587005615
photosensitivity O 1 0.9999970197677612
may O 0 2.1712094167014584e-05
also O 0 5.7131162023438264e-09
be O 0 8.611033552874403e-10
present O 0 3.3089082585036067e-09
. O 0 5.386946710927987e-08

The O 0 5.101475153423962e-07
seven O 0 1.1507988517678314e-07
exons O 0 1.2543266336706438e-07
, O 0 2.9924811517645367e-09
the O 0 8.56768966883692e-09
exon O 0 2.209205831604777e-07
/ O 0 2.1000606409415923e-07
intron O 0 4.0674990486877505e-07
boundaries O 0 2.209401994690552e-09
and O 0 1.0988794318933515e-09
part O 0 3.971242890088433e-09
of O 0 5.372089617594611e-08
3 O 0 3.0604925882471434e-07
noncoding O 0 3.416649860810139e-07
sequence O 0 4.206517800753318e-09
of O 0 1.9269030815394217e-08
the O 0 7.481898656180874e-09
CPO O 0 1.1059516680234083e-07
gene O 0 1.8147131575219078e-09
were O 0 7.983432248614974e-10
systematically O 0 5.261490687580306e-10
analyzed O 0 3.6386657575882e-10
by O 0 3.14592171757333e-11
an O 0 2.898551190733123e-11
exon O 0 9.890074537111104e-09
- O 0 6.821330611472831e-09
by O 0 1.939057581168413e-09
- O 0 7.131645247682172e-07
exon O 0 6.37407026715664e-07
denaturing O 0 4.403555976750795e-06
gradient O 0 1.788122517609736e-06
gel O 0 3.6294618439569604e-06
electrophoresis O 0 1.8050710650641122e-06
( O 0 1.2722017217470238e-08
DGGE O 0 2.030994210144854e-06
) O 0 4.148731636011149e-10
strategy O 0 2.3531616655247944e-09
followed O 0 9.166428033280383e-11
by O 0 6.0459029276038745e-12
direct O 0 7.293089049342782e-11
sequencing O 0 3.9241432325809456e-10
in O 0 2.678627597507699e-10
seven O 0 1.625873213839668e-09
unrelated O 0 2.7491379839261754e-08
heterozygous O 0 1.0477148926213431e-08
HC B-Disease 1 0.9999656677246094
patients O 0 8.329391789629881e-07
from O 0 2.4788120001062453e-08
France O 0 7.85220564125666e-08
, O 0 2.4040297530447674e-10
Holland O 0 8.521355177038004e-09
, O 0 5.896218235879047e-11
and O 0 9.637166065168401e-11
Czech O 0 1.2863829397247173e-06
Republic O 0 4.722162429970922e-06
. O 0 6.345364340631932e-07

Seven O 0 2.420515841095039e-07
novel O 0 1.471810762154746e-08
mutations O 0 4.933946140539547e-09
and O 0 5.457243545947676e-10
two O 0 2.468966697755093e-10
new O 0 9.031655423541451e-10
polymorphisms O 0 1.5390824614769372e-08
were O 0 1.4761909028493392e-08
detected O 0 2.032400743701146e-06
. O 0 1.5775133022088994e-07

Among O 0 5.2671262906756056e-09
these O 0 1.3966207357274385e-10
mutations O 0 8.394905881559112e-10
two O 0 1.9958484864801562e-10
are O 0 9.358030322870192e-11
missense O 0 6.988890355330568e-09
( O 0 3.189557506999563e-10
G197W O 0 4.6593559233087944e-08
, O 0 9.677657564211017e-10
W427R O 0 1.6485321552295318e-08
) O 0 9.338559092686438e-11
, O 0 9.788890531492456e-11
two O 0 3.6408299985968284e-11
are O 0 2.2666181431763022e-11
nonsense O 0 5.313045559063312e-09
( O 0 3.810996657138688e-11
Q306X O 0 2.1900894431325924e-09
, O 0 1.0013442852674359e-10
Q385X O 0 4.686412591325961e-09
) O 0 5.776575051630317e-11
, O 0 8.926599737169028e-11
two O 0 1.2969255877570696e-11
are O 0 5.2619670773412786e-12
small O 0 4.4362485907001314e-11
deletions O 0 5.457181373458297e-10
( O 0 5.544166237214654e-10
662de14bp O 0 3.1566912639391376e-08
; O 0 6.448652722923498e-10
1168del3bp O 0 9.479627749442443e-08
removing O 0 5.320350027204768e-08
a O 0 6.767227223036798e-09
glycine O 0 2.6305659872605247e-08
at O 0 1.4852430751943757e-07
position O 0 2.9603395290678236e-08
390 O 0 4.337060044434793e-09
) O 0 5.481014600516865e-11
, O 0 6.649177736184342e-11
and O 0 2.7699452107010636e-11
one O 0 5.648069512087517e-11
is O 0 2.1071104930325824e-11
a O 0 1.430569968041695e-10
splicing O 0 1.158610873908117e-09
mutation O 0 4.278271625857144e-10
( O 0 6.004503005918593e-10
IVS1 O 0 4.991951527699712e-07
- O 0 1.0787695003955378e-07
15c O 0 4.192538654024247e-07
- O 0 8.999266754017299e-08
- O 0 3.741263654433169e-08
> O 0 1.0847836406924216e-08
g O 0 1.4124168501439271e-08
) O 0 1.4058466890620736e-10
which O 0 4.449128565564564e-11
creates O 0 4.5847792229380957e-10
a O 0 1.771903734848479e-10
new O 0 2.9116570265941277e-10
acceptor O 0 1.2155507711497648e-09
splice O 0 2.823559270836995e-07
site O 0 1.6664419888456905e-07
. O 0 3.1698991165285406e-07

The O 0 1.6234437794082623e-07
pathological O 0 2.4607319573988207e-05
significance O 0 3.6417802107280295e-07
of O 0 5.406452885381441e-08
the O 0 7.1348127406167805e-09
point O 0 9.96681066567362e-08
mutations O 0 6.459633383748553e-10
G197W O 0 2.5397451253184045e-08
, O 0 7.488191178239845e-10
W427R O 0 2.4316557656334226e-08
, O 0 2.9196875472869976e-10
and O 0 9.883992929671237e-11
the O 0 5.054929252956697e-10
in O 0 1.0534251249083582e-09
- O 0 7.208637686773045e-09
frame O 0 8.05043001150807e-08
deletion O 0 1.5343751158525265e-08
390delGly O 0 1.6883632270037197e-08
were O 0 5.687725845859859e-10
assessed O 0 4.747778836744487e-10
by O 0 3.956878661531826e-12
their O 0 7.100130379467107e-12
respective O 0 3.0972621689606683e-10
expression O 0 3.8831482473966616e-10
in O 0 7.370223875646786e-11
a O 0 6.98379271080185e-11
prokaryotic O 0 8.363449516268773e-11
system O 0 1.440086716542055e-09
using O 0 1.3012778632415234e-09
site O 0 6.332412816334454e-09
- O 0 4.743327952638765e-09
directed O 0 5.386450840916268e-09
mutagenesis O 0 4.0456980059389025e-06
. O 0 4.081589111137873e-07

These O 0 2.9984801308557962e-09
mutations O 0 8.160514930466434e-09
resulted O 0 1.4117381930134343e-08
in O 0 5.595755525611423e-10
the O 0 1.782007985617895e-09
absence O 0 1.847409869526473e-08
or O 0 5.404787728480187e-10
a O 0 5.095994182191532e-10
dramatic O 0 6.829740772928972e-09
decrease O 0 3.9635029480677986e-08
of O 0 9.67827190834214e-07
CPO O 0 1.628795507713221e-05
activity O 0 4.909148287879361e-07
. O 0 2.3513933911090135e-07

The O 0 7.996728612624793e-08
two O 0 1.1653461529093079e-09
polymorphisms O 0 6.9388819134985624e-09
were O 0 5.780976253255687e-10
localized O 0 6.24149576466948e-09
in O 0 1.7125999507427991e-09
noncoding O 0 9.524193700372052e-08
part O 0 7.150516845300103e-10
of O 0 5.44221601117556e-09
the O 0 3.896042100048902e-10
gene O 0 3.4492142475528453e-10
1 O 0 1.8265241763515405e-08
) O 0 6.631079713104171e-11
a O 0 8.142040375247461e-10
C O 0 2.8291469789110124e-07
/ O 0 7.235502152980189e-08
G O 0 9.914272425248782e-08
polymorphism O 0 1.446176067787519e-08
in O 0 2.257486642065487e-09
the O 0 5.1279975821216794e-09
promotor O 0 1.5156168046814855e-05
region O 0 7.545691005361732e-08
, O 0 2.984296365582395e-09
142 O 0 9.980293924627404e-09
bp O 0 1.762192169962873e-08
upstream O 0 2.6715163414792187e-09
from O 0 5.232517752418175e-10
the O 0 1.6910300937311717e-10
transcriptional O 0 6.248377371065317e-10
initiation O 0 8.174655952153387e-10
site O 0 1.886823142172034e-09
( O 0 1.321388831687642e-10
- O 0 2.2315223002777884e-09
142C O 0 8.828047626252555e-09
/ O 0 2.812705979238217e-08
G O 0 7.250020672699975e-08
) O 0 2.1386532822464943e-10
, O 0 2.5201127296092807e-10
and O 0 2.780130292645566e-10
2 O 0 3.11049106471728e-08
) O 0 2.167779289408145e-10
a O 0 2.279244792902091e-09
6 O 0 2.5593912766908034e-08
bp O 0 6.2266916067699185e-09
deletion O 0 1.3162855250214989e-09
polymorphism O 0 2.041130819918635e-09
in O 0 5.307553285760491e-10
the O 0 1.668975735391598e-09
3 O 0 3.736193576742153e-08
noncoding O 0 1.2485121203553717e-07
part O 0 2.247532160382093e-09
of O 0 1.1066834559869676e-08
the O 0 4.5775290224980836e-09
CPO O 0 8.910502913295204e-08
gene O 0 2.390496689486099e-09
, O 0 8.561101827453399e-10
574 O 0 4.319123547702475e-08
bp O 0 2.0200440076223458e-07
downstream O 0 7.168631555032334e-08
of O 0 4.870405945212042e-08
the O 0 6.522705042755206e-09
last O 0 2.3617723332591822e-09
base O 0 2.3042476815504642e-09
of O 0 2.798187459518431e-09
the O 0 5.50680556710148e-10
normal O 0 1.209425271042619e-08
termination O 0 2.412832378340113e-09
codon O 0 2.136298027366479e-09
( O 0 6.648204764481136e-10
+ O 0 1.6127783553088193e-08
574 O 0 1.0398415639656378e-07
delATTCTT O 0 1.502204895587056e-06
) O 0 4.090066951789595e-08
. O 0 3.5964976063951326e-07

Five O 0 1.171099825114652e-06
intragenic O 0 1.665913987380918e-05
dimorphisms O 0 1.0947462214971893e-05
are O 0 5.692283866487458e-10
now O 0 4.044911350309377e-10
well O 0 1.0657282001336199e-10
characterized O 0 6.225477355847886e-10
and O 0 7.656413003598317e-11
the O 0 5.503812960938603e-10
high O 0 1.2372301405605413e-08
degree O 0 5.2785033233249123e-08
of O 0 9.448318794014199e-10
allelic O 0 4.949262333298066e-09
heterogeneity O 0 1.0974074982073034e-08
in O 0 3.0032654141365356e-09
HC B-Disease 1 0.9999529123306274
is O 0 7.2677810436516666e-09
demonstrated O 0 2.0020451962921015e-09
with O 0 2.3663557224828935e-11
seven O 0 4.309184953310563e-11
new O 0 8.808120031955635e-12
different O 0 4.959668960247132e-12
mutations O 0 2.8634490611967323e-11
making O 0 1.1000279853679018e-10
a O 0 1.322732895436829e-10
total O 0 1.483788508727102e-10
of O 0 2.831939838188191e-08
nineteen O 0 5.249221999292786e-07
CPO O 0 4.083869498572312e-06
gene B-Disease 0 3.111159116997442e-07
defects I-Disease 0 4.168517261859961e-05
reported O 0 3.7548748110793895e-08
so O 0 2.01525907073119e-09
far O 0 3.721490449137832e-09
. O 0 5.568509542364097e-10
. O 0 1.9539536211254926e-08

Coincidence O 0 1.3297851182869636e-05
of O 0 3.0629746561317006e-07
two O 0 1.7556492926118494e-09
novel O 0 1.91141813488116e-09
arylsulfatase O 0 3.2860228316167195e-08
A O 0 3.854305319350715e-09
alleles O 0 4.235555517428935e-10
and O 0 5.129628388722551e-10
mutation O 0 6.081403713942279e-10
459 O 0 1.699033447266629e-08
+ O 0 9.304151404876393e-08
1G O 0 2.2572610305360286e-06
> O 0 1.6992350992950378e-07
A O 0 2.7915678657564058e-08
within O 0 4.208981607689566e-09
a O 0 4.315917845332251e-09
family O 0 6.726135204360162e-10
with O 0 3.284504446199321e-09
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.8481665087222154e-09
molecular O 0 1.790512804689115e-08
basis O 0 1.0787855053706608e-08
of O 0 8.93471696628012e-09
phenotypic O 0 3.645526476248051e-06
heterogeneity O 0 1.3688768376596272e-05
. O 0 3.7995821458025603e-06

In O 0 3.672692798772914e-07
a O 0 6.947413311308992e-08
family O 0 1.358955059593825e-09
with O 0 3.492149625028418e-10
three O 0 2.494300321842502e-09
siblings O 0 9.033986003714745e-09
, O 0 7.256443362857468e-11
one O 0 9.820641695690302e-12
developed O 0 6.680618835908092e-10
classical O 0 0.00017287558875977993
late O 1 0.9938207268714905
infantile O 1 0.9999549388885498
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.383769684565777e-07
MLD B-Disease 1 0.9999992847442627
) O 0 4.7814423531633565e-09
, O 0 1.2238839941502988e-09
fatal O 0 2.613615208701958e-07
at O 0 1.667532529836535e-07
age O 0 1.3458782177622197e-07
5 O 0 2.450634184469891e-08
years O 0 1.7180081801626557e-09
, O 0 5.453349577466682e-11
with O 0 1.0233908859236251e-10
deficient O 0 4.823801873499178e-07
arylsulfatase O 0 6.29247051620041e-06
A O 0 9.504265108262189e-07
( O 0 1.8121051326147608e-09
ARSA O 0 3.3644977293079137e-07
) O 0 6.456353507378054e-11
activity O 0 1.9706482279335802e-10
and O 0 1.888192900645347e-11
increased O 0 3.2183586351486326e-10
galactosylsulfatide O 0 2.34163650247865e-07
( O 0 8.926233974193565e-09
GS O 0 0.0006745378486812115
) O 0 1.0308992770546865e-08
excretion O 0 1.6357880383566226e-07
. O 0 1.1646395137177024e-07

The O 0 2.0957470781013399e-07
two O 0 5.956813264873517e-09
other O 0 5.201541419808109e-10
siblings O 0 6.207694802640162e-09
, O 0 1.394853788028172e-09
apparently O 0 3.404926118832918e-08
healthy O 0 1.577769914717919e-08
at O 0 1.3347822687137523e-06
12 O 0 7.484585751171835e-08
( O 0 9.212600127206372e-10
1 O 0 7.634273657686208e-08
/ O 0 1.5962708488359567e-08
2 O 0 1.8773970822394404e-08
) O 0 4.5850219454468544e-11
and O 0 5.19465824522225e-11
15 O 0 7.17590264986967e-10
years O 0 1.9148838070748297e-10
, O 0 1.578983992167604e-11
respectively O 0 5.071268960321618e-10
, O 0 2.502728059516901e-11
and O 0 1.4434456234446724e-11
their O 0 4.0669568407425416e-11
father O 0 1.1464659444015979e-08
, O 0 6.015438702711151e-10
apparently O 0 5.047994466877981e-09
healthy O 0 2.6758598115073085e-10
as O 0 9.200338407788777e-11
well O 0 6.712624206484108e-11
, O 0 1.0551902407396341e-10
presented O 0 9.304929271536366e-09
ARSA O 0 7.656482921447605e-06
and O 0 2.261547393800356e-08
GS O 0 0.30480077862739563
values O 0 8.929434969218164e-09
within O 0 8.153540620448041e-10
the O 0 1.3143681976135468e-10
range O 0 6.401670304967411e-09
of O 0 1.6054860552117134e-08
MLD B-Disease 1 0.9999998807907104
patients O 0 7.46838509257941e-07
. O 0 1.7307627331319964e-07

Mutation O 0 2.327771220222985e-08
screening O 0 1.6869950769660136e-08
and O 0 5.975324124385395e-10
sequence O 0 5.190184393377706e-10
analysis O 0 5.242877798572465e-10
disclosed O 0 8.06168909406324e-09
the O 0 5.81740045024759e-10
involvement O 0 9.402768341715273e-09
of O 0 3.961052819079214e-09
three O 0 1.9007867502196518e-10
different O 0 5.416417314663136e-10
ARSA O 0 4.510184680839302e-06
mutations O 0 2.5154751615019677e-09
being O 0 7.666074997025873e-10
the O 0 2.539510268739775e-10
molecular O 0 6.568473320811563e-09
basis O 0 6.457395063108606e-09
of O 0 1.6145820680435463e-08
intrafamilial O 0 1.0823293905559694e-06
phenotypic O 0 6.873063284729142e-06
heterogeneity O 0 1.4031516002432909e-05
. O 0 1.953944547494757e-06

The O 0 1.0710952835779608e-07
late O 0 6.615287566091865e-05
infantile O 0 0.0007467103423550725
patient O 0 3.6103299407841405e-06
inherited O 0 0.026244137436151505
from O 0 5.165204584045568e-07
his O 0 1.582715185577399e-07
mother O 0 2.1320371246247305e-08
the O 0 3.4424465500393353e-09
frequent O 0 4.208933201965692e-09
0 O 0 7.55317497436181e-09
- O 0 3.576452245468431e-09
type O 0 1.1644268660404578e-08
mutation O 0 2.6511106643312132e-09
459 O 0 4.466923542167933e-08
+ O 0 4.076787973872342e-08
1G O 0 7.584793593196082e-07
> O 0 4.370644646201072e-08
A O 0 1.364802937331433e-08
, O 0 4.445704360200864e-10
and O 0 2.838621004919162e-10
from O 0 1.7450194622625759e-09
his O 0 4.1031298358973345e-09
father O 0 2.87714012614515e-08
a O 0 2.5842142314935757e-10
novel O 0 9.240894160988944e-11
, O 0 1.3124160612443259e-11
single O 0 9.090897479246962e-11
basepair O 0 5.7991929480749604e-08
microdeletion O 0 2.1618278367441235e-07
of O 0 5.8763777843751086e-08
guanine O 0 2.862787162882796e-08
at O 0 1.0626160928950412e-07
nucleotide O 0 7.186891526345107e-09
7 O 0 3.300494810787313e-08
in O 0 3.6055751717611884e-09
exon O 0 2.4302747192450624e-07
1 O 0 3.910974442078441e-07
( O 0 3.981397878050075e-09
7delG O 0 1.6246751499693346e-07
) O 0 1.1516688935842012e-08
. O 0 8.514552263250152e-08

The O 0 3.559651986506651e-07
two O 0 4.351512927769363e-08
clinically O 0 4.938401616527699e-05
unaffected O 0 6.78245157814672e-07
siblings O 0 2.2447142811188314e-08
carried O 0 7.164524529201799e-10
the O 0 2.332693760376259e-10
maternal O 0 5.2019308860451474e-09
mutation O 0 4.707005341053616e-10
459 O 0 6.512834715977078e-09
+ O 0 4.725595204035926e-08
1G O 0 1.2341942010607454e-06
> O 0 5.3397265276089456e-08
A O 0 9.552699076209592e-09
and O 0 2.773811180745156e-10
, O 0 9.407638557057396e-11
on O 0 7.540332247479853e-10
their O 0 3.006448909270709e-11
paternal O 0 2.3059083809062741e-10
allele O 0 2.5797081137923783e-10
, O 0 1.2809416027881326e-10
a O 0 1.5960621713162482e-10
novel O 0 3.2702879293466935e-10
cytosine O 0 1.416522232844386e-09
to O 0 6.770567440028685e-10
thymidine O 0 3.500076104501204e-07
transition O 0 2.5704239305923693e-06
at O 0 1.9811723177554086e-06
nucleotide O 0 2.5937038117263e-07
2435 O 0 8.469089152640663e-06
in O 0 1.57156492264221e-08
exon O 0 5.367259632294008e-07
8 O 0 3.723324226712066e-08
, O 0 2.7310834149751884e-10
resulting O 0 3.3053298986729374e-10
in O 0 8.140234319942152e-11
substitution O 0 1.193996901349692e-09
of O 0 3.9808356611104045e-09
alanine O 0 1.4072914389373636e-08
464 O 0 2.6749386705660072e-08
by O 0 3.840538997934573e-09
valine O 0 5.056640020484338e-06
( O 0 5.087317234142574e-08
A464V O 0 1.2185086006866186e-06
) O 0 3.7487779991352e-08
. O 0 1.4083056498748192e-07

The O 0 2.6642821921996074e-06
fathers O 0 1.2074888218194246e-06
genotype O 0 2.5210849230461463e-07
thus O 0 1.1207334438267935e-07
was O 0 5.308136223902693e-07
7delG O 0 2.5944730168703245e-06
/ O 0 2.7800460884463973e-06
A464V O 0 1.1469598575786222e-05
. O 0 8.662833010930626e-07

Mutation O 0 1.2967797147211968e-07
A464V O 0 1.0755948096630163e-06
was O 0 6.443863753702317e-08
not O 0 2.3868643173052817e-10
found O 0 1.427261225872556e-10
in O 0 1.0602903971479449e-10
18 O 0 2.022495415587855e-08
unrelated O 0 1.1606051657508942e-06
MLD B-Disease 1 1.0
patients O 0 3.49733340954117e-07
and O 0 8.568604492609211e-09
50 O 0 3.714245266905891e-08
controls O 0 3.353882220835658e-06
. O 0 4.1881071410898585e-07

A464V O 0 1.6561041775275953e-05
, O 0 3.82240976648518e-08
although O 0 1.0221726576276069e-08
clearly O 0 3.062127262865033e-08
modifying O 0 4.828698934034037e-07
ARSA O 0 0.0025455127470195293
and O 0 7.425447279274522e-07
GS O 1 0.9999938011169434
levels O 0 8.66451136971591e-06
, O 0 7.273106117366979e-09
apparently O 0 2.1109633152605056e-08
bears O 0 3.3258718001860643e-09
little O 0 3.6890782095788666e-10
significance O 0 1.0069507450083393e-09
for O 0 1.837417301642219e-10
clinical O 0 4.127637609485646e-08
manifestation O 0 3.9670433693572704e-07
of O 0 9.022466656460892e-06
MLD B-Disease 1 1.0
, O 0 1.9599637823830562e-07
mimicking O 0 2.873874791475828e-07
the O 0 1.9158610697900258e-08
frequent O 0 5.214828391331139e-08
ARSA O 0 4.00844837713521e-05
pseudodeficiency O 0 1.5647294276277535e-05
allele O 0 1.5506440149692935e-06
. O 0 1.2605001984411501e-06

Our O 0 7.448725369840759e-08
results O 0 7.254098211006976e-09
demonstrate O 0 2.4871458226272125e-09
that O 0 2.007147399674114e-11
in O 0 3.643434859368355e-11
certain O 0 9.007256746018655e-11
genetic O 0 4.141546661173834e-09
conditions O 0 6.079727654650924e-07
MLD B-Disease 1 1.0
- O 0 0.0006084373453631997
like O 0 2.1199133470872766e-07
ARSA O 0 0.0013999436050653458
and O 0 1.296650964377477e-07
GS O 1 0.9999914169311523
values O 0 9.800132261261751e-08
need O 0 1.190758269764558e-09
not O 0 2.1381873702153165e-11
be O 0 1.0925520904647712e-11
paralleled O 0 7.895054748852104e-11
by O 0 1.2377096743343419e-11
clinical O 0 2.0335471617727308e-07
disease O 0 8.882790325515089e-07
, O 0 1.6582372974749404e-10
a O 0 3.200532894265251e-10
finding O 0 8.428358011514092e-10
with O 0 8.243418447850814e-11
serious O 0 2.986655189829435e-08
diagnostic O 0 1.571118986021247e-07
and O 0 7.429212356413473e-09
prognostic O 0 0.00027282669907435775
implications O 0 7.728927812422626e-06
. O 0 1.957290351128904e-06

Moreover O 0 2.050107696049963e-06
, O 0 1.6893649146254575e-08
further O 0 8.784728500188521e-09
ARSA O 0 7.295718205568846e-06
alleles O 0 1.527451942706648e-08
functionally O 0 1.2394875170684827e-07
similar O 0 9.580246596030406e-10
to O 0 2.953512434622496e-10
A464V O 0 3.830123773695959e-08
might O 0 4.920870932956234e-10
exist O 0 3.1821018042776927e-10
which O 0 1.9112047014435696e-11
, O 0 1.634306752429371e-11
together O 0 2.5337948753034745e-11
with O 0 3.9699740023158014e-11
0 O 0 1.098297452983843e-08
- O 0 2.348305772059689e-09
type O 0 9.454813820752861e-09
mutations O 0 4.257133756624398e-09
, O 0 1.8711616700528566e-09
may O 0 1.8563177661690133e-08
cause O 0 2.3798168058419833e-07
pathological O 0 0.3808494806289673
ARSA O 1 0.7112396359443665
and O 0 1.7021072835632367e-06
GS O 1 0.9999895095825195
levels O 0 4.555275154416449e-06
, O 0 8.371162096842966e-10
but O 0 3.9331184142898934e-11
not O 0 1.883628322763009e-11
clinical O 0 1.934591153940346e-09
outbreak O 0 8.223635661330775e-10
of O 0 1.2729874931949325e-09
the O 0 6.25731289005671e-09
disease O 0 5.115983867653995e-07
. O 0 2.3284094652353815e-09
. O 0 4.3270887317703455e-08

Human O 0 0.0012918332358822227
MLH1 O 1 0.9999967813491821
deficiency O 1 0.9999961853027344
predisposes O 0 6.69779401505366e-05
to O 0 3.8840042293486476e-07
hematological B-Disease 1 0.9999865293502808
malignancy I-Disease 1 0.9999864101409912
and O 0 1.2322653901719605e-06
neurofibromatosis B-Disease 1 0.9999916553497314
type I-Disease 1 0.9876612424850464
1 I-Disease 0 0.48316919803619385
. O 0 1.7775893184079905e-06

Heterozygous O 0 5.608312221738743e-06
germ O 0 0.0021146307699382305
- O 0 1.4400978898265748e-06
line O 0 2.8678153185524025e-08
mutations O 0 4.91589879914045e-10
in O 0 2.7819854059307758e-11
the O 0 1.3013269628547874e-10
DNA O 0 2.160631851211292e-08
mismatch O 0 2.1042369553470053e-05
repair O 0 0.0001304055767832324
genes O 0 7.566920601220772e-08
lead O 0 1.4766379763386794e-07
to O 0 6.161385357472682e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.7867510318756104

The O 0 2.524573403661634e-07
disease O 0 1.9964325474575162e-05
susceptibility O 0 7.00870316450164e-07
of O 0 1.4063394360164239e-07
individuals O 0 1.0505397662896598e-09
who O 0 1.3935727238845175e-08
constitutionally O 0 2.367118270285573e-07
lack O 0 5.83489701000417e-08
both O 0 2.5146644766493864e-09
wild O 0 1.0906605618643539e-09
- O 0 7.637849241959316e-10
type O 0 1.4018148863925717e-09
alleles O 0 3.4121652725538354e-10
is O 0 5.023250149172043e-10
unknown O 0 9.042643256407246e-08
. O 0 6.241831584929969e-08

We O 0 1.3122559039402404e-07
have O 0 4.780454920805255e-10
identified O 0 6.634802152127861e-10
three O 0 3.647711299681333e-11
offspring O 0 5.5112369529153327e-11
in O 0 3.842491255734437e-11
a O 0 2.4245687679780303e-09
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.02101605013012886
who O 0 1.0473436873326136e-07
developed O 0 9.293309631175362e-06
hematological B-Disease 1 0.9997890591621399
malignancy I-Disease 1 0.9998123049736023
at O 0 5.2741375839104876e-05
a O 0 6.2789768939808255e-09
very O 0 2.4370580553600973e-10
early O 0 2.326589365608811e-09
age O 0 9.2232594894881e-09
, O 0 1.1397581489713815e-10
and O 0 6.456944701138667e-11
at O 0 1.1505492558683272e-08
least O 0 4.237007966700901e-11
two O 0 2.4728488354219813e-11
of O 0 1.7393629592188375e-10
them O 0 1.8747284974418577e-11
displayed O 0 4.05528011171441e-09
signs O 0 1.1525039589344033e-08
of O 0 1.1311122705137677e-07
neurofibromatosis B-Disease 0 0.05485910922288895
type I-Disease 0 0.0017400940414518118
1 I-Disease 0 0.00651285657659173
( O 0 1.3069180226921162e-07
NF1 B-Disease 0 4.3556148739298806e-05
) O 0 1.6923586088068987e-07
. O 0 6.807788963669736e-07

DNA O 0 1.71279701532967e-08
sequence O 0 2.4195101477886283e-09
analysis O 0 1.2431999873996347e-09
and O 0 3.8432538401744765e-11
allele O 0 2.2709162328382604e-10
- O 0 1.2956725969903715e-10
specific O 0 3.060972308954746e-11
amplification O 0 4.3792200976611184e-09
in O 0 1.023010787193357e-09
two O 0 1.1163799884528203e-09
siblings O 0 1.3733759018919045e-08
revealed O 0 4.25984119090117e-08
a O 0 9.254397248525947e-09
homozygous O 0 1.0784604320690505e-08
MLH1 O 0 7.886900675657671e-06
mutation O 0 7.566094417654767e-09
( O 0 2.306001833929372e-09
C676T O 0 1.1317575143721115e-07
- O 0 1.0150002083264553e-07
- O 0 9.540301704191734e-08
> O 0 2.3697603879213602e-08
Arg226Stop O 0 4.3216863332418143e-07
) O 0 4.7768753397292585e-09
. O 0 2.761045614363411e-08

Thus O 0 9.946032832885976e-07
, O 0 2.4608027615613537e-08
a O 0 3.368686662952314e-08
homozygous O 0 4.5812697635483346e-07
germ O 0 0.0018311369931325316
- O 0 9.814920304052066e-06
line O 0 1.379910941068374e-06
MLH1 O 0 0.0001796774595277384
mutation O 0 2.4520929287064064e-08
and O 0 4.2019392409997636e-09
consequent O 0 3.5195855161873624e-05
mismatch O 1 0.9999991655349731
repair O 1 0.9999995231628418
deficiency O 1 0.9999912977218628
results O 0 2.9884932928325725e-07
in O 0 1.5850423196184238e-08
a O 0 4.200480407945406e-09
mutator O 0 1.1294022215224686e-06
phenotype O 0 4.4225161310862404e-09
characterized O 0 1.2014120809311635e-09
by O 0 2.3328225462471153e-10
leukemia B-Disease 1 0.9996082186698914
and O 0 3.117633866622782e-07
/ O 1 0.9999641180038452
or O 0 0.40616706013679504
lymphoma B-Disease 1 1.0
associated O 1 0.6122820973396301
with O 0 4.4993447545493837e-07
neurofibromatosis B-Disease 1 0.9999998807907104
type I-Disease 1 0.9998546838760376
1 I-Disease 0 0.3883039057254791
. O 0 7.761346410006809e-08
. O 0 1.5859063751122449e-07

Missense O 0 5.6389955716440454e-05
mutations O 0 2.640434502154676e-07
in O 0 1.0146727014159751e-08
the O 0 3.0873903433814576e-09
most O 0 2.0782456311430053e-10
ancient O 0 5.106407741095609e-09
residues O 0 3.3139880173393976e-08
of O 0 1.9888583224769718e-08
the O 0 1.024686824280252e-08
PAX6 O 0 8.484060344926547e-06
paired O 0 1.3594799952443282e-07
domain O 0 7.062298550408741e-07
underlie O 0 1.7660636331129353e-06
a O 0 3.433227035998243e-09
spectrum O 0 8.704537890480424e-07
of O 0 4.2802878397196764e-07
human O 1 0.9998655319213867
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9874217510223389

Mutations O 0 2.1406148675851e-07
of O 0 3.6326223806781854e-08
the O 0 3.297900619259053e-09
human O 0 1.909178237724518e-08
PAX6 O 0 7.659792754566297e-05
gene O 0 4.691665708378423e-06
underlie O 1 0.9998037219047546
aniridia B-Disease 1 1.0
( O 0 0.2796991765499115
congenital B-Disease 1 1.0
absence I-Disease 1 0.9912848472595215
of I-Disease 0 0.0030601494945585728
the I-Disease 0 2.1610095757296222e-07
iris I-Disease 0 8.646985065752233e-07
) O 0 1.7370430649421564e-09
, O 0 3.9415312680368686e-10
a O 0 8.949516683287584e-10
rare O 0 7.932908374641556e-08
dominant O 1 0.9999794960021973
malformation B-Disease 1 1.0
of I-Disease 1 0.9999666213989258
the I-Disease 1 0.9783621430397034
eye I-Disease 1 0.9999990463256836
. O 0 3.939717498724349e-05

The O 0 1.0797987215482863e-07
spectrum O 0 1.8150432197217015e-06
of O 0 1.1203700722717258e-07
PAX6 O 0 2.864219823095482e-05
mutations O 0 7.551421532525637e-08
in O 0 2.5193992669869658e-08
aniridia B-Disease 1 1.0
patients O 0 9.127761302352155e-08
is O 0 4.537038245100433e-10
highly O 0 1.7783885475353145e-09
biased O 0 9.30265309229128e-10
, O 0 2.8713463898211167e-11
with O 0 9.906314483998369e-12
92 O 0 1.2476284894091805e-08
% O 0 2.720902947395132e-10
of O 0 2.75770206670245e-09
all O 0 8.745465462922652e-11
reported O 0 8.990184152679603e-10
mutations O 0 4.591499958017664e-10
leading O 0 1.6563224125576426e-09
to O 0 1.9000544193570335e-10
premature O 0 1.732970211776319e-08
truncation O 0 3.2138541428139433e-07
of O 0 2.9486335506589967e-07
the O 0 1.0495273272681516e-07
protein O 0 1.1903392760359566e-07
( O 0 2.253971453924919e-09
nonsense O 0 2.3634724399812512e-08
, O 0 2.805261301030981e-10
splicing O 0 2.104718621609436e-09
, O 0 1.5072411374550398e-10
insertions O 0 9.870056993932508e-10
and O 0 1.290919177110439e-10
deletions O 0 1.0211237411184015e-09
) O 0 5.635353295119216e-10
and O 0 1.4262986347546303e-09
just O 0 1.4711230456043722e-08
2 O 0 5.395985880340959e-08
% O 0 4.234069206354718e-10
leading O 0 1.247456471453745e-09
to O 0 4.464600564246801e-11
substitution O 0 2.4146464827623504e-09
of O 0 1.0493268476352569e-08
one O 0 3.469291798285923e-10
amino O 0 4.375477757889712e-10
acid O 0 3.6587222140838094e-10
by O 0 3.779456955732563e-11
another O 0 1.4081605881344217e-09
( O 0 1.8072727758777773e-09
missense O 0 1.455016587215141e-07
) O 0 1.3773317597554069e-08
. O 0 3.2816637940413784e-07

The O 0 1.0319482157683524e-07
extraordinary O 0 6.707666955207969e-08
conservation O 0 8.2315807503619e-09
of O 0 1.6930163937445286e-08
the O 0 2.61030912440674e-08
PAX6 O 0 3.440674117882736e-05
protein O 0 2.4517473207197327e-07
at O 0 1.9953638741299073e-07
the O 0 5.244760625799927e-09
amino O 0 2.3661877790459585e-08
acid O 0 6.521911188883678e-08
level O 0 3.7020524246145214e-07
amongst O 0 5.657026491689976e-08
vertebrates O 0 2.1302774655396206e-07
predicts O 0 3.6662566316181255e-08
that O 0 4.936381858833272e-10
pathological O 0 3.168993134750053e-05
missense O 0 1.4266170182963833e-06
mutations O 0 2.680066124582936e-08
should O 0 3.1174622883156644e-09
in O 0 1.1990404225059592e-09
fact O 0 9.352788543637303e-10
be O 0 1.7225845749813118e-10
common O 0 5.097180455493344e-10
even O 0 1.2153067441289522e-10
though O 0 9.38043948073286e-11
they O 0 1.0897071439641692e-11
are O 0 5.733980564665009e-12
hardly O 0 3.669933246186474e-10
ever O 0 1.1290996609902848e-10
seen O 0 5.684417936357988e-10
in O 0 2.4342068360994062e-09
aniridia B-Disease 1 0.9999939203262329
patients O 0 5.625435051115346e-07
. O 0 1.8044394778371498e-07

This O 0 1.743091004868802e-08
indicates O 0 2.0652237253671046e-08
that O 0 1.2666437343433756e-10
there O 0 6.795054102726183e-11
is O 0 1.540090277529771e-11
a O 0 4.638272405044219e-11
heavy O 0 4.4091937212442645e-08
ascertainment O 0 4.821355105377734e-06
bias O 0 1.02841886118199e-08
in O 0 4.7811095360561495e-11
the O 0 2.119444550419125e-11
selection O 0 8.347465774161122e-11
of O 0 2.204824933738081e-10
patients O 0 7.991258349493435e-11
for O 0 1.9579621257648228e-10
PAX6 O 0 8.93700246251683e-07
mutation O 0 1.2252807657375797e-09
analysis O 0 2.322815939592715e-09
and O 0 6.605038738172198e-11
that O 0 1.731170588825659e-11
the O 0 1.468966170925512e-09
missing O 0 4.953288339493156e-07
PAX6 O 0 0.00045294518349692225
missense O 0 1.5898125639068894e-05
mutations O 0 7.670542458981799e-07
frequently O 0 4.598778957642935e-08
may O 0 4.5078699884015805e-08
underlie O 0 1.6743496189519647e-06
phenotypes O 0 1.3372856244586728e-07
distinct O 0 2.204271964956206e-08
from O 0 7.329035156544705e-08
textbook O 0 1.581730793986935e-05
aniridia B-Disease 1 0.9999983310699463
. O 0 2.8157978704257403e-06

Here O 0 1.6817974710647832e-06
we O 0 2.329876735984726e-08
present O 0 6.654208739576006e-09
four O 0 1.4766350364681102e-09
novel O 0 3.3884428596309135e-09
PAX6 O 0 3.793564701481955e-06
missense O 0 9.376030334351526e-07
mutations O 0 3.06530019145157e-08
, O 0 1.7112155026310916e-09
two O 0 3.1080088502832837e-10
in O 0 1.2522768377820626e-09
association O 0 1.3505701002003434e-09
with O 0 4.457727242890286e-10
atypical O 0 1.8916184671979863e-06
phenotypes O 0 7.865243674132216e-07
ectopia B-Disease 0 1.0474516784597654e-05
pupillae I-Disease 0 6.820124326623045e-06
( O 0 6.732835400313775e-10
displaced B-Disease 0 7.224669751337842e-10
pupils I-Disease 0 2.4953474841993284e-09
) O 0 9.55014400894072e-10
and O 0 5.985801010410796e-08
congenital B-Disease 1 1.0
nystagmus I-Disease 0 0.021814512088894844
( O 0 7.194410045485711e-08
searching B-Disease 0 4.5791250613547163e-07
gaze I-Disease 0 3.094808562309481e-06
) O 0 6.359449633563941e-10
, O 0 4.182155455279002e-10
and O 0 1.7497980842051675e-10
two O 0 2.0067886241648125e-10
in O 0 7.878421803830804e-10
association O 0 5.455662033249098e-10
with O 0 8.953439378789341e-11
more O 0 4.0938560874614893e-10
recognizable O 0 6.275171813285851e-07
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 9.590393347025383e-06
. O 0 1.3555537634601933e-06

Strikingly O 0 2.190422264902736e-06
, O 0 4.271440978698138e-09
all O 0 3.114702940010261e-10
four O 0 1.7596510359929596e-10
mutations O 0 3.870154544061144e-11
are O 0 1.236619574102038e-11
located O 0 3.5498504136199927e-10
within O 0 8.038745225036337e-10
the O 0 1.8464154649677766e-09
PAX6 O 0 1.3133404763721046e-06
paired O 0 3.044829810505689e-08
domain O 0 3.275103566124926e-08
and O 0 2.8017870246088705e-09
affect O 0 4.441841117142076e-09
amino O 0 9.223946051406529e-09
acids O 0 3.228899148055575e-09
which O 0 5.871651775901654e-11
are O 0 9.965689731772365e-12
highly O 0 1.3876723381489597e-10
conserved O 0 1.1372961461475484e-09
in O 0 2.761527395644947e-10
all O 0 1.8740965723740288e-10
known O 0 9.638420062074715e-10
paired O 0 4.818585086496796e-09
domain O 0 3.582147911629363e-08
proteins O 0 3.521772029557724e-08
. O 0 9.272157086570587e-08

Our O 0 1.6166535488082445e-07
results O 0 8.444195565004975e-09
support O 0 2.003859966848154e-09
the O 0 9.454881322312758e-10
hypothesis O 0 3.2610567024526915e-10
that O 0 1.4552212516602547e-12
the O 0 6.386111691542018e-12
under O 0 6.099557664507316e-11
- O 0 1.2847244101887867e-10
representation O 0 2.1487608914405598e-10
of O 0 5.9584150946534464e-09
missense O 0 9.07310280240381e-08
mutations O 0 2.727097658805633e-09
is O 0 5.869840724592734e-10
caused O 0 2.2039179370381135e-09
by O 0 4.0066416850947917e-10
ascertainment O 0 9.027556370710954e-05
bias O 0 6.211190566318692e-07
and O 0 4.767543027028864e-10
suggest O 0 4.508880491194134e-10
that O 0 6.368607897988543e-12
a O 0 4.320295163284804e-11
substantial O 0 4.640504647213106e-10
burden O 0 6.327634594072151e-08
of O 0 4.825246264772431e-07
PAX6 B-Disease 1 0.5308501720428467
- I-Disease 0 0.00011537170939845964
related I-Disease 0 0.003990310709923506
disease I-Disease 1 0.9585063457489014
remains O 0 3.9128323692239064e-07
to O 0 3.5800745701308756e-10
be O 0 1.181527764515522e-09
uncovered O 0 7.7565516676259e-08
. O 0 1.3180793123623857e-09
. O 0 2.4494564598853685e-08

The O 0 7.021642289828378e-08
chromosomal O 0 2.3667264485993655e-06
order O 0 3.350558941406234e-08
of O 0 1.2029620677367348e-07
genes O 0 8.322866307253207e-08
controlling O 0 5.483508630277356e-06
the O 0 7.403838253594586e-08
major O 0 1.1513261597428937e-06
histocompatibility O 0 0.010539284907281399
complex O 0 9.54678762354888e-05
, O 0 7.724834993894092e-09
properdin O 0 2.1204672862040752e-07
factor O 0 3.06105860659045e-08
B O 0 9.994830634241225e-07
, O 0 2.8453550626750257e-09
and O 0 7.742949392763876e-09
deficiency B-Disease 0 0.0011852539610117674
of I-Disease 0 5.789947863377165e-06
the I-Disease 0 1.626247012609383e-07
second I-Disease 0 1.602989954108125e-07
component I-Disease 0 9.207300877278612e-07
of I-Disease 0 2.82212994306974e-07
complement I-Disease 0 1.2221535143908113e-06
. O 0 1.0033394346464775e-06

The O 0 3.0584007504330657e-07
relationship O 0 1.0008893269741748e-07
of O 0 1.542841410184792e-08
the O 0 7.276931834887534e-10
genes O 0 2.7856186801678007e-10
coding O 0 1.6462195162603166e-08
for O 0 4.1996933708432493e-10
HLA O 0 1.5192668456620595e-08
to O 0 1.8801257772871338e-10
those O 0 1.1085477674699362e-10
coding O 0 1.525236292820864e-08
for O 0 4.833365929712841e-10
properdin O 0 5.856561102746127e-08
Factor O 0 4.36624247868167e-09
B O 0 9.704060488502364e-08
allotypes O 0 4.9226592579998396e-08
and O 0 3.168571516276586e-10
for O 0 6.679217179339503e-10
deficiency B-Disease 0 5.007572690374218e-05
of I-Disease 0 9.536719517200254e-06
the I-Disease 0 8.442057009006021e-08
second I-Disease 0 1.785605263648904e-08
component I-Disease 0 5.827767779464921e-08
of I-Disease 0 1.0136691486195559e-07
complement I-Disease 0 2.2625656015407003e-08
( O 0 4.056734503876669e-09
C2 O 0 4.5926256575512525e-08
) O 0 9.304707004886836e-11
was O 0 2.5751769605619756e-09
studied O 0 1.9676942741853054e-08
in O 0 5.5790320280246775e-11
families O 0 2.025019475021539e-12
of O 0 2.330696746710714e-10
patients O 0 1.0953805640312453e-09
with O 0 5.174490169679302e-09
connective O 1 0.9999996423721313
tissue O 1 1.0
disorders O 1 1.0
. O 1 0.9650409817695618

Patients O 0 5.578879722634156e-07
were O 0 5.356790566679592e-09
selected O 0 5.827405780145511e-10
because O 0 4.957864674359769e-11
they O 0 4.683036944341801e-12
were O 0 7.306845406507279e-11
heterozygous O 0 1.3803654053123893e-10
or O 0 1.3441549262527275e-10
homozygous O 0 1.419901618504582e-08
for O 0 3.0838467068861064e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0003033855464309454

12 O 0 2.1761386506113922e-06
families O 0 1.1259173593458627e-09
with O 0 6.489555559596738e-10
15 O 0 1.8305280846675487e-08
matings O 0 2.530655081045552e-07
informative O 0 1.41328243330463e-07
for O 0 4.5837171569473867e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.8214816464023897e-06
found O 0 3.432619877230536e-08
. O 0 1.9809570872553195e-08

Of O 0 4.414753675519023e-06
57 O 0 1.8484090560377808e-06
informative O 0 1.4972319206663087e-07
meioses O 0 9.590233958078898e-07
, O 0 1.009054173550794e-09
two O 0 1.0905393255100648e-10
crossovers O 0 6.421404519230123e-10
were O 0 3.558432437600345e-10
noted O 0 1.944512995066816e-09
between O 0 4.842302914198626e-08
the O 0 1.0888112456086674e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.3506462554223617e-08
and O 0 2.041691482546071e-09
the O 0 1.8692138947784542e-09
HLA O 0 1.7164147436687927e-07
- O 0 4.0691946878723684e-07
B O 0 7.614784749421233e-07
gene O 0 5.767341604290266e-10
, O 0 9.346826784772944e-11
with O 0 2.7075036657109308e-11
a O 0 2.303095075761874e-10
recombinant O 0 6.015794529190543e-10
fraction O 0 4.656625751664478e-09
of O 0 4.7265508840155235e-08
0 O 0 3.6318331808615767e-07
. O 0 1.6428357696440798e-07

035 O 0 0.013814209029078484
. O 0 7.726302283117548e-05

A O 0 3.263878170400858e-06
lod O 0 4.4713684474118054e-05
score O 0 3.03848622706937e-07
of O 0 9.05507064885569e-08
13 O 0 1.577011765618863e-08
was O 0 2.6993851598433594e-09
calculated O 0 1.8761148190549193e-09
for O 0 3.9264344553480157e-10
linkage O 0 1.9544420410966268e-06
between O 1 0.7663981318473816
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.745637506355706e-07
HLA O 0 4.339674887887668e-06
- O 0 1.634488967283687e-06
B O 0 4.794719643541612e-06
at O 0 7.854572459109477e-08
a O 0 1.3057425973794778e-10
maximum O 0 3.4234301504731945e-10
likelihood O 0 1.1931743093551717e-10
value O 0 2.171627877523008e-10
of O 0 1.018979275957399e-10
the O 0 2.0864901820183412e-11
recombinant O 0 7.300701709844759e-11
fraction O 0 4.430044664438526e-10
of O 0 2.8413635888568933e-09
0 O 0 6.126616369783733e-08
. O 0 3.648496260666434e-08

04 O 0 0.005987712647765875
. O 0 9.13538970053196e-05

18 O 0 2.0963077531632734e-06
families O 0 3.3722211689735104e-09
with O 0 2.556794331809442e-09
21 O 0 3.713295981810916e-08
informative O 0 5.116351786682571e-09
matings O 0 1.7517832517910392e-08
for O 0 1.0761339597209485e-09
both O 0 9.565492842256162e-10
properdin O 0 2.0808525391657895e-07
Factor O 0 2.5724192553866487e-08
B O 0 1.9458650513115572e-07
allotype O 0 6.990639178638958e-08
and O 0 9.733563954839042e-10
HLA O 0 1.1239679764685206e-07
- O 0 4.7401064762198075e-07
B O 0 4.9588784349907655e-06
were O 0 5.9474469793485696e-09
found O 0 2.875920612765981e-09
. O 0 1.4526340130771587e-08

Of O 0 5.964403499092441e-06
72 O 0 4.77469666293473e-06
informative O 0 3.2197442578763e-07
meioses O 0 2.672078835530556e-06
, O 0 3.747517851593329e-09
three O 0 5.313681716856422e-10
recombinants O 0 1.0607692502162536e-07
were O 0 2.3315605002238726e-09
found O 0 3.582499574772413e-10
, O 0 3.844162835275888e-11
giving O 0 4.974753942121879e-11
a O 0 9.902220710067411e-11
recombinant O 0 7.511393174119974e-10
fraction O 0 5.603405295317998e-09
of O 0 6.110302308570681e-08
0 O 0 6.075241572034429e-07
. O 0 1.8777666355163092e-07

042 O 0 0.0029860450886189938
. O 0 4.404988430906087e-05

A O 0 2.0899958599329693e-06
lod O 0 4.03285666834563e-05
score O 0 3.471126035492489e-07
of O 0 1.004116967351365e-07
16 O 0 6.381338835126371e-08
between O 0 3.066294596010266e-08
HLA O 0 2.1687351647869946e-07
- O 0 1.255173742720217e-07
B O 0 1.281754862247908e-07
and O 0 3.3359720541525917e-10
Factor O 0 3.030933504177824e-09
B O 0 8.665280404329678e-08
allotypes O 0 9.514715060277013e-08
was O 0 2.764818951561665e-08
calculated O 0 1.1366375396448802e-08
at O 0 1.0098170299954745e-08
a O 0 3.1328872829305965e-10
maximum O 0 2.992719405625621e-10
likelihood O 0 1.7603594970605485e-10
value O 0 2.9581465055272815e-10
of O 0 4.6032500033987844e-10
the O 0 7.714255623181288e-11
recombinant O 0 1.6168794081394822e-10
fraction O 0 1.5378961437662042e-09
of O 0 6.0375344723695434e-09
0 O 0 7.845050475907556e-08
. O 0 9.039694504053841e-08

04 O 0 0.004409796558320522
. O 0 7.192354678409174e-05

A O 0 1.1166978310939157e-06
crossover O 0 1.8337645713017992e-07
was O 0 9.166824810336038e-08
shown O 0 2.5012560911363835e-09
to O 0 1.033715751885822e-10
have O 0 2.0257389515832003e-11
occurred O 0 1.370507263231957e-09
between O 0 5.195936736424045e-11
genes O 0 2.8191615708550444e-12
for O 0 1.2405883612065516e-11
Factor O 0 2.492030748424412e-10
B O 0 1.6006733716267263e-08
and O 0 5.063304775454469e-10
HLA O 0 6.2562655500642e-08
- O 0 2.903832694300945e-07
D O 0 1.7653665054240264e-06
, O 0 1.17127807452988e-09
in O 0 3.200404663505907e-10
which O 0 1.182194342419507e-10
HLA O 0 6.079623204868767e-08
- O 0 7.157556751735683e-07
D O 0 3.5761654544330668e-06
segregared O 0 1.109746222027752e-06
with O 0 4.184320001598962e-09
HLA O 0 5.16073714607046e-06
- O 0 2.7110120299767004e-06
A O 0 4.85112195747206e-07
and O 0 1.4476442267152834e-08
B O 0 6.880092405481264e-05
. O 0 2.495956152870349e-07

These O 0 2.9591074035550946e-09
studies O 0 3.4207947585684906e-09
suggest O 0 4.3995956877651565e-10
that O 0 3.3009918583293274e-12
the O 0 8.856147586111529e-12
genes O 0 6.840029410926096e-12
for O 0 2.8812433341962596e-11
Factor O 0 2.992743830532163e-09
B O 0 6.572425718331942e-06
and O 0 6.405232966244512e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.6269683378311584e-09
located O 0 1.5904318972914666e-09
outside O 0 1.2964593842923477e-09
those O 0 2.892150754996159e-11
for O 0 1.9580892463011423e-10
HLA O 0 2.5211923215806564e-08
, O 0 3.2038066644091145e-10
that O 0 1.0229473518252874e-11
the O 0 4.169839473711079e-11
order O 0 5.986991458151181e-11
of O 0 9.49407774619715e-10
genese O 0 3.925000768845166e-08
is O 0 4.448622026309579e-10
HLA O 0 2.251557695842621e-08
- O 0 4.755179006110666e-08
A O 0 2.8129152340738983e-08
, O 0 5.339781949942335e-10
- O 0 2.0996666627581817e-09
B O 0 3.765956080314936e-08
, O 0 3.453941022080187e-10
- O 0 1.9883794610819905e-09
D O 0 1.62762709976505e-08
, O 0 8.351096203451647e-11
Factor O 0 1.3846114255144926e-09
B O 0 1.4784966424485901e-06
allotype O 0 4.1212198993889615e-05
, O 0 7.672564606764354e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 6.832373333764963e-09
that O 0 6.534178753625497e-11
the O 0 4.5185569175210105e-10
genes O 0 1.2880423394534546e-09
coding O 0 7.593956752316444e-07
for O 0 4.404873834573664e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 6.67715980284811e-08
Factor O 0 1.5309218781567324e-07
B O 0 5.910695790589671e-07
allotypes O 0 1.1671099997556666e-07
are O 0 5.2586185406156005e-11
approximately O 0 8.806545770401186e-11
3 O 0 2.215423622331514e-09
- O 0 1.7320607170745461e-09
- O 0 1.1265575139418615e-09
5 O 0 1.7020198583850288e-09
centimorgans O 0 9.389989230612628e-09
from O 0 3.291796835114269e-10
the O 0 2.0844229120520197e-10
HLA O 0 6.548833475505944e-09
- O 0 8.605882229062445e-09
A O 0 5.425944138437444e-09
and O 0 4.619046256593151e-10
HLA O 0 4.1134043726742675e-08
- O 0 7.438545424065524e-08
B O 0 2.405493546575599e-07
loci O 0 2.39348496577918e-09
, O 0 1.901337698395622e-10
and O 0 1.9374843743258374e-11
that O 0 2.7868807522118955e-12
the O 0 5.261949556634171e-11
apparent O 0 2.5876829568005633e-09
lack O 0 6.205161717787178e-09
of O 0 7.746524310903169e-09
recombinants O 0 3.593521213929307e-08
between O 0 1.5042835865841653e-09
the O 0 2.278617711182207e-10
Factor O 0 2.1233148572719074e-09
B O 0 1.9261005945736542e-07
gene O 0 6.325052481770399e-08
and O 0 4.084995453013107e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 2.7914247766602784e-06
suggests O 0 4.973660949758596e-08
that O 0 3.395258033056514e-11
these O 0 2.069700140439057e-11
two O 0 7.161405496391993e-11
genes O 0 1.27358024126778e-09
lie O 0 2.1381215731253178e-07
in O 0 1.944735483760951e-09
close O 0 4.654284069260939e-08
proximity O 0 3.619468103011059e-08
to O 0 1.754089429262251e-09
one O 0 2.1420714091391346e-09
another O 0 1.6180162987211588e-08
. O 0 4.895888991995889e-07

Distribution O 0 2.0064888417437032e-07
of O 0 4.2876337147390586e-07
emerin O 0 1.0259882401442155e-05
and O 0 9.713538418054668e-09
lamins O 0 1.2310330930631608e-05
in O 0 2.9002684698298253e-09
the O 0 4.521214513886207e-09
heart O 0 3.9533907170152816e-07
and O 0 4.71782723998615e-10
implications O 0 2.1739300137824102e-08
for O 0 1.1968041668808382e-08
Emery B-Disease 1 0.9985983967781067
- I-Disease 1 0.9999994039535522
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0131550757214427

Emerin O 0 0.00026084439014084637
is O 0 1.1907480512718394e-07
a O 0 4.0433572934261974e-08
nuclear O 0 3.3339924812025856e-06
membrane O 0 5.054356222444767e-08
protein O 0 6.3753993195803105e-09
which O 0 4.432037029045155e-11
is O 0 9.59582205362075e-11
missing O 0 2.165222445782433e-09
or O 0 3.7046615775082614e-10
defective O 0 3.4557771755316935e-07
in O 0 3.618495014734435e-08
Emery B-Disease 1 0.9999048709869385
- I-Disease 1 0.9999998807907104
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.026820875704288483
EDMD B-Disease 1 1.0
) O 0 4.20685324797887e-07
. O 0 1.4179549623349885e-07

It O 0 2.982397262485392e-08
is O 0 3.322422781337764e-09
one O 0 7.593733419852811e-10
member O 0 3.8604341945358556e-09
of O 0 3.146640281670443e-08
a O 0 2.8484191005873072e-08
family O 0 3.956160288254296e-09
of O 0 5.357119547966249e-08
lamina O 0 2.5759460186236538e-05
- O 0 2.0522438717307523e-06
associated O 0 4.986084789493361e-08
proteins O 0 1.993019305146504e-09
which O 0 1.0750548229410128e-09
includes O 0 1.992012110818564e-09
LAP1 O 0 3.177603502990678e-06
, O 0 5.434001248971754e-09
LAP2 O 0 3.241574404455605e-06
and O 0 1.805227256568287e-08
lamin O 0 8.768225598032586e-06
B O 0 1.5732281099190004e-05
receptor O 0 2.5666344072305947e-07
( O 0 1.2257645209956536e-07
LBR O 0 1.3913192560721654e-05
) O 0 8.962678066382068e-08
. O 0 3.8076242958595685e-07

A O 0 1.680990976637986e-06
panel O 0 5.55205531327374e-07
of O 0 3.8708101612883183e-08
16 O 0 1.2416365713363575e-08
monoclonal O 0 3.2669775218430175e-10
antibodies O 0 8.396135176003128e-11
( O 0 5.037028016907641e-10
mAbs O 0 1.0824646956564266e-08
) O 0 7.356618647591517e-10
has O 0 2.9841920601292315e-10
been O 0 2.505026741594918e-10
mapped O 0 4.4106865382254057e-10
to O 0 1.3293569023353768e-10
six O 0 1.3533078824234934e-10
specific O 0 2.361229614611382e-11
sites O 0 6.071688291031663e-11
throughout O 0 1.778424907339371e-10
the O 0 2.0489777929899589e-10
emerin O 0 1.233641278020059e-08
molecule O 0 7.225152143242042e-10
using O 0 1.1339216232642002e-09
phage O 0 6.651937223267623e-09
- O 0 1.3575509605345815e-09
displayed O 0 2.515417651949292e-09
peptide O 0 8.741467549810977e-10
libraries O 0 6.636599603204729e-10
and O 0 9.329479550013176e-11
has O 0 2.4132720127800766e-11
been O 0 1.0165541151907487e-11
used O 0 5.714666153483483e-12
to O 0 1.1743504606254174e-11
localize O 0 3.109091295527833e-08
emerin O 0 5.453763378682197e-07
in O 0 2.371694618474862e-09
human O 0 1.0818515860933076e-08
and O 0 2.8024082610045298e-08
rabbit O 0 1.6185632034648734e-07
heart O 0 7.203020504675806e-05
. O 0 1.5222652791635483e-06

Several O 0 1.0310078124575739e-07
mAbs O 0 8.567910754209151e-07
against O 0 3.4114982838673313e-08
different O 0 3.208100896046062e-09
emerin O 0 2.808035048929014e-07
epitopes O 0 1.378359968384757e-07
did O 0 8.658155969953896e-09
not O 0 5.949395420756787e-10
recognize O 0 3.983524621276047e-09
intercalated O 0 1.955001636133602e-07
discs O 0 1.5601519407937303e-05
in O 0 7.765933673908876e-09
the O 0 1.1559692758567053e-08
heart O 0 4.59559669252485e-06
, O 0 6.063983204462886e-10
though O 0 5.6154150773757294e-11
they O 0 1.3276154481323132e-11
recognized O 0 1.853810854823834e-10
cardiomyocyte O 0 1.110381475655231e-08
nuclei O 0 8.697615960784333e-09
strongly O 0 3.008275850646669e-09
, O 0 3.3220662332134054e-10
both O 0 3.611354826293933e-10
at O 0 5.0597090961446156e-08
the O 0 2.9419711111700053e-09
rim O 0 5.4874245591918225e-08
and O 0 5.765108945787745e-10
in O 0 5.413081649585649e-10
intranuclear O 0 1.81993129899638e-07
spots O 0 2.3763325529557733e-08
or O 0 5.479253939455475e-09
channels O 0 3.055668855722615e-07
. O 0 1.250582073453188e-07

A O 0 5.893899469811004e-06
polyclonal O 0 1.167807454294234e-06
rabbit O 0 1.098096689133854e-07
antiserum O 0 6.226622986105212e-07
against O 0 1.5011765697181545e-07
emerin O 0 2.9555155833804747e-06
did O 0 5.986118267742313e-09
recognize O 0 2.5864492769755998e-09
both O 0 3.6658422963853354e-09
nuclear O 0 4.086450076101755e-07
membrane O 0 3.356870781345833e-09
and O 0 1.5490735083556473e-10
intercalated O 0 4.5400354586888625e-09
discs O 0 1.9118820304697692e-08
but O 0 4.586211271861984e-11
, O 0 6.593366911472609e-12
after O 0 3.0071601458958597e-11
affinity O 0 5.773788391838508e-11
purification O 0 2.9467501772018068e-09
against O 0 4.242640461171732e-09
a O 0 9.160000535857193e-10
pure O 0 7.141282765132928e-08
- O 0 4.866123060054406e-09
emerin O 0 1.942964189538543e-08
band O 0 2.0562463731721436e-08
on O 0 2.0134118372538978e-08
a O 0 9.94714643987038e-10
western O 0 3.1323510452097025e-09
blot O 0 4.186868807209976e-08
, O 0 2.7232965882362237e-10
it O 0 4.1098770220404646e-11
stained O 0 7.823233971748778e-08
only O 0 7.466570139946782e-10
the O 0 3.868571685217148e-09
nuclear O 0 5.992546903144103e-07
membrane O 0 1.3258934927762311e-07
. O 0 3.496498734989473e-08

These O 0 8.759630354404635e-09
results O 0 5.931643176637635e-09
would O 0 7.667523282961497e-10
not O 0 3.413322055556556e-11
be O 0 3.3823568945656746e-11
expected O 0 1.5330015035175393e-10
if O 0 1.245770153701642e-10
immunostaining O 0 9.631588859804197e-09
at O 0 8.570958165421416e-09
intercalated O 0 1.0482426482383289e-08
discs O 0 9.026049241356304e-08
were O 0 1.010323269490243e-09
due O 0 3.5339966508729503e-09
to O 0 2.761854078769943e-10
a O 0 5.048666484874786e-10
product O 0 4.764588723560337e-10
of O 0 3.009653193331019e-09
the O 0 1.289900852796677e-09
emerin O 0 7.003638557989689e-08
gene O 0 4.3897888102328864e-10
and O 0 4.0878092577578684e-10
, O 0 1.926775961003102e-10
therefore O 0 1.0551364226785154e-09
, O 0 1.2168933916090197e-10
cast O 0 6.922724060665075e-10
some O 0 3.825204736296328e-11
doubt O 0 9.271423628831599e-10
upon O 0 3.081352950573546e-10
the O 0 1.6893182686050778e-10
hypothesis O 0 1.9406669604649096e-09
that O 0 9.26136251022669e-11
cardiac B-Disease 0 0.011866537854075432
defects I-Disease 0 0.13714748620986938
in O 0 2.697888930924819e-06
EDMD B-Disease 1 1.0
are O 0 5.597434515891564e-09
caused O 0 1.0415242890360332e-08
by O 0 8.502919895958527e-11
absence O 0 7.247739119975449e-08
of O 0 9.15983449090163e-08
emerin O 0 1.0711586583056487e-05
from O 0 8.09863394124477e-08
intercalated O 0 4.551110578177031e-06
discs O 0 0.00033942339359782636
. O 0 1.0435743433845346e-06

Although O 0 6.404915779967268e-07
emerin O 0 7.86037890065927e-06
was O 0 1.2519662107024487e-07
abundant O 0 2.9866993322968938e-09
in O 0 2.3199370202675595e-10
the O 0 4.81620299197516e-10
membranes O 0 2.5551465387962935e-09
of O 0 1.362329626886094e-08
cardiomyocyte O 0 1.8084448072386294e-07
nuclei O 0 1.9302945020172046e-08
, O 0 5.252556167789635e-10
it O 0 4.4784766173311397e-11
was O 0 3.2878264555336045e-09
absent O 0 1.9538557438636417e-09
from O 0 1.92294680179117e-10
many O 0 4.651454915682862e-11
non O 0 3.1610657202918446e-08
- O 0 7.282909564310103e-08
myocyte O 0 1.2911959856864996e-06
cells O 0 1.9168213682974056e-09
in O 0 1.978781138944896e-09
the O 0 1.199654153793972e-08
heart O 0 1.8975568309542723e-05
. O 0 5.599272867584659e-07

This O 0 5.550380155483481e-09
distribution O 0 1.2352918687952297e-08
of O 0 2.4659476238753086e-08
emerin O 0 5.256100052974944e-07
was O 0 1.5780830864287054e-08
similar O 0 5.2978007397674887e-11
to O 0 9.535354277001584e-12
that O 0 1.556589752926829e-11
of O 0 4.416901955295316e-09
lamin O 0 4.814683620679716e-07
A O 0 5.250888790442332e-08
, O 0 7.725833306437835e-10
a O 0 4.4460854442540665e-10
candidate O 0 6.347005143680917e-10
gene O 0 5.895209320705419e-10
for O 0 3.9810768570625044e-10
an O 0 3.907487944321275e-10
autosomal O 0 1.5669368167436915e-06
form O 0 1.2263823236935423e-06
of O 1 0.8487000465393066
EDMD B-Disease 1 1.0
. O 0 0.0001025006131385453

In O 0 1.4422431604543817e-07
contrast O 0 1.482202378610964e-07
, O 0 3.398437797841325e-08
lamin O 0 1.104271268559387e-05
B1 O 0 5.335967944120057e-05
was O 0 9.934979061654303e-07
absent O 0 1.783431002877478e-07
from O 0 4.0206993290325954e-09
cardiomyocyte O 0 2.790285975606821e-07
nuclei O 0 4.1950062978912683e-08
, O 0 8.066853296462284e-10
showing O 0 6.767188587275541e-09
that O 0 1.3522067909832458e-09
lamin O 0 4.5944666453578975e-06
B1 O 0 3.455873411439825e-06
is O 0 4.5519987779130133e-10
not O 0 2.2229898477554855e-11
essential O 0 5.363954280745986e-10
for O 0 1.6242203415561818e-10
localization O 0 5.789086117147235e-07
of O 0 2.1139610950626775e-08
emerin O 0 6.992306111897051e-07
to O 0 3.336603660031301e-09
the O 0 1.9621587910023663e-08
nuclear O 0 5.330707153916592e-06
lamina O 0 7.625833404745208e-06
. O 0 3.0577183451896417e-07

Lamin O 1 0.8352502584457397
B1 O 0 0.42347267270088196
is O 0 2.5811285553345442e-08
also O 0 1.094227819464777e-09
almost O 0 3.6586895735268854e-09
completely O 0 6.165371502220296e-08
absent O 0 2.129694536279203e-07
from O 0 3.1759082474991374e-08
skeletal O 0 0.0017769176047295332
muscle O 0 5.1616956625366583e-05
nuclei O 0 0.00024293758906424046
. O 0 2.8869194466096815e-06

In O 0 3.474405730230501e-06
EDMD B-Disease 1 0.9999995231628418
, O 0 4.15136147680073e-09
the O 0 1.7010226560643105e-10
additional O 0 1.1606605954117555e-10
absence O 0 5.787708978743922e-09
of O 0 8.462708933620888e-08
lamin O 0 5.834037438035011e-05
B1 O 0 0.004126295913010836
from O 0 1.634426553209778e-06
heart O 1 0.9998277425765991
and O 0 4.327031638240442e-05
skeletal O 1 0.9999997615814209
muscle O 1 0.9970415234565735
nuclei O 0 0.2800648808479309
which O 0 4.664201824766678e-08
already O 0 7.883085295645742e-09
lack O 0 4.764221372965949e-08
emerin O 0 2.235204590306239e-07
may O 0 2.2996274329223354e-10
offer O 0 7.7198004932999e-12
an O 0 3.656653972672341e-12
alternative O 0 2.1780409420468771e-10
explanation O 0 1.9295869346791505e-09
of O 0 2.0106516451789958e-09
why O 0 3.428540229499788e-10
these O 0 1.3878992573268523e-11
tissues O 0 2.236780760611623e-09
are O 0 7.333358920114108e-11
particularly O 0 6.476819081058238e-10
affected O 0 2.2785480446874118e-10
. O 0 5.329993113534215e-10
. O 0 1.714790798246213e-08

Genetic O 0 7.257899596879724e-07
mapping O 0 8.753068527767027e-07
of O 0 1.2121939789722092e-06
the O 0 3.2083511314340285e-07
copper B-Disease 0 0.010576274245977402
toxicosis I-Disease 0 0.0015459455316886306
locus O 0 1.296967724329079e-07
in O 0 9.087026597853765e-08
Bedlington O 0 1.8625954908202402e-05
terriers O 0 2.2668693873129087e-06
to O 0 1.207367006372806e-08
dog O 0 2.0757211416366772e-07
chromosome O 0 1.596639833678637e-07
10 O 0 3.545617843769833e-08
, O 0 5.826561455535284e-10
in O 0 2.730020931540622e-10
a O 0 7.312244143520275e-10
region O 0 7.147793912309908e-09
syntenic O 0 8.256459693711804e-08
to O 0 5.115432522018182e-10
human O 0 9.940929857066294e-09
chromosome O 0 5.006750711800123e-07
region O 0 1.4814688142905652e-07
2p13 O 0 2.854573040167452e-06
- O 0 7.157809704949614e-07
p16 O 0 9.63710249379801e-07
. O 0 2.548363795540354e-07

Abnormal O 1 0.999946117401123
hepatic B-Disease 1 0.9999994039535522
copper I-Disease 1 0.9999512434005737
accumulation I-Disease 0 0.013642147183418274
is O 0 5.1761683828033256e-09
recognized O 0 2.269648691211046e-09
as O 0 6.398200302903945e-10
an O 0 1.1638096708566081e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.08573184907436371
man O 0 7.547472341684625e-05
, O 0 1.949050476568459e-09
mouse O 0 2.397406362319998e-08
, O 0 2.7520393075519678e-08
rat O 0 1.325939251728414e-06
and O 0 3.188532815556755e-08
dog O 0 4.808975063497201e-06
. O 0 5.946531018707901e-07

The O 0 1.6304895211760595e-07
major O 0 3.9162145526461245e-07
cause O 0 4.968454504705733e-06
of O 0 2.3811931896489114e-05
hepatic B-Disease 1 0.9999997615814209
copper I-Disease 1 0.9999998807907104
accumulation I-Disease 1 0.999998927116394
in O 0 0.01356420386582613
man O 0 0.002221988746896386
is O 0 2.289951117617761e-09
a O 0 4.957065868893551e-09
dysfunctional O 0 8.374601634386636e-07
ATP7B O 0 2.1718204152421094e-05
gene O 0 5.275835945894869e-08
, O 0 6.2555947089038e-09
causing O 0 4.3827571971633006e-07
Wilson B-Disease 0 1.8756898498395458e-05
disease I-Disease 0 0.010815243236720562
( O 0 5.8699921368088326e-08
WD B-Disease 0 3.062896939809434e-05
) O 0 2.5980705231631873e-07
. O 0 6.821501870035718e-07

Mutations O 0 4.718156105809612e-07
in O 0 2.0010954671079162e-08
the O 0 2.095670481594425e-08
ATP7B O 0 1.1647549399640411e-05
genes O 0 3.927567604478099e-09
have O 0 4.731991881667952e-11
also O 0 2.184630081003558e-11
been O 0 3.531722136962401e-11
demonstrated O 0 2.1700875818542187e-10
in O 0 3.6840927530867873e-10
mouse O 0 1.654188963584602e-08
and O 0 1.815676675676059e-08
rat O 0 1.6155636330950074e-06
. O 0 1.1442926961535704e-07

The O 0 6.813414188400202e-07
ATP7B O 0 7.49932587496005e-05
gene O 0 7.823995673561512e-08
has O 0 8.325621858595866e-10
been O 0 2.92160962089838e-10
excluded O 0 6.856912815322858e-10
in O 0 1.9761046965438567e-11
the O 0 4.1959925117796004e-11
much O 0 1.1641591857181055e-10
rarer O 0 6.207398595137192e-09
human O 0 5.418910653531839e-09
copper B-Disease 0 0.017788885161280632
overload I-Disease 1 0.7435025572776794
disease O 1 0.8207746148109436
non B-Disease 0 6.401199243555311e-06
- I-Disease 0 2.9361686415541044e-07
Indian I-Disease 0 1.6475167896601306e-08
childhood I-Disease 0 0.000272054981905967
cirrhosis I-Disease 1 0.9999772310256958
, O 0 8.551020336255988e-09
indicating O 0 7.116155842368244e-08
genetic O 0 1.2841860552725848e-07
heterogeneity O 0 2.1076136818010127e-06
. O 0 9.910545486491174e-07

By O 0 6.140594699388657e-09
investigating O 0 6.380523132065719e-08
the O 0 5.218556697883514e-09
common O 0 6.839624688836921e-07
autosomal O 1 0.9959652423858643
recessive O 1 0.9999092817306519
copper B-Disease 1 1.0
toxicosis I-Disease 1 0.9999996423721313
( O 0 1.9246463978106476e-07
CT B-Disease 0 0.00061189936241135
) O 0 2.0480959150859235e-09
in O 0 5.5515658736737805e-09
Bedlington O 0 4.7444336814805865e-05
terriers O 0 4.956764769303845e-06
, O 0 9.46310807492523e-10
we O 0 1.234741753286528e-10
have O 0 7.95900671757277e-12
identified O 0 4.485948765231562e-11
a O 0 1.2510388558428787e-11
new O 0 7.078279368882834e-12
locus O 0 1.5553232313170184e-10
involved O 0 7.05229152853093e-10
in O 0 8.064180434530499e-09
progressive O 1 0.9999996423721313
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0002577467530500144

We O 0 2.1229965341262869e-07
examined O 0 3.286769185706362e-07
whether O 0 9.765496855607125e-09
the O 0 6.1893223879394554e-09
WD B-Disease 0 9.553911013426841e-07
gene O 0 3.6820104298840306e-08
ATP7B O 0 2.5986952095991e-05
was O 0 4.1457857946625154e-07
also O 0 9.647616039387685e-10
causative O 0 8.508086679626103e-09
for O 0 1.053720555255211e-09
CT B-Disease 0 2.14550686905568e-06
by O 0 1.5071749404071966e-10
investigating O 0 8.446257027117099e-09
the O 0 1.5095433791856294e-09
chromosomal O 0 2.8189901968289632e-06
co O 0 1.3084661986795254e-05
- O 0 7.88633485626633e-07
localization O 0 0.00015636745956726372
of O 0 1.3081116776447743e-06
ATP7B O 0 1.7270102034672163e-05
and O 0 1.3565621959088503e-09
C04107 O 0 1.3145751154297614e-08
, O 0 1.0591135607418423e-11
using O 0 1.2124560036519405e-11
fluorescence O 0 2.0076156015402802e-10
in O 0 1.872299537630795e-10
situ O 0 3.2337140964955324e-08
hybridization O 0 5.654909429608779e-09
( O 0 5.921658718932576e-10
FISH O 0 8.690169472913567e-09
) O 0 7.657380285408522e-10
. O 0 1.165844754069667e-08

C04107 O 0 7.041026947263163e-06
is O 0 6.231978932902393e-09
an O 0 6.069872937608523e-10
anonymous O 0 1.8259354916949633e-08
microsatellite O 0 1.6170403114301735e-06
marker O 0 1.268665869247343e-06
closely O 0 6.630683060393494e-07
linked O 0 2.7902428882953245e-06
to O 0 6.430725818518113e-08
CT B-Disease 1 0.9991785883903503
. O 0 7.185809408838395e-06

However O 0 4.716775094948389e-07
, O 0 1.5357109361957555e-07
BAC O 0 2.66144925262779e-05
clones O 0 2.5415188176225456e-08
containing O 0 3.10444381312891e-09
ATP7B O 0 4.998273084311222e-07
and O 0 1.1413598954845838e-09
C04107 O 0 2.8428177145656264e-08
mapped O 0 3.5719871505079936e-09
to O 0 6.972602495380897e-10
the O 0 7.557931169799303e-09
canine O 0 2.9004257839915226e-07
chromosome O 0 3.038567513158341e-07
regions O 0 2.165913315366197e-08
CFA22q11 O 0 1.0831895451701712e-06
and O 0 1.493904444593852e-09
CFA10q26 O 0 1.6194681506931374e-07
, O 0 4.168259071235525e-10
respectively O 0 1.5138742481823897e-09
, O 0 7.269437135581924e-11
demonstrating O 0 1.091774115558053e-09
that O 0 1.3780557250875347e-10
WD B-Disease 0 6.300020771732306e-08
cannot O 0 3.7347165360301915e-09
be O 0 4.865934877251732e-10
homologous O 0 2.3340165355989484e-09
to O 0 4.376631945746112e-09
CT B-Disease 0 0.00042154552647843957
. O 0 6.485490757768275e-07

The O 0 2.0312575088610174e-06
copper O 0 1.9734445231733844e-05
transport O 0 4.270050339982845e-07
genes O 0 2.040162705441162e-08
CTR1 O 0 4.800415808858816e-06
and O 0 1.7228941606717285e-09
CTR2 O 0 4.0271779653267e-06
were O 0 1.5505255968051301e-09
also O 0 5.812018227802085e-11
excluded O 0 2.384529795840251e-10
as O 0 5.2899649938265014e-11
candidate O 0 1.847985792169382e-10
genes O 0 1.933771198725509e-10
for O 0 6.366112637046228e-10
CT B-Disease 0 1.2761099242197815e-05
since O 0 1.64220530507464e-08
they O 0 1.2488939049593029e-10
both O 0 3.102323120618422e-10
mapped O 0 1.7005629127098132e-09
to O 0 2.1254056292718815e-09
canine O 0 5.92538128785236e-07
chromosome O 0 5.752620836574351e-06
region O 0 2.9737061595369596e-06
CFA11q22 O 0 0.00020569610933307558
. O 0 1.7811920542953885e-06

2 O 0 0.0009541496983729303
- O 0 3.726960130734369e-05
22 O 0 7.4903637141687796e-06
. O 0 8.879284223439754e-07

5 O 0 0.00010879478213610128
. O 0 6.565208877873374e-06

A O 0 1.0356626489738119e-06
transcribed O 0 1.001874849748674e-07
sequence O 0 5.919741585813654e-09
identified O 0 4.1423682262120565e-09
from O 0 7.740627028240965e-10
the O 0 4.791418373173428e-10
C04107 O 0 1.8007703772582317e-08
- O 0 2.4690665068050066e-09
containing O 0 2.406260302123542e-09
BAC O 0 3.1151098482951056e-06
was O 0 6.814311603875467e-08
found O 0 1.7790151296548373e-10
to O 0 1.1167942438883305e-11
be O 0 1.4905215950378192e-11
homologous O 0 1.99148308954733e-10
to O 0 1.1716842773790148e-10
a O 0 3.360661471329962e-10
gene O 0 5.123370616644252e-10
expressed O 0 1.0548325546366755e-09
from O 0 2.852865277347405e-09
human O 0 3.5824465616229872e-09
chromosome O 0 4.746497950236517e-08
2p13 O 0 1.296837837116982e-07
- O 0 2.1506203040644323e-08
p16 O 0 2.300471990679398e-08
, O 0 4.530932573576507e-10
a O 0 4.126980146512693e-10
region O 0 3.0310145504586217e-09
devoid O 0 7.07088503304476e-08
of O 0 1.3858427738711043e-09
any O 0 5.801975011543448e-10
positional O 0 3.754087742890988e-07
candidate O 0 8.162977849224262e-08
genes O 0 9.752173468768888e-08
. O 0 2.4746555027377326e-07

Molecular O 0 6.416434530365223e-07
analysis O 0 2.69189026624872e-08
of O 0 8.01761768087772e-09
the O 0 2.35101271783833e-09
APC B-Disease 0 6.866273771777287e-09
gene O 0 2.964926526516365e-09
in O 0 1.89095183955601e-09
205 O 0 4.278942977720135e-09
families O 0 4.8609047342829115e-11
: O 0 5.2294120422846646e-11
extended O 0 1.3484774408212274e-09
genotype O 0 1.6755501874854417e-08
- O 0 2.654831199322416e-08
phenotype O 0 1.5383889717668353e-09
correlations O 0 1.750353817442374e-08
in O 0 1.0549211504340406e-09
FAP B-Disease 0 3.1680775780529302e-09
and O 0 8.090763475854246e-11
evidence O 0 5.488256515917556e-10
for O 0 1.4169667175711886e-11
the O 0 1.0646677289782858e-10
role O 0 3.0934617090139227e-09
of O 0 2.0827080504659534e-08
APC B-Disease 0 5.3624766849225125e-08
amino O 0 6.600362922881686e-08
acid O 0 1.3213818306212488e-07
changes O 0 7.615192743060106e-08
in O 0 0.0002750165294855833
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999833106994629
. O 0 3.960352478316054e-05

BACKGROUND O 0 2.204735756095033e-05
/ O 0 1.297823018830968e-06
AIMS O 0 2.8858181622126722e-08
The O 0 9.915512855229736e-10
development O 0 1.5288129873169964e-08
of O 0 0.00429554795846343
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1826470824871649e-07
a O 0 2.097521045740791e-09
variable O 0 8.768319403884561e-10
range O 0 2.300830637125273e-09
of O 0 2.400305953997872e-09
extracolonic O 0 2.59011216030558e-07
manifestations O 0 1.5760579117340967e-06
in O 0 4.681652967519767e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.999969482421875
polyposis I-Disease 1 1.0
( O 0 6.47605929771089e-07
FAP B-Disease 0 2.3864802756179415e-07
) O 0 1.535677141006886e-09
is O 0 1.0042573023172352e-10
the O 0 6.244334910254778e-11
result O 0 1.8317171390780373e-10
of O 0 9.614037344007897e-10
the O 0 2.0595256056132882e-10
dominant O 0 1.8615426711221517e-07
inheritance O 0 3.3484928962934646e-07
of O 0 1.4856647794658784e-05
adenomatous B-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9998881816864014
coli I-Disease 1 0.9999070167541504
( O 0 6.220379589194636e-08
APC B-Disease 0 3.802239518790884e-07
) O 0 4.912632434184161e-08
gene O 0 6.54377288356045e-07
mutations O 0 4.2092833609785885e-06
. O 0 2.3579511889693094e-06

In O 0 1.4208091592138317e-08
this O 0 1.907713015336654e-10
study O 0 2.8600663504185775e-10
, O 0 1.0932879601632806e-11
direct O 0 2.2723363121701645e-11
mutation O 0 2.772588235389062e-11
analysis O 0 4.5863010611491006e-10
of O 0 3.4463882858659645e-09
the O 0 3.840348483663547e-09
APC B-Disease 0 2.9273687474073995e-08
gene O 0 1.592618303902782e-08
was O 0 8.390559713689072e-08
performed O 0 1.0193612176578881e-08
to O 0 2.964483936107598e-10
determine O 0 1.5025207744656655e-08
genotype O 0 8.285502417493262e-08
- O 0 9.448741877804423e-08
phenotype O 0 9.900285924402397e-09
correlations O 0 7.486627140451674e-08
for O 0 3.6559200111696555e-09
nine O 0 3.434230677612504e-08
extracolonic O 0 7.472402785424492e-07
manifestations O 0 3.4644688184926054e-07
and O 0 9.004959555802827e-10
to O 0 1.3403787801902212e-10
investigate O 0 1.4662733249792836e-09
the O 0 4.902377948035053e-10
incidence O 0 4.341167141319602e-07
of O 0 5.6708980622488525e-08
APC B-Disease 0 5.5524370878856644e-08
mutations O 0 2.1943304062688185e-08
in O 0 7.689100023355877e-09
non O 0 0.49446266889572144
- O 1 0.9999767541885376
FAP O 1 0.9999827146530151
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0111373420804739

METHODS O 0 3.2501366149517708e-06
The O 0 4.630589245380179e-08
APC B-Disease 0 1.72031402456696e-08
gene O 0 2.959485545517282e-09
was O 0 1.1881951422765269e-08
analysed O 0 5.000692748780011e-09
in O 0 4.244580797951869e-10
190 O 0 1.1040138803153354e-09
unrelated O 0 1.7224933701598388e-09
FAP B-Disease 0 1.4326075881143652e-09
and O 0 2.9332566930939663e-10
15 O 0 2.688554978647062e-08
non O 0 0.00018891665968112648
- O 1 0.9743289947509766
FAP O 1 0.9990969896316528
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.0224981679129996e-06
using O 0 8.866116729677742e-09
denaturing O 0 1.792337798178778e-06
gradient O 0 2.535765020184044e-07
gel O 0 2.2280259770468547e-07
electrophoresis O 0 7.052351236325194e-08
, O 0 1.7084369474673622e-09
the O 0 1.1886025497176433e-09
protein O 0 9.696984326623692e-10
truncation O 0 1.3521662900473075e-08
test O 0 1.2615882782895937e-09
, O 0 8.682308344498679e-11
and O 0 5.629506236171089e-11
direct O 0 1.5204429937298869e-09
sequencing O 0 4.7960771354382814e-08
. O 0 1.431401699392154e-07

RESULTS O 0 1.6524757029401371e-06
Chain O 0 6.355666073432076e-07
terminating O 0 7.198719487178096e-08
signals O 0 2.6457422919179407e-08
were O 0 3.0509772486198017e-10
only O 0 1.4625235050802488e-11
identified O 0 6.1107008342276e-11
in O 0 4.33016157652677e-11
patients O 0 4.8593101764637936e-11
belonging O 0 2.432358481296859e-10
to O 0 2.1947204470462722e-11
the O 0 7.751397856914366e-10
FAP B-Disease 0 2.2852312042687117e-08
group O 0 1.0129304506278913e-08
( O 0 1.6988284112784413e-09
105 O 0 2.4074032012322277e-07
patients O 0 2.370465601586602e-08
) O 0 4.803856867852119e-09
. O 0 7.927388168127436e-08

Amino O 0 4.788166734215338e-07
acid O 0 4.101566730696504e-08
changes O 0 1.5438269551637518e-09
were O 0 5.372750022658579e-10
identified O 0 6.850886524745192e-10
in O 0 1.8367375675953923e-10
four O 0 9.702973841063667e-11
patients O 0 2.3050990283213224e-10
, O 0 7.74865935304625e-11
three O 0 1.741454203063597e-10
of O 0 2.9167969728405296e-07
whom O 0 1.3741285442847584e-07
belonged O 0 5.825811513204826e-07
to O 0 3.8581576822238617e-10
the O 0 4.509880024983204e-09
non O 0 3.919969003618462e-06
- O 0 2.9123884814907797e-07
FAP O 0 5.34439301702605e-08
group O 0 4.799170127967045e-08
of O 1 0.9931596517562866
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9998921155929565
. O 0 8.719362085685134e-06

Genotype O 0 4.001427805633284e-05
- O 0 9.785265319806058e-06
phenotype O 0 7.740649010656853e-08
correlations O 0 1.3806622689571668e-07
identified O 0 5.091819410552034e-09
significant O 0 4.465311675971861e-09
differences O 0 8.250257366171354e-08
in O 0 1.2764010959287475e-09
the O 0 1.9684318064427941e-10
nature O 0 5.280794135309463e-10
of O 0 2.2574121738561104e-10
certain O 0 1.1970632818325555e-10
extracolonic O 0 1.876473554318636e-08
manifestations O 0 9.89900161840751e-09
in O 0 5.115198264959986e-10
FAP B-Disease 0 6.294253118710458e-09
patients O 0 9.594546268587578e-10
belonging O 0 3.1784759269015694e-09
to O 0 8.216485825052189e-10
three O 0 3.022124550611238e-09
mutation O 0 2.021935863183444e-08
subgroups O 0 1.3434537322609685e-06
. O 0 1.4758159068151144e-06

CONCLUSIONS O 0 1.4890456441207789e-06
Extended O 0 2.91793213591518e-07
genotype O 0 8.857606985657185e-07
- O 0 1.4912752988038847e-07
phenotype O 0 8.547416996407264e-09
correlations O 0 9.735279604683456e-08
made O 0 3.6222287391751706e-09
in O 0 3.45900419418399e-10
this O 0 2.245087622754216e-11
study O 0 2.5216323473742364e-10
may O 0 3.0917374216343774e-10
have O 0 5.3943594383043525e-12
the O 0 4.728166469458728e-11
potential O 0 6.402640917446689e-11
to O 0 1.7877119923292994e-11
determine O 0 1.4063562814303765e-10
the O 0 5.403259090153156e-11
most O 0 2.821173199565874e-12
appropriate O 0 6.268595365011009e-11
surveillance O 0 2.4613695526198853e-09
and O 0 1.5840946610001794e-10
prophylactic O 0 1.1046087422528217e-07
treatment O 0 1.3807775367524755e-08
regimens O 0 3.954562544095097e-08
for O 0 6.528373674985488e-11
those O 0 6.9010866465824e-11
patients O 0 1.2731327103665535e-10
with O 0 3.0434665204692735e-11
mutations O 0 2.5953941218403997e-09
associated O 0 5.644836420515276e-08
with O 0 2.1514521275634024e-09
life O 0 3.6013986459693115e-07
threatening O 0 2.7379300604479795e-07
conditions O 0 1.3590898561233189e-05
. O 0 2.319071427336894e-06

This O 0 1.224258117105137e-08
study O 0 3.844445206624414e-09
also O 0 9.709860693263295e-11
provided O 0 8.644863991325025e-11
evidence O 0 1.8724530259639494e-10
for O 0 1.346450815425948e-11
the O 0 2.2794174880935714e-10
pathological O 0 9.682679774414282e-06
nature O 0 7.910136545774549e-09
of O 0 6.8403531727767586e-09
amino O 0 7.487295228258972e-09
acid O 0 6.808099417554558e-09
changes O 0 8.809591389713489e-10
in O 0 1.0518952375804247e-09
APC O 0 7.432869875145798e-09
associated O 0 5.325524465860099e-09
with O 0 6.112123307477901e-11
both O 0 3.717040564232832e-10
FAP B-Disease 0 5.362576604994729e-09
and O 0 3.6182927765082695e-09
non O 1 0.9994307160377502
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9749717116355896
. O 0 2.2751116546260164e-07
. O 0 4.0960946989798686e-07

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999992847442627
and O 0 0.00011059293319704011
cancer B-Disease 1 0.9997437596321106
risk O 0 7.234242730191909e-06
of O 0 2.2221170183911454e-06
the O 0 2.2400401178401808e-07
APC O 0 1.3905427067584242e-06
I1307K O 0 1.6279427654808387e-06
polymorphism O 0 6.4991616000043e-07
. O 0 2.135881942422202e-07

Germ O 0 0.24912121891975403
- O 0 1.0615444807626773e-05
line O 0 1.938035012472028e-07
and O 0 7.428217485561106e-10
somatic O 0 2.285043976257839e-08
truncating O 0 7.466975660008757e-08
mutations O 0 3.5533611608684623e-09
of O 0 1.4396151826190362e-08
the O 0 5.411825210188681e-09
APC B-Disease 0 3.4066346188410535e-08
gene O 0 1.9470153489464792e-08
are O 0 2.9576613380655203e-10
thought O 0 5.540297665085347e-10
to O 0 1.2429172968619895e-10
initiate O 0 6.837642985146886e-08
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.00018306871061213315
formation O 0 6.652231240877882e-05
in O 0 0.0007449441472999752
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.003234683535993099
sporadic O 1 0.9999990463256836
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 9.98757968773134e-07
respectively O 0 9.770260476216208e-06
. O 0 1.2148964287916897e-06

Recently O 0 1.374945441057207e-06
, O 0 1.2247346248273061e-08
an O 0 2.501189477754906e-09
isoleucine O 0 1.5602920484525384e-06
- O 0 2.760024926828919e-06
- O 0 8.388861942876247e-07
> O 0 5.962544236126632e-08
lysine O 0 2.5390379576606392e-08
polymorphism O 0 2.0081756257894767e-09
at O 0 8.296299647270189e-09
codon O 0 2.5917332724390008e-09
1307 O 0 1.325785916606037e-07
( O 0 1.3170835255760238e-10
I1307K O 0 8.612565771670688e-09
) O 0 8.390756145448819e-11
of O 0 1.5363129657330887e-09
the O 0 1.8093283538078708e-09
APC B-Disease 0 1.0070396072592303e-08
gene O 0 3.5643985540900758e-09
has O 0 1.6027124072337529e-10
been O 0 9.563627667574792e-11
identified O 0 1.6442786021642064e-10
in O 0 1.3318822433827648e-10
6 O 0 4.347959325912143e-09
% O 0 1.9475333845608844e-10
- O 0 2.081269379061723e-09
7 O 0 3.073242771378659e-09
% O 0 1.246894532069831e-10
of O 0 5.951937831483178e-10
the O 0 3.4391894887519925e-10
Ashkenazi O 0 1.0127488181410627e-08
Jewish O 0 1.3707478485613933e-09
population O 0 5.13988018813194e-11
. O 0 1.5725422741752482e-08

To O 0 2.5643558387855592e-08
assess O 0 3.290542167633248e-07
the O 0 6.71971456256415e-09
risk O 0 1.5976048928223463e-08
of O 0 5.4893587453364034e-09
this O 0 8.555025438061747e-11
common O 0 1.7407377761458065e-09
APC B-Disease 0 1.0252029447599398e-08
allelic O 0 9.849529902794529e-08
variant O 0 7.49614287087752e-07
in O 0 2.87118467667824e-07
colorectal O 1 1.0
carcinogenesis O 1 0.9999986886978149
, O 0 9.142066659251213e-08
we O 0 1.5793348850934308e-09
have O 0 1.1564349304549193e-11
analyzed O 0 3.1691335666828024e-10
a O 0 4.850920012899884e-11
large O 0 3.287653829731063e-11
cohort O 0 1.1972807190119283e-09
of O 0 1.0725315080506448e-09
unselected O 0 1.6511398825969081e-06
Ashkenazi O 0 7.243496469300226e-08
Jewish O 0 3.4354346034604077e-09
subjects O 0 2.7556477988355255e-08
with O 0 1.1702999680451853e-09
adenomatous B-Disease 0 5.192486582927813e-07
polyps I-Disease 0 1.6935970847953286e-07
and O 0 2.4203363757635543e-09
. O 0 1.006563365990587e-08
or O 0 0.06774801015853882
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.7977681920910982e-07
for O 0 2.557730693908411e-09
the O 0 1.2570109397813667e-08
APC O 0 2.485205925495393e-07
I1307K O 0 1.0662873819455854e-06
polymorphism O 0 6.817288067395566e-07
. O 0 1.3813379950988747e-07

The O 0 6.393509579538659e-07
APC O 0 4.7651664658587833e-07
I1307K O 0 1.818656159002785e-07
allele O 0 9.858340810353639e-09
was O 0 1.7359509385528327e-08
identified O 0 1.3057532832760899e-09
in O 0 5.402148728350653e-10
48 O 0 8.662996542341261e-09
( O 0 1.8380516553229143e-10
10 O 0 3.508667245633035e-10
. O 0 1.840794357221842e-11
1 O 0 3.2281601836103846e-09
% O 0 4.5415813471061384e-11
) O 0 2.9509433091545745e-11
of O 0 1.1616378969847574e-09
476 O 0 4.205164216841695e-08
patients O 0 3.941249460126528e-08
. O 0 8.119111782889377e-08

Compared O 0 7.564798920611793e-08
with O 0 2.8723010081499467e-10
the O 0 2.233646045901594e-10
frequency O 0 4.512048512594902e-09
in O 0 5.810821268603661e-11
two O 0 5.1358596195316686e-12
separate O 0 7.609385344053976e-12
population O 0 4.072293446465841e-13
control O 0 5.617067366792128e-10
groups O 0 1.0317139503834838e-11
, O 0 2.2108034153367484e-11
the O 0 1.0605776673555667e-10
APC O 0 1.7823513775994115e-09
I1307K O 0 1.601290122721366e-08
allele O 0 7.162242465774682e-10
is O 0 1.1664530452648592e-10
associated O 0 2.4824717281823894e-10
with O 0 1.241513922917159e-11
an O 0 2.8371366020407685e-11
estimated O 0 3.0711669318783663e-10
relative O 0 8.355234371038023e-08
risk O 0 9.549896873295438e-08
of O 0 2.7370998623155174e-07
1 O 0 2.1532185201067477e-05
. O 0 6.170407118588628e-07

5 O 0 4.605219146469608e-05
- O 0 1.5201445421553217e-05
1 O 0 1.2053352293150965e-05
. O 0 4.284106296381651e-07

7 O 0 2.5457029551034793e-05
for O 0 5.046527803642675e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.99528568983078
( O 0 5.145523687133391e-07
both O 0 1.208530875373981e-07
P O 0 2.8817268685088493e-05
= O 0 1.0287840979117391e-07
. O 0 1.4758184674334984e-09
01 O 0 1.6674084690748714e-07
) O 0 9.20226028711113e-09
. O 0 7.80494673335852e-08

Furthermore O 0 5.50423806089384e-07
, O 0 9.980561266331733e-09
compared O 0 5.620006682249823e-09
with O 0 8.541187201949185e-10
noncarriers O 0 8.414533567702165e-07
, O 0 2.636124873944823e-09
APC O 0 2.6646628015214446e-08
I1307K O 0 3.1635750019631814e-08
carriers O 0 3.9447276001247644e-10
had O 0 5.934341906765894e-11
increased O 0 5.767423431196628e-12
numbers O 0 5.7930899660663115e-12
of O 0 3.6136976744316485e-10
adenomas B-Disease 0 3.3426999834773596e-06
and O 0 2.7965727440459887e-06
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999949932098389
per O 0 2.6554471332929097e-06
patient O 0 8.03855925823882e-07
( O 0 1.2735559273835406e-09
P O 0 4.1408586071156606e-07
= O 0 3.541736459666822e-09
. O 0 9.047892990388107e-11
03 O 0 7.1348540409132966e-09
) O 0 1.0000635736195918e-10
, O 0 5.558998747434707e-11
as O 0 5.674676006872659e-11
well O 0 7.966513559942712e-11
as O 0 2.37032754535349e-10
a O 0 6.517466011324302e-10
younger O 0 9.584564253373173e-09
age O 0 1.3927071051966777e-07
at O 0 2.4081339233816834e-06
diagnosis O 0 1.0558189387666062e-05
. O 0 3.2796708637761185e-07

We O 0 3.593100075249822e-07
conclude O 0 3.8479655017908954e-07
that O 0 7.279847835661712e-10
the O 0 1.104418223540904e-09
APC O 0 1.5054496316224686e-08
I1307K O 0 1.0578214215684056e-07
variant O 0 2.6629606963979313e-08
leads O 0 5.859261964502593e-09
to O 0 4.111149198848807e-10
increased O 0 6.006684571957521e-08
adenoma B-Disease 1 1.0
formation O 0 8.147660082613584e-06
and O 0 2.503591289837459e-08
directly O 0 1.0394682448122694e-08
contributes O 0 4.560445909795874e-10
to O 0 1.3394843567660075e-10
3 O 0 9.738433170980443e-09
% O 0 2.8116034500591525e-10
- O 0 1.9158419295450813e-09
4 O 0 2.644888086322794e-09
% O 0 5.802735722482133e-11
of O 0 1.49641896096675e-10
all O 0 1.0716006554334356e-10
Ashkenazi O 0 2.459074437410891e-07
Jewish O 0 6.837081855337601e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6376083294744603e-05

The O 0 4.3219170464681156e-08
estimated O 0 6.862175716548791e-09
relative O 0 7.288608117050899e-08
risk O 0 6.212859560150719e-09
for O 0 3.544180782188988e-10
carriers O 0 3.2477423528298743e-10
may O 0 2.677912336324084e-10
justify O 0 2.629203799120461e-10
specific O 0 6.545326780571514e-12
clinical O 0 9.002688178272322e-11
screening O 0 5.1270338669029414e-11
for O 0 2.7896686696782247e-11
the O 0 1.2776280033932608e-10
360 O 0 4.04346334192951e-09
, O 0 1.4891925192994648e-10
000 O 0 1.6621518605930419e-09
Americans O 0 1.8934556700322958e-10
expected O 0 1.6691277526792447e-10
to O 0 6.563970894601923e-11
harbor O 0 1.2970166274328676e-08
this O 0 6.865647807219322e-12
allele O 0 8.764535625038761e-11
, O 0 1.930379987802322e-11
and O 0 5.191426715595027e-12
genetic O 0 5.054193868980761e-11
testing O 0 1.3283582567247265e-10
in O 0 1.5526697982881643e-11
the O 0 5.0607146945269577e-11
setting O 0 1.7685146680435082e-09
of O 0 2.6151214527203592e-09
long O 0 1.874204791363354e-09
- O 0 3.9888772285223695e-09
term O 0 7.461021134247403e-09
- O 0 3.375181023557161e-09
outcome O 0 1.392817305934102e-09
studies O 0 1.7541153252143005e-10
may O 0 1.9167389897489784e-11
impact O 0 1.6358076004863165e-10
significantly O 0 2.7784565759247926e-09
on O 0 1.304178385908017e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.519615559838712e-05
in O 0 3.6540498404846744e-10
this O 0 1.0670660535727627e-11
population O 0 8.07041499600869e-12
. O 0 3.726519537394779e-09

Localization O 0 0.00012952493852935731
of O 0 1.3398889677773695e-06
human O 0 7.403273372119656e-08
BRCA1 O 0 1.471271815489672e-08
and O 0 2.913779495461455e-10
its O 0 1.1884387918215111e-10
loss O 0 9.379518495222783e-09
in O 0 1.384281467231574e-09
high O 0 4.3297885099491396e-07
- O 0 2.9915128152424586e-08
grade O 0 2.688043139187357e-07
, O 0 1.8467112283815368e-09
non B-Disease 0 6.476312410086393e-05
- I-Disease 1 0.9763956069946289
inherited I-Disease 1 0.9999997615814209
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.035526324063539505

Although O 0 7.412655378402633e-08
the O 0 5.65555646758753e-09
link O 0 6.57099477052725e-08
between O 0 2.6318557999616132e-08
the O 0 1.6913897837866898e-08
BRCA1 O 0 7.13933516749421e-08
tumour B-Disease 1 0.9999983310699463
- O 0 2.0064555883436697e-06
suppressor O 0 5.185989380152023e-07
gene O 0 3.528603187419321e-08
and O 0 6.61393499967744e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 0.0001249574270332232
established O 0 2.551712441345444e-07
, O 0 3.3631045170956497e-10
the O 0 3.923282809736861e-10
role O 0 7.702765536521383e-09
, O 0 1.0498061447927753e-10
if O 0 1.544205388559483e-11
any O 0 2.5686303778416075e-11
, O 0 3.341510401710934e-11
of O 0 4.674100551049776e-10
BRCA1 O 0 5.304092165481222e-10
in O 0 2.3230108947558392e-09
non B-Disease 1 0.9953261613845825
- I-Disease 1 0.9999483823776245
familial I-Disease 1 0.9973441958427429
cancers I-Disease 1 0.9999997615814209
is O 0 3.154549119699368e-07
unclear O 0 2.5468189051025547e-06
. O 0 2.717356437642593e-07

BRCA1 O 0 7.289883342309622e-06
mutations O 0 9.092261876730845e-08
are O 0 3.0083033286665284e-10
rare O 0 2.4477830873337325e-09
in O 0 2.221737238627952e-09
sporadic B-Disease 0 3.882984856318217e-06
cancers I-Disease 0 0.004007700365036726
, O 0 2.0256949451180617e-09
but O 0 3.872940579352502e-10
loss O 0 3.737526199643071e-08
of O 0 2.5957402272069885e-07
BRCA1 O 0 1.0875078615413258e-08
resulting O 0 9.51411394112256e-09
from O 0 3.1277243017768797e-09
reduced O 0 4.3509462699375945e-09
expression O 0 8.188622557803171e-10
or O 0 1.983189307219746e-10
incorrect O 0 1.6727170759622823e-09
subcellular O 0 9.105243492513182e-08
localization O 0 3.581420457976492e-07
is O 0 3.5675049026018257e-10
postulated O 0 1.4590059160823898e-09
to O 0 1.7126963042235488e-11
be O 0 6.1031271182676594e-12
important O 0 1.798152425569466e-11
in O 0 5.541467631986485e-11
non B-Disease 0 3.230094762329827e-06
- I-Disease 0 0.001498852507211268
familial I-Disease 1 0.995557963848114
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.9997939467430115

Epigenetic O 0 0.002691417234018445
loss O 0 0.0001719016581773758
, O 0 1.1860038995337163e-07
however O 0 1.733515730961699e-08
, O 0 9.242290821553922e-10
has O 0 3.5866681152851854e-11
not O 0 7.762915310571827e-12
received O 0 1.6570128949511265e-11
general O 0 3.4433772500008786e-10
acceptance O 0 9.40893585266167e-10
due O 0 4.54685578077374e-09
to O 0 1.2864309617555136e-10
controversy O 0 4.882091952929102e-10
regarding O 0 3.836327089334901e-10
the O 0 1.742826577499912e-10
subcellular O 0 8.684341423759179e-08
localization O 0 5.100434350424621e-07
of O 0 4.2469174843517976e-08
BRCA1 O 0 2.471375326607017e-09
proteins O 0 1.8133489154692484e-10
, O 0 1.527161869185889e-10
reports O 0 9.53426781968858e-11
of O 0 1.180230357888945e-09
which O 0 3.773421158870249e-11
have O 0 1.479266535653334e-11
ranged O 0 8.178902000111066e-09
from O 0 5.231128377691796e-11
exclusively O 0 3.375861812315861e-10
nuclear O 0 9.101176701165059e-09
, O 0 9.584422665243064e-12
to O 0 7.982327472622064e-12
conditionally O 0 4.941810072267572e-09
nuclear O 0 1.6565829241699248e-07
, O 0 6.008497865916951e-11
to O 0 3.725748182192845e-11
the O 0 1.794317028291914e-09
ER O 0 9.99581288851914e-07
/ O 0 1.5888188897861255e-07
golgi O 0 8.561776212445693e-07
, O 0 2.184099123780925e-09
to O 0 9.053266469827292e-10
cytoplasmic O 0 6.537740659950941e-08
invaginations O 0 1.0590080137262703e-06
into O 0 1.280224815047859e-08
the O 0 2.3684320282768567e-08
nucleus O 0 3.707214091264177e-07
. O 0 2.8608965862986224e-07

In O 0 9.312780235859464e-08
an O 0 5.3710214054092376e-09
attempt O 0 3.333272147187927e-08
to O 0 1.8106679489093835e-09
resolve O 0 3.6956183180336666e-07
this O 0 2.430846635093076e-10
issue O 0 1.7431101007048255e-09
, O 0 4.185457189165298e-11
we O 0 2.4440531196101567e-11
have O 0 5.755665041795588e-12
comprehensively O 0 2.6776685313478765e-09
characterized O 0 5.0406439022765426e-09
19 O 0 5.765741306618111e-08
anti O 0 6.187755730024946e-07
- O 0 9.687265674074297e-07
BRCA1 O 0 2.896101847227328e-08
antibodies O 0 1.484715728139463e-08
. O 0 1.632415802532705e-07

These O 0 1.051725284639815e-08
reagents O 0 1.8781391020183946e-07
detect O 0 3.885086243826663e-07
a O 0 5.631104471603976e-08
220 O 0 8.06532156616413e-08
- O 0 1.0423217133848084e-07
kD O 0 3.6745564102602657e-07
protein O 0 1.5927975383078774e-08
localized O 0 8.258251860127075e-09
in O 0 4.345718784826147e-10
discrete O 0 2.593574421894118e-08
nuclear O 0 2.0748700535477838e-07
foci O 0 5.705855343762778e-08
in O 0 2.130973730807284e-10
all O 0 2.514359553895673e-11
epithelial O 0 3.602777631783738e-09
cell O 0 1.1871444627331584e-07
lines O 0 2.2299140312043164e-09
, O 0 2.5257176558546313e-11
including O 0 5.445946211352082e-12
those O 0 7.084424626796482e-12
derived O 0 1.6464605234745022e-09
from O 0 2.0446387694050827e-08
breast B-Disease 0 5.3225201554596424e-05
malignancies I-Disease 0 0.00015625210653524846
. O 0 4.01238821723382e-06

Immunohistochemical O 0 8.813614840619266e-06
staining O 0 5.763020908489125e-06
of O 0 1.5331631857407046e-06
human O 0 2.592842918147653e-07
breast O 0 1.8732571334112436e-06
specimens O 0 9.41705469159615e-09
also O 0 1.0667049465951095e-09
revealed O 0 8.935606388149608e-08
BRCA1 O 0 3.487706479177177e-08
nuclear O 0 1.4764085563001572e-06
foci O 0 1.432001226930879e-06
in O 0 1.591011433710321e-09
benign O 0 3.8286754715954885e-05
breast O 0 0.00020686222705990076
, O 0 4.513772111636172e-08
invasive B-Disease 1 0.8551549911499023
lobular I-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
and O 0 6.5700942286639474e-06
low B-Disease 1 0.9999901056289673
- I-Disease 1 0.9982447624206543
grade I-Disease 1 0.9999971389770508
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.0004074862808920443

Conversely O 0 5.252479240880348e-06
, O 0 8.31561450809204e-08
BRCA1 O 0 1.3695307110594968e-08
expression O 0 8.021777908595595e-09
was O 0 5.1680029145018125e-08
reduced O 0 5.24922372235892e-09
or O 0 1.0065470679165855e-10
undetectable O 0 5.881981568478523e-09
in O 0 4.509987522327563e-11
the O 0 5.234861155667403e-11
majority O 0 3.182027211168226e-11
of O 0 2.8443998267846382e-09
high O 0 3.383595128525485e-07
- O 0 7.493227371924149e-08
grade O 0 2.7470839540910674e-06
, O 0 4.1879392398413984e-08
ductal B-Disease 1 0.9998785257339478
carcinomas I-Disease 1 1.0
, O 0 8.208630930539584e-08
suggesting O 0 2.1397980276560702e-08
that O 0 4.484998830656117e-11
absence O 0 4.187539914823901e-08
of O 0 2.0899031483168073e-07
BRCA1 O 0 3.110989510446416e-08
may O 0 1.736440213839785e-09
contribute O 0 2.1008191020133182e-10
to O 0 7.928525891376381e-11
the O 0 7.003832513952091e-10
pathogenesis O 0 2.0208572095725685e-05
of O 0 1.155673867714313e-08
a O 0 3.823368566191476e-10
significant O 0 4.4088696582456066e-10
percentage O 0 5.208433684344982e-09
of O 0 1.2666039772568638e-08
sporadic B-Disease 0 0.0004080849466845393
breast I-Disease 0 0.32402506470680237
cancers I-Disease 1 0.7724086046218872
. O 0 1.2679315375407896e-07
. O 0 5.334362072062504e-07

